V1,Broad_Sample,pert_iname,smiles,pubchem_cid,clinical_phase,moa,target,disease_area,indication,target_entrez,Outcome
0,BRD-K76022557,(R)-(-)-apomorphine,CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31,6005,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A,neurology/psychiatry,Parkinson's Disease,3352|3361|50632|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,No-Effect
1,BRD-K75516118,(R)-(-)-rolipram,COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1,448055,Phase 1,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,"","",8654|5141|5142|5143|5144,No-Effect
2,BRD-K62353271,(R)-baclofen,NC[C@H](CC(O)=O)c1ccc(Cl)cc1,6918881,Phase 3,benzodiazepine receptor agonist,GABBR1|GABBR2,"","",9568|10537,No-Effect
3,BRD-K65856711,(S)-(+)-rolipram,COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1,158758,Phase 1,phosphodiesterase inhibitor,PDE4B|PDE4D,"","",5144|5142,No-Effect
4,BRD-K89787693,"[sar9,met(o2)11]-substance-p",CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O,163829,Preclinical,tachykinin antagonist,TACR1,"","",6869,No-Effect
9,BRD-K03273112,1-azakenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,6538897,Preclinical,glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,"","",2932|891|1020|983,No-Effect
10,BRD-K89665618,1-deoxymannojirimycin,OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,72258,Preclinical,alpha mannosidase inhibitor,MAN2A1,"","",4124,No-Effect
11,BRD-K70586315,1-EBIO,CCn1c2ccccc2[nH]c1=O,82320,Preclinical,potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,"","",3780|3781|3782|3783,No-Effect
13,BRD-K35114608,1-hexadecanal,CCCCCCCCCCCCCCCC=O,984,Preclinical,sphingosine 1-phosphate receptor substrate,DBI|RHO,"","",706|6010,No-Effect
15,BRD-K29542628,1-naphthyl-PP1,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12,4877,Preclinical,SRC inhibitor,SRC,"","",6714,No-Effect
17,BRD-K09338665,1-octanol,CCCCCCCCO,957,Phase 2,"",GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1,"","",81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|127534|10804|125111|57165|84694|349149|375519|219770,No-Effect
18,BRD-K31491153,1-phenylbiguanide,NC(N)=NC(=N)Nc1ccccc1,4780,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,"","",9177|3359,No-Effect
20,BRD-K06817181,"1,2,3,4,5,6-hexabromocyclohexane",BrC1C(Br)C(Br)C(Br)C(Br)C1Br,74603,Preclinical,JAK inhibitor,JAK2,"","",3717,No-Effect
22,BRD-K22346679,"1,4-butanediol",OCCCCO,8064,Phase 1,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MAN1B1|PLA2G2A|PLA2G2E,"","",5320|11253|30814,No-Effect
25,BRD-K70792160,10-DEBC,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,10521421,Preclinical,AKT inhibitor,PIM1,"","",9361,Strong (80%)
26,BRD-K63784565,10-hydroxycamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,97226,Preclinical,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
28,BRD-K68552125,12-O-tetradecanoylphorbol-13-acetate,"CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|",27924,Phase 2,PKC activator,KCNT2|TRPV4,"","",343450|59341,Low (25%)
29,BRD-K30237152,1400W,CC(=N)NCc1cccc(CN)c1,1433,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,"","",339345|342977|340719,No-Effect
30,BRD-K92301463,"16,16-dimethylprostaglandin-e2",CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,5283066,Phase 2,prostanoid receptor agonist,HPGD,"","",3248,No-Effect
31,BRD-K70264088,17-hydroxyprogesterone-caproate,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|,169870,Launched,progesterone receptor agonist,AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR,obstetrics/gynecology,spontaneous preterm birth,367|2099|2100|9971|8856|5241|2908,No-Effect
36,BRD-A66788520,2-(3-mercaptopropyl)pentanedioic-acid,"OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|",11735892,Phase 1,glutamate carboxypeptidase inhibitor,FOLH1,"","",2346,Low (25%)
38,BRD-K91868854,2-[1-(4-piperonyl)piperazinyl]benzothiazole,C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1,127902,Preclinical,serotonin receptor agonist,HTR4,"","",3360,No-Effect
39,BRD-K32681104,2-aminobenzenesulfonamide,Nc1ccccc1S(N)(=O)=O,72894,Preclinical,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA6|CA9,"","",768|771|23632|760|765,No-Effect
40,BRD-K13346085,2-APB,NCCOB(c1ccccc1)c1ccccc1,1598,Preclinical,"1,4,5-trisphosphate inhibitor",TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6,"","",140803|80036|1191|55503|7442|7220|7222|7223|7224|7225|7226,No-Effect
41,BRD-K22745370,2-BFI,C1CN=C(N1)c1cc2ccccc2o1 |c:2|,3080926,Preclinical,imidazoline receptor ligand,ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB,"","",4128|4129|150|151|152,No-Effect
42,BRD-K70088346,2-chloro-N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12,123807,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
43,BRD-K79511609,2-chloroadenosine,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,8974,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B,"","",136|134|135,Low (25%)
45,BRD-K92588747,2-CMDO,CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|,32224,Preclinical,dopamine receptor antagonist,DRD2|DRD4,"","",1813|1815,No-Effect
47,BRD-K97808269,2-deoxyglucose,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,9062,Phase 2,glycolysis inhibitor,SLC2A1|SLC2A2|SLC2A3|SLC2A4,"","",6513|6514|6515|6517,No-Effect
50,BRD-A53037300,2-fluoro-2-deoxy-D-galactose,"OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|",445913,Phase 1,"",LCT,"","",3938,No-Effect
54,BRD-K82027074,2-hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,91649,Phase 2,androgen receptor antagonist,AR,"","",367,No-Effect
55,BRD-A27924917,2-hydroxysaclofen,"NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",7005135,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,"","",9568|10537,No-Effect
56,BRD-K07954936,2-iminobiotin,NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|,135678104,Phase 2,nitric oxide synthase inhibitor,NOS1|NOS2,"","",339345|340719,No-Effect
58,BRD-K25649279,2-iodomelatonin,COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,115348,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B|NQO2,"","",4544|4835|4543,No-Effect
59,BRD-K44408410,2-methoxyestradiol,COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O,66414,Phase 2,hypoxia inducible factor inhibitor,COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB,"","",1312|1543|1545|7280|3091|1588,No-Effect
60,BRD-K64137799,2-methyl-5-hydroxytryptamine,Cc1[nH]c2ccc(O)cc2c1CCN,1574,Preclinical,serotonin receptor agonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6,"","",3362|3351|3352|9177|3354|3355|3359,No-Effect
64,BRD-K77087341,2-oleoylglycerol,CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO,5319879,Phase 1,glucose dependent insulinotropic receptor ligand,GPR119,"","",139760,No-Effect
65,BRD-K89712525,2-oxoglutaric-acid,OC(=O)CCC(=O)C(O)=O,51,Preclinical,"",OXGR1,"","",27199,No-Effect
66,BRD-K86587225,2-oxopropanoate,OC(=C)C(O)=O,37873,Preclinical,pyruvate dehydrogenase kinase inhibitor,ABAT,"","",18,No-Effect
67,BRD-K41869275,2-phenylmelatonin,COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1,4018512,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,"","",4544|4543,No-Effect
68,BRD-A04661934,2-PMDQ,"O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|",,Preclinical,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
69,BRD-K17874705,2-pyridylethylamine,NCCc1ccccn1,75919,Preclinical,histamine receptor agonist,HRH1,"","",3269,No-Effect
70,BRD-K89072800,2-TEDC,Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O,6069552,Preclinical,lipoxygenase inhibitor,ALOX12,"","",239,Low (25%)
74,BRD-K61734568,"2,3-DCPE",OCCNCCCOc1cccc(Cl)c1Cl,2250975,Preclinical,BCL-XL downregulator,BCL2L1,"","",598,No-Effect
75,BRD-K97833335,"2,4-dinitrochlorobenzene",[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O,6,Phase 2,thioredoxin inhibitor,TXN,"","",25828,No-Effect
76,BRD-K21910317,"2,4-dinitrophenol",Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O,1493,Preclinical,ATP synthase inhibitor,APP,"","",351,No-Effect
77,BRD-K29791386,"2,5-furandimethanol",OCc1ccc(CO)o1,74663,Phase 2,hemoglobin modulator,HBB,"","",85344,No-Effect
80,BRD-K63932022,2'-MeCCPA,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12,10475082,Preclinical,adenosine receptor agonist,ADORA1,"","",134,No-Effect
84,BRD-K00004218,3-alpha-bis-(4-fluorophenyl)-methoxytropane,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|",,Preclinical,dopamine uptake inhibitor,CHRM1|SLC6A2|SLC6A3|SLC6A4,"","",1128|6530|6531|6532,No-Effect
85,BRD-A43598550,3-alpha-hydroxy-5-beta-androstan-17-one,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|",5880,Preclinical,"",HSD17B11|IGHG2|SULT2A1,"","",51170|3501|6822,No-Effect
86,BRD-K08703257,3-amino-benzamide,NC(=O)c1cccc(N)c1,1645,Phase 2,PARP inhibitor,PARP1,"","",142,No-Effect
88,BRD-K38370968,3-AQC,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,3073499,Preclinical,serotonin receptor agonist,HTR3A,"","",3359,No-Effect
89,BRD-K24689407,3-bromo-7-nitroindazole,[O-][N+](=O)c1cccc2c(Br)[nH]nc12,1649,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,"","",339345|342977|340719,No-Effect
91,BRD-K92980438,3-bromopyruvate,OC(=O)C(O)=CBr,129924149,Preclinical,hexokinase inhibitor,HK2,"","",3099,No-Effect
92,BRD-K76592088,3-carboxy-4-hydroxyphenylglycine-(R),N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,6604713,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,"","",2904|2905|114787|2903,No-Effect
93,BRD-K61585876,3-carboxy-4-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,5311460,Preclinical,glutamate receptor antagonist,GRM1|GRM5,"","",2915|2911,No-Effect
95,BRD-A79431551,3-deazaadenosine,"Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|",12769724,Phase 2,adenosylhomocysteinase inhibitor,AHCY,"","",191,No-Effect
96,BRD-K77791657,3-deazaneplanocin-A,Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|,73087,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
99,BRD-K43187796,3-indolebutyric-acid,OC(=O)CCCc1c[nH]c2ccccc12,8617,Preclinical,"",B2M|HLA-A|TRAC|TRBC1,"","",3105|28639|28755|567,No-Effect
100,BRD-A87125127,3-MATIDA,"Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|",92327883,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
101,BRD-K01825682,3-methyl-GABA,C[C@@H](CN)CC(O)=O |&1:1|,6604938,Preclinical,GABA aminotransferase activator,ABAT,"","",18,No-Effect
102,BRD-K81647657,3-methyladenine,Cn1cnc(=N)c2[nH]cnc12,135398661,Preclinical,PI3K inhibitor,PI3,"","",5266,No-Effect
103,BRD-K62581435,3-MPPI,COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1,4013695,Preclinical,adrenergic receptor ligand,ADRA1A,"","",146,No-Effect
104,BRD-K82903013,"3,3'-dichlorobenzaldazine",Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1,6861557,Preclinical,glutamate receptor modulator,GRM5,"","",2915,No-Effect
105,BRD-K37846922,"3,3'-diindolylmethane",C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12,3071,Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",AR|HIF1A|IFNG|PI3,"","",5266|3458|3091|367,No-Effect
106,BRD-A49947412,"3,4-DCPG-(+/-)","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|",6604849,Preclinical,glutamate receptor agonist,GRM8,"","",2918,No-Effect
108,BRD-K86305586,"3,4-DCPG-(S)",N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O,16062593,Preclinical,glutamate receptor agonist,GRM8,"","",2918,No-Effect
109,BRD-K42205652,"3,4-methylenedioxy-beta-nitrostyrene",[O-][N+](=O)\C=C\c1ccc2OCOc2c1,672296,Preclinical,SRC inhibitor|SYK inhibitor,SRC|SYK,"","",6850|6714,Weak (50%)
110,BRD-K57796080,"3,5-DHPG-(S)",N[C@H](C(O)=O)c1cc(O)cc(O)c1,71668376,Preclinical,glutamate receptor agonist,GRM1,"","",2911,No-Effect
111,BRD-K45662124,3'-fluorobenzylspiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1,3248000,Preclinical,dopamine receptor ligand,DRD2,"","",1813,Weak (50%)
112,BRD-K58413118,3PO,O=C(\C=C\c1cccnc1)c1ccncc1,5720233,Preclinical,phosphofructokinase inhibitor,PFKFB3,"","",5209,No-Effect
113,BRD-K47337578,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1,5234410,Preclinical,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
116,BRD-K65544384,4-aminohippuric-acid,Nc1ccc(cc1)C(=O)NCC(O)=O,2148,Launched,"",SLC22A6,nephrology,renal diagnostic agent,9356,No-Effect
117,BRD-A80383043,4-carboxy-3-hydroxyphenylglycine-(RS),"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|",6604709,Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1,"","",2911,No-Effect
118,BRD-K74133873,4-carboxy-3-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1,5311455,Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1|GRM2,"","",2912|2911,No-Effect
119,BRD-K39160765,4-chlorophenylguanidine,NC(=N)Nc1ccc(Cl)cc1,2757788,Preclinical,urokinase inhibitor,PLAUR,"","",5329,No-Effect
120,BRD-A54139254,4-CMTB,"CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|",854190,Preclinical,free fatty acid receptor agonist,FFAR2,"","",2867,No-Effect
121,BRD-K29313239,4-DAMP,C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1,1734,Preclinical,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,"","",1128|1129|1131|1132|1133,No-Effect
123,BRD-K91758890,4-HQN,O=c1nc[nH]c2ccccc12,135408753,Preclinical,PARP inhibitor,PARP1,"","",142,No-Effect
125,BRD-K62537556,4-IBP,Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1,132995,Preclinical,sigma receptor agonist,SIGMAR1,"","",10280,No-Effect
126,BRD-K25690923,4-iodo-6-phenylpyrimidine,Ic1cc(ncn1)-c1ccccc1,817368,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,"","",4282,No-Effect
127,BRD-K66664625,4-iodo-L-phenylalanine,N[C@H](Cc1ccc(I)cc1)C(O)=O,7047041,Preclinical,"",DPP4,"","",1803,No-Effect
128,BRD-K73303757,4-methylgenistein,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,5280373,Preclinical,protein tyrosine kinase inhibitor,CYP19A1|ESRRA|ESRRB|ESRRG|FASN,"","",2194|1588|2101|2103|2104,No-Effect
129,BRD-K70821460,4-methylhistamine,Cc1nc[nH]c1CCN,37463,Preclinical,histamine receptor agonist,HRH4,"","",59340,No-Effect
130,BRD-K81316007,4-mu-8C,Cc1cc(=O)oc2c(C=O)c(O)ccc12,12934390,Preclinical,IRE1 inhibitor,ERN1,"","",2081,No-Effect
131,BRD-K00004224,4-P-PDOT,"CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|",24750357,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,"","",4544|4543,No-Effect
134,BRD-K78061844,4-PPBP,C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1,3035672,Preclinical,sigma receptor ligand,SIGMAR1,"","",10280,No-Effect
140,BRD-K97118047,"4,5,6,7-tetrabromobenzotriazole",Brc1c(Br)c(Br)c2n[nH]nc2c1Br,1694,Preclinical,casein kinase inhibitor,AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,"","",5600|5604|5578|6093|6446|207|6300|1459|2932|6198|1111|1432|5594|3932|5599,No-Effect
141,BRD-A18598741,4BP-TQS,"NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|",6979017,Preclinical,nicotinic receptor agonist,CHRNA7,"","",89832,No-Effect
142,BRD-K67173685,4E1RCat,OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|,16195554,Preclinical,protein synthesis inhibitor,EIF4E|EIF4G1,"","",1977|1981,No-Effect
143,BRD-K00004308,4EGI-1,OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1,2831024,Preclinical,protein synthesis inhibitor,EIF4E,"","",1977,No-Effect
144,BRD-K11773281,4SC-202,Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1,15985904,Phase 1,HDAC inhibitor,HDAC1,"","",3065,No-Effect
146,BRD-K87535339,"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135409474,Preclinical,"",TLR7,"","",51284,No-Effect
147,BRD-K57631554,5-aminolevulinic-acid,NCC(=O)CCC(O)=O,7048523,Launched,oxidizing agent,ALAD,oncology|dermatology,glioma|actinic keratosis (AK),210,No-Effect
148,BRD-K33690734,5-BDBD,Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|,9841560,Preclinical,purinergic receptor antagonist,P2RX4,"","",5025,No-Effect
149,BRD-K92382976,5-carboxamidotryptamine,NCCc1c[nH]c2ccc(cc12)C(N)=O,1809,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,"","",3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358,No-Effect
152,BRD-K24844714,5-fluorouracil,Fc1c[nH]c(=O)[nH]c1=O,3385,Launched,thymidylate synthase inhibitor,DPYD|TYMS,oncology,colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma,7298|1806,No-Effect
153,BRD-K34437622,5-FP,Fc1cnc(=O)[nH]c1,101498,Phase 1,thymidylate synthase inhibitor,TYMS,"","",7298,No-Effect
157,BRD-K24603946,5-hydroxymethyl-tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,9819382,Phase 1,acetylcholine receptor antagonist,CHRM3,"","",1131,No-Effect
158,BRD-A73930134,5-hydroxytryptophan,"N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|",6971044,Launched,neurotransmitter,SLC36A1|SLC36A2,neurology/psychiatry,insomnia,153201|206358,No-Effect
160,BRD-K45437867,5-methylfurmethiodide,Cc1ccc(C[N+](C)(C)C)o1,4141,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
164,BRD-K60287130,"5,7-dichlorokynurenic-acid",OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1,1779,Preclinical,glutamate receptor antagonist,GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2742|2903|2904|2905|2906,No-Effect
165,BRD-K00004289,5'-chloro-5'-deoxy-ENBA-(+/-),"O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|",,Preclinical,adenosine receptor agonist,ADORA1,"","",134,No-Effect
169,BRD-K34663752,6-chloromelatonin,COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,1858,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,"","",4544|4543,No-Effect
171,BRD-K49236613,6-iodo-nordihydrocapsaicin,CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,5149140,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
174,BRD-K84214706,7-chlorokynurenic-acid,OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1,1884,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,"","",2904|2905|114787|2903,No-Effect
175,BRD-K01826780,7-hydroxy-DPAT,CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|,23928184,Preclinical,dopamine receptor agonist,DRD2|DRD3,"","",1813|1814,No-Effect
176,BRD-K01825667,7-hydroxy-PIPAT,CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|,10317104,Preclinical,dopamine receptor ligand,DRD3,"","",1814,No-Effect
177,BRD-K45293975,7-hydroxystaurosporine,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,3078519,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,"","",11200|5578|4139|4140|5579|5580|5581|5582|983|5170|2932|1111|1432|3932,Cyto
179,BRD-K53156626,7-methoxytacrine,COc1ccc2nc3CCCCc3c(N)c2c1,119053,Phase 2,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
181,BRD-K04430056,7-nitroindazole,[O-][N+](=O)c1cccc2c[nH]nc12,1893,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,"","",339345|342977|340719,No-Effect
184,BRD-A00077618,8-bromo-cGMP,"Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|",135419186,Preclinical,PKA activator,PRKG1,"","",5592,No-Effect
185,BRD-K01826732,8-hydroxy-DPAT,CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|,10125797,Preclinical,serotonin receptor agonist,HTR5A|HTR7,"","",3361|3363,No-Effect
186,BRD-A60594020,8-hydroxy-PIPAT,CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|,15288637,Preclinical,dopamine receptor ligand,DRD2|DRD3,"","",1813|1814,No-Effect
187,BRD-A07232941,8-M-PDOT,"CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|",92211535,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,"","",4544|4543,No-Effect
190,BRD-K09291936,9-aminocamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O,72402,Phase 2,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
191,BRD-K62607075,9-anthracenecarboxylic-acid,OC(=O)c1c2ccccc2cc2ccccc12,2201,Preclinical,"",ANO1|CLCN1,"","",55107|1180,No-Effect
192,BRD-K70329400,A-1070722,COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1,49830684,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,"","",2931|2932,No-Effect
193,BRD-K59060513,A-1120,OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F,25138295,Preclinical,retinoid receptor ligand,RBP4,"","",5433,No-Effect
194,BRD-K38019854,A-317491,OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12,9829395,Preclinical,purinergic receptor antagonist,P2RX3,"","",5024,No-Effect
196,BRD-K06182768,A-366,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|,76285486,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,No-Effect
198,BRD-K62066682,A-412997,Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1,10425450,Preclinical,dopamine receptor agonist,DRD4,"","",1815,No-Effect
199,BRD-K13223831,A-438079,Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,11673921,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,No-Effect
201,BRD-K79743788,A-582941,CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1,44190553,Preclinical,nicotinic receptor agonist,CHRNA7,"","",89832,No-Effect
202,BRD-K00004225,A-61603,"CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|",10804826,Preclinical,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,"","",146|147,No-Effect
203,BRD-K78177893,A-674563,Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,11314340,Preclinical,AKT inhibitor,AKT1|PKIA|PRKACA,"","",5569|5578|207,Cyto
206,BRD-K87665527,A-784168,FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|,11420211,Preclinical,transient receptor potential channel antagonist,TRPV1,"","",7442,No-Effect
207,BRD-K28570407,A-803467,COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1,16038374,Preclinical,sodium channel blocker,SCN10A,"","",6336,No-Effect
208,BRD-K94313941,A-804598,C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1,53325874,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,No-Effect
210,BRD-K60427831,A-839977,Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1,53325875,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,No-Effect
211,BRD-K33059059,A-867744,CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O,23642319,Preclinical,acetylcholine receptor allosteric modulator,CHRNA3|CHRNA4|CHRNA7,"","",1136|1137|89832,No-Effect
212,BRD-K20239555,A-887826,CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1,46919335,Preclinical,sodium channel blocker,SCN10A,"","",6336,No-Effect
213,BRD-K81614372,A-922500,OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,24768261,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,"","",8694,No-Effect
214,BRD-K99308908,A-939572,CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1,24905400,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,"","",6319,No-Effect
215,BRD-K70744942,A-967079,CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1,42641861,Preclinical,transient receptor potential channel antagonist,TRPA1,"","",8989,No-Effect
216,BRD-K68982262,A-987306,Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|,25109291,Preclinical,histamine receptor antagonist,ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2,"","",134|552|1129|1128|1131|1132|1230|6865|106480180|3356|1814|3350|3351|3359,No-Effect
218,BRD-A30000356,A12B4C3,"CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|",,Preclinical,polynucleotide kinase/phosphatase inhibitor,PNKP,"","",11284,No-Effect
219,BRD-K77627880,A205804,Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1,9839311,Preclinical,ICAM1 expression inhibitor,ICAM1|SELE,"","",6401|3383,No-Effect
220,BRD-A83650191,A61603,"CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|",6604803,Preclinical,adrenergic receptor agonist,ADRA1A,"","",146,No-Effect
221,BRD-K49055432,A66,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C,42636535,Preclinical,PI3K inhibitor,PIK3CA,"","",5290,No-Effect
222,BRD-A78952587,A740003,"COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|",98050091,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,No-Effect
223,BRD-K72226571,A77636,NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2,,Preclinical,dopamine receptor agonist,CALY,"","",50632,No-Effect
224,BRD-K28861668,A922500,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,24768273,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,"","",8694,No-Effect
225,BRD-K13944729,AA-29504,CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N,23188887,Preclinical,GABA receptor positive allosteric modulator,GABRA1|GABRA4|GABRB3,"","",2554|2562|2557,No-Effect
230,BRD-K00004970,abamectin,"[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|",6858005,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,infectious disease,gastrointestinal parasites,9568|10537,No-Effect
231,BRD-K65498798,abametapir,Cc1ccc(nc1)-c1ccc(C)cn1,15664,Phase 3,metalloproteinase inhibitor,MMP9,"","",4318,No-Effect
232,BRD-K00003158,abarelix,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,16131215,Phase 3,gonadotropin releasing factor hormone receptor antagonist,GNRHR,"","",2798,No-Effect
234,BRD-K01825984,ABC-294640,"Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|",,Phase 2,sphingosine kinase inhibitor,SPHK2,"","",56848,No-Effect
235,BRD-K33622447,abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,46220502,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021,No-Effect
236,BRD-K50071428,abiraterone,"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|",132971,Launched,androgen biosynthesis inhibitor,CYP11B1|CYP17A1,oncology,prostate cancer,1584|1586,No-Effect
237,BRD-K24048528,abiraterone-acetate,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|",9821849,Launched,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,1586,No-Effect
240,BRD-K22749967,ABT-239,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,9818903,Phase 1,histamine receptor antagonist,HRH1|HRH2|HRH3,"","",1665|3269|11255,No-Effect
241,BRD-K97233161,ABT-491,CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C,154087,Phase 1,platelet activating factor receptor antagonist,PTAFR,"","",5724,No-Effect
242,BRD-K11792081,ABT-639,Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F,46851313,Phase 2,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,"","",8912|8913|150350,No-Effect
243,BRD-K36021395,ABT-702,Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1,1973,Preclinical,adenosine kinase inhibitor,ADK,"","",132,No-Effect
244,BRD-K37714784,ABT-724,C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1,5025739,Phase 2,dopamine receptor agonist,DRD4,"","",1815,No-Effect
245,BRD-K56301217,ABT-737,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1,11228183,Phase 1/Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,"","",596|598|599,No-Effect
246,BRD-K91623615,ABT-751,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1,3035714,Phase 2,tubulin polymerization inhibitor,TUBB,"","",7280,Low (25%)
249,BRD-K53788420,AC-186,Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F,71245042,Preclinical,estrogen receptor agonist,ESR2,"","",2100,No-Effect
250,BRD-K31144453,AC-261066,CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1,11530459,Preclinical,retinoid receptor agonist,RARB,"","",5915,No-Effect
251,BRD-K81548480,AC-264613,C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1,25108278,Preclinical,PAR agonist,F2RL1,"","",2150,Very Weak (35%)
252,BRD-A27911617,AC-55541,"C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|",129362181,Preclinical,PARP inhibitor,PARP2,"","",10038,No-Effect
253,BRD-K93176058,AC-55649,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O,1714884,Preclinical,retinoid receptor agonist,RARA|RARB,"","",5914|5915,Low (25%)
254,BRD-K15819326,AC-710,CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1,54760053,Preclinical,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,"","",5156|5159|3815|2322|1436,Very Weak (35%)
255,BRD-A49544621,AC-7954-(+/-),CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|,10937426,Preclinical,urotensin receptor agonist,UTS2R,"","",2837,No-Effect
259,BRD-K64034691,acalabrutinib,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12,71226662,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BTK,hematologic malignancy,mantle cell lymphoma (MCL),695,No-Effect
260,BRD-K92517771,acalisib,C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,11618268,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,"","",5291|22883,No-Effect
261,BRD-K26262077,acamprosate,CC(=O)NCCCS(O)(=O)=O,71158,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5,neurology/psychiatry,abstinence from alcohol,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2903|2904|2905|2906|116443|116444|114787|2915|2554|2555|2556|2557|2558|2559,No-Effect
262,BRD-K44276885,acarbose,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|,444254,Launched,glucosidase inhibitor,AMY2A|MGAM,endocrinology,diabetes mellitus,8972|279,Low (25%)
263,BRD-K68633617,ACDPP,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,16759169,Preclinical,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
265,BRD-A29260609,acebutolol,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O,657184,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension|ventricular arrhythmias,153,No-Effect
266,BRD-K07753030,acecainide,CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,4342,Phase 3,polarization inhibitor,SCN5A,"","",6331,No-Effect
267,BRD-K01825000,aceclidine,"CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|",1273944,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology,glaucoma,1128|1129|1131|1132|1133,No-Effect
268,BRD-K68538666,aceclofenac,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,71771,Launched,prostanoid receptor antagonist,PTGS2,rheumatology,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia,5743,No-Effect
271,BRD-K44004064,acefylline,Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O,69550,Launched,adenosine receptor agonist,ADORA1,pulmonary,asthma,134,No-Effect
274,BRD-K67563174,acemetacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1,1981,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis,5742|5743,Very Weak (35%)
275,BRD-K36262466,aceneuramic-acid,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,445063,Phase 3,"",CES1|SELE|SELP,"","",6401|1066|6414,No-Effect
276,BRD-A65051990,acenocoumarol,"CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|",54683745,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),79001,No-Effect
277,BRD-K37814297,acepromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O,6077,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,sedative,146|147|1812|1813|3350|3356,Strong (80%)
281,BRD-K43457670,acetazolamide,CC(=O)Nc1nnc(s1)S(N)(=O)=O,1986,Launched,carbonic anhydrase inhibitor,AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7,ophthalmology,glaucoma,771|23632|84182|759|760|761|762|766,No-Effect
282,BRD-K52960356,acetohexamide,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,1989,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus,6833|3766|3758|3767,No-Effect
283,BRD-K21615095,acetohydroxamic-acid,CC(=O)NO,1990,Launched,urease inhibitor,MMP12,infectious disease,urinary tract infections,4321,No-Effect
284,BRD-K42938903,acetophenazine,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,17676,Launched,dopamine receptor antagonist,DRD1|DRD2,neurology/psychiatry,psychosis,1812|1813,No-Effect
286,BRD-A44696962,acetyl-11-keto-beta-boswellic-acid,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|",,Phase 2,lipoxygenase inhibitor,HSD11B1|HSD11B2,"","",3290|3291,No-Effect
287,BRD-K79437791,acetyl-farnesyl-cysteine,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O,6438381,Launched,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV),5468,No-Effect
289,BRD-K82381502,acetylcholine,CC(=O)OCC[N+](C)(C)C,187,Launched,acetylcholine receptor agonist,ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,neurology/psychiatry|gastroenterology|pulmonary,drowsiness|fatigue|headache|indigestion|chest congestion,1128|1129|43|1132|1131|1133|1135,No-Effect
290,BRD-K59058747,acetylcysteine,CC(=O)N[C@@H](CS)C(O)=O,12035,Launched,mucolytic agent,ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11,gastroenterology,acetaminophen overdose|hepatic injury,114787|3551|682|5970|5621|2903|2904|2906|1147|116443|95,No-Effect
293,BRD-K72215350,acexamic-acid,CC(=O)NCCCCCC(O)=O,2005,Launched,5 alpha reductase inhibitor,GAST,dermatology,wound healing,2520,No-Effect
294,BRD-A29520968,acifran,"C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|",76969700,Phase 3,cholesterol inhibitor,HCAR2|HCAR3,"","",338442|8843,No-Effect
295,BRD-K63736853,acipimox,Cc1cnc(c[n+]1[O-])C(O)=O,5310993,Launched,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,338442,No-Effect
297,BRD-K62012036,acitretin,COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C,5284513,Launched,retinoid receptor agonist,RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3,dermatology,psoriasis,5926|6256|6257|6258|6774|5914|5915|5916,No-Effect
298,BRD-K13050541,acivicin,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|,16758175,Phase 2,gamma glutamyltransferase inhibitor,CTPS1,"","",1503,No-Effect
299,BRD-K31965398,aclarubicin,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC,86289437,Launched,topoisomerase inhibitor,TOP1|TOP2A,hematologic malignancy,acute myeloid leukemia (AML),7153|7150,Cyto
300,BRD-K74363950,aclidinium,OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1,11434515,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchitis|emphysema|chronic obstructive pulmonary disease (COPD),1128|1129|1131|1132|1133,No-Effect
304,BRD-M87138257,acriflavine,Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12,452192,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,3091,No-Effect
305,BRD-K97874492,acriflavinium,C[n+]1c2cc(N)ccc2cc2ccc(N)cc12,2016,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,3091,No-Effect
307,BRD-K50163129,acrivastine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,5284514,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,No-Effect
309,BRD-K34843150,ACT-132577,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,25099191,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910,No-Effect
310,BRD-K19781342,ACT-462206,COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1,40924317,Phase 1,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
312,BRD-K35936936,ACTB-1003,COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1,23653175,Phase 1,FGFR inhibitor|VEGFR inhibitor,KDR|TEK,"","",7010|3791,No-Effect
316,BRD-K82928847,ACY-1215,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,53340666,Phase 1/Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6|HDAC8,"","",55869|8841|3065|3066|10013,No-Effect
317,BRD-K32318651,acyclovir,Nc1nc(=O)c2ncn(COCCO)c2[nH]1,135398513,Launched,DNA polymerase inhibitor,PNP,infectious disease,genitial herpes|shingles|chicken pox,5539,Very Weak (35%)
318,BRD-A80280426,AD-5467,"CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|",6933882,Phase 2,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
319,BRD-K33127281,adapalene,COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O,60164,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRA|RXRB|RXRG,dermatology,acne vulgaris (AV),6256|6257|6258|5914|5915|5916,Cyto
320,BRD-A73427433,adaprev,"O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|",439284,Phase 3,TGF beta receptor inhibitor,AKR1B1|GPI|HK1|M6PR|PYGM,"","",231|4074|5837|10007|3098,No-Effect
321,BRD-K37151368,adaptavir,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O,184644,Phase 2,CC chemokine receptor antagonist,CCR5,"","",1234,No-Effect
322,BRD-K00152668,adarotene,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,9864378,Phase 1,retinoid receptor agonist,RARB|RARG,"","",5915|5916,No-Effect
323,BRD-K67789209,adatanserin,O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2,130918,Phase 2,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR2A,"","",3356|3350,No-Effect
330,BRD-K26060080,adenine,Nc1ncnc2nc[nH]c12,190,Preclinical,protein synthesis stimulant,ACACB|ACP1|APRT|MTAP|PECR|SRPK2,"","",32|353|4706|6733|55825|4507,No-Effect
331,BRD-K01577834,adenosine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,60961,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4,cardiology,Wolff-Parkinson-White Syndrome (WPW),55361|55300|134|135|136|54795|140,No-Effect
332,BRD-K85767870,adenosine-phosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,6083,Launched,adenosine receptor agonist,ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4,"","",2180|132|1385|107|5836|54795|9361|84532|3094|5142|5144|5562|2203|5564|5565|55902,No-Effect
333,BRD-K00003709,adenosine-triphosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,5957,Phase 2,adenosine receptor agonist,ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7,"","",2180|54795|269|19|9619|2840|25|27|156|157|291|5028|65061|5029|5030|54822|6833|8883|84532|439|440|5562|10939|317|445|22978|53829|8647|10060|10188|207|692312|90|91|1244|94|55902|107|238|369|6261|6262|6263|5243|3708,No-Effect
334,BRD-K60907894,adiphenine,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,2031,Launched,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms,1134,No-Effect
335,BRD-K10656395,adipic-acid,OC(=O)CCCCC(O)=O,22494954,Preclinical,solute carrier family member inhibitor,SLC22A6,"","",9356,No-Effect
336,BRD-K68810443,adiporon,O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1,16307093,Preclinical,adiponectin receptor agonist,ADIPOR1|ADIPOR2,"","",79602|51094,No-Effect
337,BRD-K39624409,ADL5859,CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|,11417954,Phase 2,opioid receptor agonist,OPRD1,"","",4985,No-Effect
339,BRD-K34870043,adoprazine,Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1,9887537,Phase 2,dopamine receptor antagonist|serotonin receptor agonist,DRD2|HTR1A,"","",1813|3350,No-Effect
341,BRD-K82343404,adrenalone,CNCC(=O)c1ccc(O)c(O)c1,7436,Launched,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage,146,No-Effect
342,BRD-K17368287,adrenosterone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|,223997,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1|HSD11B2,"","",3290|3291,No-Effect
343,BRD-K77911775,ADX-10059,Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1,10331863,Phase 2,glutamate receptor negative allosteric modulator,GRM5,"","",2915,No-Effect
344,BRD-K56543881,ADX-47273,Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1,11383075,Preclinical,glutamate receptor modulator,GRM5,"","",2915,No-Effect
345,BRD-K40718343,AEE788,CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1,10297043,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR,"","",1956|3791|2064|2066|2261|2263,No-Effect
347,BRD-K47816470,AF38469,Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1,72706115,Preclinical,sortilin inhibitor,SORT1,"","",6272,No-Effect
348,BRD-K53205568,afalanine,CC(=O)N[C@@H](Cc1ccccc1)C(O)=O,74839,Phase 3,dopamine receptor agonist,DRD2,"","",1813,No-Effect
350,BRD-K66175015,afatinib,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,10184653,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,oncology,non-small cell lung cancer (NSCLC),2064|2066|1956,Strong (80%)
351,BRD-K04210847,afimoxifene,CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,449459,Phase 2,estrogen receptor antagonist,ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ,"","",5580|5581|2099|2100|5589|5588|5590|2104,No-Effect
355,BRD-K08310154,AG-1024,CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,2044,Preclinical,insulin growth factor receptor inhibitor,IGF1R,"","",3480,No-Effect
356,BRD-K00615600,AG-14361,CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23,9840076,Preclinical,PARP inhibitor,PARP1,"","",142,No-Effect
357,BRD-K47105409,AG-490,Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O,5328779,Preclinical,EGFR inhibitor|JAK inhibitor,EGFR|JAK2|JAK3,"","",1956|3717|3718,No-Effect
358,BRD-K34428485,AG-555,Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O,5328770,Preclinical,tyrosine kinase inhibitor,CDK2,"","",1017,No-Effect
360,BRD-A56371469,AGI-5198,"Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|",97161269,Preclinical,isocitrate dehydrogenase inhibitor,IDH1,"","",3417,No-Effect
361,BRD-K04691817,AGI-6780,FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1,71299339,Preclinical,isocitrate dehydrogenase inhibitor,IDH2,"","",3418,No-Effect
362,BRD-A78111609,AGM-1470,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|",14942882,Phase 2,cell cycle inhibitor,METAP2,"","",10988,No-Effect
363,BRD-K49738308,agmatine,NCCCCNC(N)=N,199,Phase 3,nitric oxide synthase inhibitor,ADRA2C|ASIC3|CACNA1B|CHRNA1|GRIN1|KCNJ1|NISCH,"","",114787|774|1134|3758|11188|152|9311,No-Effect
364,BRD-A18074780,AGN-192403,"CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|",124581813,Preclinical,imidazoline receptor ligand,NISCH,"","",11188,No-Effect
365,BRD-K70262971,AGN-194310,CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|,9867046,Phase 3,retinoid receptor antagonist,RXRA|RXRB|RXRG,"","",6256|6257|6258,No-Effect
366,BRD-K32533226,AGN-195183,CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1,9867758,Phase 1/Phase 2,retinoid receptor agonist,RARA,"","",5914,Strong (80%)
367,BRD-K84698278,agomelatine,COc1ccc2cccc(CCNC(C)=O)c2c1,82148,Launched,melatonin receptor agonist|serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B,neurology/psychiatry,depression,4544|106480180|3356|3358|4543,No-Effect
369,BRD-K10852420,AH-7614,Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12,233085,Preclinical,free fatty acid receptor antagonist,FFAR4,"","",338557,No-Effect
370,BRD-A64808605,AH11110,O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|,6604792,Preclinical,adrenergic receptor ligand,ADRA1B,"","",147,No-Effect
371,BRD-K59339270,AH6809,CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O,119461,Preclinical,prostanoid receptor antagonist,PTGDR|PTGER1|PTGER2|PTGER3,"","",5729|5731|5732|5733,No-Effect
372,BRD-K89899948,AI-10-49,FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1,49806644,Preclinical,core binding factor inhibitor,CBFB,"","",865,No-Effect
373,BRD-K85139301,AIM-100,C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1,11501591,Preclinical,tyrosine kinase inhibitor,TNK2,"","",10188,No-Effect
374,BRD-K76677554,AJ76-(+),CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,122334,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,"","",1813|1814|1815,No-Effect
376,BRD-K09143580,AK-7,Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1,1328033,Preclinical,SIRT inhibitor,SIRT2,"","",22933,No-Effect
377,BRD-K54907283,AKBA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|,11168203,Phase 3,lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
379,BRD-K44731351,AL-8697,Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1,25060093,Preclinical,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
380,BRD-K51784806,alacepril,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,71992,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
385,BRD-K53731810,alantolactone,C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|,72724,Preclinical,apoptosis stimulant|STAT inhibitor,STAT3,"","",6774,No-Effect
386,BRD-K01826783,alaproclate,C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|,23622192,Phase 2,serotonin receptor antagonist,SLC6A4,"","",6532,Cyto
387,BRD-K42140276,alarelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,9855027,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRH1,"","",2796,No-Effect
388,BRD-K79131256,albendazole,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,2082,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis,7280|7846|10383,No-Effect
390,BRD-K01825118,albuterol,CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|,182176,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154,No-Effect
391,BRD-K55991142,alcaftadine,CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12,19371515,Launched,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis,3269,No-Effect
392,BRD-K47492008,alclofenac,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,30951,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis,5742,No-Effect
393,BRD-A17407635,alclometasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|",,Launched,glucocorticoid receptor agonist,CYP3A4|NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses,1576|866|2908,No-Effect
394,BRD-A84907376,alcuronium,"OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|",,Launched,muscle relaxant,CHRM1|CHRM2|CHRM3|CHRM4|CHRNA7,neurology/psychiatry,muscle relaxant,1128|1129|89832|1131|1132,No-Effect
395,BRD-K06890060,alda-1,Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1,831629,Preclinical,aldehyde dehydrogenase activator,ALDH2,"","",217,No-Effect
396,BRD-K68928792,aldoxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|,9810709,Phase 3,topoisomerase inhibitor,TOP2A,"","",7153,No-Effect
398,BRD-K75527158,alendronate,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,44400013,Launched,bone resorption inhibitor,ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS,orthopedics,osteoporosis,5802|523|5775|2224|5791,No-Effect
400,BRD-K49522529,alfacalcidol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5282181,Launched,vitamin D receptor agonist,CYP27B1|VDR,endocrinology,vitamin D deficiency,1594,No-Effect
402,BRD-K01826519,alfuzosin,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|,37888195,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,urology,benign prostatic hyperplasia (BPH),6336|11280|146|147|6323|6326|6328|6329|6331|6332|6334|6335,Very Weak (35%)
405,BRD-K01827280,alimemazine,C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|,6604496,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1,neurology/psychiatry|allergy|pulmonary,sedative|urticaria|itching|cough suppressant,3269,No-Effect
407,BRD-K75295174,alisertib,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|,24771867,Phase 3,Aurora kinase inhibitor,AURKA,"","",6790,No-Effect
408,BRD-K30020243,aliskiren-hemifumarate,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC,5493444,Launched,renin inhibitor,REN,cardiology,hypertension,147040,Low (25%)
413,BRD-A60402836,allicin,"C=CCS[S@@](=O)CC=C |&1:4,r|",51399529,Phase 2,cytokine production inhibitor,TRPA1|TRPV1,"","",7442|8989,No-Effect
414,BRD-K86307448,allopurinol,O=c1nc[nH]c2n[nH]cc12,135401907,Launched,xanthine oxidase inhibitor,XDH,rheumatology|urology,gout|kidney stones,6652,No-Effect
417,BRD-K12872829,allylestrenol,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|,235905,Launched,steroidal progestin,ESR1|PGR|SLC6A9,obstetrics/gynecology,premature labor,6536|5241|2099,No-Effect
418,BRD-K33219225,allylisothiocyanate,C=CCN=C=S,5971,Preclinical,TRPV agonist,TRPA1,"","",8989,No-Effect
420,BRD-K82677201,almitrine,Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1,33887,Launched,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD),476,No-Effect
421,BRD-K84810405,almorexant,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,23727689,Phase 3,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
422,BRD-K67601717,almotriptan,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,123606,Launched,serotonin receptor agonist,HTR1B|HTR1D,neurology/psychiatry,migraine headache,3352|3351,No-Effect
423,BRD-K04851519,aloe-emodin,OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,10207,Preclinical,anticancer agent,CASP8,"","",841,No-Effect
424,BRD-K83003151,alogliptin,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,11450633,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
427,BRD-K46742498,alosetron,Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C,2099,Withdrawn,serotonin receptor antagonist,HTR3A,"","",3359,No-Effect
429,BRD-K91188791,aloxistatin,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,65663,Phase 3,protease inhibitor,CTSG,"","",1511,Strong (80%)
430,BRD-K54997624,alpelisib,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,56649450,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,oncology,breast cancer,5290|5291|5294|22883,No-Effect
431,BRD-K72536715,alpha-asarone,COc1cc(OC)c(\C=C\C)cc1OC,636822,Preclinical,cytochrome P450 inhibitor|HMGCR inhibitor,HMGCR,"","",3156,No-Effect
434,BRD-K33396764,alpha-linolenic-acid,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,5280934,Phase 3,omega 3 fatty acid stimulant,ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1,"","",6785|5743|2864|4593|6546|7442|5913|338557,No-Effect
435,BRD-K80028314,alpha-methylhistamine-dihydrobromide-(R)-(-),C[C@@H](N)Cc1cnc[nH]1,156615,Preclinical,histamine receptor agonist,HRH3,"","",11255,No-Effect
436,BRD-K28308851,alpha-methylhistamine-dihydrobromide-(S)-(+),C[C@H](N)Cc1cnc[nH]1,6603865,Preclinical,histamine receptor agonist,HRH3,"","",11255,No-Effect
437,BRD-K01826806,alpha-methylserotonin,C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|,14083218,Preclinical,serotonin receptor agonist,HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4,"","",3360|106480180|3352|3354|3355|3356|3358,No-Effect
440,BRD-K66896751,alpidem,CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1,54897,Withdrawn,benzodiazepine receptor agonist,GABRA1,"","",2554,No-Effect
441,BRD-K01825817,alprenolol,"CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|",203685,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,angina pectoris,153|154,No-Effect
442,BRD-K52459643,alprostadil,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,5280723,Launched,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR,cardiology,congenital heart defects,5729|117155|5731|5732|5734|5739|347732|378807|117144,No-Effect
443,BRD-K35498378,alrestatin,OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23,2120,Preclinical,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
446,BRD-K00610438,altanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,3033677,Phase 2,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
448,BRD-K52681925,altinicline,CN1CCC[C@H]1c1cncc(c1)C#C,3036156,Phase 2,nicotinic receptor agonist,CHRNA4|CHRNB2,"","",1137|1141,No-Effect
449,BRD-K78627070,altiratinib,Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1,54576299,Phase 1,MET inhibitor|VEGFR inhibitor,KDR|MET|TEK,"","",7010|8731|3791,No-Effect
450,BRD-K50276048,altrenogest,"C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|",10041070,Launched,progestogen hormone,PGR,endocrinology,estrus,5241,No-Effect
452,BRD-K89055274,alverine,CCN(CCCc1ccccc1)CCCc1ccccc1,3678,Launched,muscle relaxant,HTR1A,gastroenterology,irritable bowel syndrome|diverticular disease,3350,No-Effect
453,BRD-K83988098,alvespimycin,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|",59996481,Phase 2,HSP inhibitor,HSP90AA1,"","",3320,Cyto
454,BRD-K07857022,alvimopan,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1,5488548,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,postoperative ileus,4985|4986|4988,No-Effect
455,BRD-K87909389,alvocidib,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,5287969,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM,"","",1024|1025|1956|5837|983|1017|1019|1020|1021|1022,Cyto
457,BRD-K53979406,ALX-5407,CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O,86306255,Phase 1,glycine transporter inhibitor,SLC6A9,"","",6536,No-Effect
458,BRD-A66116161,AM-1241,"CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|",23583507,Preclinical,cannabinoid receptor agonist,CNR1|CNR2,"","",1268|56142,Very Weak (35%)
459,BRD-K59013864,AM-24,Oc1c(I)cc(I)cc1I,11862,Phase 2,lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
460,BRD-K92000912,AM-251,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,2125,Preclinical,cannabinoid receptor antagonist,CNR1|GPR18|GPR55,"","",2841|9290|1268,No-Effect
461,BRD-K59419204,AM-281,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1,4302962,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2|GPR55,"","",9290|1268|56142,Very Weak (35%)
462,BRD-K55462201,AM-404,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,6604822,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,CNR1|CNR2|FAAH|TRPV1,"","",79152|7442|1268|56142,No-Effect
463,BRD-K06854232,AM-580,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,2126,Preclinical,retinoid receptor agonist,RARA,"","",5914,No-Effect
464,BRD-K63533170,AM-630,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12,4302963,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2,"","",1268|56142,No-Effect
465,BRD-K01826811,AM-92016,CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|,6604771,Preclinical,potassium channel blocker,GRIN1,"","",114787,No-Effect
468,BRD-K88443722,AM679,COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1,44627267,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,ALOX5AP|CNR1|CNR2,"","",241|1268|56142,No-Effect
469,BRD-K70330367,amantadine,NC12CC3CC(CC(C3)C1)C2,2130,Launched,glutamate receptor antagonist,DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A,infectious disease|neurology/psychiatry,influenza A virus infection|Parkinson's Disease,1813|2903|2904|2905|2906|116443,No-Effect
471,BRD-K11292736,ambenonium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,2131,Launched,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,43,No-Effect
472,BRD-K41185545,ambrisentan,COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1,6918493,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910,No-Effect
473,BRD-K56558538,ambroxol,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|,,Launched,sodium channel blocker,CYP3A4,pulmonary,bronchitis,1576,No-Effect
475,BRD-A36010170,amcinonide,"CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|",40469418,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,Low (25%)
476,BRD-K03019184,AMD-3465,C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1,483559,Preclinical,CC chemokine receptor antagonist,CXCR4,"","",7852,No-Effect
477,BRD-K42948882,AMD11070,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12,11256587,Phase 3,CC chemokine receptor antagonist,CCR5|CXCR4,"","",1234|7852,No-Effect
482,BRD-K51387999,amezinium,COc1cc(N)cn[n+]1-c1ccccc1,71927,Launched,adrenergic receptor agonist,ADRB2,cardiology,hypotension,154,No-Effect
483,BRD-K82122102,amfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,2136,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
484,BRD-K50813454,amflutizole,Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O,54833,Phase 2,xanthine oxidase inhibitor,XDH,"","",6652,No-Effect
486,BRD-K32285926,AMG-208,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,24864821,Phase 1,tyrosine kinase inhibitor,MET,"","",8731,Low (25%)
487,BRD-K64925568,AMG-232,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,58573469,Phase 2,MDM inhibitor,MDM2,"","",4193,No-Effect
488,BRD-K21077415,AMG-319,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,68947304,Phase 2,PI3K inhibitor,PIK3CD,"","",22883,No-Effect
489,BRD-K27061362,AMG-337,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1,44181686,Phase 2,MET inhibitor,MET,"","",8731,No-Effect
491,BRD-A01307728,AMG-487-(+/-),"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|",24957182,Phase 2,CC chemokine receptor antagonist,CXCR3,"","",2833,No-Effect
493,BRD-K34185671,AMG-517,CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1,16007367,Phase 1,TRPV antagonist,TRPV1,"","",7442,No-Effect
494,BRD-K86673452,AMG-548,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,11167112,Phase 1,MAP kinase inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,"","",5600|5603|6300|1432,No-Effect
495,BRD-K43802723,AMG-837,CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1,46854655,Phase 1,free fatty acid receptor agonist,FFAR1,"","",2864,No-Effect
496,BRD-K97452254,AMG-925,C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|,,Phase 1,CDK inhibitor|FLT3 inhibitor,CDK4|CDK6|FLT3,"","",2322|1019|1021,No-Effect
497,BRD-K01995783,AMG-9810,CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1,680502,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
498,BRD-K04374714,AMG-PERK-44,Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N,86583045,Preclinical,PERK inhibitor,EIF2AK4,"","",440275,Very Weak (35%)
499,BRD-A58947127,AMG319,"C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|",133547162,Phase 2,PI3K inhibitor,PIK3CD,"","",22883,No-Effect
500,BRD-K21782625,AMG458,COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,24764449,Preclinical,MET inhibitor,MET,"","",8731,No-Effect
501,BRD-K21728777,AMG900,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,24856041,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
502,BRD-K75114721,AMI-1,Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O,67254,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,"","",3276,No-Effect
503,BRD-K24610819,amibegron,CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1,3035442,Phase 3,adrenergic receptor agonist,ADRB3,"","",155,No-Effect
506,BRD-A19401019,amiflamine,"C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|",6336525,Phase 1,monoamine oxidase inhibitor,MAOA|SLC6A2,"","",4128|6530,No-Effect
507,BRD-K73947551,amifostine,NCCCNCCSP(O)(O)=O,29927142,Launched,reducing agent,ALPPL2|ENPP1,nephrology,renal toxicity,251|5167,No-Effect
509,BRD-K97181089,amiloride,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,16231,Launched,sodium channel blocker,AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2,cardiology,hypertension|congestive heart failure,6337|6338|6339|6340|7226|51393|40|41|25865|9033|5328|6548|26|9311,No-Effect
510,BRD-K24219278,amineptine,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,38988248,Withdrawn,dopamine receptor agonist,SLC6A2|SLC6A4,"","",6530|6532,Weak (50%)
511,BRD-K64931368,aminocaproic-acid,NCCCCCC(O)=O,564,Launched,plasminogen activator inhibitor,LPA|PLAT|PLG,hematology,fibrinolytic bleeding,4018|5340|5327,No-Effect
512,BRD-A25234499,aminoglutethimide,"CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|",1548995,Launched,glucocorticoid receptor antagonist,CYP11A1|CYP19A1,endocrinology|oncology,Cushing's syndrome|breast cancer,1588|1583,No-Effect
513,BRD-K25114078,aminoguanidine,NN=C(N)N,2146,Phase 3,nitric oxide synthase inhibitor,AKR1B1|NOS2|TIMP3,"","",339345|7078|231,No-Effect
516,BRD-A28318179,aminomethyltransferase,"C[C@H]1CCN=C(N)S1 |&1:1,t:4|",7059445,Preclinical,nitric oxide synthase inhibitor,NOS2,"","",339345,No-Effect
517,BRD-A69917777,aminopentamide,CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,176163,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea,1128,Very Weak (35%)
518,BRD-K97799481,aminophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,2153,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary,asthma|bronchitis|emphysema,134|135|136|140|8654|5139|5140|5141|5142|5143|5144|3066,No-Effect
519,BRD-K87544030,aminopterin,Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,169371,Phase 3,dihydrofolate reductase inhibitor,DHFR|SLC46A1,"","",113235|1719,No-Effect
520,BRD-K07762753,aminopurvalanol-a,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,6604931,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,CDK1|CDK2|CDK5,"","",1017|1020|983,No-Effect
521,BRD-K80267133,aminosalicylate,Nc1ccc(C(O)=O)c(O)c1,4649,Launched,cyclooxygenase inhibitor,ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2,gastroenterology,inflammatory bowel disease|ulcerative colitis,5742|5743|240|1147|30814,Low (25%)
522,BRD-K94837153,aminothiadiazole,Nc1nncs1,19909,Phase 2,inosine monophosphate dehydrogenase inhibitor,ADORA3|IMPDH1,"","",727833|140,No-Effect
523,BRD-K13421763,aminothiazole,Nc1nccs1,2155,Preclinical,cyclin D inhibitor,NOS2,"","",339345,Low (25%)
524,BRD-K17561142,amiodarone,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,2157,Launched,potassium channel blocker,ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2,cardiology,ventricular arrhythmias,9254|3757|8912|153|3743,Strong (80%)
527,BRD-A60197193,amisulpride,"CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|",5746246,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,psychosis|bipolar disorder|schizophrenia,1813,No-Effect
528,BRD-A68942014,amitifadine,"Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|",11658655,Phase 3,serotonin transporter (SERT) inhibitor,SLC6A2|SLC6A3|SLC6A4,"","",6530|6531|6532,No-Effect
529,BRD-K33335792,amitraz,CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C,,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,infectious disease,generalized demodicosis,146|150,No-Effect
530,BRD-K53737926,amitriptyline,CN(C)CCC=C1c2ccccc2CCc2ccccc12,2160,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI),ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression,1665|6530|6532|146|147|150|3350|3352|153|154|155|3356|3351|3358|3736|3362|3363|3751|3752|10280|4914|4915|3269|3785|3786|59340|1128|1129|1131|1132|1133|4985|4986|4988,Strong (80%)
531,BRD-K29530284,amlexanox,CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O,2161,Launched,histamine receptor modulator,FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13,dental|pulmonary|ophthalmology|allergy,aphthous ulcers|asthma|conjunctivitis|allergic rhinitis,2246|3562|6283|6284|5141|5142|5143|5144,No-Effect
532,BRD-K01825117,amlodipine,"CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|",9801597,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1,cardiology,hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD),775|776|778|779|781,No-Effect
533,BRD-K83486494,ammonium-glycyrrhizinate,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|,14982,Launched,thrombin inhibitor,HSD11B1|HSD11B2|SLCO1B1|SLCO1B3,dermatology,cosmetic,3290|3291|28234|10599,Weak (50%)
534,BRD-M29182745,ammonium-lactate,"N.C[C@@H](O)C(O)=O |&1:2,r|",10313098,Launched,"",HCAR1,dermatology,xerosis cutis|ichthyosis vulgaris,27198,No-Effect
535,BRD-K32531356,ammonium-perfluorocaprylate,OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,9554,Phase 1,Pim kinase inhibitor,PIM1,"","",9361,No-Effect
536,BRD-K23335153,AMN-082,C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1,1894361,Preclinical,glutamate receptor modulator,GRM7,"","",2917,No-Effect
537,BRD-K91290917,amodiaquine,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,3647519,Launched,histamine receptor agonist,HNMT,infectious disease,malaria,3176,Strong (80%)
538,BRD-K56334280,amonafide,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,50515,Phase 3,topoisomerase inhibitor,TOP2A|TOP2B,"","",7153|7155,No-Effect
540,BRD-K02265150,amoxapine,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|,2170,Launched,norepinephrine reputake inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,2560|2561|2562|2563|2564|2565|2566|2567|2568|6530|6531|6532|146|147|1812|1813|150|1815|1816|151|152|1814|3350|3351|3356|3358|3359|3362|3363|106480180|3269|55879|59340|1128|1129|1131|1132|1133|2554|2555|2556|2557|2558|2559,No-Effect
541,BRD-K55044200,amoxicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O,40467057,Launched,penicillin binding protein inhibitor,CYP2C19|SLC15A1|SLC15A2|SLC22A6,infectious disease|gastroenterology,skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections,9356|6564|1557|6565,No-Effect
542,BRD-K01826817,AMPA-(RS),Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|,7059442,Preclinical,glutamate receptor agonist,GRIN1,"","",114787,No-Effect
543,BRD-K92493880,AMPA-(S),Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O,7000183,Preclinical,glutamate receptor agonist,GRIA2|GRIN1,"","",114787|2891,No-Effect
544,BRD-K24771047,ampalex,O=C(N1CCCCC1)c1ccc2nccnc2c1,148184,Phase 2,glutamate receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
545,BRD-K52397688,amperozide,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,73333,Launched,dopamine receptor antagonist,FAAH|HTR2A,neurology/psychiatry,psychosis,79152|3356,No-Effect
548,BRD-A39172021,ampiroxicam,"CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|",25273583,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,Low (25%)
552,BRD-K45924332,amrinone,Nc1cc(c[nH]c1=O)-c1ccncc1,3698,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B|PDE4B|TNF,cardiology,congestive heart failure,5139|5140|5142|7124,Very Weak (35%)
553,BRD-K13843533,amrubicin,CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1,3035016,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,small cell lung cancer,7153|7155,No-Effect
554,BRD-K68346641,amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,2179,Launched,topoisomerase inhibitor,KCNH2|TOP2A,hematologic malignancy,acute lymphoblastic leukemia (ALL),7153|3757,No-Effect
555,BRD-K39670393,amthamine,Cc1nc(N)sc1CCN,126688,Preclinical,histamine receptor agonist,HRH2,"","",1665,No-Effect
556,BRD-K70924353,amtolmetin-guacil,COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,65655,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743,No-Effect
557,BRD-K66538826,amuvatinib,S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12,11282283,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,KIT|MET,"","",8731|3815,No-Effect
558,BRD-K03504028,amygdalin,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,656516,Phase 2,caspase activator,CASP3,"","",836,No-Effect
564,BRD-A19609491,ANA-12,"O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|",6977265,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,"","",4915,No-Effect
566,BRD-K77118600,anacetrapib,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,11556427,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,"","",1071,No-Effect
567,BRD-K05355328,anagliptin,Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N,44513473,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
568,BRD-K62200014,anagrelide,Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|,135409400,Launched,phosphodiesterase inhibitor,PDE3A,hematology|hematologic malignancy,thrombocythemia|myeloproliferative neoplasms,5139,No-Effect
569,BRD-K01174345,anamorelin,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N,9828911,Phase 3,growth hormone secretagogue receptor agonist,GHSR,"","",2693,No-Effect
570,BRD-K42352790,anandamide,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO,5281969,Phase 2,cannabinoid receptor agonist,CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1,"","",3777|51305|9290|150350|56142|8912|8913|3737|79054|1268|2741|7442|2841,No-Effect
571,BRD-K52172416,anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N,2187,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588,No-Effect
572,BRD-K82164249,andarine,CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1,9824562,Phase 1,androgen receptor modulator,AR,"","",367,No-Effect
573,BRD-K89282837,andrographolide,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12,5318517,Phase 2,tumor necrosis factor production inhibitor,IL1B|IL6|NFKB1|NFKB2|TNF,"","",3553|3569|7124|4790|4791,No-Effect
581,BRD-K88611939,aniracetam,COc1ccc(cc1)C(=O)N1CCCC1=O,2196,Launched,glutamate receptor agonist,DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A,"","",2890|2891|2892|2893|1813|3356,No-Effect
582,BRD-K47458712,anisindione,COc1ccc(cc1)C1C(=O)c2ccccc2C1=O,2197,Launched,vitamin K antagonist,GGCX,hematology,deep vein thrombosis (DVT),2677,No-Effect
583,BRD-A29623586,anisodamine,"CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|",,Phase 3,lipid peroxidase inhibitor,ADRA1A,"","",146,Low (25%)
584,BRD-K91370081,anisomycin,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,253602,Preclinical,DNA synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,"","",23521|140801|6147|9349|4809|6122|51121|51187|6167|6132|6135|6138|6143,Cyto
586,BRD-K36949735,anlotinib,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,25017411,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR|PDGFRB,"","",5159|3791,No-Effect
587,BRD-K55424922,anpirtoline,Clc1cccc(SC2CCNCC2)n1,65854,Phase 1,serotonin receptor agonist,HTR1B,"","",3351,No-Effect
588,BRD-K31170746,ANR-94,CCOc1nc2c(N)ncnc2n1CC,11805896,Preclinical,adenosine receptor antagonist,ADORA2A,"","",135,No-Effect
590,BRD-K25863791,antagonist-g,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O,163960,Phase 1,neuropeptide receptor antagonist,MAPK8,"","",5599,No-Effect
591,BRD-K01363385,antalarmin,CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C,177990,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,"","",1394,No-Effect
592,BRD-K99300445,antazoline,C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|,2200,Launched,antihistamine,HRH1,ophthalmology|otolaryngology,conjunctivitis|nasal congestion,3269,No-Effect
594,BRD-K15957397,anthraquinone,O=C1c2ccccc2C(=O)c2ccccc12,6780,Preclinical,CDC inhibitor,CDC25B,"","",994,No-Effect
597,BRD-K90152265,antimycin-A,CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O,14957,Preclinical,ATP synthase inhibitor,CYCS,"","",54205,No-Effect
599,BRD-K32143970,AP-18,C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O,9584673,Preclinical,transient receptor potential channel antagonist,TRPA1,"","",8989,No-Effect
600,BRD-K28383148,AP1903,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,16135625,Phase 1/Phase 2,"",MTOR,"","",2475,No-Effect
601,BRD-K56032964,AP26113,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,57390074,Phase 2,ALK tyrosine kinase receptor inhibitor,ALK|EGFR,"","",1956|238,No-Effect
602,BRD-K20001883,apabetalone,COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1,135564749,Phase 3,apolipoprotein expression enhancer,BRD3,"","",8019,No-Effect
603,BRD-K28115081,apafant,Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|,65889,Phase 3,platelet activating factor receptor antagonist,PTAFR,"","",5724,No-Effect
606,BRD-K25244359,apatinib,O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1,11315474,Phase 3,RET tyrosine kinase inhibitor,CSK|KDR|KIT|RET,"","",5979|3815|1445|3791,No-Effect
607,BRD-K07449869,APC-100,Cc1c(C)c2OC(C)(C)CCc2c(C)c1O,99479,Phase 1/Phase 2,androgen receptor antagonist|anti-inflammatory agent,AR,"","",367,No-Effect
608,BRD-K72748448,APcK-110,COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1,24786010,Preclinical,KIT inhibitor,KIT|STAT3,"","",6774|3815,No-Effect
609,BRD-K86226872,APD597,COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C,11691484,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,"","",139760,No-Effect
610,BRD-K10859802,APD668,CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O,11705608,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,"","",139760,No-Effect
612,BRD-K26325692,API-001,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,44247568,Phase 2,sigma receptor antagonist,SIGMAR1,"","",10280,No-Effect
613,BRD-K97840621,API-1,NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O,24773090,Preclinical,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,Cyto
614,BRD-K01493881,apigenin,Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1,5280443,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1,"","",231|1545|367|1588|1080|3292|1021,Very Weak (35%)
615,BRD-K67121414,apixaban,COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O,10182969,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT),2159,No-Effect
616,BRD-K64990520,apocynin,COc1cc(ccc1O)C(C)=O,2214,Phase 1,NADPH oxidase inhibitor,NOX4,"","",50507,No-Effect
617,BRD-K15164005,apoptosis-activator-II,Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl,1901244,Preclinical,carboxylesterase inhibitor,BCHE|CES1,"","",1066|590,No-Effect
618,BRD-A09004963,APR-246,"COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|",76965201,Phase 3,p53 activator,TP53,"","",7157,No-Effect
619,BRD-K38911213,apraclonidine,Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|,2216,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C,ophthalmology,glaucoma|intraocular pressure,152|146|150|151,Very Weak (35%)
621,BRD-K06883221,apratastat,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1,11452716,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,ADAM17|MMP1|MMP13|MMP9,"","",4312|4322|6868|4318,No-Effect
622,BRD-K93208532,apremilast,CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O,11561674,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology|rheumatology,psoriasis|psoriatic arthritis,5144|5141|5142|5143,No-Effect
623,BRD-K52827117,aprepitant,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,135413536,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869,No-Effect
625,BRD-K53236343,aprindine,CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1,2218,Launched,voltage-gated sodium channel blocker,CALM1|SCN5A,cardiology,cardiac arrythmia,801|6331,No-Effect
627,BRD-K63919159,aptiganel,CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12,60840,Phase 3,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
628,BRD-K68003372,APTO-253,Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21,11960271,Phase 1,krppel-like factor expression enhancer,KLF4,"","",9314,No-Effect
629,BRD-K17511755,APY-29,C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1,42627755,Preclinical,serine/threonine kinase inhibitor,ERN1,"","",2081,No-Effect
630,BRD-K38627885,APY0201,Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1,56927660,Preclinical,phosphoinositide dependent kinase inhibitor,IL12A|IL12B|PIKFYVE,"","",3592|3593|200576,Weak (50%)
633,BRD-K81729199,AQ-RA741,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,129989,Preclinical,acetylcholine receptor antagonist,CHRM2,"","",1129,Low (25%)
635,BRD-K90497590,AR-12,NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F,10027278,Phase 1,phosphoinositide dependent kinase inhibitor,PDPK1,"","",5170,No-Effect
636,BRD-K13167095,AR-42,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,6918848,Phase 1,HDAC inhibitor,HDAC1,"","",3065,Cyto
637,BRD-K67860401,AR-A014418,COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1,448014,Preclinical,glycogen synthase kinase inhibitor,GSK3B,"","",2932,No-Effect
638,BRD-K42325600,AR-C155858,CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O,10226546,Preclinical,monocarboxylate transporter inhibitor,SLC16A1|SLC16A7,"","",9194|6566,No-Effect
639,BRD-K03070961,arachidonic-acid,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,444899,Phase 1,cytochrome P450 inhibitor,CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2,"","",3776|338567|1191|5742|3761|5590|7225|1181|54207,Low (25%)
641,BRD-K73881242,arbidol,CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,28446253,Launched,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection,1576,Weak (50%)
642,BRD-K08037784,arbutin,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,440936,Phase 2/Phase 3,melanin inhibitor,TYR,"","",7299,No-Effect
643,BRD-K93188295,ARC-239,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,609483,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,"","",152|150|151,No-Effect
644,BRD-K53523901,arctigenin,COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC,64981,Preclinical,MEK inhibitor,CHUK|MAP2K1,"","",1147|5604,No-Effect
645,BRD-K72726508,arcyriaflavin-a,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,5327723,Preclinical,CDK inhibitor,CCND1|CDK4,"","",595|1019,No-Effect
646,BRD-K00003590,ardeparin,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,100942142,Withdrawn,thrombin inhibitor,SERPIND1,"","",3053,No-Effect
647,BRD-K63792901,arecaidine-but-2-ynyl-ester,CC#CCOC(=O)C1=CCCN(C)C1 |t:7|,4214594,Preclinical,acetylcholine receptor agonist,CHRM2,"","",1129,No-Effect
648,BRD-K23922020,arecaidine-propargyl-ester,CN1CCC=C(C1)C(=O)OCC#C |c:4|,2229,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
649,BRD-K88646909,arecoline,COC(=O)C1=CCCN(C)C1 |t:4|,2230,Phase 1,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
650,BRD-A48261811,argatroban,"C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|",152951,Launched,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT),2147,No-Effect
652,BRD-K62734952,arglabin,CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|,5574924,Launched,farnesyltransferase inhibitor,FNTA|NFKB1,"","",2339|4790,No-Effect
653,BRD-K70358946,aripiprazole,Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl,60795,Launched,serotonin receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7,neurology/psychiatry,depression|schizophrenia|bipolar disorder,146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133,No-Effect
655,BRD-K33852358,arofylline,CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O,166553,Phase 3,phosphodiesterase inhibitor,PDE4A,"","",5141,No-Effect
656,BRD-A28044053,arotinolol,"CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|",12797283,Launched,adrenergic receptor antagonist,ADRB3,cardiology|neurology/psychiatry,hypertension|tremors,155,No-Effect
657,BRD-K60171656,ARQ-092,Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1,53262401,Phase 1,AKT inhibitor,AKT2,"","",208,No-Effect
658,BRD-K43436647,ARQ-621,NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F,25110841,Phase 1,kinesin-like spindle protein inhibitor,KIF11,"","",3832,No-Effect
659,BRD-K46386702,ARRY-334543,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|,42642648,Phase 2/Phase 3,EGFR inhibitor,ERBB2,"","",2064,No-Effect
660,BRD-K24179883,arsanilic-acid,Nc1ccc(cc1)[As](O)(O)=O,7389,Phase 1,"",LYZ,"","",4069,No-Effect
661,BRD-K32786395,arsenic-trioxide,O=[As]O[As]=O,261004,Launched,apoptosis stimulant,AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1,gastroenterology,diarrhea,7296|3725|207|595|5594|5595|3551,Very Weak (35%)
662,BRD-K39621635,artemether,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,68911,Launched,antimalarial agent,ATP1A1,infectious disease,malaria,476,No-Effect
663,BRD-K13112821,artemisinin,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,68827,Launched,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,1555,No-Effect
667,BRD-K49223707,arundic-acid,CCCCCC[C@@H](CCC)C(O)=O,208925,Phase 2/Phase 3,astrocyte modulating agent,PTGS2|S100B,"","",6285|5743,No-Effect
668,BRD-A00047421,ARV-825,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|",124870683,Preclinical,bromodomain inhibitor,BRD4,"","",23476,No-Effect
669,BRD-K07656463,AS-1269574,Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1,5332859,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,"","",139760,No-Effect
670,BRD-K27051047,AS-1892802,OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1,46911016,Preclinical,rho associated kinase inhibitor,ROCK1,"","",6093,No-Effect
671,BRD-K61936403,AS-1949490,C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,44473434,Preclinical,SHIP2 phosphatase inhibitor,INPP5D,"","",3635,No-Effect
672,BRD-K75254015,AS-2034178,OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F,24808572,Preclinical,free fatty acid receptor agonist,FFAR1,"","",2864,No-Effect
673,BRD-K73565918,AS-2444697,Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1,52913874,Preclinical,interleukin inhibitor,IRAK4,"","",51135,No-Effect
674,BRD-K14988953,AS-252424,Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1,11630874,Preclinical,PI3K inhibitor,PIK3CG,"","",5294,No-Effect
675,BRD-K63915849,AS-604850,FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1,5287855,Preclinical,PI3K inhibitor,PIK3CA|PIK3CG,"","",5290|5294,No-Effect
676,BRD-K89014967,AS-703026,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,44187362,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,"","",5604|5605,No-Effect
677,BRD-K62427771,AS-77,O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,11302540,Phase 1,potassium channel blocker,KCNA3|KCNA5|KCNN4,"","",3738|3741|3783,No-Effect
680,BRD-K88219015,asaraldehyde,COc1cc(OC)c(C=O)cc1OC,20525,Preclinical,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
681,BRD-K30331124,ASC-J9,COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC,74891315,Phase 2,androgen receptor enhancer,AR,"","",367,No-Effect
683,BRD-K88882192,ascomycin,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|,134129697,Preclinical,calcineurin inhibitor,FKBP1A,"","",2280,No-Effect
684,BRD-A85242401,ascorbic-acid,"OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|",,Launched,antioxidant,SLC23A1|SLC23A2,endocrinology,scurvy,9962|9963,No-Effect
685,BRD-K00003551,asenapine,"[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|",163091,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder,3269|1813|3350|3351|3352|3354|3356,Strong (80%)
687,BRD-K00003477,asimadoline,CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1,179340,Phase 3,opioid receptor agonist,OPRK1,"","",4986,No-Effect
689,BRD-K07150325,ASP-2535,CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12,9800113,Phase 1,glycine transporter inhibitor,SLC6A9,"","",6536,No-Effect
692,BRD-K06542892,ASP3026,COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,25134326,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,"","",238,No-Effect
693,BRD-K78841970,aspartame,COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O,6992066,Launched,"",TAS1R2|TRPV1,"","",80834|7442,No-Effect
694,BRD-K11433652,aspirin,CC(=O)Oc1ccccc1C(O)=O,2244,Launched,cyclooxygenase inhibitor,AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53,neurology/psychiatry|endocrinology|dental,headache|fever|toothache|muscle pain,53632|6197|4790|4791|4792|5562|5563|5564|5565|5571|51422|9311|3551|3309|1645|5742|5743|7157|1909,No-Effect
695,BRD-K26838195,AST-1306,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,24739943,Phase 1,EGFR inhibitor,EGFR|ERBB2,"","",2064|1956,No-Effect
697,BRD-K37249724,astemizole,COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,2247,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,"","",3756|3269|3757,Weak (50%)
702,BRD-K36269323,asymmetrical-dimethylarginine,CN(C)C(=N)NCCC[C@H](N)C(O)=O,123831,Phase 1,nitric oxide synthase inhibitor,NOS2|NOS3,"","",339345|342977,No-Effect
703,BRD-K06496777,AT-1015,O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|,9805664,Preclinical,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
705,BRD-K13390322,AT-7519,Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1,11338033,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK9,"","",1025|983|1017|1019|1020|1021,No-Effect
706,BRD-K24576554,AT-9283,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1,135398495,Phase 2,Aurora kinase inhibitor|JAK inhibitor,AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A,"","",27330|3717|3718|6790|9263|9212,No-Effect
707,BRD-K32127727,AT13148,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1,24905401,Phase 1,protein kinase inhibitor,AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3,"","",9475|6093|207|208|10000|23678,No-Effect
708,BRD-K58435339,AT13387,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,11955716,Phase 2,HSP inhibitor,HSP90AA1,"","",3320,Very Weak (35%)
709,BRD-K12040459,AT7867,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1,11175137,Preclinical,AKT inhibitor,AKT2|GSK3B|PKIA|PRKACA,"","",208|5569|5578|2932,No-Effect
710,BRD-K94830329,ataluren,OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F,11219835,Launched,CFTR channel agonist|dystrophin stimulant,DMD,genetics|pulmonary,duchenne muscular dystrophy (DMD)|cystic fibrosis,1756,No-Effect
712,BRD-A52551912,ATB-346,"COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|",76963724,Phase 2,cyclooxygenase inhibitor,PTGER2,"","",5732,No-Effect
715,BRD-A20239487,atenolol-(+/-),"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|",180559,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|LTF|PLA2G2E,cardiology,hypertension|angina pectoris,153|154|4057|30814,No-Effect
719,BRD-K38527262,atiprimod,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,129869,Phase 2,JAK inhibitor|STAT inhibitor,JAK2|STAT3,"","",3717|6774,Strong (80%)
720,BRD-K76614248,atizoram,COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1,9861730,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,"","",5144|5141|5142|5143,No-Effect
721,BRD-K00521308,ATN-161,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,9960285,Phase 2,integrin antagonist,ITGA5|ITGAV|ITGB1|ITGB3,"","",3688|3690|3685|3678,No-Effect
722,BRD-K20141153,atomoxetine,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,54841,Launched,norepinephrine transporter inhibitor,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD),6530|114787|6531|6532|2903|2904|2905|2906|116443|116444,No-Effect
723,BRD-K69726342,atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1,60823,Launched,HMGCR inhibitor,AHR|DPP4|HMGCR,neurology/psychiatry|cardiology,stroke|heart attack,1803|196|3156,No-Effect
724,BRD-A85261566,atosiban,"CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|",,Launched,oxytocin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,neurology/psychiatry|cardiology|endocrinology,stroke|angina pectoris|myocardial infarction|hyperlipidemia,552|553|554|5021,Low (25%)
726,BRD-A65145453,ATPA,"CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|",11345201,Preclinical,glutamate receptor agonist,GRIK1,"","",2897,No-Effect
729,BRD-K16295392,atrasentan,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1,159594,Phase 3,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
730,BRD-K01825666,atropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,ophthalmology,cycloplegia|mydriasis|amblyopia,1128|1129|1131,No-Effect
731,BRD-K00004526,atropine-oxide,"C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|",,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,"","",1128|1129|1131|1132|1133,No-Effect
733,BRD-K45995181,auranofin,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,6918453,Launched,NFkB pathway inhibitor,IKBKB|PRDX5|TRPA1,rheumatology,rheumatoid arthritis,25824|8989|3551,No-Effect
734,BRD-K53561341,aurora-a-inhibitor-i,CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1,44139710,Preclinical,Aurora kinase inhibitor,AURKA,"","",6790,No-Effect
735,BRD-K00003601,aurothioglucose,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,6916934,Launched,PKC inhibitor,PRKCI,rheumatology,rheumatoid arthritis,5584,No-Effect
737,BRD-A94640958,autotaxin-modulator-1,"C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|",,Preclinical,autotaxin inhibitor,ENPP2,"","",5168,No-Effect
738,BRD-K23190681,AV-412,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,9806229,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,"","",2064|1956,No-Effect
739,BRD-K96615647,AV-608,FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12,9917079,Phase 2,tachykinin antagonist,TACR1,"","",6869,No-Effect
742,BRD-K83720053,avagacestat,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,46883536,Phase 2,gamma secretase inhibitor,PSEN1,"","",5663,No-Effect
743,BRD-K65781196,avanafil,COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl,9869929,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,8654,No-Effect
745,BRD-K67901620,avasimibe,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C,166558,Phase 3,ACAT inhibitor,CES1,"","",1066,No-Effect
746,BRD-K68544925,avatrombopag,OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1,9852519,Launched,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia,4352,No-Effect
747,BRD-K36154108,AVE-0991,CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1,9851724,Preclinical,angiotensin receptor agonist,MRGPRX1,"","",259249,No-Effect
752,BRD-K87782578,AVL-292,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,59174488,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,BTK|YES1,"","",7525|695,No-Effect
754,BRD-K62196610,AVN-944,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,9918559,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,"","",727833|3615,No-Effect
759,BRD-K29905972,axitinib,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1,6450551,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|FLT1|FLT4|KDR|PLK4,oncology,renal cell carcinoma (RCC),10733|3791|2321|2324|1435,No-Effect
761,BRD-K36258877,AZ-10417808,[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1,135665263,Preclinical,caspase inhibitor,CASP3,"","",836,No-Effect
762,BRD-K09907507,AZ-10606120,OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1,10310632,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,No-Effect
763,BRD-K05973499,AZ-12080282,Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1,25253556,Preclinical,hedgehog pathway inhibitor,DHH,"","",50846,No-Effect
764,BRD-K05804044,AZ-628,Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1,11676786,Preclinical,RAF inhibitor,BRAF|RAF1,"","",673|6037,No-Effect
766,BRD-K80935598,AZ191,COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1,72716071,Preclinical,DYRK inhibitor,DYRK1B,"","",9149,No-Effect
767,BRD-K42436189,AZ20,C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O,46244454,Preclinical,ATR kinase inhibitor,ATR|MTOR,"","",545|2475,No-Effect
769,BRD-K76244476,AZ505,Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12,24961094,Preclinical,histone lysine methyltransferase inhibitor,SMYD2,"","",56950,No-Effect
770,BRD-K81958169,AZ5104,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12,71496460,Preclinical,EGFR inhibitor,EGFR,"","",1956,Strong (80%)
772,BRD-K64888243,AZ960,C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1,25099184,Preclinical,JAK inhibitor,JAK2,"","",3717,No-Effect
773,BRD-K03406345,azacitidine,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,9444,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL),1786|1788,No-Effect
774,BRD-K97061094,azacyclonol,OC(C1CCNCC1)(c1ccccc1)c1ccccc1,15723,Preclinical,histamine receptor antagonist,HRH1,"","",3269,No-Effect
775,BRD-K53114651,azaguanine-8,Nc1nc2nn[nH]c2c(=O)[nH]1,135403646,Preclinical,purine antagonist,PNP,"","",5539,No-Effect
777,BRD-K45861246,azaperone,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,15443,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,sedative,1813|1814,No-Effect
778,BRD-A70182876,azapropazone,"CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|",6604340,Withdrawn,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
780,BRD-K01826751,azasetron,CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|,25271863,Launched,serotonin receptor antagonist,HTR3A|HTR3B,infectious disease,genitial herpes,9177|3359,No-Effect
781,BRD-K77821588,azatadine,CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12,19861,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,No-Effect
782,BRD-K32821942,azathioprine,Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O,2265,Launched,dehydrogenase inhibitor,HPRT1|IMPDH1|PPAT,transplant|rheumatology,renal homotransplantation|rheumatoid arthritis,727833|3251|80347,No-Effect
784,BRD-K61041538,AZD1080,O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N,10065474,Phase 1,glycogen synthase kinase inhibitor,GSK3A|GSK3B,"","",2931|2932,No-Effect
785,BRD-K21908111,AZD1208,N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1,58423153,Phase 1,Pim kinase inhibitor,PIM1|PIM2|PIM3,"","",11040|9361|415116,No-Effect
786,BRD-K77060810,AZD1283,CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1,23649325,Preclinical,purinergic receptor antagonist,P2RY12,"","",64805,No-Effect
788,BRD-A44188509,AZD1446,"Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|",96568205,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2,"","",1137|1141,No-Effect
789,BRD-K65928735,AZD1480,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1,16659841,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,"","",3716|3717|3718,No-Effect
790,BRD-K83186168,AZD1981,CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12,11292191,Phase 2,CRTH receptor antagonist,PTGDR2,"","",11251,No-Effect
791,BRD-K99113996,AZD2014,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,25262792,Phase 2,mTOR inhibitor,MTOR,"","",2475,Very Weak (35%)
794,BRD-K14287049,AZD3264,Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1,91666658,Preclinical,IKK inhibitor,IKBKB,"","",3551,No-Effect
795,BRD-K24593301,AZD3463,COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1,56599293,Preclinical,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,ALK|IGF1R,"","",3480|238,Weak (50%)
796,BRD-K84996356,AZD3514,CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|,46893585,Phase 1,androgen receptor modulator,AR,"","",367,No-Effect
797,BRD-K41626799,AZD3759,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,78209992,Phase 2/Phase 3,EGFR inhibitor,EGFR,"","",1956,No-Effect
798,BRD-K00004606,AZD3839,NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|,46202416,Phase 1,beta-secretase inhibitor,BACE1,"","",23621,No-Effect
799,BRD-K25210703,AZD3965,CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O,10369242,Phase 1,monocarboxylate transporter inhibitor,SLC16A1,"","",6566,No-Effect
800,BRD-K73984371,AZD3988,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|,,Preclinical,diacylglycerol kinase inhibitor,DGAT1,"","",8694,No-Effect
801,BRD-K72369578,AZD4282,NCC(O)=O,750,Phase 1,glutamate receptor antagonist,AGXT|AGXT2|ALAS1|ALAS2|BAAT|GARS|GATM|GCAT|GCSH|GLDC|GLRA1|GLRA2|GLRA3|GLRB|GLYAT|GLYATL1|GLYATL2|GNMT|GPR18|GPRC6A|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3B|GSS|PIPOX|SHMT1|SHMT2|SLC32A1|SLC36A1|SLC6A5|SLC6A9,"","",6530|92292|64902|140679|6536|10249|206358|2841|23464|2731|2741|2742|2743|570|189|8001|219970|2628|51268|6470|6472|222545|211|212|2903|2904|2905|2906|116444|2653|27232|114787|5621,No-Effect
802,BRD-K28392481,AZD4547,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1,51039095,Phase 2/Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR,"","",3480|3791|2260|2261|2263|2264,No-Effect
805,BRD-K00003297,AZD5069,C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,56645576,Phase 2,CC chemokine receptor antagonist,CXCR2,"","",3579,No-Effect
807,BRD-K99023089,AZD5363,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,25227436,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,No-Effect
808,BRD-K72414522,AZD5438,CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1,16747683,Phase 1,CDK inhibitor,KCNH2,"","",3757,Weak (50%)
809,BRD-K88767641,AZD5582,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1,49847690,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,"","",329|330|331,No-Effect
811,BRD-K58772419,AZD6482,C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,44137675,Phase 1,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,No-Effect
812,BRD-A36013532,AZD6738,"C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|",54761305,Phase 2,ATR kinase inhibitor,ATR,"","",545,No-Effect
813,BRD-A94033181,AZD6765,"N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|",9794203,Phase 2,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
814,BRD-K52836380,AZD7545,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1,16741245,Phase 1,pyruvate dehydrogenase kinase inhibitor,PDK1,"","",5170,No-Effect
816,BRD-K31495718,AZD7687,Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|,,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,"","",8694,No-Effect
817,BRD-K86525559,AZD7762,NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1,11152667,Phase 1,CHK inhibitor,CHEK1|CHEK2,"","",11200|1111,Cyto
819,BRD-K69932463,AZD8055,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,25262965,Phase 1,mTOR inhibitor,MTOR,"","",2475,No-Effect
820,BRD-K47289408,AZD8186,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C,52913813,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,"","",5291|22883,No-Effect
821,BRD-K37687095,AZD8330,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,16666708,Phase 1,MEK inhibitor,MAP3K1,"","",4214,No-Effect
823,BRD-K82894950,AZD8835,CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO,76685059,Phase 1,PI3K inhibitor,PIK3CA|PIK3CD,"","",5290|22883,No-Effect
824,BRD-K98572433,AZD8931,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,11488320,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB3,"","",2064|2065|1956,No-Effect
827,BRD-K73235735,AZD9496,C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F,86287635,Phase 1,estrogen receptor agonist,ESR1,"","",2099,No-Effect
828,BRD-K31476763,AZD9668,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,46861623,Phase 2,elastase inhibitor,ELANE,"","",1991,No-Effect
829,BRD-K08976401,azelaic-acid,OC(=O)CCCCCCCC(O)=O,2266,Launched,tyrosinase inhibitor,AKR1D1|SRD5A2|TYR,dermatology,rosacea,7299|6716|6718,No-Effect
830,BRD-A68888262,azelastine,CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|,12831281,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269,No-Effect
831,BRD-K51899933,azeliragon,CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1,11180124,Phase 3,RAGE receptor antagonist,AGER,"","",177,No-Effect
832,BRD-A01098288,azelnidipine,"CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|",9873077,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension,775,Low (25%)
833,BRD-K81074237,azilsartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,135415867,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension,185|186,Very Weak (35%)
834,BRD-K25723200,azilsartan-medoxomil,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,135409642,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension,185|186,Weak (50%)
835,BRD-K38913877,azimilide,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,9571004,Phase 3,potassium channel blocker,KCNA5,"","",3741,Very Weak (35%)
836,BRD-K74501079,azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,71206984,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,pelvic inflammatory disease|pneumonia,2862,No-Effect
838,BRD-K51329597,AZM-475271,COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,5330175,Preclinical,SRC inhibitor,SRC,"","",6714,No-Effect
841,BRD-K68770713,azosemide,NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl,2273,Launched,electrolyte reabsorption inhibitor,SLC12A1|SLC12A2,cardiology,edema,6557|6558,Low (25%)
844,BRD-K14079729,bacitracin,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|,,Launched,bacterial cell wall synthesis inhibitor,IDE,infectious disease,first-aid antibiotic,3416,No-Effect
846,BRD-K01826724,baclofen,NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|,6923772,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,neurology/psychiatry,multiple sclerosis|spasms,9568|115207|10537|57528|386617,No-Effect
848,BRD-K82196541,bafetinib,CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1,11387605,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,ABL1|BCR|LYN,"","",25|4067|106480993,Weak (50%)
850,BRD-K00652956,BAG-956,Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1,24882589,Preclinical,phosphoinositide dependent kinase inhibitor,PIK3CG,"","",5294,Very Weak (35%)
851,BRD-K72327355,baicalein,Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1,,Preclinical,lipoxygenase inhibitor,ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH,"","",6402|5550|6414|240|2739|7124|6652,No-Effect
852,BRD-K49962337,baicalin,O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O,,Launched,beta glucuronidase inhibitor,PREP,neurology/psychiatry,anxiety,5550,Very Weak (35%)
853,BRD-K09785578,bakuchiol,CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1,5468522,Phase 2,DNA polymerase inhibitor,HIF1A,"","",3091,No-Effect
854,BRD-A00147595,balaglitazone,Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|,76968728,Phase 3,insulin sensitizer|PPAR receptor partial agonist,PPARG,"","",5468,No-Effect
856,BRD-K27204852,balicatib,CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N,10201696,Phase 2,cathepsin inhibitor,CTSK,"","",1513,Strong (80%)
860,BRD-K00003656,balsalazide,OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O,,Launched,cyclooxygenase inhibitor,ALOX5|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis,240|5468|5742|5743,No-Effect
861,BRD-K07442505,BAM7,CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|,,Preclinical,BAX activator,BAX,"","",581,No-Effect
863,BRD-A17462676,bambuterol,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,57515921,Launched,adrenergic receptor agonist,ADRB2|BCHE,pulmonary,asthma,154|590,No-Effect
864,BRD-K47049295,BAN-ORL-24,O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1,10296561,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,"","",4987,No-Effect
865,BRD-K00003159,banoxantrone,C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12,9955116,Phase 1/Phase 2,topoisomerase inhibitor,TOP2A,"","",7153,No-Effect
866,BRD-K31928526,barasertib,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O,11497983,Phase 2/Phase 3,Aurora kinase inhibitor,AURKA|AURKB,"","",9212|6790,No-Effect
867,BRD-K63923597,barasertib-HQPA,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,16007391,Phase 2/Phase 3,Aurora kinase inhibitor,AURKB,"","",9212,No-Effect
868,BRD-K20545304,bardoxolone,"CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|",400010,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,NOS2|PPARG,"","",339345|5468,Strong (80%)
869,BRD-K69694239,bardoxolone-methyl,"COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|",400769,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,PPARG|STAT3,"","",5468|6774,Strong (80%)
870,BRD-K53581288,baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,44205240,Launched,JAK inhibitor,JAK1|JAK2,rheumatology,rheumatoid arthritis,3716|3717,No-Effect
874,BRD-K62387885,basimglurant,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,11438771,Phase 2,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
877,BRD-K82818427,batimastat,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO,5362422,Phase 3,matrix metalloprotease inhibitor,ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8,"","",4321|4325|10863|11096|4313|4317,No-Effect
878,BRD-K79595931,bavisant,O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1,16061509,Phase 2,histamine receptor antagonist,HRH3,"","",11255,No-Effect
879,BRD-K01826533,BAX-channel-blocker,O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|,981054,Preclinical,cytochrome C release inhibitor,BAX,"","",581,Strong (80%)
880,BRD-K15025317,BAY-11-7082,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,5353431,Preclinical,NFkB pathway inhibitor,RELA,"","",5970,No-Effect
881,BRD-K48684885,BAY-11-7085,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,5353432,Preclinical,NFkB pathway inhibitor,NFKBIA,"","",4792,No-Effect
886,BRD-K32033120,BAY-41-2272,Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12,9798973,Preclinical,guanylyl cyclase activator,GUCY1A3|GUCY1B3,"","",2982|2983,No-Effect
887,BRD-K32952627,BAY-60-6583,NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N,11717831,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
888,BRD-K86932920,BAY-60-7550,COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC,135564787,Preclinical,phosphodiesterase inhibitor,PDE2A,"","",5138,No-Effect
889,BRD-K53281329,BAY-61-3606,COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1,10200390,Preclinical,SYK inhibitor,SYK,"","",6850,No-Effect
892,BRD-K70463136,BAY-87-2243,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,67377767,Phase 1,hypoxia inducible factor inhibitor,HIF1A,"","",3091,No-Effect
894,BRD-K14329163,BAY-K-8644-(s)-(-),"COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|",6603728,Preclinical,L-type calcium channel activator,CACNA1C,"","",775,No-Effect
898,BRD-K66830666,BAZ2-ICR,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1,91654625,Preclinical,bromodomain inhibitor,ZNF215,"","",7762,No-Effect
899,BRD-K90195324,bazedoxifene,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,154257,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|endocrinology,osteoporosis|menopause,2099|2100,No-Effect
900,BRD-K14646328,BC-11,NC(=N)SCc1ccc(cc1)B(O)O,60126757,Preclinical,urokinase inhibitor,PLAU,"","",5328,No-Effect
902,BRD-K66541497,BCTC,CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1,9929425,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
903,BRD-K90472149,BCX-1470,NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1,9822205,Phase 1,complement inhibitor|serine protease inhibitor,CFD,"","",200576,No-Effect
905,BRD-K36864847,BD-1047,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,188914,Preclinical,adrenergic receptor antagonist,SIGMAR1,"","",10280,No-Effect
906,BRD-K29668683,BD-1063,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,574780,Preclinical,sigma receptor antagonist,SIGMAR1,"","",10280,No-Effect
907,BRD-A24429032,BE-2254,Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|,86308637,Phase 2,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
911,BRD-A73385064,beclomethasone,"C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|",,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908,No-Effect
912,BRD-K97810537,beclomethasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|",21700,Launched,glucocorticoid receptor agonist,GPR97|NR3C1,allergy,allergic rhinitis,2908|222487,No-Effect
915,BRD-K58319700,begacestat,OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F,11269353,Phase 1,gamma secretase inhibitor,PSEN1,"","",5663,No-Effect
917,BRD-K17743125,belinostat,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,6918638,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,peripheral T-cell lymphoma (PTCL),55869|9734|8841|10013|79885|3065|3066|83933|10014|9759,Cyto
920,BRD-K14993104,bemegride,CCC1(C)CC(=O)NC(=O)C1,2310,Launched,chemoreceptor agonist,GABRA1,critical care,poison antidote,2554,No-Effect
921,BRD-K00004211,bemesetron,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|",,Phase 3,serotonin receptor antagonist,HTR3A|HTR3B,"","",9177|3359,No-Effect
923,BRD-K63177377,bempedoic-acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,10472693,Launched,AMPK inhibitor,ACLY,"","",47,Very Weak (35%)
926,BRD-K49807096,benazepril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O,5362124,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
928,BRD-K19515365,bendazac,OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,2313,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743,No-Effect
930,BRD-A80017228,bendroflumethiazide,"NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|",9845085,Launched,sodium/potassium/chloride transporter inhibitor,SLC12A1|SLC12A3,cardiology,hypertension,6557|6559,No-Effect
932,BRD-K00003672,benfluorex,C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|,6604374,Withdrawn,gluconeogenesis inhibitor,HMGCR,"","",3156,No-Effect
933,BRD-K33903083,benfluralin,CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O,2319,Phase 3,"",CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1,"","",54658|6822|1543|1544|1576|2099|1555|4312,No-Effect
934,BRD-K05319475,benfotiamine,C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1,3032771,Launched,antioxidant,AGER,rheumatology,lumbago,177,No-Effect
935,BRD-K97181463,benidipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1,656667,Launched,calcium channel blocker,CACNA1C|CACNA1G,cardiology,hypertension,8913|775,No-Effect
936,BRD-K79425933,benperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,16363,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,1813,No-Effect
937,BRD-K01826024,benproperine,"C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|",14456347,Launched,antitussive,SCN5A,pulmonary,cough suppressant,6331,No-Effect
938,BRD-A61194565,benserazide,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,657280,Launched,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,1644,No-Effect
939,BRD-K58794715,bentiromide,OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1,6957673,Launched,"",HPN,gastroenterology,pancreas diagnostic agent,3249,Very Weak (35%)
942,BRD-K87158025,benzamil,NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N,108107,Phase 2,sodium channel blocker,ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1,"","",6337|6338|6339|6340|9033|41|6546,No-Effect
943,BRD-K11717138,benzbromarone,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,2333,Launched,chloride channel blocker,ABCC1,rheumatology,gout,4363,No-Effect
945,BRD-K72723676,benzethonium,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,2335,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,6336,No-Effect
948,BRD-K75466013,benzocaine,CCOC(=O)c1ccc(N)cc1,2337,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,6336,Very Weak (35%)
951,BRD-K53397409,benzoic-acid,OC(=O)c1ccccc1,243,Launched,food preservative,DAO|HRSP12|PRDX5|RAB9A,infectious disease,tinea pedis,25824|26|9367|10247,No-Effect
952,BRD-A55748233,benzoin,"O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|",640038,Preclinical,"",CES1,"","",1066,No-Effect
953,BRD-K91699951,benzonatate,CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,7699,Launched,local anesthetic,SCN5A,pulmonary,cough suppressant,6331,No-Effect
954,BRD-K18772613,benzoquinonium-dibromide,"CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|",9394,Preclinical,cholinergic receptor antagonist,CHRNA1,"","",1134,No-Effect
955,BRD-K33219230,benzotript,OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,2060890,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,"","",886|887,No-Effect
959,BRD-K21450440,benzthiazide,NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl,132458842,Launched,carbonic anhydrase inhibitor,CA2,cardiology,hypertension|edema,760,No-Effect
960,BRD-K68804560,benztropine-mesylate,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|HRH1|SLC6A3,neurology/psychiatry,extrapyramidal symptoms (EPS)|Parkinson's Disease,1128|6531|3269,Low (25%)
963,BRD-K52072429,benzyl-benzoate,O=C(OCc1ccccc1)c1ccccc1,2345,Launched,lipase inhibitor,LIPE,allergy,sweet itch,3991,No-Effect
969,BRD-K98624455,bepotastine,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,25273609,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269,Low (25%)
970,BRD-A91008255,bepridil,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,50088,Launched,calcium channel blocker,KCNQ4,cardiology,angina pectoris,9132,No-Effect
971,BRD-K14796088,berberine,COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC,2353,Launched,LDL receptor activator,LDLR,"","",3949,No-Effect
973,BRD-K04176066,bergenin,COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O,66065,Preclinical,interleukin inhibitor,IL1B|TNF,"","",3553|7124,No-Effect
976,BRD-K38687824,beta-amyloid-synthesis-inhibitor,Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,9882580,Preclinical,beta amyloid synthesis inhibitor,APP,"","",351,No-Effect
978,BRD-K87349602,beta-CCB,CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,128618,Launched,benzodiazepine receptor ligand,GABRA1|GABRG2,"","",2554|2566,No-Effect
979,BRD-K21045639,beta-elemene,CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C,6918391,Launched,apoptosis stimulant,MMP2|MMP9,"","",4313|4318,No-Effect
980,BRD-K95110148,beta-funaltrexamine,COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45,5311018,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
982,BRD-M02899238,beta-hydroxy-beta-methylbutyrate,CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O,129010087,Launched,protein synthesis stimulant,MTOR,"","",2475,No-Effect
983,BRD-A41387824,beta-hydroxybutyrate,CC(O)CC(O)=O,441,Phase 1,"",HCAR2,"","",338442,No-Effect
984,BRD-K28061410,beta-lapachone,CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|,3885,Phase 2,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
986,BRD-K91315211,betahistine,CNCCc1ccccn1,2366,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1|HRH3,neurology/psychiatry,Meniere's disease,3269|11255,Very Weak (35%)
988,BRD-K39188321,betamethasone,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",9782,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
989,BRD-K00025439,betamethasone-acetate,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|",443967,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
991,BRD-K58148589,betamethasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|",21800,Launched,anti-inflammatory agent,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,Low (25%)
993,BRD-K34032314,betamethasone-valerate,"CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|",16533,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
995,BRD-K01825592,betaxolol,"CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|",6093355,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,153|154,No-Effect
996,BRD-K20075662,betazole,NCCc1ccn[nH]1,7741,Launched,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic,1665,No-Effect
997,BRD-K00003637,bethanechol,C[C@@H](C[N+](C)(C)C)OC(N)=O |r|,6603779,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,urology,urinary retention,1128|1129|1131|1132,Low (25%)
998,BRD-K00004305,BETP,"CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|",97182196,Preclinical,GLP receptor positive allosteric modulator,GLP1R,"","",2740,No-Effect
999,BRD-K45275534,betrixaban,COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1,10275777,Launched,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT),3757,No-Effect
1000,BRD-K45401373,betulinic-acid,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,64971,Phase 1/Phase 2,apoptosis stimulant|NFkB pathway inhibitor,GPBAR1,"","",151306,No-Effect
1005,BRD-K92441787,bexarotene,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,82146,Launched,retinoid receptor agonist,RXRA|RXRB|RXRG,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),6256|6257|6258,No-Effect
1006,BRD-K46018455,bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,39042,Launched,PPAR receptor agonist,PPARA|PPARD|PPARG,cardiology,cholesterol,5465|5467|5468,No-Effect
1009,BRD-K29415052,BGT226,COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1,11978790,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CG,"","",5290|2475|5291|5294,Low (25%)
1010,BRD-K95603879,BHQ,CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C,2374,Preclinical,ATPase inhibitor,ATP2A1,"","",487,No-Effect
1012,BRD-K64890080,BI-2536,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,11364421,Phase 2,PLK inhibitor,BRD4|PLK1|PLK2|PLK3,"","",10769|5347|23476|1263,Cyto
1014,BRD-K73982490,BI-78D3,[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1,2747117,Preclinical,JNK inhibitor,MAPK8,"","",5599,No-Effect
1015,BRD-K37492701,BI-847325,CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1,,Phase 1,Aurora kinase inhibitor|MEK inhibitor,AURKA|AURKB|AURKC|MAP2K1|MAP2K2,"","",5604|5605|6790|6795|9212,No-Effect
1016,BRD-A81370665,BI-D1870,"CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|",44141268,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6,"","",27330|6195|6196|6197,Cyto
1019,BRD-K43927145,BIBN4096,NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1,6918509,Phase 2,calcitonin antagonist,CALCA|CALCRL|RAMP1,"","",10267|10203|796,No-Effect
1020,BRD-K04623885,BIBR-1532,C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1,9927531,Preclinical,telomerase inhibitor,TERT,"","",7015,Low (25%)
1021,BRD-K49294207,BIBU-1361,CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,17756796,Preclinical,EGFR inhibitor,EGFR,"","",1956,Weak (50%)
1022,BRD-K70914287,BIBX-1382,CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,6918508,Phase 1,EGFR inhibitor,EGFR|ERBB2,"","",2064|1956,Weak (50%)
1023,BRD-A29485665,bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|,2375,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367,Low (25%)
1026,BRD-K84363966,bicuculline-(+),CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21,10237,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1,"","",3780|2554|2555|2556|2557|2558|2559,No-Effect
1028,BRD-K16546375,bicyclol,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO,9821754,Launched,NFkB pathway inhibitor,HSPA1A|HSPB1,infectious disease,hepatitis B|hepatitis C,3315|3303,No-Effect
1029,BRD-K18779551,bifemelane,CNCCCCOc1ccccc1Cc1ccccc1,2377,Launched,acetylcholine release enhancer,MAOA|MAOB,ophthalmology|neurology/psychiatry,glaucoma|senile dementia,4128|4129,No-Effect
1032,BRD-K51967704,BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,16736529,Phase 2,HSP inhibitor,HSP90AA1,"","",3320,Weak (50%)
1033,BRD-K51937257,bilastine,CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1,40467029,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269,No-Effect
1034,BRD-K32039267,bilobalide,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123,73581,Preclinical,GABA receptor modulator,GLRA1|GLRA2|GLRB|HTR3A|HTR3B,"","",2741|2742|2743|9177|3359,No-Effect
1035,BRD-K00003616,bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1,5311027,Launched,prostanoid receptor agonist,AKR1C3|PTGER1|PTGER3|PTGFR,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,5737|5731|8644|5733,No-Effect
1036,BRD-K00004300,BIMU-8,"CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|",,Preclinical,serotonin receptor agonist,HTR4,"","",3360,Low (25%)
1037,BRD-K00004296,BINA,"Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|",86311024,Preclinical,glutamate receptor positive allosteric modulator,GRM2,"","",2912,No-Effect
1038,BRD-K36467523,bindarit,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,71354,Phase 2,NFkB pathway inhibitor,CCL2|CCL7|CCL8,"","",6354|6347|6355,No-Effect
1039,BRD-K82244583,binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,10288191,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma,5604|5605,No-Effect
1040,BRD-K03399463,BIO-1211,CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O,9961766,Phase 2,integrin antagonist,ITGA4|ITGB1,"","",3688|3676,No-Effect
1041,BRD-K21318844,BIO-5192,CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O,10350459,Preclinical,integrin inhibitor,ITGA4|ITGB1,"","",3688|3676,No-Effect
1042,BRD-K89210380,biotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,171548,Launched,vitamin B,ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6,"","",32|5091|3141|5095|5096|8884|64087|56922|31,No-Effect
1043,BRD-K47690382,bipenamol,NCc1ccccc1Sc1ccccc1CO,43961,Phase 2,dipeptidyl peptidase inhibitor,CTSC,"","",1075,No-Effect
1044,BRD-K01824983,biperiden,"O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|",12147323,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,neurology/psychiatry,Parkinson's Disease,1128|1129|1131|1132|1133,Very Weak (35%)
1045,BRD-K71221037,birinapant,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC,49836020,Phase 2,XIAP inhibitor,BIRC2|XIAP,"","",329|331,No-Effect
1046,BRD-K64880136,BIRT-377,CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1,9803375,Preclinical,lymphocyte function-associated antigen negative modulator,ICAM1,"","",3383,No-Effect
1047,BRD-K16180792,bis(maltolato)oxovanadium(IV),Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,3035454,Phase 2,tyrosine phosphatase inhibitor,PTPN1,"","",5770,No-Effect
1050,BRD-K06543683,bisindolylmaleimide-IX,Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|,5083,Preclinical,PKC inhibitor,AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1,"","",5600|5578|6093|207|6300|23411|2932|6198|1432|5594|3932|5599,No-Effect
1053,BRD-K65978409,bismuth-subgallate,O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O,73415769,Launched,nitric oxide synthase inhibitor,NOS1,gastroenterology,internal deoderant,340719,No-Effect
1057,BRD-A89175223,bisoprolol,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|,6604464,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153,No-Effect
1058,BRD-K41494493,bisphenol-A,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,6623,Phase 1,synthetic estrogen,AR|ESR1|ESR2|ESRRG|PPARG,"","",367|2099|2100|2104|5468,No-Effect
1059,BRD-K39120595,bithionol,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,2406,Withdrawn,autotaxin inhibitor,ESR1|ESR2|MCL1,"","",4170|2099|2100,Weak (50%)
1060,BRD-K13756951,bitopertin,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,24946690,Phase 3,glycine transporter inhibitor,SLC6A5|SLC6A9,"","",6536|6530,No-Effect
1062,BRD-K73504359,bivalirudin,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O,73952246,Launched,thrombin inhibitor,F2,cardiology,angina pectoris,2147,No-Effect
1063,BRD-K26818574,BIX-01294,COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1,25150857,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,Strong (80%)
1064,BRD-K20290250,BIX-02188,CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1,,Preclinical,MEK inhibitor,MAP2K5,"","",5607,No-Effect
1065,BRD-K73368362,BIX-02189,CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1,,Preclinical,MEK inhibitor,MAP2K5|MAPK7,"","",5598|5607,No-Effect
1068,BRD-A75817871,blebbistatin-(+/-),"Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|",5287792,Preclinical,ATPase inhibitor,MYH14|MYH2,"","",57644|4620,Low (25%)
1071,BRD-K25943794,blonanserin,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,125564,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813,No-Effect
1072,BRD-K72898849,BLU9931,COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1,72710839,Preclinical,FGFR inhibitor,FGFR4,"","",2264,No-Effect
1074,BRD-K94379058,BML-190,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1,2415,Preclinical,cannabinoid receptor inverse agonist,CNR2,"","",56142,No-Effect
1076,BRD-K56509348,BMS-182874,CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C,122272,Phase 2,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
1077,BRD-K95609758,BMS-191011,Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F,10474339,Preclinical,potassium channel activator,KCNMA1,"","",3778,No-Effect
1081,BRD-K62814476,BMS-265246,CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F,5329775,Preclinical,CDK inhibitor,CDK1|CDK2,"","",1017|983,No-Effect
1083,BRD-K87956243,BMS-309403,CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1,16122583,Preclinical,fatty acid binding protein inhibitor,FABP4,"","",2167,No-Effect
1084,BRD-K13566078,BMS-345541,Cc1cnc2c(NCCN)nc3ccc(C)cc3n12,9813758,Preclinical,IKK inhibitor,CHUK|IKBKB,"","",1147|3551,No-Effect
1085,BRD-K43389698,BMS-387032,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,3025986,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK2|CDK7|CDK9,"","",1025|1017|1022,No-Effect
1086,BRD-K22000702,BMS-470539,CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1,9915813,Preclinical,melanocortin receptor agonist,MC1R,"","",4157,Low (25%)
1087,BRD-K34581968,BMS-536924,Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1,135440466,Preclinical,IGF-1 inhibitor,AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB,"","",898|5156|5159|1576|207|2064|3791|3480|1017|5594|8731|3932,No-Effect
1088,BRD-K56932272,BMS-566419,CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F,9913339,Preclinical,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,"","",727833|3615,Strong (80%)
1090,BRD-K20093108,BMS-587101,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,11635371,Phase 2,integrin antagonist,ITGAL|ITGB2,"","",3689|3683,No-Effect
1091,BRD-K07106112,BMS-599626,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12,10437018,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,EGFR|ERBB2|ERBB4,"","",2064|2066|1956,No-Effect
1094,BRD-K25991633,BMS-649,CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O,127019,Preclinical,retinoid receptor agonist,RXRA,"","",6256,No-Effect
1095,BRD-K85649978,BMS-688521,CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1,11699447,Preclinical,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,ICAM1,"","",3383,No-Effect
1096,BRD-K76239644,BMS-690514,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,11349170,Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|FLT3|KDR,"","",2064|2322|1956|3791,No-Effect
1098,BRD-K13049116,BMS-754807,C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1,24785538,Phase 2,IGF-1 inhibitor,AKT1|IGF1R,"","",3480|207,No-Effect
1100,BRD-K40738845,BMS-777607,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,24794418,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,AXL|MERTK|MET|MST1R|TYRO3,"","",7301|4486|558|8731|10461,No-Effect
1104,BRD-K81026553,BMS-817378,Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,44137813,Phase 1,c-Met inhibitor|VEGFR inhibitor,KDR|MET,"","",8731|3791,No-Effect
1105,BRD-K33245965,BMS-833923,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,57662985,Phase 2,smoothened receptor antagonist,SMO,"","",54498,Very Weak (35%)
1106,BRD-K12511835,BMS-863233,Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1,135564632,Phase 1/Phase 2,CDC inhibitor,CDC7|PIM1,"","",9361|8317,No-Effect
1111,BRD-K00004586,BMS-986020,C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1,49792850,Phase 2,lysophosphatidic acid receptor antagonist,LPAR1,"","",1902,No-Effect
1116,BRD-K15119094,BMS-CCR2-22,CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F,24801690,Preclinical,CC chemokine receptor antagonist,CCR2,"","",729230,No-Effect
1117,BRD-A15435692,BMY-14802,O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|,10020651,Phase 2,sigma receptor antagonist,HTR1A,"","",3350,No-Effect
1118,BRD-K84895041,BMY-45778,OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1,127861,Preclinical,IP1 prostacyclin receptor agonist,PTGIR,"","",5739,No-Effect
1119,BRD-K31054881,BMY-7378,COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,2419,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A,"","",146|147|3350,No-Effect
1121,BRD-K18722736,BNTX,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1,5310988,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
1122,BRD-A09735281,boceprevir,"CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|",10324368,Launched,HCV inhibitor,CMA1|CTSA|CTSF|CTSK|CTSL|CTSS,infectious disease,hepatitis C,5476|1513|1514|1520|8722|1215,No-Effect
1127,BRD-K88510285,bortezomib,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,387447,Launched,NFkB pathway inhibitor|proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL),106480180|5682|5683|5684|5685|5686|5687|5688|5689|5690|5691|5692|5693|5694|5695|5696|5698|5699|5708|122706|5970|143471,Cyto
1129,BRD-K74763371,bosentan,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,104865,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910,No-Effect
1130,BRD-K99964838,bosutinib,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,5328940,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML),6789|6793|2444|25|57118|11183|818|6714|10188|106480993|4067|5604|5605|2534|8428|3055|1017|10746|7294,No-Effect
1131,BRD-K45479396,BP-554,C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1,134117,Preclinical,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
1132,BRD-K17378184,BP-897,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,3038495,Phase 2,dopamine receptor agonist,ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B,"","",1815|146|1812|1813|150|1814|3350|106480180,No-Effect
1133,BRD-K00003554,BQ-123,[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C,443289,Phase 2,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
1134,BRD-K02490038,BQ-788,CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O,5311032,Phase 1,endothelin receptor antagonist,EDNRB,"","",1910,No-Effect
1135,BRD-A40257118,BQU57,"Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|",,Preclinical,Ras GTPase inhibitor,RALA|RALB,"","",5898|5899,No-Effect
1136,BRD-K72264770,BRD4770,COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1,72193870,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,"","",10919,No-Effect
1137,BRD-K15107389,BRD7389,O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23,1080352,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3,"","",6195|6196|6197,No-Effect
1138,BRD-K89329876,BRD9876,CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N,613000,Preclinical,kinesin inhibitor,KIF11,"","",3832,No-Effect
1139,BRD-K77841042,brefeldin-A,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|",5287620,Preclinical,protein synthesis inhibitor,ARF1|CYTH2,"","",9266|442334,Cyto
1140,BRD-K06328344,bremelanotide,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O,,Launched,melanocortin receptor agonist,MC1R|MC2R|MC3R|MC4R|MC5R,neurology/psychiatry,hypoactive sexual desire disorder,4160|4161|4157|4158|4159,No-Effect
1141,BRD-K96123349,brequinar,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,57030,Phase 2,dihydroorotate dehydrogenase inhibitor,DHODH,"","",1723,Strong (80%)
1142,BRD-K96936751,bretazenil,CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21,107926,Phase 2,GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,"","",2554|2555|2556|2557|2558|2559,Very Weak (35%)
1143,BRD-K49669424,bretylium,CC[N+](C)(C)Cc1ccccc1Br,2431,Launched,norepinephrine inhibitor,ATP1A1,cardiology,ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT),476,No-Effect
1144,BRD-K00911143,brexpiprazole,O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1,11978813,Launched,dopamine receptor partial agonist,DRD2,neurology/psychiatry,depression|schizophrenia,1813,No-Effect
1145,BRD-K05531427,briciclib,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1,11248490,Phase 1,cyclin D inhibitor,CCND1,"","",595,Weak (50%)
1146,BRD-K56981171,brigatinib,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1,68165256,Launched,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,ALK|EGFR,oncology,non-small cell lung cancer (NSCLC),1956|238,Very Weak (35%)
1148,BRD-K68264559,brimonidine,Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|,2435,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,152|150|151,No-Effect
1150,BRD-K74913225,brinzolamide,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,68844,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA5A|CA7,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,771|23632|759|760|762|763|766,No-Effect
1151,BRD-K28428262,brivanib,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,11234052,Phase 3,FGFR inhibitor|VEGFR inhibitor,CYP3A4|FGFR1|FLT1|KCNH2|KDR,"","",1576|3757|3791|2321|2260,No-Effect
1152,BRD-K57187269,brivanib-alaninate,C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N,11154925,Phase 3,FGFR inhibitor|VEGFR inhibitor,FGFR3,"","",2261,No-Effect
1154,BRD-K01826777,BRL-15572,O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|,92844253,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,"","",3362|106480180|3350|3351|3352|3354|3355|3356|3358,No-Effect
1155,BRD-A57806482,BRL-26314,"OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|",14259155,Phase 1,cholesterol inhibitor,LPL,"","",3936,No-Effect
1156,BRD-K07507905,BRL-37344,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,9841972,Phase 2,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
1157,BRD-K01825677,BRL-44408,"C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|",6604824,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,"","",152|150|151,No-Effect
1159,BRD-A37347161,BRL-52537,Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|,14810948,Preclinical,opioid receptor agonist,OPRK1,"","",4986,No-Effect
1160,BRD-K17868609,BRL-54443,CN1CCC(CC1)c1c[nH]c2ccc(O)cc12,2438,Preclinical,serotonin receptor agonist,HTR1E|HTR1F,"","",3354|3355,No-Effect
1161,BRD-K76021681,brolitene,OCCNC(=O)\C=C\c1ccccc1,1550874,Launched,muscle relaxant,RYR1,rheumatology,lumbago,6261,Cyto
1164,BRD-K47679368,bromfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1,60726,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
1168,BRD-K14496212,bromocriptine,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|,31101,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,endocrinology|neurology/psychiatry,hyperprolactinemia|Parkinson's Disease|acromegaly,3352|3362|3363|1815|1816|146|147|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,No-Effect
1169,BRD-K73642618,bromopride,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,2446,Launched,dopamine receptor antagonist,DRD2,gastroenterology,nausea|vomiting|gastroesophageal reflux disease (GERD),1813,No-Effect
1171,BRD-K78643075,bromperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,2448,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,1813,No-Effect
1172,BRD-K01825159,brompheniramine,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|,16960,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold,3269,No-Effect
1176,BRD-A08316590,broxaterol,"CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|",13626987,Phase 3,adrenergic receptor agonist,ADRB2,"","",154,No-Effect
1181,BRD-K31313613,BS-181,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,49867929,Preclinical,CDK inhibitor,CDK7,"","",1022,No-Effect
1183,BRD-K37933329,BTB06584,[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1,2799764,Preclinical,ATPase inhibitor,ATP5F1,"","",515,No-Effect
1184,BRD-K89000287,BTB1,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1,291461,Preclinical,mitotic kinesin inhibitor,KIF18A,"","",81930,No-Effect
1187,BRD-A68304895,BTS-54505,CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|,9900576,Withdrawn,dopamine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,"","",6530|6531|6532,No-Effect
1189,BRD-A65793993,BTS-72664,"C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|",1480409,Phase 1,GABA receptor antagonist,GABBR1,"","",10537,No-Effect
1190,BRD-K01492390,BTT-3033,CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1,49841251,Preclinical,integrin inhibitor,ITGA2|ITGB1,"","",3688|3673,No-Effect
1192,BRD-K55344148,BU-224,C1CN=C(N1)c1ccc2ccccc2n1 |c:2|,2457,Preclinical,imidazoline receptor ligand,MAOA|MAOB,"","",4128|4129,No-Effect
1197,BRD-A94624445,bucladesine,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",9687,Launched,adenosine receptor agonist|cAMP stimulant,PRKACA,dermatology,skin ulcer,5578,No-Effect
1199,BRD-A91444184,buclizine,CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|,3246096,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,migraine headache,3269,No-Effect
1200,BRD-A34299591,budesonide,"CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|",63006,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology,Crohn's disease,2908,No-Effect
1201,BRD-K18324993,budipine,CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1,68778,Launched,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease,114787,No-Effect
1202,BRD-K36660044,bufexamac,CCCCOc1ccc(CC(=O)NO)cc1,2466,Withdrawn,cyclooxygenase inhibitor,HDAC10|HDAC6,"","",10013|83933,No-Effect
1203,BRD-K19462402,buflomedil,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,2467,Launched,adrenergic receptor antagonist|calcium channel blocker,ADRA1A,cardiology,peripheral artery disease (PAD),146,No-Effect
1204,BRD-K38197229,bumetanide,CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O,2471,Launched,solute carrier family member inhibitor,CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5,cardiology,edema|congestive heart failure,6560|2859|1080|57468|6557|6558,No-Effect
1205,BRD-K35034482,bunazosin,CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,2472,Launched,adrenergic receptor antagonist,ADRA1A,ophthalmology,glaucoma|intraocular pressure,146,No-Effect
1206,BRD-K42191735,buparlisib,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,16654980,Phase 3,PI3K inhibitor,PIK3CA|PIK3CG,"","",5290|5294,Cyto
1208,BRD-A36267905,buphenine,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,657392,Launched,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,154,No-Effect
1209,BRD-K51700582,bupicomide,CCCCc1ccc(nc1)C(N)=O,31447,Phase 1,adrenergic receptor antagonist,ADRB1,"","",153,No-Effect
1210,BRD-K00003636,bupivacaine,"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|",92253,Launched,sodium channel blocker,KCNA5|SCN10A,neurology/psychiatry,peripheral nerve block|caudal epidural block|lumbar epidural block,6336|3741,No-Effect
1211,BRD-A48420483,bupranolol,"Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|",66601885,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology|ophthalmology,hypertension|glaucoma,153|154|155,No-Effect
1212,BRD-K01826729,bupropion,"C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|",688387,Launched,dopamine reuptake inhibitor,SLC6A2|SLC6A3,neurology/psychiatry,depression,6530|6531,No-Effect
1215,BRD-K93461745,buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,2477,Launched,serotonin receptor agonist,DRD2|HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD),1813|3350,No-Effect
1217,BRD-K40581315,butabindide,CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC,9817923,Preclinical,tripeptidyl peptidase inhibitor,TPP2,"","",7174,No-Effect
1219,BRD-K20620780,butaclamol,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,37459,Phase 2,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A,"","",1812|1813|1814|1815|1816|3350|3356,No-Effect
1220,BRD-K71350836,butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,2481,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,headache|muscle relaxant,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559,Very Weak (35%)
1223,BRD-K17497770,butein,Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1,5281222,Preclinical,EGFR inhibitor|SRC inhibitor,ACE,"","",1636,Weak (50%)
1224,BRD-K90630139,butenafine,CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12,2484,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis,6713,No-Effect
1225,BRD-A47706533,buthionine-sulfoximine,"CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|",1548918,Phase 1,glutathione transferase inhibitor,GCLM,"","",2730,No-Effect
1231,BRD-K53153417,butylated-hydroxytoluene,Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,31404,Phase 1,carbonic anhydrase inhibitor,CA2,"","",760,No-Effect
1233,BRD-A59378440,butylphthalide,"CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|",9990075,Launched,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke,3776,Weak (50%)
1236,BRD-K01742705,BVT-2733,CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1,6918651,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,"","",3292,No-Effect
1237,BRD-K68567222,BVT-948,CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|,6604934,Preclinical,tyrosine phosphatase inhibitor,PTPN1|PTPN11|PTPN2,"","",5770|5771|5781,No-Effect
1238,BRD-K00003548,BW-180C,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,6917707,Phase 2,opioid receptor agonist,OPRD1|OPRM1,"","",4985|4988,No-Effect
1240,BRD-K74990253,BW-373U86,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1,119029,Preclinical,opioid receptor agonist,OPRD1,"","",4985,No-Effect
1241,BRD-K07061232,BW-616U,CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1,11722381,Preclinical,monoamine oxidase inhibitor,MAOA,"","",4128,No-Effect
1243,BRD-K80194255,BW-A4C,CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1,6438354,Phase 1,lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
1244,BRD-A55946879,BW-B70C,"C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|",88473969,Preclinical,lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
1245,BRD-K47983010,BX-795,Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1,10077147,Preclinical,IKK inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,"","",3791|5170|2932|1111|1017,No-Effect
1246,BRD-K49669041,BX-912,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1,11754511,Preclinical,pyruvate dehydrogenase kinase inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,"","",3791|5170|2932|1111|1017,No-Effect
1247,BRD-K61665160,BYK-204165,Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12,25113764,Preclinical,PARP inhibitor,PARP1,"","",142,No-Effect
1248,BRD-K98179423,C-021,COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1,25141190,Preclinical,CC chemokine receptor antagonist,CCR4,"","",57472,Strong (80%)
1249,BRD-K72462751,C-1,O=S(=O)(N1CCNCC1)c1cccc2cnccc12,3545,Preclinical,protein kinase inhibitor,PRKCA,"","",5578,No-Effect
1252,BRD-K83914624,C11-Acetate,[Y+3],168049,Phase 3,"",ABAT|ACE|AKR1C3|CA2|CELA1|ESR2|FFAR2|FFAR3|HPRT1|LTA4H|MMP12|NOS1|NOS3|PLA2G1B|PTPN1|SOD1|TXN,"","",4321|342977|8644|1636|1990|5319|25828|5770|340719|4048|2865|18|2867|2100|3251|6647|760,No-Effect
1254,BRD-K43167535,C34,CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O,91691128,Preclinical,toll-like receptor inhibitor,TLR4,"","",7099,No-Effect
1255,BRD-K73383190,C646,CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|,2871948,Preclinical,histone acetyltransferase inhibitor,EP300,"","",2033,No-Effect
1259,BRD-K10384176,cabazitaxel,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|,9854073,Launched,microtubule inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,prostate cancer,7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|347733|84790|203068,No-Effect
1260,BRD-K86882815,cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,54746,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7,endocrinology,hyperprolactinemia,146|147|1812|1813|150|1815|3352|3351|1816|151|152|153|154|1814|3356|3358|3363|106480180|3350,No-Effect
1262,BRD-K51544265,cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC,25102847,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR|MET|RET,oncology,medullary thyroid cancer (MTC),5979|8731|3791,No-Effect
1263,BRD-A90751343,CaCCinh-A01,"CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|",747218,Preclinical,calcium-activated chloride channel inhibitor,CLCA1,"","",1179,No-Effect
1267,BRD-K09900591,caffeic-acid,OC(=O)\C=C\c1ccc(O)c(O)c1,689043,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,ALOX5|MIF,"","",240|4282,No-Effect
1268,BRD-K96188950,caffeic-acid-phenethyl-ester,Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O,5281787,Preclinical,HIV integrase inhibitor,RELA,"","",5970,Cyto
1269,BRD-K02404261,caffeine,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,2519,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3,neurology/psychiatry,fatigue|drowsiness,134|135|136|140|5136|5137|5138|5139|5140|5141|5142|5143|5144|5145|5146|5150|5151|5152|5153|5158|5290|5291|8622|8654|5591|472|10846|3708|22883|27115|6261|6262|6263|50940|3709|3710,No-Effect
1270,BRD-K77175907,calcifediol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5283731,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594,No-Effect
1271,BRD-K56429665,calcipotriol,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5288783,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis,1594,No-Effect
1273,BRD-K27316855,calcitriol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5280453,Launched,vitamin D receptor agonist,VDR,endocrinology|orthopedics,hypocalcemia|hypoparathyroidism|osteoporosis,1594,Very Weak (35%)
1276,BRD-K19811997,Calhex-231,C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12,11849514,Preclinical,calcium sensing receptor negative allosteric modulator,CASR,"","",846,No-Effect
1278,BRD-K23248433,camicinal,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1,15984937,Phase 2,motilin receptor agonist,MLNR,"","",2862,Low (25%)
1279,BRD-K35772771,CaMKII-IN-1,Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12,50898538,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,AKT1|CAMK2A|CAMK4|MYLK,"","",4638|815|814|207,No-Effect
1281,BRD-K43806473,camostat-mesilate,CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1,2536,Launched,protease inhibitor,PRSS1,gastroenterology,pancreatitis,136541,No-Effect
1283,BRD-K15714472,camphor-(1R),CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2,5284500,Phase 1,TRPV activator,TRPV1,"","",7442,No-Effect
1284,BRD-K37890730,camptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O,24360,Phase 3,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
1286,BRD-K90868879,canagliflozin,Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,24812758,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524,No-Effect
1287,BRD-K84091759,candesartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,2541,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure,185,Weak (50%)
1290,BRD-K50168500,canertinib,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,156414,Phase 3,EGFR inhibitor,AKT1|EGFR|ERBB2|ERBB4,"","",2064|2066|1956|207,Low (25%)
1292,BRD-K81644801,canrenone,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|",13789,Withdrawn,mineralocorticoid receptor antagonist,NR3C2,"","",4306,No-Effect
1294,BRD-K97025174,capadenoson,Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N,9936489,Phase 2,adenosine receptor agonist,ADORA1,"","",134,No-Effect
1295,BRD-K61192372,capecitabine,CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,60953,Launched,DNA synthesis inhibitor|thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer,7298,No-Effect
1300,BRD-K50590187,capsaicin,COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O,1548943,Launched,TRPV agonist,CFTR|TRPV1,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis,1080|7442,No-Effect
1301,BRD-K44849676,capsazepine,Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1,2733484,Preclinical,TRPV agonist,TRPV1|TRPV4,"","",7442|59341,No-Effect
1304,BRD-K54529596,captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,44093,Launched,angiotensin converting enzyme inhibitor,ACE|LTA4H|MMP2|MMP9,cardiology|endocrinology|nephrology,hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy,4048|4313|1636|4318,No-Effect
1305,BRD-K62790656,caracemide,CNC(=O)ON(C(C)=O)C(=O)NC,54747,Phase 2,ribonucleotide reductase inhibitor,RRM1,"","",6240,No-Effect
1306,BRD-K59895502,caramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1,6472,Launched,cholinergic receptor antagonist,CHRM1|CHRM2,neurology/psychiatry,Parkinson's Disease,1128|1129,No-Effect
1307,BRD-A50675490,carazolol,"CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|",13023331,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|cardiac arrythmia|hypertension|myocardial infarction,153|154|155,No-Effect
1308,BRD-K75037734,carbachol,C[N+](C)(C)CCOC(N)=O,2551,Launched,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,ophthalmology,intraocular pressure,1128|1129|1131|1132|1133|1135,No-Effect
1310,BRD-K71799949,carbamazepine,NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|,2554,Launched,carboxamide antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
1314,BRD-K12906202,carbendazim,COC(=O)Nc1nc2ccccc2[nH]1,25429,Launched,microtubule inhibitor|tubulin polymerization inhibitor,TP53|TUBB,infectious disease,fungicide,7280|7157,No-Effect
1316,BRD-K12765235,carbenoxolone,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|,636403,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3,gastroenterology|dental,peptic ulcer disease (PUD)|mouth inflammation,81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|127534|10804|125111|57165|24145|84694|3290|56666|349149|375519|116337|219770,No-Effect
1317,BRD-K06181161,carbetapentane,CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1,2562,Launched,acetylcholine receptor antagonist,CHRM2,otolaryngology|pulmonary,common cold|nasal congestion|bronchitis,1129,No-Effect
1318,BRD-K56107812,carbetocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,,Launched,oxytocin receptor agonist,OXTR,hematology,hemorrhage,5021,No-Effect
1319,BRD-K78712176,carbidopa,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O,34359,Launched,aromatic L-amino acid decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,1644,Very Weak (35%)
1320,BRD-K87156652,carbimazole,CCOC(=O)n1ccn(C)c1=S,31072,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism,7066,Very Weak (35%)
1321,BRD-K01826745,carbinoxamine,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|,170336,Launched,histamine receptor antagonist,HRH1,allergy|ophthalmology|otolaryngology|dermatology,allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism,3269,Low (25%)
1323,BRD-K68408772,carboxyamidotriazole,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,108144,Phase 3,calcium channel blocker,CXCL8,"","",3576,No-Effect
1324,BRD-K23533833,carboxylosartan,CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,108185,Phase 1,angiotensin antagonist,AGTR1,"","",185,No-Effect
1327,BRD-K50905564,cardionogen-1,C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1,663145,Preclinical,WNT signaling inhibitor,CTNNB1,"","",1499,No-Effect
1328,BRD-K49554218,carebastine,CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,65820,Phase 1,histamine receptor antagonist,HRH1,"","",3269,No-Effect
1329,BRD-K15179879,carfilzomib,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,11556711,Launched,proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9,hematologic malignancy,multiple myeloma,5682|5683|5684|5685|5686|5687|5688|5689|5690|5691|5692|5693|5694|5695|5696|5698|5699|122706|143471,Weak (50%)
1330,BRD-K60240222,carglumic-acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,121396,Launched,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia,1589,No-Effect
1331,BRD-K90215590,caricotamide,"NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|",403128,Phase 2,NADPH quinone oxidoreductase inhibitor,NQO2,"","",4835,No-Effect
1332,BRD-K21670884,cariporide,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,151172,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,"","",6548,No-Effect
1333,BRD-K57764956,cariprazine,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|,,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,schizophrenia,1813|1814,No-Effect
1334,BRD-K11630072,carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,2577,Launched,thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer,7298,Cyto
1335,BRD-K25095405,carmoterol,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,86306667,Phase 2,adrenergic receptor agonist,ADRB2,"","",154,No-Effect
1336,BRD-K82484965,carmoxirole,OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|,86308157,Phase 2,dopamine receptor agonist,DRD2,"","",1813,No-Effect
1337,BRD-K36234266,carmustine,[O-][NH2+]N(CCCl)C(=O)NCCCl,59087767,Launched,DNA alkylating agent|DNA inhibitor,GSR,hematologic malignancy|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma,2936,No-Effect
1341,BRD-K92129045,caroxazone,NC(=O)CN1Cc2ccccc2OC1=O,29083,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,"","",4128|4129,No-Effect
1342,BRD-A17411484,carprofen,"C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|",6997572,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743,Low (25%)
1344,BRD-A42167015,carteolol,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,49852288,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,153|154|155,No-Effect
1346,BRD-K01826535,carvedilol,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|,185394,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,myocardial infarction|hypertension,153|154|155,No-Effect
1347,BRD-K09295674,carzenide,NS(=O)(=O)c1ccc(cc1)C(O)=O,8739,Preclinical,"",CA1|CA12|CA14|CA2|CA6|CA9,"","",768|771|23632|759|760|765,No-Effect
1351,BRD-K20897876,castanospermine,O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12,54445,Phase 2,glucosidase inhibitor,GAA|GBA,"","",2548|2630,No-Effect
1355,BRD-K41779183,CB-03-01,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|,11750009,Phase 3,androgen receptor antagonist,AR,"","",367,No-Effect
1357,BRD-K49048664,CB-5083,Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O,73051434,Phase 1,valosin-containing protein inhibitor,VCP,"","",7415,No-Effect
1358,BRD-K58070273,CB-839,FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1,71577426,Phase 2,glutaminase inhibitor,GLS,"","",27165,No-Effect
1359,BRD-K34675210,CBiPES,CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N,9864510,Preclinical,glutamate receptor positive allosteric modulator,GRM2,"","",2912,No-Effect
1361,BRD-K91874254,CBS-1114,NC(=NNc1ccccc1)c1ccccc1,6338223,Phase 1,lipoxygenase inhibitor,ALOX5,"","",240,Very Weak (35%)
1362,BRD-K16755045,CC-115,"CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|",58298318,Phase 2,DNA protein kinase inhibitor|mTOR inhibitor,MTOR,"","",2475,Strong (80%)
1363,BRD-K88737571,CC-223,CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|,,Phase 2,mTOR inhibitor,MTOR,"","",2475,No-Effect
1364,BRD-K00004320,CC-401,C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1,10430360,Phase 1,JNK inhibitor,MAPK8,"","",5599,No-Effect
1367,BRD-K17751100,CC4,O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12,91654624,Preclinical,nicotinic receptor agonist,CHRNB2,"","",1141,No-Effect
1368,BRD-A79726147,CCG-1423,"C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|",40782280,Preclinical,apoptosis stimulant,RHOC|SRF,"","",6722|389,No-Effect
1369,BRD-K08893438,CCG-50014,Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O,2733079,Preclinical,G protein signaling inhibitor,RGS4|RGS8,"","",85397|5999,No-Effect
1370,BRD-K26970495,CCG-63802,Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1,6057678,Preclinical,G protein signaling inhibitor,RGS4,"","",5999,No-Effect
1371,BRD-K68474505,CCG-63808,Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O,5948316,Preclinical,G protein signaling inhibitor,RGS4,"","",5999,No-Effect
1372,BRD-K16338837,CCMI,Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1,67042344,Preclinical,acetylcholine receptor allosteric modulator,CHRNA7,"","",89832,No-Effect
1374,BRD-K90999434,CCT-031374,O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|,2853753,Preclinical,WNT signaling inhibitor,CTNNB1,"","",1499,Weak (50%)
1375,BRD-K65503129,CCT018159,CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O,984170,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,"","",3320|3326,No-Effect
1377,BRD-K57136142,CCT129202,CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1,16202152,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
1378,BRD-K03289018,CCT137690,CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1,25154041,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
1381,BRD-K09619322,CD-1530,OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2,9952709,Preclinical,retinoid receptor agonist,RARG,"","",5916,Weak (50%)
1382,BRD-K28907958,CD-437,OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,135411,Preclinical,retinoid receptor agonist,RARG,"","",5916,No-Effect
1384,BRD-K87932577,CDK1-5-inhibitor,Nc1[nH]nc2nc3ccccc3nc12,438981,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3B,"","",2932|1020|983,No-Effect
1385,BRD-K43914553,CDK9-IN-6,COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1,,Preclinical,CDK inhibitor,CDK9,"","",1025,No-Effect
1386,BRD-K02213468,CDPPB,O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N,11245456,Preclinical,glutamate receptor positive allosteric modulator,GRM5,"","",2915,No-Effect
1387,BRD-A47940219,CE3F4,"C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|",73669656,Preclinical,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,"","",10411,Low (25%)
1388,BRD-K48141473,cebranopadol,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|,,Phase 3,opioid receptor agonist,OPRL1|OPRM1,"","",4987|4988,No-Effect
1389,BRD-K86930074,cediranib,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,9933475,Phase 3,KIT inhibitor|VEGFR inhibitor,CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB,"","",5156|3815|5159|3791|2321|2322|2324|1436,No-Effect
1393,BRD-K63242551,cefadroxil,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|,6560167,Launched,bacterial cell wall synthesis inhibitor,SLC15A1|SLC15A2|SLC22A6|SLC22A8,infectious disease|otolaryngology,urinary tract infections|skin infections|tonsillitis|pharyngitis,9376|9356|6564|6565,No-Effect
1398,BRD-K99750640,cefazolin,Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|,33255,Launched,bacterial cell wall synthesis inhibitor,PON1,infectious disease,urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections,5444,No-Effect
1400,BRD-K15766189,cefdinir,Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|,6915944,Launched,bacterial cell wall synthesis inhibitor,MPO,infectious disease|otolaryngology|pulmonary,pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis,4353,No-Effect
1425,BRD-K13797099,cefradine,"CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|",40467109,Launched,bacterial cell wall synthesis inhibitor,CYP3A4,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia,1576,No-Effect
1436,BRD-K02637541,celecoxib,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,2662,Launched,cyclooxygenase inhibitor,CA12|PDPK1|PTGS2,rheumatology|endocrinology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD),5170|771|5743,No-Effect
1438,BRD-A95602221,celiprolol,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|,11406333,Launched,adrenergic receptor antagonist,ADRA2A|ADRB1|ADRB2,genetics,Ehlers-Danlos syndrome (EDS),153|154|150,No-Effect
1446,BRD-K20722021,CEP-32496,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,56846693,Phase 1/Phase 2,RAF inhibitor,BRAF|RAF1,"","",673|6037,No-Effect
1447,BRD-K37237504,CEP-33779,CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1,57336812,Preclinical,JAK inhibitor,JAK2,"","",3717,No-Effect
1448,BRD-K72827473,CEP-37440,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,71721648,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,"","",238,Weak (50%)
1458,BRD-K22149900,ceritinib,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,57379345,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FLT3|IGF1R|INSR|TSSK1B,oncology,non-small cell lung cancer (NSCLC),83942|238|2322|3480|3643,No-Effect
1459,BRD-K52075040,cerulenin,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,5282054,Launched,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,2194,No-Effect
1460,BRD-K00003320,ceruletide,[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,16129675,Preclinical,CCK receptor agonist,CCKAR,"","",886,No-Effect
1461,BRD-K86954340,cetaben,CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O,47263,Phase 2,ACAT inhibitor|cholesterol inhibitor,PPARA,"","",5465,Strong (80%)
1462,BRD-K94863486,cetilistat,CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1,9952916,Phase 3,triacylglycerol lipase inhibitor,PNLIP,"","",5406,No-Effect
1463,BRD-K01826520,cetirizine,OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|,28145930,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,Low (25%)
1465,BRD-K76315403,cetrorelix,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,25074887,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR|LHCGR,endocrinology,premature luteinizing hormone surges,3973|2798,No-Effect
1467,BRD-K00004291,cevimeline,"C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|",18642481,Launched,acetylcholine receptor agonist,CHRM3,rheumatology,sjogren's syndrome,1131,No-Effect
1468,BRD-K00003570,cevipabulin,[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F,11488110,Phase 1,microtubule stimulant|tubulin polymerization inhibitor,TUBB,"","",7280,No-Effect
1469,BRD-K52396582,CF102,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12,3035850,Phase 2,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
1474,BRD-K72004355,CFTRinh-172,OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1,1554210,Preclinical,chloride channel blocker,CFTR,"","",1080,No-Effect
1476,BRD-K82028950,CGH2466,Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1,5282339,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,"","",136|140|134,No-Effect
1477,BRD-A50737080,CGK-733,"[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|",92509770,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,ATM|ATR,"","",472|545,No-Effect
1478,BRD-K79584249,CGM097,COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1,,Phase 1,MDM inhibitor,MDM2,"","",4193,No-Effect
1479,BRD-A40084411,CGP-12177,CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|,76962943,Phase 1,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
1480,BRD-K95851186,CGP-13501,CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C,3519541,Preclinical,GABA receptor modulator,GABBR1,"","",10537,No-Effect
1481,BRD-K01827291,CGP-20712A,"CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|",91667713,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB3,"","",153|155,No-Effect
1483,BRD-A35623999,CGP-37157,"Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|",6604821,Preclinical,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,SLC8A1,"","",6546,No-Effect
1484,BRD-A90272038,CGP-37849,"C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|",6604869,Phase 1,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",2904|2905|2906|2903,Low (25%)
1486,BRD-K13087974,CGP-52411,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,1697,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
1487,BRD-K32292990,CGP-53353,Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1,6711154,Preclinical,EGFR inhibitor|PKC inhibitor,EGFR|PRKCB,"","",5579|1956,No-Effect
1488,BRD-A74208568,CGP-54626,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|",197584,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,"","",9568|115207|10537|57528|386617,No-Effect
1489,BRD-K00004232,CGP-55845,C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,5311042,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,"","",9568|115207|10537|57528|386617,No-Effect
1490,BRD-K42500029,CGP-57380,Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12,11644425,Preclinical,MAP kinase inhibitor,AURKB|LCK|MKNK1|MKNK2|SGK1,"","",3932|6446|2872|8569|9212,No-Effect
1491,BRD-K79090631,CGP-60474,OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1,644215,Preclinical,CDK inhibitor,CDK1|CDK2,"","",1017|983,Cyto
1492,BRD-K34321528,CGP-71683,Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|,,Preclinical,neuropeptide receptor antagonist,NPY5R,"","",4889,No-Effect
1493,BRD-K56239177,CGP-74514,CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12,2794188,Preclinical,CDK inhibitor,CDK1,"","",983,No-Effect
1495,BRD-K65786282,CGP-7930,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,5024764,Preclinical,GABA receptor modulator,GABBR1,"","",10537,No-Effect
1496,BRD-K49049886,CGS-15943,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,2690,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
1497,BRD-K68103045,CGS-20625,COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O,163844,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,"","",2554|2555|2556|2557|2558|2559,No-Effect
1498,BRD-K27176996,CGS-21680,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,3086599,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
1499,BRD-K54093161,CGS-9896,Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O,108030,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,"","",2561|2554|2566,No-Effect
1501,BRD-K11683436,CH-5183284,Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N,66555680,Phase 2,fibroblast growth factor inhibitor,FGFR1|FGFR2|FGFR3,"","",2260|2261|2263,No-Effect
1502,BRD-K22314899,CH223191,Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1,,Preclinical,aryl hydrocarbon receptor antagonist,AHR,"","",196,No-Effect
1503,BRD-K28352084,CH5132799,CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1,49784945,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",22883|5290|2475|5291|5294,No-Effect
1504,BRD-K71487808,CH55,CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O,6184667,Preclinical,retinoid receptor binder,RARA|RARB,"","",5914|5915,No-Effect
1505,BRD-K60302405,CHC,OC(=O)C(=C\c1ccc(O)cc1)\C#N,5328791,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,"","",6566,No-Effect
1506,BRD-K18135438,chenodeoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,10133,Launched,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,HSD11B1|NR1H4,cardiology|gastroenterology,cerebral cholesterosis|gallstones,3290|9971,No-Effect
1507,BRD-K34508702,CHF5074,OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1,9996409,Phase 2,gamma secretase modulator,PSEN1,"","",5663,No-Effect
1508,BRD-K56483981,chicago-sky-blue-6b,"COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|",6817703,Preclinical,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,MIF,"","",4282,No-Effect
1509,BRD-K28537285,chidamide,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,9800555,Launched,HDAC inhibitor,HDAC10|HDAC3,hematologic malignancy,peripheral T-cell lymphoma (PTCL),8841|83933,No-Effect
1511,BRD-K02241333,CHIR-124,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,135399748,Preclinical,CHK inhibitor,CHEK1,"","",1111,Low (25%)
1513,BRD-K16189898,CHIR-99021,Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl,9956119,Preclinical,glycogen synthase kinase inhibitor,CDK1|GSK3A|GSK3B|MAPK1,"","",5594|2931|2932|983,No-Effect
1517,BRD-K08111712,chloramphenicol,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,5959,Launched,bacterial 50S ribosomal subunit inhibitor,CD55,infectious disease|endocrinology,meningitis|fever|cholera,1604,No-Effect
1526,BRD-K18030938,chlorisondamine-diiodide,C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl,6244,Preclinical,acetylcholine receptor antagonist,CHRNA1,"","",1134,No-Effect
1527,BRD-K38704569,chlormadinone-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",9324,Launched,5 alpha reductase inhibitor,PGR,endocrinology,hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea,5241,No-Effect
1528,BRD-A20348246,chlormezanone,"CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|",6604211,Withdrawn,GABA receptor modulator,GABRA1,"","",2554,No-Effect
1532,BRD-K47114202,chlorogenic-acid,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O,1794427,Launched,antioxidant,SLC37A4,neurology/psychiatry|pulmonary|allergy,headache|chest congestion|allergic rhinitis,2542,No-Effect
1535,BRD-K86864073,chloroprocaine,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,8612,Launched,sodium channel blocker,ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3,neurology/psychiatry,local anesthetic,6336|6531|116443|476|57053|3359,No-Effect
1536,BRD-K83257731,chloropyramine,CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,25295,Launched,histamine receptor antagonist,HRH1,cardiology|ophthalmology|allergy|pulmonary,edema|conjunctivitis|allergic rhinitis|asthma,3269,No-Effect
1537,BRD-A91699651,chloroquine,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|,444810,Launched,antimalarial agent,MRGPRX1,infectious disease,malaria|amebiasis,259249,Very Weak (35%)
1538,BRD-K88682005,chlorothiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|,2720,Launched,diuretic,CA1|CA2|CA4|SLC12A3,cardiology,hypertension,760|762|6559|759,No-Effect
1540,BRD-K27062708,chlorotrianisene,COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1,11289,Launched,estrogenic hormone,ESR1|ESR2,endocrinology|oncology,menopause|prostate cancer,2099|2100,No-Effect
1541,BRD-K17075857,chloroxine,Oc1c(Cl)cc(Cl)c2cccnc12,2722,Launched,opioid receptor antagonist,OPRK1,gastroenterology|infectious disease|dermatology,diarrhea|inflammatory bowel disease|giardiasis|dandruff,4986,No-Effect
1548,BRD-K25494650,chlorproguanil,CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1,9571037,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,1719,Weak (50%)
1549,BRD-K89997465,chlorpromazine,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,2726,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5,neurology/psychiatry|gastroenterology|hematology|infectious disease,schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus,5004|5005|146|147|1812|1813|150|1815|1816|151|152|1814|3350|3356|3358|801|3362|3363|3757|106480180|7224|3269|59340|6609|1128|1131,Strong (80%)
1550,BRD-K97746869,chlorpropamide,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,2727,Launched,ATP channel blocker,ABCC8|KCNJ10,endocrinology,diabetes mellitus,6833|3766,No-Effect
1552,BRD-K36207157,chlorprothixene,CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12,667467,Launched,dopamine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C,neurology/psychiatry,schizophrenia|bipolar disorder,3269|1128|1129|1131|1132|1133|1812|1813|1814|106480180|3356|3358,No-Effect
1553,BRD-K08303368,chlorpyrifos,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,2730,Launched,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
1556,BRD-A26384407,chlorthalidone,"NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|",688424,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1,cardiology|gastroenterology|rheumatology|nephrology,hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure,771|23632|759|760|762|6557|766,No-Effect
1557,BRD-K98174813,chlorzoxazone,Clc1ccc2oc(=O)[nH]c2c1,2733,Launched,bacterial 30S ribosomal subunit inhibitor,KCNMA1|KCNN4,neurology/psychiatry,muscle relaxant,3778|3783,No-Effect
1558,BRD-K62779383,cholecalciferol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5280795,Launched,"",VDR,endocrinology,vitamin D deficiency,1594,No-Effect
1559,BRD-K19338361,cholesterol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|,5997,Preclinical,"",RORA,"","",6095,No-Effect
1560,BRD-K43164539,cholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,221493,Launched,bile acid,ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B,gastroenterology|neurology/psychiatry|genetics,bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome,9377|1345|1346|1349|1350|1351|5319|1066|151306|2235|107075310|1327|2172|1329|2104|1339|1340|126,Very Weak (35%)
1561,BRD-K77300776,choline,C[N+](C)(C)CCO,305,Phase 3,acetylcholine precursor,ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2,"","",162466|5130|43|590|1135|5589|5338|9468,No-Effect
1563,BRD-A19381518,CHPG,"N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|",6604802,Preclinical,glutamate receptor agonist,GRM5,"","",2915,No-Effect
1564,BRD-K76259716,CHR-6494,CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1,70679308,Preclinical,serine/threonine kinase inhibitor,GSG2,"","",83903,Weak (50%)
1569,BRD-K22861715,chrysin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,5281607,Phase 1,breast cancer resistance protein inhibitor,AKR1B1|CDK6|CYP19A1|CYP1B1,"","",1545|1588|1021|231,No-Effect
1575,BRD-K67680372,CI-966,OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|,198693,Phase 1,GAT inhibitor,SLC6A1,"","",6529,No-Effect
1576,BRD-K88544581,CI-976,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,122327,Phase 1,ACAT inhibitor,ACAT1|CES1,"","",1066|6646,No-Effect
1578,BRD-K58736316,cianidanol,O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1,9064,Withdrawn,fatty acid synthase inhibitor,PTGS1,"","",5742,No-Effect
1580,BRD-K35245662,ciclesonide,"CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|",6918155,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908,No-Effect
1581,BRD-K13044802,ciclopirox,Cc1cc(C2CCCCC2)n(O)c(=O)c1,2749,Launched,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,476,Cyto
1582,BRD-A94965935,cicloprofen,"C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|",14694110,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
1583,BRD-K00004311,CID-16020046,"Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|",51436118,Preclinical,G protein-coupled receptor antagonist,GPR55,"","",9290,No-Effect
1584,BRD-K92781136,CID-2011756,Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1,2011756,Preclinical,protein kinase inhibitor,PKD1,"","",5310,No-Effect
1585,BRD-K06405316,CID-2745687,COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F,9581011,Preclinical,G protein-coupled receptor antagonist,GPR35,"","",2859,No-Effect
1586,BRD-A08840375,CID-5458317,"OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|",,Preclinical,MAP kinase phosphatase inhibitor,MAPK3,"","",5595,No-Effect
1588,BRD-A93000692,ciglitazone,CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|,6604850,Phase 2,PPAR receptor agonist,PPARG,"","",5468,No-Effect
1589,BRD-K85518562,cilastatin,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,6435415,Launched,dehydropeptidase inhibitor,DPEP1,"","",1800,No-Effect
1590,BRD-K96177243,cilazapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,56330,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636,No-Effect
1591,BRD-K57252450,cilengitide,CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,176873,Phase 3,integrin antagonist,ITGAV|ITGB3,"","",3690|3685,No-Effect
1592,BRD-K00004281,cilnidipine,"COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|",28248392,Launched,calcium channel blocker,CACNA1B,cardiology,hypertension,774,No-Effect
1594,BRD-K00003550,cilomilast,COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|,,Phase 3,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4D,"","",5144|5141|5142,No-Effect
1595,BRD-K28578425,cilostamide,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,2753,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE3B,"","",5139|5140,No-Effect
1596,BRD-K67017579,cilostazol,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,2754,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B,cardiology,claudication,5139|5140,No-Effect
1598,BRD-A75514485,CIM-0216,"Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|",25331887,Preclinical,transient receptor potential channel agonist,TRPM3,"","",80036,Very Weak (35%)
1599,BRD-A65440446,cimaterol,"CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|",10911051,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
1600,BRD-K34157611,cimetidine,CN\C(NCCSCc1[nH]cnc1C)=N/C#N,2756,Launched,histamine receptor antagonist,HRH2|SLC29A4|SLC47A1|SLC47A2,gastroenterology|hematologic malignancy|endocrinology,duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma,1665|222962|55244|146802,No-Effect
1601,BRD-A99899486,cimetropium,"C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|",,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,1128,No-Effect
1602,BRD-K73838513,cinacalcet,C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,156419,Launched,calcium channel activator,CASR,endocrinology|nephrology|oncology,hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia,846,No-Effect
1603,BRD-K73440166,cinaciguat,OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O,9808022,Phase 2,guanylate cyclase activator,GUCY1A3|GUCY1B3,"","",2982|2983,Cyto
1604,BRD-K53720352,cinalukast,CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O,6436135,Phase 2,leukotriene receptor antagonist,CYSLTR1,"","",10800,No-Effect
1605,BRD-K40901640,cinanserin,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,5475158,Preclinical,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
1606,BRD-K99121711,cinchocaine,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,3025,Launched,sodium channel blocker,CALM1|SCN10A|SCN5A,neurology/psychiatry,local anesthetic,6336|801|6331,Weak (50%)
1608,BRD-K36551084,cinchonine,O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12,90454,Preclinical,P glycoprotein inhibitor,CYP2D6,"","",1565,No-Effect
1613,BRD-K26875402,cinnamaldehyde,O=C\C=C\c1ccccc1,637511,Preclinical,aldose reductase inhibitor|TRPV agonist,TRPA1,"","",8989,No-Effect
1619,BRD-K24570280,CINPA-1,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1,969470,Preclinical,CAR antagonist,NR1H4|NR1I3|PPARG,"","",9970|9971|5468,No-Effect
1625,BRD-K95362002,cipemastat,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,9824350,Phase 3,metalloproteinase inhibitor,ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9,"","",4322|6868|4312|4313|4314|4317|4318,Low (25%)
1626,BRD-A49358627,ciprofibrate,"CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|",9882424,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,5465,No-Effect
1627,BRD-K04804440,ciprofloxacin,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,4011971,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis,7153,No-Effect
1628,BRD-K01767299,ciproxifan,O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1,6422124,Preclinical,histamine receptor antagonist,ADRA2A|ADRA2C|HRH3|HRH4|HTR3A,"","",59340|150|11255|152|3359,Low (25%)
1629,BRD-A35425966,CIQ,"COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|",40450008,Preclinical,glutamate receptor potentiator,GRIN2C|GRIN2D,"","",2905|2906,No-Effect
1630,BRD-K54142781,cirazoline,C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|,2765,Preclinical,adrenergic receptor agonist,ADRA1A,"","",146,No-Effect
1632,BRD-K71756122,cis-aconitic-acid,OC(=O)C\C(=C\C(O)=O)C(O)=O,643757,Preclinical,"",ACO2,"","",50,No-Effect
1633,BRD-K00004205,cis-ACPD,"[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|",231345,Preclinical,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM7|GRM8,"","",2912|2913|2916|2917|2918,No-Effect
1634,BRD-K41962502,"cis-exo-camphanediol-2,3",CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O,21626088,Phase 1,nitric oxide stimulant,NOS3,"","",342977,No-Effect
1635,BRD-K52670952,cis-urocanic-acid,OC(=O)\C=C\c1cnc[nH]1,736715,Phase 2,serotonin receptor agonist,HTR2A,"","",3356,No-Effect
1636,BRD-K25146005,cis-urocanic-acid,OC(=O)\C=C/c1cnc[nH]1,1549103,Phase 2,serotonin receptor agonist,HTR2A,"","",3356,No-Effect
1637,BRD-K06895174,cisapride,CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC,6917698,Withdrawn,serotonin receptor agonist,HTR2A|HTR3A|HTR4|KCNH2,"","",3360|3356|3757|3359,No-Effect
1638,BRD-K17498618,cisatracurium,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,62887,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry|critical care,muscle relaxant|endotracheal intubation,1135,No-Effect
1639,BRD-K69172251,cisplatin,N[Pt](N)(Cl)Cl,86820626,Launched,DNA alkylating agent|DNA synthesis inhibitor,XIAP,oncology,testicular carcinoma|ovarian cancer|bladder cancer,331,No-Effect
1640,BRD-A47598013,citalopram,CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|,146570,Launched,selective serotonin reuptake inhibitor (SSRI),ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532|3269|1128|146,No-Effect
1642,BRD-K53263234,CITCO,Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1,9600409,Preclinical,constitutive androstane receptor (CAR) agonist,NR1I3,"","",9970,No-Effect
1643,BRD-K01827268,citicoline,"C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|",13805,Launched,glutathione transferase stimulant|membrane permeability enhancer,ACHE|SLC1A2,neurology/psychiatry|ophthalmology,stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma,6506|43,No-Effect
1645,BRD-K76792669,citric-acid,OC(=O)CC(O)(CC(O)=O)C(O)=O,88113319,Preclinical,coagulation factor inhibitor,AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2,"","",6035|11157|6037|1431|283|10673|9146|4282|6714|9033|59338|7371|58190|8654|1360|733|4191|27232|353|9955|231|259307|3704|762|635,No-Effect
1646,BRD-K21306330,CJ-033466,CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1,10429706,Preclinical,serotonin receptor agonist,HTR4,"","",3360,No-Effect
1649,BRD-K81572616,CK-636,Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,588963,Preclinical,actin related protein inhibitor,ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5,"","",100526693|10092|10094|10095|10096|10097|10109,No-Effect
1650,BRD-A26458246,CKD-712,Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|,9861304,Phase 1,NFkB pathway inhibitor,JAK2|STAT1,"","",6772|3717,No-Effect
1651,BRD-K34303607,CKI-7,NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12,129236,Preclinical,casein kinase inhibitor,CSNK1G2,"","",1455,No-Effect
1652,BRD-K00662280,CL-218872,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,107950,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,"","",2561|2566|2554|2555|2556|2558,No-Effect
1654,BRD-K06467130,CL316243,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,5486546,Phase 2,adrenergic receptor agonist,ADRB3|UCP1|UCP2|UCP3,"","",7352|155|7350|7351,No-Effect
1655,BRD-K93034159,cladribine,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,20279,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B,hematologic malignancy,hairy cell leukemia,6240|6241|5539|100|5422|56655|5426|5427|50484|54107,No-Effect
1658,BRD-K49668410,clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,,Launched,bacterial 50S ribosomal subunit inhibitor,CYP3A4,otolaryngology|pulmonary|infectious disease,pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis,1576,No-Effect
1660,BRD-K17294426,clebopride,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,2780,Launched,dopamine receptor antagonist,ACHE|DRD2,gastroenterology,nausea,43|1813,No-Effect
1661,BRD-K30240666,clemastine,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,26987,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269,Strong (80%)
1663,BRD-K00003701,clenbuterol,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|,688428,Launched,adrenergic receptor agonist,ABCC8|ADRB2|KCNJ11,pulmonary,chronic obstructive pulmonary disease (COPD)|asthma,6833|154|3767,Very Weak (35%)
1664,BRD-A01563671,cleviprex,"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|",22884799,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension,776|778|779|775,No-Effect
1666,BRD-K01827265,clidinium,"C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|",24867263,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis,1128|1131,No-Effect
1672,BRD-A90625545,clinofibrate,"CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|",,Launched,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia,3936,No-Effect
1673,BRD-K09255212,clioquinol,Oc1c(I)cc(Cl)c2cccnc12,2788,Withdrawn,chelating agent,OPRK1,"","",4986,No-Effect
1674,BRD-K71430621,clobenpropit,Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1,2790,Preclinical,histamine receptor antagonist,HRH1|HRH2|HRH3|HRH4,"","",1665|59340|3269|11255,No-Effect
1675,BRD-K10799896,clobetasol-propionate,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|",32798,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319,Weak (50%)
1676,BRD-K58810291,clobetasone-butyrate,"CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|",71386,Launched,corticosteroid agonist,NR3C1,dermatology,eczema|psoriasis|dermatitis,2908,No-Effect
1678,BRD-K38003476,clocortolone-pivalate,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|",5282493,Launched,steroid,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319,No-Effect
1679,BRD-K72542090,clodronic-acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,25419,Launched,bone resorption inhibitor,SLC25A4|SLC25A5|SLC25A6,orthopedics|endocrinology|hematologic malignancy,osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma,291|292|293,No-Effect
1680,BRD-K34022604,clofarabine,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,119182,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,acute lymphoblastic leukemia (ALL),6240|6241|5422|5424|5426|50484,No-Effect
1682,BRD-A15687940,clofedanol,"CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|",688422,Launched,histamine receptor antagonist,HRH1,pulmonary,cough suppressant,3269,Low (25%)
1683,BRD-K45252063,clofibrate,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,2796,Launched,PPAR receptor agonist,LPL|PPARA,endocrinology|cardiology,hyperlipidemia|cholesterol,3936|5465,No-Effect
1684,BRD-K19111024,clofibric-acid,CC(C)(Oc1ccc(Cl)cc1)C(O)=O,2797,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,5465,No-Effect
1685,BRD-K02680176,clofilium,CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1,2798,Phase 2,potassium channel blocker,KCNA5|KCNH1,"","",3756|3741,No-Effect
1688,BRD-K50422030,clomethiazole,Cc1ncsc1CCCl,10783,Launched,GABA receptor antagonist|GABA receptor modulator,GABRA1,neurology/psychiatry,Parkinson's Disease|sedative|muscle relaxant,2554,No-Effect
1689,BRD-K29950728,clomifene,CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1,1548955,Launched,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,2099,Strong (80%)
1690,BRD-K52989797,clomipramine,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,2801,Launched,serotonin transporter (SERT) inhibitor,GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),6530|6531|6532|2950|106480180|3356|3358,Very Weak (35%)
1691,BRD-K98530306,clonidine,Clc1cccc(Cl)c1NC1=NCCN1 |t:10|,2803,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|neurology/psychiatry,hypertension|attention-deficit/hyperactivity disorder (ADHD),146|147|150|151|152,No-Effect
1692,BRD-K18399440,clonixin,Cc1c(Cl)cccc1Nc1ncccc1C(O)=O,28718,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|infectious disease,rheumatoid arthritis|soft tissue infection,5742|5743,No-Effect
1697,BRD-K27721098,clopidogrel,COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl,60606,Launched,purinergic receptor antagonist,P2RY12,cardiology|neurology/psychiatry,myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS),64805,No-Effect
1699,BRD-K17850764,cloprostenol-(+/-),O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,5311053,Launched,prostaglandin receptor agonist,PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R,obstetrics/gynecology,endometriosis,5729|5731|6915|5733|5737,No-Effect
1700,BRD-A04971881,cloranolol,CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|,76964677,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,hypertension,153|154|155,No-Effect
1701,BRD-K73251053,clorgiline,CN(CCCOc1ccc(Cl)cc1Cl)CC#C,4380,Phase 2,monoamine oxidase inhibitor,MAOA,"","",4128,No-Effect
1702,BRD-A19053834,clorotepine,CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|,12765746,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6,neurology/psychiatry,psychosis,3362|3269|146|147|1813|3358,Strong (80%)
1703,BRD-K01825579,clorprenaline,CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|,12463921,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,asthma,153|154,No-Effect
1707,BRD-K15916496,clotrimazole,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,2812,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8,infectious disease,vulvovaginal candidiasis|oropharyngeal candidiasis,1191|1576|3783|54795|79054|9970|8856,No-Effect
1709,BRD-K46982791,cloxyquin,Oc1ccc(Cl)c2cccnc12,2817,Preclinical,potassium channel activator,KCNK18,"","",338567,No-Effect
1710,BRD-K37289225,clozapine,CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|,135398737,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia,146|147|1812|1813|150|1815|1816|151|152|1814|3350|3351|3352|3354|3355|3356|3358|3359|3361|3362|3363|106480180|3269|50632|59340|1128|1129|1131|1132|1133,Very Weak (35%)
1712,BRD-K54095730,CMPD-1,Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1,11382492,Preclinical,p38 MAPK inhibitor,GNRHR|MAPK14,"","",1432|2798,No-Effect
1713,BRD-K19438463,CNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N,3721046,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
1714,BRD-K24869513,CNX-2006,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,56968072,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
1715,BRD-K48443249,CNX-774,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,59174579,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,Very Weak (35%)
1716,BRD-K55677650,CO-101244,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,6918409,Preclinical,glutamate receptor antagonist,GRIN2B,"","",2904,No-Effect
1717,BRD-K70912147,CO-102862,NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1,9816959,Phase 1,sodium channel blocker,SCN4A|SCN9A,"","",6329|6335,No-Effect
1718,BRD-K51040301,cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,25151504,Launched,cytochrome P450 inhibitor,CYP3A4|CYP3A43|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1576|1577|64816|100861540,No-Effect
1719,BRD-K03390685,cobimetinib,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,16222096,Launched,MEK inhibitor,MAP2K1,oncology,melanoma,5604,Strong (80%)
1720,BRD-A67956599,coenzyme-A,"CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|",87642,Launched,"",ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5,"","",706|1384|8850|8435|3156|1431|2648|10524,Weak (50%)
1721,BRD-K01825730,coenzyme-I,"NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|",439153,Phase 2,"",AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH,"","",29920|1036|374291|3615|160287|35|5160|5161|5162|1579|10797|1586|56901|3156|1109|4694|4695|4696|3162|3163|4698|4700|4190|4191|4701|4705|4702|4704|4706|4707|4708|4709|4200|4710|4711|4712|4716|1645|1646|622|4713|4714|4715|4717|4718|4719|4720|4722|4724|4725|4726|4728|124|125|126|4729|128|4731|50814|131|644|645|7299|8854|55967|6307|3248|1717|1719|2746|2747|7358|1727|7264|5831|1737|1738|3283|3284|4723|216|217|3290|3291|218|3293|219|3295|220|221|222|223|224|3292|3294|231|360165|4329|4835|7915|5860|7923|2819|275|727833|56110|92483|100240709|5959|3419|3420|3421|9563|3939|4967|11112|3945|3948|26227|57717|2936|26330|126328|51079|1962|4522|10157|8644|158160|8659|3028|3030|23530|501|6652,No-Effect
1724,BRD-K00259736,colchicine,COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,6167,Launched,microtubule inhibitor,GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,rheumatology|endocrinology,gout|fever,7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|2741|84790|2742|347733|203068,Cyto
1725,BRD-A55416093,colforsin,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|",47936,Phase 2,adenylyl cyclase activator,ADCY2|ADCY5,"","",108|111,No-Effect
1731,BRD-K19655798,compound-401,O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1,10039361,Preclinical,DNA dependent protein kinase inhibitor,MTOR|PRKDC,"","",2475|5591,No-Effect
1733,BRD-K98143539,compound-w,OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1,16760376,Preclinical,beta-secretase inhibitor,BACE1,"","",23621,No-Effect
1734,BRD-K37385792,conivaptan,Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1,151171,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology,hyponatremia,552|554,No-Effect
1736,BRD-K24666289,copanlisib,"COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|",,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,follicular lymphoma,5290|5291|5294|22883,Low (25%)
1737,BRD-K36449075,copper-histidine,N[C@H](Cc1cnc[nH]1)C(O)=O,71083,Phase 3,"",SLC15A3|SLC15A4|SLC38A5,"","",51296|92745|121260,No-Effect
1738,BRD-K74965187,COR-170,CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1,25033736,Preclinical,cannabinoid receptor inverse agonist,CNR2,"","",56142,No-Effect
1740,BRD-K27885593,corosolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|,6918774,Phase 2,PKC inhibitor|protein tyrosine kinase inhibitor,HSD11B1|PTPN1,"","",3290|5770,No-Effect
1742,BRD-K73589401,corticosterone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|,5753,Preclinical,mineralocorticoid receptor agonist,HSD11B1|NCOA1|NR3C2,"","",8648|4306|3290,No-Effect
1743,BRD-K00025572,cortisone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|,222786,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology|rheumatology|dermatology,ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema,2908,No-Effect
1744,BRD-K86161929,cortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|,5745,Launched,glucocorticoid receptor agonist,NR3C1,pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease,asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis,2908,No-Effect
1745,BRD-K32891457,cortodoxone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|,440707,Phase 3,androgen receptor antagonist,AR,"","",367,No-Effect
1747,BRD-K98710228,cot-inhibitor-1,Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl,11584834,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,"","",1326,No-Effect
1748,BRD-K49468759,cot-inhibitor-2,CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1,44143370,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,"","",1326,No-Effect
1751,BRD-K23913458,coumarin,O=c1ccc2ccccc2o1,323,Launched,vitamin K antagonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6,gastroenterology|pulmonary,ulcerative colitis|asthma|celiac disease,768|771|1548|23632|759|760|762|765,Weak (50%)
1754,BRD-K53913008,CP-316819,CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,10273347,Preclinical,glycogen phosphorylase inhibitor,PYGL,"","",5836,No-Effect
1755,BRD-K00004233,CP-339818,CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12,,Preclinical,potassium channel blocker,KCNA3,"","",3738,No-Effect
1756,BRD-K31394475,CP-376395,CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C,9862166,Phase 1,corticotropin releasing factor receptor antagonist,CRHR1,"","",1394,No-Effect
1757,BRD-K33234937,CP-471474,CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO,9907286,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,"","",4322|4312|4313|4314|4318,No-Effect
1758,BRD-K36611520,CP-532623,CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F,10145345,Phase 1,cholesteryl ester transfer protein inhibitor,CETP,"","",1071,No-Effect
1760,BRD-K26921335,CP-640186,O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1,449097,Preclinical,acetyl-CoA carboxylase inhibitor,ACACA|ACACB,"","",32|31,Weak (50%)
1761,BRD-K43621685,CP-673451,COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1,10158940,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA|PDGFRB,"","",5156|5159|3815,No-Effect
1762,BRD-K76908866,CP-724714,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,9874913,Phase 2,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB2,"","",2064,No-Effect
1765,BRD-K81876028,CP-93129,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|,124007,Preclinical,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
1766,BRD-K33860217,CP-94253,CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|,4029677,Preclinical,serotonin receptor agonist,HTR1B,"","",3351,No-Effect
1767,BRD-K09090949,"CP-945,598",CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,10052040,Phase 3,cannabinoid receptor antagonist,CNR1,"","",1268,No-Effect
1768,BRD-K09946180,CP-99994,COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1,5311057,Phase 2,tachykinin antagonist,TACR1,"","",6869,No-Effect
1769,BRD-A69126730,CPA-inhibitor,"ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|",124386386,Preclinical,carboxypeptidase inhibitor,CPA1|CPA2,"","",1357|1358,No-Effect
1770,BRD-K00004223,CPCCOEt,"CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|",10106002,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
1771,BRD-K19871656,CPI-0610,Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|,57389999,Phase 2,bromodomain inhibitor,BRD4,"","",23476,Weak (50%)
1772,BRD-K11073688,CPI-1189,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,151118,Phase 2,tumor necrosis factor release inhibitor,TNF,"","",7124,No-Effect
1774,BRD-K97181972,CPI-169,CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12,71712226,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
1775,BRD-K15811707,CPI-203,Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|,71291068,Preclinical,bromodomain inhibitor,BRD4,"","",23476,No-Effect
1776,BRD-K18319422,CPI-360,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12,73442743,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
1778,BRD-A06916187,CPI-613,"OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|",70881528,Phase 3,pyruvate dehydrogenase inhibitor,PDHA1,"","",5160,No-Effect
1779,BRD-K66094457,CPP,OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1,6603754,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
1780,BRD-A81603255,CPSI-1306-(+/-),"Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|",52936269,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,"","",4282,No-Effect
1782,BRD-K40331046,CR8-(R),CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1,10224714,Preclinical,CDK inhibitor,CCNA2,"","",890,No-Effect
1783,BRD-K19615002,creatine,CN(CC(O)=O)C(N)=N,586,Launched,"",CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8,"","",1120|2593|1158|6535|1160|548596,No-Effect
1787,BRD-K22127577,crenolanib,CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,10366136,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,"","",5156|5159|3815|2322|1436,No-Effect
1790,BRD-K97939847,cridanimod,OC(=O)Cn1c2ccccc2c(=O)c2ccccc12,38072,Launched,progesterone receptor agonist,PGR,infectious disease,influenza A virus infection,5241,No-Effect
1791,BRD-K43230258,crisaborole,OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12,44591583,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology,dermatitis,5144|5141|5142|5143,No-Effect
1793,BRD-K78431006,crizotinib,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,11626560,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC),8731|238,No-Effect
1794,BRD-K40308497,crizotinib-(S),C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,56671814,Preclinical,MTH1 inhibitor,NUDT1,"","",4521,Very Weak (35%)
1797,BRD-M89827113,cromakalim,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,76968376,Phase 2,"",KCNJ8,"","",3764,No-Effect
1798,BRD-K20920669,cromoglicic-acid,OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O,2882,Launched,immunosuppressant,KCNMA1|S100P,pulmonary|ophthalmology|allergy|gastroenterology,asthma|conjunctivitis|urticaria|ulcerative colitis,3778|6286,Very Weak (35%)
1801,BRD-K33336844,cryptotanshinone,C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|,160254,Preclinical,acetylcholinesterase inhibitor|STAT inhibitor,STAT3,"","",6774,No-Effect
1803,BRD-K15519488,CS-110266,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,123692,Preclinical,dopamine receptor agonist,SLC6A3,"","",6531,No-Effect
1804,BRD-K35601925,CS-917,CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O,11289630,Phase 2,fructose biphosphate inhibitor,FBP1,"","",2203,No-Effect
1805,BRD-K40870905,CT-7758,OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|,10186367,Phase 2,integrin antagonist,ITGA4,"","",3676,No-Effect
1807,BRD-K30572193,CTEP,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,11646823,Preclinical,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
1808,BRD-K53508936,CTS-1027,ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,3342298,Phase 2,metalloproteinase inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,"","",4322|4312|4313|4314|4318,No-Effect
1810,BRD-K58234744,CU-CPT-4a,OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl,53242268,Preclinical,toll-like receptor inhibitor,TLR3,"","",7098,No-Effect
1811,BRD-K89462779,CU-T12-9,CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O,91826088,Preclinical,toll-like receptor agonist,TLR1|TLR2,"","",7096|7097,No-Effect
1812,BRD-K41278234,CUDC-101,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,24756910,Phase 1,EGFR inhibitor,EGFR|ERBB2,"","",2064|1956,No-Effect
1813,BRD-K69351586,CUDC-427,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1,71600094,Phase 1,apoptosis inhibitor,XIAP,"","",331,No-Effect
1814,BRD-K77638923,CUDC-907,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,54575456,Phase 2,PI3K inhibitor,HDAC2|PIK3R1,"","",3066|5295,Cyto
1815,BRD-K69624312,CUR-61414,COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1,10392802,Phase 1,smoothened receptor antagonist,DHH|IHH|SMO,"","",54498|3549|50846,No-Effect
1816,BRD-K07572174,curcumin,COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O,6971205,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,"","",768|4322|771|1576|1789|1131|5742|5743|23632|2033|339345|759|760|762|6652|765|4318|351,No-Effect
1817,BRD-K41933240,curcumol,CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C,14240392,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,"","",3716|3717|3718,Low (25%)
1818,BRD-K90777969,cutamesine,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,9907323,Phase 2,sigma receptor agonist,SIGMAR1,"","",10280,No-Effect
1819,BRD-K49197823,CV-1808,Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,6917803,Preclinical,adenosine receptor agonist,ADORA2A,"","",135,No-Effect
1820,BRD-K60659193,CVT-10216,CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O,23661666,Phase 1,aldehyde dehydrogenase inhibitor,ALDH2,"","",217,No-Effect
1821,BRD-K84068331,CW-008,COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1,59528098,Preclinical,PKA activator,PRKACA,"","",5578,No-Effect
1822,BRD-K81458380,CX-4945,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,24748573,Phase 1/Phase 2,casein kinase inhibitor,CSNK2A1|CSNK2A2|DAPK3|HIPK3,"","",10114|1459|1613,Very Weak (35%)
1826,BRD-K79353516,CY208-243,CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,58144,Phase 2,dopamine receptor agonist,CALY,"","",50632,No-Effect
1828,BRD-A42881122,cyamemazine,"C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|",14050069,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C|HTR7,neurology/psychiatry,schizophrenia|anxiety,3363|3356|3350|3358,No-Effect
1829,BRD-A18627414,cyanocobalamin,"C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|",,Launched,methylmalonyl CoA mutase stimulant|vitamin B,MUT,hematology|infectious disease|gastroenterology,anemia|fish tapeworm infestation|celiac disease,4594,No-Effect
1830,BRD-K01825675,cyanopindolol,CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|,6604791,Phase 2,adrenergic receptor antagonist,ADRB1|HTR1A|HTR1D,"","",3352|153|3350,No-Effect
1832,BRD-K64866502,CYC116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,6420138,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|KDR,"","",9212|6790|3791,No-Effect
1835,BRD-A41840684,cyclic-AMP,"Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|",40467852,Preclinical,"",CNGA3|TRPM7,"","",1261|54822,No-Effect
1836,BRD-K79501723,cyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,6726,Launched,histamine receptor modulator,HRH1|SULT1E1,gastroenterology|neurology/psychiatry,nausea|vomiting|vertigo|motion sickness,3269|6783,Very Weak (35%)
1837,BRD-K42348709,cyclobenzaprine,CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|,2895,Launched,adrenergic receptor agonist|serotonin receptor agonist,HTR2A,neurology/psychiatry,spasms,3356,Low (25%)
1840,BRD-K36055864,cycloheximide,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1,6197,Preclinical,protein synthesis inhibitor,RPL3,"","",6122,Weak (50%)
1844,BRD-A09722536,cyclophosphamide,ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|,9554282,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7,hematologic malignancy|oncology,Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer,100861540|1576|1577|1548|1555|1557|1558|1559|1562|1565,No-Effect
1845,BRD-A10420615,cyclopiazonic-acid,"CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|",54682463,Preclinical,ATPase inhibitor,ATP2A1,"","",487,No-Effect
1846,BRD-K87226815,cycloserine-(D),N[C@@H]1CONC1=O,6234,Launched,bacterial cell wall synthesis inhibitor,GRIN1,infectious disease,tuberculosis|tuberculosis,114787,No-Effect
1847,BRD-K13533483,cyclosporin-A,"CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|",,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis,5478|8647|10599|28234|6554|819|2357|10105|5530|5535,Very Weak (35%)
1848,BRD-K13533483,cyclosporin-A,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,5284373,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis,5478|8647|10599|28234|6554|819|2357|10105|5530|5535,Very Weak (35%)
1849,BRD-A38675539,cyclothiazide,"NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|",101691640,Launched,glutamate receptor modulator,CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3,cardiology,hypertension,2890|2891|2892|2893|760|6559,No-Effect
1850,BRD-K59866480,cyclovalone,COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O,1550234,Launched,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,9429,Very Weak (35%)
1853,BRD-K69877120,CYM-50260,FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1,44620894,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR4,"","",8698,No-Effect
1854,BRD-K80666802,CYM-50358,Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl,53358422,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR4,"","",8698,Weak (50%)
1855,BRD-K27732927,CYM-50769,COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1,50904505,Preclinical,neuropeptide receptor antagonist,NPBWR1,"","",2831,No-Effect
1856,BRD-A43005764,CYM-5442,CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|,93977386,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,"","",1901,Strong (80%)
1857,BRD-K29151923,CYM-5520,Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1,25110470,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR2,"","",9294,No-Effect
1858,BRD-K75940276,CYM-5541,O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1,17253208,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR3,"","",1903,No-Effect
1860,BRD-K28143534,cyproheptadine,CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|,2913,Launched,histamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7,allergy|otolaryngology|ophthalmology|dermatology,allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism,3362|3363|3269|1128|1129|1131|146|147|3356|3358,No-Effect
1861,BRD-K41141507,cyproterone-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",9880,Launched,androgen receptor antagonist,ADORA1|AR,oncology,prostate cancer,134|367,No-Effect
1863,BRD-K92611362,cysteamine,NCCS,6058,Launched,tissue transglutaminase inhibitor,NPY2R|SST,metabolism,cystinosis,6750|4887,No-Effect
1864,BRD-K23363278,CYT-997,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,11351021,Phase 2,tubulin polymerization inhibitor,TUBB,"","",7280,Cyto
1865,BRD-K87737963,cyt387,O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,25062766,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3,"","",3716|3717|3718,No-Effect
1866,BRD-K33106058,cytarabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,6253,Launched,ribonucleotide reductase inhibitor,POLA1|POLB|POLD1|POLE,hematologic malignancy,acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL),11232|5424|5426|5422,No-Effect
1868,BRD-K74186897,cytisine,O=c1cccc2[C@H]3CNC[C@H](C3)Cn12,10235,Launched,acetylcholine receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4,neurology/psychiatry,nicotinism,89832|8973|1135|1136|1137|1141|1143,No-Effect
1869,BRD-K26664453,cytochalasin-B,"C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|",5311281,Phase 2,microtubule inhibitor,ACTB,"","",728378,No-Effect
1871,BRD-K87021635,CZC-54252,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1,44252734,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,"","",120892,No-Effect
1872,BRD-K01377300,CZC24832,CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1,42623951,Preclinical,PI3K inhibitor,PIK3CG,"","",5294,No-Effect
1876,BRD-K09132007,D-4476,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1,6419753,Preclinical,TGF beta receptor inhibitor,CSNK1A1|CSNK1D|TGFB1,"","",7040|1452|1453,No-Effect
1877,BRD-K26997899,D-64131,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,3921152,Preclinical,microtubule inhibitor,TUBB,"","",7280,Cyto
1882,BRD-K00911807,D-phenylalanine,N[C@H](Cc1ccccc1)C(O)=O,71567,Preclinical,enkephalinase inhibitor,CCBL1|CRH|HCAR3,"","",1392|883|8843,No-Effect
1883,BRD-K71822263,D-serine,N[C@H](CO)C(O)=O,71077,Launched,glutamate receptor agonist,GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3,"","",114787|6317|2741|2903|2904|2905|2906,No-Effect
1886,BRD-K01080633,DAA-1106,COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1,10430788,Preclinical,benzodiazepine receptor agonist,TSPO,"","",706,No-Effect
1887,BRD-K38168441,dabigatran,Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1,216210,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT),2147,No-Effect
1888,BRD-K57041787,dabigatran-etexilate,CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1,9578572,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT),2147,No-Effect
1889,BRD-K09951645,dabrafenib,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F,44462760,Launched,RAF inhibitor,BRAF|LIMK1|NEK11|RAF1|SIK1,oncology,melanoma,673|102724428|3984|79858|6037,Very Weak (35%)
1890,BRD-K35520305,dacarbazine,CN(C)\N=N\c1nc[nH]c1C(N)=O,135398738,Launched,DNA alkylating agent,PGD|POLA2,oncology|hematologic malignancy,melanoma|Hodgkin's lymphoma,23649|26227,No-Effect
1891,BRD-K56957086,dacinostat,OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1,6445533,Phase 1,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,"","",55869|9734|8841|3065|3066|10013|10014|9759,Cyto
1893,BRD-K57169635,dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,11511120,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,"","",2064|2066|1956,No-Effect
1894,BRD-K70578146,dactinomycin,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O,457193,Launched,RNA polymerase inhibitor,POLR2A,oncology,testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD),5430,Cyto
1895,BRD-K42095107,daidzein,Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,5281708,Phase 2,estrogen receptor agonist,ESRRA|ESRRB|ESRRG|TRPC5,"","",2104|7224|2101|2103,No-Effect
1896,BRD-K12979078,daidzin,OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O,107971,Phase 1,antioxidant,ALDH2,"","",217,No-Effect
1897,BRD-A89196962,dalargin,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|",,Phase 2,opioid receptor agonist,OPRM1,"","",4988,No-Effect
1898,BRD-K30177383,dalbavancin,CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2,16134627,Launched,bacterial cell wall synthesis inhibitor,PNLIP,infectious disease,skin infections,5406,No-Effect
1899,BRD-K18849474,dalcetrapib,CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C,6918540,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,"","",1071,No-Effect
1900,BRD-K22482860,dalfampridine,Nc1ccncc1,1727,Launched,potassium channel blocker,KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2,neurology/psychiatry,multiple sclerosis,56479|27012|81033|26251|90134|3736|3737|3738|3739|131096|3741|3742|3743|3744|3745|3746|3747|3748|3749|3750|3751|3752|3754|3755|3756|3757|9132|3762|93107|169522|3769|3784|3785|3786|3787|3788|3790|9312|170850|23415|23416|27133,Weak (50%)
1902,BRD-K26813177,daltroban,OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,54343,Phase 3,thromboxane receptor antagonist,TBXA2R,"","",6915,No-Effect
1903,BRD-K83452553,daminozide,CN(C)NC(=O)CCC(O)=O,72200802,Preclinical,KDM2A inhibitor,KDM2A|KDM7A|PHF8,"","",22992|23133|80853,No-Effect
1904,BRD-K48970916,danazol,C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|,28417,Launched,estrogen receptor antagonist|progesterone receptor agonist,AR|CCL2|ESR1|GNRHR|GNRHR2|PGR,obstetrics/gynecology|cardiology,endometriosis|angioedema,6347|2798|367|2099|5241|114814,No-Effect
1906,BRD-K13769342,danirixin,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,24780598,Phase 2,CC chemokine receptor antagonist,CXCR2,"","",3579,No-Effect
1909,BRD-K81272440,dantrolene,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,6914273,Launched,calcium channel blocker,RYR1|RYR3,neurology/psychiatry|endocrinology,spasms|malignant hyperthermia (MH),6261|6263,No-Effect
1911,BRD-K07881437,danusertib,CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1,11442891,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK,"","",6790|2534|6795|4914|2260|5979|9212,No-Effect
1912,BRD-K58160573,dapagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,9887712,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524,Very Weak (35%)
1915,BRD-K33133047,dapiprazole,Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1,3033538,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,ophthalmology,mydriasis,146|147,No-Effect
1916,BRD-K12885236,dapivirine,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,214347,Phase 3,non-nucleoside reverse transcriptase inhibitor,CYP3A4|CYP3A5,"","",1576|1577,No-Effect
1917,BRD-K51579475,dapoxetine,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,71353,Launched,selective serotonin reuptake inhibitor (SSRI),HTR1A|HTR1B|HTR2C|SLC6A4,urology,premature ejaculation (PE),6532|3358|3350|3351,Low (25%)
1918,BRD-K06455935,daprodustat,OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O,24831508,Phase 3,hypoxia inducible factor inhibitor,EGLN1,"","",54583,No-Effect
1919,BRD-K62363391,dapsone,Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1,2955,Launched,bacterial antifolate,DHFR,dermatology|infectious disease,dermatitis herpetiformis (DH)|leprosy,1719,No-Effect
1922,BRD-K19085898,darapladib,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,9939609,Phase 3,phospholipase inhibitor,PLA2G7,"","",7941,No-Effect
1923,BRD-K82908348,darglitazone,Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1,60870,Phase 2,PPAR receptor antagonist,PPARG,"","",5468,No-Effect
1924,BRD-K95773607,darifenacin,NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1,444031,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence,1128|1129|1131|1132|1133,No-Effect
1925,BRD-A44971162,darolutamide,"C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|",121489720,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367,No-Effect
1926,BRD-K84986517,darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,213039,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576,No-Effect
1927,BRD-K54863166,darusentan,COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1,177236,Phase 3,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
1929,BRD-K49328571,dasatinib,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,3062316,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL),640|4067|6725|2534|3815|3932|5159|7525|2444|3055|1969|6777|25|6714|27|2268,No-Effect
1931,BRD-K31633810,DAU-5884,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O,,Preclinical,acetylcholine receptor antagonist,CHRM3,"","",1131,No-Effect
1933,BRD-K43389675,daunorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O,30323,Launched,RNA synthesis inhibitor|topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL),7153|7155,Cyto
1934,BRD-K20738689,dazmegrel,Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O,53555,Phase 2,thromboxane synthase inhibitor,TBXAS1,"","",6916,No-Effect
1935,BRD-K82767007,dazoxiben,OC(=O)c1ccc(OCCn2ccnc2)cc1,53001,Phase 2,thromboxane synthase inhibitor,TBXAS1,"","",6916,No-Effect
1936,BRD-K59204667,DBeQ,C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1,676352,Preclinical,ATPase inhibitor,CASP3,"","",836,No-Effect
1938,BRD-K83020231,DBPR108,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,44201003,Phase 1,dipeptidyl peptidase inhibitor,DPP4,"","",1803,No-Effect
1939,BRD-K10596918,DC-260126,CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1,2843133,Preclinical,free fatty acid receptor antagonist,FFAR1,"","",2864,No-Effect
1940,BRD-K49246350,DCC-2618,Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1,46208890,Phase 1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA,"","",5156|3815,No-Effect
1941,BRD-K89299012,DCEBIO,CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O,656765,Preclinical,potassium channel activator,KCNN2|KCNN3|KCNN4,"","",3781|3782|3783,No-Effect
1943,BRD-A39255369,DCPIB,"CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|",12761153,Preclinical,chloride channel blocker|gap junction modulator|glutamate inhibitor,SLC1A2,"","",6506,No-Effect
1944,BRD-K61845293,DDR1-IN-1,CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1,72836888,Preclinical,discoidin domain receptor inhibitor,DDR1|DDR2,"","",4921|780,Strong (80%)
1947,BRD-K80419150,debrisoquin,NC(=N)N1CCc2ccccc2C1,2966,Launched,adrenergic neuron blocker,SLC6A2,cardiology,hypertension,6530,No-Effect
1948,BRD-K49783248,decamethonium,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,2968,Launched,acetylcholine receptor agonist,ACHE|CHRNA2,neurology/psychiatry,muscle relaxant,43|1135,No-Effect
1950,BRD-A95300432,decernotinib,"CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|",59422203,Phase 2/Phase 3,JAK inhibitor,JAK3,"","",3718,No-Effect
1951,BRD-K79254416,decitabine,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,451668,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML),1786|1788,No-Effect
1955,BRD-K43578482,defactinib,CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1,25117126,Phase 2,focal adhesion kinase inhibitor,PTK2,"","",5747,No-Effect
1956,BRD-K97010173,deferasirox,OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,214348,Launched,chelating agent,CYP3A4,hematology,transfusional hemosiderosis|thalassemia|iron overload,1576,No-Effect
1958,BRD-K06878038,deferiprone,Cc1c(O)c(=O)ccn1C,2972,Launched,chelating agent,UGT1A6,hematology,transfusional hemosiderosis|thalassemia|iron overload,54578,No-Effect
1960,BRD-K30468934,deflazacort,"CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|",189821,Launched,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,2908,No-Effect
1961,BRD-K62304154,deforolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|",,Phase 3,mTOR inhibitor,MTOR,"","",2475,No-Effect
1962,BRD-K00003578,degarelix,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,16136245,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer,2798,No-Effect
1966,BRD-K67186445,dehydrocorydaline,COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC,34781,Phase 3,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
1967,BRD-K41256143,dehydroepiandrosterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|,5881,Launched,protein synthesis stimulant,ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1,endocrinology,menopause,2560|2561|2562|2563|2564|2565|2566|2567|2568|8856|6820|6822|10280|2099|2100|55879|8266|2903|2904|2905|2906|116443|116444|3292|5465|114787|9970|2554|2555|2556|2557|2558|2559,No-Effect
1968,BRD-K15360631,dehydroepiandrosterone-sulfate,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|,12594,Launched,androgen receptor agonist|estrogen receptor agonist,AR|ESR1|ESR2,endocrinology,menopause,2099|2100|367,No-Effect
1971,BRD-K59325863,delanzomib,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O,24800541,Phase 1/Phase 2,proteasome inhibitor,CMA1|CTSG|CYP3A4|ELANE,"","",1576|1991|1511|1215,Cyto
1972,BRD-K00573984,delapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1,5362116,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
1973,BRD-K34068325,delavirdine,CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1,5625,Launched,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576,No-Effect
1976,BRD-K45503887,delivert,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O,78357780,Launched,angiotensin receptor agonist,AGTR1|AGTR2,critical care,sepsis,185|186,Low (25%)
1978,BRD-K79107392,delphinidin,Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1,128853,Phase 2,membrane permeability inhibitor,GLO1,"","",2739,No-Effect
1979,BRD-K85776940,delta-tocotrienol,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1,5282350,Phase 1,HMGCR inhibitor,HMGCR,"","",3156,No-Effect
1980,BRD-K90830492,deltarasin,C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1,73292904,Preclinical,phosphodiesterase inhibitor,KRAS,"","",3265,Strong (80%)
1981,BRD-K51471001,demecarium,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,5966,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,ophthalmology,intraocular pressure|glaucoma,43|590,No-Effect
1987,BRD-K41170226,deoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,222528,Launched,biliverdin reductase A activator|G protein-coupled receptor agonist,FPR1|GPBAR1,endocrinology,submental fat,151306|2357,No-Effect
1989,BRD-K33151569,deoxyepinephrine,CNCCc1ccc(O)c(O)c1,4382,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,ADRA1A|DRD1|DRD2,"","",146|1812|1813,No-Effect
1990,BRD-K00005351,deptropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|",,Preclinical,histamine receptor antagonist,HRH1,"","",3269,Very Weak (35%)
1991,BRD-K77685957,dequalinium,Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12,2993,Launched,PKC inhibitor,KCNN1|KCNN3,infectious disease,first-aid antiseptic,3780|3782,No-Effect
1992,BRD-K68558722,deracoxib,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,3058754,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743,No-Effect
1994,BRD-K29462201,deserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,8550,Launched,angiotensin converting enzyme inhibitor,ACE|SLC18A2,cardiology,hypertension,6571|1636,Very Weak (35%)
1996,BRD-K60762818,desipramine,CNCCCN1c2ccccc2CCc2ccccc12,2995,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1,neurology/psychiatry,depression,6530|6532|146|147|1813|150|151|152|153|154|3350|3356|3358|3269|6609|1128|1129|1131|1132|1133,No-Effect
1998,BRD-K99919177,deslanoside,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|,28620,Launched,Na/K-ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia,480|481|482|483|486|476|477|478,Strong (80%)
1999,BRD-K82357231,desloratadine,Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1,124087,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269,No-Effect
2001,BRD-K10042277,desmethylclozapine,Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|,135409468,Phase 2,acetylcholine receptor agonist,HTR2C,"","",3358,No-Effect
2002,BRD-K00003582,desmopressin-acetate,NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|,,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,endocrinology|urology,central diabetes insipidus|nocturnal enuresis,552|553|554|5021,No-Effect
2003,BRD-K46061689,desogestrel,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|,40973,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099,No-Effect
2004,BRD-K21528677,desonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",5311066,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,gastroenterology,Crohn's disease,2908|5319,No-Effect
2005,BRD-K30697463,desoximetasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|",5311067,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319,No-Effect
2006,BRD-K26024145,desoxycorticosterone-pivalate,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|,11876263,Launched,corticosteroid agonist,NR3C2,endocrinology,Addison's disease,4306,No-Effect
2007,BRD-K98521173,desoxycortone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|,6166,Preclinical,mineralocorticoid receptor agonist,NR3C1|NR3C2,"","",4306|2908,No-Effect
2008,BRD-K13819402,desoxypeganine,C1CN2Cc3ccccc3N=C2C1 |c:11|,442894,Phase 1,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,ACHE,"","",43,No-Effect
2009,BRD-K01825598,desvenlafaxine,CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|,12018336,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532,No-Effect
2010,BRD-K77597856,detomidine,Cc1cccc(Cc2cnc[nH]2)c1C,56032,Launched,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative,150,No-Effect
2012,BRD-K38775274,dexamethasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",5743,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR0B1|NR3C1|NR3C2,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis,301|339345|4306|2908|190,No-Effect
2015,BRD-K30019776,dexfosfoserine,N[C@@H](COP(O)(O)=O)C(O)=O,68841,Preclinical,membrane integrity inhibitor,CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2,"","",9344|2914|2916|2917|2918|3749|5578|5836|5837|6317|5967|9361|5170|5588|4087|1080|6010,No-Effect
2016,BRD-K05900209,dexlansoprazole,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,9578005,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE),495,No-Effect
2017,BRD-K07609981,dexloxiglumide,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,65937,Phase 3,CCK receptor antagonist,CCKAR,"","",886,No-Effect
2018,BRD-K18423410,dexmedetomidine,C[C@H](c1cnc[nH]1)c1cccc(C)c1C,5311068,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative,152|150|151,Low (25%)
2019,BRD-K44309363,dexniguldipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",6918097,Phase 2,calmodulin antagonist,ADORA3,"","",140,No-Effect
2021,BRD-K07265709,dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,71384,Launched,chelating agent|topoisomerase inhibitor,TOP2A|TOP2B,cardiology,cardiomyopathy,7153|7155,No-Effect
2023,BRD-K33211335,dextromethorphan,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,5360696,Launched,glutamate receptor antagonist|sigma receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4,pulmonary,cough suppressant,1536|6530|6532|6035|10280|653361|4688|4689|116443|89832|10857|1135|1136|1137|1141|1143|5880|4985|4986|4988|1535,No-Effect
2026,BRD-K82002057,DFB,Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1,6604893,Preclinical,glutamate receptor agonist,GRM5,"","",2915,No-Effect
2027,BRD-K75748943,DG-172,CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1,57342889,Preclinical,PPAR receptor inverse agonist,PPARD,"","",5467,No-Effect
2029,BRD-K06014311,DH-97,CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,3467177,Preclinical,melatonin receptor antagonist,MTNR1B,"","",4544,No-Effect
2031,BRD-K69122748,diacerein,CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O,26248,Launched,interleukin inhibitor,IL1B,rheumatology,osteoarthritis,3553,No-Effect
2033,BRD-A52394261,diadenosine-tetraphosphate,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|",21706,Phase 1,adenosine kinase inhibitor,P2RY13|P2RY2,"","",53829|5029,No-Effect
2035,BRD-A27143604,diarylpropionitrile,"Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|",6604873,Preclinical,estrogen receptor agonist,ESR2,"","",2100,No-Effect
2038,BRD-K73109821,diazoxide,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|,3019,Launched,potassium channel activator,ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3,endocrinology,hypoglycemia,3778|759|3764|3767|760|476|6559,No-Effect
2042,BRD-K73477617,dibutyl-phthalate,CCCCOC(=O)c1ccccc1C(=O)OCCCC,3026,Preclinical,"",TRPA1,"","",8989,No-Effect
2048,BRD-K08252256,diclofenac,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,3033,Launched,cyclooxygenase inhibitor,AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A,rheumatology|neurology/psychiatry,rheumatoid arthritis|osteoarthritis|migraine headache,8644|5320|41|3785|3786|5742|5743|240|6329|5468|9311,No-Effect
2049,BRD-K71499074,diclofenamide,NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,3038,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA4|CA7,ophthalmology|neurology/psychiatry,glaucoma|epilepsy,771|759|760|762|766,No-Effect
2050,BRD-A51078674,diclofensine,COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|,23872188,Phase 3,dopamine reuptake inhibitor,DRD1|MAOA|MAOB,"","",4128|4129|1812,No-Effect
2053,BRD-K82236179,dicoumarol,Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12,54676038,Launched,NADPH inhibitor,CRYZ|NQO1|VKORC1,hematology,deep vein thrombosis (DVT),1728|79001|1429,No-Effect
2055,BRD-K68507560,dicycloverine,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,3042,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,irritable bowel syndrome,1128|1129|1131,Very Weak (35%)
2056,BRD-K99063460,didanosine,OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O,135398739,Launched,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1),5539,No-Effect
2058,BRD-K94146583,didox,ONC(=O)c1ccc(O)c(O)c1,3045,Launched,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer,6240,No-Effect
2059,BRD-K95309561,dienestrol,C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1,667476,Launched,estrogen receptor agonist,ESR1,endocrinology,menopause,2099,No-Effect
2060,BRD-K50853363,dienogest,"C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|",68861,Launched,progesterone receptor agonist,PGR,endocrinology|obstetrics/gynecology,contraceptive|endometriosis,5241,Low (25%)
2061,BRD-K45542189,diethylcarbamazine,CCN(CC)C(=O)N1CCN(C)CC1,3052,Launched,lipoxygenase inhibitor,ALOX5|PTGS1,infectious disease,filariasis,240|5742,No-Effect
2062,BRD-K45330754,diethylstilbestrol,CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1,448537,Withdrawn,estrogen receptor agonist,ESR1|ESR2|ESRRB|ESRRG,"","",2104|2099|2100|2103,No-Effect
2065,BRD-A66869276,diflorasone-diacetate,"C[C@H]1C[C@H]2[C@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O |a:1,6,14,16,18,21,23,&1:3,&2:4,c:12,t:8|",51895260,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
2067,BRD-K22031190,diflunisal,OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F,3059,Launched,prostanoid receptor antagonist,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743,No-Effect
2068,BRD-K72992801,difluprednate,"CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|",443936,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,2908,Low (25%)
2071,BRD-K63668566,digitoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|,441207,Launched,ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia,480|481|482|483|486|476|477|478,Strong (80%)
2073,BRD-K00004302,digoxin,[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|,12940973,Launched,ATPase inhibitor,ATP1A1,cardiology,congestive heart failure|atrial fibrillation (AF),476,Strong (80%)
2074,BRD-K20152659,dihomo-gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,5280581,Phase 2,prostanoid receptor agonist,PTGS1|PTGS2,"","",5742|5743,No-Effect
2075,BRD-K31471398,dihydrexidine,Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O,6603820,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|DRD5,"","",1812|1813|1814|1815|1816,No-Effect
2077,BRD-K97440753,dihydroergocristine,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,107715,Launched,adrenergic receptor antagonist|prolactin inhibitor,ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7,neurology/psychiatry,senile dementia|cerebrovascular insufficiency,3360|3361|3362|3363|146|1812|1813|1814|1815|1816|153|3350|3356|3359,No-Effect
2078,BRD-K72166146,dihydroergotamine,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,10531,Launched,serotonin receptor agonist,ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache,3363|106480180|1813|150|3351|3352|3354|3355,No-Effect
2081,BRD-A34455052,dihydrotachysterol,"CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|",,Launched,vitamin analog,VDR,orthopedics|endocrinology,rickets|hypocalcemia|osteomalacia,1594,No-Effect
2083,BRD-A20589515,dihydroxyphenylglycine,"N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|",10197959,Preclinical,glutamate receptor agonist,GRM1|GRM5,"","",2915|2911,No-Effect
2085,BRD-K48722258,dilazep,COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1,3074,Launched,adenosine reuptake inhibitor,SLC29A1,cardiology,coronary heart disease,2030,No-Effect
2088,BRD-K24023109,diltiazem,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,39186,Launched,calcium channel blocker,CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5,cardiology,hypertension|angina pectoris,775|779|781|786|3741|3359,No-Effect
2090,BRD-K23541596,dimaprit,CN(C)CCCSC(N)=N,3077,Preclinical,histamine receptor agonist,HRH2|HRH3|HRH4,"","",1665|59340|11255,No-Effect
2091,BRD-K29812331,dimemorfan,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31,3037918,Launched,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant,10280,No-Effect
2092,BRD-M98649031,dimenhydrinate,Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1,10660,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|gastroenterology,motion sickness|nausea|vomiting,3269,No-Effect
2094,BRD-K88701661,dimercaptosuccinic-acid,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,2724354,Launched,chelating agent,DNMT1,neurology/psychiatry,metal toxicity,1786,No-Effect
2098,BRD-K83192048,dimethindene-(S)-(+),C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|,6604866,Preclinical,acetylcholine receptor antagonist,HRH1,"","",3269,No-Effect
2100,BRD-K31111078,dimethyl-fumarate,COC(=O)\C=C\C(=O)OC,637568,Launched,nuclear factor erythroid derived|like (NRF2) activator,KEAP1,neurology/psychiatry,multiple sclerosis,9817,No-Effect
2102,BRD-K01826026,dimetindene,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|",6604866,Launched,cholinergic receptor antagonist|histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,No-Effect
2104,BRD-K92848252,diminazene-aceturate,NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1,2354,Phase 3,angiotensin converting enzyme activator,AOC1|PRDX5|PRSS1,"","",25824|26|136541,No-Effect
2105,BRD-K60567437,dimpylate,CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C,3017,Launched,acetylcholinesterase inhibitor,ACHE,infectious disease,flea control,43,No-Effect
2106,BRD-K13662825,dinaciclib,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,46926350,Phase 3,CDK inhibitor,CDK1|CDK2|CDK5|CDK9,"","",1017|1020|1025|983,Cyto
2108,BRD-K81672972,dinoprost,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,5280363,Launched,prostacyclin analog,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,obstetrics/gynecology,labor induction,5729|5731|5732|5733|5734|6915|5737|11251,No-Effect
2109,BRD-K26521938,dinoprostone,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,5280360,Withdrawn,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,"","",5729|117155|5731|5732|5733|5734|6915|5737|11251|347732|378807|117144,No-Effect
2110,BRD-K67340225,dioscin,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|,119245,Preclinical,apoptosis stimulant,CXCR3,"","",2833,No-Effect
2112,BRD-K26862302,diosmetin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1,5281612,Launched,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic,1545,No-Effect
2113,BRD-K94436377,diosmin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1,5281613,Launched,aryl hydrocarbon receptor agonist|capillary stabilizing agent,AHR,cardiology|hematology|dermatology,chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome,196,No-Effect
2117,BRD-K93441486,diphemanil,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,6127,Launched,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,1131,No-Effect
2119,BRD-K47278471,diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,3100,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,headache,3269,No-Effect
2120,BRD-K01663662,diphenidol,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,3055,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,vertigo,1128|1129|1131|1132,No-Effect
2121,BRD-K65814004,diphenyleneiodonium,[I]1c2ccccc2-c2ccccc12 |^1:0|,,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,"","",339345|342977,No-Effect
2123,BRD-K22936972,diphenylpyraline,CN1CCC(CC1)OC(c1ccccc1)c1ccccc1,3103,Launched,dopamine reuptake inhibitor,HRH1|SLC6A3,allergy,allergic rhinitis,6531|3269,No-Effect
2125,BRD-K64838454,dipraglurant,Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,44557636,Phase 2,glutamate receptor negative allosteric modulator,GRM5,"","",2915,No-Effect
2126,BRD-K75385383,DIPT,CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,26903,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR1A|HTR2A|HTR2C,"","",3356|3350|3358,No-Effect
2127,BRD-K86301799,dipyridamole,OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO,3108,Launched,phosphodiesterase inhibitor,ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1,cardiology,coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension,5136|5137|5138|5139|5140|5141|5142|5143|5144|5145|5146|5147|5148|5149|5150|5151|5152|5153|5158|8622|8654|10846|100|27115|2030,Low (25%)
2132,BRD-K66672047,disodium-sebacate,OC(=O)CCCCCCCCC(O)=O,5192,Phase 1,"",HBB,"","",85344,No-Effect
2133,BRD-A29734509,disopyramide,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|,3114,Launched,sodium channel blocker,CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A,cardiology,ventricular tachycardia (VT)|ventricular arrhythmias,3751|1128|1129|3752|1131|3757|6331,Low (25%)
2134,BRD-K32744045,disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,3117,Launched,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol,217|1621,No-Effect
2136,BRD-K40654626,ditiocarb-sodium-trihydrate,CCN(CC)C(S)=S,8987,Phase 3,immunostimulant,CA1|CA2|CA4,"","",760|762|759,No-Effect
2137,BRD-K33459542,ditolylguanidine,Cc1ccccc1NC(=N)Nc1ccccc1C,7333,Preclinical,sigma receptor agonist,GRIN1|GRIN2A|GRIN2B|SIGMAR1,"","",2904|10280|114787|2903,No-Effect
2141,BRD-K58930050,dizocilpine-(+),C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,180081,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
2142,BRD-K26573499,DMAB-anabaseine,CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|,9926048,Preclinical,adrenergic receptor agonist,CHRNA7,"","",89832,No-Effect
2143,BRD-K36775483,DMeOB,COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1,6891506,Preclinical,glutamate receptor modulator,GRM5,"","",2915,No-Effect
2144,BRD-K39381259,DMH1,CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,50997747,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1,"","",90,No-Effect
2145,BRD-K40575944,DMH4,C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1,5329447,Preclinical,VEGFR inhibitor,KDR,"","",3791,No-Effect
2148,BRD-K54936858,DMP-777,CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1,177992,Phase 2,elastase inhibitor,MPO,"","",4353,Low (25%)
2151,BRD-K64400208,DNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O,3899541,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B,"","",114787|2890|2891|2897|2903|2904,No-Effect
2152,BRD-A78322124,dobutamine,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,65324,Launched,adrenergic receptor agonist,ADRB1|ADRB2,cardiology,congestive heart failure,153|154,No-Effect
2153,BRD-K08290224,docebenone,"CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|",1967,Phase 2,lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
2154,BRD-K30577245,docetaxel,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|,148124,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC),10376|84617|10381|10382|10383|8856|4134|7846|347688|4137|113457|84790|203068|112714|596|347733|10988|7277|7278|7280,No-Effect
2155,BRD-K39965020,doconexent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,445580,Launched,PPAR receptor agonist,FFAR1|PTGS1|PTGS2,"","",2864|5742|5743,No-Effect
2157,BRD-K50050533,docosanol,CCCCCCCCCCCCCCCCCCCCCCO,12620,Launched,lipase clearing factor inhibitor,TLR7,dental,cold sore,51284,No-Effect
2159,BRD-K05680146,dodecyl-sulfate,CCCCCCCCCCCCOS(O)(=O)=O,8778,Preclinical,"",LYZ,"","",4069,Low (25%)
2160,BRD-A14941520,dofequidar,OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1,9960287,Phase 3,MRP inhibitor|P glycoprotein inhibitor,ABCB1,"","",5243,No-Effect
2161,BRD-K86887724,dofetilide,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,71329,Withdrawn,potassium channel blocker,KCNH1|KCNH2|KCNJ12|KCNK2,"","",3768|3756|3757|3776,No-Effect
2162,BRD-K28029915,dolasetron,O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12,,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359,No-Effect
2163,BRD-K78567475,dolastatin-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,9810929,Phase 2,tubulin polymerization inhibitor,TUBB,"","",7280,Strong (80%)
2164,BRD-K67463151,dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,54726191,Launched,HIV integrase inhibitor,CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1,infectious disease,human immunodeficiency virus (HIV-1),54658|100861540|1576|1577|5452,No-Effect
2166,BRD-K38305202,domperidone,Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1,3151,Launched,dopamine receptor antagonist,DRD2|DRD3,infectious disease,fescue toxicosis,1813|1814,No-Effect
2167,BRD-A49160188,donepezil,COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|,1150567,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,Alzheimer's disease,43,No-Effect
2168,BRD-K31092604,donitriptan,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12,197706,Phase 2,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6,"","",3361|3362|3350|3351|3352|3354|3355|3356,No-Effect
2169,BRD-K43887077,dopamine,NCCc1ccc(O)c(O)c1,681,Launched,dopamine receptor agonist,DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4,cardiology|neurology/psychiatry,ventricular arrhythmias|depression|headache|tremors,6530|3363|6531|6532|1815|1812|1813|1621|1814|1816|3350,No-Effect
2170,BRD-K74065929,doramapimod,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C,156422,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,"","",5600|5603|6300|1432,No-Effect
2173,BRD-K45319714,doripenem,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|,73303,Launched,bacterial cell wall synthesis inhibitor,DPEP1,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis,1800,No-Effect
2174,BRD-K54233340,dorsomorphin,C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1,11524144,Preclinical,AMPK inhibitor,ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC,"","",2280|3791|5562|657|1969|658|2321|2322|6195|6714|8569|90|3932,Weak (50%)
2175,BRD-K48617017,dorzolamide,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,5284549,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,intraocular pressure|glaucoma,771|23632|759|760|762|766,No-Effect
2176,BRD-K54759182,dosulepin,CN(C)CC\C=C1/c2ccccc2CSc2ccccc12,5284550,Launched,norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|3269|1128|1129|1131|1132|1133,No-Effect
2178,BRD-K85402309,dovitinib,CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O,135398510,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,"","",1956|5156|3815|5159|3791|2321|2322|2260|2261|2324|2263|3643|1436,No-Effect
2180,BRD-K01825125,doxazosin,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|",6604102,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,146|147,No-Effect
2181,BRD-K37694030,doxepin,CN(C)CC\C=C1\c2ccccc2COc2ccccc12,667468,Launched,histamine receptor antagonist,HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression|anxiety,6530|6532|3269,No-Effect
2182,BRD-K82928892,doxercalciferol,CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C,46931009,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperparathyroidism,1594,Low (25%)
2183,BRD-K58262659,doxifluridine,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,18343,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,7298,No-Effect
2184,BRD-K70507123,doxofylline,Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O,50942,Launched,adenosine receptor antagonist,ADORA1|PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,asthma,134|5141|5142|5143|5144,No-Effect
2185,BRD-K92093830,doxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,31703,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy|oncology,acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma,7153,No-Effect
2186,BRD-K01825679,doxycycline,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|",,Launched,bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor,MMP8,dental,periodontitis,4317,No-Effect
2187,BRD-A44008656,doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,43833352,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,sedative,3269,No-Effect
2190,BRD-K01824921,DPCPX,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1,1329,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
2191,BRD-A64553394,DPI-201106,"O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|",10389826,Phase 2,sodium channel activator,ADRB2,"","",154,No-Effect
2192,BRD-K99922388,DPO-1,CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1,21678144,Preclinical,potassium channel blocker,KCNA5,"","",3741,No-Effect
2193,BRD-K80315159,DPPE,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,108092,Phase 3,histamine receptor antagonist,ABCB1|HRH1,"","",5243|3269,No-Effect
2194,BRD-A67976398,DQP-1105,"Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|",136902743,Preclinical,glutamate receptor antagonist,GRIN2C|GRIN2D,"","",2905|2906,No-Effect
2195,BRD-K94920105,DR-2313,Cc1nc(=O)c2CSCCc2[nH]1,135522417,Preclinical,PARP inhibitor,PARP1|PARP3,"","",142|10039,No-Effect
2196,BRD-A39794701,DR-4485,"Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|",92211523,Preclinical,serotonin receptor antagonist,HTR7,"","",3363,No-Effect
2197,BRD-K25486274,DRF053-(R),CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1,25168304,Preclinical,CDK inhibitor,CSNK1A1,"","",1452,No-Effect
2199,BRD-K38477637,droloxifene,CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,3033767,Phase 3,selective estrogen receptor modulator (SERM),ESR1,"","",2099,No-Effect
2200,BRD-A38706605,dromostanolone-propionate,"CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|",,Launched,androgen receptor modulator,AR,oncology,breast cancer,367,No-Effect
2201,BRD-K05524748,dronedarone,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,208898,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A,cardiology,atrial fibrillation (AF),3776|775|776|778|779|3757|782|783|784|785|146|147|6323|150|151|152|153|3741,No-Effect
2202,BRD-K97158071,droperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|,3168,Launched,dopamine receptor antagonist,ADRA1A|DRD2|DRD3|DRD4|HTR2A,gastroenterology,nausea|vomiting,146|1813|1814|1815|3356,No-Effect
2204,BRD-K04394237,drospirenone,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|,68873,Launched,mineralocorticoid receptor antagonist,AR|NR3C2|PGR,endocrinology,contraceptive,5241|4306|367,No-Effect
2206,BRD-K17219082,droxicam,CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O,65679,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis|osteoarthritis,5742,No-Effect
2207,BRD-K20372197,droxidopa,N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O,92974,Launched,norepinephrine precursor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH,cardiology|neurology/psychiatry,hypertension|Parkinson's Disease,146|147|150|151|152|153|154|155|5053,No-Effect
2208,BRD-K11558771,droxinostat,Cc1cc(Cl)ccc1OCCCC(=O)NO,568416,Preclinical,HDAC inhibitor,HDAC6|HDAC8,"","",55869|10013,No-Effect
2212,BRD-K46384285,DSR-6434,CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1,25071151,Preclinical,toll-like receptor agonist,TLR7,"","",51284,No-Effect
2213,BRD-K08859203,DU-728,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,107775,Phase 1,structural glycoprotein antagonist,ITGA2B|ITGB3,"","",3674|3690,No-Effect
2214,BRD-K71103788,duloxetine,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,60835,Launched,norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI),HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy,3362|6531|6530|6532|3356|3358,Strong (80%)
2215,BRD-K06221026,DUP-697,CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1,3177,Phase 1,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
2216,BRD-K30373883,dutasteride,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|,6918296,Launched,5 alpha reductase inhibitor,SRD5A1|SRD5A2|SRD5A3,urology,benign prostatic hyperplasia (BPH),6715|6716|79644,No-Effect
2217,BRD-K93468883,duvelisib,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,50905713,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,Low (25%)
2221,BRD-K72259270,dyclonine,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,3180,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,local anesthetic,6336|6331,Weak (50%)
2222,BRD-K68620903,dydrogesterone,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|",9051,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility,5241,Very Weak (35%)
2223,BRD-K87718015,dynasore,Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O,135533054,Preclinical,dynamin inhibitor,DNM1|DNM1L|DNM2,"","",1785|10059|1759,No-Effect
2224,BRD-K23479488,dynole-34-2,CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N,44157463,Preclinical,dynamin inhibitor,DNM1,"","",1759,No-Effect
2225,BRD-A00827783,dyphylline,"Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|",688353,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4A,pulmonary,asthma|bronchitis|emphysema,5141,No-Effect
2227,BRD-K50564936,E-2012,COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,11560787,Phase 1,gamma secretase modulator,APH1A|APH1B|PSENEN,"","",83464|55851|51107,No-Effect
2228,BRD-K41713976,E-4031,Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1,3185,Phase 1,potassium channel blocker,KCNH1|KCNH2,"","",3756|3757,No-Effect
2229,BRD-K00004314,E-64,CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N,123985,Preclinical,calpain inhibitor|cysteine protease inhibitor,CTSS,"","",1520,No-Effect
2232,BRD-K05444225,E7449,O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23,135565981,Phase 2,PARP inhibitor,PARP1|PARP2|TNKS|TNKS2,"","",10038|8658|142|80351,No-Effect
2234,BRD-K53030960,eact,COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1,3173542,Preclinical,calcium-activated chloride channel inhibitor,ANO1,"","",55107,No-Effect
2235,BRD-K66998413,EB-47,Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1,53229989,Preclinical,PARP inhibitor,PARP1,"","",142,No-Effect
2236,BRD-K13314656,ebastine,CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,3191,Launched,histamine receptor antagonist,CYP3A4|HRH1,allergy,allergic rhinitis|urticaria,1576|3269,No-Effect
2237,BRD-K00004209,EBPC,"CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|",6919079,Preclinical,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
2238,BRD-K22421059,ebrotidine,NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1,65869,Withdrawn,histamine receptor antagonist,HRH2,"","",1665,Low (25%)
2239,BRD-K29359156,ebselen,O=c1n([se]c2ccccc12)-c1ccccc1,3194,Phase 2/Phase 3,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,ALB,"","",213,Low (25%)
2240,BRD-K41705163,EC-144,COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C,11517212,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,"","",3320|3326,Low (25%)
2241,BRD-K81004638,EC-23,CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O,10314719,Preclinical,retinoid receptor agonist,RARA|RARB|RARG,"","",5914|5915|5916,No-Effect
2243,BRD-K03353589,ecabet,CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O,65781,Launched,gastrin inhibitor|urease inhibitor,NOXO1,ophthalmology,dry eye syndrome,124056,No-Effect
2246,BRD-A51820102,econazole,Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|,6604378,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,NPY1R|NPY2R|TRPM2|TRPV5,infectious disease,tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis,1191|56302|4886|4887,No-Effect
2248,BRD-K00004306,edaglitazone,"Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|",76961439,Phase 2,PPAR receptor agonist,PPARG,"","",5468,No-Effect
2249,BRD-K35458079,edaravone,Cc1cc(=O)n([nH]1)-c1ccccc1,70335,Launched,nootropic agent,BCL2,neurology/psychiatry,stroke,596,No-Effect
2255,BRD-K97058489,edoxaban,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1,10280735,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF),2159,No-Effect
2257,BRD-K81128206,edrophonium,CC[N+](C)(C)c1cccc(O)c1,3202,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis,43|590,No-Effect
2259,BRD-K19002914,EED226,CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12,123132228,Preclinical,polycomb protein inhibitor,EED,"","",8726,No-Effect
2261,BRD-K37355418,efaproxiral,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1,122335,Phase 3,hemoglobin oxygen release stimulant,HBA1|HBB,"","",85344|3039,No-Effect
2262,BRD-A10739734,efaroxan,CCC1(Cc2ccccc2O1)C1=NCCN1,11957548,Phase 2,adrenergic receptor antagonist,ADORA2A,"","",135,No-Effect
2263,BRD-A24560335,efatutazone,Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|,76962475,Phase 2,PPAR receptor agonist,PPARG,"","",5468,No-Effect
2264,BRD-K40758068,efavirenz,FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1,64139,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1544|1576|1555|1557|1559|1565,No-Effect
2265,BRD-A30774155,efinaconazole,"C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|",9819704,Launched,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis,1595,No-Effect
2267,BRD-A96292436,eflornithine,NCCCC(N)(C(F)F)C(O)=O |&1:4|,3009,Launched,ornithine decarboxylase inhibitor,ARG2|ODC1,dermatology,facial hair reduction,384|89874,No-Effect
2270,BRD-K50653584,EG00229,NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O,44631827,Preclinical,neuropilin receptor antagonist,NRP1,"","",4745,No-Effect
2271,BRD-K22514639,EGF816,CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12,72703790,Phase 2,EGFR inhibitor,EGFR,"","",1956,Weak (50%)
2272,BRD-K65359424,eglumetad,N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,213056,Phase 2,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM8,"","",2912|2913|2916|2918,No-Effect
2273,BRD-K32289541,EHop-016,CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12,51031035,Preclinical,Ras GTPase inhibitor,RAC1|RAC3,"","",8202|6035,No-Effect
2274,BRD-K91535048,EI1,CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O,72199293,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
2275,BRD-K88120876,EIPA,CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N,1795,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,ADRA2A|ASIC1|PKD2L1,"","",9033|41|150,No-Effect
2276,BRD-K81623406,EIT-hydrobromide,CCSC(N)=N,5139,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,"","",339345|342977,No-Effect
2278,BRD-K88807631,elacridar,COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC,119373,Phase 1,P glycoprotein inhibitor,ABCB1,"","",5243,No-Effect
2280,BRD-K00004609,elacytarabine,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O,6438895,Phase 3,antineoplastic agent,DCK,"","",1633,No-Effect
2281,BRD-K03165895,elafibranor,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,9864881,Phase 3,PPAR receptor agonist,PPARA|PPARD|PPARG,"","",5465|5467|5468,No-Effect
2282,BRD-K55808645,elagolix,COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O,11250647,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,"","",2798,No-Effect
2284,BRD-K00003316,eldecalcitol,[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C,6918141,Phase 3,bone formation stimulant,VDR,"","",1594,No-Effect
2287,BRD-K82135108,elesclomol,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,300471,Phase 3,oxidative stress inducer,HSPA1A,"","",3303,No-Effect
2288,BRD-K30652337,eletriptan,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,77993,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache,3363|106480180|3350|3351|3352|3354|3355,Weak (50%)
2289,BRD-K86410485,eliglustat,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,23652731,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,7357,Strong (80%)
2290,BRD-K59271229,elinogrel,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,16066663,Phase 2,purinergic receptor antagonist,P2RY12,"","",64805,No-Effect
2291,BRD-A61392169,eliprodil,"O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|",9798372,Phase 3,glutamate receptor antagonist,GRIN1|GRIN2B,"","",2904|114787,No-Effect
2292,BRD-K30466858,ellagic-acid,Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O,5281855,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK,"","",768|6850|771|11238|5578|5579|6713|23632|1459|2932|759|760|761|762|763|765|766,No-Effect
2293,BRD-K50699835,ELN-441958,Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1,11848206,Preclinical,bradykinin receptor antagonist,BDKRB1,"","",623,Strong (80%)
2296,BRD-K86171477,eltoprazine,C1CN(CCN1)c1cccc2OCCOc12,65853,Phase 2,serotonin receptor agonist,HTR1A|HTR1B,"","",3350|3351,No-Effect
2297,BRD-K00003572,eltrombopag,CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|,,Launched,thrombopoietin receptor agonist,MPL,hematology|infectious disease,anemia|hepatitis C|thrombocytopenia,4352,No-Effect
2298,BRD-K39560679,eluxadoline,COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O,130406582,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome,4985|4986|4988,No-Effect
2301,BRD-K86727142,embelin,CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|,,Preclinical,HCV inhibitor|XIAP inhibitor,XIAP,"","",331,No-Effect
2302,BRD-K97963946,EMD-1214063,CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1,25171648,Phase 2,hepatocyte growth factor receptor inhibitor,MET,"","",8731,No-Effect
2303,BRD-K47659338,EMD-386088,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|,10131112,Preclinical,serotonin receptor agonist,HTR6,"","",3362,No-Effect
2304,BRD-A65248799,EMD-53998,"COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|",446286,Phase 1,phosphodiesterase inhibitor,TNNC1,"","",7137,No-Effect
2305,BRD-K88759641,EMD-66684,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,9892554,Preclinical,angiotensin receptor antagonist,AGTR1,"","",185,No-Effect
2307,BRD-K15010214,emedastine,CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1,3219,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269,No-Effect
2309,BRD-K03067624,emetine,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12,10219,Phase 2,protein synthesis inhibitor,RPS2,"","",6187,Strong (80%)
2313,BRD-K58685305,emodin,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,3220,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,"","",1459,No-Effect
2316,BRD-K53765467,empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1,11949646,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524,No-Effect
2317,BRD-K00023644,emricasan,C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F,12000240,Phase 2,caspase inhibitor,CASP1|CASP3|CASP7,"","",840|834|836,No-Effect
2319,BRD-K86063171,EN460,OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|,1016023,Preclinical,endoplasmic reticulum oxidation inhibitor,ERO1A,"","",30001,No-Effect
2320,BRD-K57545991,enalapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,5388962,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD),1636,Low (25%)
2321,BRD-K99447003,enalaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,5462501,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
2322,BRD-K70601687,enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F,89683805,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),3417,Very Weak (35%)
2324,BRD-A62197763,enciprazine,"COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|",29919953,Phase 3,GABA receptor modulator,GABRA1,"","",2554,No-Effect
2325,BRD-K00003576,encorafenib,COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,50922675,Launched,RAF inhibitor,BRAF,oncology,melanoma,673,No-Effect
2326,BRD-K61314889,endo-IWR-1,O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|,44483163,Preclinical,PARP inhibitor,TNKS|TNKS2,"","",8658|80351,No-Effect
2327,BRD-K62752296,endoxifen,CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1,10090750,Phase 2,estrogen receptor antagonist,ESR1,"","",2099,Strong (80%)
2328,BRD-A51831848,enflurane,"FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|",7059516,Launched,membrane permeability inhibitor,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,anesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|2743|54207|3776|3777|55879|51305|2554|2555|2556|2557|2558|2559,No-Effect
2329,BRD-K01825690,enilconazole,Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|,6992070,Launched,sterol demethylase inhibitor,CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2,infectious disease,skin infections,5732|1573|1544|1576|1577|1555|1588|1559|8856|5465,No-Effect
2330,BRD-K26425819,eniluracil,O=c1[nH]cc(C#C)c(=O)[nH]1,43157,Phase 3,dihydropyrimidine dehydrogenase inhibitor,AOX1|DPYD|XDH,"","",6652|316|1806,No-Effect
2333,BRD-K68488863,ENMD-2076,CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1,16041424,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,"","",5156|6790|3791|2322|5747|6714,No-Effect
2334,BRD-K32007074,enocitabine,CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,71734,Launched,DNA synthesis inhibitor,CMPK1|RRM1|TYMS,hematologic malignancy,acute myeloid leukemia (AML),6240|7298|51727,No-Effect
2335,BRD-K78113049,enoxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1,3229,Launched,topoisomerase inhibitor,TOP2A,infectious disease,urinary tract infections|gonorrhea,7153,No-Effect
2336,BRD-K21152241,enoximone,CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C,53708,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139,No-Effect
2337,BRD-K96137854,enoxolone,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|,10114,Launched,gap junction modulator,HSD11B1,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|common cold,3290,No-Effect
2338,BRD-K35007173,enprofylline,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,1676,Phase 3,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B,"","",134|135|136|140|5141|5142,No-Effect
2340,BRD-K83636919,entacapone,CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N,5281081,Launched,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease,1312,No-Effect
2343,BRD-K77908580,entinostat,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,4261,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC9,"","",3065|3066|8841|9734,No-Effect
2344,BRD-K39009484,entrectinib,CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1,25141092,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,ALK|NTRK1|NTRK2|NTRK3|ROS1,oncology,non-small cell lung cancer (NSCLC),238|6098|4914|4915|4916,No-Effect
2345,BRD-K56851771,enzalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,15951529,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367,No-Effect
2346,BRD-K79404599,enzastaurin,Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|,176167,Phase 3,PKC inhibitor,AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG,"","",5578|5579|5580|5582|207|2932,No-Effect
2347,BRD-K42452249,EO-1428,Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,9801969,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14,"","",5600|1432,No-Effect
2348,BRD-K79450420,epacadostat,NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1,135564890,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",IDO1,"","",3620,No-Effect
2349,BRD-K98054437,epalrestat,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1,1549120,Launched,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy,231,No-Effect
2351,BRD-K01825729,eperisone,CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|,37888265,Launched,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury,1573,Weak (50%)
2353,BRD-K45014108,ephedrine,CN[C@@H](C)[C@H](O)c1ccccc1,9294,Launched,adrenergic receptor agonist,ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity,6530|43|6571|146|154,No-Effect
2354,BRD-A54236247,ephedrine-(racemic),"CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|",7028,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity,6530|6531|6532|11016|3725|22926|146|150|22809|153|154|4772|2353|122953|467|468|7124|3558|2668,No-Effect
2355,BRD-K03972660,epiandrosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,441302,Preclinical,steroid,G6PD,"","",8266,Cyto
2356,BRD-K50660797,epicatechin-gallate-(-),Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1,107905,Phase 2,bacterial DNA gyrase inhibitor,BACE1|FASN,"","",2194|23621,No-Effect
2359,BRD-K55591206,epigallocatechin-gallate-(-),Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1,65064,Phase 2/Phase 3,bacterial DNA gyrase inhibitor,ELANE|EP300|FASN|KAT2B|MMP14|MMP2,"","",4323|1991|2033|2194|8850|4313,No-Effect
2360,BRD-A98990573,epinastine,"NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|",15629776,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269,No-Effect
2361,BRD-K63126190,epinephrine,CNC[C@H](O)c1ccc(O)c(O)c1,5816,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma,146|147|7124|150|151|152|153|154|155|5053,No-Effect
2362,BRD-K39339537,epirizole,COc1cc(C)nn1-c1nc(C)cc(OC)n1,3242,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
2363,BRD-K04548931,epirubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,41867,Launched,topoisomerase inhibitor,CHD1|TOP2A,oncology,breast cancer,1105|7153,No-Effect
2364,BRD-K02314383,epitiostanol,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O,443935,Launched,androgen receptor agonist,AR,oncology,breast cancer,367,No-Effect
2365,BRD-K19761926,eplerenone,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|,443872,Launched,cytochrome P450 inhibitor,NR3C2,cardiology,congestive heart failure|hypertension,4306,No-Effect
2366,BRD-A59329714,epomediol,"CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|",,Launched,cholesterol inhibitor,CYP7A1,neurology/psychiatry,itching,1581,No-Effect
2367,BRD-K64054020,epoprostenol,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O,5282411,Launched,prostacyclin analog,P2RY12|PTGER1|PTGER4|PTGIR|PTGIS,cardiology,hypertension,5731|64805|5734|5739|5740,No-Effect
2369,BRD-K48935217,epothilone-B,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,118184795,Phase 3,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,"","",7280,No-Effect
2370,BRD-K52762805,epothilone-D,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|,,Phase 2,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,"","",7280,No-Effect
2371,BRD-K42536037,EPPTB,CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1,25175634,Preclinical,trace amine associated receptor antagonist,TAAR1,"","",134864,No-Effect
2375,BRD-K17979676,eprobemide,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,65659,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,4128,Low (25%)
2376,BRD-K11463116,eprodisate,OS(=O)(=O)CCCS(O)(=O)=O,428573,Phase 3,amyloid protein inhibitor|antiamyloidogenic agent,SAA1,"","",6289,No-Effect
2377,BRD-K67977190,eprosartan,CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O,5281037,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185,No-Effect
2378,BRD-K68830460,eptifibatide,NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O,134812820,Launched,platelet aggregation inhibitor,ITGA2B|ITGB3,cardiology,acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI),3674|3690,No-Effect
2379,BRD-K26531771,EPZ-5676,CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1,,Phase 1,histone lysine methyltransferase inhibitor,DOT1L,"","",84444,No-Effect
2380,BRD-K69070623,EPZ004777,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12,56962336,Preclinical,histone lysine methyltransferase inhibitor,DOT1L,"","",84444,No-Effect
2381,BRD-K57754230,EPZ005687,Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,60160561,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
2382,BRD-K87468701,EPZ011989,CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|,,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
2383,BRD-K70446295,EPZ015666,O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1,90241673,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,"","",10419,No-Effect
2384,BRD-K33586289,EPZ020411,CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|,,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT6,"","",55170,No-Effect
2385,BRD-A88080608,equilin,"C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|",41097932,Preclinical,estrogen receptor agonist,HSD17B1,"","",3292,No-Effect
2386,BRD-K54847683,equol,Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1,91469,Launched,estrogen receptor agonist,ESR1|ESR2,"","",2099|2100,No-Effect
2387,BRD-K11927976,ER-27319,Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O,9799509,Preclinical,mediator release inhibitor|SYK inhibitor,SYK,"","",6850,Cyto
2389,BRD-A25004090,erastin,"CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|",91669533,Preclinical,ion channel antagonist,VDAC2,"","",7417,No-Effect
2391,BRD-K35573744,erbstatin-analog,COC(=O)\C=C\c1cc(O)ccc1O,5353609,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,"","",1956,Very Weak (35%)
2392,BRD-K84163249,ercalcitriol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,9547243,Phase 1,vitamin D receptor agonist,VDR,"","",1594,No-Effect
2393,BRD-K84868168,erdafitinib,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,67462786,Launched,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4,"","",2264|2260|2261|2263,No-Effect
2395,BRD-K56155962,ergocalciferol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5280793,Launched,vitamin analog,VDR,endocrinology|orthopedics,hypoparathyroidism|rickets|hypophosphatemia,1594,No-Effect
2396,BRD-K17311468,ergonovine,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|,443884,Launched,adrenergic receptor agonist|serotonin receptor agonist,ADRA1A|HTR1E,hematology,postpartum hemorrhage (PPH),146|3354,No-Effect
2398,BRD-K15380626,ergotamine,CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|,8223,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2,neurology/psychiatry,migraine headache,3352|3361|3362|6530|146|147|1812|1813|150|151|1816|3350|3354|3355|3351|3356|106480180|3358,No-Effect
2400,BRD-K64857848,ERK5-IN-1,COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1,46844147,Preclinical,MAP kinase inhibitor,MAPK7,"","",5598,Very Weak (35%)
2401,BRD-K70401845,erlotinib,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,176870,Launched,EGFR inhibitor,EGFR|NR1I2,oncology,non-small cell lung cancer (NSCLC)|pancreatic cancer,8856|1956,No-Effect
2403,BRD-K80608265,erteberel,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,10286159,Phase 2,estrogen receptor agonist,ESR1|ESR2,"","",2099|2100,No-Effect
2404,BRD-K00003574,ertugliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,44814423,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,6524,No-Effect
2406,BRD-K63550407,erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,NFkB pathway inhibitor,MLNR,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,2862,No-Effect
2407,BRD-K39746403,erythromycin-estolate,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,bacterial 50S ribosomal subunit inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,1576|5243|55244|3757|2862|213|1595,No-Effect
2408,BRD-K51677086,erythromycin-ethylsuccinate,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,132274075,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,1576|5243|55244|3757|2862|213|1595,No-Effect
2413,BRD-K70301876,escitalopram,CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,146570,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD),6532,No-Effect
2416,BRD-K13629382,eseroline-(-),CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21,119198,Preclinical,acetylcholinesterase inhibitor,OPRD1|OPRM1,"","",4985|4988,No-Effect
2417,BRD-K77139516,ESI-09,CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N,6077765,Preclinical,EPAC inhibitor,RAPGEF3|RAPGEF4,"","",10411|11069,No-Effect
2418,BRD-K61237927,eslicarbazepine-acetate,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12,179344,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
2419,BRD-K01825842,esmolol,"COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|",28125476,Launched,adrenergic receptor antagonist,ADRB1,cardiology,ventricular tachycardia (VT)|hypertension,153,No-Effect
2420,BRD-K61443506,esomeprazole,COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C,9568614,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD),495,Low (25%)
2422,BRD-K75445017,estetrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,27125,Phase 3,selective estrogen receptor modulator (SERM),ESR1,"","",2099,No-Effect
2423,BRD-K18910433,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,5757,Launched,estrogen receptor agonist,ESR1|ESR2|GPER1|KCNMA1|NR1I2,endocrinology,contraceptive,3778|2852|2099|2100|8856,No-Effect
2425,BRD-K53319039,estradiol-acetate,CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,9818306,Launched,estrogen receptor agonist,ESR1,endocrinology|obstetrics/gynecology,menopause|vaginal atrophy,2099,No-Effect
2426,BRD-K44412991,estradiol-benzoate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O,222757,Preclinical,contraceptive agent,ESR1,"","",2099,Low (25%)
2427,BRD-K64984393,estradiol-cypionate,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,9403,Launched,estrogen receptor agonist,ESR1,endocrinology,hypoestrogenism|menopause,2099,No-Effect
2428,BRD-K66766661,estradiol-valerate,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,13791,Launched,estrogen receptor agonist,ESR1,oncology|endocrinology|obstetrics/gynecology,prostate cancer|hypoestrogenism|menopause|vaginal atrophy,2099,No-Effect
2429,BRD-A70858459,estramustine,"C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O |a:1,27,&1:4,&2:5,&3:24|",259331,Launched,DNA alkylating agent,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer,2099|2100|23173|10988,No-Effect
2430,BRD-K00077635,estramustine-phosphate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,259329,Launched,DNA synthesis inhibitor|microtubule inhibitor,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer,2099|2100|23173|10988,No-Effect
2431,BRD-K17016787,estriol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,5756,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology|obstetrics/gynecology|infectious disease,menopause|vaginal atrophy|urinary tract infections,2099|2100,No-Effect
2432,BRD-K81839095,estrone,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,5870,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2,endocrinology,menopause,2099|2100,Very Weak (35%)
2433,BRD-K51095933,estropipate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O,3001028,Launched,estrogen receptor agonist,ESR1|ESR2,orthopedics|endocrinology|obstetrics/gynecology,osteoporosis|menopause|vaginal atrophy|hypoestrogenism,2099|2100,No-Effect
2434,BRD-K63630713,etacrynic-acid,CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl,3278,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|SLC12A1,cardiology|gastroenterology|nephrology|rheumatology,hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome,476|6557,No-Effect
2438,BRD-K64755930,etazolate,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,3277,Phase 2,phosphodiesterase inhibitor,GABRB3|PDE4A,"","",2562|5141,No-Effect
2439,BRD-K54264768,ETC-159,Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O,86280523,Phase 1,beta catenin inhibitor|porcupine inhibitor,PORCN,"","",64840,No-Effect
2447,BRD-M75061779,ethanolamine-oleate,NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O,5282489,Launched,immunostimulant,F12|FABP4|FFAR1|FFAR4|PLD2,gastroenterology,esophageal varices,2864|2161|2167|5338|338557,No-Effect
2451,BRD-K48195008,ethinyl-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C,5991,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2|NR1I2,endocrinology,contraceptive,8856|2099|2100,No-Effect
2453,BRD-K03981224,ethisterone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|,5284557,Launched,progestogen hormone,TYR,endocrinology,amenorrhea,7299,Very Weak (35%)
2455,BRD-A99633051,ethosuximide,"CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|",10630591,Launched,succinimide antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,epilepsy,8912|8913|150350,No-Effect
2456,BRD-A30205217,ethotoin,CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|,12309784,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,6331,Low (25%)
2458,BRD-K18131774,ethoxzolamide,CCOc1ccc2nc(sc2c1)S(N)(=O)=O,3295,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9,ophthalmology|gastroenterology,glaucoma|duodenal ulcer disease,768|771|11238|377677|23632|759|760|761|762|763|765|766,Low (25%)
2465,BRD-K46331928,ethynodiol-diacetate,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|,9270,Launched,"",ESR1|PGR,endocrinology,contraceptive,5241|2099,No-Effect
2467,BRD-K50417881,eticlopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,57267,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,"","",1813|1814|1815,Low (25%)
2468,BRD-K37949327,etidronic-acid,CC(O)(P(O)(O)=O)P(O)(O)=O,3305,Launched,bone resorption inhibitor,ATP6V1A|PTPRS,endocrinology|orthopedics,Paget's disease|heterotopic ossification,5802|523,No-Effect
2470,BRD-K01826330,etifoxine,"CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|",135564604,Launched,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,neurology/psychiatry,anxiety,2554|2555|2556|2558,Weak (50%)
2471,BRD-A09925278,etilefrine,CCNCC(O)c1cccc(O)c1,164652,Launched,adrenergic receptor agonist,ADRA1A|ADRB1,neurology/psychiatry|otolaryngology|endocrinology|pulmonary,headache|nasal congestion|fever|cough suppressant|common cold,153|146,No-Effect
2472,BRD-K90982969,etilevodopa,CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,170345,Phase 3,dopamine receptor agonist,DRD3,"","",1814,No-Effect
2473,BRD-K68232413,etizolam,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|,3307,Launched,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,insomnia|anxiety,2554,No-Effect
2474,BRD-A74667430,etodolac,"CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|",688461,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5743,No-Effect
2475,BRD-K73541271,etofenamate,OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,35375,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743,No-Effect
2476,BRD-K49338325,etofibrate,CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,65777,Launched,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia,5465,No-Effect
2477,BRD-K83064458,etofylline,Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,1892,Launched,adenosine receptor antagonist,ADORA1,pulmonary,asthma|bronchitis,134,No-Effect
2478,BRD-K49840922,etofylline-clofibrate,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,41109,Launched,platelet aggregation inhibitor,PPARA,endocrinology,hyperlipidemia,5465,No-Effect
2479,BRD-K55055802,etomidate,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,667484,Launched,GABA receptor modulator,ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|151|2554|2555|2556|2557|2558|2559,No-Effect
2480,BRD-K32405725,etomoxir,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,9840324,Phase 2,carnitine palmitoyltransferase inhibitor,CPT1A,"","",1374,No-Effect
2481,BRD-K00003655,etonogestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|,6917715,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099,No-Effect
2482,BRD-K37798499,etoposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,36462,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,non-small cell lung cancer (NSCLC),7153|7155,No-Effect
2483,BRD-K72533376,etoposide-phosphate,COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,6918092,Launched,topoisomerase inhibitor,TOP2A,oncology,testicular carcinoma|small cell lung cancer,7153,Weak (50%)
2484,BRD-K54770957,etoricoxib,Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O,123619,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis,5743,No-Effect
2487,BRD-K15858023,ETP-45658,Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1,25229608,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,Low (25%)
2491,BRD-K74717603,etravirine,Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N,193962,Launched,non-nucleoside reverse transcriptase inhibitor,CYP2C19|CYP2C9|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576|1557|1559,No-Effect
2492,BRD-K49076555,etretinate,CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C,5282375,Withdrawn,protein synthesis inhibitor,RARA|RXRG,"","",5914|6258,No-Effect
2493,BRD-K29996876,eucalyptol,CC12CCC(CC1)C(C)(C)O2,2758,Launched,acetylcholinesterase inhibitor,ACHE,dental,gingivitis,43,No-Effect
2495,BRD-K32977963,eugenol,COc1cc(CC=C)ccc1O,3314,Launched,androgen receptor antagonist,AR,dental,toothache,367,No-Effect
2496,BRD-K19741031,EUK-134,"COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|",,Preclinical,catalase stimulant,APP|SOD2,"","",100129518|351,No-Effect
2498,BRD-K16551357,evacetrapib,Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1,,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,"","",1071,No-Effect
2499,BRD-K24548560,evans-blue,"Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|",6804600,Launched,glutamate receptor negative allosteric modulator,GRIA1|PTPN1,"","",2890|5770,No-Effect
2500,BRD-K11452913,evatanepag,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1,9890801,Phase 2,prostaglandin inhibitor,PTGER2|PTGER4,"","",5732|5734,No-Effect
2502,BRD-K13514097,everolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|",,Launched,mTOR inhibitor,MTOR,oncology|neurology/psychiatry|genetics|urology,breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma,2475,No-Effect
2505,BRD-A68631409,evodiamine,"CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|",442088,Preclinical,ATPase inhibitor|TRPV agonist,TRPV1,"","",7442,No-Effect
2506,BRD-K71603915,EVP-6124,Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2,46196517,Phase 3,acetylcholine receptor agonist,CHRNA7,"","",89832,No-Effect
2508,BRD-K74396648,EW-7197,Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1,54766013,Phase 2,TGF beta receptor inhibitor,ACVR1B|TGFBR1,"","",91|7046,No-Effect
2509,BRD-A73908300,EX-527,"NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|",707029,Phase 2,SIRT inhibitor,SIRT1,"","",23411,No-Effect
2511,BRD-K35304636,examorelin,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,6918297,Phase 2,growth hormone releasing factor agonist,GHRHR|GHSR,"","",2692|2693,No-Effect
2512,BRD-K92150287,exatecan-mesylate,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45,151115,Phase 3,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
2513,BRD-K33425534,exemestane,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|",60198,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588,No-Effect
2514,BRD-K00003559,exenatide,[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|,91935542,Launched,GLP receptor agonist,GLP1R,endocrinology,diabetes mellitus,2740,No-Effect
2515,BRD-K81795818,exherin,CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O,,Phase 2,cadherin antagonist,CDH2,"","",1000,No-Effect
2516,BRD-K65716359,exifone,Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O,40399,Withdrawn,nootropic agent,TYR,"","",7299,No-Effect
2517,BRD-K37708699,exisulind,CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|,5472495,Phase 3,phosphodiesterase inhibitor,PDE5A,"","",8654,No-Effect
2519,BRD-K96155658,exo-IWR-1,O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|,1163034,Preclinical,WNT signaling inhibitor negative control,TNKS,"","",8658,No-Effect
2520,BRD-K98963219,ezatiostat,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,5310939,Phase 2,glutathione transferase inhibitor,GSTP1,"","",2950,No-Effect
2521,BRD-K42260897,ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1,150311,Launched,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,ANPEP|NPC1L1|SOAT1,endocrinology|metabolism,hyperlipidemia|hypercholesterolemia|sitosterolemia,29881|290|6646,No-Effect
2522,BRD-K25570267,ezutromid,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,886736,Phase 2,utrophin enhancer,UTRN,"","",7402,No-Effect
2523,BRD-K87948281,F-11440,Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O,208928,Phase 2,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
2525,BRD-K41267922,F351,Cc1ccc(=O)n(c1)-c1ccc(O)cc1,11217901,Phase 2,TGF beta receptor inhibitor,TGFB1,"","",7040,No-Effect
2526,BRD-A25619068,fadrozole,N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|,9815923,Launched,aromatase inhibitor,CYP11B1|CYP19A1,oncology,breast cancer,1584|1588,No-Effect
2527,BRD-K61536264,fagomine,OC[C@H]1NCC[C@@H](O)[C@@H]1O,72259,Phase 2,glucosidase inhibitor,GLB1,"","",2720,No-Effect
2528,BRD-K08251020,falecalcitriol,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5282190,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594,Low (25%)
2530,BRD-K00673382,famotidine,NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1,5702160,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn,1665,No-Effect
2532,BRD-K08998509,fananserin,Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1,60785,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
2536,BRD-K14590126,farnesyl-thiosalicylic-acid-amide,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O,25187973,Phase 1,Ras GTPase inhibitor,HRAS,"","",3265,No-Effect
2540,BRD-K76617868,fasudil,O=S(=O)(N1CCCNCC1)c1cccc2cnccc12,3547,Launched,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1|ROCK2,neurology/psychiatry,cerebral vasospasm,5569|5578|9475|6093,Low (25%)
2545,BRD-K48367671,febuxostat,CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O,134018,Launched,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia,6652,No-Effect
2546,BRD-K12502280,fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C,16722836,Launched,FLT3 inhibitor|JAK inhibitor,BRD4|JAK1|JAK2|JAK3|TYK2,hematologic malignancy,myelofibrosis,7297|3716|3717|3718|23476,Cyto
2547,BRD-K99107520,felbamate,NC(=O)OCC(COC(N)=O)c1ccccc1,3331,Launched,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,neurology/psychiatry,epilepsy,114787|2903|2904|2905|2906|116443|116444,No-Effect
2548,BRD-K91740057,felbinac,OC(=O)Cc1ccc(cc1)-c1ccccc1,3332,Launched,cyclooxygenase inhibitor,CTSL,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain,1514,No-Effect
2549,BRD-K26404903,felbinac-ethyl,CCOC(=O)Cc1ccc(cc1)-c1ccccc1,26436,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
2550,BRD-A30815329,felodipine,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|",941699,Launched,calcium channel blocker,CFTR,cardiology,hypertension,1080,Low (25%)
2553,BRD-K51318897,fenbendazole,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,3334,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites|gastrointestinal roundworms,7280,No-Effect
2554,BRD-K12513978,fenbufen,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,3335,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,Low (25%)
2555,BRD-K01825694,fenclonine-(+/-),N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|,736190,Preclinical,tryptophan hydroxylase inhibitor,PAH|TPH1|TPH2,"","",5053|7166|6999,No-Effect
2558,BRD-A66920069,fenigam,"NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|",685623,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,neurology/psychiatry,posttraumatic stress disorder|anxiety|depression,9568|10537,No-Effect
2560,BRD-K41160163,fenobam,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|,135659063,Phase 2,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
2561,BRD-K50388907,fenofibrate,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,3339,Launched,PPAR receptor agonist,MMP25|PPARA,endocrinology,hypercholesterolemia|hypertriglyceridemia,5465|64386,No-Effect
2562,BRD-K30213273,fenofibric-acid,CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O,64929,Launched,cytochrome P450 inhibitor,CLCN1|PPARA,cardiology,dyslipidemia,5465|1180,No-Effect
2563,BRD-K01826790,fenoldopam,Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|,30026875,Launched,dopamine receptor agonist,DRD1|DRD4,cardiology,hypertension,1812|1815,Low (25%)
2564,BRD-K01827286,fenoprofen,C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|,41097863,Launched,prostaglandin inhibitor,PTGS1|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis,160728|5742,No-Effect
2565,BRD-K00003668,fenoterol,"C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|",688469,Withdrawn,adrenergic receptor agonist,ADRB2,"","",154,No-Effect
2567,BRD-K44777569,fenoxaprop-p-ethyl,CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1,91707,Preclinical,"",NOS3,"","",342977,No-Effect
2568,BRD-K89085489,fenretinide,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|,5288209,Phase 3,apoptosis stimulant|retinoid receptor agonist,RARA,"","",5914,No-Effect
2571,BRD-K16077845,fentiazac,OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1,28871,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743,No-Effect
2573,BRD-K61642990,FERb-033,O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1,135931707,Preclinical,EGFR inhibitor,ERBB2,"","",2064,No-Effect
2576,BRD-K66295376,ferulic-acid,COc1cc(\C=C\C(O)=O)ccc1O,445858,Phase 2,antioxidant,CA1|CA12|CA14|CA2|CA4|CA6|CA9,"","",768|771|23632|759|760|762|765,No-Effect
2577,BRD-K46731503,fesoterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C,6918558,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence,1128|1129|1131|1132|1133,No-Effect
2579,BRD-K08864679,fexaramine,COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1,5326713,Preclinical,FXR agonist,NR1H4,"","",9971,No-Effect
2581,BRD-A73368467,fexofenadine,CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|,6603853,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269,Low (25%)
2583,BRD-K56807945,FG-2216,OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O,6914666,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|HIF1A,"","",100529264|3091|54583,No-Effect
2584,BRD-K14385366,FG-4592,Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12,11256664,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|EGLN3,"","",100529264|112399|54583,No-Effect
2586,BRD-K09778810,FGIN-1-27,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1,132496,Preclinical,inositol monophosphatase inhibitor,TSPO,"","",706,No-Effect
2587,BRD-K66093087,FGIN-1-43,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,3995234,Preclinical,benzodiazepine receptor agonist,TSPO,"","",706,No-Effect
2588,BRD-K48112880,FH-535,Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O,3463933,Preclinical,PPAR receptor antagonist|WNT signaling inhibitor,PPARD|PPARG,"","",5467|5468,No-Effect
2591,BRD-A63752151,fidarestat,"NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|",449156,Phase 3,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
2593,BRD-K37379014,filanesib,CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|,44224257,Phase 3,kinesin inhibitor|kinesin-like spindle protein inhibitor,KIF11,"","",3832,No-Effect
2594,BRD-K16803204,filgotinib,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,49831257,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,"","",7297|3716|3717|3718,No-Effect
2595,BRD-K21586122,fimasartan,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,9870652,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure,185,No-Effect
2597,BRD-K01095011,finasteride,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|,57363,Launched,5 alpha reductase inhibitor,AKR1D1|SRD5A1|SRD5A2,endocrinology,androgenetic alopecia,6715|6716|6718,No-Effect
2598,BRD-K88025533,fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,107970,Launched,immunosuppressant|sphingosine 1-phosphate receptor agonist,S1PR1|S1PR5,neurology/psychiatry,multiple sclerosis,1901|53637,No-Effect
2600,BRD-K61560897,FIPI,Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,16739265,Preclinical,phospholipase inhibitor,PLD1|PLD2,"","",5338|5589,No-Effect
2602,BRD-K17513304,firategrast,CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1,9935681,Phase 2,integrin antagonist,ITGA4,"","",3676,No-Effect
2603,BRD-K09090523,firocoxib,CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|,208910,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743,No-Effect
2605,BRD-K31836715,fisetin,Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,5281614,Preclinical,Aurora kinase inhibitor,CDK6|FASN,"","",2194|1021,No-Effect
2607,BRD-K17896185,FIT,CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1,84008,Preclinical,opioid receptor agonist,OPRD1,"","",4985,No-Effect
2608,BRD-A01907367,FK-33-824,"C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|",,Phase 2,opioid receptor agonist,OPRM1,"","",4988,No-Effect
2609,BRD-K38350380,FK-3311,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,164009,Phase 2,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
2611,BRD-K58550667,FK-866,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,6914657,Phase 2,niacinamide phosphoribosyltransferase inhibitor,NAMPT,"","",10135,Low (25%)
2612,BRD-K83508485,FK-888,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,107967,Phase 2,tachykinin antagonist,TACR1|TACR2,"","",6865|6869,No-Effect
2614,BRD-K01666925,flavin-adenine-dinucleotide,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|",643975,Preclinical,"",ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH,"","",3712|7296|1806|26|27034|56605|4128|4129|34|35|9131|51|2232|1727|1728|1738|2639|4835|259307|2671|340719|2936|7417|51706|6652,No-Effect
2615,BRD-K47639036,flavoxate,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,3354,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2,urology,urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis,1128|1129,No-Effect
2616,BRD-A09472452,flecainide,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1,46864232,Launched,sodium channel blocker,KCNA5|KCNA7|SCN5A,cardiology,ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias,6331|3741|3743,No-Effect
2617,BRD-K61717546,fleroxacin,CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O,40466912,Launched,topoisomerase inhibitor,TOP2A,infectious disease|gastroenterology,gonorrhea|enteritis|diarrhea|respiratory tract infections,7153,No-Effect
2619,BRD-K33637378,flibanserin,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,6918248,Launched,serotonin receptor agonist,DRD4|HTR1A|HTR2A,neurology/psychiatry,hypoactive sexual desire disorder,3356|3350|1815,No-Effect
2620,BRD-K56740996,flindokalner,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F,214350,Phase 3,potassium channel agonist,KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5,"","",3778|3783|3785|9132|56479,No-Effect
2621,BRD-A23418262,floctafenine,"OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|",76958517,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
2622,BRD-K43383936,flopropione,CCC(=O)c1c(O)cc(O)cc1O,3362,Launched,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms,3350,No-Effect
2626,BRD-K47832606,floxuridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,5790,Launched,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,7298,No-Effect
2628,BRD-K86003836,flubendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1,35802,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,7280,Weak (50%)
2630,BRD-K05977355,fluconazole,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,3365,Launched,sterol demethylase inhibitor,CYP51A1,infectious disease,esophageal candidiasis|meningitis,1595,No-Effect
2631,BRD-K82143716,flucytosine,Nc1nc(=O)[nH]cc1F,3366,Launched,other antifungal,DNMT1,infectious disease,bacterial septicemia|endocarditis|urinary tract infections|meningitis,1786,No-Effect
2632,BRD-K66788707,fludarabine,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,657237,Launched,ribonucleotide reductase inhibitor,ADA|DCK|POLA1|RRM1|RRM2,hematologic malignancy,chronic lymphocytic leukemia (CLL),6240|1633|6241|100|5422,Very Weak (35%)
2633,BRD-K71106091,fludarabine-phosphate,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O,30751,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,chronic lymphocytic leukemia (CLL),6240|6241|5422|5424|5426|50484,No-Effect
2634,BRD-K06408664,fludrocortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|,225609,Launched,"",NR3C2,endocrinology,Addison's disease|adrenogenital syndrome,4306,Very Weak (35%)
2635,BRD-K00824317,fludroxycortide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|,15209,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,infectious disease|dermatology,skin infections|psoriasis,866|2908,No-Effect
2636,BRD-K44067360,flufenamic-acid,OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,3371,Preclinical,chloride channel blocker,AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5,"","",81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|29850|1191|127534|10804|125111|7224|55107|8644|9033|57165|24145|84694|56666|349149|375519|5742|367|5743|116337|219770,Low (25%)
2637,BRD-K68870568,flumatinib,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,46848036,Phase 3,Bcr-Abl kinase inhibitor,ABL1|PDGFRB,"","",25|5159,Strong (80%)
2638,BRD-K98769987,flumazenil,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21,3373,Launched,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,sedative,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2554|2555|2556|2557|2558|2559,No-Effect
2641,BRD-K61496577,flumethasone,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|",16490,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,otolaryngology|infectious disease|dermatology,otitis|ear infections|corticosteroid-responsive dermatoses,2908|5319,Low (25%)
2642,BRD-K00025599,flumethasone-pivalate,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|",443980,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908,No-Effect
2644,BRD-K29582677,flunarizine,Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,941361,Launched,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1,neurology/psychiatry|cardiology,migraine headache|vertigo|peripheral artery disease (PAD),801|3269|150350|8912|8913,No-Effect
2645,BRD-K49577446,flunisolide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",82153,Launched,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,2908,No-Effect
2647,BRD-K94353609,fluocinolone-acetonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",6215,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,dermatology,seborrheic dermatitis,866|2908,No-Effect
2648,BRD-K57886322,fluocinonide,"CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|",9642,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6|SMO,dermatology,seborrheic dermatitis|eczema,54498|866|2908,No-Effect
2649,BRD-K21913543,fluorescein,Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1,16850,Launched,"",SLC22A6,ophthalmology,ophthalmology diagnostic,9356,No-Effect
2650,BRD-K64862097,fluorometholone,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",9878,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,2908,No-Effect
2651,BRD-K02528732,fluorometholone-acetate,"C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|",240767,Launched,"",NR3C1,ophthalmology,eye inflammation,2908,No-Effect
2653,BRD-A31159102,fluoxetine,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,657320,Launched,selective serotonin reuptake inhibitor (SSRI),ANO1|HTR2B|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder,6532|55107|106480180,Low (25%)
2654,BRD-K70487031,flupentixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,5281881,Launched,dopamine receptor antagonist,ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A,neurology/psychiatry,schizophrenia|depression,1128|146|1812|1813|1814|1816|3356,Low (25%)
2655,BRD-K55127134,fluphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,3372,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia,801|3362|3363|3269|1812|1813|1816|3356,Low (25%)
2656,BRD-K27898013,fluphenazine-decanoate,CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,3388,Launched,dopamine receptor antagonist,DRD2|HTR1B|HTR4,neurology/psychiatry,schizophrenia,3360|1813|3351,No-Effect
2657,BRD-K50720187,flupirtine,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,53276,Launched,glutamate receptor antagonist,ADRA2A|KCNQ1|KCNQ2,neurology/psychiatry,pain relief,3784|3785|150,No-Effect
2658,BRD-K44091134,fluprazine,NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F,71153,Phase 1,serotonin receptor agonist,HTR1A|HTR1B,"","",3350|3351,No-Effect
2661,BRD-K69907333,flurbiprofen-(S)-(+),C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1,72099,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743,No-Effect
2663,BRD-K75410565,flurizan,C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1,92337,Phase 3,gamma secretase inhibitor,APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2,"","",5664|8517|23621|83464|5742|5743|5663,No-Effect
2667,BRD-K77947974,fluspirilene,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,3396,Launched,dopamine receptor antagonist,CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia,3269|786|1813|3350|3352|3354|3356,No-Effect
2668,BRD-K28307902,flutamide,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,3397,Launched,androgen receptor antagonist,AHR|AR,oncology,prostate cancer,196|367,No-Effect
2669,BRD-K62310379,fluticasone-propionate,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|",444036,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|PGR|PLA2G4A,dermatology,corticosteroid-responsive dermatoses,5241|4306|5321|2908,Low (25%)
2671,BRD-K66296774,fluvastatin,CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12,446155,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hypercholesterolemia|congenital heart defects,3156,No-Effect
2672,BRD-K53517854,fluvoxamine,COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F,5324346,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),6532,No-Effect
2675,BRD-K18673820,folic-acid,Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1,6037,Launched,folate receptor ligand,FOLR2|FOLR3|SLC19A1|SLC46A1,hematology,megaloblastic anemia,2352|113235|6573|2350,Low (25%)
2676,BRD-K56810756,fomepizole,Cc1cn[nH]c1,3406,Launched,alcohol dehydrogenase inhibitor,ADH1A|ADH1B|ADH1C|AKR1A1|CAT,critical care,poison antidote,847|10327|124|125|126,No-Effect
2678,BRD-K00003513,fondaparinux,[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O,5282448,Launched,coagulation factor inhibitor,F10|SERPINC1,hematology,deep vein thrombosis (DVT),462|2159,No-Effect
2679,BRD-K03449891,foretinib,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,42642645,Phase 2,VEGFR inhibitor,FLT1|FLT4|KDR|MET,"","",2321|8731|2324|3791,No-Effect
2680,BRD-A26503646,formestane,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|",,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588,No-Effect
2681,BRD-K55567017,formononetin,COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,5280378,Preclinical,alcohol dehydrogenase inhibitor,ADH1C|SLC5A2,"","",6524|126,No-Effect
2682,BRD-K54006094,formoterol,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,3034756,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm,154,No-Effect
2683,BRD-K16505263,forodesine,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O,135409409,Launched,purinergic receptor antagonist,PNP,hematologic malignancy,peripheral T-cell lymphoma (PTCL),5539,No-Effect
2684,BRD-K57774929,foropafant,CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C,119368,Phase 3,platelet activating factor receptor antagonist,PTAFR,"","",5724,Very Weak (35%)
2685,BRD-K09602097,forskolin,CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C,47936,Launched,adenylyl cyclase activator,ADCY2|ADCY5|GNAS,"","",2778|108|111,No-Effect
2687,BRD-K23848629,fosaprepitant-dimeglumine,C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,135413538,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869,Low (25%)
2688,BRD-K06814349,fosbretabulin,COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O,5351387,Phase 3,tubulin polymerization inhibitor|VE-cadherin antagonist,CDH5,"","",1003,Strong (80%)
2690,BRD-K20801936,fosfestrol,CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1,3032325,Launched,synthetic estrogen,ESR1|ESR2,oncology,prostate cancer,2099|2100,No-Effect
2693,BRD-K28687144,fosfosal,OC(=O)c1ccccc1OP(O)(O)=O,3418,Launched,phosphodiesterase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
2695,BRD-A51382177,fosinopril,"CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|",6708482,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636,No-Effect
2696,BRD-A33506612,fosinoprilat,"OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|",62956,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
2697,BRD-K53809807,fosphenytoin,OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1,56339,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,epilepsy|seizures,6331,No-Effect
2698,BRD-K85178109,fostamatinib,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC,11671467,Launched,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),6850,No-Effect
2701,BRD-K13005598,foxy-5,CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O,44628955,Phase 2,WNT5a peptide mimetic,WNT5A,"","",7474,No-Effect
2707,BRD-K78959463,FPL-64176,COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,3423,Preclinical,calcium channel activator,CACNA1C|CACNA1S,"","",779|775,No-Effect
2708,BRD-K87691185,FPS-ZM1,Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1,24752728,Preclinical,RAGE receptor antagonist,AGER,"","",177,No-Effect
2710,BRD-K19318328,FR-139317,CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O,107810,Phase 1,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
2711,BRD-K68756823,FR-180204,Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1,53338808,Preclinical,MAP kinase inhibitor,MAPK1|MAPK3,"","",5594|5595,No-Effect
2712,BRD-K57243773,FRAX486,CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O,68060125,Preclinical,serine/threonine kinase inhibitor,PAK1|PAK2|PAK3|PAK4,"","",8874|5585|5586|10298,Cyto
2714,BRD-K00004668,freselestat,CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C,46936829,Preclinical,elastase inhibitor,CELA1|ELANE,"","",1990|1991,No-Effect
2715,BRD-K08255599,frovatriptan,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,77992,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,neurology/psychiatry,migraine headache,3352|3350|3351,Weak (50%)
2716,BRD-K70504253,fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,44480399,Launched,VEGFR inhibitor,KDR,oncology,colorectal cancer,3791,No-Effect
2719,BRD-K99383816,ftorafur,Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O,288216,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,7298,No-Effect
2722,BRD-A85667082,fulvestrant,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|",57300161,Launched,estrogen receptor antagonist,ESR1|ESR2|GPER1,oncology,breast cancer,2099|2100|2852,No-Effect
2723,BRD-A99367815,fumagillin,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|",12015870,Launched,methionine aminopeptidase inhibitor,METAP2,infectious disease,microsporidiosis,10988,No-Effect
2724,BRD-K61915943,fumonisin-B1,CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O,2733487,Preclinical,"",CERS1,"","",2657,No-Effect
2728,BRD-K77758223,furamidine,NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N,126437,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,"","",3276,No-Effect
2730,BRD-K55529781,furegrelate,OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1,3437,Phase 1,thromboxane synthase inhibitor,TBXAS1,"","",6916,Low (25%)
2731,BRD-K78010432,furosemide,NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl,3440,Launched,diuretic,CA2|GPR35|SLC12A1|SLC12A2,cardiology|rheumatology,edema|hypertension|congestive heart failure|nephrotic syndrome,760|2859|6557|6558,No-Effect
2736,BRD-K62696033,G-1,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|,5322399,Preclinical,G protein-coupled receptor agonist,GPER1,"","",2852,No-Effect
2737,BRD-K00004290,G-15,"Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|",25727983,Preclinical,estrogen receptor antagonist,GPER1,"","",2852,No-Effect
2739,BRD-K26878113,g-caryophyllene,C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|,5281515,Preclinical,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
2740,BRD-K12198961,G007-LK,CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl,67960134,Preclinical,tankyrase inhibitor,TNKS|TNKS2,"","",8658|80351,No-Effect
2742,BRD-K62737565,gabapentin,NCC1(CC(O)=O)CCCCC1,6919078,Launched,calcium channel blocker,ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,infectious disease|neurology/psychiatry,virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome,10368|10369|773|134|775|776|774|777|778|779|781|782|783|784|785|786|59283|59284|93589|59285|9254|150350|8912|8913|27091|27092|2903|2904|2905|2906|116443|116444|114787|55799,No-Effect
2743,BRD-A86665761,gabapentin-enacarbil,"CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|",66864580,Launched,adrenergic receptor agonist,CACNA1G,neurology/psychiatry,restless leg syndrome|postherpetic neuralgia,8913,No-Effect
2744,BRD-K79905821,gabazine,COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1,107896,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2,"","",2566|2554|2555|2556|2557|2558|2559,No-Effect
2745,BRD-K59256312,gabexate,CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1,3447,Launched,serine protease inhibitor,PRSS1|TPSAB1,gastroenterology,pancreatitis,7177|136541,Very Weak (35%)
2746,BRD-K89104321,gaboxadol,O=c1[nH]oc2CNCCc12,3448,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3,"","",2563|200959|2569|2570|2554|2555|2556|2557|2558|2559,No-Effect
2749,BRD-K25106841,gadopentetic-acid,OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,6857474,Launched,contrast agent,PGD,radiology,contrast agent,26227,No-Effect
2753,BRD-K49481516,galantamine,COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|,9651,Launched,acetylcholinesterase inhibitor,ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG,neurology/psychiatry,senile dementia,55584|89832|43|8973|1134|590|1135|1136|1137|1138|1140|1141|1142|1143|1144|1145|1146|57053,No-Effect
2754,BRD-K00004319,galeterone,"[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|",11188409,Phase 3,androgen receptor modulator,AR|CYP17A1,"","",1586|367,No-Effect
2756,BRD-K43106192,gallamine-triethiodide,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,3450,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA1,neurology/psychiatry,muscle relaxant,1129|1134,No-Effect
2757,BRD-K77345217,gallic-acid,OC(=O)c1cc(O)c(O)c(O)c1,370,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP,"","",768|771|6414|23632|759|760|762|765,No-Effect
2759,BRD-A52922642,gallopamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|,1234,Launched,L-type calcium channel blocker,ATP2A2,cardiology,hypertension|cardiac arrythmia,488,No-Effect
2760,BRD-K08542803,gambogic-acid,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|",9852185,Phase 2,caspase activator,BCL2,"","",596,No-Effect
2762,BRD-K77245796,gamma-aminobutyric-acid,NCCCC(O)=O,6992099,Preclinical,benzodiazepine receptor agonist,GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1,"","",9568|2561|6529|2628|2566|115207|10537|57528|386617|2554|2555|2556|2558,No-Effect
2763,BRD-K18059238,gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,5280933,Phase 2,cyclooxygenase inhibitor|prostanoid receptor agonist,PTGS1|PTGS2,"","",5742|5743,No-Effect
2764,BRD-K28217197,ganaxolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,6918305,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,"","",2554|2555|2556|2557|2558|2559,No-Effect
2766,BRD-K38852836,ganetespib,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,135564985,Phase 3,HSP inhibitor,HSP90AA1,"","",3320,Weak (50%)
2768,BRD-K64451768,GANT-58,c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1,253078,Preclinical,GLI antagonist,GLI1,"","",2735,No-Effect
2769,BRD-K09485525,GANT-61,CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1,421610,Preclinical,GLI antagonist,GLI1|GLI2,"","",2736|2735,No-Effect
2770,BRD-K77038618,garenoxacin,C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1,40461170,Launched,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections,7153,No-Effect
2773,BRD-K81981783,gavestinel,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1,6450546,Phase 3,glutamate receptor antagonist,GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,"","",114787|2743|2903|2904|2905|2906|116443|116444,No-Effect
2775,BRD-K50135270,GBR-12935,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,3456,Preclinical,dopamine reuptake inhibitor,AGTR1|SLC6A3,"","",185|6531,No-Effect
2776,BRD-K92577649,GBR-13069,Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,5974189,Preclinical,dopamine reuptake inhibitor,SLC6A3,"","",6531,No-Effect
2777,BRD-K43002773,GDC-0068,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,24788740,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3|PRKG1,"","",208|10000|5592|207,No-Effect
2780,BRD-K68938568,GDC-0152,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,46940575,Phase 1,XIAP inhibitor,BIRC2|BIRC3|BIRC7|XIAP,"","",329|330|331|79444,No-Effect
2781,BRD-K43187018,GDC-0349,CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1,59239165,Phase 1,Pim kinase inhibitor,PIK3CA,"","",5290,No-Effect
2784,BRD-K61923022,GDC-0810,CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl,56941241,Phase 2,selective estrogen receptor destabilizer,ESR1,"","",2099,Low (25%)
2785,BRD-A30984645,GDC-0834,"CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|",25234917,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,No-Effect
2786,BRD-K67578145,GDC-0879,OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O,11717001,Preclinical,RAF inhibitor,BRAF,"","",673,No-Effect
2788,BRD-K52911425,GDC-0941,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1,17755052,Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,Weak (50%)
2789,BRD-K23228615,GDC-0980,C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1,25254071,Phase 2,mTOR inhibitor|PI3K inhibitor,FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK,"","",6850|22883|4293|5290|2475|5291|5294|2268,Weak (50%)
2790,BRD-A20830788,GDC-0994,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|",124583908,Phase 1,MAP kinase inhibitor,MAPK1|MAPK3,"","",5594|5595,No-Effect
2791,BRD-K02703275,gedunin,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|,12004512,Preclinical,HSP inhibitor,HSP90AA1,"","",3320,No-Effect
2793,BRD-K64052750,gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,123631,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956,No-Effect
2794,BRD-K43570081,geldanamycin,"CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|",,Preclinical,HSP inhibitor,HSP90AA1,"","",3320,Weak (50%)
2796,BRD-K15108141,gemcitabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,60750,Launched,ribonucleotide reductase inhibitor,CMPK1|RRM1|RRM2|TYMS,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer,6240|6241|7298|51727,Low (25%)
2797,BRD-K09456915,gemcitabine-elaidate,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O,9828310,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,CMPK1|RRM1|TYMS,"","",6240|7298|51727,No-Effect
2798,BRD-K11129031,gemfibrozil,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,3463,Launched,lipoprotein lipase activator,LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1,endocrinology|cardiology,hyperlipidemia|coronary heart disease,3936|10599|28234|11309|5465,No-Effect
2802,BRD-K57275767,geniposide,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|",107848,Preclinical,GLP receptor agonist,GLP1R,"","",2740,No-Effect
2804,BRD-K43797669,genistein,Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,5280961,Phase 2/Phase 3,tyrosine kinase inhibitor,CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5,"","",10499|8648|2185|7224|7153|2099|2100|2101|2103|1080|2104|5468,Very Weak (35%)
2805,BRD-K97891829,gentamycin,CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,72395,Launched,bacterial 50S ribosomal subunit inhibitor,HSPA8,infectious disease|critical care,bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis,3312,No-Effect
2806,BRD-K33131085,gentiopicrin,"OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|",88708,Phase 3,glutamate receptor downregulator,GRIN2B,"","",2904,No-Effect
2807,BRD-K70693421,genz-123346,CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,23652732,Preclinical,glucosylceramidase inhibitor,UGCG,"","",7357,No-Effect
2808,BRD-K99475619,genz-644282,CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O,10294813,Phase 1,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
2814,BRD-K97472745,gestrinone,"CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|",27812,Launched,progesterone receptor antagonist,AR|ESR1|PGR,obstetrics/gynecology,endometriosis,5241|2099|367,No-Effect
2815,BRD-K31342827,GF109203X,CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|,2396,Preclinical,PKC inhibitor,PDPK1|PIM1|PRKCI|PRKCZ,"","",5584|9361|5170|5590,No-Effect
2816,BRD-A25625670,GGsTop,"COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|",139340107,Preclinical,gamma glutamyltransferase Inhibitor,GGT1,"","",2678,No-Effect
2818,BRD-K72280606,gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,49803313,Launched,FLT3 inhibitor,FLT3,"","",2322,Cyto
2819,BRD-K35687421,gimeracil,Oc1cc(=O)[nH]cc1Cl,54679224,Launched,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,1806,No-Effect
2821,BRD-K93816012,ginkgolide-B,C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,,Phase 3,platelet activating factor receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,"","",8001|2741|2742|2743|9177|3359,No-Effect
2822,BRD-K01942833,ginsenoside-C-K,CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,9852086,Phase 1,NFkB pathway inhibitor|nitric oxide synthase inhibitor,PTGS2,"","",5743,No-Effect
2825,BRD-A44511856,ginsenoside-RE3,"CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|",46887680,Launched,angiogenesis inhibitor|apoptosis stimulant,KCNH2,"","",3757,Weak (50%)
2826,BRD-K13810148,givinostat,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,9804992,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,"","",55869|9734|8841|3065|3066|10013|10014|9759,Cyto
2827,BRD-K38272302,GK921,C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1,56682080,Preclinical,transglutaminase inhibitor,TGM2,"","",7052,No-Effect
2828,BRD-K03827870,GKA-50,COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O,11340230,Preclinical,glucokinase activator,GCK,"","",5871,No-Effect
2829,BRD-K79710622,GKT137831,CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12,58496428,Phase 2,NADPH oxidase inhibitor,NOX1|NOX4,"","",50507|27035,Very Weak (35%)
2830,BRD-K01826515,glafenine,OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|,969495,Withdrawn,DeltaF508-CFTR Correctors,CFTR,"","",1080,No-Effect
2831,BRD-K34341643,glasdegib,CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N,25166913,Launched,hedgehog pathway inhibitor,SMO,hematologic malignancy,acute myeloid leukemia (AML),54498,No-Effect
2835,BRD-K34776109,glimepiride,"CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|",,Launched,insulin secretagogue,ABCC8|KCNJ1|KCNJ11,endocrinology,diabetes mellitus,6833|3758|3767,No-Effect
2836,BRD-K12219985,glipizide,Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,3478,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus|hyperglycemia,6833|5468|3766|3767,No-Effect
2837,BRD-K80396088,gliquidone,COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C,91610,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ8,endocrinology,diabetes mellitus,6833|3764|3766,No-Effect
2840,BRD-K15893360,GLPG0492,CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F,59317190,Phase 1,androgen receptor modulator,AR,"","",367,No-Effect
2841,BRD-K04643927,GLPG0492-R-enantiomer,CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F,59317173,Phase 1,androgen receptor modulator,AR,"","",367,No-Effect
2844,BRD-K04288422,gluconolactone,OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O,1549082,Launched,"",LCT,"","",3938,No-Effect
2845,BRD-K29918010,glucosamine,N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,441477,Launched,glycosylated protein precursor,IL1B,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis|joint pain|backache,3553,No-Effect
2846,BRD-K69346723,glutathione,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,25246407,Phase 3,antioxidant,ESD|GGT1|GLO1|GLRX|GLRX2|GPX1|GPX2|GPX3|GPX4|GPX5|GPX6|GPX7|GPX8|GSR|GSS|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GSTK1|GSTM1|GSTM2|GSTM3|GSTM4|GSTM5|GSTO1|GSTO2|GSTP1|GSTT1|GSTZ1|HAGH|HPGDS|LTC4S|MGST1|MGST2|MGST3|TXNDC12,"","",2944|2946|2947|2948|2949|2950|2952|2954|4257|4258|4259|373156|27306|493869|221357|2098|2739|2745|2876|2877|2878|2879|2880|2882|51022|3029|4056|119391|9446|51060|5621|2678|2936|2938|2939|2940|2941,No-Effect
2849,BRD-K36927236,glyburide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,3488,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia,8647|10060|11309|3758|6833|3762|19|3764|3767|1080|1374,No-Effect
2852,BRD-K78303961,glycitein,COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O,5317750,Phase 3,tumor necrosis factor release inhibitor,TNF,"","",7124,No-Effect
2853,BRD-A81233518,glycopyrrolate,"C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|",9933193,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132|1133,Low (25%)
2854,BRD-K00004613,GM-1485,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O,9837656,Preclinical,immunophilin ligand,FKBP1A,"","",2280,No-Effect
2855,BRD-K69832040,GMX1778,Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1,148198,Phase 1/Phase 2,NAMPT inhibitor,NAMPT,"","",10135,No-Effect
2857,BRD-K97056771,GNF-2,NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1,5311510,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,"","",25|106480993,No-Effect
2858,BRD-K87632963,GNF-5,OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1,44129660,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,"","",25|106480993,No-Effect
2859,BRD-K19975102,GNF-5837,Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1,59397065,Preclinical,growth factor receptor inhibitor,NTRK1|NTRK2|NTRK3,"","",4914|4915|4916,No-Effect
2860,BRD-K69075588,GNF-7,CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C,11478363,Preclinical,glucokinase inhibitor|protein kinase inhibitor,GCK|TNK2,"","",10188|5871,No-Effect
2861,BRD-K64748124,GNTI,NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O,9826034,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,"","",4986|4988,No-Effect
2862,BRD-K36984403,go-6983,COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|,3499,Preclinical,protein kinase inhibitor,PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ,"","",5578|5579|5580|5582|5590,No-Effect
2863,BRD-A57886255,golgicide-A,"Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|",1085377,Preclinical,ARF inhibitor,GBF1,"","",80142,No-Effect
2864,BRD-K69001009,golvatinib,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,16118392,Phase 2,VEGFR inhibitor,KDR|MET,"","",8731|3791,Weak (50%)
2865,BRD-K96874295,gonadorelin,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,638793,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,obstetrics/gynecology,cystic ovaries|reproductive synchrony,2798,No-Effect
2866,BRD-K99504665,goserelin-acetate,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,5311128,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR|LHCGR,oncology|obstetrics/gynecology,prostate cancer|breast cancer|endometriosis,3973|2798,No-Effect
2867,BRD-K19295594,gossypol,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,3503,Phase 2,BCL inhibitor|MCL1 inhibitor,BCL2,"","",596,No-Effect
2868,BRD-K65285700,GP1a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,10252734,Preclinical,cannabinoid receptor agonist,CNR2,"","",56142,No-Effect
2869,BRD-K34608650,GP2a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1,16094766,Preclinical,cannabinoid receptor agonist,CNR2,"","",56142,No-Effect
2870,BRD-K67397687,GPBAR-A,Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12,11656002,Preclinical,G protein-coupled receptor agonist,GPBAR1,"","",151306,No-Effect
2871,BRD-K44869961,GPI-1046,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1,445501,Preclinical,FKBP inhibitor,FKBP1A,"","",2280,No-Effect
2873,BRD-K83289131,GPP-78,O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1,44819697,Preclinical,NAMPT inhibitor,NAMPT,"","",10135,Weak (50%)
2874,BRD-K19409553,GPR120-modulator-1,Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O,25017320,Preclinical,G protein-coupled receptor modulator,FFAR4,"","",338557,No-Effect
2875,BRD-K50891186,GR-103691,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,4302960,Preclinical,dopamine receptor antagonist,DRD3,"","",1814,No-Effect
2876,BRD-K49945136,GR-113808,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,119376,Preclinical,serotonin receptor antagonist,HTR4,"","",3360,No-Effect
2877,BRD-K11911061,GR-127935,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,107780,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,"","",3362|106480180|3350|3351|3352|3354|3355|3356|3358,Strong (80%)
2879,BRD-K12120659,GR-144053,NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1,173614,Preclinical,integrin antagonist,ITGA2B|ITGB3,"","",3674|3690,No-Effect
2880,BRD-K52394958,GR-159897,COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,9953599,Preclinical,tachykinin antagonist,TAC1|TACR2,"","",6865|6863,No-Effect
2881,BRD-K00004242,GR-235,[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|,146898,Launched,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,NR1H4,"","",9971,No-Effect
2882,BRD-K40578143,GR-79236,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,9884817,Phase 1,adenosine receptor agonist,ADORA1|ADORA2A,"","",134|135,No-Effect
2883,BRD-K62594868,GR125487,COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,4284721,Preclinical,serotonin receptor antagonist,HTR4,"","",3360,No-Effect
2884,BRD-K98155362,GR46611,COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,6160690,Preclinical,serotonin receptor agonist,HTR1D,"","",3352,No-Effect
2887,BRD-A10967948,granisetron,"CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|",,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359,No-Effect
2888,BRD-K62050508,grapiprant,CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,11677589,Launched,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis,5734,No-Effect
2890,BRD-K08273968,griseofulvin,COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|,441140,Launched,tubulin polymerization inhibitor,KRT12,infectious disease,ringworm|tinea pedis,3859,No-Effect
2891,BRD-K99916169,GS-143,OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|,121513876,Preclinical,ubiquitin ligase inhibitor,BTRC|NFKBIA,"","",4792|8945,No-Effect
2892,BRD-K75478907,GS-39783,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,6604928,Preclinical,GABA receptor modulator,GABBR1,"","",10537,No-Effect
2893,BRD-K68453341,GS-6201,CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1,11270783,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
2894,BRD-K73585091,GS-9620,CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1,46241268,Phase 2,toll-like receptor agonist,TLR7,"","",51284,No-Effect
2896,BRD-K76719364,GS-9973,C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1,59473233,Phase 2,SYK inhibitor,SYK,"","",6850,No-Effect
2897,BRD-K04923131,GSK-3-inhibitor-IX,O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12,,Preclinical,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,GSK3A|GSK3B,"","",2931|2932,No-Effect
2898,BRD-K32847255,GSK-J1,OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,56963315,Preclinical,histone demethylase inhibitor,KDM6B,"","",23135,No-Effect
2900,BRD-K98203492,GSK-J4,CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,71729975,Preclinical,histone lysine demethylase inhibitor,KDM6A|KDM6B,"","",7403|23135,No-Effect
2902,BRD-K33521504,GSK-LSD-1,C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1,71522234,Preclinical,histone lysine demethylase inhibitor,KDM1A,"","",23028,No-Effect
2903,BRD-K98684188,GSK0660,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,46233311,Preclinical,PPAR receptor antagonist,PPARD,"","",5467,No-Effect
2904,BRD-K06750613,GSK1059615,O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1,23582824,Phase 1,PI3K inhibitor,PIK3CG,"","",5294,No-Effect
2905,BRD-K36740062,GSK1070916,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,46885626,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC|CYP2D6|CYP3A4,"","",6790|1576|6795|9212|1565,No-Effect
2906,BRD-K60341624,GSK1292263,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,24996872,Phase 2,glucose dependent insulinotropic receptor agonist,GRPR,"","",2925,No-Effect
2907,BRD-K36697397,GSK1562590,CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12,46846503,Preclinical,urotensin receptor antagonist,UTS2R,"","",2837,Weak (50%)
2908,BRD-K69669039,GSK163090,Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1,11292933,Phase 2,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D,"","",3352|3350|3351,No-Effect
2909,BRD-K06749501,GSK1838705A,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,25182616,Preclinical,insulin growth factor receptor inhibitor,ALK|IGF1R|INSR|RPS6KA1,"","",3480|6195|3643|238,No-Effect
2911,BRD-K04833372,GSK1904529A,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,25124816,Preclinical,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,IGF1R|INSR,"","",3480|3643,No-Effect
2912,BRD-K25412176,GSK2110183,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,46843057,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,Low (25%)
2913,BRD-K07972848,GSK2126458,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,25167777,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",22883|5290|2475|5291|5294,Strong (80%)
2914,BRD-K15691453,GSK2190915,CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1,44473151,Phase 2,lipoxygenase inhibitor,ALOX5AP,"","",241,No-Effect
2915,BRD-K90737788,GSK2193874,FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1,53464483,Preclinical,transient receptor potential channel antagonist,TRPV4,"","",59341,No-Effect
2916,BRD-K95123482,GSK2194069,O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1,67376285,Preclinical,fatty acid synthase inhibitor,FASN,"","",2194,Very Weak (35%)
2919,BRD-K62738477,GSK2256294A,CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1,59448236,Phase 1,epoxide hydolase inhibitor,EPHX2,"","",2053,No-Effect
2920,BRD-K05858796,GSK2330672,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1,53492727,Phase 2,bile acid transporter inhibitor,SLC10A2,"","",6555,No-Effect
2921,BRD-K70642949,GSK2334470,CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1,46215815,Preclinical,phosphoinositide dependent kinase inhibitor,AURKA|AURKB|PDPK1,"","",5170|9212|6790,Cyto
2923,BRD-K37590257,GSK256066,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,9827968,Phase 2,phosphodiesterase inhibitor,PDE4A,"","",5141,No-Effect
2925,BRD-K81689258,GSK2606414,Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12,53469448,Preclinical,protein kinase inhibitor,EIF2AK3|MYLK2,"","",9451|85366,Strong (80%)
2926,BRD-K49215523,GSK2636771,Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O,56949517,Phase 2,PI3K inhibitor,PIK3CB,"","",5291,Very Weak (35%)
2928,BRD-K89464729,GSK269962,CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N,16095342,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,"","",9475|6093,Low (25%)
2929,BRD-K48062199,GSK2801,CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O,73010930,Preclinical,bromodomain inhibitor,BAZ2A|BAZ2B,"","",11176|29994,No-Effect
2930,BRD-K21867462,GSK2816126,CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,68210102,Phase 1,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
2931,BRD-K17472821,GSK2830371,Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1,70983932,Preclinical,protein phosphatase inhibitor,PPM1D,"","",8493,No-Effect
2932,BRD-K50679358,GSK2837808A,COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1,71533725,Preclinical,lactate dehydrogenase inhibitor,LDHA,"","",3939,No-Effect
2934,BRD-K09223495,GSK2879552,OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1,66571643,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,"","",23028,No-Effect
2943,BRD-K26514105,GSK37647,COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C,743974,Preclinical,free fatty acid receptor agonist,FFAR4,"","",338557,No-Effect
2944,BRD-K03155172,GSK3787,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1,2800647,Preclinical,PPAR receptor antagonist,PPARD,"","",5467,No-Effect
2945,BRD-A10523515,GSK429286A,"CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|",92472001,Preclinical,rho associated kinase inhibitor,ROCK1,"","",6093,No-Effect
2946,BRD-K92428232,GSK461364,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,15983966,Phase 1,PLK inhibitor,PLK1,"","",5347,Strong (80%)
2947,BRD-K72293620,GSK503,CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,67469117,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
2948,BRD-K14991967,GSK650394,OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1,25022668,Preclinical,serum/glucocorticoid regulated kinase inhibitor,SGK1|SGK2,"","",23678|6446,Low (25%)
2950,BRD-K25325018,GSK690693,CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N,16725726,Phase 1,AKT inhibitor,AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX,"","",106821730|5592|5613|207|208|10000|5588|57144|10298,No-Effect
2951,BRD-K29328421,GSK9027,Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F,24882669,Preclinical,glucocorticoid receptor agonist,NR3C1,"","",2908,No-Effect
2952,BRD-K89015388,GSK923295,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,46898058,Phase 1,centromere associated protein inhibitor,CENPE,"","",1062,No-Effect
2954,BRD-K14235254,GTS21,COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|,5310985,Phase 1/Phase 2,cholinergic receptor agonist,CHRNA7,"","",89832,No-Effect
2957,BRD-K96282009,guaiacol,COc1ccccc1O,460,Launched,local anesthetic,CA2,pulmonary,cough suppressant,760,No-Effect
2959,BRD-K62736196,guanaben-acetate,NC(=N)N\N=C\c1c(Cl)cccc1Cl,5702063,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151,No-Effect
2962,BRD-K62676709,guanethidine,NC(=N)NCCN1CCCCCCC1,3518,Launched,adrenergic inhibitor,SLC6A2,cardiology,hypertension,6530,No-Effect
2963,BRD-K32830106,guanfacine,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,3519,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151,No-Effect
2964,BRD-K76037122,guanidine,NC(N)=N,3520,Launched,HSP inhibitor,ALDH2|DLG4|GAMT|RNASE1,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),217|6035|3996|2593,No-Effect
2965,BRD-K69191882,guanidinoethyldisulfide-bicarbonate,NC(=N)NCCSSCCNC(N)=N,3521,Phase 2,nitric oxide synthase inhibitor,NOS2,"","",339345,No-Effect
2966,BRD-K50781608,guanidinopropionic-acid,NC(=N)NCCC(O)=O,67701,Phase 2,creatine kinase inhibitor,CKM,"","",1158,No-Effect
2967,BRD-K67644125,guanosine,Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135398635,Preclinical,"",PNP,"","",5539,Strong (80%)
2968,BRD-K18745919,Gue-1654,CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1,5066134,Preclinical,oxoeicosanoid receptor modulator,OXER1,"","",165140,No-Effect
2969,BRD-K01980392,guvacine,OC(=O)C1=CCCNC1 |t:3|,40468028,Preclinical,GABA uptake inhibitor,SLC6A1|SLC6A11|SLC6A12|SLC6A13,"","",6529|6538|6539|6540,No-Effect
2970,BRD-K82983861,GW-0742,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F,9934458,Preclinical,PPAR receptor agonist,PPARD,"","",5467,No-Effect
2971,BRD-K23614267,GW-1100,CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1,11692123,Preclinical,G protein-coupled receptor agonist,FFAR1,"","",2864,No-Effect
2972,BRD-K00004238,GW-1929,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,6518171,Preclinical,PPAR receptor agonist,PPARG,"","",5468,No-Effect
2973,BRD-K24242599,GW-2580,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,11617559,Preclinical,cFMS kinase inhibitor,CSF1R,"","",1436,No-Effect
2974,BRD-K37864785,GW-311616,CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O,9800961,Phase 1,elastase inhibitor|leukocyte elastase inhibitor,ELANE,"","",1991,No-Effect
2976,BRD-K10705233,GW-405833,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,9911463,Preclinical,cannabinoid receptor agonist,CNR2,"","",56142,No-Effect
2977,BRD-K88186167,GW-4064,CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl,9893571,Preclinical,FXR agonist,NR1H4,"","",9971,No-Effect
2978,BRD-K13039700,GW-438014A,O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1,6918627,Preclinical,neuropeptide receptor antagonist,NPY5R,"","",4889,No-Effect
2979,BRD-K41312087,GW-441756,Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12,9943465,Preclinical,growth factor receptor inhibitor,NTRK1,"","",4914,No-Effect
2980,BRD-K14880289,GW-501516,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F,9803963,Phase 2,PPAR receptor agonist,PPARA|PPARD,"","",5465|5467,No-Effect
2981,BRD-K39520573,GW-5074,Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br,5034,Phase 1/Phase 2,leucine rich repeat kinase inhibitor|RAF inhibitor,NTRK1|RAF1,"","",4914|6037,No-Effect
2982,BRD-K36485341,GW-542573X,COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C,24885053,Preclinical,calcium channel activator,KCNN1,"","",3780,No-Effect
2983,BRD-K79930101,GW-583340,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,5329480,Preclinical,EGFR inhibitor,EGFR|ERBB2,"","",2064|1956,No-Effect
2985,BRD-K20828910,GW-6471,CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F,446738,Preclinical,PPAR receptor antagonist,PPARA,"","",5465,No-Effect
2986,BRD-K96263742,GW-7647,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O,3392731,Preclinical,PPAR receptor agonist,PPARA,"","",5465,No-Effect
2987,BRD-K78086729,GW-788388,O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1,10202642,Preclinical,ALK tyrosine kinase receptor inhibitor,LCK|MAPK14|TGFBR1,"","",1432|3932|7046,No-Effect
2988,BRD-K65576800,GW-803430,COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1,9826520,Phase 1,melanin inhibitor,KCNH2|MCHR1,"","",3757|2847,No-Effect
2989,BRD-K26823213,GW-842166,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,10253143,Phase 2,cannabinoid receptor agonist,CNR2,"","",56142,No-Effect
2990,BRD-K90382497,GW-843682X,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC,9826308,Preclinical,PLK inhibitor,PLK1|PLK3,"","",5347|1263,No-Effect
2991,BRD-K71534238,GW-9508,OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,11595431,Preclinical,free fatty acid receptor agonist|G protein-coupled receptor agonist,FFAR1|FFAR4,"","",2864|338557,No-Effect
2992,BRD-K93258693,GW-9662,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1,644213,Preclinical,PPAR receptor antagonist,NCOA2|PPARG|RXRA,"","",6256|10499|5468,Low (25%)
2994,BRD-K24240364,GYKI-52466,"CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|",3538,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
2996,BRD-K35329391,GZD824,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1,51038269,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,"","",25|106480993,Strong (80%)
2998,BRD-K27737647,H-89,Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1,449241,Preclinical,PKA inhibitor,GSG2|PKIA|PRKACA,"","",5569|5578|83903,No-Effect
2999,BRD-K26439554,H2L-5765834,OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1,1365686,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,"","",1902|23566,No-Effect
3001,BRD-K64452997,HA-130,OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1,46911532,Preclinical,autotaxin inhibitor,ENPP2,"","",5168,No-Effect
3002,BRD-K58046914,HA-966-(R)-(+),N[C@@H]1CCN(O)C1=O,6603720,Preclinical,glutamate receptor agonist,GRIA1,"","",2890,No-Effect
3003,BRD-K41304947,HA-966-(S)-(-),N[C@H]1CCN(O)C1=O,183351,Preclinical,glutamate receptor antagonist,GRIA1,"","",2890,No-Effect
3004,BRD-K18163608,HA14-1,"CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|",6976314,Preclinical,BCL inhibitor,BCL2,"","",596,No-Effect
3006,BRD-K81709173,halcinonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|,443943,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
3007,BRD-K71487404,halobetasol-propionate,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|",6918178,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319,Very Weak (35%)
3008,BRD-A51964809,halofantrine,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|,36688213,Launched,antimalarial agent,KCNN4,infectious disease,malaria,3783,No-Effect
3009,BRD-K54247840,halofuginone,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,456390,Launched,collagenase inhibitor,COL1A1|MMP2,rheumatology,scleroderma,4313|1277,Strong (80%)
3010,BRD-K50055394,halopemide,Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O,65490,Phase 2,phospholipase inhibitor,PLD1|PLD2,"","",5338|5589,No-Effect
3011,BRD-K67783091,haloperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,3559,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1,neurology/psychiatry,schizophrenia|Tourette's disorder,3352|3363|3269|3756|2904|1812|1813|1814|1815|1816|3350|106480180|3356,No-Effect
3012,BRD-K80859331,haloperidol-decanoate,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,52919,Launched,psychoactive drug,DRD2|DRD3|DRD4|HTR2A,neurology/psychiatry,schizophrenia,3356|1813|1814|1815,No-Effect
3014,BRD-A20550616,halothane,"FC(F)(F)[C@@H](Cl)Br |&1:4,r|",4369439,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|60598|2743|54207|3776|3777|55879|56659|56660|51305|2554|2555|2556|2557|2558|2559,Low (25%)
3015,BRD-K12630395,harmane,Cc1nccc2c3ccccc3[nH]c12,5281404,Preclinical,monoamine oxidase inhibitor,MAOA|MAOB,"","",4128|4129,No-Effect
3018,BRD-K73815512,HC-030031,CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1,1150897,Phase 1,TRPA1 channel blocker,TRPA1,"","",8989,No-Effect
3019,BRD-K03391209,HC-067047,Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F,2742550,Preclinical,transient receptor potential channel antagonist,TRPV4,"","",59341,No-Effect
3021,BRD-K49788188,heclin,CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1,7464118,Preclinical,ubiquitin ligase inhibitor,NEDD4|SMURF2|WWP1,"","",64750|11059|4734,Low (25%)
3022,BRD-K34672903,HEMADO,CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,10981286,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
3026,BRD-K15231341,hemomex-s,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C,11468733,Launched,"",PPARG,"","",5468,No-Effect
3030,BRD-K58122457,hesperadin,CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1,,Preclinical,Aurora kinase inhibitor,AURKB,"","",9212,No-Effect
3031,BRD-K30553453,hesperetin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,72281,Launched,ACAT inhibitor,DGAT1|MTTP|SOAT1|SOAT2,"","",4571|6646|8694|8435,Low (25%)
3032,BRD-K38903228,hesperidin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1,10621,Launched,flavanone glycoside,AURKB|CACNA1B,"","",9212|774,No-Effect
3034,BRD-K99792991,hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,3598,Launched,potassium channel activator,GLUD1|SDHD,infectious disease,gram-positive bacterial infections,6392|2746,Weak (50%)
3036,BRD-K04710043,hexamethylenebisacetamide,CC(=O)NCCCCCCNC(C)=O,3616,Phase 2,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,AKT1,"","",207,No-Effect
3039,BRD-K69253806,hexestrol,CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1,192197,Launched,synthetic estrogen,AKR1C1|ESR1|ESR2,endocrinology,hypoestrogenism,2099|2100|1645,No-Effect
3042,BRD-A33894669,hexoprenaline,"O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|",24993924,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154,No-Effect
3043,BRD-A97730597,hexylcaine,C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|,6604266,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,local anesthetic,6331,No-Effect
3044,BRD-A14234430,hexylene-glycol,"C[C@@H](O)CC(C)(C)O |&1:1,r|",5288845,Preclinical,"",AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP,"","",342977|8644|5319|5770|5228|6414|3320|3996|1503,No-Effect
3045,BRD-K99946902,hexylresorcinol,CCCCCCc1ccc(O)cc1O,3610,Launched,local anesthetic,TYR,infectious disease,skin infections|first-aid antiseptic,7299,Weak (50%)
3046,BRD-A55204514,higenamine,Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|,440988,Phase 1,adrenergic receptor agonist,ADRB2,"","",154,No-Effect
3048,BRD-K01674964,histamine,NCCc1cnc[nH]1,774,Launched,histamine receptor agonist,HRH1|HRH2|HRH3|HRH4,allergy,allergic rhinitis,1665|59340|3269|11255,No-Effect
3049,BRD-K34411045,HJC-0350,Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C,22200891,Preclinical,GTPase inhibitor,RAPGEF4,"","",11069,No-Effect
3050,BRD-K58811567,HKI-357,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,11238512,Phase 1,EGFR inhibitor,EGFR,"","",1956,No-Effect
3051,BRD-K73746696,HLCL-61,CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12,2250650,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,"","",10419,No-Effect
3053,BRD-K70511574,HMN-214,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,9888590,Phase 1,PLK inhibitor,PLK1,"","",5347,No-Effect
3055,BRD-K01826529,homatropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",,Launched,acetylcholine receptor antagonist,CHRM1,ophthalmology,uveal tract inflammation|pupil dilation,1128,No-Effect
3056,BRD-A54234250,homatropine-methylbromide,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|",,Launched,acetylcholine receptor antagonist,CHRM5,ophthalmology,uveal tract inflammation,1133,No-Effect
3058,BRD-K01826562,homochlorcyclizine,CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|,5393145,Launched,antihistamine,HRH1,allergy,allergic rhinitis,3269,No-Effect
3059,BRD-K76674262,homoharringtonine,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|,285033,Launched,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),6122,Strong (80%)
3060,BRD-K30519779,homoquinolinic-acid,OC(=O)Cc1cccnc1C(O)=O,3080554,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
3063,BRD-K98493452,honokiol,Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O,72303,Phase 3,AKT inhibitor,ALOX5|PTGS1|PTGS2,"","",240|5742|5743,No-Effect
3071,BRD-K58726989,HTH-01-015,CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12,78357766,Preclinical,protein kinase inhibitor,NUAK1,"","",9891,No-Effect
3073,BRD-K01825665,HTMT,C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|,6604743,Preclinical,histamine receptor agonist,HRH4,"","",59340,No-Effect
3074,BRD-K62240499,huperzine-A,C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|,854026,Phase 2,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
3075,BRD-K59788572,hyaluronic-acid,CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O,6852395,Launched,"",C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN,rheumatology|urology,osteoarthritis|interstitial cystitis (IC),960|1463|708|404037|145864|3026|1462|3383|3161|1404,No-Effect
3081,BRD-K13078532,hydrochlorothiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl,3639,Launched,thiazide diuretic,CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3,cardiology,hypertension|congestive heart failure,768|3778|771|759|760|762|6559,No-Effect
3082,BRD-K93568044,hydrocortisone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|,5754,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR3C1|NR3C2,dermatology|neurology/psychiatry,eczema|psoriasis|seborrheic dermatitis|itching,339345|4306|2908|301,Very Weak (35%)
3083,BRD-K11612998,hydrocortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|,5744,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
3084,BRD-K99199077,hydrocortisone-butyrate,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|,26133,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses|eczema,2908,No-Effect
3087,BRD-K09968782,hydrocortisone-valerate,CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|,5282494,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
3088,BRD-K36862742,hydroflumethiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,3647,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension,768|3778|771|759|760|762|476|6557|6559,No-Effect
3090,BRD-K11227669,hydroquinone,Oc1ccc(O)cc1,785,Launched,melanin inhibitor,TYR,dermatology,dyschromia,7299,No-Effect
3092,BRD-A80871782,hydroxyamphetamine,C[C@@H](N)Cc1ccc(O)cc1 |&1:1|,12234986,Launched,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis,134864,No-Effect
3093,BRD-A99117172,hydroxychloroquine,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,12947,Launched,antimalarial agent,TLR7|TLR9,infectious disease,malaria,54106|51284,No-Effect
3094,BRD-K77793136,hydroxyfasudil,O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1,3064778,Preclinical,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1,"","",5569|5578|6093,No-Effect
3095,BRD-K44932450,hydroxyprogesterone,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|,6238,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth,5241,No-Effect
3096,BRD-K92902018,hydroxyprogesterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|,10156152,Launched,progesterone receptor agonist,PGR,"","",5241,No-Effect
3100,BRD-K01825165,"hydroxytacrine-maleate-(R,S)",Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|,667530,Preclinical,cholinesterase inhibitor,ACHE,"","",43,No-Effect
3102,BRD-K51747290,hydroxyurea,NC(=O)NO,3657,Launched,ribonucleotide reductase inhibitor,RRM1|RRM2|RRM2B,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC),6240|6241|50484,No-Effect
3103,BRD-K01826510,hydroxyzine,OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|,1548976,Launched,antihistamine,HRH1,neurology/psychiatry|allergy|dermatology,anxiety|urticaria|itching|dermatosis,3269,No-Effect
3105,BRD-K46424862,hymecromone,Cc1cc(=O)oc2cc(O)ccc12,5280567,Phase 2,monoamine oxidase inhibitor,MAOA|MAOB,"","",4128|4129,No-Effect
3107,BRD-K40530731,hyoscyamine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology|urology|neurology/psychiatry|allergy,peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis,1128|1129|1131|1132,No-Effect
3109,BRD-A63780829,hyperin,"OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|",5742688,Preclinical,aldose reductase inhibitor,ACE|AKR1B1,"","",1636|231,No-Effect
3110,BRD-K13881745,hypoestoxide,CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C,11199742,Phase 1,IKK inhibitor,IKBKB|IL1B|TNF,"","",3553|7124|3551,Strong (80%)
3111,BRD-K03739921,hypoxanthine,O=c1nc[nH]c2nc[nH]c12,790,Preclinical,PARP inhibitor,PNP,"","",5539,No-Effect
3112,BRD-K08109215,I-BET-762,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|,46943432,Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,"","",8019|23476|6046,Weak (50%)
3113,BRD-K36363294,I-BET151,COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C,52912189,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4,"","",8019|23476|6046,No-Effect
3114,BRD-K04972057,I-BRD9,CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1,91668541,Preclinical,bromodomain inhibitor,BRD9,"","",65980,No-Effect
3117,BRD-K57090026,I-CBP-112,CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1,90488984,Preclinical,bromodomain inhibitor,CREBBP|EP300,"","",2033|1387,No-Effect
3119,BRD-K31135544,IB-MECA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,123683,Phase 3,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
3120,BRD-K08681769,ibandronate,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,60852,Launched,bone resorption inhibitor,FDPS,orthopedics,osteoporosis,2224,No-Effect
3121,BRD-K15196155,IBC-293,CC(C)n1nnc2cc(ccc12)C(O)=O,2736690,Preclinical,hydroxycarboxylic acid receptor agonist,HCAR3,"","",8843,No-Effect
3124,BRD-K94979336,IBMX,CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O,3758,Preclinical,phosphodiesterase inhibitor,ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A,"","",5152|134|8654|5138|5140|5144|5148|5150|5151,No-Effect
3125,BRD-A02971356,ibotenic-acid,"N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|",6971210,Preclinical,glutamate receptor agonist,GRIN1,"","",114787,No-Effect
3126,BRD-K62490786,ibrolipim,CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC,131601,Phase 2,lipoprotein lipase activator,LPL,"","",3936,No-Effect
3127,BRD-K70301465,ibrutinib,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,24821094,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BLK|BMX|BTK,hematologic malignancy,chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM),640|660|695,No-Effect
3128,BRD-K16444452,ibudilast,CC(C)C(=O)c1c(nn2ccccc12)C(C)C,3671,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary|neurology/psychiatry,asthma|stroke,3553|8654|3569|5139|5141|5142|5143|5144,No-Effect
3130,BRD-K14965640,ibuprofen-(S),CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O,39912,Launched,cyclooxygenase inhibitor,ASIC1|PTGS1|PTGS2|SLC5A8,neurology/psychiatry,pain relief,160728|41|5742|5743,No-Effect
3132,BRD-A75224450,ibuprofen-piconol,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|",76968625,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
3133,BRD-A40940854,ibuproxam,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|,11458696,Launched,cyclooxygenase inhibitor|prostaglandin inhibitor,ALOX5,endocrinology|rheumatology|neurology/psychiatry,fever|joint inflammation|pain relief,240,Low (25%)
3134,BRD-K44771174,ibutamoren,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1,178024,Phase 2,growth hormone secretagogue receptor agonist,GHR|GHSR,"","",2690|2693,No-Effect
3135,BRD-A74391928,ibutilide,CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|,21149973,Launched,potassium channel blocker,CACNA1C|KCNH2,cardiology,atrial fibrillation (AF),3757|775,No-Effect
3136,BRD-K09638361,IC261,COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1,5288600,Preclinical,casein kinase inhibitor,CSNK1A1|CSNK1D|CSNK1E|CSNK1G2,"","",1452|1453|1454|1455,No-Effect
3137,BRD-K59839632,ICA-069673,Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1,10149311,Preclinical,voltage-gated potassium channel activator,KCNQ2|KCNQ3,"","",3785|3786,Low (25%)
3138,BRD-K71686520,ICA-110381,Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1,4314115,Preclinical,voltage-gated potassium channel activator,KCNQ2,"","",3785,No-Effect
3139,BRD-K03149601,ICA-121431,O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1,998021,Preclinical,sodium channel blocker,SCN1A|SCN3A,"","",6328|6323,No-Effect
3140,BRD-K65639003,icariin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,5318997,Phase 3,phosphodiesterase inhibitor,PDE5A,"","",8654,No-Effect
3141,BRD-K24476327,icaritin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O,5318980,Phase 3,PPAR receptor antagonist,PDE5A,"","",8654,No-Effect
3142,BRD-K63772874,icatibant-acetate,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,6918173,Launched,bradykinin receptor antagonist,BDKRB2,cardiology,angioedema,623,No-Effect
3143,BRD-K73261812,ICG-001,Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,11238147,Preclinical,beta-catenin inhibitor,CTNNB1,"","",1499,No-Effect
3144,BRD-K74603273,"ICI-118,551",CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12,5311179,Phase 2,adrenergic receptor antagonist,ADRB2|ADRB3,"","",154|155,No-Effect
3145,BRD-K66782112,ICI-162846,NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1,134778,Phase 1,histamine receptor antagonist,HRH2,"","",1665,No-Effect
3148,BRD-K59433843,ICI-192605,OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl,6604763,Phase 2,thromboxane receptor antagonist,TBXA2R,"","",6915,No-Effect
3149,BRD-K73290745,ICI-199441,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1,3082718,Preclinical,opioid receptor agonist,CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R,"","",2837|4985|4986|4988|1565,Low (25%)
3150,BRD-K52487250,"ICI-215,001",O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,164451,Preclinical,adrenergic receptor agonist,ADRB3,"","",155,No-Effect
3152,BRD-A03359064,ICI-89406,"O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|",92211532,Phase 1,adrenergic receptor antagonist,ADRB1|ADRB2,"","",153|154,No-Effect
3153,BRD-K48869804,icilin,Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|,161930,Phase 1,TRPV agonist,TRPA1|TRPM8,"","",8989|79054,No-Effect
3155,BRD-K41234004,icomucret,CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O,5280724,Phase 3,mucin production enhancer,LTB4R2,"","",56413,No-Effect
3156,BRD-K47192521,icosapent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,446284,Launched,platelet aggregation inhibitor,ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1,endocrinology,hypertriglyceridemia,2181|2182|5742|5743|2864|4593|6546|7442|5467|5468,No-Effect
3157,BRD-K31698212,icotinib,C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,22024915,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956,Very Weak (35%)
3158,BRD-K18634484,iCRT-14,Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1,5967294,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,CTNNB1|TCF4,"","",1499|6934,No-Effect
3159,BRD-K90305467,ID-1101,C[C@H](O)[C@H](C)[C@H](N)C(O)=O,6918732,Phase 1,insulin sensitizer,INS,"","",3630,No-Effect
3161,BRD-K79102359,idalopirdine,FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1,21071390,Phase 3,serotonin receptor antagonist,HTR6,"","",3362,No-Effect
3162,BRD-K69650333,idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O,42890,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),7153,Strong (80%)
3163,BRD-K62627508,idasanutlin,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,53358942,Phase 3,MDM inhibitor,MDM2|TP53,"","",4193|7157,No-Effect
3164,BRD-A18696154,idazoxan,"C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|",12866829,Phase 3,adrenergic receptor antagonist,ADRA2A|PTGS2,"","",150|5743,Low (25%)
3166,BRD-K60866521,idelalisib,CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,11625818,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,chronic lymphocytic leukemia (CLL),5290|5291|5294|22883,No-Effect
3169,BRD-K22356203,IDO5L,Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1,135424953,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",IDO1,"","",3620,No-Effect
3171,BRD-A14344385,IDRA-21,"C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|",7048549,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
3173,BRD-K74671368,idronoxil,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|,219100,Phase 3,XIAP inhibitor,ENOX2|SPHK1,"","",8877|10495,No-Effect
3174,BRD-K13829090,IEM1460,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,3248290,Preclinical,glutamate receptor antagonist,GRIA2,"","",2891,No-Effect
3175,BRD-K80060353,IEM1754,NCCCCCNCC12CC3CC(CC(C3)C1)C2,9887868,Preclinical,glutamate receptor antagonist,GRIA1,"","",2890,No-Effect
3176,BRD-K00004210,ifenprodil,"C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|",6604117,Launched,adrenergic receptor antagonist|glutamate receptor antagonist,GRIN2B,"","",2904,No-Effect
3177,BRD-A67097164,ifosfamide,ClCCN[P@@]1(=O)OCCCN1CCCl |r|,9588020,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1,oncology|urology,testicular carcinoma|hemorrhagic cystitis,100861540|1576|1577|1548|5742|1555|1557|1558|1559|1562,No-Effect
3178,BRD-A48376327,igmesine,CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|,6438340,Phase 2,sigma receptor agonist,SIGMAR1,"","",10280,No-Effect
3179,BRD-K15426076,iguratimod,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,124246,Launched,cyclooxygenase inhibitor|NFkB pathway inhibitor,PTGS2,rheumatology,rheumatoid arthritis,5743,No-Effect
3180,BRD-K14618467,IKK-16,O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1,9549298,Preclinical,IKK inhibitor,IKBKB,"","",3551,No-Effect
3181,BRD-K26373640,IKK-2-inhibitor,NC(=O)c1sc(cc1N)-c1ccsc1,2807869,Preclinical,IKK inhibitor|SYK inhibitor,IKBKB,"","",3551,No-Effect
3182,BRD-K74305673,IKK-2-inhibitor-V,Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,5081913,Phase 1,IKK inhibitor|NFkB pathway inhibitor,IKBKB,"","",3551,Weak (50%)
3185,BRD-K51662849,ilomastat,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO,132519,Phase 3,matrix metalloprotease inhibitor,ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9,"","",4321|4322|4323|10863|176|4312|4313|4314|4317|4318,No-Effect
3186,BRD-K48722833,iloperidone,COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O,71360,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia,3362|3363|3269|146|1812|1813|1814|1815|152|3350|3356,No-Effect
3187,BRD-A45664787,iloprost,"CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|",51397006,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R,pulmonary,pulmonary arterial hypertension (PAH),5729|5731|5732|5733|5734|6915|5737|5739,No-Effect
3188,BRD-K92723993,imatinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,5291,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST),5156|3815|5159|780|4914|25|5979|1436,Very Weak (35%)
3191,BRD-K33183200,imetit,NC(=N)SCCc1cnc[nH]1,3692,Preclinical,histamine receptor agonist,HRH3|HRH4,"","",59340|11255,No-Effect
3194,BRD-K29626940,imidafenacin,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,6433090,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,neurology/psychiatry,spasms,1128|1131,No-Effect
3195,BRD-K11466259,imidapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O,5464343,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636,Low (25%)
3198,BRD-A10903566,imiloxan,CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|,76966048,Phase 1,adrenergic receptor antagonist,ADRA2A|ADRA2B,"","",150|151,No-Effect
3200,BRD-K38436528,imipramine,CN(C)CCCN1c2ccccc2CCc2ccccc12,3696,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry|urology,depression|nocturnal enuresis,6530|6531|6532|146|147|1812|1813|3350|1816|3356|3358|3362|3363|3751|3752|3756|3757|3269|1128|1129|1131|1132|1133,Weak (50%)
3201,BRD-K26657438,imiquimod,CC(C)Cn1cnc2c(N)nc3ccccc3c12,57469,Launched,interferon inducer|toll-like receptor agonist,TLR7|TLR8,dermatology|infectious disease|oncology,actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC),51284|51311,No-Effect
3204,BRD-K25906698,immepip,C(C1CCNCC1)c1cnc[nH]1,3035842,Preclinical,histamine receptor agonist,HRH3|HRH4,"","",59340|11255,No-Effect
3205,BRD-K49519092,immethridine,C(c1cnc[nH]1)c1ccncc1,9989505,Phase 1,histamine receptor agonist,HRH3,"","",11255,No-Effect
3206,BRD-K20049318,impentamine,NCCCCCc1cnc[nH]1,9793868,Preclinical,histamine receptor antagonist,HRH3,"","",11255,No-Effect
3210,BRD-K81016934,INC-280,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,25145656,Phase 3,c-Met inhibitor,MET,"","",8731,No-Effect
3211,BRD-K33308633,INCA-6,"O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|",230748,Preclinical,calcineurin inhibitor,NFATC1,"","",4772,No-Effect
3214,BRD-K67628093,INCB-3284,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,,Phase 2,CC chemokine receptor antagonist,CCR2,"","",729230,Low (25%)
3216,BRD-K89208535,indacaterol,CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,6918554,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD),153|154,No-Effect
3217,BRD-K64973364,indalpine,C(Cc1c[nH]c2ccccc12)C1CCNCC1,44668,Withdrawn,selective serotonin reuptake inhibitor (SSRI),SLC6A4,"","",6532,No-Effect
3218,BRD-A95869247,indapamide,"C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|",12598931,Launched,thiazide diuretic,CA2|HTR3A|KCNQ1,cardiology,hypertension|congestive heart failure,760|3784|3359,No-Effect
3219,BRD-K01649396,indatraline,CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1,126280,Preclinical,norepinephrine transporter inhibitor,MAOA|MAOB,"","",4128|4129,Weak (50%)
3220,BRD-K00003177,indeglitazar,COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12,11395145,Phase 2,PPAR receptor agonist,NCOA1|PPARA|PPARD|PPARG,"","",8648|5465|5467|5468,No-Effect
3223,BRD-K33226500,indinavir,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,5362440,Launched,HIV protease inhibitor,CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1576|1577|100861540,Very Weak (35%)
3224,BRD-K90948141,indiplon,CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1,6450813,Phase 3,benzodiazepine receptor agonist,GABRA1,"","",2554,No-Effect
3225,BRD-K17894950,indirubin,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3A,"","",2931|1020|983,Low (25%)
3226,BRD-K19136521,indirubin-3-monoxime,O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12,,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK2|CDK5|CDK5R1|GSK3B,"","",8851|2932|983|1017|1020,No-Effect
3227,BRD-K17610631,indisulam,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,216468,Phase 2,CDK inhibitor,CA1|CA12|CA14|CA2|CA6|CA7|CA9,"","",768|771|23632|759|760|765|766,No-Effect
3230,BRD-A16296925,indobufen,"CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|",189556,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor,PTGS1|PTGS2,hematology,thrombosis,5742|5743,No-Effect
3231,BRD-K80762071,indocyanine-green,CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|,9919342,Launched,contrast agent,SLCO1B1,cardiology,vascular imaging agent,10599,Very Weak (35%)
3232,BRD-K01815685,indole-3-carbinol,OCc1c[nH]c2ccccc12,3712,Phase 2/Phase 3,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",AHR,"","",196,No-Effect
3234,BRD-K57222227,indomethacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1,3715,Launched,cyclooxygenase inhibitor,GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1,rheumatology|orthopedics,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis,5320|145482|5742|5743|2739|11251|113235|5465|5468,No-Effect
3235,BRD-A44090213,indoprofen,"C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|",93283,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,CXCR1|CXCR2|PTGS1|PTGS2,"","",3577|3579|5742|5743,No-Effect
3236,BRD-K76953762,indoramin,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,33625,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,152|146|147|151,No-Effect
3237,BRD-K93255255,indoximod,Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12,6920151,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",IDO1,"","",3620,No-Effect
3238,BRD-K00003329,ingenol,"[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|",442042,Launched,PKC activator,PRKCD|PRKCE,dermatology,keratosis,5580|5581,No-Effect
3239,BRD-K93779381,ingenol-mebutate,"C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|",6918670,Launched,PKC activator,PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,dermatology,actinic keratosis (AK),5578|5579|5580|5581|5582,Weak (50%)
3240,BRD-K70177501,INH1,Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1,959043,Preclinical,Hec1 inhibitor,NDC80,"","",10403,No-Effect
3242,BRD-K11153516,iniparib,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,9796068,Phase 3,PARP inhibitor,PARP1,"","",142,No-Effect
3243,BRD-K79612754,inosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O,135398641,Launched,neurotrophic agent,PARP1|PNP,"","",5539|142,No-Effect
3244,BRD-K52618540,inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,,Launched,insulin sensitizer,CDIPT,obstetrics/gynecology,polycystic ovary syndrom (PCOS),10423,Very Weak (35%)
3248,BRD-K33067152,INT-767,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,23642339,Phase 1,FXR agonist,GPBAR1,"","",151306,No-Effect
3249,BRD-K88165431,integrin-antagonist-1,Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O,86272865,Phase 1,integrin antagonist,ITGAV|ITGB6,"","",3685|3694,No-Effect
3253,BRD-K67261995,iodipamide,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,3739,Launched,radiopaque medium,ALB,radiology,contrast agent,213,Weak (50%)
3257,BRD-K51918615,iodophenpropit,Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1,3035746,Preclinical,histamine receptor antagonist,HRH3|HRH4,"","",59340|11255,No-Effect
3266,BRD-K84892605,IOWH032,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,135565181,Phase 2,CFTR channel antagonist,CFTR,"","",1080,No-Effect
3267,BRD-K70751730,IOX1,OC(=O)c1ccc(O)c2ncccc12,459617,Preclinical,histone demethylase inhibitor,EGLN1|KDM3A|KDM4C|KDM6B,"","",23081|55818|23135|54583,No-Effect
3268,BRD-K98251413,IOX2,OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,54685215,Preclinical,hypoxia inducible factor inhibitor,EGLN1|KDM2A|KDM5C,"","",22992|8242|54583,No-Effect
3271,BRD-K38727704,IPA-3,Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,521106,Preclinical,p21 activated kinase inhibitor,PAK1,"","",5585,No-Effect
3274,BRD-K66896231,ipidacrine,Nc1c2CCCc2nc2CCCCc12,604519,Phase 3,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
3275,BRD-K51247865,ipragliflozin-L-proline,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1,10453870,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,6524,Low (25%)
3276,BRD-K01826778,ipratropium,"CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|",,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131|1132|1133,No-Effect
3278,BRD-K88568253,iproniazid,CC(C)NNC(=O)c1ccncc1,3748,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,"","",4128|4129,No-Effect
3279,BRD-K90574421,ipsapirone,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,56971,Phase 3,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
3280,BRD-K60038276,irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|,3749,Launched,angiotensin receptor antagonist,AGTR1|JUN|SLC10A1,cardiology|nephrology,hypertension|diabetic nephropathy,185|6554|3725,No-Effect
3283,BRD-K08547377,irinotecan,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12,60838,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,colorectal cancer,7150|116447,No-Effect
3284,BRD-K98357249,IRL-2500,CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1,5311192,Preclinical,endothelin receptor antagonist,EDNRB,"","",1910,No-Effect
3285,BRD-K87777313,irosustat,NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1,5287541,Phase 2,steroid sulfatase inhibitor,CA2|STS,"","",760|412,No-Effect
3286,BRD-K74195153,irsogladine,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,3752,Launched,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD),5141,Low (25%)
3287,BRD-K01825673,isamoltane,CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|,6604790,Phase 1,adrenergic receptor antagonist,HTR1A|HTR1B,"","",3350|3351,No-Effect
3288,BRD-A17009129,isavuconazole,"C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|",92043107,Phase 3,cytochrome P450 inhibitor,CYP3A4,"","",1576,No-Effect
3292,BRD-A94055480,ISO-1,"COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|",5288525,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,"","",4282,No-Effect
3294,BRD-K54057105,isobutyramide,CC(C)C(N)=O,68424,Phase 2,gene expression stimulant,HBE1|HBG1,"","",3046|3047,No-Effect
3295,BRD-K93332168,isocarboxazid,Cc1cc(no1)C(=O)NNCc1ccccc1,3759,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression,4128|4129,No-Effect
3296,BRD-K01825590,isoconazole,Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|,25273632,Launched,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections,1586,No-Effect
3300,BRD-K29173907,isoflupredone-acetate,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|",224246,Preclinical,"",NR3C1,"","",2908,No-Effect
3301,BRD-A31564021,isoflurane,"FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|",4369440,Launched,inhaled anaesthetic,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|2743|54207|3776|3777|55879|51305|2554|2555|2556|2557|2558|2559,No-Effect
3302,BRD-K56575995,isoflurophate,CC(C)OP(F)(=O)OC(C)C,5936,Launched,cholinesterase inhibitor,ACHE|BCHE,ophthalmology,glaucoma,43|590,No-Effect
3303,BRD-K66480997,isoguvacine,OC(=O)C1=CCNCC1 |t:3|,7059534,Preclinical,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,"","",200959|2569|2570|2554|2555|2556|2557|2558|2559,No-Effect
3305,BRD-K33583600,isoliquiritigenin,Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1,638278,Preclinical,guanylate cyclase activator,GABBR1,"","",10537,No-Effect
3307,BRD-K87202646,isoniazid,NNC(=O)c1ccncc1,3767,Launched,FABI inhibitor,CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4,infectious disease,tuberculosis,1571|1544|1576|1557|1558,No-Effect
3309,BRD-A04322457,isoprenaline,CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|,5808,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,cardiology|pulmonary,bradycardia|heart block|asthma,153|154|155,No-Effect
3310,BRD-K14127446,isopropamide-iodide,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,3775,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)|gastrointestinal acidosis,1131|1132,No-Effect
3316,BRD-K55853390,isosorbide-dinitrate,[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O,6883,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1,cardiology,angina pectoris|coronary artery disease (CAD),2977|2982|2983|4881|2974,No-Effect
3317,BRD-K82225283,isosorbide-mononitrate,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O,27661,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,angina pectoris|coronary artery disease (CAD),2977|2974|2982|2983,No-Effect
3320,BRD-K76723084,isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|,5282379,Launched,retinoid receptor agonist,RARA|RARB|RARG,dermatology,acne vulgaris (AV),5914|5915|5916,Low (25%)
3323,BRD-A75552914,isoxicam,CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|,54677972,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
3324,BRD-K00003690,isoxsuprine,"C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|",42066885,Launched,adrenergic receptor agonist,ADRB2,rheumatology|cardiology,Raynaud's disease|arteriosclerosis|Buerger's disease,154,No-Effect
3325,BRD-K64881305,ispinesib,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1,6851740,Phase 2,kinesin inhibitor,KIF11,"","",3832,No-Effect
3326,BRD-A90799790,isradipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|",13773524,Launched,calcium channel blocker,CACNA1D|CACNA1F|CACNA2D1,cardiology,hypertension,776|778|781,No-Effect
3327,BRD-K12826175,ISRIB,Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|,,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,EIF2A|EIF2AK3,"","",9451|1965,No-Effect
3328,BRD-K95412502,istaroxime,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,9841834,Phase 2,ATPase inhibitor,ATP1A1,"","",476,Weak (50%)
3329,BRD-K87774949,istradefylline,CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O,5311037,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,neurology/psychiatry,Parkinson's Disease|dyskinesia,136|140|134|135,Low (25%)
3330,BRD-K53903639,ISX-9,O=C(NC1CC1)c1cc(on1)-c1cccs1,19582717,Preclinical,neural stem cell inducer,NEUROD1,"","",4760,No-Effect
3331,BRD-K73499906,IT1t,"CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|",25147749,Preclinical,CC chemokine receptor antagonist,CXCR4,"","",7852,Strong (80%)
3332,BRD-K67482377,itacitinib,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,53380437,Phase 3,JAK inhibitor,JAK1,"","",3716,No-Effect
3334,BRD-K60298136,ITE,COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12,4668801,Preclinical,aryl hydrocarbon receptor agonist,AHR,"","",196,No-Effect
3335,BRD-K77987496,ITI214,CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|,42639643,Phase 1/Phase 2,phosphodiesterase inhibitor,PDE1A,"","",5136,No-Effect
3336,BRD-K96740444,itopride,COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,3792,Launched,dopamine receptor antagonist,CHRM3|DRD2,gastroenterology|neurology/psychiatry,dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia,1131|1813,No-Effect
3338,BRD-K36515744,ITX3,Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1,1362865,Preclinical,GEF inhibitor,TRIO,"","",7204,No-Effect
3340,BRD-K45841694,IU1,Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1,675434,Preclinical,ubiquitin C-terminal hydrolase inhibitor,USP14,"","",9097,No-Effect
3341,BRD-K33972682,ivabradine,COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC,132999,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris,57657|348980|10021,No-Effect
3342,BRD-K52818472,ivacaftor,CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C,16220172,Launched,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis,1080,No-Effect
3343,BRD-K85554912,ivermectin,"CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|",6321424,Launched,benzodiazepine receptor agonist,CHRNA7|P2RX7,infectious disease,gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies,89832|5027,No-Effect
3344,BRD-K93073858,ivosidenib,Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N,71657455,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),3417,No-Effect
3345,BRD-K53234107,IWP-L6,O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1,71601111,Preclinical,porcupine inhibitor,PORCN,"","",64840,No-Effect
3346,BRD-K03601870,ixabepilone,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,,Launched,microtubule stabilizing agent,TUBB,oncology,breast cancer,7280,No-Effect
3350,BRD-K95676198,JAK3-inhibitor-V,C=CC(=O)c1ccc2ccccc2c1,3799,Preclinical,JAK inhibitor,JAK3,"","",3718,No-Effect
3352,BRD-K95837862,JDTic,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,9956146,Phase 1,opioid receptor antagonist,OPRK1,"","",4986,No-Effect
3353,BRD-K32892871,JHW-007,CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,,Preclinical,dopamine reuptake inhibitor,SLC6A3,"","",6531,Strong (80%)
3355,BRD-K76180386,JIB04,Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1,6519698,Preclinical,histone lysine demethylase inhibitor,KDM4E,"","",390245,No-Effect
3357,BRD-K22010301,JLK-6,COc1oc(=O)c2cc(N)ccc2c1Cl,3803,Preclinical,gamma secretase inhibitor,PSEN1,"","",5663,Low (25%)
3358,BRD-K15086322,JNJ-10191584,CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1,10446295,Preclinical,histamine receptor antagonist,HRH4,"","",59340,No-Effect
3359,BRD-K61721596,JNJ-10397049,CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1,9869934,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
3360,BRD-K25596805,JNJ-16259685,CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|,,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
3361,BRD-K47376733,JNJ-1661010,O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1,2809273,Preclinical,FAAH inhibitor,FAAH,"","",79152,No-Effect
3362,BRD-K51770398,JNJ-17203212,FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1,11339118,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
3363,BRD-K83837640,JNJ-26481585,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,11538455,Phase 2,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2,"","",4193|55869|9734|8841|10013|79885|3065|3066|83933|10014|9759,Cyto
3365,BRD-K41895652,JNJ-27141491,CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1,11703589,Preclinical,CC chemokine receptor antagonist,CCR2,"","",729230,No-Effect
3366,BRD-K31802667,JNJ-37822681,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,16058752,Phase 2,dopamine receptor antagonist,DRD2,"","",1813,No-Effect
3367,BRD-K02123250,JNJ-38877605,Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1,46911863,Phase 1,tyrosine kinase inhibitor,MET,"","",8731,No-Effect
3370,BRD-K55029398,JNJ-40411813,CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O,25195461,Phase 2,glutamate receptor positive allosteric modulator,GRM2,"","",2912,No-Effect
3371,BRD-K01036220,JNJ-42041935,OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1,45102710,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,"","",5164,No-Effect
3372,BRD-K70330032,JNJ-42165279,FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1,54576693,Phase 2,FAAH inhibitor,FAAH,"","",79152,No-Effect
3373,BRD-K83547600,JNJ-47965567,O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1,66553218,Preclinical,purinergic receptor antagonist,P2RX7,"","",5027,Very Weak (35%)
3375,BRD-K19482962,JNJ-63533054,C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1,2548547,Preclinical,G protein-coupled receptor agonist,GPR139,"","",124274,Low (25%)
3378,BRD-K11636097,JNJ-7706621,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,5330790,Preclinical,CDK inhibitor,AURKA|AURKB|CDK1|CDK2,"","",1017|9212|6790|983,Cyto
3379,BRD-K17774839,JNJ-7777120,CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1,4908365,Preclinical,histamine receptor antagonist,HRH4,"","",59340,No-Effect
3382,BRD-K54606188,JQ1-(+),Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|,46907787,Preclinical,bromodomain inhibitor,BRD4|BRDT,"","",676|23476,No-Effect
3383,BRD-K17705806,JTC-801,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,5311340,Phase 2,opioid receptor antagonist,OPRL1,"","",4987,Strong (80%)
3384,BRD-K43330982,JTE-013,CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12,10223146,Preclinical,lysophospholipid receptor antagonist,P2RY10|S1PR2,"","",9294|27334,No-Effect
3385,BRD-K81405859,JTE-607,CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,9938545,Phase 2,cytokine production inhibitor,IL10|IL1B|IL6|TNF,"","",3553|3586|7124|3569,No-Effect
3386,BRD-K63150726,JTE-907,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12,9867770,Phase 1,cannabinoid receptor inverse agonist,CNR2,"","",56142,No-Effect
3387,BRD-K53328210,JW-55,COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1,2946601,Preclinical,tankyrase inhibitor,TNKS|TNKS2,"","",8658|80351,No-Effect
3388,BRD-K48424871,JW-642,FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F,71656520,Preclinical,monoacylglycerol lipase inhibitor,MGLL,"","",11343,No-Effect
3389,BRD-K24554037,JW-67,O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12,644733,Preclinical,WNT pathway inhibitor,APC|AXIN1|GSK3B,"","",5624|2932|8312,No-Effect
3390,BRD-K75664313,JW-74,COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1,16013152,Preclinical,tankyrase inhibitor|WNT signaling inhibitor,TNKS|TNKS2,"","",8658|80351,No-Effect
3391,BRD-K05464208,JX-401,COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,1126109,Preclinical,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
3392,BRD-K45446451,JZL-184,OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1,25021165,Preclinical,monoacylglucerol lipase inhibitor,MGLL,"","",11343,No-Effect
3393,BRD-K38875233,JZL-195,[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1,46232606,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,FAAH|MGLL,"","",79152|11343,No-Effect
3395,BRD-A67748489,K-858,"CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|",686905,Preclinical,kinesin-like spindle protein inhibitor,KIF11,"","",3832,No-Effect
3397,BRD-K90756851,K-Ras(G12C)-inhibitor-12,Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C,73555129,Preclinical,K-Ras inhibitor,KRAS,"","",3265,No-Effect
3399,BRD-K84595254,K-strophanthidin,C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|,6185,Phase 2,ATPase inhibitor,ATP1A1,"","",476,Strong (80%)
3400,BRD-K58568447,K02288,COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1,46173038,Preclinical,bone morphogenic protein inhibitor,BMP1,"","",649,Weak (50%)
3401,BRD-K12106308,K145,CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1,71714682,Preclinical,sphingosine kinase inhibitor,SPHK2,"","",56848,No-Effect
3402,BRD-K12807006,kaempferol,Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O,5280863,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1,"","",231|1545|367|240|2739|247|133688|3292,No-Effect
3404,BRD-K52459018,kainic-acid,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O,44338126,Preclinical,kainate receptor agonist,GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5,"","",2890|2897|2899|2900|2901,No-Effect
3407,BRD-K00003176,karenitecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O,148202,Phase 3,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
3408,BRD-K27584835,kartogenin,OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1,2826191,Preclinical,chondrocyte differentiation stimulator,FLNA,"","",2316,No-Effect
3410,BRD-K17743697,KB-R7943,NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1,4534086,Preclinical,sodium/calcium exchange inhibitor,SLC8A1|TRPC3|TRPC5|TRPC6,"","",7224|7225|6546|7222,Very Weak (35%)
3411,BRD-K88154110,KB-SRC-4,Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1,73349077,Preclinical,SRC inhibitor,SRC,"","",6714,No-Effect
3412,BRD-A00376169,KBG,"O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|",92461199,Phase 2,neprilysin inhibitor,MME,"","",4321,No-Effect
3413,BRD-K71164191,KD-023,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,115175,Phase 2,ACAT inhibitor,ACACA|ACACB,"","",32|31,No-Effect
3414,BRD-K88506063,KD025,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1,11950170,Phase 2,rho associated kinase inhibitor,ROCK2,"","",9475,No-Effect
3415,BRD-K37312348,kenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1,3820,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,"","",2932|891|1020|983,No-Effect
3416,BRD-K49671696,ketanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,3822,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2,cardiology,hypertension,3352|3361|3363|6570|6571|146|147|1812|106480180|3350|3351|1816|3356|3358,No-Effect
3417,BRD-K29113274,ketoconazole,"CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|",47576,Launched,sterol demethylase inhibitor,KCNA10,dermatology,seborrheic dermatitis,3744,No-Effect
3419,BRD-A97739905,ketoprofen,"C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|",180540,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis,160728|5742|5743,No-Effect
3420,BRD-K01825750,ketorolac,"OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|",181817,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
3421,BRD-K28936863,ketotifen,CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|,57392700,Launched,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor,HRH1,neurology/psychiatry,itching,3269,No-Effect
3423,BRD-A54927599,KF-38789,"COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|",135565372,Preclinical,P selectin inhibitor,SELP,"","",6414,Cyto
3424,BRD-K90747162,KG-5,CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1,53328059,Preclinical,RAF inhibitor,BRAF|FLT3|KIT|PDGFRB,"","",673|2322|5159|3815,No-Effect
3425,BRD-K66430217,KH-CB19,CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C,91899919,Preclinical,CDC inhibitor,CLK1|CLK3|DYRK1A,"","",1859|1195|1198,No-Effect
3427,BRD-K84605263,KHK-IN-1,CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1,53348216,Preclinical,hexokinase inhibitor,KHK,"","",3795,No-Effect
3428,BRD-K78978711,KHS-101,CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1,71304818,Preclinical,neural stem cell inducer,TACC3,"","",10460,No-Effect
3429,BRD-A25569250,KI-16425,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|",40467027,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,"","",1902|23566,No-Effect
3430,BRD-A88787317,KI-20227,"COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|",57881591,Preclinical,c-Fms inhibitor,CSF1R|KDR|KIT|PDGFRB,"","",3815|1436|5159|3791,No-Effect
3431,BRD-K47150025,KI-8751,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,11317348,Preclinical,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,"","",3791,No-Effect
3433,BRD-K02898090,kifunensine,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,130611,Phase 1,mannosidase inhibitor,MAN1B1|MAN2A1,"","",4124|11253,Very Weak (35%)
3435,BRD-A94580299,KL-001,"CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|",1367681,Preclinical,proteasome inhibitor,CRY1|CRY2,"","",1408|1407,No-Effect
3438,BRD-K46734292,KML29,OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1,71656212,Preclinical,monoacylglucerol lipase inhibitor,MGLL,"","",11343,No-Effect
3439,BRD-A81177136,KN-62,"CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|",5312126,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1,"","",5600|5027|5578|6093|6446|815|207|6300|6198|1111|1432|5594|3932|5599,No-Effect
3440,BRD-K93480852,KN-93,COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1,5312122,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,"","",815,No-Effect
3441,BRD-K64642496,Ko143,COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O,10322450,Preclinical,BCRP inhibitor,ABCB1|ABCC1,"","",4363|5243,No-Effect
3443,BRD-K71467466,KPT-185,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,53495165,Preclinical,exportin antagonist,XPO1,"","",7514,No-Effect
3444,BRD-K75352575,KPT-276,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1,71496742,Preclinical,exportin antagonist,XPO1,"","",7514,No-Effect
3447,BRD-K40604024,KRCA-0008,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O,72547474,Preclinical,ALK inihibitor,ALK,"","",238,No-Effect
3448,BRD-K90993449,KRN-633,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,9549295,Preclinical,VEGFR inhibitor,FLT1|FLT4|KDR,"","",2321|2324|3791,No-Effect
3449,BRD-K81053848,KS-176,OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1,49779726,Preclinical,BCRP inhibitor,ABCG2,"","",9429,No-Effect
3451,BRD-K67566344,KU-0063794,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1,16736978,Preclinical,mTOR inhibitor,MTOR,"","",2475,No-Effect
3452,BRD-K25311561,KU-55933,O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1,5278396,Preclinical,ATM kinase inhibitor,ATM|PRKDC,"","",472|5591,Low (25%)
3453,BRD-K36016295,KU-60019,C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1,15953870,Preclinical,ATM kinase inhibitor,ATM,"","",472,Strong (80%)
3455,BRD-K51337109,kuromanin,OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O,441667,Preclinical,ribosyl cyclase inhibitor,CD38,"","",952,No-Effect
3456,BRD-K21718444,KW-2449,O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1,11427553,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,ABL1|AURKA|AURKB|FLT3,"","",25|2322|9212|6790,No-Effect
3458,BRD-A95683721,KW-3902,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|",,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,Very Weak (35%)
3459,BRD-K29968218,KX2-391,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,23635314,Phase 3,SRC inhibitor|tubulin polymerization inhibitor,SRC,"","",6714,Very Weak (35%)
3460,BRD-K13302470,KY02111,COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,8582409,Preclinical,WNT pathway inhibitor,DKK1,"","",22943,No-Effect
3461,BRD-K85872723,kynurenic-acid,OC(=O)c1cc(=O)c2ccccc2[nH]1,3845,Phase 1,glutamate receptor antagonist,GPR35|GRIN1|GRIN2A|GRIN2B,"","",114787|2904|2859|2903,No-Effect
3463,BRD-K01827100,L-152804,"CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|",969478,Preclinical,neuropeptide receptor antagonist,NPY5R,"","",4889,No-Effect
3464,BRD-K39733634,L-161982,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C,9961192,Preclinical,prostanoid receptor antagonist,PTGER4,"","",5734,No-Effect
3465,BRD-K98372770,L-165041,CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O,6603901,Preclinical,PPAR receptor agonist,PPARD,"","",5467,No-Effect
3466,BRD-K18036262,L-168049,CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1,5311276,Preclinical,glucagon receptor antagonist,GCGR,"","",2642,No-Effect
3467,BRD-K34277641,L-365260,CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|,5311201,Phase 2,CCK receptor antagonist,CCKAR|CCKBR|KCNQ1,"","",3784|886|887,No-Effect
3468,BRD-K00004282,L-368899,Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,9872389,Phase 1,oxytocin receptor antagonist,AVPR1A|AVPR2|OXTR,"","",552|554|5021,No-Effect
3469,BRD-K13474508,"L-655,708",CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21,5311203,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRG2,"","",2566|2554|2555|2556|2558,No-Effect
3470,BRD-K89402695,L-655240,Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,122070,Phase 1,thromboxane receptor antagonist,PTGES,"","",9536,No-Effect
3472,BRD-K74284736,L-689560,OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1,6604749,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
3473,BRD-K28470988,L-690330,CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O,132449,Preclinical,inositol monophosphatase inhibitor,IMPA1,"","",3612,No-Effect
3474,BRD-K83322645,L-693403,C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1,4687238,Preclinical,sigma receptor agonist|sigma receptor antagonist,DRD2|SIGMAR1,"","",10280|1813,No-Effect
3475,BRD-K18816859,L-694247,CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1,132059,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,"","",3352|3350|3351,No-Effect
3476,BRD-K10176267,L-701252,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,54687453,Preclinical,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
3477,BRD-K08109516,L-701324,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,54682505,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
3478,BRD-K37952347,"L-732,138",CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,44396853,Preclinical,tachykinin antagonist,TACR1|TACR2,"","",6865|6869,No-Effect
3479,BRD-K15791587,L-733060,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,132846,Preclinical,tachykinin antagonist,TACR1,"","",6869,No-Effect
3480,BRD-K13211965,L-741742,Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1,133008,Preclinical,dopamine receptor antagonist,DRD3|DRD4|SCN1A|SCN3A,"","",6328|6323|1814|1815,Low (25%)
3481,BRD-K05528470,L-745870,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,5311200,Preclinical,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7,"","",3362|3363|1815|1812|1813|3350|1814|3356,No-Effect
3482,BRD-K39359968,L-755507,CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,9829836,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
3483,BRD-K30425481,L-760735,C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,9809077,Preclinical,tachykinin antagonist,TACR1,"","",6869,No-Effect
3484,BRD-K10958118,L-778123,Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O,216454,Phase 1,farnesyltransferase inhibitor,FNTA|FNTB|PGGT1B,"","",2339|100529261|5229,No-Effect
3485,BRD-K43905307,L-798106,COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1,15551229,Preclinical,prostanoid receptor antagonist,PTGER3,"","",5733,No-Effect
3486,BRD-K46647427,L-838417,Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F,9908880,Preclinical,GABA receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,No-Effect
3487,BRD-K25125382,L-alanine,C[C@H](N)C(O)=O,7311724,Launched,"",AARS|AARS2|ABAT|AGXT|AGXT2|GPRC6A|GPT|GPT2|KYNU|NFS1|PHYKPL|SLC1A4|SLC36A1|SLC7A8,"","",57505|84706|23428|64902|1798|6509|8942|85007|16|222545|18|206358|189|9054,Weak (50%)
3488,BRD-K06033833,L-arginine,N[C@@H](CCCNC(N)=N)C(O)=O,6322,Launched,nitric oxide precursor,ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4,cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology,congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold,384|342977|113451|6541|222545|339345|6545|84889|445|158,No-Effect
3490,BRD-K06665116,L-asparagine,N[C@@H](CC(N)=O)C(O)=O,6992089,Phase 3,"",ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3,"","",4677|6510|10991|79731|80150|440,No-Effect
3492,BRD-K97163964,L-aspartic-acid,N[C@@H](CC(O)=O)C(O)=O,5960,Launched,metallic radical formation stimulant,ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13,"","",6035|80150|790|8604|159|10165|91703|440|443|444|445|1615|2903|2904|2905|2906|95|114787|4069|6505|10606|55157|2806|2805|122622,Very Weak (35%)
3493,BRD-A12237696,L-citrulline,"N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|",9750,Launched,nitric oxide stimulant,ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6,cardiology|urology,hypertension|erectile dysfunction,342977|11240|23564|340719|222545|339345|5009|23569|51702|29943|23576|353238|445,No-Effect
3494,BRD-K00795468,L-cysteine,N[C@@H](CS)C(O)=O,6419722,Launched,"",CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3,rheumatology,osteoarthritis|rheumatoid arthritis,23584|833|80704|79587|2729|2730|1036|102724560|51380|2805|5621|9054|4255,No-Effect
3495,BRD-A25800195,L-cysteinesulfinic-acid,"N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|",28167170,Preclinical,glutamate receptor agonist,GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2,"","",10914|2915|3158|2936|7001|2911,Very Weak (35%)
3496,BRD-K99679910,L-cystine,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,6992103,Launched,"",CTNS|SLC3A1|SLC7A11|SLC7A9,"","",11136|1497|682|6519,Very Weak (35%)
3498,BRD-K62309135,L-glutamic-acid,N[C@@H](CCC(O)=O)C(O)=O,88747398,Launched,glutamate receptor agonist,AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT,"","",8833|1798|79751|2058|2571|2572|29968|18|83733|55191|27165|10404|124454|2729|2346|2730|5198|10157|682|79969|2356|440|2746|2747|2752|5188|5832|586|587|56267|2890|2891|2892|2893|2894|2895|2897|2899|2901|2900|2903|2904|10841|2905|2906|116443|116444|51166|2911|2912|2913|84706|114787|2914|2916|2917|2918|51557|6505|6506|6507|2028|6511|6512|162417|2677|2805|2806|26873|23549,Very Weak (35%)
3499,BRD-K83896451,L-glutamine,N[C@@H](CCC(N)=O)C(O)=O,6992086,Launched,"",CTPS1|GLUL|GPRC6A|PPAT,gastroenterology|dental|neurology/psychiatry|rheumatology,diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia,2752|222545|80347|1503,No-Effect
3502,BRD-K12853841,L-leucine,CC(C)C[C@H](N)C(O)=O,7045798,Phase 3,"",BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2,"","",51520|23395|586|587|9836|51451,No-Effect
3503,BRD-K86016185,L-lysine,NCCCC[C@H](N)C(O)=O,71774817,Phase 2,serotonin receptor agonist,GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4,"","",6541|6542|222545|6545|3735|84889,No-Effect
3504,BRD-K06502269,L-methionine,CSCC[C@H](N)C(O)=O,6992087,Launched,voltage-gated calcium channel ligand,BHMT|BHMT2|METAP2|MTR|MTRR,pulmonary|allergy|neurology/psychiatry,asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia,4548|4552|10988|635|23743,No-Effect
3505,BRD-K00004529,L-mimosine,N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|,129010056,Preclinical,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,DBH|EIF5A,"","",143244|1621,No-Effect
3506,BRD-K20946707,L-monomethylarginine,CN[C@@H](CCCNC(N)=N)C(O)=O,73046,Phase 3,nitric oxide synthase inhibitor,NOS1|NOS2,"","",339345|340719,No-Effect
3507,BRD-K33141550,L-NAME,COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O,39836,Phase 2/Phase 3,nitric oxide synthase inhibitor,NOS3,"","",342977,No-Effect
3508,BRD-K60036103,L-NIL,CC(=N)NCCCC[C@H](N)C(O)=O,2733506,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,"","",339345|342977|340719,No-Effect
3510,BRD-K01666412,L-proline,OC(=O)[C@@H]1CCCN1,6971047,Launched,glutamate receptor agonist,EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7,"","",6534|2058|8974|9360|10105|10536|5033|55214|64175|5831|11212|112849|29920|10465|5478|5479|5480|65263|25973|11254|5625,No-Effect
3511,BRD-K92404805,L-quisqualic-acid,N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O,6971145,Preclinical,glutamate receptor agonist,FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8,"","",2912|2913|2915|2917|2918|2346|2891|2897|2901|2911,No-Effect
3513,BRD-K75508643,L-threonine,C[C@@H](O)[C@H](N)C(O)=O,6971019,Phase 2,"",TARS|TARS2|THNSL1,"","",79896|6897|80222,No-Effect
3515,BRD-K01825098,labetalol,"C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|",134043,Launched,adrenergic receptor antagonist,ADRA1D|ADRB1|ADRB2,cardiology,hypertension,153|146|154,No-Effect
3516,BRD-K43586850,lacidipine,"CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|",5311217,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension,775,No-Effect
3519,BRD-K00003615,lafutidine,O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|,40490609,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|peptic ulcer disease (PUD),1665,Low (25%)
3521,BRD-K93460210,lamotrigine,Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl,3878,Launched,serotonin receptor antagonist|sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|bipolar disorder,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
3524,BRD-K86436199,landiolol,CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,114905,Launched,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia,153,No-Effect
3527,BRD-K00004280,lansoprazole,"Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|",9578005,Launched,ATPase inhibitor,ATP4A|ATP4B,gastroenterology,heartburn,496|495,No-Effect
3528,BRD-K19687926,lapatinib,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,208908,Launched,EGFR inhibitor,EGFR|ERBB2,oncology,breast cancer,2064|1956,No-Effect
3530,BRD-K60918217,laquinimod,CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,54677946,Phase 3,immunosuppressant,CXCL2,"","",2920,No-Effect
3532,BRD-K48894757,laropiprant,CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12,9867642,Launched,prostanoid receptor antagonist,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R,cardiology,cholesterol,5729|5731|5732|5733|6915|5737|5739|11251,No-Effect
3533,BRD-K36574127,larotrectinib,O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,46188928,Launched,tropomyosin receptor kinase inhibitor,NTRK1|NTRK2|NTRK3,"","",4914|4915|4916,Low (25%)
3536,BRD-M93148412,lasofoxifene,O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1,3081919,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer,2099|2100,Strong (80%)
3537,BRD-K10961822,latanoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,5311221,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma,5737,Very Weak (35%)
3538,BRD-K55703048,latrepirdine,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1,197033,Phase 3,glutamate receptor antagonist,HRH1|HTR6,"","",3362|3269,No-Effect
3539,BRD-K61292460,latrunculin-B,"C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|",6436219,Phase 1,actin polymerization inhibitor,ACTA1|MKL1|SPIRE2,"","",58|84501|57591,Strong (80%)
3540,BRD-K67375056,lauric-acid,CCCCCCCCCCCC(O)=O,3893,Phase 3,bacterial permeability inducer,GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4,"","",7099|53831|5320|6927|4057|23643,No-Effect
3543,BRD-K51486818,lazabemide,NCCNC(=O)c1ccc(Cl)cn1,71307,Phase 3,monoamine oxidase inhibitor,MAOB,"","",4129,No-Effect
3547,BRD-K08248804,LCL-161,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,24737642,Phase 2,XIAP inhibitor,BIRC2|XIAP,"","",329|331,No-Effect
3548,BRD-K20008181,LCQ908,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|,,Phase 3,diacylglycerol O acyltransferase inhibitor,DGAT1,"","",8694,No-Effect
3550,BRD-K44715996,LDC1267,CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C,56847486,Preclinical,protein tyrosine kinase inhibitor,AXL|MERTK|TYRO3,"","",10461|558|7301,No-Effect
3551,BRD-K61795638,LDN-209929,COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1,46871867,Preclinical,haspin kinase inhibitor,GSG2,"","",83903,No-Effect
3552,BRD-K59831625,LDN-212854,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,60182388,Preclinical,bone morphogenic protein inhibitor,ABL1|ACVR1|RIPK2,"","",25|90|8767,No-Effect
3555,BRD-K04853698,LDN193189,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,25195294,Preclinical,bone morphogenic protein inhibitor,ACVR1|BMPR1A,"","",657|90,No-Effect
3556,BRD-K06593056,LE-135,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|,10410894,Preclinical,retinoid receptor agonist,RARB,"","",5915,No-Effect
3558,BRD-K78692225,leflunomide,Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F,3899,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,AHR|DHODH|PTK2B,rheumatology,rheumatoid arthritis,2185|1723|196,No-Effect
3559,BRD-K78666663,lemborexant,Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1,56944144,Launched,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
3560,BRD-A17883755,lenalidomide,"Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|",12044976,Launched,anticancer agent,TNF,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS),7124,Very Weak (35%)
3562,BRD-K39974922,lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,9823820,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4|KDR,oncology,thyroid cancer,2324|3791,No-Effect
3565,BRD-A18992208,lercanidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|",9809926,Launched,calcium channel blocker,CACNA2D1,cardiology,hypertension,781,No-Effect
3566,BRD-K62398570,lerisetron,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,65997,Phase 3,serotonin receptor antagonist,HTR3A,"","",3359,No-Effect
3568,BRD-K75024268,lesinurad,OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,53465279,Launched,uric acid diuretic,SLC22A12,rheumatology,gout,116085,No-Effect
3569,BRD-A27376179,lestaurtinib,"C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|",9932888,Phase 3,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,FLT3|NTRK1,"","",2322|4914,No-Effect
3574,BRD-K88789588,letrozole,N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1,3902,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588,No-Effect
3575,BRD-K27460187,leucomethylene-blue,CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C,164695,Phase 3,nitric oxide production inhibitor|tau aggregation inhibitor,MAPT,"","",4137,Strong (80%)
3578,BRD-K45300898,leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,657181,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer,2798,No-Effect
3579,BRD-K34469523,levalbuterol,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,123600,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm,154,No-Effect
3580,BRD-K30634073,levallorphan,Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1,5359371,Launched,opioid receptor antagonist,CHRNA2|OPRM1,pulmonary,respiratory depression,4988|1135,Weak (50%)
3581,BRD-K73107279,levamisole,C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|,26879,Withdrawn,acetylcholine receptor agonist,ALPL,"","",249,Very Weak (35%)
3583,BRD-K24526313,levcromakalim,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N,93504,Phase 3,potassium channel activator,KCNJ5,"","",3762,No-Effect
3584,BRD-K49404994,levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,5284583,Launched,calcium channel blocker,CACNA1B|SCN1A|SV2A,neurology/psychiatry,seizures,6323|9900|774,Weak (50%)
3585,BRD-A64698388,levo-phencynonate,"CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|",,Launched,acetylcholine receptor antagonist,CHRM1,"","",1128,No-Effect
3586,BRD-K43883465,levobetaxolol,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,60657,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma,153|154,No-Effect
3587,BRD-K31812033,levobunolol,CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12,39468,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,glaucoma|ocular hypertension,153|154|155,No-Effect
3590,BRD-K33453211,levocabastine,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,,Launched,histamine receptor antagonist,HRH1|NTSR2,ophthalmology,conjunctivitis,23620|3269,No-Effect
3591,BRD-K59647213,levocarnitine,C[N+](C)(C)C[C@H](O)CC(O)=O,10918,Launched,"",CRAT|CROT,endocrinology,carnitine deficiency,1384|54677,No-Effect
3592,BRD-K84366268,levocarnitine-propionate,CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C,157837,Launched,carnitine palmitoyltransferase inhibitor,CRAT,neurology/psychiatry|endocrinology,peripheral neuropathy|carnitine deficiency,1384,No-Effect
3593,BRD-K27184429,levocetirizine,OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,28145931,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269,No-Effect
3594,BRD-K34730807,levodopa,N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O,6971033,Launched,dopamine precursor,DRD1|DRD2|DRD3|DRD4|DRD5|GPR143,neurology/psychiatry,Parkinson's Disease,4935|1812|1813|1814|1815|1816,No-Effect
3596,BRD-K09471561,levofloxacin,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,6956357,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|otolaryngology|pulmonary|urology,pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague,7153,No-Effect
3598,BRD-K50329370,levomenthol,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16666,Launched,"",OPRK1|TRPA1|TRPM8|TRPV3,neurology/psychiatry,pain relief,162514|4986|8989|79054,No-Effect
3599,BRD-K35559145,levomepromazine,COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,72287,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C,neurology/psychiatry|gastroenterology,psychosis|schizophrenia|bipolar disorder|nausea|insomnia,3269|1128|1129|1131|1132|1133|1815|1816|146|147|1812|1813|150|151|152|1814|3356|3358,Strong (80%)
3600,BRD-A67616246,levomequitazine,"C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|",3246605,Phase 2,histamine receptor antagonist,HRH1,"","",3269,Weak (50%)
3601,BRD-K02976377,levonordefrin,C[C@H](N)[C@H](O)c1ccc(O)c(O)c1,164739,Launched,vasodilator,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2,hematology,hemorrhage,6530|146|147|150|151|152,No-Effect
3602,BRD-K35189033,levonorgestrel,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|,13109,Launched,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist,PGR,endocrinology,contraceptive,5241,No-Effect
3604,BRD-K03095347,levosimendan,C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|,3033825,Launched,calcium sensitizer,KCNJ11|KCNJ8|PDE3A|TNNC1,cardiology,congestive heart failure,7137|5139|3764|3767,No-Effect
3605,BRD-K51671335,levosulpiride,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,688272,Launched,dopamine receptor antagonist,CA1|CA12|CA7|DRD2|DRD3,neurology/psychiatry|gastroenterology|urology,schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE),771|1813|1814|759|766,Very Weak (35%)
3606,BRD-K30685142,levothyroxine,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O,5819,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,myxedema coma,7067|7068,Very Weak (35%)
3607,BRD-A30655177,LFM-A13,"CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|",,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,No-Effect
3609,BRD-K16810791,LGK-974,Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C,46926973,Phase 2,porcupine inhibitor,PORCN,"","",64840,No-Effect
3610,BRD-K47409078,LH846,Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl,851474,Preclinical,casein kinase inhibitor,CSNK1D,"","",1453,No-Effect
3611,BRD-K00004284,liarozole,"Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|",76956376,Phase 2/Phase 3,cytochrome P450 inhibitor,CYP19A1|CYP26A1,"","",1592|1588,No-Effect
3612,BRD-A22642447,licarbazepine,"NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|",9816485,Phase 3,voltage-gated sodium channel blocker,SCN5A,"","",6331,No-Effect
3613,BRD-K99667445,licochalcone-A,COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C,5318998,Phase 3,topoisomerase inhibitor,PTPN1,"","",5770,No-Effect
3614,BRD-K08439945,licofelone,CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1,133021,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5|PLA2G2E|PTGS2,"","",240|30814|5743,No-Effect
3618,BRD-K52662033,lidocaine,CCN(CC)CC(=O)Nc1c(C)cccc1C,3676,Launched,histamine receptor agonist,EGFR|SCN10A|SCN5A|SCN9A,neurology/psychiatry|dermatology|hematology,itching|eczema|hemorrhage,6336|6331|1956|6335,No-Effect
3619,BRD-K62996583,lidoflazine,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,3926,Launched,calcium channel blocker,SCN1A|SCN3A|SLC29A1,cardiology,coronary artery disease (CAD),6328|6323|2030,No-Effect
3622,BRD-K48875051,ligustilide,"CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|",5319022,Preclinical,tumor necrosis factor production inhibitor,TNF,"","",7124,No-Effect
3623,BRD-K25015158,limaprost-alfadex,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,6438378,Launched,prostanoid receptor agonist,PTGER1,cardiology,claudication,5731,No-Effect
3624,BRD-K75373031,LIMKi-3,CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F,56965901,Preclinical,LIM kinase inhibitor,LIMK1,"","",3984,No-Effect
3626,BRD-K00003592,linaclotide,[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O,16158208,Launched,guanylate cyclase activator,GUCY2C,gastroenterology,irritable bowel syndrome|constipation,2984,Very Weak (35%)
3627,BRD-K96550715,linagliptin,CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1,10096344,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
3631,BRD-K93814253,lindane,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,,Launched,"",GABRB1|GLRA1|GLRA2|GLRA3|GLRB,infectious disease,scabies,2560|8001|2741|2742|2743,No-Effect
3632,BRD-K66876909,linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1,441401,Launched,bacterial 50S ribosomal subunit inhibitor,MAOA|MAOB,infectious disease,pneumonia|skin infections,4128|4129,Low (25%)
3633,BRD-K99749624,linifanib,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1,11485656,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK,"","",5979|7010|3815|5159|3791|2321|2322|2324|1435|1436,Low (25%)
3634,BRD-K08973992,linoleic-acid,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,5280450,Phase 3,oxidative stress inducer,FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8,"","",3745|79054|6927|2864|2167|5468|338557,No-Effect
3635,BRD-K59332007,linopirdine,O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1,3932,Phase 3,potassium channel blocker,KCNQ2|KCNQ3|KCNQ4|KCNQ5,"","",3785|3786|9132|56479,No-Effect
3637,BRD-K86118762,linsitinib,C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|,,Phase 3,IGF-1 inhibitor,IGF1R|INSR|INSRR,"","",3480|3643|3645,No-Effect
3639,BRD-K89152108,liothyronine,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,7048703,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,hypothyroidism|myxedema coma,7067|7068,No-Effect
3643,BRD-K00003717,liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,16153050,Launched,GLP receptor agonist,GLP1R,endocrinology,weight-loss aid|diabetes mellitus,2740,Very Weak (35%)
3647,BRD-K67966701,lisinopril,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,5362119,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology|endocrinology,hypertension|congestive heart failure|diabetes mellitus,59272|1636,No-Effect
3649,BRD-K67943528,lisuride,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|,28864,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6,neurology/psychiatry,Parkinson's Disease,3352|3362|1815|1816|146|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,Low (25%)
3650,BRD-K73234506,lithium-acetoacetate,CC(=O)CC(O)=O,96,Preclinical,"",FAH,"","",2175,No-Effect
3652,BRD-K20986251,lithocholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,9903,Preclinical,FXR antagonist|vitamin D receptor agonist,GPBAR1|NR1H4|NR1I2|VDR,"","",8856|151306|9971|1594,No-Effect
3653,BRD-K83029223,litronesib,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|,25167017,Phase 2,kinesin-like spindle protein inhibitor,KIF11,"","",3832,No-Effect
3654,BRD-K59391348,lixivaptan,Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1,172997,Phase 3,vasopressin receptor antagonist,AVPR2,"","",554,No-Effect
3655,BRD-K70404782,LM-22A4,OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO,2054170,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,"","",4915,No-Effect
3656,BRD-A04649065,LM11A-31,"CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|",28174760,Phase 1,neurotrophic agent,NGFR,"","",4804,No-Effect
3657,BRD-K08532119,LMI070,CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1,135565042,Phase 1/Phase 2,survival motor neuron protein modulator,SMN1,"","",6606,No-Effect
3658,BRD-K49921286,LMK-235,Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO,71520717,Preclinical,HDAC inhibitor,HDAC4|HDAC5,"","",10014|9759,Cyto
3659,BRD-K66206289,lobeline,CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1,101616,Launched,acetylcholine receptor antagonist,CHRNA10|CHRNA9|SLC18A2,neurology/psychiatry,smoking cessation,55584|6571|57053,No-Effect
3665,BRD-K82147103,lofepramine,CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1,3947,Launched,norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI),HTR1A|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|3350,No-Effect
3668,BRD-K27955832,lomeguatrib,Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1,3025944,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,"","",4255,No-Effect
3669,BRD-K62858456,lomerizine,COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC,3949,Launched,calcium channel blocker,CACNA1B|SCN5A,neurology/psychiatry,migraine headache,6331|774,No-Effect
3670,BRD-K66036108,lometrexol,Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1,135413518,Phase 2,glycinamide ribonucleotide formyltransferase inhibitor,GART,"","",2618,Weak (50%)
3671,BRD-K92213669,lomitapide,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,9853053,Launched,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,4571,No-Effect
3673,BRD-K41599323,lonafarnib,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,148195,Phase 3,farnesyltransferase inhibitor,FNTA|HRAS|KRAS|NRAS,"","",3265|2339|4893,No-Effect
3674,BRD-K78513633,lonidamine,OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,39562,Launched,glucokinase inhibitor,GCK,"","",5871,No-Effect
3675,BRD-K61250553,loperamide,CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1,3955,Launched,opioid receptor agonist,CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC,gastroenterology,diarrhea,801|5443|773|4985|4986|4988,No-Effect
3678,BRD-K82795137,loratadine,CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12,3957,Launched,histamine receptor antagonist,HRH1,allergy|neurology/psychiatry,allergic rhinitis|itching,3269,No-Effect
3679,BRD-K09659835,loreclezole,Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl,3034012,Phase 2,benzodiazepine receptor agonist,GABRB2|GABRB3,"","",2561|2562,No-Effect
3680,BRD-K42066335,lorediplon,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,12004146,Phase 2,GABA receptor modulator,GABRA1,"","",2554,No-Effect
3681,BRD-K01825818,lorglumide,"CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|",13605417,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,"","",886|887,No-Effect
3682,BRD-K99879819,lorlatinib,C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,78162481,Launched,ALK tyrosine kinase receptor inhibitor,ALK,oncology,non-small cell lung cancer (NSCLC),238,No-Effect
3683,BRD-A90551241,lornoxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|,54690031,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|neurology/psychiatry,osteoarthritis|sciata,5742|5743,No-Effect
3684,BRD-K76205745,losartan,CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,3961,Launched,angiotensin receptor antagonist,AGTR1,cardiology|nephrology,hypertension|diabetic nephropathy|hypertension,185,No-Effect
3685,BRD-K56195681,losmapimod,Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1,11552706,Phase 3,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
3687,BRD-K39983086,loteprednol,"CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|",444025,Launched,glucocorticoid receptor agonist|phospholipase inhibitor,NR3C1,ophthalmology,conjunctivitis,2908,No-Effect
3688,BRD-K09416995,lovastatin,"CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|",53232,Launched,HMGCR inhibitor,HDAC2|HMGCR|ITGAL|NR1I2,cardiology|endocrinology,coronary heart disease|myocardial infarction|hypercholesterolemia,8856|3066|3683|3156,No-Effect
3689,BRD-K39915878,loxapine,CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|,3964,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,schizophrenia,1665|6530|6531|6532|146|147|1812|1813|150|1815|1816|151|152|153|1814|3350|3351|3352|3354|3356|3358|3359|3361|3362|3363|3269|59340|1128|1129|1131|1132|1133,No-Effect
3690,BRD-K21937671,loxistatin-acid,CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O,123664,Preclinical,cysteine peptidase inhibitor,CTSB,"","",1508,No-Effect
3691,BRD-K01825691,loxoprofen,"C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|",13049027,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,neurology/psychiatry,pain relief,5743,No-Effect
3693,BRD-K32322923,LPA2-antagonist-1,C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12,24882686,Preclinical,lysophosphatidic acid receptor antagonist,LPAR2,"","",9170,No-Effect
3694,BRD-K01436366,LRRK2-IN-1,COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1,46843906,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,"","",120892,No-Effect
3695,BRD-K79337272,LSN-2463359,CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1,72551298,Preclinical,glutamate receptor positive allosteric modulator,GRM5,"","",2915,No-Effect
3698,BRD-K53124401,LTB4,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,5280492,Phase 2,leukocyte activator,LTB4R|LTB4R2,"","",1241|56413,No-Effect
3700,BRD-K83970940,Lu-AA-47070,CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O,,Phase 2,adenosine receptor antagonist,ADORA2A,"","",135,No-Effect
3701,BRD-K33814251,lubiprostone,CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,9800568,Launched,chloride channel activator,CLCN2,gastroenterology,constipation|irritable bowel syndrome,1181,No-Effect
3702,BRD-K00003521,lucanthone,CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,10180,Phase 2,endonuclease inhibitor,APEX1|TOP1|TOP2A,"","",328|7153|7150,No-Effect
3703,BRD-K31309378,lucitanib,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,25031915,Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,"","",5156|3815|5159|3791|2321|2260|5979,No-Effect
3704,BRD-K67079690,LUF-5834,Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N,135543624,Preclinical,adenosine receptor agonist,ADORA2A|ADORA2B,"","",136|135,Weak (50%)
3707,BRD-K69236721,lumacaftor,Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O,16678941,Launched,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis,1080,No-Effect
3708,BRD-K10031916,lumateperone,CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23,21302490,Launched,dopamine receptor modulator|serotonin receptor antagonist,DRD2|HTR2A,"","",3356|1813,Weak (50%)
3709,BRD-A05926236,lumefantrine,"CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|",73416445,Launched,antimalarial agent,ATP1A1,infectious disease,malaria,476,No-Effect
3710,BRD-K26901728,lumiracoxib,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1,151166,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
3711,BRD-K00004532,lupanine,[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H],91471,Phase 1,sodium channel blocker,INS,"","",3630,No-Effect
3712,BRD-K51143828,lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,213046,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7,neurology/psychiatry,schizophrenia,3363|1813|150|3350|152|3356,No-Effect
3717,BRD-K05236810,luteolin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1,5280445,Phase 2,glucosidase inhibitor,TOP1,"","",7150,No-Effect
3719,BRD-K32101625,LX1031,COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,23633604,Phase 2,tryptophan hydroxylase inhibitor,TPH1,"","",7166,No-Effect
3720,BRD-K21038058,LX7101,CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1,56962369,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,LIMK2|ROCK1|ROCK2,"","",3985|9475|6093,No-Effect
3722,BRD-K54520417,LXR-623,Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F,16734800,Phase 1,LXR agonist,AR|NR1H2|NR1H3|NR1I2|NR3C1,"","",10062|367|7376|8856|2908,No-Effect
3724,BRD-K78055238,LY2090314,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|,10029385,Phase 2,glycogen synthase kinase inhibitor,GSK3B,"","",2932,No-Effect
3725,BRD-K47557313,LY2109761,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1,11655119,Preclinical,TGF beta receptor inhibitor,TGFBR1|TGFBR2,"","",7048|7046,No-Effect
3726,BRD-K49519144,LY2140023,N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,9834591,Phase 3,glutamate receptor agonist,GRM3,"","",2913,No-Effect
3727,BRD-K34313798,LY215490,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,127894,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1,"","",2890|2891|2892|2893|2897,No-Effect
3728,BRD-K78118466,LY2157299,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O,10090485,Phase 2/Phase 3,TGF beta receptor inhibitor,TGFBR1,"","",7046,No-Effect
3729,BRD-K37865504,LY2183240,CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1,11507802,Preclinical,FAAH inhibitor|FAAH reuptake inhibitor,FAAH,"","",79152,No-Effect
3730,BRD-K59227464,LY2228820,CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C,11539025,Phase 2,p38 MAPK inhibitor,MAPK14,"","",1432,Strong (80%)
3731,BRD-K35367061,LY223982,COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1,6444688,Phase 2,leukotriene receptor antagonist,LTB4R,"","",1241,No-Effect
3732,BRD-K33864865,LY225910,CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O,4355450,Preclinical,CCK receptor antagonist,CCKBR,"","",887,No-Effect
3735,BRD-K13888115,LY2365109,CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O,11552757,Preclinical,glycine transporter inhibitor,SLC6A9,"","",6536,No-Effect
3736,BRD-K90171280,LY2452473,CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N,24963749,Phase 2,androgen receptor modulator,AR,"","",367,No-Effect
3738,BRD-K92492521,LY255283,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1,122023,Preclinical,leukotriene receptor antagonist,LTB4R|LTB4R2,"","",1241|56413,Low (25%)
3739,BRD-K21833260,LY2584702,Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F,25118925,Phase 1,ribosomal protein inhibitor,RPS6KB1,"","",6198,No-Effect
3740,BRD-K14109347,LY2603618,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,11955855,Phase 2,CHK inhibitor,CHEK1,"","",1111,No-Effect
3741,BRD-K20463415,LY2606368,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1,46700756,Phase 2,CHK inhibitor,CHEK1,"","",1111,No-Effect
3742,BRD-K12068470,LY2608204,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1,46832368,Phase 2,glucokinase activator,GCK,"","",5871,No-Effect
3743,BRD-A64004759,LY266097,COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|,92845961,Preclinical,serotonin receptor antagonist,HTR2B,"","",106480180,No-Effect
3744,BRD-K25630527,LY2784544,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,46213929,Phase 2,JAK inhibitor,JAK2|JAK3,"","",3717|3718,No-Effect
3746,BRD-K18961567,LY2801653,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,44603533,Phase 2,MET inhibitor,MET,"","",8731,No-Effect
3747,BRD-K94534639,LY2811376,C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|,44251605,Phase 1,beta-secretase inhibitor,BACE1,"","",23621,No-Effect
3749,BRD-K15382985,LY2857785,CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|,,Preclinical,CDK inhibitor,CDK9,"","",1025,Weak (50%)
3750,BRD-K17203476,LY2874455,C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,46944259,Phase 1,FGFR antagonist,FGFR1|FGFR2|FGFR3|FGFR4|KDR,"","",3791|2260|2261|2263|2264,No-Effect
3751,BRD-K24675965,LY288513,Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1,2802894,Preclinical,CCK receptor antagonist,CCKBR,"","",887,No-Effect
3752,BRD-K51258098,LY2886721,NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|,49837968,Phase 1/Phase 2,beta-secretase inhibitor,BACE1,"","",23621,No-Effect
3753,BRD-K27305650,LY294002,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1,3973,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,"","",9361|1432|6300|5290|2475|5291|5294|6446|6198|5578|6093|207|5591|1111|5594|3932|5599|5600|22883|5347|2932,No-Effect
3754,BRD-K68220839,LY2979165,C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,53246986,Phase 1,glutamate receptor agonist,GRM2,"","",2912,Low (25%)
3755,BRD-K21070437,LY3000328,CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1,67475270,Phase 1,cathepsin inhibitor,CTSS,"","",1520,No-Effect
3756,BRD-K38385169,LY3009120,CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C,71721540,Phase 1,RAF inhibitor,BRAF|RAF1,"","",673|6037,No-Effect
3757,BRD-K82967180,LY3023414,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,57519748,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR,"","",2475,Very Weak (35%)
3758,BRD-K22385716,LY303511,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1,3971,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD2|BRD3|BRD4,"","",8019|23476|6046,No-Effect
3759,BRD-K41194171,LY310762,CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12,4282258,Preclinical,serotonin receptor antagonist,HTR1D,"","",3352,No-Effect
3762,BRD-K78637815,LY320135,COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N,5311257,Preclinical,cannabinoid receptor antagonist,CNR1,"","",1268,No-Effect
3766,BRD-K95899059,LY344864,CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,5311097,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7,"","",3363|106480180|3350|3351|3352|3354|3355|3356|3358,No-Effect
3767,BRD-K06234293,LY364947,c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1,447966,Preclinical,p38 MAPK inhibitor|TGF beta receptor inhibitor,TGFBR1,"","",7046,No-Effect
3768,BRD-K08534264,LY393558,CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|,10347428,Preclinical,serotonin receptor antagonist,HTR1B|HTR1D|HTR2A|HTR2B,"","",3352|3356|106480180|3351,No-Effect
3769,BRD-A50062753,LY404187,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|",66857735,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
3772,BRD-K87696786,LY456236,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,9926999,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
3774,BRD-K62289640,lylamine,CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1,62034,Preclinical,cannabinoid receptor agonist,CNR1,"","",1268,Strong (80%)
3777,BRD-K93331255,lypressin,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,133588927,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2,endocrinology,central diabetes insipidus,552|553|554,Low (25%)
3778,BRD-A96977263,M-14157,CCCCCC(O)CCCC(O)=O,1825,Phase 2,ATP-sensitive potassium channel antagonist,KCNQ1,"","",3784,No-Effect
3779,BRD-K51265828,M-25,CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC,44250034,Preclinical,smoothened receptor antagonist,DHH|IHH|SMO,"","",54498|3549|50846,No-Effect
3780,BRD-K45528773,M-344,CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO,3994,Preclinical,HDAC inhibitor,HDAC8,"","",55869,Cyto
3781,BRD-K09635314,m-3M3FBS,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F,761523,Preclinical,phospholipase activator,PLCB2|PLCB3|PLCD1|PLCG1|PLCG2,"","",5330|5331|5333|5335|5336,No-Effect
3782,BRD-K36965586,m-chlorophenylbiguanide,NC(N)=NC(=N)Nc1cccc(Cl)c1,1354,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,"","",9177|3359,No-Effect
3784,BRD-K90410034,M8-B,COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1,11675630,Preclinical,transient receptor potential channel antagonist,TRPM8,"","",79054,No-Effect
3786,BRD-A13116749,mabuterol,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|,11551355,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154,No-Effect
3788,BRD-K48812570,macitentan,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,16004692,Launched,endothelin receptor antagonist,EDNRA|EDNRB,endocrinology,contraceptive,1909|1910,No-Effect
3793,BRD-K30649484,mafenide,NCc1ccc(cc1)S(N)(=O)=O,3998,Launched,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA4|CA6|CA9,infectious disease,first-aid antibiotic|skin infections,768|771|23632|760|762|765,No-Effect
3794,BRD-K26168087,magnolol,Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O,72300,Preclinical,PPAR receptor agonist,GABRA1|PPARG,"","",2554|5468,No-Effect
3795,BRD-A01976766,malathion,"CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|",12358970,Launched,cholinesterase inhibitor,ACHE,infectious disease,lice,43,No-Effect
3796,BRD-A18396475,malic-acid,"O[C@@H](CC(O)=O)C(O)=O |&1:1,r|",222656,Launched,"",PKD2L1,"","",9033,No-Effect
3801,BRD-K01825587,manidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|",13632719,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension,776|775,No-Effect
3804,BRD-K03319035,maprotiline,CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|,,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2,neurology/psychiatry,depression|dysthymic disorder,6530,Low (25%)
3805,BRD-K00004293,maraviroc,CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,,Launched,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1),1234,No-Effect
3807,BRD-K59524082,maribavir,CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,471161,Phase 3,cytomegalovirus inhibitor|protein kinase inhibitor,PYGM,"","",5837,No-Effect
3808,BRD-K21396683,marimastat,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,119031,Phase 3,matrix metalloprotease inhibitor,MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9,"","",64386|10893|79148|8510|8511|64066|4312|4313|4314|4316|4317|4318|4319|4320|4321|4322|4323|4324|4325|4326|4327|56547,No-Effect
3809,BRD-K76594255,maropitant,COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C,204108,Launched,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting,6869,Weak (50%)
3810,BRD-K71035033,masitinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1,10074640,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma,5159|5156|2261|3815,Weak (50%)
3811,BRD-A87130939,masoprocol,"C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|",688035,Launched,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK),240,No-Effect
3812,BRD-K08623988,matrine,O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,91466,Phase 2,opioid receptor agonist,OPRK1,"","",4986,No-Effect
3815,BRD-K07790550,mavoglurant,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,9926832,Phase 2,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
3816,BRD-K47318833,maxacalcitol,C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,6398761,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594,No-Effect
3818,BRD-K32218650,MBX-2982,CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1,25025505,Phase 2,glucose dependent insulinotropic receptor agonist,GPR119,"","",139760,No-Effect
3819,BRD-K50712474,MC-1,Cc1ncc(COP(O)(O)=O)c(C=O)c1O,1051,Phase 3,"",AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1,"","",285313|23042|64902|1798|55304|2571|2572|113675|85007|29968|18|89874|51091|79896|23584|23464|113451|2731|9517|51119|8879|51380|339896|189|10558|57026|6470|6472|586|587|56267|11212|4942|5834|102724560|5836|5837|211|51540|63826|10841|51166|9054|79969|84706|1644|8942|51696|883|2805|2806|55034|55163,No-Effect
3820,BRD-K24031866,MC1568,Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1,71311876,Preclinical,HDAC inhibitor,HDAC2,"","",3066,No-Effect
3821,BRD-K55418700,MCC950,CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12,9910393,Preclinical,NOD like receptor inhibitor,NLRP3,"","",114548,No-Effect
3823,BRD-K73276278,MCOPPB,CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1,24800108,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,"","",4987,Strong (80%)
3824,BRD-K75844781,mCPP,Clc1cccc(c1)N1CCNCC1,1355,Phase 2,serotonin receptor agonist,HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6,"","",3362|106480180|3350|3352|3354|3356|3358,No-Effect
3825,BRD-K92758126,MD-920,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|,6466,Phase 1,NFkB pathway inhibitor,AADACL2,"","",344752,No-Effect
3826,BRD-K61128465,mdivi-1,COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O,3825829,Preclinical,dynamin inhibitor,DNM1,"","",1759,No-Effect
3827,BRD-A62057054,MDL-11939,"O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|",76958673,Phase 2,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
3829,BRD-K59753853,MDL-29951,OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O,446916,Preclinical,glutamate receptor antagonist,FBP1,"","",2203,No-Effect
3830,BRD-K01825683,MDL-72832,O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|,6604720,Preclinical,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
3831,BRD-K01826803,MDL-73005EF,O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|,6604719,Phase 1,serotonin receptor antagonist,HTR1A,"","",3350,No-Effect
3833,BRD-K24283677,ME-0328,C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,135566764,Preclinical,PPAR receptor antagonist,PARP3,"","",10039,No-Effect
3834,BRD-A63444178,ME0328,"C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|",136229577,Preclinical,PARP inhibitor,PARP3,"","",10039,No-Effect
3835,BRD-K77987382,mebendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,4030,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,pinworm|whipworm|hookworm|ascariasis,7280|7846|10383,No-Effect
3836,BRD-A09467419,mebeverine,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|,6604311,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,1128,No-Effect
3840,BRD-A20119038,mecamylamine,CNC1(C)C2CCC(C2)C1(C)C,46912050,Launched,acetylcholine receptor antagonist,CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4,cardiology,hypertension,89832|8973|1134|1135|1136|1137|1143,No-Effect
3842,BRD-K25075681,meclinertant,COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,119192,Phase 2/Phase 3,neurotensin receptor antagonist,NTSR1|NTSR2,"","",4923|23620,No-Effect
3843,BRD-K01826560,meclizine,Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|,6604289,Launched,constitutive androstane receptor (CAR) agonist,NR1I3,gastroenterology|neurology/psychiatry,nausea|vomiting|motion sickness,9970,Weak (50%)
3845,BRD-K50398167,meclofenamic-acid,Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,4037,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2,rheumatology|neurology/psychiatry|endocrinology,joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD),3785|3786|5742|5743|240|1268,Low (25%)
3848,BRD-A66563878,medetomidine,C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|,60612,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative,146|147|150|151|152,No-Effect
3849,BRD-K92908289,medica-16,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O,121871,Phase 2,ATP citrase lyase inhibitor,FFAR1,"","",2864,No-Effect
3852,BRD-K99615199,medroxyprogesterone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|,10631,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive,5241,No-Effect
3853,BRD-K82216340,medroxyprogesterone-acetate,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|,6279,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099,No-Effect
3854,BRD-K56515112,medrysone,C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|,247839,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis|episcleritis,2908,Low (25%)
3855,BRD-K92778217,mefenamic-acid,Cc1cccc(Nc2ccccc2C(O)=O)c1C,4044,Launched,cyclooxygenase inhibitor,KCNQ1|PTGS1|PTGS2|TRPM3,endocrinology,primary dysmenorrhea (PD),3784|80036|5742|5743,No-Effect
3859,BRD-K19507340,megestrol-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",11683,Launched,progesterone receptor agonist,NR3C1|PGR,neurology/psychiatry|endocrinology,anorexia|cachexia,5241|2908,No-Effect
3860,BRD-K51324732,meglitinide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,41214,Phase 2,potassium channel blocker,CCR2,"","",729230,No-Effect
3862,BRD-K00495673,meglutol,CC(O)(CC(O)=O)CC(O)=O,1662,Launched,HMGCR inhibitor,HMGCR,"","",3156,Strong (80%)
3863,BRD-K14529030,meisoindigo,CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12,,Phase 3,STAT inhibitor,STAT3,"","",6774,No-Effect
3864,BRD-K12244279,MEK1-2-inhibitor,Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1,54483521,Preclinical,MEK inhibitor,MAP2K2,"","",5605,No-Effect
3866,BRD-K97530723,melatonin,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,896,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB,neurology/psychiatry,sleep cycle support,8288|801|4353|4544|4835|811|6096|2099|106480180|438|4543,No-Effect
3867,BRD-K79392608,meldonium,C[N+](C)(C)NCCC(O)=O,123869,Launched,gamma butyrobetaine hydroxylase inhibitor,BBOX1,cardiology,coronary artery disease (CAD),8424,No-Effect
3869,BRD-K18749874,melevodopa,COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,23497,Launched,dopamine precursor|dopamine receptor agonist,DDC,neurology/psychiatry,Parkinson's Disease,1644,No-Effect
3870,BRD-K01826742,meloxicam,CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|,54677470,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743,No-Effect
3871,BRD-K92984783,melperone,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,15387,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,psychosis,3356|1813,No-Effect
3873,BRD-K36394566,melphalan-n-oxide,N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O,11234795,Phase 1,hypoxia inducible factor inhibitor,HIF1A,"","",3091,No-Effect
3876,BRD-K78126613,menadione,CC1=CC(=O)c2ccccc2C1=O |t:1|,4055,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1,gastroenterology|neurology/psychiatry|dermatology|rheumatology,ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis,1728|2147|4835|5624|2155|2158|2159|2677|154807|632|79001|8858|5627|316,No-Effect
3877,BRD-K01826025,menadione-bisulfite,C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|,1711949,Phase 2,vitamin K,GGCX|VKORC1|VKORC1L1,"","",79001|2677|154807,No-Effect
3880,BRD-A45889380,mepacrine,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|,446536,Launched,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator,PLA2G1B,infectious disease,giardiasis,5319,Cyto
3882,BRD-K01825575,mepazine,"CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|",7047378,Phase 2,MALT1 inhibitor (JH),MALT1,"","",10892,No-Effect
3885,BRD-K18194590,mephentermine,CNC(C)(C)Cc1ccccc1,3677,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3,cardiology,hypotension,146|147|150|151|152|153|154|155,No-Effect
3886,BRD-A83937277,mephenytoin,"CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|",107921,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,6331,No-Effect
3889,BRD-K18207669,meprednisone,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",5284587,Launched,"",NR3C1,"","",2908,No-Effect
3891,BRD-A02710418,meptazinol,CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|,25271754,Launched,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief,590,No-Effect
3892,BRD-K97564742,mepyramine,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,4992,Launched,histamine receptor antagonist,HRH1,otolaryngology|obstetrics/gynecology,common cold|menstrual pain,3269,No-Effect
3893,BRD-K45216060,mequinol,COc1ccc(O)cc1,9015,Launched,"",TYR,dermatology,skin depigmentation,7299,No-Effect
3894,BRD-K45152786,merbarone,Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1,3000671,Phase 2,topoisomerase inhibitor,TOP2A,"","",7153,No-Effect
3896,BRD-K91601245,mercaptopurine,S=c1nc[nH]c2nc[nH]c12,667490,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL),727833|3251|80347|3615,No-Effect
3898,BRD-K04466929,Merck60,CC(=O)Nc1ccc(cc1)C(=O)Nc1cc(ccc1N)-c1cccs1,6918878,Preclinical,HDAC inhibitor,HDAC1|HDAC2,"","",3065|3066,No-Effect
3900,BRD-K09372874,merimepodib,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,153241,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1,"","",727833,No-Effect
3903,BRD-K28849549,mesalazine,Nc1ccc(O)c(c1)C(O)=O,4075,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease,4353|5742|5743|240|1147|5468|3551,Low (25%)
3905,BRD-K01827307,mesoridazine,"CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|",57146948,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813,No-Effect
3906,BRD-K69688083,mestinon,CN(C)C(=O)Oc1ccc[n+](C)c1,4991,Launched,cholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis,43|590,No-Effect
3907,BRD-K31920458,mestranol,COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1,6291,Launched,estrogen receptor agonist,ESR1,endocrinology,contraceptive,2099,No-Effect
3908,BRD-K91336023,mesulergine,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,68848,Phase 2,dopamine receptor agonist,HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7,"","",3362|3363|106480180|9177|3356|3358|3359,No-Effect
3911,BRD-K22518984,metacresol,Cc1cccc(O)c1,342,Launched,"",INS,"","",3630,Very Weak (35%)
3913,BRD-K76812510,metamizole,CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O,3111,Withdrawn,cyclooxygenase inhibitor|opioid receptor agonist,PTGS1,"","",5742,No-Effect
3915,BRD-K01826731,metaproterenol,CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|,25271693,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|asthma|bronchitis|emphysema,154,No-Effect
3916,BRD-K96253961,metaraminol,C[C@H](N)[C@H](O)c1cccc(O)c1,5906,Launched,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,146,No-Effect
3917,BRD-K27182532,metatinib,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,44155856,Phase 1,Bcr-Abl kinase inhibitor,ABL1|BCR,"","",25|106480993,No-Effect
3919,BRD-A78277353,metazosin,"CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|",51057264,Phase 2,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
3920,BRD-A38218502,metenkephalin,"CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|",73265283,Phase 2,immunostimulant,OPRD1,"","",4985,No-Effect
3921,BRD-K56699285,metergoline,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13,28693,Launched,dopamine receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry|endocrinology,seasonal affective disorder|anxiety|hyperprolactinemia,3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358,Low (25%)
3922,BRD-K79602928,metformin,CN(C)C(=N)N=C(N)N,4091,Launched,insulin sensitizer,ACACB|PRKAB1,endocrinology,diabetes mellitus,32|5564,No-Effect
3923,BRD-A18056626,methacholine,C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|,6603706,Launched,acetylcholine receptor agonist,CHRM2|CHRM4,pulmonary,bronchial hyperresponsiveness diagnostic,1129|1132,No-Effect
3925,BRD-K53896891,methanesulfonyl-fluoride,CS(F)(=O)=O,11207,Phase 2,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
3926,BRD-K09859624,methantheline,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12,4097,Launched,acetylcholine receptor antagonist,CHRM1|HRH2,gastroenterology|neurology/psychiatry|urology,peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder,1128|1665,No-Effect
3927,BRD-K47323024,methapyrilene,CN(C)CCN(Cc1cccs1)c1ccccn1,4098,Withdrawn,histamine receptor antagonist,HRH1,"","",3269,No-Effect
3928,BRD-K88143662,metharbital,CCC1(CC)C(=O)NC(=O)N(C)C1=O,4099,Launched,GABA receptor modulator,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,epilepsy,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559,No-Effect
3929,BRD-K00002562,methazolamide,CC(=O)N=c1sc(nn1C)S(N)(=O)=O,4100,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,glaucoma|intraocular pressure,771|23632|759|760|762|766,No-Effect
3933,BRD-K54416256,methimazole,Cn1cc[nH]c1=S,1349907,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism,7066,No-Effect
3934,BRD-A39515206,methionine,"CSCC[C@@H](N)C(O)=O |&1:4,r|",84815,Launched,"",METAP2,"","",10988,No-Effect
3935,BRD-K00004541,methiopril,"C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|",667560,Phase 2,angiotensin converting enzyme inhibitor,ACE,"","",1636,No-Effect
3936,BRD-A31521121,methocarbamol,"COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|",688484,Launched,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,759,Low (25%)
3938,BRD-K59456551,methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,126941,Launched,dihydrofolate reductase inhibitor,DHFR,oncology|hematologic malignancy|dermatology|rheumatology,gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis,1719,Strong (80%)
3939,BRD-A39189014,methoxamine,COc1ccc(OC)c(c1)C(O)C(C)N,657286,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,cardiology,hypotension,146|147,No-Effect
3940,BRD-K63430059,methoxsalen,COc1c2occc2cc2ccc(=O)oc12,4114,Launched,DNA synthesis inhibitor,CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4,dermatology,psoriasis,1543|1544|1576|1548|1553,No-Effect
3941,BRD-K79277568,methoxyamine,CON,4113,Phase 2,DNA repair enzyme inhibitor,APEX1,"","",328,No-Effect
3942,BRD-K06152156,methoxyflurane,COC(F)(F)C(Cl)Cl,4116,Launched,membrane permeability inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1,neurology/psychiatry,general anaesthetic,2560|513|2561|2562|2563|2564|2565|2566|2567|2568|27032|3736|2741|2743|55879|2890|2554|2555|2556|2557|2558|2559,No-Effect
3944,BRD-K48619321,methscopolamine,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131,No-Effect
3945,BRD-A57592049,methsuximide,"CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|",25271978,Launched,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures,8912|8913|150350,No-Effect
3946,BRD-A95340155,methyclothiazide,"CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",12309469,Launched,chloride reabsorption inhibitor,SLC12A1|SLC12A3,cardiology,hypertension|edema,6557|6559,No-Effect
3948,BRD-K01292611,methyl-aminolevulinate,COC(=O)CCC(=O)CN,157922,Launched,oxidizing agent,FCGR1A|FECH,dermatology,actinic keratosis (AK),2210|2235,No-Effect
3951,BRD-K00004543,methylatropine-nitrate,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|",,Preclinical,acetylcholine receptor antagonist,CHRM1,"","",1128,No-Effect
3955,BRD-K48578705,methyldopa,C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O,6919173,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|DDC,cardiology,hypertension,152|1644|150|151,No-Effect
3957,BRD-K54770538,methylene-blue,CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C,4139,Launched,guanylyl cyclase inhibitor|nitric oxide production inhibitor,ACHE,hematology,methemoglobinemia,43,Weak (50%)
3958,BRD-K34685430,methylergometrine,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|,8226,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C,hematology|neurology/psychiatry,postpartum hemorrhage (PPH)|migraine headache,1812|106480180|3354|3355|3356|3358,No-Effect
3959,BRD-K43192255,methyllycaconitine,CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14,5288811,Preclinical,acetylcholine receptor antagonist,CHRNA7,"","",89832,No-Effect
3960,BRD-K00003599,methylnaltrexone,[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O,16089915,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,constipation,4985|4986|4988,No-Effect
3962,BRD-K35240538,methylprednisolone,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",6741,Launched,glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology,hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis,2908,No-Effect
3963,BRD-K24452555,methylprednisolone-aceponate,"CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|",63019,Launched,anti-inflammatory agent|glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology,congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia,2908,No-Effect
3966,BRD-K35941380,methysergide,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|,9681,Launched,serotonin receptor antagonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry,headache,3361|3362|3363|106480180|3351|3352|3354|3355|3356|3358,No-Effect
3969,BRD-K83766205,metirosine,C[C@](N)(Cc1ccc(O)cc1)C(O)=O,6918925,Launched,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension,7054,No-Effect
3970,BRD-K01826545,metitepine,"CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|",969502,Preclinical,anti-HCVE2,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,"","",3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358,Weak (50%)
3971,BRD-K01826531,metixene,CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|,6604302,Launched,acetylcholine receptor antagonist,CHRM5,neurology/psychiatry,Parkinson's Disease,1133,Weak (50%)
3972,BRD-K75641298,metoclopramide,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,4168,Launched,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1|DRD2|HTR3A|HTR3B|HTR4,gastroenterology,gastroparesis|nausea|vomiting,3360|1128|1813|9177|3359,No-Effect
3973,BRD-K16484091,metocurine,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,21233,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2,neurology/psychiatry,muscle relaxant,1129|1135,No-Effect
3974,BRD-A61793559,metolazone,"C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|",28125490,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension,6559,No-Effect
3975,BRD-K01826568,metoprolol,COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|,157716,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,hypertension|angina pectoris|myocardial infarction,153|154,No-Effect
3976,BRD-A71725768,metoxibutropate,"COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|",836891,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
3977,BRD-A22101059,metrifonate,"COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|",6604183,Phase 3,acetylcholinesterase inhibitor,ACHE,"","",43,No-Effect
3980,BRD-K52020312,metronidazole,Cc1ncc(n1CCO)[N+]([O-])=O,4173,Launched,DNA inhibitor,CYP2C9|CYP3A4,dermatology,rosacea,1576|1559,No-Effect
3981,BRD-K46862739,metyrapone,CC(C)(C(=O)c1cccnc1)c1cccnc1,4174,Launched,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,1584,No-Effect
3982,BRD-K94441233,mevastatin,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|",64715,Preclinical,HMGCR inhibitor,HMGCR,"","",3156,No-Effect
3984,BRD-A64092382,mexiletine,C[C@@H](N)COc1c(C)cccc1C |&1:1|,180621,Launched,sodium channel blocker,PLAU|SCN4A|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT),5328|6329|6331,No-Effect
3986,BRD-K34328244,MF-101,Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1,114829,Phase 3,estrogen receptor agonist,CYP19A1|XDH,"","",6652|1588,No-Effect
3987,BRD-K60230970,MG-132,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,462382,Preclinical,proteasome inhibitor,PSMB1,"","",5689,Cyto
3988,BRD-K03128577,MG-624,CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1,5824382,Preclinical,acetylcholine receptor antagonist,CHRNA7,"","",89832,No-Effect
3989,BRD-K56277358,MGCD-265,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,24901704,Preclinical,VEGFR inhibitor,AXL|MET,"","",8731|558,No-Effect
3990,BRD-K26726854,MI-14,CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12,91758319,Preclinical,PI4K inhibitor,PI4KB,"","",5298,Very Weak (35%)
3991,BRD-A19661776,mianserin,CN1CCN2C(C1)c1ccccc1Cc1ccccc21,68551,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,depression,1665|3362|3363|3269|146|147|106480180|3356|3358,Strong (80%)
3992,BRD-K42981054,mibampator,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,9889366,Phase 2,glutamate receptor modulator,GRIA1,"","",2890,No-Effect
3993,BRD-K09549677,mibefradil,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,60663,Withdrawn,T-type calcium channel blocker,ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4,"","",55107|117155|775|776|778|779|150350|782|8912|8913|783|784|785|347732|378807|117144,Strong (80%)
3995,BRD-K01826511,miconazole,"Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|",1150344,Launched,bacterial cell wall synthesis inhibitor,TRPM2|TRPV5,infectious disease|neurology/psychiatry,yeast infection|itching,56302|1191,No-Effect
3997,BRD-K45163704,midafotel,OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1,6435801,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",2904|2905|2906|2903,No-Effect
4000,BRD-K13646352,midostaurin,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,9829523,Launched,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML),2322|5582,No-Effect
4001,BRD-K37270826,mifepristone,"CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|",55245,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,AR|NR1I2|NR3C1|PGR,endocrinology,hyperglycemia|diabetes mellitus,8856|5241|2908|367,Low (25%)
4002,BRD-K00004244,mifobate,"COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|",76958126,Phase 2,PPAR receptor antagonist,PPARG,"","",5468,No-Effect
4003,BRD-K44779798,miglitol,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,441314,Launched,glucosidase inhibitor,GAA|GANAB|GANC|MGAM,endocrinology,diabetes mellitus,23193|2595|2548|8972,Low (25%)
4004,BRD-K33251802,miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,51634,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,7357,Weak (50%)
4005,BRD-K64338723,milacemide,CCCCCNCC(N)=O,53569,Phase 3,monoamine oxidase inhibitor,MAOB,"","",4129,No-Effect
4007,BRD-K00004287,milnacipran,CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|,6917779,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,rheumatology,fibromyalgia,6530|6532,No-Effect
4008,BRD-K67080878,milrinone,Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N,4197,Launched,phosphodiesterase inhibitor,PDE2A|PDE3A|PDE3B|PDE5A,cardiology,congestive heart failure,5138|5139|5140|8654,No-Effect
4009,BRD-K01824991,miltefosine,CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|,3600,Launched,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis,5319,No-Effect
4010,BRD-K67642028,mimosine,N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O,6971294,Preclinical,DNA replication inhibitor,CCL2|SHMT1|SHMT2|TYR,"","",6472|6347|7299|6470,No-Effect
4011,BRD-K02867583,minaprine,Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1,4199,Withdrawn,serotonin reuptake inhibitor,ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4,"","",4128|6532|1128|43|1812|1813|106480180|3356|3358,No-Effect
4014,BRD-K89337853,minodronic-acid,OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O,130956,Launched,bone resorption inhibitor,FDPS|GGPS1,orthopedics,osteoporosis,2224|9453,No-Effect
4015,BRD-K06902185,minoxidil,Nc1cc(nc(N)[n+]1[O-])N1CCCCC1,,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia,10060|3758|5742|3764|3766|3767,No-Effect
4018,BRD-K47949423,mirabegron,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,9865528,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,urology,urinary incontinence,153|154|155,No-Effect
4020,BRD-K55420858,mirin,NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|,137319711,Preclinical,MRE11A exonuclease inhibitor,MRE11A,"","",4361,No-Effect
4022,BRD-K82967685,mirodenafil,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,135497803,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,8654,Very Weak (35%)
4024,BRD-A64977602,mirtazapine,"CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|",3085219,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C,neurology/psychiatry,depression,150|151|152|3356|3358,No-Effect
4026,BRD-A72351335,misoprostol,"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|",5282381,Launched,prostanoid receptor agonist,PTGER2|PTGER3|PTGER4|PTGIR,gastroenterology,duodenal ulcer disease,5739|5732|5733|5734,No-Effect
4028,BRD-K52959329,mitiglinide,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,121891,Launched,insulin secretagogue,ABCC8|KCNJ10|PPARG,endocrinology,diabetes mellitus,6833|5468|3766,No-Effect
4029,BRD-K35882976,mitoflaxone,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,55748,Phase 2,antitumor agent,VWF,"","",7450,No-Effect
4032,BRD-A31204924,mitotane,"ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|",6603772,Launched,antineoplastic agent,CYP11A1|CYP11B1|ESR1,oncology,adrenal cortical carcinoma,1584|2099|1583,Very Weak (35%)
4033,BRD-K21680192,mitoxantrone,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,4212,Launched,topoisomerase inhibitor,TOP2A,neurology/psychiatry|oncology|hematologic malignancy,multiple sclerosis|prostate cancer|acute myeloid leukemia (AML),7153,No-Effect
4034,BRD-A48465967,mivacurium,"COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|",22839211,Launched,acetylcholine receptor antagonist,CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant,1135,Low (25%)
4038,BRD-K21884483,mizolastine,CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1,65906,Launched,histamine receptor antagonist,HRH1,allergy,urticaria|allergic rhinitis,3269,No-Effect
4039,BRD-K88061624,mizoribine,NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|,11949547,Launched,immunosuppressant|inosine monophosphate dehydrogenase inhibitor,IMPDH1,transplant|rheumatology,organ rejection|nephrotic syndrome,727833,No-Effect
4040,BRD-K71315565,MJ-15,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1,59377482,Preclinical,cannabinoid receptor antagonist,CNR1,"","",1268,No-Effect
4041,BRD-K91405252,MK-0354,C1Cc2[nH]nc(-c3nn[nH]n3)c2C1,11159621,Phase 2,niacin receptor agonist,HCAR2|HCAR3,"","",338442|8843,No-Effect
4045,BRD-K38868394,MK-0773,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|,11950726,Phase 2,androgen receptor modulator,AR,"","",367,No-Effect
4046,BRD-K14175878,MK-0812,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,11180808,Phase 2,CC chemokine receptor antagonist,CCR2,"","",729230,No-Effect
4047,BRD-K16732600,MK-0893,COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1,11570626,Phase 2,glucagon receptor antagonist,GCGR,"","",2642,Very Weak (35%)
4049,BRD-K54256913,MK-1775,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,24856436,Phase 2,WEE1 kinase inhibitor,WEE1,"","",7465,No-Effect
4052,BRD-K68065987,MK-2206,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,24964624,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,Strong (80%)
4053,BRD-K43316319,MK-2295,FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1,11247522,Phase 2,TRPV antagonist,TRPV1,"","",7442,No-Effect
4054,BRD-K56405753,MK-2461,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,44137946,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB,"","",4486|5159|3791|2321|2322|4914|2260|2261|2324|2263|4915|8731|10461,No-Effect
4055,BRD-K27983781,MK-2894,Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F,24952929,Preclinical,prostaglandin inhibitor,PTGER4,"","",5734,No-Effect
4056,BRD-K66911501,MK-3207,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,25019940,Phase 2,calcitonin antagonist,CALCA,"","",796,No-Effect
4057,BRD-K95828359,MK-3697,COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC,46190695,Phase 2,orexin receptor antagonist,HCRTR2,"","",131450,No-Effect
4059,BRD-K03886848,MK-5046,O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F,49871766,Preclinical,bombesin receptor agonist,BRS3|GRPR|NMBR,"","",680|4829|2925,No-Effect
4060,BRD-K53665955,MK-5108,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|,,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
4061,BRD-A73679382,MK-571,CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|,14325224,Phase 2,leukotriene receptor antagonist,ABCC2|CYSLTR1,"","",10800|1244,No-Effect
4062,BRD-K03894385,MK-6096,C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1,25128145,Phase 2,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,Low (25%)
4065,BRD-K55512740,MK-8033,Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1,45142457,Phase 1,c-Met inhibitor,MET,"","",8731,No-Effect
4066,BRD-K29656036,MK-8245,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,24988881,Phase 2,stearoyl-CoA desaturase inhibitor,SCD,"","",6319,No-Effect
4068,BRD-K25279140,MK-8745,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,11676373,Preclinical,Aurora kinase inhibitor,AURKA,"","",6790,No-Effect
4071,BRD-K90316462,MK2-IN-1,Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1,53475321,Preclinical,MAP kinase inhibitor,MAPKAPK2,"","",9261,No-Effect
4073,BRD-K69343602,ML10302,COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1,5311299,Preclinical,serotonin receptor partial agonist,HTR3A|HTR3B|HTR4,"","",3360|9177|3359,No-Effect
4076,BRD-A28422330,ML141,"COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|",7454812,Preclinical,GTPase inhibitor,CDC42,"","",998,No-Effect
4078,BRD-K64835161,ML167,Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1,44968231,Preclinical,CLK inhibitor|DYRK inhibitor,CLK4|DYRK1B,"","",57396|9149,No-Effect
4079,BRD-K77547509,ML179,FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1,45100448,Preclinical,liver receptor homolog inverse agonist,NR5A2,"","",2494,No-Effect
4080,BRD-K27539181,ML193,Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C,1261822,Preclinical,G protein-coupled receptor antagonist,GPR55,"","",9290,No-Effect
4081,BRD-K80021413,ML204,Cc1cc(nc2ccccc12)N1CCCCC1,230710,Preclinical,transient receptor potential channel antagonist,TRPC4|TRPC5,"","",7224|7223,No-Effect
4082,BRD-K00004301,ML213,"Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|",1219187,Preclinical,potassium channel activator,KCNQ4,"","",9132,No-Effect
4083,BRD-K92995792,ML218,CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1,,Preclinical,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,"","",8912|8913|150350,No-Effect
4084,BRD-K44432556,ML228,C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1,46742353,Preclinical,hypoxia inducible factor activator,HIF1A,"","",3091,No-Effect
4085,BRD-K60020910,ML277,COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1,53347902,Preclinical,potassium channel activator,KCNQ1,"","",3784,No-Effect
4086,BRD-K48188942,ML281,CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O,53377448,Preclinical,serine/threonine kinase inhibitor,STK33,"","",65975,No-Effect
4087,BRD-K51137250,ML297,Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1,56642816,Preclinical,inward rectifier potassium channel activator,KCNJ3,"","",3760,No-Effect
4088,BRD-K24600306,ML298,Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1,53393916,Preclinical,phospholipase inhibitor,PLD2,"","",5338,No-Effect
4089,BRD-K92606079,ML314,COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1,53245590,Preclinical,neurotensin agonist,NTSR1,"","",4923,No-Effect
4090,BRD-K93942811,ML323,CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1,60167849,Preclinical,ubiquitin specific protease inhibitor,USP1,"","",7398,No-Effect
4091,BRD-K25611237,ML324,CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1,44143209,Preclinical,histone lysine demethylase inhibitor,KDM4A,"","",9682,No-Effect
4093,BRD-K33892651,ML347,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,44577753,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1|ACVRL1|BMPR1A,"","",657|90|94,No-Effect
4094,BRD-K81044214,ML348,FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1,3238952,Preclinical,lysophospholipase inhibitor,LYPLA1,"","",10434,No-Effect
4095,BRD-K02160913,ML365,COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1,46785920,Preclinical,potassium channel blocker,KCNK3|KCNK9,"","",51305|3777,No-Effect
4097,BRD-K68402494,ML9,Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1,4217,Preclinical,myosin light chain kinase inhibitor,TRPC6,"","",7225,No-Effect
4098,BRD-K59317601,MLN0128,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,45375953,Phase 2,mTOR inhibitor,MTOR|PIK3CA|PIK3CD|PIK3CG,"","",5290|2475|5294|22883,No-Effect
4099,BRD-K73877023,MLN1117,Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1,70798655,Phase 2,PI3K inhibitor,PIK3CA,"","",5290,No-Effect
4101,BRD-K83963101,MLN8054,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|,11712649,Phase 1,Aurora kinase inhibitor,AURKA,"","",6790,No-Effect
4104,BRD-K98353094,MM-11253,CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O,10389639,Preclinical,retinoid receptor antagonist,RARG,"","",5916,No-Effect
4106,BRD-K50293352,MM77,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,3994476,Preclinical,serotonin receptor antagonist,HTR1A,"","",3350,No-Effect
4109,BRD-K16183658,MN-64,CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1,2802462,Preclinical,tankyrase inhibitor,TNKS,"","",8658,Low (25%)
4111,BRD-K16485616,mocetinostat,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1,9865515,Phase 2,HDAC inhibitor,HDAC1|HDAC11|HDAC2|HDAC3,"","",3065|3066|8841|79885,No-Effect
4112,BRD-K07237224,moclobemide,Clc1ccc(cc1)C(=O)NCCN1CCOCC1,4235,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression|anxiety,4128|4129,No-Effect
4114,BRD-K34441861,moexipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O,91270,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology,hypertension,59272|1636,No-Effect
4115,BRD-K52598503,mofegiline,NC\C(CCc1ccc(F)cc1)=C\F,6437850,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB,"","",4128|4129,No-Effect
4116,BRD-K49372556,mofezolac,COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,4237,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology|orthopedics,rheumatoid arthritis|osteoporosis,5742,No-Effect
4118,BRD-K01291782,molidustat,O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1,59603622,Phase 3,hypoxia inducible factor inhibitor,EGLN2,"","",100529264,No-Effect
4119,BRD-A65280694,molindone,CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|,6604347,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia,3269|3356|1813,No-Effect
4120,BRD-K63861289,molsidomine,CCOC(=O)Nc1c[n+](no1)N1CCOCC1,4239,Launched,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD),2982,No-Effect
4121,BRD-K50265942,mometasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|",441335,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
4122,BRD-K60640630,mometasone-furoate,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|",441336,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
4123,BRD-A78377521,monastrol,"CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|",794325,Preclinical,kinesin inhibitor,KIF11,"","",3832,No-Effect
4126,BRD-K54262262,monobenzone,Oc1ccc(OCc2ccccc2)cc1,7638,Launched,melanin inhibitor,TYR,dermatology,skin depigmentation,7299,No-Effect
4132,BRD-K69470111,montelukast,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,5281040,Launched,leukotriene receptor antagonist,ALOX5|CYSLTR1,pulmonary|allergy,asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB),240|10800,Low (25%)
4134,BRD-K21548250,moracizine,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1,34633,Withdrawn,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias,6331,No-Effect
4136,BRD-K11590034,morin,Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O,5281670,Preclinical,cytochrome P450 inhibitor,ADORA2A|ESR2|FASN|MCL1|SLC22A12,"","",135|4170|2194|2100|116085,No-Effect
4137,BRD-A40546373,morinidazole,"Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|",102486242,Launched,other antibiotic,CYP51A1,"","",1595,No-Effect
4141,BRD-A39052811,mosapride,CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|,9979608,Launched,serotonin receptor agonist,HTR4,gastroenterology,hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome,3360,No-Effect
4143,BRD-K99616396,motesanib,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12,11667893,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1|FLT4|KDR|KIT,"","",2321|3815|2324|3791,No-Effect
4144,BRD-K11785681,motolimod,"CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|",16049404,Phase 2,toll-like receptor agonist,TLR8,"","",51311,No-Effect
4148,BRD-K66615216,moxifloxacin,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,40467042,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology|pulmonary|infectious disease,sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections,7153,Weak (50%)
4150,BRD-K77771411,moxonidine,COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|,4810,Launched,imidazoline receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151,No-Effect
4151,BRD-A31095847,mozavaptan,"CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|",11441742,Launched,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2,endocrinology,hyponatremia,552|553|554,No-Effect
4152,BRD-K60690191,MPEP,Cc1cccc(n1)C#Cc1ccccc1,3025961,Preclinical,glutamate receptor antagonist,GRM1|GRM4|GRM5,"","",2914|2915|2911,No-Effect
4153,BRD-K45551181,MPI-0479605,Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1,46909588,Preclinical,mitotic kinase inhibitor,TTK,"","",7272,No-Effect
4154,BRD-K18530250,Mps-BAY-2a,CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12,57381882,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,"","",7272,No-Effect
4155,BRD-K94853001,Mps1-IN-1,COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1,25195352,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,"","",7272,No-Effect
4158,BRD-K84883208,MR-948,OCCc1ccc(OCCn2ccnc2)cc1,10443938,Phase 1,thromboxane synthase inhibitor,TBXAS1,"","",6916,No-Effect
4159,BRD-K44022883,MRK-016,Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C,6918583,Phase 1,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,No-Effect
4161,BRD-K68795758,MRK-560,Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|,,Preclinical,gamma secretase inhibitor,APP,"","",351,No-Effect
4162,BRD-K37618799,MRS-1220,Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1,393595,Preclinical,adenosine receptor antagonist,ADORA2B|ADORA3,"","",136|140,No-Effect
4163,BRD-A06784547,MRS-1334,"CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|",6604859,Preclinical,adenosine receptor antagonist,ADORA3,"","",140,No-Effect
4165,BRD-K91135178,MRS-2578,S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1,16078986,Preclinical,purinergic receptor antagonist,P2RY6,"","",5031,No-Effect
4166,BRD-K10575656,MRS-3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12,,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
4167,BRD-K10575656,MRS-3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12,11771279,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
4172,BRD-K25143390,MSX-122,C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1,11687907,Phase 2,CC chemokine receptor antagonist,CXCR4,"","",7852,Very Weak (35%)
4173,BRD-A28329383,MTPG,C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|,10752093,Preclinical,glutamate receptor antagonist,GRM2|GRM3,"","",2912|2913,No-Effect
4174,BRD-K19061412,mubritinib,FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,6444692,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,"","",2064|1956,No-Effect
4176,BRD-K60441002,muscimol,NCc1cc(=O)[nH]o1,4266,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,"","",200959|2569|2570|2554|2555|2556|2557|2558|2559,No-Effect
4178,BRD-K90524085,MY-5445,Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1,1348,Preclinical,phosphodiesterase inhibitor|platelet aggregation inhibitor,PDE5A,"","",8654,No-Effect
4179,BRD-K92428153,mycophenolate-mofetil,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1,5281078,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection,727833|3615,Strong (80%)
4180,BRD-K63750851,mycophenolic-acid,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O,446541,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection,727833|3615,Strong (80%)
4181,BRD-K43149758,myricetin,Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O,5281672,Preclinical,androgen receptor agonist|cytochrome P450 inhibitor,PIK3CG,"","",5294,No-Effect
4187,BRD-K80653534,N-acetyl-D-glucosamine,CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,1738118,Phase 2/Phase 3,"",B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP,"","",8704|51172|5973|55577|2683|4669|8702|8703,Low (25%)
4193,BRD-K75390981,N-alpha-methylhistamine-dihydrochloride,CNCCc1cnc[nH]1,912,Phase 3,histamine receptor agonist,HRH4,"","",59340,No-Effect
4206,BRD-K60150510,N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,657378,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1,"","",134|135|136|140|2030,No-Effect
4208,BRD-K82522873,N6022,Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O,44623946,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,ADH5,"","",128,No-Effect
4209,BRD-K36804890,NAB-2,Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl,82017756,Preclinical,ubiquitin ligase transport promoter,NEDD4,"","",4734,No-Effect
4210,BRD-K65146499,nabumetone,COc1ccc2cc(CCC(C)=O)ccc2c1,4409,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743,No-Effect
4211,BRD-K01824972,nadide,"NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|",5893,Launched,free radical scavenger,AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2,"","",3295|644|1191|1738|3615|8972|6652|3156|2582|10327|692312|217|3292|1725|191,No-Effect
4213,BRD-A87606379,nadolol,"CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|",7048578,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|hypertension,153|154|155,No-Effect
4214,BRD-M06409173,NADPH,"NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|",71312102,Preclinical,"",DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C,"","",2693|1813|1814|1815|3356|3358,No-Effect
4215,BRD-A71262238,nafadotride,"CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|",6604854,Preclinical,dopamine receptor antagonist,DRD2|DRD3|HTR1A,"","",1813|1814|3350,No-Effect
4216,BRD-K06674495,nafamostat,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N,4413,Launched,serine protease inhibitor,ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7,cardiology,anticoagulent,54822|40|41|7177|715|136541|9311,No-Effect
4217,BRD-K18574842,nafcillin,CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,8982,Launched,bacterial cell wall synthesis inhibitor,CYP1A2|CYP3A4|SLC22A6,infectious disease,gram-positive bacterial infections,1544|1576|9356,No-Effect
4220,BRD-K01826561,naftopidil,COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|,6603939,Launched,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH),146,Low (25%)
4221,BRD-K66404838,nalbuphine,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45,5311304,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,neurology/psychiatry,pain relief,4985|4986|4988,No-Effect
4222,BRD-K89272869,nalfurafine,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1,6445230,Launched,opioid receptor agonist,OPRK1|OPRM1,nephrology,uremic pruritus,4986|4988,No-Effect
4224,BRD-K68407436,nalmefene,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O,5284594,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,pulmonary,respiratory depression,4985|4986|4988,No-Effect
4225,BRD-K41458421,naloxegol,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45,56959087,Launched,opioid receptor antagonist,OPRM1,gastroenterology,constipation,4988,No-Effect
4226,BRD-K67511046,naloxone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,5284596,Launched,opioid receptor antagonist,CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4,pulmonary,respiratory depression,1385|2099|4985|4986|7099|4988,No-Effect
4227,BRD-K70898774,naloxone-benzoylhydrazone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1,9601084,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,"","",4986|4988,No-Effect
4228,BRD-K88172511,naltrexone,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,5360515,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1|SIGMAR1,neurology/psychiatry,abstinence from alcohol,10280|4985|4986|4988,No-Effect
4229,BRD-K81275354,naltriben,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O,5486827,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
4230,BRD-K34088084,naltrindole,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O,5497186,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
4232,BRD-K69195780,NAN-190,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,4431,Preclinical,serotonin receptor agonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F,"","",3355|146|147|3350,No-Effect
4234,BRD-K22064724,napabucasin,CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,10331844,Phase 3,STAT inhibitor,STAT3,"","",6774,Weak (50%)
4236,BRD-K77641333,naphazoline,C(C1=NCCN1)c1cccc2ccccc12 |t:1|,4436,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,ophthalmology,eye irritation,146|150,No-Effect
4239,BRD-K59197931,naproxen,COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O,156391,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology,pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever,5742|5743,No-Effect
4242,BRD-K61337602,naratriptan,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,4440,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355,No-Effect
4243,BRD-K08832567,naringenin,Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,439246,Phase 1,aromatase inhibitor|TRPV antagonist,CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1,"","",1545|2739|1588|2100|3292,No-Effect
4244,BRD-K87122641,naringeninic-acid,OC(=O)\C=C\c1ccc(O)cc1,637542,Phase 1,"",HCAR2|PTGR1,"","",338442|22949,No-Effect
4245,BRD-K02953697,naringin,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,442428,Preclinical,cytochrome P450 inhibitor,SLCO1A2,"","",6579,No-Effect
4248,BRD-K00004235,NAS-181,C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|,9955015,Preclinical,serotonin receptor antagonist,HTR1B,"","",3351,No-Effect
4249,BRD-K17295893,nastorazepide,CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1,9872609,Phase 2,CCK receptor antagonist,CCKBR,"","",887,No-Effect
4251,BRD-K44353683,nateglinide,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O,,Launched,insulin secretagogue,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus,6833|5468|3766|3767,No-Effect
4252,BRD-A84202322,NAV-26,"FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|",60201418,Preclinical,voltage-gated sodium channel blocker,SCN9A,"","",6335,No-Effect
4253,BRD-K82850175,navarixin,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,9865554,Phase 2,CC chemokine receptor antagonist,CXCR1|CXCR2,"","",3577|3579,No-Effect
4254,BRD-K82746043,navitoclax,CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|,24978538,Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,"","",596|598|599,Weak (50%)
4257,BRD-K61177364,NBI-27914,CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,176157,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,"","",1394,No-Effect
4260,BRD-K11796549,NBQX,NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O,3272524,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B,"","",114787|2890|2891|2892|2893|2897|2903|2904,No-Effect
4261,BRD-K01826782,NCS-382,O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|,6604757,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|SLC52A2,"","",9568|10537|79581,No-Effect
4264,BRD-K17539220,NDT-9513727,CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1,10210160,Preclinical,complement antagonist,C5AR1,"","",728,No-Effect
4265,BRD-K11443721,NE-100,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,9841596,Phase 2,sigma receptor antagonist,SIGMAR1,"","",10280,Very Weak (35%)
4266,BRD-K00003617,nebivolol,"O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|",189562,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153,Low (25%)
4267,BRD-A51355958,nebracetam,NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|,25136943,Phase 3,acetylcholine receptor agonist,CHRM1,"","",1128,Very Weak (35%)
4268,BRD-K14395568,NECA,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,448222,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,Weak (50%)
4269,BRD-K01825019,necrostatin-1,CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|,738301,Preclinical,RIPK inhibitor,RIPK1,"","",8737,No-Effect
4270,BRD-K68851986,necrostatin-2,CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O,11288934,Preclinical,necroptosis inhibitor|RIPK inhibitor,RIPK2,"","",8767,No-Effect
4272,BRD-K64716392,nedocromil,CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O,50294,Launched,histamine receptor antagonist,CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR,neurology/psychiatry|ophthalmology,itching|conjunctivitis,5729|10800|57105|2357|3320,Very Weak (35%)
4273,BRD-K90789829,nefazodone,CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1,4449,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,"","",6530|6531|6532|1576|146|147|150|3350|3356|3358,No-Effect
4274,BRD-K65678996,nefiracetam,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,71157,Phase 3,acetylcholine receptor agonist|benzodiazepine receptor agonist,CHRM1,"","",1128,No-Effect
4276,BRD-K84466663,nelarabine,COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,3011155,Launched,DNA synthesis inhibitor|T cell inhibitor,POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL),5422,No-Effect
4277,BRD-K74117820,nelfinavir,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,64143,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),100861540|1544|1576|1555|1557|1559|1565,Strong (80%)
4282,BRD-K47289124,nemonapride,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|",156333,Launched,dopamine receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia,1813|1814|1815,No-Effect
4284,BRD-K51911221,nemorubicin,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,65907,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,"","",7153|7150,Weak (50%)
4288,BRD-K71013094,neomycin,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,8378,Launched,bacterial 30S ribosomal subunit inhibitor,CXCR4,infectious disease|gastroenterology,first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections,7852,Low (25%)
4289,BRD-K18922609,neostigmine,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,4456,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,43,Very Weak (35%)
4290,BRD-K04112579,nepafenac,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,151075,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,ophthalmology,eye inflammation,5742|5743,Very Weak (35%)
4291,BRD-K09126848,nepicastat,NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,9796181,Phase 2,dopamine beta hydroxylase inhibitor,DBH,"","",1621,No-Effect
4292,BRD-K85606544,neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,9915743,Launched,EGFR inhibitor,EGFR|ERBB2|KDR,oncology,breast cancer,2064|1956|3791,No-Effect
4294,BRD-K60212747,neridronic-acid,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,71237,Launched,bone resorption inhibitor,FDPS,endocrinology,brittle bone disease|Paget's disease,2224,No-Effect
4297,BRD-K97428065,netupitant,CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,6451149,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869,No-Effect
4300,BRD-K28567778,neuropathiazol,CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1,11667240,Preclinical,neural stem cell inducer,BMP2|LIF,"","",3976|650,No-Effect
4301,BRD-K15502390,nevirapine,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,4463,Launched,non-nucleoside reverse transcriptase inhibitor,CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5,infectious disease,human immunodeficiency virus (HIV-1),1544|1576|1577|1548|1555|1559|1565,No-Effect
4302,BRD-K70402238,nexturastat-A,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,71462653,Preclinical,HDAC inhibitor,HDAC1|HDAC6,"","",3065|10013,No-Effect
4303,BRD-K83354763,NFKB-activation-inhibitor-II,Cc1ccc(NCCCc2ccccc2)c(N)c1,16760588,Preclinical,NFkB pathway inhibitor,RELA,"","",5970,No-Effect
4304,BRD-K89223384,NG-nitro-arginine,N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O,440005,Phase 1,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,"","",339345|342977|340719,Weak (50%)
4305,BRD-K05181084,NGB-2904,Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl,9891901,Preclinical,dopamine receptor antagonist,DRD3,"","",1814,No-Effect
4306,BRD-K28639661,NGD-94-1,C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1,188942,Phase 1,dopamine receptor antagonist,DRD4,"","",1815,No-Effect
4307,BRD-K81779590,NGD-98-2,CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC,9822241,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,"","",1394,No-Effect
4310,BRD-K05653025,NHI-2,COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F,51355147,Preclinical,lactate dehydrogenase inhibitor,LDHA,"","",3939,No-Effect
4311,BRD-K03042257,NI-57,COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N,91827373,Preclinical,bromodomain inhibitor,BRD1|BRPF1|BRPF3,"","",27154|23774,No-Effect
4312,BRD-K60237333,niacin,OC(=O)c1cccnc1,938,Launched,NAD precursor|vitamin B,DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT,endocrinology,hypertriglyceridemia,4837|84649|338442|8843|23475|27198,No-Effect
4313,BRD-K12102668,nialamide,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,4472,Withdrawn,monoamine oxidase inhibitor,COMT|MAOA|MAOB,"","",1312|4129|4128,No-Effect
4317,BRD-A26711594,nicardipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|",6603948,Launched,calcium channel blocker,ADORA3,cardiology,chronic stable angina|hypertension,140,No-Effect
4318,BRD-K76810206,nicergoline,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,34040,Launched,adrenergic receptor antagonist,ADRA1A,rheumatology|neurology/psychiatry|cardiology|hematology,Raynaud's disease|migraine headache|atherosclerosis|thrombosis,146,No-Effect
4320,BRD-K35960502,niclosamide,Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O,4477,Launched,DNA replication inhibitor|STAT inhibitor,STAT3,infectious disease,tapeworm,6774,Weak (50%)
4322,BRD-K97752965,nicorandil,[O-][N+](=O)OCCNC(=O)c1cccnc1,47528,Launched,nitric oxide donor|potassium channel activator,KCNJ11,cardiology,angina pectoris,3767,No-Effect
4323,BRD-K28912512,nicotinamide,NC(=O)c1cccnc1,936,Launched,protein synthesis stimulant,BST1|LDHA|PARP1|SIRT5,dermatology,acne vulgaris (AV),3939|683|23408|142,No-Effect
4324,BRD-K05395900,nicotine,CN1CCC[C@H]1c1cccnc1,89594,Launched,acetylcholine receptor agonist,CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1,neurology/psychiatry,smoking cessation,55584|6916|89832|8989|8973|1135|1136|1137|1138|1588|1141|1142|1143|10044|57053,No-Effect
4326,BRD-K17617556,NIDA-41020,COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,11037861,Preclinical,cannabinoid receptor antagonist,CNR1,"","",1268,No-Effect
4327,BRD-K96354014,nifedipine,"COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|",4485,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3,cardiology,vasospastic angina|chronic stable angina,801|8001|80036|775|776|778|779|781|8856|783|8912|2741|2743|3736|3741,No-Effect
4329,BRD-A21280314,nifenalol,"CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|",202035,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,"","",153|154,No-Effect
4331,BRD-K98763141,niflumic-acid,OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F,4488,Launched,cyclooxygenase inhibitor,ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9,rheumatology|neurology/psychiatry,joint pain|muscle pain,55107|1188|1187|5319|3784|5321|54600|5742|5743|1180,No-Effect
4336,BRD-K59333713,niguldipine-(S)-(+),"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",60602,Preclinical,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
4338,BRD-K81528515,nilotinib,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,644241,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,ABL1|KIT,hematologic malignancy,chronic myeloid leukemia (CML),25|3815,No-Effect
4339,BRD-K23566484,nilutamide,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,4493,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367,No-Effect
4340,BRD-A84687895,nilvadipine,"COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|",10340038,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension|cerebral artery occlusion,776|775,No-Effect
4342,BRD-K76775527,nimesulide,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,4495,Launched,cyclooxygenase inhibitor,LTF|PLA2G2E|PTGS1|PTGS2,rheumatology|obstetrics/gynecology,osteoarthritis|menstrual pain,4057|5742|30814|5743,No-Effect
4343,BRD-A58048407,nimodipine,"COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|",157132,Launched,calcium channel blocker,CFTR|NR3C2,hematology,hemorrhage,1080|4306,No-Effect
4347,BRD-K49075727,nintedanib,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF),5156|5159|3791|2321|2260|2261|2324|2263|2264,No-Effect
4348,BRD-K54955827,niraparib,NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1,24958200,Launched,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),142,No-Effect
4351,BRD-A84465106,nisoldipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|",28248400,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension,776|778|779|775,No-Effect
4352,BRD-K01825513,nisoxetine,"CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|",10107248,Phase 1,norepinephrine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,"","",6530|6531|6532,No-Effect
4355,BRD-K75551531,nitecapone,CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O,5464105,Phase 2,catechol O methyltransferase inhibitor,COMT,"","",1312,No-Effect
4359,BRD-A02006392,nitrendipine,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|",157702,Launched,calcium channel blocker,CACNA1D|CACNA2D1|KCNN4,cardiology,hypertension,776|781|3783,No-Effect
4360,BRD-K28453807,nitrocaramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,3941250,Preclinical,cholinergic receptor antagonist,CHRM1,"","",1128,No-Effect
4366,BRD-K97534525,nitroxoline,Oc1ccc([N+]([O-])=O)c2cccnc12,19910,Launched,cathepsin inhibitor,METAP2,infectious disease,urinary tract infections,10988,No-Effect
4367,BRD-K73589491,nizatidine,CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O,3033637,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD),1665,No-Effect
4369,BRD-K47441935,NK-252,O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1,71618700,Preclinical,nuclear factor erythroid derived|like (NRF2) activator,NFE2L2,"","",4780,No-Effect
4371,BRD-A75015151,NKY-80,"Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|",777417,Preclinical,adenylyl cyclase inhibitor,ADCY5,"","",111,No-Effect
4372,BRD-A62133859,NLG919,"O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|",70874604,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",IDO1,"","",3620,No-Effect
4374,BRD-K62414032,NMDA,CN[C@H](CC(O)=O)C(O)=O,22880,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
4375,BRD-K83699324,NMS-1286937,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,49792852,Phase 2,PLK inhibitor,FLT3|PLK1|PLK2|PLK3,"","",10769|2322|5347|1263,No-Effect
4376,BRD-K26253904,NMS-873,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O,71521142,Preclinical,ATPase inhibitor,VCP,"","",7415,Cyto
4379,BRD-K00004640,NN-DNJ,CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,501640,Preclinical,glucosidase inhibitor,GBA,"","",2630,Low (25%)
4380,BRD-K85015012,NNC-05-2090,COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1,9888030,Preclinical,GABA uptake inhibitor|GAT inhibitor,SLC6A12,"","",6539,Weak (50%)
4381,BRD-K78122587,NNC-55-0396,CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,9957280,Preclinical,T-type calcium channel blocker,CATSPER1|CATSPER2|CATSPER3|CATSPER4,"","",117144|117155|347732|378807,Strong (80%)
4382,BRD-K72904818,NNC-63-0532,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,9803475,Preclinical,opioid receptor agonist,OPRL1,"","",4987,No-Effect
4383,BRD-K42221274,NNC-711,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|,4515,Preclinical,GABA uptake inhibitor,SIGMAR1|SLC6A1,"","",10280|6529,No-Effect
4384,BRD-K08807999,NO-ASA,CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1,119032,Phase 2,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
4385,BRD-K06753942,nobiletin,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,72344,Preclinical,MEK inhibitor,MAP2K1,"","",5604,No-Effect
4386,BRD-K12539581,nocodazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1,4122,Preclinical,tubulin polymerization inhibitor,HPGDS,"","",27306,Weak (50%)
4387,BRD-K36636143,nolatrexed,Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1,135400184,Phase 3,thymidylate synthase inhibitor,TYMS,"","",7298,No-Effect
4388,BRD-K27351809,nomegestrol-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|",91668,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive,5241,Low (25%)
4389,BRD-A29644307,nomifensine,CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|,55993,Withdrawn,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,DRD2|SLC6A2|SLC6A3,"","",6530|6531|1813,No-Effect
4390,BRD-K05907307,nonivamide,CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,2998,Launched,TRPV agonist,TRPV1,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain,7442,No-Effect
4392,BRD-K36381762,nor-binaltorphimine,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O,5480230,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
4394,BRD-K42504537,norelgestromin,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|,9568628,Launched,"",PGR,endocrinology,contraceptive,5241,Weak (50%)
4395,BRD-K87349682,norepinephrine,NC[C@H](O)c1ccc(O)c(O)c1,439260,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2,cardiology|allergy|neurology/psychiatry,hypertension|urticaria|headache|seasonal affective disorder,6570|6571|146|147|150|151|152|153|154|155|5053,No-Effect
4396,BRD-K92073408,norethindrone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|,6230,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,5241,No-Effect
4397,BRD-K96037667,norethindrone-acetate,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|,5832,Launched,progesterone receptor agonist,PGR,endocrinology|orthopedics|obstetrics/gynecology,menopause|osteoporosis|vaginal atrophy,5241,No-Effect
4399,BRD-A00758722,noretynodrel,"C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|",6231,Launched,progestogen hormone,PGR,endocrinology,contraceptive,5241,No-Effect
4400,BRD-K11196887,norfloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1,6919051,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,urinary tract infections|gonorrhea|prostatitis,7153,No-Effect
4401,BRD-A79769222,norfluoxetine,"NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|",9797657,Phase 1,selective serotonin reuptake inhibitor (SSRI),HTR2B,"","",106480180,Very Weak (35%)
4402,BRD-K38041788,norgestimate,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|,6540478,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099,No-Effect
4403,BRD-A14886633,norgestrel,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|",13109,Launched,progesterone receptor agonist,AR|ESR1|PGR|SRD5A1,endocrinology,contraceptive,5241|2099|6715|367,Very Weak (35%)
4405,BRD-K91263825,nortriptyline,CNCCC=C1c2ccccc2CCc2ccccc12,4543,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|146|147|1813|150|151|152|153|154|155|3350|3356|3358|3362|10280|3766|3269|1128|1129|10857|1131|1132|1133,Low (25%)
4407,BRD-K89237706,noscapine,COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12,275196,Launched,bradykinin receptor antagonist|tubulin polymerization inhibitor,SIGMAR1,pulmonary,cough suppressant,10280,No-Effect
4408,BRD-K11411329,NOV-002,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,16401161,Phase 3,"",GSR,"","",2936,No-Effect
4411,BRD-K65275554,NPC-15199,CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,1549477,Phase 2,ICAM1 antagonist,PPARG,"","",5468,No-Effect
4412,BRD-K89272762,NPPB,OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O,4549,Preclinical,chloride channel blocker,ANO1|CLCN2|CLCN7|TRPA1,"","",8989|1186|55107|1181,No-Effect
4413,BRD-K75506300,NPS-2143,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,6918446,Preclinical,calcium receptor antagonist,CASR,"","",846,Very Weak (35%)
4415,BRD-K95600043,NPY-5RA972,CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12,9884833,Preclinical,neuropeptide receptor antagonist,NPY5R,"","",4889,No-Effect
4416,BRD-K61918008,NQDI-1,CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23,5522952,Preclinical,caspase inhibitor,CASP3,"","",836,No-Effect
4417,BRD-K21865955,NS-018,C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1,46866319,Phase 1/Phase 2,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,"","",7297|3716|3717|3718,No-Effect
4418,BRD-K94342292,NS-11021,FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F,24825677,Preclinical,calcium-activated potassium channel activator,KCNMA1,"","",3778,Very Weak (35%)
4420,BRD-K73738482,NS-1643,Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F,10177784,Preclinical,voltage-gated potassium channel activator,KCNH2|KCNH6|KCNMA1,"","",81033|3778|3757,No-Effect
4421,BRD-K03808106,NS-19504,Nc1ncc(Cc2ccc(Br)cc2)s1,727750,Preclinical,calcium-activated potassium channel activator,KCNMA1,"","",3778,No-Effect
4422,BRD-K00004295,NS-309,O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl,,Preclinical,calcium-activated potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,"","",3780|3781|3782|3783,No-Effect
4423,BRD-K24434292,NS-3623,FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1,9954236,Preclinical,voltage-gated potassium channel activator,KCNH2,"","",3757,No-Effect
4424,BRD-K00004309,NS-3861,"CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|",,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNB4,"","",1136|1143,No-Effect
4425,BRD-K93314017,NS-5806,FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F,11642685,Preclinical,voltage-gated potassium channel activator,KCND3,"","",3752,No-Effect
4426,BRD-K22667752,NS-8,Cc1c([nH]c(N)c1C#N)-c1ccccc1F,10176749,Phase 2,potassium channel agonist,KCNMA1,"","",3778,No-Effect
4427,BRD-K34624869,NS-8593,C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1,11587013,Preclinical,calcium-activated potassium channel modulator,KCNN1|KCNN2|KCNN3,"","",3780|3781|3782,No-Effect
4428,BRD-K40176866,NS-9283,N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1,11998180,Preclinical,acetylcholine receptor allosteric modulator,CHRNA4,"","",1137,No-Effect
4431,BRD-K13169950,NSC-3852,Oc1ccc(N=O)c2cccnc12,19103,Preclinical,HDAC inhibitor,HDAC1,"","",3065,No-Effect
4432,BRD-A67975844,NSC-405020,"CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|",879610,Preclinical,matrix metalloprotease inhibitor,MMP1,"","",4312,No-Effect
4433,BRD-K64874225,NSC-4644,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,72326,Phase 2,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,PYGM,"","",5837,No-Effect
4434,BRD-K73799155,NSC-5844,Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1,221354,Preclinical,CC chemokine receptor agonist,CCR1,"","",1230,No-Effect
4435,BRD-K62949423,NSC-625987,COc1ccc(OC)c2c1[nH]c1ccccc1c2=S,3004085,Preclinical,CDK inhibitor,CDK2|CDK4,"","",1017|1019,No-Effect
4436,BRD-K81197548,NSC-632839,Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1,5351363,Preclinical,ubiquitin specific protease inhibitor,SENP2|USP1|USP2|USP7,"","",7874|9099|7341|7398,Cyto
4437,BRD-K61120504,NSC-636819,[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O,6288112,Preclinical,histone demethylase inhibitor,KDM4A|KDM4B,"","",9682|23030,No-Effect
4438,BRD-K03109492,NSC-663284,ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|,379077,Preclinical,CDC inhibitor,CDC25A|CDC25B|CDC25C,"","",993|994|995,No-Effect
4439,BRD-K20605374,NSC-697923,Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O,394449,Preclinical,ubiquitin-conjugating enzyme inhibitor,UBE2N,"","",7334,No-Effect
4440,BRD-K68143200,NSC-95397,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|,262093,Preclinical,CDC inhibitor,CDC25A|CDC25B,"","",993|994,No-Effect
4441,BRD-K49811169,NSC-9965,"CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|",31762,Preclinical,acetylcholine receptor antagonist,CHRNA4|CHRNB2,"","",1137|1141,No-Effect
4444,BRD-K54098378,NT157,Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O,135398520,Preclinical,IGF-1 inhibitor,IGF1R,"","",3480,No-Effect
4445,BRD-A40413915,NTNCB,"[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|",,Preclinical,neuropeptide receptor antagonist,NPY5R,"","",4889,Weak (50%)
4446,BRD-K07788774,NTRC-824,CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O,101873359,Preclinical,neurotensin receptor antagonist,NTSR2,"","",23620,No-Effect
4447,BRD-K54708045,nTZDpa,OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1,9954280,Preclinical,PPAR receptor agonist,PPARG,"","",5468,No-Effect
4448,BRD-K48692744,NU-1025,Cc1nc(=O)c2cccc(O)c2[nH]1,135398517,Preclinical,PARP inhibitor,PARP1,"","",142,No-Effect
4449,BRD-K20976221,NU-2058,Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1,4564,Preclinical,cyclin D inhibitor,CCNA2|CDK2,"","",1017|890,No-Effect
4450,BRD-K03294269,NU-6027,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,398148,Preclinical,CDK inhibitor,CCNA2|CDK2,"","",1017|890,Low (25%)
4451,BRD-K09537769,NU-7026,O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1,9860529,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,PRKDC,"","",5591,No-Effect
4452,BRD-K00337317,NU-7441,O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1,11327430,Preclinical,DNA dependent protein kinase inhibitor,PRKDC,"","",5591,No-Effect
4454,BRD-K00002882,nutlin-3,"COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|",11433190,Preclinical,MDM inhibitor,MDM2|TP53,"","",4193|7157,No-Effect
4456,BRD-K01573278,NVP-231,O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1,4096211,Preclinical,ceramidase inhibitor,CERK,"","",64781,No-Effect
4457,BRD-K15179513,NVP-ADW742,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|,,Preclinical,insulin growth factor receptor inhibitor,IGF1R,"","",3480,Strong (80%)
4458,BRD-K24696047,NVP-AEW541,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|,,Preclinical,IGF-1 inhibitor,IGF1R|INSR,"","",3480|3643,Strong (80%)
4459,BRD-K41859756,NVP-AUY922,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,135539077,Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,"","",3320|3326,Very Weak (35%)
4460,BRD-K12184916,NVP-BEZ235,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1,11977753,Phase 3,mTOR inhibitor|PI3K inhibitor,ATR|MTOR|PIK3CA|PIK3CD|PIK3CG,"","",545|22883|5290|2475|5294,Cyto
4461,BRD-K42728290,NVP-BGJ398,CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1,53235510,Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|KDR,"","",3791|2260|2261|2263|2264,No-Effect
4462,BRD-K79259477,NVP-BHG712,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,16747388,Preclinical,ephrin inhibitor,EPHB4,"","",2050,Strong (80%)
4463,BRD-K02017404,NVP-BSK805,Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1,46398810,Preclinical,JAK inhibitor,JAK2,"","",3717,No-Effect
4464,BRD-K77943374,NVP-BVU972,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,44206063,Preclinical,MET inhibitor,MET,"","",8731,No-Effect
4465,BRD-K77396579,NVP-DPP728,O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N,9796290,Phase 2,dipeptidyl peptidase inhibitor,DPP4,"","",1803,No-Effect
4466,BRD-K67915505,NVP-HSP990,COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1,46216556,Phase 1,HSP inhibitor,HSP90AA1|HSP90AB1,"","",3320|3326,Weak (50%)
4467,BRD-K21025364,NVP-TAE226,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl,9934347,Preclinical,protein tyrosine kinase inhibitor,PTK2,"","",5747,No-Effect
4468,BRD-K50140147,NVP-TAE684,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,16038120,Preclinical,ALK tyrosine kinase receptor inhibitor,ALK|INSR,"","",3643|238,No-Effect
4469,BRD-K87454346,NVP-TNKS656,COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1,136237316,Preclinical,tankyrase inhibitor,TNKS2,"","",80351,No-Effect
4470,BRD-K28132190,NVS-PAK1-1,CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|,137125241,Preclinical,p21 activated kinase inhibitor,PAK1,"","",5585,No-Effect
4476,BRD-K63247785,O-acetyl-L-serine,CC(=O)OC[C@H](N)C(O)=O,99478,Preclinical,"",PTGS1,"","",5742,No-Effect
4478,BRD-K53849769,O4I1,COc1ccc(COc2ccc(CC#N)cc2)cc1,2774690,Preclinical,Oct inducer,POU5F1,"","",5460,No-Effect
4479,BRD-K92041145,O6-benzylguanine,Nc1nc(OCc2ccccc2)c2[nH]cnc2n1,4578,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,"","",4255,No-Effect
4481,BRD-K18305454,OAC2,O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1,2814138,Preclinical,Oct activator,POU5F1,"","",5460,No-Effect
4482,BRD-K15600710,obatoclax,"COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|",,Phase 3,BCL inhibitor,BCL2,"","",596,Strong (80%)
4483,BRD-A75838038,obeticholic-acid,"CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|",,Launched,FXR agonist,NR1H4,gastroenterology,primary biliary cholangitis,9971,No-Effect
4484,BRD-K33588785,obidoxime,O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1,8251,Launched,cholinesterase reactivator,ACHE,critical care|neurology/psychiatry,poison antidote|nerve gas poisoning,43,No-Effect
4485,BRD-K36463073,OC000459,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O,11462174,Phase 2,CRTH receptor antagonist,PTGDR2,"","",11251,Low (25%)
4487,BRD-K92524032,ochromycinone,C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21,11808929,Phase 1,STAT inhibitor,STAT3,"","",6774,No-Effect
4488,BRD-K92581468,ocinaplon,O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1,216456,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,No-Effect
4497,BRD-A14240607,octopamine,NCC(O)c1ccc(O)cc1,657354,Preclinical,trace amine associated receptor agonist,F10|TAAR1,"","",134864|2159,No-Effect
4498,BRD-A64173453,octreotide,"C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|",,Launched,somatostatin receptor agonist,SSTR2|SSTR3|SSTR5,gastroenterology|endocrinology|oncology,diarrhea|acromegaly|carcinoid tumors,6752|6753|6755,No-Effect
4499,BRD-K22822991,odanacatib,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,10152654,Phase 3,cathepsin inhibitor,CTSK,"","",1513,No-Effect
4500,BRD-K26015241,ODQ,O=c1onc2cnc3ccccc3n12,1456,Preclinical,guanylyl cyclase inhibitor,GUCY1A2|GUCY1A3|GUCY1B3,"","",2977|2982|2983,No-Effect
4501,BRD-K92658264,OF-1,COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C,35397514,Preclinical,bromodomain inhibitor,BRD1,"","",23774,No-Effect
4507,BRD-K94083718,OICR-9429,CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1,91623360,Preclinical,WDR5/MLL interaction inhibitor,WDR5,"","",11091,No-Effect
4508,BRD-K18895904,olanzapine,CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|,135398745,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder,2560|2561|2562|2563|2564|2565|2566|2567|2568|1665|146|147|1812|1813|150|1815|1816|151|152|153|154|155|1814|3350|3351|3352|3354|3355|3356|3358|3359|3361|3362|3363|106480180|3269|55879|59340|1128|1129|1131|1132|1133|2554|2555|2556|2557|2558|2559,No-Effect
4509,BRD-K02113016,olaparib,Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1,23725625,Launched,PARP inhibitor,PARP1|PARP2,oncology,ovarian cancer,10038|142,Very Weak (35%)
4510,BRD-K95523387,OLDA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,5282106,Preclinical,TRPV agonist,GPR119,"","",139760,No-Effect
4511,BRD-K06644925,oleamide,CCCCCCCC\C=C/CCCCCCCC(N)=O,5283387,Preclinical,cannabinoid receptor agonist,HTR7|PLA2G2A,"","",5320|3363,No-Effect
4513,BRD-K90647725,oleanolic-acid,CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|,10494,Preclinical,G protein-coupled receptor agonist,GPBAR1,"","",151306,No-Effect
4514,BRD-K66956375,oleoylethanolamide,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,5283454,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,CNR1|GPR119|GPR55|PPARA,"","",139760|5465|9290|1268,No-Effect
4516,BRD-A00842753,oleuropein,"COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|",,Phase 2,estrogen receptor agonist,GPER1,"","",2852,No-Effect
4517,BRD-K00003580,oligomycin-A,"[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|",133268482,Preclinical,ATP synthase inhibitor|ATPase inhibitor,ATP5A1,"","",498,No-Effect
4518,BRD-K83144676,olmesartan,CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,158781,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185,No-Effect
4519,BRD-K78485176,olmesartan-medoxomil,CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,130881,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185,No-Effect
4520,BRD-K60421517,olmutinib,CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1,54758501,Launched,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,BTK|EGFR,oncology,non-small cell lung cancer (NSCLC),1956|695,Very Weak (35%)
4522,BRD-K82731415,olomoucine,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,4592,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5|MAPK1,"","",1017|5594|1020|983,No-Effect
4523,BRD-K67637637,olopatadine,CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12,5281071,Launched,histamine receptor antagonist,HRH1|S100A1|S100A12|S100A13|S100A2|S100B,ophthalmology,conjunctivitis,6273|3269|6283|6284|6285|6271,No-Effect
4524,BRD-K20745393,olprinone,Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N,4593,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139,No-Effect
4525,BRD-K57853941,olsalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O,,Launched,cyclooxygenase inhibitor,IFNG|TPMT,gastroenterology,ulcerative colitis,3458|7172,No-Effect
4526,BRD-K86972824,oltipraz,Cc1c(ssc1=S)-c1cnccn1,47318,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,ANG,"","",283,No-Effect
4528,BRD-K31560319,olvanil,CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1,5311093,Preclinical,TRPV agonist,CNR1|GPR119|TRPV1,"","",139760|7442|1268,No-Effect
4530,BRD-K00003265,omapatrilat,[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O,656629,Preclinical,metalloproteinase inhibitor,ACE|MME,"","",4321|1636,No-Effect
4531,BRD-K14171291,omarigliptin,CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F,46209133,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,Very Weak (35%)
4534,BRD-K48830578,OMDM-2,CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,6604915,Preclinical,FAAH inhibitor,GPR119,"","",139760,No-Effect
4535,BRD-K36680103,omecamtiv-mecarbil,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,11689883,Phase 3,cardiac myosin activator,MYBPC3,"","",4607,No-Effect
4538,BRD-A55962179,omeprazole,COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,9568614,Launched,ATPase inhibitor,ATP4A|CLCN2,gastroenterology,heartburn,1181|495,No-Effect
4539,BRD-A56892734,omeprazole-magnesium,COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,9601083,Launched,proton pump inhibitor,ATP4A|ATP4B,gastroenterology,gastroesophageal reflux disease (GERD)|heartburn,496|495,No-Effect
4543,BRD-K88554883,ON123300,CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1,56649281,Preclinical,CDK inhibitor,CDK4|NUAK1|PDGFRB,"","",1019|9891|5159,No-Effect
4544,BRD-K58529924,ONC201,"Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|",73777259,Phase 2,AKT inhibitor|MAP kinase inhibitor,TNFSF10,"","",8743,No-Effect
4546,BRD-K01826546,ondansetron,Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|,667538,Launched,serotonin receptor antagonist,HTR3A|HTR3B,gastroenterology,nausea|vomiting,9177|3359,No-Effect
4547,BRD-K00003197,ONO-4059,CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O,54755438,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,No-Effect
4548,BRD-K58894520,ONO-4817,CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1,9888141,Phase 1,matrix metalloprotease inhibitor,MMP8,"","",4317,No-Effect
4549,BRD-K76725781,ONO-8130,CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1,9827317,Preclinical,prostanoid receptor antagonist,PTGER1,"","",5731,No-Effect
4550,BRD-A80567330,ONO-AE3-208,"C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|",92978378,Preclinical,prostanoid receptor antagonist,PTGER4,"","",5734,No-Effect
4553,BRD-K19426040,OPC-21268,CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12,114904,Phase 1,vasopressin receptor antagonist,AVPR1A|AVPR2|OXTR,"","",552|554|5021,No-Effect
4554,BRD-K66192203,opicapone,Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O,135565903,Phase 3,catechol O methyltransferase inhibitor,COMT,"","",1312,No-Effect
4557,BRD-K18602506,OR-486,Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O,3870203,Preclinical,catechol O methyltransferase inhibitor,COMT,"","",1312,No-Effect
4558,BRD-K55966568,orantinib,Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O,5329099,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,"","",1956|5156|6790|5159|3791|2260|2263|9212,No-Effect
4560,BRD-K67068943,ORE1001,CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O,448281,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,ACE2,"","",59272,No-Effect
4561,BRD-K07409305,ORG-12962,FC(F)(F)c1ccc(nc1Cl)N1CCNCC1,9796408,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
4562,BRD-K32853922,ORG-25543,COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C,5311287,Preclinical,glycine transporter inhibitor,GLRB|SLC6A5,"","",6530|2743,No-Effect
4564,BRD-K57597776,ORG-27569,CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1,44828492,Preclinical,cannabinoid receptor modulator,CNR1,"","",1268,No-Effect
4565,BRD-K41434598,ORG-9768,CC1(CN)Cc2ccccc2C1,22152353,Phase 1,adrenergic receptor antagonist,ADRA2A,"","",150,No-Effect
4566,BRD-K00003710,oridonin,[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O,5321010,Preclinical,BCL inhibitor,BCL2,"","",596,Weak (50%)
4568,BRD-K63343048,orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,3034010,Launched,lipase inhibitor,CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP,endocrinology,weight-loss aid,8513|221955|747|2194|1268|5406,No-Effect
4572,BRD-K01825132,ornithine,"Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|",74765349,Launched,NFkB pathway modulator,GPRC6A,"","",222545,No-Effect
4573,BRD-K32572029,orotic-acid,OC(=O)c1cc(=O)[nH]c(=O)[nH]1,967,Phase 2,"",DHODH,"","",1723,No-Effect
4574,BRD-K05717154,orphanin-fq,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O,56947112,Phase 1,opioid receptor agonist,OPRL1|OPRM1,"","",4987|4988,No-Effect
4576,BRD-K00674894,orteronel,CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12,10335364,Phase 3,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,CYP17A1,"","",1586,No-Effect
4577,BRD-K59711701,ORY-1001,NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1,71543365,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,"","",23028,No-Effect
4579,BRD-K76011241,oseltamivir-phosphate,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|,65028,Launched,neuraminidase inhibitor,CES1|NEU1|NEU2,infectious disease,influenza A virus infection,51162|1066|4759,No-Effect
4580,BRD-K60371362,osemozotan,C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1,198747,Phase 2/Phase 3,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
4581,BRD-K87124298,OSI-027,COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|,,Phase 1,mTOR inhibitor,MTOR,"","",2475,Weak (50%)
4582,BRD-K73309154,OSI-420,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,10317566,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
4583,BRD-K25340465,OSI-930,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1,9868037,Phase 1,KIT inhibitor|VEGFR inhibitor,FLT1|KDR|KIT,"","",2321|3815|3791,No-Effect
4585,BRD-K42805893,osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,71496458,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956,Strong (80%)
4586,BRD-K44184170,ospemifene,OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1,3036505,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,obstetrics/gynecology|endocrinology,vaginal atrophy|dyspareunia|menopause,2099|2100,No-Effect
4587,BRD-K29735307,ostarine,C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,11326715,Phase 3,androgen receptor modulator,AR,"","",367,No-Effect
4589,BRD-K42009284,OT-R-antagonist-1,CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1,9690136,Preclinical,oxytocin receptor antagonist,AVPR1A|OXTR,"","",552|5021,No-Effect
4590,BRD-K80082640,otamixaban,COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1,5496659,Phase 3,coagulation factor inhibitor,F10,"","",2159,No-Effect
4591,BRD-A00520476,otenzepad,"CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|",76966449,Phase 3,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,"","",1128|1129|1131|1132|1133,No-Effect
4592,BRD-K85337334,otilonium,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,72093,Launched,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome,775,No-Effect
4593,BRD-K53417444,OTS167,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|,,Phase 1/Phase 2,maternal embryonic leucine zipper kinase inhibitor,MELK,"","",9833,Weak (50%)
4595,BRD-K43471985,OTX015,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|,9936746,Phase 1/Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,"","",8019|23476|6046,Cyto
4596,BRD-K33277808,ouabain,C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|,11527152,Launched,ATPase inhibitor,ATP1A1,cardiology,hypertension|cardiac arrythmia,476,Strong (80%)
4597,BRD-K98736329,OXA-06,Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12,24857242,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,"","",9475|6093,No-Effect
4604,BRD-K25394294,oxaprozin,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,4614,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743,No-Effect
4605,BRD-K22556255,oxatomide,O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,4615,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,No-Effect
4606,BRD-K04196797,oxcarbazepine,NC(=O)N1c2ccccc2CC(=O)c2ccccc12,34312,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
4609,BRD-A73891132,OXF-BD-02,"Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|",70699441,Preclinical,bromodomain inhibitor,BRD4,"","",23476,Weak (50%)
4611,BRD-K30373577,oxfenicine,N[C@@H](C(O)=O)c1ccc(O)cc1,89853,Phase 1,carnitine palmitoyltransferase inhibitor,CPT1A|CPT1B,"","",386593|1374,No-Effect
4612,BRD-K52075715,oxibendazole,CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,4622,Launched,tubulin polymerization inhibitor,TUBB|TUBB4B,infectious disease,strongyles,7280|10383,No-Effect
4621,BRD-K01942991,oxotremorine-M,C[N+](C)(C)CC#CCN1CCCC1=O,4629,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
4622,BRD-K21936341,oxotremorine-sesquifumarate,O=C1CCCN1CC#CCN1CCCC1,4630,Preclinical,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
4623,BRD-A43671941,oxprenolol,CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|,94423,Launched,adrenergic receptor antagonist,ADRB1,cardiology,angina pectoris|hypertension|cardiac arrythmia,153,No-Effect
4624,BRD-K59037100,oxybenzone,COc1ccc(C(=O)c2ccccc2)c(O)c1,4632,Launched,lipase inhibitor,LIPE,dermatology,sunscreen lotion,3991,Weak (50%)
4625,BRD-K04185004,oxybuprocaine,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,4633,Launched,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic,6336,Very Weak (35%)
4626,BRD-K01825580,oxybutynin,"CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|",6098167,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,urology,urinary incontinence,1128|1129|1131,No-Effect
4630,BRD-K16195444,oxymetazoline,Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|,4636,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C,otolaryngology,nasal congestion,3352|146|147|150|151|152|3351|3358,No-Effect
4633,BRD-A14208071,oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,5748,Launched,cholinergic receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD),1128|1131,No-Effect
4634,BRD-K31841515,oxypurinol,O=c1nc2[nH][nH]cc2c(=O)[nH]1,135398752,Phase 2/Phase 3,xanthine oxidase inhibitor,XDH,"","",6652,No-Effect
4635,BRD-K66808046,oxyquinoline,Oc1cccc2cccnc12,1923,Launched,chelating agent,METAP2,dermatology,cosmetic,10988,No-Effect
4637,BRD-K25243230,oxytocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,133698923,Launched,oxytocin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,obstetrics/gynecology,labor induction,552|553|554|5021,No-Effect
4638,BRD-K53061490,ozagrel,OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1,5282440,Launched,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke,6916,No-Effect
4639,BRD-K46625559,ozanimod,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO,52938427,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,"","",1901,No-Effect
4643,BRD-K97714174,P22077,CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O,46931953,Preclinical,ubiquitin specific protease inhibitor,USP7,"","",7874,No-Effect
4644,BRD-K51791723,P276-00,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,23643976,Phase 2,CDK inhibitor,CDK1|CDK4|CDK9,"","",1025|1019|983,Cyto
4645,BRD-K13606314,P5091,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,2819993,Preclinical,ubiquitin specific protease inhibitor,USP7,"","",7874,No-Effect
4646,BRD-A09487507,P7C3,"O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|",981442,Preclinical,NAMPT inhibitor,NAMPT,"","",10135,No-Effect
4648,BRD-K92991072,PAC-1,Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1,9675990,Phase 1,caspase activator,CASP3,"","",836,No-Effect
4649,BRD-K62008436,paclitaxel,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|,36314,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC),10376|84617|10381|10382|10383|8856|4134|7846|347688|4137|113457|84790|7099|203068|112714|596|347733|10988|7277|7278|7280,No-Effect
4650,BRD-K05677083,PACOCF3,CCCCCCCCCCCCCCCC(=O)C(F)(F)F,4670,Preclinical,phospholipase inhibitor,PLA2G4A,"","",5321,No-Effect
4651,BRD-K19034817,pacritinib,C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|,46216796,Phase 3,FLT3 inhibitor|JAK inhibitor,FLT3|JAK1|JAK2|JAK3,"","",2322|3716|3717|3718,Strong (80%)
4657,BRD-K51313569,palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O,5330286,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021,No-Effect
4659,BRD-A99888680,paliperidone,"Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|",9823781,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813,No-Effect
4660,BRD-K58466253,palmatine-chloride,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,19009,Preclinical,dopamine synthesis inhibitor,CYP3A4,"","",1576,No-Effect
4663,BRD-K68095457,palmitoylethanolamide,CCCCCCCCCCCCCCCC(=O)NCCO,4671,Launched,cannabinoid receptor agonist,CNR2|GPR119|GPR55,"","",139760|9290|56142,No-Effect
4664,BRD-A50998626,palomid-529,"COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|",86324425,Phase 1,AKT inhibitor|mTOR inhibitor,MTOR,"","",2475,No-Effect
4665,BRD-K08924299,palonosetron,O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2,6337614,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359,No-Effect
4666,BRD-K07682953,palosuran,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,10173280,Phase 2,urotensin receptor antagonist,UTS2R,"","",2837,No-Effect
4667,BRD-K83794243,palovarotene,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,10295295,Phase 3,retinoid receptor agonist,RARG,"","",5916,No-Effect
4669,BRD-K58513245,pamidronate,NCCC(O)(P(O)(O)=O)P(O)(O)=O,4674,Launched,bone resorption inhibitor,FDPS,endocrinology|oncology|hematologic malignancy,hypercalcemia|Paget's disease|breast cancer|multiple myeloma,2224,No-Effect
4671,BRD-K50817623,pancuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,441289,Launched,acetylcholine receptor antagonist,CHRM2|CHRM3|CHRNA1|CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant,1129|1131|1134|1135,No-Effect
4673,BRD-K02130563,panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1,6918837,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,multiple myeloma,55869|9734|8841|3065|3066|10013|9759,Cyto
4675,BRD-K00003243,pantoprazole,COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|,11181988,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome,495,Very Weak (35%)
4677,BRD-K18573821,PAOPA,NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O,44281634,Preclinical,dopamine receptor modulator,DRD2,"","",1813,No-Effect
4678,BRD-K15567136,papaverine,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,4680,Launched,phosphodiesterase inhibitor,PDE10A|PDE4B|PDE5A,cardiology|hematology|gastroenterology,myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm,8654|10846|5142,Very Weak (35%)
4680,BRD-K62412084,para-toluenesulfonamide,Cc1ccc(cc1)S(N)(=O)=O,6269,Phase 3,"",CA12|CA2|CA6|CA9,"","",760|768|771|765,No-Effect
4681,BRD-K41524689,paracetamol,CC(=O)Nc1ccc(O)cc1,1983,Launched,cyclooxygenase inhibitor,FAAH|PTGS1|PTGS2|TRPV1,neurology/psychiatry|endocrinology,pain relief|fever,79152|7442|5742|5743,No-Effect
4683,BRD-A22128695,paramethadione,"CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|",51380897,Launched,anticonvulsant,CACNA1G,neurology/psychiatry,seizures,8913,No-Effect
4685,BRD-K02407574,parbendazole,CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1,26596,Preclinical,tubulin polymerization inhibitor,TUBB,"","",7280,No-Effect
4687,BRD-K11851476,pardoprunox,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,6918525,Phase 3,dopamine receptor agonist|serotonin receptor agonist,DRD2|DRD3|DRD4|HTR1A|HTR7,"","",3363|1815|1813|3350|1814,No-Effect
4688,BRD-K13800121,parecoxib,CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1,119828,Launched,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief,4057,No-Effect
4690,BRD-K83597974,pargyline,CN(CC#C)Cc1ccccc1,4688,Launched,monoamine oxidase inhibitor,MAOA|MAOB,cardiology,hypertension,4128|4129,No-Effect
4691,BRD-K60585088,paricalcitol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1,5281104,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperthyroidism,1594,No-Effect
4694,BRD-K37991163,paroxetine,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,43815,Launched,selective serotonin reuptake inhibitor (SSRI),CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder,6530|6532|1128|1129|1131|1132|1133|3356,No-Effect
4698,BRD-K34851558,parthenolide-(-),C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|,5420805,Preclinical,NFkB pathway inhibitor,HDAC1,"","",3065,No-Effect
4699,BRD-K28120222,parthenolide-(alternate-stereo),C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|,7251185,Preclinical,NFkB pathway inhibitor,IKBKB|RELA,"","",5970|3551,No-Effect
4700,BRD-K59715032,pasireotide,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1,9941444,Launched,somatostatin receptor agonist,SSTR1|SSTR2|SSTR3|SSTR5,endocrinology,Cushing's syndrome|acromegaly,6752|6753|6755|6751,No-Effect
4703,BRD-K74514084,pazopanib,CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1,10113978,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS),10019|5156|2246|3815|5159|3791|2321|2260|2261|2324|3702|1436,No-Effect
4707,BRD-A29289453,PCA-4248,"COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|",6604734,Phase 1,platelet activating factor receptor antagonist,PTAFR,"","",5724,No-Effect
4708,BRD-K12867552,PCI-24781,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,11749858,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6,"","",3065|3066|8841|10013,No-Effect
4710,BRD-K71223042,PCI-29732,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1,22347110,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,No-Effect
4711,BRD-K88742110,PCI-34051,COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1,24753719,Preclinical,HDAC inhibitor,HDAC1|HDAC10|HDAC6|HDAC8,"","",3065|10013|55869|83933,No-Effect
4712,BRD-K52721684,PCO-400,CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|,129348,Phase 1,potassium channel activator,KCNJ8,"","",3764,No-Effect
4713,BRD-K49865102,PD-0325901,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,9826528,Phase 2,MEK inhibitor,MAP2K1,"","",5604,No-Effect
4714,BRD-A89337244,PD-102807,"CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|",92845316,Preclinical,acetylcholine receptor antagonist,CHRM4,"","",1132,Low (25%)
4715,BRD-K34657753,PD-118057,OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1,9864959,Preclinical,potassium channel activator,KCNH2,"","",3757,Low (25%)
4716,BRD-K34713073,PD-123319,CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C,5311345,Phase 1,angiotensin antagonist,AGTR2,"","",186,No-Effect
4717,BRD-K62456038,PD-128907,CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21,5311346,Preclinical,dopamine receptor agonist,DRD2|DRD3,"","",1813|1814,No-Effect
4718,BRD-K26603252,PD-153035,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,4705,Phase 1,EGFR inhibitor,EGFR|KDR,"","",1956|3791,Weak (50%)
4719,BRD-K13826399,PD-156707,COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1,9871594,Preclinical,endothelin receptor antagonist,EDNRA|EDNRB,"","",1909|1910,No-Effect
4720,BRD-K48735772,PD-158780,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,4707,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
4721,BRD-K12079898,PD-160170,CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O,9820766,Preclinical,neuropeptide receptor antagonist,NPY1R,"","",4886,No-Effect
4722,BRD-K97152684,PD-161570,CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl,5328135,Preclinical,FGFR inhibitor,FGFR1,"","",2260,Very Weak (35%)
4723,BRD-K93217218,PD-166285,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,5311382,Preclinical,SRC inhibitor,EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1,"","",9088|1956|5159|7465|2260|6714,Cyto
4724,BRD-K60984070,PD-166793,CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O,9887870,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,MMP13|MMP2|MMP3,"","",4313|4322|4314,No-Effect
4725,BRD-K47761761,PD-168077,Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N,3645619,Preclinical,dopamine receptor agonist,DRD2,"","",1813,No-Effect
4726,BRD-K17702546,PD-168393,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,4708,Preclinical,EGFR inhibitor,EGFR|ERBB2|SRC,"","",2064|6714|1956,Weak (50%)
4727,BRD-A82013137,PD-168568,Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|,9928335,Preclinical,dopamine receptor antagonist,DRD2|DRD4,"","",1813|1815,No-Effect
4728,BRD-K97764662,PD-173074,CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1,1401,Preclinical,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,"","",5156|5159|3791|2321|2260|2261|2324|2263|2264,Low (25%)
4729,BRD-K04426574,PD-173212,CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C,9916734,Preclinical,calcium channel blocker,CACNA1B,"","",774,No-Effect
4730,BRD-K05104363,PD-184352,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,6918454,Phase 2,MEK inhibitor,MAP2K1|MAP3K1|MAP3K2,"","",10746|5604|4214,No-Effect
4731,BRD-K88677950,PD-198306,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,9956637,Preclinical,MAP kinase inhibitor|MEK inhibitor,MAP2K1|MAP2K2,"","",5604|5605,No-Effect
4733,BRD-K82823804,PD-407824,Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1,4369491,Preclinical,PKC inhibitor,WEE1,"","",7465,No-Effect
4734,BRD-K77951111,PD-81723,Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C,122028,Preclinical,adenosine receptor agonist,ADORA1,"","",134,No-Effect
4735,BRD-K62810658,PD-98059,COc1cccc(c1N)-c1cc(=O)c2ccccc2o1,4713,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,"","",5600|5604|5578|6093|6446|207|6300|2932|6037|6198|1111|1432|5594|3932|5599,No-Effect
4736,BRD-K04032780,PD1-PDL-inhibitor-1,COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O,91663303,Preclinical,programmed death ligand inhibitor,CD274,"","",29126,No-Effect
4738,BRD-K38145871,PDE10-IN-1,Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1,72709059,Preclinical,phosphodiesterase inhibitor,PDE10A,"","",10846,Low (25%)
4739,BRD-K26358347,PDP-EA,CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1,69724031,Preclinical,FAAH activator,FAAH,"","",79152,No-Effect
4740,BRD-A14577621,peficitinib,"NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|",,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis,3716|3717|3718,No-Effect
4741,BRD-K55034111,pefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1,6919009,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,gastrointestinal infections|urethritis|gonorrhea|urinary tract infections,7153,Low (25%)
4742,BRD-K96436774,pelanserin,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,65435,Phase 2,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
4743,BRD-K08799216,pelitinib,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,6445562,Phase 2,EGFR inhibitor,EGFR,"","",1956,No-Effect
4746,BRD-K32842773,pemetrexed,Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1,135410875,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,ATIC|DHFR|GART|TYMS,oncology,non-small cell lung cancer (NSCLC)|mesothelioma,1719|2618|7298|471,Very Weak (35%)
4747,BRD-K31731454,pemirolast,Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O,57697,Launched,mediator release inhibitor,HRH1,pulmonary,asthma,3269,No-Effect
4749,BRD-K55705469,penbutolol,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,37464,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR1B,cardiology,hypertension,153|154|3350|3351,No-Effect
4751,BRD-K15409150,penfluridol,OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F,33630,Launched,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,8913,No-Effect
4756,BRD-K78789465,pentagastrin,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,9853654,Launched,CCK receptor agonist,CCKBR,gastroenterology,anacidity diagnostic|gastric hypersecretion diagnostic,887,No-Effect
4757,BRD-K13183738,pentamidine,NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1,4735,Launched,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,1787,Low (25%)
4759,BRD-K44942604,pentolinium,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,5850,Launched,cholinergic receptor antagonist,CHRNA10|CHRNA3|CHRNA4|CHRNB4,cardiology,hypertension,1136|1137|57053|1143,No-Effect
4760,BRD-K91543828,pentostatin,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|,439693,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA,hematologic malignancy,hairy cell leukemia,100,No-Effect
4761,BRD-K57569181,pentoxifylline,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,4740,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF,cardiology,claudication,134|135|136|5136|5137|5138|5139|5140|5141|5142|151|5143|5144|5145|5146|5147|5148|5149|5150|5151|5153|5152|5158|4907|8622|8654|7124|10846|27115,No-Effect
4764,BRD-K13571841,pepstatin,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,5478883,Preclinical,aspartic protease inhibitor,CTSB|CTSD|CTSL|REN,"","",147040|1514|1508|1509,No-Effect
4767,BRD-K99431849,peretinoin,CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O,6437836,Phase 3,retinoid receptor agonist,RXRA,"","",6256,No-Effect
4772,BRD-K60770992,pergolide,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,47811,Withdrawn,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,"","",3352|1815|1816|146|147|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,No-Effect
4773,BRD-A19633847,perhexiline,C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|,38988177,Launched,carnitine palmitoyltransferase inhibitor,CPT1A,cardiology,angina pectoris,1374,Strong (80%)
4774,BRD-A89082344,perifosine,CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|,148178,Phase 3,AKT inhibitor,AKT1,"","",207,No-Effect
4775,BRD-A13323580,perillyl-alcohol,"CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|",369312,Phase 2,apoptosis stimulant|farnesyltransferase inhibitor,FNTA,"","",2339,No-Effect
4776,BRD-K92731339,perindopril,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,40466996,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction|coronary artery disease (CAD),1636,No-Effect
4777,BRD-K00768353,perindoprilat,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O,72022,Phase 2,angiotensin converting enzyme inhibitor,ACE,"","",1636,No-Effect
4779,BRD-K85503079,perospirone,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12,115368,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia|bipolar disorder,1813|1814|1815,No-Effect
4780,BRD-K10995081,perphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,4748,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry|gastroenterology,schizophrenia|nausea|vomiting,801|3362|3363|3269|1812|1813|3356|3358,Weak (50%)
4782,BRD-K04643877,perzinfotel,OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O,6918236,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B,"","",2904|114787|2903,No-Effect
4783,BRD-A93477898,PETCM,"O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|",736879,Preclinical,caspase activator,CASP3,"","",836,No-Effect
4784,BRD-K67844266,pevonedistat,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,16720766,Phase 3,nedd activating enzyme inhibitor,NAE1|UBA3,"","",8883|9039,No-Effect
4785,BRD-K54519451,pexidartinib,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,25151352,Launched,tyrosine kinase inhibitor,CSF1R|FLT3|KIT,"","",2322|1436|3815,No-Effect
4786,BRD-K53405000,pexmetinib,Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C,24765037,Phase 1,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MAPK14|TEK,"","",1432|7010,No-Effect
4788,BRD-K31519811,PF-02545920,Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1,11581936,Phase 2,phosphodiesterase inhibitor,PDE10A,"","",10846,Low (25%)
4789,BRD-K07070922,PF-03049423,CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1,24963293,Phase 2,phosphodiesterase inhibitor,PDE5A,"","",8654,No-Effect
4791,BRD-K37764012,PF-03758309,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1,25227462,Phase 1,p21 activated kinase inhibitor,PAK4,"","",10298,No-Effect
4792,BRD-K68747584,PF-03814735,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21,51346455,Phase 1,Aurora kinase inhibitor,AURKA|AURKB,"","",9212|6790,No-Effect
4795,BRD-K73319509,PF-04217903,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,17754438,Phase 1,c-Met inhibitor,MET,"","",8731,No-Effect
4796,BRD-K54871792,PF-04418948,COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1,25114442,Phase 1,prostaglandin inhibitor,PTGER2,"","",5732,No-Effect
4797,BRD-K50031829,PF-04447943,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1,135564558,Phase 2,phosphodiesterase inhibitor,PDE9A,"","",5152,No-Effect
4798,BRD-K86816506,PF-04457845,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,24771824,Phase 2,FAAH inhibitor,FAAH,"","",79152,No-Effect
4799,BRD-K30550578,PF-04620110,Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|,,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,"","",8694,No-Effect
4800,BRD-K07310275,PF-04691502,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|,,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,"","",5290|2475,Weak (50%)
4801,BRD-K92435527,PF-04885614,CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1,65459349,Preclinical,voltage-gated sodium channel blocker,SCN10A,"","",6336,No-Effect
4802,BRD-K27755542,PF-04937319,CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1,46916694,Phase 2,glucokinase activator,GCK,"","",5871,No-Effect
4807,BRD-K02554563,PF-05190457,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,58438464,Phase 2,growth hormone secretagogue receptor inverse agonist,GHSR,"","",2693,No-Effect
4808,BRD-K07955840,PF-05212384,CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1,44516953,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,"","",5290|2475,No-Effect
4815,BRD-K83114366,PF-06447475,N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12,72706840,Preclinical,serine/threonine kinase inhibitor,LRRK2,"","",120892,No-Effect
4817,BRD-A23124853,PF-06463922,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|",78162481,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FES|ROS1,oncology,non-small cell lung cancer (NSCLC),6098|2242|238,No-Effect
4825,BRD-K31417912,PF-3274167,COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1,11683187,Phase 2,oxytocin receptor antagonist,AVPR1A|OXTR,"","",552|5021,No-Effect
4826,BRD-K68997413,PF-3845,FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1,25154867,Preclinical,FAAH inhibitor,FAAH,"","",79152,No-Effect
4828,BRD-K11821338,PF-429242,CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1,23661637,Preclinical,SREBP inhibitor,MBTPS1,"","",8720,Very Weak (35%)
4829,BRD-K93788137,PF-431396,CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O,11598628,Preclinical,focal adhesion kinase inhibitor,PTK2|PTK2B,"","",2185|5747,Cyto
4830,BRD-K14711741,PF-4708671,CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1,51371303,Preclinical,ribosomal protein inhibitor,RPS6KB1,"","",6198,No-Effect
4831,BRD-K03063480,PF-477736,Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O,135565545,Phase 1,CHK inhibitor,CHEK1|CHEK2,"","",11200|1111,No-Effect
4832,BRD-K43428468,PF-4800567,Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1,53472153,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,"","",1453|1454,No-Effect
4833,BRD-K78318619,PF-4981517,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,71315139,Preclinical,cytochrome P450 inhibitor,CYP3A4,"","",1576,No-Effect
4835,BRD-K40302533,PF-5274857,Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O,56956240,Preclinical,smoothened receptor antagonist,SMO,"","",54498,No-Effect
4836,BRD-K99545815,PF-562271,CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O,11713159,Phase 1,focal adhesion kinase inhibitor,PTK2|PTK2B,"","",2185|5747,No-Effect
4837,BRD-K79239947,PF-573228,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1,11612883,Preclinical,focal adhesion kinase inhibitor,CDK1|CDK2|CDK7|GSK3B|IKBKB,"","",2932|983|1017|1022|3551,No-Effect
4838,BRD-K96295391,PF-670462,Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1,11681588,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,"","",1453|1454,No-Effect
4839,BRD-K83213911,PF-750,O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1,25154868,Preclinical,FAAH inhibitor,FAAH,"","",79152,No-Effect
4840,BRD-K50865540,PF-8380,Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1,25265312,Preclinical,autotaxin inhibitor,ENPP2,"","",5168,No-Effect
4841,BRD-K18289362,PF-915275,Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1,23725123,Phase 1,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,"","",3290,No-Effect
4842,BRD-K13094524,PFI-1,COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1,71271629,Preclinical,bromodomain inhibitor,BRD4,"","",23476,Weak (50%)
4843,BRD-K61524559,PFI-3,Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1,78243717,Preclinical,bromodomain inhibitor,PBRM1|SMARCA4,"","",55193|6597,No-Effect
4844,BRD-K13106865,PFI-4,COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1,40642506,Preclinical,bromodomain inhibitor,BRPF1,"","",23774,No-Effect
4845,BRD-K95573441,PFK-015,O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1,25142799,Phase 1,phosphofructokinase inhibitor,PFKFB3,"","",5209,No-Effect
4846,BRD-K28010364,PFK-158,FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1,71730058,Phase 1,phosphofructokinase inhibitor,PFKFB3,"","",5209,Low (25%)
4848,BRD-A53813595,PGL5001,"N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|",76969933,Phase 2,JNK inhibitor,MAPK10|MAPK8|MAPK9,"","",5601|5602|5599,No-Effect
4849,BRD-K95880107,PH-797804,CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O,22049997,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK14,"","",5600|1432,No-Effect
4851,BRD-K48053228,PHA-568487,O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1,9932000,Preclinical,nicotinic receptor agonist,CHRNA7,"","",89832,No-Effect
4852,BRD-K95435023,PHA-665752,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,10461815,Preclinical,c-Met inhibitor,MET,"","",8731,No-Effect
4853,BRD-K09443272,PHA-680632,CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,11249084,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
4854,BRD-K50000283,PHA-767491,O=C1NCCc2[nH]c(cc12)-c1ccncc1,11715767,Preclinical,CDC inhibitor,CDK1|RPS6KB1,"","",6198|983,No-Effect
4855,BRD-K64800655,PHA-793887,CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,46191454,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK7|CDK9,"","",1025|983|1017|1019|1020|1022,No-Effect
4856,BRD-K60997853,PHA-848125,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,16718576,Phase 2,CDK inhibitor|growth factor receptor inhibitor,CDK2|CDK4|CDK7|NTRK1,"","",1017|4914|1019|1022,Cyto
4857,BRD-K00004222,PHCCC,"O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|",44572113,Preclinical,glutamate receptor agonist,GRM1|GRM4,"","",2914|2911,No-Effect
4859,BRD-K40905133,phenacemide,NC(=O)NC(=O)Cc1ccccc1,4753,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
4860,BRD-K38323065,phenacetin,CCOc1ccc(NC(C)=O)cc1,4754,Withdrawn,cyclooxygenase inhibitor,PTGS1,"","",5742,No-Effect
4861,BRD-K46937689,phenazone,Cc1cc(=O)n(-c2ccccc2)n1C,2206,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
4862,BRD-K76304753,phenazopyridine,Nc1ccc(\N=N\c2ccccc2)c(N)n1,,Launched,local anesthetic,SCN1A,infectious disease,urinary tract infections,6323,No-Effect
4863,BRD-K87024524,phenelzine,NNCCc1ccccc1,3675,Launched,monoamine oxidase inhibitor,ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,4128|4129|84706|6530|6531|6532|1798|2572|18|8639,No-Effect
4865,BRD-K56700933,phenethyl-isothiocyanate,S=C=NCCc1ccccc1,16741,Phase 2,anticancer agent,CYP2E1,"","",1571,No-Effect
4866,BRD-K11399644,phenformin,NC(N)=NC(=N)NCCc1ccccc1,8249,Withdrawn,AMPK activator,KCNJ8|PRKAA1,"","",5562|3764,No-Effect
4867,BRD-A33178345,phenindamine,"CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|",57086802,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold,3269,No-Effect
4868,BRD-K70592963,phenindione,O=C1C(C(=O)c2ccccc12)c1ccccc1,4760,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),79001,Low (25%)
4869,BRD-A23072235,pheniramine,CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|,667440,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269,No-Effect
4870,BRD-K76549667,phenol,Oc1ccccc1,996,Preclinical,"",CA1|CA12|CA14|CA2|CA4|CA9,otolaryngology,pharyngitis,768|771|23632|759|760|762,No-Effect
4871,BRD-K19227686,phenolphthalein,Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1,4764,Withdrawn,indicator dye,UGT1A9,"","",54600,No-Effect
4875,BRD-A67799922,phenoxybenzamine,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,657233,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|endocrinology,hypertension|pheochromocytoma,146|147|150|151|152,No-Effect
4877,BRD-A49838158,phenprocoumon,"CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|",54681533,Launched,vitamin K antagonist,VKORC1,hematology,thrombosis|pulmonary embolism (PE),79001,No-Effect
4878,BRD-K46580984,phenserine,CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21,192706,Phase 3,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,ACHE|BCHE,"","",43|590,No-Effect
4880,BRD-K90333595,phentolamine,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|,5775,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,endocrinology|cardiology,pheochromocytoma|hypertension,146|147|150|151|152,No-Effect
4885,BRD-K10843433,phenylbutazone,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,4781,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGIS|PTGS1|PTGS2,"","",5740|5742|5743,No-Effect
4886,BRD-K67102207,phenylbutyrate,OC(=O)CCCc1ccccc1,4775,Launched,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders,3065,No-Effect
4887,BRD-K73381542,phenylephrine,CNC[C@H](O)c1cccc(O)c1,6041,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,otolaryngology|gastroenterology|cardiology,nasal congestion|hemorrhoids|hypotension,146|147,Very Weak (35%)
4892,BRD-K55930204,phenytoin,O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1,1775,Launched,hydantoin antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
4893,BRD-K44400149,PhiKan-083,CCn1c2ccccc2c2cc(CNC)ccc12,4722579,Preclinical,p53 stabilizing agent,TP53,"","",7157,No-Effect
4894,BRD-K15563106,phloretin,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1,4788,Launched,sodium/glucose cotransporter inhibitor,AQP9|CLCN3|SLC23A1,"","",9962|1182|366,No-Effect
4895,BRD-K73756878,phlorizin,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,6072,Preclinical,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A11|SLC5A2|SLC5A3,"","",115584|6523|6524|6526,No-Effect
4897,BRD-K74558903,phortress,Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1,399465,Phase 1,aryl hydrocarbon receptor ligand,AHR,"","",196,No-Effect
4899,BRD-K07460388,PHP-501,On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1,46204221,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,"","",2561|2554|2566,No-Effect
4903,BRD-K76568384,PHTPP,Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1,11201035,Preclinical,estrogen receptor antagonist,ESR2,"","",2100,No-Effect
4904,BRD-K25650355,physostigmine,CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1,5983,Launched,acetylcholinesterase inhibitor|cholinesterase inhibitor,ACHE|BCHE,cardiology|neurology/psychiatry|ophthalmology|gastroenterology,hypotension|Alzheimer's disease|glaucoma|gastroparesis,43|590,No-Effect
4905,BRD-K76661572,phytonadione,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|,5284607,Launched,"",BGLAP|GGCX,hematology,vitamin K deficiency|anticoagulation reversal,632|2677,No-Effect
4907,BRD-K67868012,PI-103,Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,9884685,Preclinical,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,"","",22883|5290|2475|5291|5294|5591,Weak (50%)
4911,BRD-K75528696,PI4KIII-beta-inhibitor-1,COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C,71549093,Preclinical,PI4K inhibitor,PI4K2B,"","",55300,No-Effect
4913,BRD-K02750403,piboserod,CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1,177336,Phase 2,serotonin receptor antagonist,HTR2B|HTR4,"","",3360|106480180,No-Effect
4914,BRD-A71765060,picartamide,"CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|",76960918,Phase 2,H+/K+-ATPase inhibitor,ATP4A,"","",495,No-Effect
4915,BRD-K91509126,piceatannol,Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1,667639,Preclinical,SYK inhibitor,ATP5A1|ATP5B|ATP5C1|IRF3,"","",498|506|3661|509,No-Effect
4916,BRD-K47642186,piclamilast,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,154575,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,"","",5144|5141|5142|5143,No-Effect
4920,BRD-K67277431,picotamide,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,4814,Launched,thromboxane receptor antagonist|thromboxane synthase inhibitor,TBXA2R,hematology,thrombosis,6915,No-Effect
4921,BRD-A91822151,picrotin,"CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|",,Phase 2,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB,"","",8001|2741|2742|2743,No-Effect
4922,BRD-K36461289,picrotoxinin,CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,7098683,Preclinical,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,"","",8001|2741|2742|2743|9177|3359,No-Effect
4923,BRD-K57313110,pidolic-acid,OC(=O)[C@@H]1CCC(=O)N1,7405,Launched,"",ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA,dermatology,xerosis cutis,57830|10863|3537|6355|276|3060|7032|279|280|283|7422,No-Effect
4925,BRD-K66874953,pifithrin-alpha,Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N,4817,Preclinical,TP53 inhibitor,TP53,"","",7157,No-Effect
4926,BRD-K31792052,pifithrin-cyclic,Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1,443278,Preclinical,TP53 inhibitor,TP53,"","",7157,No-Effect
4927,BRD-K96799727,pifithrin-mu,NS(=O)(=O)C#Cc1ccccc1,327653,Preclinical,HSP inhibitor,HSPA1A|TP53,"","",7157|3303,Weak (50%)
4928,BRD-K30977212,PIK-293,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,53245636,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,No-Effect
4929,BRD-K50631926,PIK-294,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O,24905149,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,"","",5291|5294|22883,No-Effect
4930,BRD-K49371609,PIK-75,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,10275789,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,"","",22883|5290|5291|5294|5591,No-Effect
4931,BRD-K29395450,PIK-93,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO,6852167,Preclinical,PI3K inhibitor,PI4KB|PIK3C3|PIK3CG,"","",5289|5298|5294,Very Weak (35%)
4935,BRD-K85090592,pilocarpine,CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,5910,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology|cardiology,glaucoma|hypertension,1128|1129|1131|1132|1133,No-Effect
4936,BRD-K83245588,pilsicainide,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,4820,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,6331,No-Effect
4937,BRD-K48832421,PIM-1-Inhibitor-2,Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1,2765355,Preclinical,Pim kinase inhibitor,PIM1,"","",9361,No-Effect
4939,BRD-K83405785,pimavanserin,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,10071196,Launched,serotonin receptor inverse agonist,DRD2|HTR2A,neurology/psychiatry,Parkinson's Disease,3356|1813,Strong (80%)
4942,BRD-K01826269,pimobendan,"COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|",7120080,Launched,calcium sensitizer|phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139,No-Effect
4945,BRD-K01292756,pimozide,Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1,16362,Launched,dopamine receptor antagonist,CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2,neurology/psychiatry,Tourette's disorder,3744|801|3269|3757|150350|1812|1813|1814|1815|1816|3350|3356,No-Effect
4946,BRD-A43882281,pinacidil,"C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|",12428581,Launched,ATP channel activator|potassium channel activator,ABCC8|ABCC9,cardiology,hypertension,6833|10060,No-Effect
4948,BRD-A13175897,pinaverium,"COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|",73416161,Launched,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome,775,No-Effect
4950,BRD-A97701745,pindolol,"CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|",155030,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR2A|HTR2B,cardiology,hypertension,106480180|3350|153|154|3356,No-Effect
4951,BRD-K95598440,pindolol-(-),CC(C)NC[C@H](O)COc1cccc2[nH]ccc12,688095,Phase 2,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,"","",3350,No-Effect
4953,BRD-K94689771,pinocembrin,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,68071,Phase 2,cytochrome P450 inhibitor,CYP1B1,"","",1545,No-Effect
4954,BRD-K01826904,pioglitazone,CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|,29010894,Launched,insulin sensitizer|PPAR receptor agonist,PPARG|TRPM3,endocrinology,diabetes mellitus,80036|5468,No-Effect
4955,BRD-K26801045,pipamperone,NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1,4830,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A,neurology/psychiatry,schizophrenia,3269|1813|3350|3351|3352|3356,No-Effect
4956,BRD-A21544762,pipecuronium,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1 |a:5,7,8,11,13,18,20,22,25,&1:4|",50192,Launched,neuromuscular blocker,CHRM2|CHRM3|CHRNA2,neurology/psychiatry,anesthetic,1129|1131|1135,No-Effect
4958,BRD-A53561827,pipenzolate,"CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|",16048561,Launched,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms,1128,No-Effect
4962,BRD-K13249881,piperazine,C1CNCCN1,4837,Launched,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,2562,No-Effect
4964,BRD-A97479839,piperidolate,CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|,688565,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms,1128,No-Effect
4965,BRD-K59522102,piperine,O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1,638024,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB|TRPV1,"","",4128|4129|7442,No-Effect
4969,BRD-K00004560,pipotiazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,62867,Launched,dopamine receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,3356|1812|1813|3350,Low (25%)
4970,BRD-K48429278,pipotiazine-palmitate,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,37767,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,3356|1812|1813|3350,No-Effect
4971,BRD-K19456237,piracetam,NC(=O)CN1CCCC1=O,4843,Launched,acetylcholine receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,neurology/psychiatry,senile dementia,2890|2891|2892|2893,No-Effect
4972,BRD-K83794624,pirarubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,11296583,Launched,topoisomerase inhibitor,TOP2A,oncology,breast cancer,7153,No-Effect
4975,BRD-K89375097,pirenzepine,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,4848,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132|1133,No-Effect
4976,BRD-K87990216,piretanide,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,4849,Launched,glucocorticoid receptor agonist,SLC12A1|SLC12A2,cardiology,hypertension|edema,6557|6558,No-Effect
4977,BRD-K96862998,pirfenidone,Cc1ccc(=O)n(c1)-c1ccccc1,40632,Launched,TGF beta receptor inhibitor,FURIN|TNF,pulmonary,idiopathic pulmonary fibrosis (IPF),7124|5045,No-Effect
4978,BRD-K47936004,piribedil,C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,4850,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B,neurology/psychiatry,Parkinson's Disease|dizziness,1815|146|106480180|1813|150|1814|152|3350,Low (25%)
4979,BRD-K00004544,piricapiron,"CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|",5545745,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
4980,BRD-K01902415,pirinixic-acid,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,5694,Preclinical,PPAR receptor agonist,PPARA,"","",5465,No-Effect
4981,BRD-K01826702,pirlindole,Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|,667444,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,4128,No-Effect
4986,BRD-K01826746,piroxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|,54676228,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743,No-Effect
4987,BRD-K71977764,piroximone,CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1,55263,Phase 2,phosphodiesterase inhibitor,PDE3A,"","",5139,No-Effect
4990,BRD-K43978949,PIT,[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|,124334,Preclinical,purinergic receptor antagonist,P2RY1,"","",5028,No-Effect
4991,BRD-K75958547,pitavastatin,O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O,5282452,Launched,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,3156,Strong (80%)
4992,BRD-K21673112,pitolisant,Clc1ccc(CCCOCCCN2CCCCC2)cc1,9948102,Launched,histamine receptor antagonist,HRH3,"","",11255,Weak (50%)
4993,BRD-K62264492,pivagabine,CC(C)(C)C(=O)NCCCC(O)=O,68888,Launched,corticotropin releasing factor receptor antagonist,CRHR1|CRHR2,neurology/psychiatry,depression,1394|1395,No-Effect
4995,BRD-K20504455,pivanex,CCCC(=O)OCOC(=O)C(C)(C)C,60748,Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,"","",3065|3066|8841|55869,No-Effect
4997,BRD-K48304345,pixantrone,NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12,134019,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,non-Hodgkin lymphoma (NHL),7153,No-Effect
4998,BRD-K75958195,pizotifen,CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12,27400,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C,neurology/psychiatry,migraine headache,3356|3350|3358,No-Effect
4999,BRD-K11853856,PJ-34,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,4858,Preclinical,PARP inhibitor,EEF2|PARP1|PARP15|PARP3,"","",1938|10039|142|165631,No-Effect
5000,BRD-A41451487,PK-11195,"CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|",24839733,Phase 1,benzodiazepine receptor antagonist,TSPO,"","",706,No-Effect
5001,BRD-K04035716,PK-44,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12,46208486,Preclinical,dipeptidyl peptidase inhibitor,DPP4,"","",1803,No-Effect
5002,BRD-K44043890,PK-THPP,CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1,53464059,Preclinical,potassium channel blocker,KCNK9,"","",51305,No-Effect
5003,BRD-K10115470,PKI-166,C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1,6918403,Phase 1,EGFR inhibitor,EGFR,"","",1956,No-Effect
5004,BRD-A28467416,PKI-179,"O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|",76958312,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR,"","",2475,No-Effect
5006,BRD-K33240821,plerixafor,C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1,65015,Launched,CC chemokine receptor antagonist,ACKR3|CCR4|CXCR4,hematologic malignancy,non-Hodgkin lymphoma (NHL)|multiple myeloma,57472|7852|57007,No-Effect
5009,BRD-A20781140,plovamer-acetate,"N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|",6942100,Phase 2,"",TAT|TH|YARS|YARS2,"","",79969|51067|8565|7054,No-Effect
5011,BRD-K99149715,plurisin-1,O=C(NNc1ccccc1)c1ccncc1,225362,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,"","",6319,No-Effect
5012,BRD-K16478699,PLX4720,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,24180719,Preclinical,RAF inhibitor,BRAF|KDR,"","",673|3791,No-Effect
5014,BRD-K79294107,PLX647,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1,11545419,Preclinical,receptor tyrosine protein kinase inhibitor,CSF1R|KIT,"","",1436|3815,No-Effect
5015,BRD-K53723268,PLX8394,F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F,90116675,Phase 1/Phase 2,serine/threonine kinase inhibitor,BRAF,"","",673,No-Effect
5016,BRD-A74387232,PMPA,"OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|",11031538,Preclinical,glutamate receptor antagonist,FOLH1,"","",2346,No-Effect
5017,BRD-K71731651,PNU-120596,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,311434,Preclinical,acetylcholine receptor agonist,CHRNA7,"","",89832,No-Effect
5018,BRD-K81616657,PNU-142633,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,9845148,Phase 2,serotonin receptor agonist,HTR1D,"","",3352,No-Effect
5019,BRD-K04635846,PNU-177864,CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1,9887351,Preclinical,dopamine receptor antagonist,DRD3,"","",1814,No-Effect
5020,BRD-K16551401,PNU-22394,Cn1c2CCNCCc2c2ccccc12,27559,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C|MAOA|MAOB,"","",4128|4129|106480180|3356|3358,No-Effect
5021,BRD-K28863208,PNU-282987,Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2,9795278,Preclinical,cholinergic receptor agonist,CHRNA7,"","",89832,No-Effect
5023,BRD-K30707190,PNU-74654,Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1,9836739,Preclinical,beta-catenin inhibitor,CTNNB1|TCF4,"","",1499|6934,No-Effect
5024,BRD-K84507776,PNU-89843,Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1,154689,Preclinical,benzodiazepine receptor agonist,GABBR1,"","",10537,No-Effect
5026,BRD-K47869605,podophyllotoxin,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,10607,Launched,microtubule inhibitor|tubulin polymerization inhibitor,IGF1R|TOP2A|TUBA4A|TUBB,infectious disease,genital warts,3480|7153|7280|7277,Cyto
5029,BRD-K43236057,polydatin,OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,5281718,Phase 2,ICAM1 expression inhibitor,ICAM1,"","",3383,No-Effect
5030,BRD-A67531813,polyinosine,"O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|",138454308,Preclinical,immunostimulant,HPRT1|IMPDH2|PYGM,"","",3251|5837|3615,No-Effect
5032,BRD-A15739803,polythiazide,"CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",12876779,Launched,sodium/chloride cotransporter inhibitor,SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension,6559,No-Effect
5034,BRD-K44227013,ponatinib,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1,24826799,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL),106480993|7010|4067|5156|3815|3791|2322|2260|2261|2263|2264|25|6714|5979|3932,No-Effect
5035,BRD-K44030614,ponesimod,CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,"","",1901,No-Effect
5036,BRD-K06222852,posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O,468595,Launched,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,1576,No-Effect
5037,BRD-K46556543,potassium-canrenoate,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|",656615,Launched,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,4306,No-Effect
5040,BRD-K79803033,pozanicline,Cc1ncccc1OC[C@@H]1CCCN1,178052,Phase 2,acetylcholine receptor antagonist,CHRNA4|CHRNB2,"","",1137|1141,No-Effect
5041,BRD-K50010139,poziotinib,COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C,25127713,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB4,"","",2064|2066|1956,No-Effect
5042,BRD-K47598052,PP-1,Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C,1400,Preclinical,SRC inhibitor,HCK|RET,"","",5979|3055,No-Effect
5043,BRD-K81801188,PP-121,Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1,24905142,Preclinical,protein tyrosine kinase inhibitor,ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC,"","",22883|1956|5156|5290|2475|5291|5294|3791|3055|5591|25|6714,No-Effect
5044,BRD-K95785537,PP-2,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12,4878,Preclinical,SRC inhibitor,ABL1|LCK|RIPK2|SRC,"","",25|6714|3932|8767,No-Effect
5045,BRD-K87112191,PP242,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12,135565635,Preclinical,mTOR inhibitor,MTOR|PASK,"","",2475|27347,No-Effect
5046,BRD-K00312224,PPT,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,5040063,Preclinical,estrogen receptor agonist,ESR1,"","",2099,Strong (80%)
5047,BRD-K72514671,PPY-A,COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C,16750094,Preclinical,Abl kinase inhibitor,ABL1|BCR,"","",25|106480993,No-Effect
5048,BRD-K67537649,PQ-401,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,9549305,Preclinical,IGF-1 inhibitor,IGF1R,"","",3480,No-Effect
5050,BRD-A41304429,practolol,"CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|",6918924,Withdrawn,adrenergic receptor antagonist,ADRB1,"","",153,No-Effect
5052,BRD-A74914197,pralatrexate,"Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|",11155808,Launched,dihydrofolate reductase inhibitor,DHFR,hematologic malignancy,peripheral T-cell lymphoma (PTCL),1719,Strong (80%)
5053,BRD-K84281997,pralidoxime,C[n+]1ccccc1\C=N\O,4884,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,critical care,organophosphate poisoning,43|590,No-Effect
5054,BRD-K24221957,pralidoxime-chloride,C[n+]1ccccc1CN=O,54072659,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,pulmonary,respiratory depression,43|590,No-Effect
5056,BRD-K06388322,pramipexole,CCCN[C@H]1CCc2nc(N)sc2C1,119570,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease,3352|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,No-Effect
5059,BRD-A68083442,pranidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|",29986494,Phase 2,calcium channel blocker,CACNA1C,"","",775,No-Effect
5060,BRD-K97045029,pranlukast,O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1,4887,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF,pulmonary,bronchospasm|asthma,4583|3567|10800|57105|7124|6037|4790,No-Effect
5063,BRD-A83029242,prasugrel,"CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|",51698431,Launched,purinergic receptor antagonist,P2RY12,cardiology,myocardial infarction|acute coronary syndrome (ACS),64805,No-Effect
5064,BRD-K46209126,pravadoline,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12,56463,Preclinical,cyclooxygenase inhibitor,CNR1|CNR2,"","",1268|56142,No-Effect
5065,BRD-K60511616,pravastatin,"CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|",54687,Launched,HMGCR inhibitor,HMGCR|SLCO1B1,endocrinology|cardiology,hypercholesterolemia|myocardial infarction|hyperlipidemia,3156|10599,No-Effect
5067,BRD-K49111258,prazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1,4893,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7,cardiology,hypertension,81033|3757|146|147|150|151|152|90134,No-Effect
5068,BRD-K57304726,PRE-084,O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1,126402,Preclinical,sigma receptor agonist,SIGMAR1,"","",10280,Low (25%)
5069,BRD-K02908048,preclamol,CCCN1CCC[C@@H](C1)c1cccc(O)c1,202478,Phase 2,dopamine receptor agonist,DRD2,"","",1813,No-Effect
5070,BRD-A93963402,prednicarbate,"CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|",,Launched,phospholipase activator,PLA2G1B,dermatology|ophthalmology|neurology/psychiatry,eczema|contact dermatitis|itching,5319,No-Effect
5071,BRD-A27887842,prednisolone,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",5755,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|SERPINA6,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis,4306|2908|866,No-Effect
5072,BRD-K45664306,prednisolone-acetate,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|",5834,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis,2908,No-Effect
5074,BRD-A78391468,prednisolone-hemisuccinate,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",656804,Preclinical,glucocorticoid receptor agonist,NR3C1,"","",2908,No-Effect
5075,BRD-K00003654,prednisolone-sodium-phosphate,"[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|",72078,Launched,glucocorticoid receptor agonist,NR3C1,allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology,allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis,2908,No-Effect
5077,BRD-K85883481,prednisone,"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|",5865,Launched,glucocorticoid receptor agonist,HSD11B1|NR3C1,endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry,congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis,3290|2908,No-Effect
5078,BRD-K43880410,pregnenolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|,8955,Launched,glutamate receptor modulator,SULT2B1,rheumatology,rheumatoid arthritis,6820,No-Effect
5079,BRD-A35912562,pregnenolone-succinate,"CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|",,Preclinical,GABA receptor negative allosteric modulator,CYP17A1,"","",1586,No-Effect
5080,BRD-K46290096,preladenant,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,10117987,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
5083,BRD-K96671969,pretomanid,[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1,456199,Launched,nitric oxide donor,FASN,"","",2194,No-Effect
5086,BRD-K01825595,prilocaine,"CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|",6603976,Launched,local anesthetic,SCN5A,neurology/psychiatry,anesthetic,6331,Low (25%)
5087,BRD-K15318909,PRIMA1,OCC1(CO)N2CCC(CC2)C1=O,322968,Preclinical,TP53 inhibitor,ACHE,"","",43,No-Effect
5089,BRD-K32247306,primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,4909,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,2560|2561|2562|2563|2564|2565|2566|2567|2568|11280|6323|6326|6328|6329|6331|6332|6334|6335|6336|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559,No-Effect
5090,BRD-K87316765,prinaberel,Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1,656954,Phase 2,estrogen receptor agonist,ESR2|NCOA1,"","",8648|2100,No-Effect
5092,BRD-K01662324,priralfinamide,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,5745207,Phase 3,sodium channel blocker,CACNA1B,"","",774,No-Effect
5099,BRD-K46317332,proadifen,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,4910,Preclinical,nitric oxide synthase inhibitor,NOS1,"","",340719,Strong (80%)
5100,BRD-K95237249,probenecid,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O,4911,Launched,uricosuric blocker,PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1,nephrology|rheumatology,hyperuricemia|gout,9376|9356|24145|55867|53919,No-Effect
5101,BRD-K72029282,probucol,CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,4912,Launched,atherogenesis inhibitor,ABCA1|ABCB11|CES1,cardiology,coronary artery disease (CAD),1066|19|8647,No-Effect
5102,BRD-K75089421,procainamide,CCN(CC)CCNC(=O)c1ccc(N)cc1,4913,Launched,sodium channel blocker,DNMT1|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT),1786|6331,No-Effect
5103,BRD-K24616672,procaine,CCN(CC)CCOC(=O)c1ccc(N)cc1,4914,Launched,HMGCR inhibitor,CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3,neurology/psychiatry,anesthetic,4128|4129|3778|3779|3780|3781|3782|3783|6336|6531|1135|27345|6261|27094|6262|116443|3359,No-Effect
5105,BRD-K78666826,procaterol,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,688561,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154,No-Effect
5106,BRD-K19352500,prochlorperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,4917,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4,gastroenterology,nausea|vomiting,1812|1813|1814|1815,Strong (80%)
5111,BRD-A16311756,profenamine,CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|,667534,Launched,butyrylcholinesterase inhibitor|cholinergic receptor antagonist,CHRM1,neurology/psychiatry,Parkinson's Disease,1128,Weak (50%)
5112,BRD-K68408467,proflavine-hemisulfate,Nc1ccc2cc3ccc(N)cc3nc2c1,7099,Phase 2,topical anesthetic,F2,"","",2147,No-Effect
5113,BRD-K64994968,progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|,5994,Launched,progesterone receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5,obstetrics/gynecology|endocrinology,infertility|amenorrhea,117155|7224|1586|2099|347732|4306|378807|117144|5241|4986,Weak (50%)
5114,BRD-A19458515,proglumetacin,"CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|",76965948,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,No-Effect
5115,BRD-K01826553,proglumide,CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|,6603906,Withdrawn,CCK receptor antagonist,CCKAR|CCKBR,"","",886|887,No-Effect
5116,BRD-K28183345,proguanil,CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1,6178111,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,1719,No-Effect
5118,BRD-K06980535,promazine,CN(C)CCCN1c2ccccc2Sc2ccccc12,4926,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C,neurology/psychiatry,schizophrenia,3269|1128|1129|1131|1132|1133|146|147|1812|1813|1814|1815|3356|3358,Weak (50%)
5119,BRD-K75097983,promestriene,CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC,9883915,Launched,estrogen receptor agonist,ESR1,endocrinology,androgenetic alopecia,2099,No-Effect
5120,BRD-A46335897,promethazine,CC(CN1c2ccccc2Sc2ccccc12)N(C)C,89044377,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|allergy,sedative|allergic rhinitis,3269,Very Weak (35%)
5122,BRD-K54496168,propacetamol,CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,68865,Launched,cyclooxygenase inhibitor,PTGS2,endocrinology|neurology/psychiatry,fever|pain relief,5743,No-Effect
5123,BRD-K01826541,propafenone,"CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|",184819,Launched,antiarrhythmic,ADRB1|ADRB2|KCNA5|KCNH2,cardiology,atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias,153|154|3741|3757,No-Effect
5124,BRD-K53382462,propagermanium,OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O,83030,Launched,CCR agonist|interferon receptor agonist,CCR2,infectious disease,hepatitis B,729230,No-Effect
5125,BRD-K90885812,propantheline,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C,4934,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132,No-Effect
5127,BRD-K59273480,propentofylline,CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12,4938,Launched,adenosine reuptake inhibitor|phosphodiesterase inhibitor,PDE1A,neurology/psychiatry,stroke,5136,No-Effect
5128,BRD-K14821965,propidium-iodide,CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12,4939,Preclinical,"",ACHE,"","",43,No-Effect
5130,BRD-K91244729,propiverine,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,4942,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence,1128,Weak (50%)
5131,BRD-K82255054,propofol,CC(C)c1cccc(C(C)C)c1O,4943,Launched,benzodiazepine receptor agonist,FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A,neurology/psychiatry,anesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|79152|6326|6329|55879|2554|2555|2556|2557|2558|2559,No-Effect
5134,BRD-A10070317,propranolol,CC(C)NCC(O)COc1cccc2ccccc12,62882,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology|neurology/psychiatry,hypertension|angina pectoris|migraine headache,153|154,No-Effect
5135,BRD-K92830582,propranolol-(R),CC(C)NC[C@@H](O)COc1cccc2ccccc12,21138,Preclinical,adrenergic receptor antagonist,ADRB2|ADRB3,"","",154|155,Cyto
5136,BRD-K13994703,propranolol-(S),CC(C)NC[C@H](O)COc1cccc2ccccc12,91536,Preclinical,adrenergic receptor antagonist,ADRB1|HTR1A|HTR5A|SLC10A1,"","",153|6554|3350|3361,No-Effect
5141,BRD-K48168960,propylthiouracil,CCCc1cc(=O)[nH]c(=S)[nH]1,657298,Launched,thyroid peroxidase inhibitor,DIO1|TPO,endocrinology,hyperthyroidism|Grave's disease|goiter,7066|11083,No-Effect
5143,BRD-K54339150,proquazone,CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1,31508,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743,Low (25%)
5146,BRD-K00003716,protirelin,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,638678,Launched,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,7201,No-Effect
5147,BRD-K26813314,protoporphyrin-IX,Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C,,Preclinical,heme oxygenase inhibitor,HMOX1,"","",3162,Weak (50%)
5148,BRD-K42098891,protriptyline,CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|,4976,Launched,tricyclic antidepressant,SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532,No-Effect
5150,BRD-K77171813,proxyfan,C(COCc1ccccc1)Cc1cnc[nH]1,6421522,Preclinical,histamine receptor modulator,HRH3,"","",11255,No-Effect
5151,BRD-K79116891,proxymetacaine,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,4935,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,anesthetic,6336|6331,No-Effect
5153,BRD-K25835157,PRT062070,CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1,44595079,Phase 2/Phase 3,JAK inhibitor|SYK inhibitor,SYK,"","",6850,No-Effect
5154,BRD-K53734668,PRT062607,N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1,44462758,Phase 2,SYK inhibitor,FGR|MAP3K9|SYK,"","",6850|2268|4293,Strong (80%)
5155,BRD-K32456483,PRT4165,O=C1C(=Cc2cccnc2)C(=O)c2ccccc12,207893,Preclinical,polycomb repressive complex inhibitor,PRC1,"","",9055,No-Effect
5156,BRD-K33681278,prucalopride,COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12,3052762,Launched,serotonin receptor agonist,HTR4,gastroenterology,constipation,3360,No-Effect
5158,BRD-K43837174,pruvanserin,Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1,6433122,Phase 2,serotonin receptor antagonist,HTR2A|HTR2C,"","",3356|3358,No-Effect
5160,BRD-K16757695,PRX-08066,Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N,11502243,Phase 2,serotonin receptor antagonist,HTR2B,"","",106480180,No-Effect
5161,BRD-K99092662,PS178990,Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N,9882972,Phase 1,androgen receptor modulator,AR,"","",367,No-Effect
5162,BRD-K71266197,PSB-06126,Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O,25124826,Preclinical,NTPDase inhibitor,ENTPD3,"","",956,No-Effect
5164,BRD-K49027941,PSB-1115,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O,5311479,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,"","",136|140|134,No-Effect
5165,BRD-K00004243,PSB-36,"[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|",,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
5166,BRD-K05419687,PSB-603,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1,44185871,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
5170,BRD-K25524093,PSN-375963,CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1,2875918,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,"","",139760,No-Effect
5171,BRD-K33502629,PSNCBAM-1,Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1,11560249,Preclinical,cannabinoid receptor modulator,CNR1,"","",1268,Cyto
5172,BRD-K47264279,psoralen,O=c1ccc2cc3ccoc3cc2o1,6199,Launched,"",MAOA|MAOB,dermatology,psoriasis|eczema|vitiligo,4128|4129,No-Effect
5173,BRD-K20850787,PT-2385,CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12,91754484,Phase 1,hypoxia inducible factor inhibitor,EPAS1,"","",2034,No-Effect
5176,BRD-K92870997,pterostilbene,COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1,5281727,Phase 2/Phase 3,cyclooxygenase inhibitor|PPAR receptor agonist,PTGS2,"","",5743,No-Effect
5177,BRD-K36529613,PU-H71,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,9549213,Phase 1,HSP inhibitor,HSP90AA1,"","",3320,Strong (80%)
5179,BRD-K44164034,pumosetrag,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,154104,Phase 2,serotonin receptor agonist,HTR3A|HTR4,"","",3360|3359,No-Effect
5180,BRD-K73397362,purmorphamine,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12,5284329,Preclinical,smoothened receptor agonist,SMO,"","",54498,No-Effect
5181,BRD-K36007650,puromycin,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,439530,Preclinical,protein synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,"","",23521|140801|6147|9349|4809|6122|51121|51187|6167|6132|6135|6138|6143,No-Effect
5182,BRD-K50836978,purvalanol-A,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,456214,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC,"","",1456|6195|983|1017|6714|1019|1020,No-Effect
5183,BRD-K41564320,purvalanol-B,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1,448991,Preclinical,tyrosine kinase inhibitor,CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2,"","",6733|5595|1017|5594|1019|1020,No-Effect
5184,BRD-K75282878,putrescine,NCCCCN,1045,Phase 2,tissue transglutaminase inhibitor,AMD1|KCNJ4|ODC1,"","",3761|89874|262,No-Effect
5185,BRD-A56592690,PX-12,"CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|",86308851,Phase 2,thioredoxin inhibitor,CNR1|TXN,"","",1268|25828,No-Effect
5191,BRD-K28667793,pyrazinamide,NC(=O)c1cnccn1,1046,Launched,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis,2194,No-Effect
5193,BRD-K01567962,pyrazolanthrone,O=C1c2ccccc2-c2[nH]nc3cccc1c23,8515,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK,"","",5601|5602|9479|7272|5599,No-Effect
5194,BRD-K42607789,pyrazoloacridine,COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O,,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,"","",7153|7150,No-Effect
5196,BRD-K76204040,pyridoxal,Cc1ncc(CO)c(C=O)c1O,1050,Launched,"",PDXK,neurology/psychiatry,epilepsy,8566,No-Effect
5199,BRD-K14349461,pyridoxine,Cc1ncc(CO)c(CO)c1O,1054,Launched,vitamin B,DDC|PDXK,metabolism,vitamin B6 deficiency,1644|8566,Low (25%)
5200,BRD-K88429204,pyrimethamine,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,4993,Launched,dihydrofolate reductase inhibitor,DHFR|SLC47A1,infectious disease,malaria,55244|1719,No-Effect
5202,BRD-K16136380,pyrithione-zinc,O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1,,Launched,ATP synthase inhibitor,KCNQ1|KCNQ2|KCNQ4|KCNQ5,dermatology,dandruff|cosmetic,3784|3785|9132|56479,Strong (80%)
5207,BRD-K11663430,pyroxamide,ONC(=O)CCCCCCC(=O)Nc1cccnc1,4996,Phase 1,HDAC inhibitor,HDAC1,"","",3065,No-Effect
5208,BRD-K80970344,pyrrolidine-dithiocarbamate,SC(=S)N1CCCC1,65351,Preclinical,NFkB pathway inhibitor,HSD11B1|RELA,"","",3290|5970,No-Effect
5209,BRD-K39479472,pyrvinium-pamoate,CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1,5281035,Launched,androgen receptor antagonist,AR,infectious disease,pinworm,367,No-Effect
5212,BRD-K63631219,quazinone,CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|,135511466,Phase 2,phosphodiesterase inhibitor,PDE3A|PDE3B,"","",5139|5140,No-Effect
5213,BRD-K97399794,quercetin,Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,5280343,Launched,polar auxin transport inhibitor,ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1,neurology/psychiatry|allergy,fatigue|allergic rhinitis|drowsiness,26275|5294|3055|9262|9361|498|133688|506|509,Very Weak (35%)
5214,BRD-K68867920,quetiapine,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|,5002,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2,neurology/psychiatry,schizophrenia|bipolar disorder,6530|146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3355|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133,No-Effect
5215,BRD-K39503511,quiflapon,CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,60923,Phase 2,leukotriene synthesis inhibitor,ALOX5|ALOX5AP,"","",240|241,No-Effect
5216,BRD-K02995728,quinagolide,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,3086401,Launched,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia,1813,No-Effect
5217,BRD-K72222507,quinapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,54892,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|angioedema,1636,No-Effect
5218,BRD-K42317111,quinaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,107994,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|angioedema,1636,No-Effect
5219,BRD-K13261168,quinelorane,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12,57242,Phase 3,dopamine receptor agonist,DRD2|DRD3,"","",1813|1814,Very Weak (35%)
5220,BRD-K63794707,quinestrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C,9046,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology,menopause,2099|2100,No-Effect
5222,BRD-K59632282,quinidine,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,441074,Launched,sodium channel blocker,KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4,infectious disease|cardiology,malaria|atrial fibrillation (AF)|ventricular arrhythmias,3741|3756|3757|9424|3775|222962|6331|27133|3743,Strong (80%)
5223,BRD-K07940445,quinine,COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,3034034,Launched,hemozoin biocrystallization inhibitor,GP9|KCNB2|KCNN4|SLC29A4,infectious disease,malaria,9312|3783|222962|2815,No-Effect
5226,BRD-K26548821,quinpirol-(-),CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12,54562,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C,"","",1815|1812|1813|3350|1814|106480180|3356|3358,No-Effect
5227,BRD-K77925998,quipazine,C1CN(CCN1)c1ccc2ccccc2n1,5011,Preclinical,serotonin receptor agonist,HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4,"","",3362|6532|106480180|3350|3352|9177|3356|3358|3359,No-Effect
5228,BRD-K93918653,quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,24889392,Phase 3,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET,"","",5156|5159|3815|2322|5979|1436,No-Effect
5230,BRD-K56596464,QX-314,CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,3925,Preclinical,sodium channel blocker,MAPK14|TGFBR1,"","",1432|7046,No-Effect
5233,BRD-K96418224,R-1485,Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1,11689373,Phase 1,serotonin receptor antagonist,HTR6,"","",3362,No-Effect
5235,BRD-K83904070,R-268712,Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1,11703284,Preclinical,serine/threonine kinase inhibitor,TGFBR1,"","",7046,No-Effect
5236,BRD-K14870255,R-428,Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1,46215462,Phase 2,AXL kinase inhibitor,AXL,"","",558,Strong (80%)
5237,BRD-K54665485,R-59022,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1,3012,Preclinical,diacylglycerol kinase inhibitor|protein kinase inhibitor,DGKA,"","",1606,No-Effect
5238,BRD-K15588452,R-96544,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,10668211,Preclinical,serotonin receptor antagonist,HTR2A,"","",3356,No-Effect
5239,BRD-K23902832,R112,Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1,9904854,Phase 1,SYK inhibitor,SYK,"","",6850,No-Effect
5241,BRD-K20285085,R406,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC,11213558,Phase 1,SYK inhibitor,RET|SYK,"","",6850|5979,No-Effect
5242,BRD-K52233191,R547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,6918852,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK7,"","",1017|1019|1022|983,Cyto
5243,BRD-K01826765,rabeprazole,COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|,9906855,Launched,ATPase inhibitor|gastrin inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome,495,No-Effect
5244,BRD-A11069678,rac-BHFF,"CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|",7023847,Preclinical,GABA receptor positive allosteric modulator,GABBR1,"","",10537,No-Effect
5245,BRD-A08187463,racecadotril,"CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|",60561,Launched,enkephalinase inhibitor,MME,gastroenterology,diarrhea,4321,No-Effect
5246,BRD-K04111260,raclopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,3033769,Launched,dopamine receptor antagonist,DRD2|DRD3|HTR1A,"","",1813|1814|3350,No-Effect
5249,BRD-K13394247,radafaxine,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,9795056,Phase 2,dopamine-norepinephrine reuptake inhibitor,SLC6A3,"","",6531,No-Effect
5253,BRD-K93123848,RAF265,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,11656518,Phase 2,RAF inhibitor|VEGFR inhibitor,BRAF,"","",673,No-Effect
5256,BRD-K63828191,raloxifene,Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1,5035,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer,2099|2100,Very Weak (35%)
5258,BRD-K08151102,raltitrexed,CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,135400182,Launched,thymidylate synthase inhibitor,FPGS|TYMS,oncology,mesothelioma,7298|2356,No-Effect
5259,BRD-K08586861,ramatroban,OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,123879,Launched,prostanoid receptor antagonist,PTGDR2|TBXA2R,cardiology|pulmonary,coronary artery disease (CAD)|asthma,6915|11251,Low (25%)
5260,BRD-K28761891,ramelteon,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,208902,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,insomnia,4544|4543,Low (25%)
5262,BRD-K89348303,ramipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O,6992028,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
5263,BRD-K85046107,ramosetron,Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12,135418340,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting|irritable bowel syndrome,3359,No-Effect
5264,BRD-K50489389,ranirestat,Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O,153948,Phase 3,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
5265,BRD-K30816563,ranitidine,CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1,9883333,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn,1665,No-Effect
5266,BRD-K01825102,ranolazine,COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|,13560750,Launched,sodium channel blocker,SCN10A|SCN9A,cardiology,chronic stable angina,6336|6335,No-Effect
5268,BRD-K58114536,rasagiline,C#CCN[C@@H]1CCc2ccccc12,3052776,Launched,monoamine oxidase inhibitor,BCL2|MAOB,neurology/psychiatry,Parkinson's Disease,4129|596,No-Effect
5269,BRD-K77474816,rauwolscine,COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,643606,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B,"","",3352|106480180|150|3351|152|151|3354,No-Effect
5270,BRD-K86309810,ravoxertinib,Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1,71727581,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,MAPK1|MAPK3,"","",5594|5595,No-Effect
5272,BRD-A67036568,RBC8,"COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|",,Preclinical,Ral GTPase inhibitor,RALA|RALB,"","",5898|5899,No-Effect
5273,BRD-A15909516,rebamipide,"OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|",969464,Launched,free radical scavenger,FPR1,gastroenterology,peptic ulcer disease (PUD)|gastritis,2357,No-Effect
5274,BRD-K76694128,rebastinib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1,25066467,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,"","",106480993|4067|3055|2322|25|6714|2268,No-Effect
5275,BRD-K77224738,reboxetine,"CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|",127151,Launched,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression,6530,No-Effect
5276,BRD-K84924479,Rec-15/2615,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C,9891980,Phase 2,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
5277,BRD-K85751432,refametinib,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,44182295,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,"","",5604|5605,No-Effect
5278,BRD-K00003609,regadenoson,CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,219024,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,radiology,myocardial perfusion imaging (MPI),136|140|134|135,Weak (50%)
5279,BRD-K16730910,regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,11167602,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST),5600|673|7010|5156|3815|5159|2444|3791|1969|2321|4914|2260|2324|6037|4921|25|2263|5979,No-Effect
5280,BRD-K96720755,relcovaptan,COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl,60943,Phase 2,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,"","",552|553|554|5021,No-Effect
5283,BRD-A36074203,remacemide,C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|,760423,Phase 3,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
5285,BRD-K89413285,remimazolam,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|,9867812,Phase 3,benzodiazepine receptor agonist,GABBR1,"","",10537,No-Effect
5286,BRD-K75349868,remodelin,N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1,44442376,Preclinical,transferase inhibitor,NAT10,"","",55226,No-Effect
5287,BRD-K54094468,remoxipride,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,54477,Withdrawn,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR2A|SIGMAR1,"","",10280|1813|1814|1815|3356,No-Effect
5288,BRD-K82846253,repaglinide,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O,65981,Launched,insulin secretagogue,ABCC8|KCNJ11|PPARG,endocrinology,diabetes mellitus,6833|5468|3767,Low (25%)
5289,BRD-K58486055,reparixin,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O,9838712,Phase 3,CC chemokine receptor antagonist,CXCR1|CXCR2,"","",3577|3579,No-Effect
5291,BRD-K80480517,repsox,Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1,449054,Preclinical,TGF beta receptor inhibitor,TGFBR1,"","",7046,Low (25%)
5292,BRD-K61567297,resatorvid,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|,11703255,Phase 3,toll-like receptor inhibitor,TLR4,"","",7099,No-Effect
5293,BRD-K95921201,reserpine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,5770,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,cardiology,hypertension,6570|6571,No-Effect
5295,BRD-K76210423,resiquimod,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,159603,Phase 3,toll-like receptor agonist,TLR7|TLR8,"","",51284|51311,No-Effect
5297,BRD-K28822270,resminostat,CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1,11609955,Phase 2,HDAC inhibitor,HDAC1|HDAC3|HDAC6|HDAC8,"","",3065|8841|55869|10013,No-Effect
5298,BRD-K74190368,resorcinol,Oc1cccc(O)c1,5054,Launched,phosphodiesterase inhibitor,CA12|CA14|CA2|PTGS1,dermatology,acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis,23632|760|771|5742,No-Effect
5300,BRD-K80738081,resveratrol,Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1,445154,Launched,cytochrome P450 inhibitor|SIRT activator,CSNK2A1|NQO2|PTGS1|PTGS2,"","",5743|1459|5742|4835,No-Effect
5303,BRD-K67935717,retaspimycin,"CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|",25169033,Phase 3,HSP inhibitor,HSP90AA1,"","",3320,Weak (50%)
5305,BRD-K22429181,retinol,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|,445354,Launched,retinoid receptor ligand,ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG,dermatology,cosmetic|acne vulgaris (AV)|keratosis,6017|9227|50700|7182|10901|8854|9249|51109|5926|57665|5959|145226|1869|112724|216|220|54884|6256|6257|6258|6010,No-Effect
5308,BRD-A68281735,REV-5901,"CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|",40428144,Phase 2,leukotriene receptor antagonist|lipoxygenase inhibitor,ALOX5,"","",240,No-Effect
5309,BRD-A51497544,revaprazan,"C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|",40462255,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,gastritis,495,No-Effect
5311,BRD-K79700588,reversan,O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1,2298706,Preclinical,MRP inhibitor,ABCC1,"","",4363,No-Effect
5312,BRD-K77286328,reversine,C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12,210332,Preclinical,Aurora kinase inhibitor,AURKB|INCENP|MAP2K1,"","",5604|3619|9212,No-Effect
5314,BRD-K89391146,RG108,OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,702558,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3B,"","",1786|1789,No-Effect
5315,BRD-K32942258,RG1530,"COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|",,Phase 1,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2,"","",2260|2263,No-Effect
5316,BRD-K02389548,RG2833,Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N,56654642,Phase 1,HDAC inhibitor,HDAC1|HDAC3,"","",3065|8841,No-Effect
5317,BRD-K22024824,RG4733,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O,49867930,Phase 2,gamma secretase inhibitor,PSEN1,"","",5663,No-Effect
5318,BRD-K13178532,RG7112,CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|,57406853,Phase 1,MDM inhibitor,MDM2,"","",4193,No-Effect
5321,BRD-K20986415,RGB-286638,COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1,11285002,Phase 1,CDK inhibitor,CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9,"","",1025|5601|3717|6885|2322|2932|983|1017|1018|1019|1020|1021|1022,No-Effect
5322,BRD-K61688984,RGFP966,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,56650312,Preclinical,HDAC inhibitor,HDAC3,"","",8841,No-Effect
5324,BRD-K56047318,RHC-80267,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,5063,Preclinical,triacylglycerol lipase inhibitor,DAGLA|DAGLB,"","",221955|747,No-Effect
5325,BRD-K27335680,rhein,OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,10168,Phase 1,"",HSP90AA1,"","",3320,No-Effect
5326,BRD-K67772619,rheochrysidin,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,10639,Preclinical,protein tyrosine kinase inhibitor,PTPN1,"","",5770,No-Effect
5328,BRD-K79555887,RI-1,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|,1074953,Preclinical,"",RAD51,"","",5888,No-Effect
5329,BRD-K60369935,ribavirin,NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,37542,Launched,antiviral,ADK|ENPP1|IMPDH1|IMPDH2|NT5C2,infectious disease,hepatitis C,22978|132|5167|727833|3615,No-Effect
5331,BRD-K36788280,ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1,44631912,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021,No-Effect
5332,BRD-K92760278,riboflavin,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,493570,Launched,vitamin B,BLVRB|RFK,gastroenterology,jaundice,55312|645,No-Effect
5333,BRD-K09229706,riboflavin-5-phosphate-sodium,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C,643976,Launched,"",BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1,"","",55163|645|60490|51179|1806|340719|55312|6446|7417|8986|54363|1723,Very Weak (35%)
5335,BRD-K55188888,ribostamycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,33042,Launched,bacterial 30S ribosomal subunit inhibitor,P4HB,infectious disease,human immunodeficiency virus (HIV-1),5034,No-Effect
5337,BRD-K33682646,ricinoleic-acid,CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O,643684,Launched,prostanoid receptor agonist,PTGER3,"","",5733,No-Effect
5340,BRD-K01507359,rifampin,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|",135925261,Launched,RNA polymerase inhibitor,NR1I2|SLCO1A2|SLCO1B1|SLCO1B3,infectious disease,tuberculosis|meningitis,8856|28234|6579|10599,No-Effect
5341,BRD-K38512030,rifamycin,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|",5282048,Launched,DNA directed RNA polymerase inhibitor,SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1,infectious disease,tuberculosis|leprosy,28234|6579|11309|10599,No-Effect
5343,BRD-K28346421,rifapentine,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|",136238508,Launched,RNA polymerase inhibitor,CYP2C8|CYP2C9|CYP3A4,infectious disease,tuberculosis,1576|1558|1559,No-Effect
5345,BRD-K55187425,rigosertib,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1,6918736,Phase 3,cell cycle inhibitor|PLK inhibitor,PLK1,"","",5347,Cyto
5347,BRD-K01638814,rilmenidine,C1CC1C(NC1=NCCO1)C1CC1 |t:6|,68712,Launched,adrenergic receptor agonist|imidazoline receptor agonist,ADRA2A,cardiology,hypertension,150,Low (25%)
5348,BRD-K06240250,rilpivirine,Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1,6451164,Launched,non-nucleoside reverse transcriptase inhibitor,NR1I2|SCN10A,infectious disease,human immunodeficiency virus (HIV-1),8856|6336,Low (25%)
5349,BRD-K21283037,riluzole,Nc1nc2ccc(OC(F)(F)F)cc2s1,5070,Launched,glutamate inhibitor,KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11,neurology/psychiatry,amyotrophic lateral sclerosis (ALS),3776|6336|6335|3783|682|11280|50801|6323|6326|6328|6329|6331|6332|6334|54207,Very Weak (35%)
5351,BRD-K70490179,rimcazole,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,53389,Phase 1,sigma receptor antagonist,SIGMAR1,"","",10280,Weak (50%)
5352,BRD-K55781385,rimegepant,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F,51049968,Launched,calcitonin antagonist,CALCA,"","",796,No-Effect
5354,BRD-K31627533,rimexolone,"CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|",5311412,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,ophthalmology,anterior uveitis,866|2908,No-Effect
5355,BRD-K13296708,rimonabant,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,104850,Withdrawn,cannabinoid receptor antagonist,CNR1|GPR55,"","",9290|1268,No-Effect
5356,BRD-K84783599,riociguat,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,11304743,Launched,guanylate cyclase stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,hypertension,2977|2974|2982|2983,No-Effect
5359,BRD-K53814070,ripasudil,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,9863672,Launched,rho associated kinase inhibitor,ROCK1|ROCK2,ophthalmology,glaucoma|ocular hypertension,9475|6093,No-Effect
5360,BRD-K57427145,ripazepam,CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|,33474,Phase 2,benzodiazepine receptor agonist,GABRA1,"","",2554,Cyto
5363,BRD-K05185389,risedronate,OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O,5245,Launched,osteoclast inhibitor,FDPS,orthopedics|endocrinology,osteoporosis|Paget's disease,2224,No-Effect
5365,BRD-K53857191,risperidone,Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,5073,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder|irritability,146|147|1812|1813|150|1815|3352|151|3354|152|1814|3350|3355|3351|3356|3358|3362|3363|3269,No-Effect
5366,BRD-K00317371,RITA,OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1,374536,Preclinical,MDM inhibitor,MDM2,"","",4193,No-Effect
5367,BRD-K40887525,ritanserin,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1,5074,Phase 3,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,"","",3361|3362|3363|146|147|106480180|3350|3351|3352|3356|3358,No-Effect
5369,BRD-K51485625,ritonavir,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,392622,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1571|100861540|1544|1576|1577|1555|1557|1558|1559|1565,No-Effect
5370,BRD-K79966802,rivanicline,CNCC\C=C\c1cccnc1,5310967,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2|CXCL8,"","",3576|1137|1141,No-Effect
5371,BRD-K37130656,rivaroxaban,Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O,9875401,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE),2159,No-Effect
5372,BRD-K10706131,rivastigmine,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,77991,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease|Parkinson's Disease|senile dementia,43|590,No-Effect
5373,BRD-K75699339,rizatriptan,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,5078,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355,No-Effect
5374,BRD-K19333160,RKI-1447,Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1,60138149,Preclinical,rho associated kinase inhibitor,CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2,"","",1760|9475|6093|3984|5585|8476|4638,No-Effect
5377,BRD-K41415459,RN-1,CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1,45376076,Preclinical,histone demethylase inhibitor,KDM1A,"","",23028,No-Effect
5378,BRD-K95581532,RN-1734,CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,3601086,Preclinical,TRPV antagonist,TRPV4,"","",59341,No-Effect
5379,BRD-K45519571,RN-1747,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,5068295,Preclinical,TRPV agonist,TRPV4,"","",59341,Cyto
5380,BRD-A63546914,Ro-04-5595,COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|,92169474,Preclinical,glutamate receptor antagonist,GRIN2B,"","",2904,No-Effect
5381,BRD-K00486786,Ro-08-2750,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O,17756791,Preclinical,NGF binding inhibitor,NGF|NGFR,"","",4803|4804,No-Effect
5382,BRD-K79684402,Ro-10-5824,Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|,16759175,Preclinical,dopamine receptor agonist,DRD4,"","",1815,Low (25%)
5384,BRD-K77220725,Ro-1138452,CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|,9839644,Preclinical,prostanoid receptor antagonist,PTGIR,"","",5739,Cyto
5385,BRD-K82823076,Ro-15-4513,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-],5081,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,"","",2561|2566|2554|2555|2556|2557|2558|2559,No-Effect
5386,BRD-K80778372,Ro-19-4605,CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C,127382,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,No-Effect
5387,BRD-A07207424,Ro-20-1724,"CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|",6998998,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE4A|PDE4B|PDE4C|PDE4D,"","",5139|5141|5142|5143|5144,No-Effect
5388,BRD-K51541829,Ro-25-6981,C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1,6604887,Preclinical,glutamate receptor antagonist|monamine transporter modulator,GRIN2B,"","",2904,No-Effect
5389,BRD-K21672174,Ro-28-1675,CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1,9886086,Preclinical,glucokinase activator,GCK,"","",5871,No-Effect
5390,BRD-K00354853,Ro-3,COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C,11289644,Preclinical,purinergic receptor antagonist,P2RX3,"","",5024,No-Effect
5391,BRD-K78373679,Ro-3306,O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|,135400873,Preclinical,CDK inhibitor,CDK1,"","",983,No-Effect
5393,BRD-K55192287,Ro-48-8071,CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C,1949,Preclinical,oxidosqualene cyclase inhibitor,LSS,"","",64327,No-Effect
5394,BRD-K64538373,Ro-4987655,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,11548630,Phase 1,MEK inhibitor,MAP2K1,"","",5604,No-Effect
5396,BRD-K82804538,Ro-5126766,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,16719221,Phase 1,MEK inhibitor|RAF inhibitor,BRAF|MAP2K1|MAP2K2|RAF1,"","",673|5604|5605|6037,No-Effect
5398,BRD-K28007504,Ro-60-0175,C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12,3045227,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5399,BRD-K12639498,Ro-61-8048,COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O,5282337,Preclinical,kynurenine 3-monooxygenase inhibitor,KMO,"","",8564,No-Effect
5400,BRD-K91333421,Ro-67-7476,Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1,32681978,Preclinical,glutamate receptor positive allosteric modulator,GRM1,"","",2911,No-Effect
5401,BRD-K58299615,Ro-90-7501,Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1,824226,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,"","",351,No-Effect
5403,BRD-K26169680,robalzotan,NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1,3055171,Phase 2,serotonin receptor antagonist,HTR1A,"","",3350,No-Effect
5405,BRD-K33610132,rociletinib,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,57335384,Phase 3,EGFR inhibitor,EGFR,"","",1956,No-Effect
5406,BRD-K43305603,rocuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,441290,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2|HTR3A,neurology/psychiatry,anesthetic,1129|3359|1135,No-Effect
5407,BRD-K21733600,rofecoxib,CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|,5090,Withdrawn,cyclooxygenase inhibitor,ELN|PTGS2,"","",100130933|5743,No-Effect
5408,BRD-K03194791,roflumilast,FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl,449193,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis,5144|5141|5142|5143,No-Effect
5415,BRD-K61397605,romidepsin,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|,56840936,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),55869|9734|8841|3065|3066|10013|10014|9759,Cyto
5417,BRD-K15933101,ropinirole,CCCN(CCC)CCc1cccc2NC(=O)Cc12,5095,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease|restless leg syndrome,3352|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358,No-Effect
5418,BRD-K50938786,ropivacaine,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,175805,Launched,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic,6336,No-Effect
5421,BRD-K07691486,roscovitine,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,160355,Phase 2,CDK inhibitor,CDK2|CDK9,"","",1017|1025,No-Effect
5424,BRD-K01826734,rosiglitazone,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|,10021239,Withdrawn,insulin sensitizer|PPAR receptor agonist,FFAR1|PPARG|TRPC5|TRPM3,"","",2864|80036|7224|5468,No-Effect
5426,BRD-K20313525,rosmarinic-acid,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1,5281792,Launched,GABA transaminase inhibitor,MCL1|TYR,"","",4170|7299,No-Effect
5428,BRD-K11672787,rostafuroxine,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1,153976,Phase 2,ATPase inhibitor,ATP1A1,"","",476,No-Effect
5429,BRD-K82941592,rosuvastatin,CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O,446157,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis,3156,Low (25%)
5430,BRD-K91111634,rotigotine,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,59227,Launched,dopamine receptor agonist,ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A,neurology/psychiatry,Parkinson's Disease|restless leg syndrome,1816|1812|1813|1814|1815|151|3350,No-Effect
5431,BRD-K35719256,rotundine,COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC,72301,Launched,serotonin receptor agonist,DRD1|DRD2|DRD3|HTR1A,neurology/psychiatry,anxiety|sedative,1812|1813|1814|3350,No-Effect
5434,BRD-K81855038,roxatidine-acetate,CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,5105,Launched,histamine receptor antagonist,HRH2,gastroenterology,Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis,1665,No-Effect
5435,BRD-K38684403,roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,respiratory tract infections|urinary tract infections|skin infections,2862,No-Effect
5436,BRD-A29148886,RP-001,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|,58344861,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,"","",1901,No-Effect
5438,BRD-K87973152,RQ-00203078,OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F,49783953,Preclinical,transient receptor potential channel antagonist,TRPM8,"","",79054,No-Effect
5439,BRD-K06894065,RRx-001,[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O,15950826,Phase 3,glucose 6-phosphate dehydrogenase inhibitor,G6PD,"","",8266,No-Effect
5441,BRD-K08640512,RS-100329,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,3567002,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,"","",146,No-Effect
5442,BRD-K87048468,RS-102221,COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,3693566,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5443,BRD-K83063356,RS-102895,FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1,10000456,Preclinical,CCR antagonist,CCR2,"","",729230,No-Effect
5444,BRD-K90825648,RS-127445,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,196968,Phase 1,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5446,BRD-K76840893,RS-17053,CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,3894573,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,"","",146,Very Weak (35%)
5447,BRD-K01868942,RS-23597-190,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,182593,Preclinical,serotonin receptor antagonist,HTR4,"","",3360,No-Effect
5448,BRD-K20742498,RS-39604,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,5145950,Preclinical,serotonin receptor antagonist,HTR4,"","",3360,No-Effect
5450,BRD-K87510569,RS-504393,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,9953769,Preclinical,CC chemokine receptor antagonist,CCL2|CCR2,"","",6347|729230,No-Effect
5451,BRD-K00004219,RS-56812,Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12,6604789,Preclinical,serotonin receptor partial agonist,HTR3A,"","",3359,No-Effect
5452,BRD-K46142322,RS-67333,CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,183782,Preclinical,serotonin receptor partial agonist,HTR4,"","",3360,No-Effect
5453,BRD-K50018155,RS-67506,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,133076,Preclinical,serotonin receptor partial agonist,HTR4,"","",3360,No-Effect
5454,BRD-K86600316,RS-79948,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,9908992,Preclinical,adrenergic receptor antagonist,ADRA2A,"","",150,No-Effect
5456,BRD-K56211775,RTA-408,"CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|",71811910,Phase 2,nitric oxide production inhibitor,NFE2L2,"","",4780,Low (25%)
5457,BRD-K00234327,RU-24969,COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|,108029,Phase 1,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6,"","",3361|3362|106480180|3350|3351|3352|3356|3358,No-Effect
5458,BRD-K37687387,RU-28318,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|,3034004,Phase 2,cytochrome P450 inhibitor,NR3C2,"","",4306,No-Effect
5459,BRD-K85285268,RU-42173,CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O,3086576,Phase 2,adrenergic receptor agonist,ADRB2,"","",154,No-Effect
5460,BRD-K62762455,RU-58841,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,132981,Phase 2,androgen receptor antagonist,AR,"","",367,No-Effect
5461,BRD-A33603104,RU-SKI-43,"CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|",93160320,Preclinical,hedgehog pathway inhibitor,HHAT,"","",55733,No-Effect
5462,BRD-K79821389,rubitecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,472335,Phase 3,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
5464,BRD-K88560311,rucaparib,CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23,9931954,Phase 3,PARP inhibitor,PARP1|PARP2,"","",10038|142,No-Effect
5465,BRD-K61036791,rucinol,CCCCc1ccc(O)cc1O,205912,Phase 1,tyrosinase inhibitor,TYR,"","",7299,No-Effect
5466,BRD-K20079257,rufinamide,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,129228,Launched,voltage-gated sodium channel blocker,GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|2915|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
5468,BRD-K98004573,rupatadine,Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1,133017,Launched,histamine receptor antagonist|platelet activating factor receptor antagonist,HRH1|PTAFR,allergy,allergic rhinitis|urticaria,5724|3269,No-Effect
5469,BRD-K94723713,rutaecarpine,O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12,65752,Preclinical,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
5470,BRD-K20482099,rutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,5280805,Launched,antioxidant|capillary stabilizing agent|nitric oxide scavenger,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis,8644,No-Effect
5471,BRD-K53972329,ruxolitinib,N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,25126798,Launched,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,hematologic malignancy|hematology,myelofibrosis|polycythemia vera,7297|3716|3717|3718,No-Effect
5472,BRD-K19601669,ruxolitinib-(S),N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,50878566,Preclinical,JAK inhibitor,JAK1|JAK2,"","",3716|3717,No-Effect
5474,BRD-K00091711,RWJ-21757,Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135410906,Phase 2,toll-like receptor agonist,TLR7,"","",51284,No-Effect
5475,BRD-K94623186,RWJ-50271,Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO,9953357,Preclinical,integrin inhibitor,ICAM1,"","",3383,No-Effect
5476,BRD-K07074923,RWJ-67657,OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1,3008319,Phase 1,MAP kinase inhibitor,MAPK14|PTGS2,"","",1432|5743,No-Effect
5477,BRD-K66213167,RX-3117,Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|,11242315,Phase 1/Phase 2,CDK inhibitor|DNA synthesis inhibitor,CDK2|DNMT1,"","",1017|1786,No-Effect
5478,BRD-A65597028,RX-821002,"CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|",67743720,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,"","",146|147|150|151|152,No-Effect
5479,BRD-K06426971,ryuvidine,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|,481747,Preclinical,histone lysine methyltransferase inhibitor,CDK2|CDK4,"","",1017|1019,No-Effect
5480,BRD-K37635256,S-07662,Cc1oc2ccccc2c1CNC(=O)NCc1cccs1,2732040,Preclinical,CAR antagonist,NR1I3,"","",9970,No-Effect
5481,BRD-K60005752,S-111,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,11213350,Phase 2,PARP inhibitor,PARP1,"","",142,No-Effect
5482,BRD-K46766488,S-14506,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,131906,Preclinical,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
5487,BRD-K63123526,S-methylcysteine,CSC[C@H](N)C(O)=O,7058174,Phase 1,"",CTSD|MGMT,"","",1509|4255,No-Effect
5488,BRD-K00024724,S-nitrosoglutathione,N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O,104858,Phase 1,nitric oxide stimulant,PTPN1,"","",5770,No-Effect
5492,BRD-K02501528,S18986,O=S1(=O)N[C@H]2CCCN2c2ccccc12,637863,Phase 2,glutamate receptor modulator,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
5493,BRD-K12745498,S1P1-agonist-III,COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F,54764919,Preclinical,sphingosine kinase inhibitor,S1PR1,"","",1901,No-Effect
5494,BRD-K48826825,S26948,COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC,9958279,Preclinical,PPAR receptor agonist,PPARG,"","",5468,No-Effect
5495,BRD-K96798615,S4,Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1,53342705,Preclinical,carbonic anhydrase inhibitor,CA12|CA9,"","",768|771,No-Effect
5498,BRD-K99819791,SA-47,CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1,9840648,Preclinical,FAAH inhibitor,FAAH,"","",79152,No-Effect
5499,BRD-K46493214,saccharin,O=C1NS(=O)(=O)c2ccccc12,5143,Launched,DNA polymerase inhibitor,CA1|CA12|CA2|CA9,"","",760|768|771|759,Cyto
5500,BRD-A24122750,saclofen,"NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",57453816,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,"","",9568|115207|10537|57528|386617,No-Effect
5501,BRD-K91456750,sacubitril,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O,9811834,Launched,neprilysin inhibitor,MME,cardiology,congestive heart failure,4321,No-Effect
5504,BRD-K92613113,safinamide,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,131682,Launched,dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease,4129,No-Effect
5505,BRD-K93944989,safingol,CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO,91486,Phase 1,PKC inhibitor,TRPM3,"","",80036,No-Effect
5506,BRD-K90582192,safranal,"CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|",61041,Phase 2,benzodiazepine receptor agonist,GABBR1,"","",10537,No-Effect
5507,BRD-K99433989,SAG,CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|,,Preclinical,smoothened receptor agonist,SMO|TRPC6,"","",7225|54498,No-Effect
5508,BRD-K01828772,sal003,"Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|",2252542,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2A,"","",1965,No-Effect
5514,BRD-K93632104,salicylic-acid,OC(=O)c1ccccc1O,338,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,AKR1C1|ASIC3|PTGS1|PTGS2,dermatology|endocrinology|neurology/psychiatry,acne vulgaris (AV)|fever|pain relief,5743|1645|5742|9311,Low (25%)
5515,BRD-K66030860,salidroside,OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,159278,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,"","",351,No-Effect
5517,BRD-K98453471,salirasib,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O,5469318,Phase 2,mTOR inhibitor,TRPA1,"","",8989,No-Effect
5518,BRD-K01826763,salmeterol,OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|,6604001,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm,154,No-Effect
5520,BRD-A45107007,salubrinal,"ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|",2305942,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2S1,"","",1965,No-Effect
5522,BRD-K18898553,salvianolic-acid-B,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,11629084,Phase 2,EGFR inhibitor|metalloproteinase inhibitor,MMP9,"","",4318,No-Effect
5523,BRD-K19284129,salvinorin-A,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,128563,Phase 1,opioid receptor agonist,OPRD1|OPRK1|OPRM1,"","",4985|4986|4988,No-Effect
5529,BRD-K66898851,sanguinarium-chloride,C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12,5154,Phase 1,apoptosis stimulant,CASP3,"","",836,Low (25%)
5530,BRD-K99741577,SANT-1,Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1,6878030,Preclinical,smoothened receptor antagonist,SHH|SMO,"","",54498|6469,No-Effect
5531,BRD-K35781423,SANT-2,CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1,1367095,Preclinical,smoothened receptor antagonist,SHH|SMO,"","",54498|6469,No-Effect
5533,BRD-K36859431,sapropterin,C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1,135398654,Launched,phenylalanine 4-hydroxylase stimulant,NOS3|PAH|TH|TPH1,metabolism,hyperphenylalaninemia (HPA),342977|7166|5053|7054,No-Effect
5534,BRD-K09963420,saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,441243,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576,No-Effect
5535,BRD-K75308783,SAR-245409,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,49867926,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CG,"","",2475|5294,No-Effect
5536,BRD-K38904395,SAR131675,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,71295845,Preclinical,VEGFR inhibitor,FLT4,"","",2324,No-Effect
5537,BRD-K72868067,SAR405,C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F,72709209,Preclinical,PI3K inhibitor,PIK3C3,"","",5289,Strong (80%)
5538,BRD-K45349653,SAR405838,CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1,,Phase 1,MDM inhibitor,MDM2,"","",4193,No-Effect
5539,BRD-K56912469,SAR407899,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,15604510,Phase 2,rho associated kinase inhibitor,ROCK1,"","",6093,No-Effect
5540,BRD-K19540840,saracatinib,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,10302451,Phase 2/Phase 3,SRC inhibitor,ABL1|LCK|SRC|YES1,"","",25|6714|3932|7525,No-Effect
5542,BRD-K51263939,sarcosine,CNCC(O)=O,7311726,Phase 2,glycine transporter inhibitor,SLC6A9,"","",6536,No-Effect
5545,BRD-K79878800,saroglitazar,CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O,60151560,Launched,PPAR receptor agonist,PPARA|PPARG,endocrinology|cardiology|gastroenterology,diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH),5465|5468,Very Weak (35%)
5546,BRD-A34358106,sarpogrelate,COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|,40468125,Launched,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,endocrinology|cardiology|rheumatology,diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease,3356|106480180|3358,No-Effect
5547,BRD-K48892307,sasapyrine,OC(=O)c1ccccc1OC(=O)c1ccccc1O,5161,Launched,NFkB pathway inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743,No-Effect
5549,BRD-K98028353,savolitinib,C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1,68289010,Phase 3,c-Met inhibitor,MET,"","",8731,No-Effect
5550,BRD-K00003546,saxagliptin,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2,,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
5551,BRD-K77677632,SB-200646,Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12,126769,Preclinical,serotonin receptor antagonist,HTR2B|HTR2C,"","",106480180|3358,No-Effect
5552,BRD-K54330070,SB-202190,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1,5169,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,"","",5600|5578|6093|6446|207|240|6300|2932|6198|1111|1432|5594|3932|5599,Very Weak (35%)
5553,BRD-K27141178,SB-203186,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,3272300,Preclinical,serotonin receptor antagonist,HTR4,"","",3360,No-Effect
5554,BRD-K01826796,SB-203580,C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|,40467016,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF,"","",2580|6037|1432|6300|1565|1576|6446|6198|6714|8767|5578|6093|207|7124|1111|5594|3932|5599|5600|5601|5602|240|2932,No-Effect
5555,BRD-A22707317,SB-205384,"CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|",15991599,Preclinical,GABA receptor modulator,GABRA3|GABRA5|GABRA6,"","",2556|2558|2559,No-Effect
5556,BRD-K36395411,SB-206553,Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1,5163,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5557,BRD-K30867024,SB-216641,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,3292447,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,"","",106480180|3350|3351|3352|3356|3358,No-Effect
5558,BRD-K59184148,SB-216763,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|,176158,Preclinical,glycogen synthase kinase inhibitor,CCNA2|CDK2|GSK3A|GSK3B,"","",1017|890|2931|2932,No-Effect
5559,BRD-A06352508,SB-218078,"O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|",3387354,Preclinical,CHK inhibitor,CHEK1,"","",1111,Cyto
5560,BRD-K61097567,SB-218795,COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1,6604858,Preclinical,tachykinin antagonist,TACR3,"","",6870,No-Effect
5561,BRD-K14807180,SB-221284,CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F,443389,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5562,BRD-K04414442,SB-222200,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,6604009,Preclinical,tachykinin antagonist,TACR3,"","",6870,Very Weak (35%)
5563,BRD-K61323504,SB-225002,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,3854666,Preclinical,CC chemokine receptor antagonist,CXCR2,"","",3579,No-Effect
5564,BRD-K15424032,SB-228357,COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F,443390,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,No-Effect
5565,BRD-K98795921,SB-2343,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,46912230,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",22883|5290|2475|5291|5294,Very Weak (35%)
5566,BRD-K82091397,SB-239063,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|,,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14|PTGS2,"","",5600|1432|5743,No-Effect
5567,BRD-K19412355,SB-242235,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,9863367,Phase 1,p38 MAPK inhibitor,HSPB1|MAPK14,"","",1432|3315,No-Effect
5568,BRD-K99968849,SB-243213,Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F,443391,Phase 1,serotonin receptor inverse agonist,HTR2A|HTR2B|HTR2C|HTR6,"","",3362|3356|106480180|3358,No-Effect
5569,BRD-K80639402,SB-258585,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,3248571,Preclinical,serotonin receptor antagonist,HTR6,"","",3362,No-Effect
5570,BRD-A91031770,SB-268262,"CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|",93475590,Preclinical,calcitonin antagonist,CALCA,"","",796,No-Effect
5571,BRD-K24201553,SB-269970,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,6604889,Preclinical,serotonin receptor antagonist,HTR7,"","",3363,No-Effect
5572,BRD-K82467063,SB-271046,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,5312149,Phase 1,serotonin receptor antagonist,HTR6,"","",3362,Very Weak (35%)
5573,BRD-K16107558,SB-297006,CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1,9840971,Preclinical,CC chemokine receptor antagonist,CCR3,"","",1232,No-Effect
5575,BRD-K41567364,SB-334867,Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,6604926,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
5576,BRD-K61536336,SB-366791,COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1,667594,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
5577,BRD-K03988082,SB-399885,COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC,6918649,Preclinical,serotonin receptor antagonist,HTR6,"","",3362,No-Effect
5578,BRD-K53913732,SB-408124,CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1,4331799,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,"","",131450|3061,No-Effect
5579,BRD-K76805682,SB-415286,Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|,4210951,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B|RPS6KB1,"","",2931|2932|6198,No-Effect
5580,BRD-K67298865,SB-431542,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1,4521392,Preclinical,TGF beta receptor inhibitor,ACVR1C|TGFBR1,"","",7046|130399,No-Effect
5581,BRD-K03665769,SB-452533,CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1,9842609,Preclinical,TRPV antagonist,TRPV1,"","",7442,No-Effect
5582,BRD-K40109029,SB-505124,Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C,9858940,Preclinical,ALK tyrosine kinase receptor inhibitor,TGFBR1,"","",7046,No-Effect
5583,BRD-K37720887,SB-525334,Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C,9967941,Preclinical,TGF beta receptor inhibitor,TGFBR1,"","",7046,No-Effect
5584,BRD-K78809024,SB-590885,CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1,135421339,Preclinical,RAF inhibitor,BRAF,"","",673,Weak (50%)
5585,BRD-K08333979,SB-612111,Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12,10047612,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,"","",4987,No-Effect
5587,BRD-K95292280,SB-657510,COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1,11272107,Preclinical,urotensin receptor antagonist,UTS2R,"","",2837,No-Effect
5588,BRD-K24968862,SB-683698,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1,9912743,Phase 1,integrin antagonist,ITGA4|ITGAV|ITGB1|ITGB7,"","",3688|3676|3685|3695,No-Effect
5589,BRD-K65991129,SB-705498,FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br,9910486,Phase 2,TRPV antagonist,TRPV1,"","",7442,No-Effect
5590,BRD-K68633027,SB-706375,COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F,21023902,Preclinical,urotensin receptor antagonist,UTS2R,"","",2837,No-Effect
5591,BRD-K78941306,SB-742457,O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1,11256720,Phase 3,serotonin receptor antagonist,HTR6,"","",3362,No-Effect
5592,BRD-K68532323,SB-743921,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1,9936388,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,KIF11,"","",3832,Strong (80%)
5593,BRD-K49597925,SB-747651A,CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N,11393719,Preclinical,kinase inhibitor,AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1,"","",9252|6093|207|10000|6198,No-Effect
5594,BRD-K45168550,SB-756050,COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1,1520267,Phase 1,G protein-coupled receptor agonist,GPBAR1,"","",151306,No-Effect
5595,BRD-K49110935,SB-772077B,CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N,16095343,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,"","",9475|6093,No-Effect
5596,BRD-K86797399,SB-939,CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC,49855250,Phase 3,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9,"","",9734|8841|10013|3065|3066|83933|10014|9759,Cyto
5597,BRD-K71667152,SBE-13,COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC,4719406,Preclinical,PLK inhibitor,PLK1,"","",5347,No-Effect
5598,BRD-K54729176,SBHA,ONC(=O)CCCCCCC(=O)NO,5173,Preclinical,HDAC inhibitor,HDAC1|HDAC3,"","",3065|8841,No-Effect
5600,BRD-K05361803,SC-10,CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,5175,Preclinical,protein kinase activator,PRKCA,"","",5578,No-Effect
5601,BRD-K40797222,SC-12267,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|,9820008,Phase 2,dihydroorotate dehydrogenase inhibitor,IL17A,"","",3605,No-Effect
5603,BRD-K52512893,SC-19220,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12,4336830,Preclinical,prostanoid receptor antagonist,PTGER1,"","",5731,No-Effect
5604,BRD-K76365178,SC-236,NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,9865808,Preclinical,cyclooxygenase inhibitor,PTGS2,"","",5743,No-Effect
5605,BRD-K62715847,SC-51089,Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1,132749,Preclinical,prostanoid receptor antagonist,PTGER1,"","",5731,No-Effect
5606,BRD-K14767410,SC-560,COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,4306515,Preclinical,cyclooxygenase inhibitor,PTGS1,"","",5742,No-Effect
5607,BRD-K25875056,SC-9,Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1,124172,Preclinical,protein tyrosine kinase activator,PRKCA,"","",5578,No-Effect
5609,BRD-K29562203,SCH-202676,CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1,682802,Preclinical,G protein-coupled receptor modulator,CHRM1|CHRM2|DRD1|DRD2,"","",1128|1129|1812|1813,No-Effect
5610,BRD-K00004286,SCH-221510,"Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|",,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,"","",4987,No-Effect
5612,BRD-K55748775,SCH-28080,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,108137,Phase 1,ATPase inhibitor,ATP4A,"","",495,Low (25%)
5613,BRD-K02460719,SCH-51344,COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1,9995890,Preclinical,MTH1 inhibitor,NUDT1,"","",4521,No-Effect
5614,BRD-K81225797,SCH-58261,Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1,176408,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
5615,BRD-K75009076,SCH-900776,Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1,46239015,Phase 2,CHK inhibitor,CDK2|CHEK1,"","",1017|1111,No-Effect
5620,BRD-K33809398,SCMC-Lys,N[C@@H](CSCC(O)=O)C(O)=O,193653,Launched,mucolytic agent,GSTP1,pulmonary,chronic obstructive pulmonary disease (COPD),2950,No-Effect
5622,BRD-K89923877,scopolamine,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI,neurology/psychiatry|gastroenterology,motion sickness|vomiting|nausea,1128|1129|1131|1132|1133|6490,Very Weak (35%)
5623,BRD-A49906757,scopolamine-N-oxide,"C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|",,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,No-Effect
5625,BRD-K22503835,scriptaid,ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23,5186,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,"","",55869|9734|8841|3065|3066|10013|10014|9759,No-Effect
5628,BRD-K91904471,SD-169,NC(=O)c1ccc2[nH]ccc2c1,14973220,Preclinical,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
5629,BRD-K24566386,SD-208,Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,10316032,Preclinical,TGF beta receptor inhibitor,TGFBR1,"","",7046,No-Effect
5630,BRD-K51102532,SD-2590,COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1,9892815,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2,"","",4312|4313|4322,Low (25%)
5631,BRD-K01826797,SDM25N,"CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|",9931601,Preclinical,opioid receptor antagonist,OPRD1,"","",4985,No-Effect
5632,BRD-K15868788,SDZ-205-557,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,5191,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,"","",9177|3359,No-Effect
5633,BRD-A15530910,SDZ-21009,"CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|",6604875,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A|HTR1B,"","",3350|3351,No-Effect
5634,BRD-K82266792,SDZ-220-040,N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O,6604839,Preclinical,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
5635,BRD-K27168049,SDZ-220-581,N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O,128019,Preclinical,glutamate receptor antagonist,GRIN1,"","",114787,No-Effect
5636,BRD-K65820248,SDZ-NKT-343,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O,9851211,Phase 1,tachykinin antagonist,TACR1,"","",6869,No-Effect
5637,BRD-K31339597,SDZ-SER-082,CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34,9859407,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,"","",3356|106480180|3358,Low (25%)
5638,BRD-K39558284,SDZ-WAG-994,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12,164305,Phase 2,adenosine receptor agonist,ADORA1,"","",134,No-Effect
5640,BRD-K02965577,secalciferol,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5283748,Launched,vitamin D receptor agonist,VDR,critical care,bone fracture,1594,No-Effect
5646,BRD-K49071277,securinine,"O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|",442872,Preclinical,GABA receptor antagonist|TP53 activator,GABRA1,"","",2554,No-Effect
5647,BRD-K00003150,segesterone-acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|,108059,Launched,progesterone receptor agonist,PGR,"","",5241,Low (25%)
5650,BRD-K86434416,selegiline,C[C@H](Cc1ccccc1)N(C)CC#C,26757,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,Parkinson's Disease,4128|4129,Very Weak (35%)
5653,BRD-K21191422,selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1,9913767,Launched,IP1 prostacyclin receptor agonist|platelet aggregation inhibitor,PTGIR,pulmonary,pulmonary arterial hypertension (PAH),5739,No-Effect
5654,BRD-K48738253,selfotel,OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1,6604838,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",2904|2905|2906|2903,No-Effect
5655,BRD-K21361524,selinexor,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,71481097,Launched,exportin antagonist,XPO1,hematologic malignancy,multiple myeloma,7514,No-Effect
5658,BRD-K57080016,selumetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,10127622,Phase 3,MEK inhibitor,MAP2K1,"","",5604,No-Effect
5659,BRD-K65592642,semagacestat,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O,9843750,Phase 3,gamma secretase inhibitor,PSEN1,"","",5663,No-Effect
5660,BRD-K21237892,semapimod,CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N,492132,Phase 2,cytokine production inhibitor|p38 MAPK inhibitor,MAPK14,"","",1432,Weak (50%)
5661,BRD-K63504947,semaxanib,Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1,5329098,Phase 3,VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,"","",5156|3815|5159|3791|2321|2260|5979,No-Effect
5663,BRD-K70614402,SEN-1269,CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1,46835756,Preclinical,beta amyloid inhibitor,APP,"","",351,No-Effect
5664,BRD-K21295289,senicapoc,NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,216327,Phase 3,intermediate conductance potassium channel blocker,KCNN4,"","",3783,No-Effect
5667,BRD-K28456624,seocalcitol,CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5288149,Phase 3,vitamin D receptor agonist,VDR,"","",1594,No-Effect
5668,BRD-K49504902,SEP-227900,OC(=O)c1cc2occc2[nH]1,7141881,Phase 1,D-amino acid oxidase Inhibitor,DAO,"","",26,No-Effect
5669,BRD-A60765580,seratrodast,"CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|",73346713,Launched,prostanoid receptor antagonist,TBXA2R,pulmonary,asthma,6915,No-Effect
5670,BRD-K65924316,serdemetan,C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1,11609586,Phase 1,MDM inhibitor,MDM2,"","",4193,Strong (80%)
5671,BRD-K38580127,serotonin,NCCc1c[nH]c2ccc(O)cc12,5202,Launched,growth factor receptor activator,DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1,neurology/psychiatry,anxiety|depression|sleeplessness,3360|3352|3361|3362|3363|1812|106480180|3350|3351|1816|9177|3354|3355|3356|206358|3358|3359,No-Effect
5673,BRD-K69116396,sertindole,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,60149,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2,"","",3352|3362|3269|3757|146|147|1813|1814|1815|3350|3356|3354|3355|3351|3358,Low (25%)
5674,BRD-K82036761,sertraline,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12,68617,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A3|SLC6A4,neurology/psychiatry|obstetrics/gynecology,depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder,6531|6532,Strong (80%)
5676,BRD-K24497734,setipiprant,OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12,49843471,Phase 3,prostaglandin inhibitor,PTGDR2,"","",11251,No-Effect
5677,BRD-K36732695,setiptiline,CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|,5205,Launched,adrenergic receptor antagonist,HRH1|HTR2A|HTR2C,neurology/psychiatry,depression,3356|3269|3358,No-Effect
5679,BRD-K05638300,sevoflurane,FCOC(C(F)(F)F)C(F)(F)F,5206,Launched,membrane integrity inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1,neurology/psychiatry,anesthetic,2560|513|2561|2562|2563|2564|2565|2566|2567|2568|338567|27032|3736|2741|2743|54207|3776|3777|55879|2890|51305|2554|2555|2556|2557|2558|2559,No-Effect
5680,BRD-K15601958,SEW-2871,FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F,4077460,Preclinical,lysophospholipid receptor agonist,S1PR1,"","",1901,No-Effect
5681,BRD-K42629487,SF-11,CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1,2936384,Preclinical,neuropeptide receptor antagonist,MCOLN3|NPY2R,"","",55283|4887,No-Effect
5683,BRD-K86718786,SGC-707,O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,90642938,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,"","",10196,No-Effect
5684,BRD-K24821794,SGC-CBP30,COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl,72201027,Preclinical,bromodomain inhibitor,CREBBP|EP300,"","",2033|1387,No-Effect
5685,BRD-K61228301,SGI-1027,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,24858111,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3A|DNMT3B,"","",1786|1788|1789,Very Weak (35%)
5686,BRD-K80700417,SGI-1776,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,24795070,Phase 1,Pim kinase inhibitor,FLT3|PIM1|PIM2|PIM3,"","",11040|9361|2322|415116,No-Effect
5687,BRD-K00004650,SGS-742,CCCCP(O)(=O)CCCN,130021,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,"","",9568|10537,No-Effect
5688,BRD-K19477839,SGX523,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1,24779724,Phase 1,hepatocyte growth factor receptor inhibitor,MET,"","",8731,No-Effect
5689,BRD-A63344375,SHA-68,"Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|",52951680,Preclinical,neuropeptide receptor antagonist,NPSR1,"","",387129,No-Effect
5692,BRD-K01826006,SIB-1553A,CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|,10609936,Phase 2,acetylcholine receptor agonist,CHRNB4,"","",1143,No-Effect
5693,BRD-K98157055,SIB-1757,C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|,132466061,Preclinical,glutamate receptor antagonist,GRM5,"","",2915,No-Effect
5694,BRD-K14561059,SIB-1893,Cc1cccc(\C=C\c2ccccc2)n1,5311432,Preclinical,glutamate receptor antagonist,GRM4|GRM5,"","",2914|2915,No-Effect
5695,BRD-A43885598,SID-7969543,"CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|",2149494,Preclinical,steroidogenic factor antagonist,NR5A1,"","",2516,No-Effect
5696,BRD-A62071884,siguazodan,"CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|",6604007,Phase 1,phosphodiesterase inhibitor,PDE3A,"","",5139,No-Effect
5697,BRD-K79759585,sildenafil,CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1,135398744,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3,urology,erectile dysfunction,10599|28234|8654|5148|5149,No-Effect
5698,BRD-K80353138,silibinin,COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O,31553,Launched,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis,240,No-Effect
5699,BRD-K10906636,silodosin,C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F,5312125,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH),146|147,No-Effect
5702,BRD-K00003545,simeprevir,COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|,24873435,Launched,HCV inhibitor,CYP1A2|CYP3A4,infectious disease,hepatitis C,1544|1576,Low (25%)
5704,BRD-K22134346,simvastatin,"CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|",54454,Launched,HMGCR inhibitor,HMGCR|ITGB2,endocrinology|cardiology|neurology/psychiatry,hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia,3689|3156,No-Effect
5706,BRD-K91100918,sinefungin,N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,65482,Preclinical,DNA methyltransferase inhibitor|RNA synthesis inhibitor,CARM1,"","",10498,No-Effect
5708,BRD-K53195974,sipatrigine,CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl,60803,Phase 2,voltage-gated sodium channel blocker,CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A,"","",6336|776|6323|6328|6329|6331|6335,No-Effect
5709,BRD-K62384160,siponimod,CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F,44599207,Launched,sphingosine 1-phosphate receptor modulator,S1PR1,neurology/psychiatry,multiple sclerosis,1901,No-Effect
5710,BRD-K51333959,siramesine,Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12,9829526,Phase 2,sigma receptor antagonist,ADRA1A|ADRA1B|ADRA1D,"","",146|147,No-Effect
5712,BRD-K84937637,sirolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|",134812764,Launched,mTOR inhibitor,FKBP1A|MTOR,transplant|pulmonary,organ rejection|lymphangioleiomyomatosis,2280|2475,Very Weak (35%)
5713,BRD-K16472653,SirReal-2,Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1,1096292,Preclinical,SIRT inhibitor,SIRT2,"","",22933,Low (25%)
5714,BRD-A23747351,sirtinol,"C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|",,Preclinical,SIRT inhibitor,SIRT1|SIRT2,"","",23411|22933,No-Effect
5715,BRD-K38905597,SIS3,COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12,10138988,Preclinical,serine/threonine kinase inhibitor,SMAD3|TGFBR1,"","",4088|7046,No-Effect
5719,BRD-K19416115,sitagliptin,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F,4369359,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
5720,BRD-K63806092,sitaxentan,Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,216235,Withdrawn,endothelin receptor antagonist,EDNRA|EDNRB,"","",1909|1910,No-Effect
5723,BRD-K02152879,sivelestat,CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O,107706,Launched,elastase inhibitor,CELA1|ELANE,pulmonary,acute lung injury,1990|1991,Low (25%)
5724,BRD-K35945299,SJ-172550,CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|,1317464,Preclinical,MDM inhibitor,MDM4,"","",4194,No-Effect
5727,BRD-K00004226,SK&F-10047-(+),C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,3036222,Phase 1,sigma receptor agonist,SIGMAR1,"","",10280,No-Effect
5728,BRD-K67304264,SKA-31,Nc1nc2c(ccc3ccccc23)s1,94880,Preclinical,potassium channel activator,KCNN4,"","",3783,No-Effect
5729,BRD-K83607951,skepinone-L,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,45279963,Preclinical,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
5730,BRD-K01826815,SKF-38393,Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|,6603799,Preclinical,dopamine receptor agonist,CALY|DRD1|DRD5,"","",50632|1816|1812,No-Effect
5731,BRD-A64227845,SKF-77434,Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|,6603997,Preclinical,dopamine receptor agonist,DRD1,"","",1812,No-Effect
5732,BRD-A09828896,SKF-81297,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,11957706,Preclinical,dopamine receptor agonist,DRD1|DRD5,"","",1816|1812,No-Effect
5733,BRD-A52588987,SKF-83566,CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|,6604885,Preclinical,dopamine receptor antagonist,DRD1|DRD5,"","",1816|1812,No-Effect
5734,BRD-K96809896,SKF-86002,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,5228,Preclinical,p38 MAPK inhibitor,ALOX5|MAPK14,"","",240|1432,No-Effect
5735,BRD-K01826728,SKF-89976A,OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|,6604015,Preclinical,GABA uptake inhibitor,SLC6A1,"","",6529,No-Effect
5736,BRD-K49776472,SKF-91488,CN(C)CCCCSC(N)=N,5227,Preclinical,histamine N-methyltransferase inhibitor,HNMT,"","",3176,No-Effect
5737,BRD-K01826819,SKF-96365,COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|,6604827,Preclinical,calcium channel blocker,CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2,"","",51393|1576|25865|7220|7222|7223|7224,No-Effect
5738,BRD-K20755323,SKI-II,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1,753704,Preclinical,sphingosine kinase inhibitor,SPHK1,"","",8877,Strong (80%)
5740,BRD-K29895144,SKLB1002,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,71461003,Preclinical,VEGFR inhibitor,KDR,"","",3791,No-Effect
5741,BRD-K00004304,SLV-319-(+/-),"C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|",9826744,Phase 2,cannabinoid receptor antagonist,CNR1|DRD2|HTR1A,"","",1268|1813|3350,No-Effect
5742,BRD-K34445261,SLV-320,O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|,,Phase 2,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,Low (25%)
5744,BRD-K06191411,SM-164,CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1,17756618,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,"","",329|330|331,No-Effect
5745,BRD-K00004213,SM-21,"CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|",,Preclinical,sigma receptor antagonist,PGRMC1,"","",10857,No-Effect
5746,BRD-K08478539,SMER-28,Brc1ccc2ncnc(NCC=C)c2c1,1560402,Preclinical,autophagy inducer,SNCA,"","",6622,No-Effect
5747,BRD-K98396737,SMI-4a,FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1,1361334,Preclinical,Pim kinase inhibitor,PIM1,"","",9361,No-Effect
5748,BRD-K00004310,SN-2,"Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|",,Preclinical,transient receptor potential channel agonist,MCOLN3,"","",55283,No-Effect
5749,BRD-K89561498,SN-38,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12,104842,Launched,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,7150,No-Effect
5751,BRD-A67006024,SNAP,"CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|",,Phase 2,nitric oxide donor,PTPN1,"","",5770,Low (25%)
5752,BRD-A21428877,SNAP-5089,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|",10326374,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D,"","",775|776|146|147|150|151|152,Strong (80%)
5753,BRD-K49702221,SNAP-94847,CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,16756754,Preclinical,"",ADRA1A|DRD2,"","",146|1813,No-Effect
5754,BRD-K29546239,SNC-80,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1,123924,Preclinical,"",OPRD1,"","",4985,No-Effect
5755,BRD-K75016267,SNG-1153,CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F,71621167,Preclinical,selective estrogen receptor modulator (SERM),ESR1,"","",2099,No-Effect
5756,BRD-K71512533,SNS-314,Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1,24995524,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,"","",6795|9212|6790,No-Effect
5758,BRD-K73197500,SNX-5422,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|,,Phase 1/Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,"","",3320|3326,No-Effect
5759,BRD-K85406984,sobetirome,CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O,9862248,Phase 1/Phase 2,thyroid hormone receptor agonist,THRA|THRB,"","",7067|7068,No-Effect
5764,BRD-K05878375,sodium-butyrate,CCCC(O)=O,264,Phase 2,HDAC inhibitor,BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8,"","",8841|590|2865|2867|3065|3066|55869,No-Effect
5766,BRD-M58433298,sodium-dodecyl-sulfate,[Na].CCCCCCCCCCCCOS(O)(=O)=O,,Launched,"",ALB,"","",213,No-Effect
5769,BRD-K99308954,sodium-monofluorophosphate,OP(O)(F)=O,24267,Launched,"",PYGM,dental,cavities,5837,No-Effect
5774,BRD-K00003543,sodium-stibogluconate,[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO,,Launched,tyrosine phosphatase inhibitor,PTPN6,infectious disease,leishmaniasis,5777,No-Effect
5776,BRD-A55664972,sodium-tetradecyl-sulfate,"CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|",51382662,Launched,"",PROC,dermatology,varicose veins,5624,No-Effect
5777,BRD-K01039503,sofalcone,CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1,5282219,Launched,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD),873,No-Effect
5782,BRD-K69215269,solcitinib,CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12,44603362,Phase 1,JAK inhibitor,JAK1,"","",3716,No-Effect
5783,BRD-K00003600,solifenacin-succinate,[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1,154059,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency,1128|1129|1131|1132|1133,No-Effect
5787,BRD-K14681867,somatostatin,C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,,Launched,somatostatin receptor agonist,OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5,hematology,hemorrhage,6752|6753|6754|6755|4985|4988|6751,Weak (50%)
5789,BRD-K19796430,sonidegib,C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1,24775005,Launched,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),54498,No-Effect
5791,BRD-K23984367,sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,216239,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC),673|3815|5159|3791|2321|2322|2260|2324|6037|4921|5979,No-Effect
5794,BRD-A89164055,sorbinil,"Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|",337359,Phase 3,aldose reductase inhibitor,AKR1B1,"","",231,No-Effect
5797,BRD-K05850076,sotagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1,24831714,Phase 3,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,"","",6523|6524,No-Effect
5798,BRD-A33168282,sotalol,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,67108155,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|KCNH2,cardiology,atrial fibrillation (AF)|ventricular arrhythmias,153|154|3757,Weak (50%)
5799,BRD-K16761703,sotrastaurin,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|,10296883,Phase 2,PKC inhibitor,PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ,"","",5578|5579|5580|5581|5583|5588,No-Effect
5800,BRD-K71900389,SP-100030,FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F,9910975,Preclinical,NFkB pathway inhibitor,JUN|NFKB1,"","",3725|4790,No-Effect
5801,BRD-K28571773,SP-141,COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12,59620153,Preclinical,ubiquitin ligase inhibitor,MDM2,"","",4193,Low (25%)
5803,BRD-K68405354,spaglumic-acid,CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O,188803,Launched,glutamate receptor antagonist,GRM3,allergy,allergic conjunctivitis|allergic rhinitis,2913,Very Weak (35%)
5804,BRD-K07612980,sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1,6956367,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,"","",7153,No-Effect
5805,BRD-A81539525,sparfosate,OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|,46936683,Phase 3,aspartate carbamoyltransferase inhibitor,CA2|CA4,"","",760|762,No-Effect
5810,BRD-K84964099,spautin-1,Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1,51037431,Preclinical,deubiquitinase inhibitor,USP10|USP13,"","",84669|8975,No-Effect
5812,BRD-K40438880,spermidine,NCCCCNCCCN,1102,Preclinical,glutamate receptor modulator,KCNJ4|TXNRD1,"","",7296|3761,No-Effect
5813,BRD-K18375018,spermine,NCCCNCCCCNCCCN,1103,Preclinical,"",CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5,"","",768|54498|114787|10743|29850|54795|846|23632|3761|89874|2903|762|765,No-Effect
5814,BRD-K01825110,sphingosylphosphorylcholine,"CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|",5280613,Preclinical,gene expression stimulant,GPR12,"","",2835,No-Effect
5815,BRD-K55468218,spiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,5265,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia,3352|3362|3363|146|147|1812|1813|1814|1815|1816|3350|106480180|3356|3358,Strong (80%)
5816,BRD-K28192623,spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,55652,Phase 2,opioid receptor agonist,OPRK1,"","",4986,No-Effect
5819,BRD-K90027355,spironolactone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|,5833,Launched,mineralocorticoid receptor antagonist,AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG,endocrinology|cardiology|gastroenterology|rheumatology,hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia,773|774|775|776|778|779|781|782|783|784|785|786|9254|1585|6462|150350|8912|8913|4306|2908|367|55799|5241,No-Effect
5820,BRD-A72483914,spiroxatrine,"O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|",6603993,Preclinical,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B,"","",146|147|106480180|150|151|152|3350,No-Effect
5822,BRD-K27710560,splitomycin,O=C1CCc2c(O1)ccc1ccccc21,5269,Preclinical,SIRT inhibitor,SIRT1,"","",23411,No-Effect
5823,BRD-K19203487,SPP301,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,9912992,Phase 3,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
5824,BRD-K63253858,SPP86,CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12,66549796,Preclinical,receptor tyrosine protein kinase inhibitor,RET,"","",5979,Strong (80%)
5825,BRD-A08772153,SQ-109,CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|,,Phase 3,bacterial cell wall synthesis inhibitor,FDFT1,"","",2222,Low (25%)
5826,BRD-A56987319,SQ-22536,"Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|",22879197,Preclinical,adenylyl cyclase inhibitor,ADCY1,"","",107,No-Effect
5829,BRD-K26501486,SR-1078,OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,17980288,Preclinical,retinoid receptor agonist,RORA|RORC,"","",6097|6095,Low (25%)
5831,BRD-K60931454,SR-140333,CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1,108167,Phase 2,neurokinin receptor antagonist,TACR1,"","",6869,No-Effect
5832,BRD-K62814487,SR-1664,C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O,53239854,Preclinical,PPAR receptor ligand,PPARG,"","",5468,No-Effect
5833,BRD-K11641193,SR-2211,OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F,51035449,Preclinical,retinoid receptor inverse agonist,RORC,"","",6097,No-Effect
5834,BRD-K62562723,SR-2640,OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1,128355,Phase 2,leukotriene receptor antagonist,CYSLTR1,"","",10800,No-Effect
5835,BRD-K35629949,SR-27897,OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl,122077,Phase 2,CCK receptor antagonist,CCKAR,"","",886,No-Effect
5836,BRD-K60952143,SR-3306,Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1,57519510,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK9,"","",5601|5602|5599,No-Effect
5839,BRD-A86468475,SR-3677,CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|,93600633,Preclinical,rho associated kinase inhibitor,ROCK2,"","",9475,No-Effect
5840,BRD-K09397065,SR-57227A,NC1CCN(CC1)c1cccc(Cl)n1,131747,Phase 2,serotonin receptor agonist,HTR3A,"","",3359,No-Effect
5841,BRD-K35430135,SR-59230A,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12,5311452,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
5842,BRD-K19309090,SR-95639A,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,195165,Preclinical,acetylcholine receptor agonist,CHRM1,"","",1128,No-Effect
5843,BRD-K50495309,SRC-kinase-inhibitor-I,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,1474853,Preclinical,SRC inhibitor,CSK|LCK|RIPK2,"","",3932|1445|8767,No-Effect
5845,BRD-K95926480,SRT1720,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,24180125,Preclinical,SIRT activator,SIRT1,"","",23411,Strong (80%)
5846,BRD-K48452630,SRT2104,Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1,25108829,Phase 2,SIRT activator,SIRT1,"","",23411,No-Effect
5849,BRD-K00004316,SSR180711,Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|,9797360,Phase 2,acetylcholine receptor agonist,CHRNA7,"","",89832,No-Effect
5853,BRD-K68470841,ST-2825,NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12,24808138,Preclinical,myeloid differentiation primary response inhibitor,MYD88,"","",4615,No-Effect
5855,BRD-K41783120,STA-5326,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,10173277,Phase 2,interleukin synthesis inhibitor,IL12A,"","",3592,Strong (80%)
5856,BRD-K40853697,STAT3-inhibitor-VI,Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1,252682,Preclinical,STAT inhibitor,STAT3,"","",6774,No-Effect
5860,BRD-K36739687,stemregenin-1,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,46199207,Preclinical,aryl hydrocarbon receptor antagonist,AHR,"","",196,No-Effect
5863,BRD-K13049524,STF-083010,Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1,135398515,Preclinical,serine/threonine kinase inhibitor,ERN1,"","",2081,No-Effect
5864,BRD-K39171998,STF-118804,Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1,20916937,Preclinical,NAMPT inhibitor,NAMPT,"","",10135,No-Effect
5865,BRD-K22477529,STF-31,CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1,984333,Preclinical,NAMPT inhibitor,NAMPT|SLC2A1,"","",6513|10135,Weak (50%)
5868,BRD-A72441487,stiripentol,"CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|",25271730,Launched,GABA uptake inhibitor,GABRA3,neurology/psychiatry,epilepsy,2556,No-Effect
5869,BRD-K33839500,stobadine,CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1,108089,Phase 2,adrenergic receptor antagonist,ADRA1A,"","",146,No-Effect
5872,BRD-K83146339,strontium-ranelate,OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N,,Launched,bone formation stimulant|bone resorption inhibitor,CASR,orthopedics|rheumatology,osteoporosis|osteoarthritis,846,No-Effect
5874,BRD-K00003547,SU014813,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,10138259,Phase 2,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,"","",3791,No-Effect
5875,BRD-K02965346,SU11274,CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1,9549297,Preclinical,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,MET,"","",8731,No-Effect
5876,BRD-K91106808,SU16f,Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O,5329150,Preclinical,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,"","",5159,No-Effect
5877,BRD-K32730239,SU3327,Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1,11837140,Preclinical,JNK inhibitor,MAPK8,"","",5599,No-Effect
5878,BRD-K20287671,SU4312,CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1,6450842,Preclinical,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,KDR|PDGFRB,"","",5159|3791,No-Effect
5879,BRD-K94883909,SU9516,COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1,5289419,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5,"","",1017|1019|1020|983,No-Effect
5880,BRD-K23106423,substance-P,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O,36511,Phase 1,neurokinin receptor antagonist,TACR1|TACR2|TACR3,"","",6865|6869|6870,No-Effect
5881,BRD-K45238818,succinic-acid,OC(=O)CCC(O)=O,21952380,Launched,"",ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE,"","",8974|8985|5019|6561|10536|5033|55214|64175|55217|8630|444|1468|64064|642502|64849|56670|8801|9058|8803|8802|5351|8424|7915|6389|6390|6392,No-Effect
5882,BRD-K00003183,succinobucol,CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C,216325,Phase 2/Phase 3,antioxidant,VCAM1,"","",7412,Very Weak (35%)
5883,BRD-K45497762,succinylcholine-chloride,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,5314,Launched,"",CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10,neurology/psychiatry,muscle relaxant,89832|1129|1128|1131|1134|57053,No-Effect
5884,BRD-K01950558,succinylsulfathiazole,OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,5315,Phase 2,dihydrofolate reductase inhibitor,DHFR,"","",1719,No-Effect
5887,BRD-K74724920,sucrose,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,5988,Launched,"",ACTA1|ATOX1|C22orf28|LYZ,"","",4069|58|475|51493,No-Effect
5906,BRD-K87492696,sulfameter,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,5326,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections,1719,No-Effect
5914,BRD-K02594908,sulfanilamide,Nc1ccc(cc1)S(N)(=O)=O,5333,Launched,carbonic anhydrase inhibitor,CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4,infectious disease,vulvovaginal candidiasis,1571|1576|1557|1559|1565,Very Weak (35%)
5917,BRD-K10671814,sulfaphenazole,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1,5335,Launched,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections,1725,No-Effect
5920,BRD-K10670311,sulfasalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1,,Launched,cyclooxygenase inhibitor,ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1,gastroenterology,ulcerative colitis,6916|5319|682|5742|5743|240|113235|6646|1147|5468|3551,No-Effect
5923,BRD-K00004525,sulfinpyrazone,"O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|",25273605,Launched,uricosuric blocker,ABCC1|FPR1|SLC22A12,rheumatology,gout,116085|4363|2357,No-Effect
5926,BRD-A58955223,sulforaphane,C[S@@](=O)CCCCN=C=S |r|,9577379,Phase 2,anticancer agent|aryl hydrocarbon receptor antagonist,NFE2L2,"","",4780,Strong (80%)
5927,BRD-K01827279,sulindac,"CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|",16046677,Launched,cyclooxygenase inhibitor,AKR1B1,rheumatology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis,231,No-Effect
5930,BRD-K29570907,sulmetozine,COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1,65790,Launched,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD),2520,No-Effect
5936,BRD-K00003488,sultiame,NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O,5356,Phase 3,carbonic anhydrase inhibitor,CA2,"","",760,No-Effect
5938,BRD-K30485548,sumanirole,CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23,9818479,Phase 3,dopamine receptor agonist,DRD2,"","",1813,No-Effect
5939,BRD-K50938287,sumatriptan,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,5358,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7,neurology/psychiatry,migraine headache,3361|3362|3363|3350|3351|3352|3354|3355,No-Effect
5940,BRD-K71250460,SUN-11602,CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C,22245705,Preclinical,fibroblast growth factor mimetic,FGFR1,"","",2260,No-Effect
5941,BRD-K36274133,SUN-B-8155,C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O,,Preclinical,calcitonin agonist,CALCR,"","",799,No-Effect
5942,BRD-K42828737,sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,5329102,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET),5156|3815|5159|3791|2321|2322|2260|2324|5979|1436,No-Effect
5944,BRD-A34006693,suprofen,"C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|",688581,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
5945,BRD-K70327167,suramin,Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O,5361,Launched,DNA synthesis inhibitor,F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5,infectious disease,African trypanosomiasis|onchocerciasis,2147|5028|53829|5029|5320|23408|6261|6262|692312|2492,Low (25%)
5946,BRD-K98557884,suritozole,Cn1nc(-c2cccc(F)c2)n(C)c1=S,25431,Phase 2,GABA receptor inverse agonist,GABBR1,"","",10537,No-Effect
5949,BRD-K15170068,swainsonine,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,51683,Phase 2,alpha mannosidase inhibitor,MAN2A1,"","",4124,No-Effect
5950,BRD-K45385835,SX-011,CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,9935015,Preclinical,MAP kinase inhibitor,MAPK14,"","",1432,No-Effect
5952,BRD-K72106461,SYM-2081,C[C@H](C[C@H](N)C(O)=O)C(O)=O,95883,Preclinical,kainate receptor antagonist,GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2,"","",6506|2897|2899|2900|2901,No-Effect
5953,BRD-A77218119,SYM-2206,"CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|",92209239,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
5955,BRD-K01825585,synephrine,CNC[C@@H](O)c1ccc(O)cc1 |&1:3|,667452,Launched,adrenergic receptor agonist,ADRA1A,otolaryngology,sinusitis,146,No-Effect
5956,BRD-K31843556,T-0070907,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1,2777391,Preclinical,PPAR receptor antagonist,PPARG,"","",5468,Weak (50%)
5957,BRD-K63516691,T-0156,COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,5368,Preclinical,phosphodiesterase inhibitor,PDE5A,"","",8654,No-Effect
5959,BRD-K23383398,T-0901317,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F,447912,Preclinical,LXR agonist,NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB,"","",10499|8648|10062|7376|6257|8856,No-Effect
5961,BRD-K84925803,T-5224,OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O,23626877,Phase 2,AP inhibitor,JUN,"","",3725,No-Effect
5962,BRD-K83492904,T-5601640,Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F,9438169,Preclinical,LIM kinase inhibitor,LIMK2,"","",3985,No-Effect
5963,BRD-K09001147,T-62,Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1,855908,Phase 2,adenosine receptor modulator,ADORA2A,"","",135,No-Effect
5965,BRD-K79856806,TA-01,Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F,91691129,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,CSNK1D|CSNK1E|MAPK14,"","",1432|1453|1454,No-Effect
5966,BRD-K53600683,tabimorelin,CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N,9810101,Phase 2,growth hormone secretagogue receptor agonist,GHSR,"","",2693,No-Effect
5967,BRD-K73237276,tacalcitol,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5283734,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis|chapped lips,1594,No-Effect
5968,BRD-K52313696,tacedinaline,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,2746,Phase 3,HDAC inhibitor,HDAC1,"","",3065,No-Effect
5969,BRD-K81473089,tacrine,Nc1c2CCCCc2nc2ccccc12,1935,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease,43|590,Very Weak (35%)
5970,BRD-K69608737,tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|,445643,Launched,calcineurin inhibitor,FKBP1A,transplant,organ rejection,2280,No-Effect
5971,BRD-K93645900,tadalafil,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O,110635,Launched,phosphodiesterase inhibitor,PDE11A|PDE5A,urology,erectile dysfunction,50940|8654,No-Effect
5972,BRD-K23728141,tafamidis-meglumine,OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1,11001318,Launched,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP),7276,No-Effect
5974,BRD-K65059905,tafluprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1,9868491,Launched,prostaglandin inhibitor,PTGFR,ophthalmology,glaucoma|ocular hypertension,5737,Low (25%)
5975,BRD-K18320600,tagatose,OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO,92092,Launched,phosphorylase inhibitor,PYGL,"","",5836,No-Effect
5976,BRD-K57155378,TAK-063,COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1,46848915,Phase 2,phosphodiesterase inhibitor,PDE10A,"","",10846,No-Effect
5977,BRD-K38793468,TAK-220,CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1,5275766,Phase 1,CC chemokine receptor antagonist,CCR5,"","",1234,No-Effect
5979,BRD-K80343549,TAK-285,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,11620908,Phase 1,EGFR inhibitor,ERBB2,"","",2064,No-Effect
5980,BRD-K67262033,TAK-593,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,24767976,Phase 1,VEGFR inhibitor,PDGFRA,"","",5156,No-Effect
5981,BRD-K31866293,TAK-632,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,46209401,Preclinical,RAF inhibitor,BRAF,"","",673,No-Effect
5983,BRD-K52751261,TAK-715,CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1,9952773,Phase 2,p38 MAPK inhibitor,MAPK14,"","",1432,No-Effect
5984,BRD-K26667523,TAK-733,Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O,24963252,Phase 1,MEK inhibitor,MAP2K1,"","",5604,No-Effect
5986,BRD-K58501140,TAK-875,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1,24857286,Phase 3,insulin secretagogue,FFAR1,"","",2864,No-Effect
5987,BRD-K01683783,TAK-901,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,16124208,Phase 1,Aurora kinase inhibitor,AURKB,"","",9212,No-Effect
5988,BRD-K48059512,TAK-960,COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1,53357478,Phase 1,PLK inhibitor,PLK1,"","",5347,Cyto
5989,BRD-K37419961,talabostat,CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,6918572,Phase 3,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,DPP4,"","",1803,No-Effect
5990,BRD-K50498985,taladegib,CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F,49848070,Phase 2,smoothened receptor antagonist,DHH|IHH|SMO,"","",54498|3549|50846,No-Effect
5991,BRD-K80359953,talampanel,C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|,164509,Phase 2,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,"","",2890|2891|2892|2893,No-Effect
5993,BRD-A95755460,talarozole,"CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|",76958553,Phase 2,cytochrome P450 inhibitor,CYP26A1,"","",1592,No-Effect
5994,BRD-K95142244,talazoparib,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,135565082,Launched,PARP inhibitor,PARP2,oncology,breast cancer,10038,No-Effect
5995,BRD-A94276798,talinolol,"CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|",156154,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153,No-Effect
5996,BRD-K75615183,talipexole,Nc1nc2CCN(CC=C)CCc2s1,5374,Launched,adrenergic receptor agonist|dopamine receptor agonist,ADRA2A|DRD2|HTR3A,infectious disease,genitial herpes,1813|150|3359,Very Weak (35%)
5997,BRD-K17555800,talmapimod,C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C,9871074,Phase 2,p38 MAPK inhibitor,IL1B|MAPK11|MAPK14|MT-CO2|TNF,"","",5600|3553|107075310|7124|1432,No-Effect
5998,BRD-K47095176,talnetant,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,5311424,Phase 2,tachykinin antagonist,TACR2|TACR3,"","",6865|6870,No-Effect
5999,BRD-A98378129,talniflumate,"FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|",25273599,Launched,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief,1179,No-Effect
6000,BRD-A02532772,talopram,CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|,76958671,Phase 2,adrenergic inhibitor,SLC6A2,"","",6530,No-Effect
6002,BRD-K93869735,taltirelin,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,114750,Launched,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,7201,No-Effect
6005,BRD-K36627727,tamibarotene,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,108143,Launched,retinoid receptor agonist,RARA|RARB,hematologic malignancy,acute promyelocytic leukemia (APL),5914|5915,No-Effect
6007,BRD-K93754473,tamoxifen,CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,2733526,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ,oncology,breast cancer,2852|5578|5579|5580|5581|5582|5584|2099|2100|5588|5590|10682,No-Effect
6008,BRD-K74339692,tamsulosin,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O,129211,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH),146|147,Low (25%)
6009,BRD-K99604664,tanaproget,Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N,4369524,Phase 2,progesterone receptor agonist,PGR,"","",5241,No-Effect
6010,BRD-K65904673,tandospirone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1,91273,Launched,serotonin receptor agonist,HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)|dysthymic disorder,3350,No-Effect
6011,BRD-K89162000,tandutinib,COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1,3038522,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,"","",5159|3815|2322|80310|1436,Very Weak (35%)
6012,BRD-K81473043,tanespimycin,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|",59996479,Phase 3,HSP inhibitor,HSP90AA1,"","",3320,Very Weak (35%)
6014,BRD-K01584643,tannic-acid,Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,16129778,Launched,PARG inhibitor,ANO1,gastroenterology,constipation,55107,Low (25%)
6015,BRD-K34073885,tanshinone-I,Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,114917,Phase 2,AP inhibitor,IFNG,"","",3458,No-Effect
6016,BRD-K00141480,tanshinone-IIA,Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21,164676,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,IL1B|NR1I2|TNF,"","",8856|3553|7124,No-Effect
6018,BRD-K88854110,taprenepag,OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1,18376177,Phase 2,prostaglandin receptor agonist,PTGER2,"","",5732,No-Effect
6019,BRD-K00003568,tarafenacin,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2,25147683,Phase 2,acetylcholine receptor antagonist,CHRM3,"","",1131,No-Effect
6020,BRD-K35169477,taranabant,C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N,11226090,Phase 3,cannabinoid receptor inverse agonist,CNR1,"","",1268,No-Effect
6021,BRD-K22227508,targinine,CNC(=N)NCCC[C@H](N)C(O)=O,46906075,Phase 3,nitric oxide synthase inhibitor,NOS3,"","",342977,No-Effect
6022,BRD-K09353376,tariquidar,COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC,148201,Phase 3,P glycoprotein inhibitor,ABCB1,"","",5243,No-Effect
6024,BRD-K09426783,TAS-103,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,135413533,Phase 1,topoisomerase inhibitor,TOP1,"","",7150,No-Effect
6025,BRD-K44844162,taselisib,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,51001932,Phase 3,PI3K inhibitor,PIK3CA,"","",5290,Weak (50%)
6026,BRD-K62971431,tasimelteon,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12,10220503,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder,4544|4543,Weak (50%)
6028,BRD-K14653796,tasquinimod,COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12,54682876,Phase 3,angiogenesis inhibitor|S100A9 inhibitor,HDAC4,"","",9759,No-Effect
6031,BRD-K81062487,taurocholate,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,6675,Phase 1,G protein-coupled receptor agonist,CEL|FABP6|SLCO1C1,"","",1056|2172|53919,No-Effect
6036,BRD-K94649603,taxifolin,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1,439533,Phase 2,opioid receptor antagonist,ADIPOR2,"","",79602,No-Effect
6037,BRD-K76841105,tazarotene,CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1,5381,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRB,dermatology,cosmetic|sunscreen lotion,6257|5914|5915|5916,Low (25%)
6038,BRD-K11215326,tazemetostat,CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1,66558664,Launched,histone lysine methyltransferase inhibitor,EZH2,"","",2146,No-Effect
6041,BRD-M77041484,TBOA-(DL),N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O,90479771,Preclinical,excitatory amino acid transporter inhibitor,SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7,"","",6505|6506|6507|6511|6512,No-Effect
6042,BRD-A12147465,TC-A-2317,C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|,24783396,Preclinical,Aurora kinase inhibitor,AURKA,"","",6790,No-Effect
6043,BRD-K29660062,TC-ASK-10,CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1,24944925,Preclinical,MAP kinase inhibitor,MAP3K5|MAP3K6,"","",9064|4217,No-Effect
6045,BRD-A66521565,TC-E-5006,"C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|",97289132,Preclinical,gamma secretase modulator,APP,"","",351,No-Effect
6046,BRD-K26041695,TC-F-2,CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O,25198728,Preclinical,FAAH inhibitor,FAAH,"","",79152,No-Effect
6047,BRD-K16497916,TC-FPR-43,CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C,24776341,Preclinical,formyl peptide receptor agonist,FPR2,"","",2358,No-Effect
6048,BRD-K27010807,TC-G-1000,Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|,10220232,Preclinical,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,"","",152|150|151,No-Effect
6049,BRD-K76989898,TC-G-1004,COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C,25074316,Preclinical,adenosine receptor antagonist,ADORA2A,"","",135,No-Effect
6050,BRD-K16939217,TC-G-1005,Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1,71450251,Preclinical,G protein-coupled receptor agonist,GPBAR1,"","",151306,No-Effect
6051,BRD-K87199310,TC-G-1008,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1,91826086,Preclinical,G protein-coupled receptor agonist,GPR39,"","",2863,No-Effect
6052,BRD-K45044657,TC-H-106,Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1,16070100,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,"","",3065|3066|8841|55869,No-Effect
6053,BRD-K17621556,TC-I-15,CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1,90488948,Preclinical,integrin inhibitor,ITGA2|ITGB1,"","",3688|3673,No-Effect
6054,BRD-A83792282,TC-I-2000,"Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|",57326391,Preclinical,transient receptor potential channel antagonist,TRPM8,"","",79054,No-Effect
6055,BRD-K05262258,TC-I-2014,FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|,135883253,Preclinical,transient receptor potential channel antagonist,TRPM8,"","",79054,No-Effect
6056,BRD-K32031961,TC-LPA5-4,COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O,66552906,Preclinical,lysophosphatidic acid receptor antagonist,LPAR5,"","",57121,No-Effect
6057,BRD-K76792630,TC-Mps1-12,CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N,70682875,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,"","",7272,No-Effect
6058,BRD-K78161388,TC-N-1752,CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C,53361524,Preclinical,sodium channel blocker,SCN9A,"","",6335,No-Effect
6060,BRD-K54297077,TC-O-9311,COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12,3376937,Preclinical,G protein-coupled receptor agonist,GPR139,"","",124274,Low (25%)
6061,BRD-K55013981,TC-OT-39,CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12,135413563,Preclinical,oxytocin receptor agonist|vasopressin receptor agonist,AVPR1A|OXT,"","",552|5020,No-Effect
6062,BRD-K34362291,TC-S-7003,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1,11785878,Preclinical,SRC inhibitor,LCK,"","",3932,No-Effect
6064,BRD-K89584803,TC-S-7005,C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1,24971422,Preclinical,PLK inhibitor,PLK2,"","",10769,Low (25%)
6065,BRD-K51776215,TC-S-7006,Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl,9549300,Preclinical,MAP kinase inhibitor,MAP3K8,"","",1326,No-Effect
6066,BRD-K21894922,TC-S-7009,[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12,70697712,Preclinical,hypoxia inducible factor inhibitor,EPAS1,"","",2034,No-Effect
6067,BRD-K87461578,TC-SP-14,OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1,51346934,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,"","",1901,No-Effect
6068,BRD-K01825674,TC1,"O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|",,Preclinical,beta-secretase inhibitor,BACE1,"","",23621,No-Effect
6069,BRD-K24227647,TC2559,CCOc1cncc(\C=C\CCNC)c1,9823180,Preclinical,acetylcholine receptor agonist,CHRNA4,"","",1137,No-Effect
6071,BRD-K09787262,TCN201,Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1,4787937,Preclinical,glutamate receptor antagonist,GRIN2A,"","",2903,No-Effect
6072,BRD-K77915400,TCN238,Nc1nccc(\C=C\c2ccccc2)n1,46911068,Preclinical,glutamate receptor positive allosteric modulator,GRM4,"","",2914,No-Effect
6073,BRD-K00004294,TCS-2002,"Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|",44247646,Preclinical,glycogen synthase kinase inhibitor,GSK3B,"","",2932,No-Effect
6074,BRD-K49461364,TCS-21311,CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|,50925411,Preclinical,JAK inhibitor,JAK3,"","",3718,No-Effect
6076,BRD-K55216666,TCS-2314,Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1,11226207,Preclinical,integrin inhibitor,ITGA4|ITGB1,"","",3688|3676,No-Effect
6077,BRD-K81935556,TCS-3035,OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1,2295463,Preclinical,G protein-coupled receptor agonist,GPR35,"","",2859,No-Effect
6078,BRD-K81376179,TCS-359,COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O,1048845,Preclinical,FLT3 inhibitor,FLT3,"","",2322,No-Effect
6079,BRD-A16560607,TCS-5861528,"CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|",1116244,Preclinical,transient receptor potential channel antagonist,TRPA1,"","",8989,No-Effect
6080,BRD-K68358632,TCS-HDAC6-20b,CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2,23636017,Preclinical,HDAC inhibitor,HDAC6,"","",10013,Low (25%)
6081,BRD-K29424831,TCS-OX2-29,COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C,10408514,Preclinical,orexin receptor antagonist,HCRTR2,"","",131450,No-Effect
6082,BRD-K08902330,TCS-PIM-1-1,Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1,1235170,Preclinical,Pim kinase inhibitor,PIM1,"","",9361,No-Effect
6085,BRD-K28224173,tebipenem,"C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|",9892071,Launched,bacterial cell wall synthesis inhibitor,CNR1,infectious disease|otolaryngology,pneumonia|otitis,1268,No-Effect
6086,BRD-K00003289,tecadenoson,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12,158795,Phase 2,adenosine receptor agonist,ADORA1,"","",134,No-Effect
6087,BRD-K41662846,tecalcet,COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl,158797,Phase 2,calcium-sensing receptor agonist,CASR,"","",846,No-Effect
6088,BRD-K48195801,tecastemizole,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,123618,Phase 3,histamine receptor antagonist,KCNH2,"","",3757,No-Effect
6092,BRD-K88743730,tegaserod,CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12,135409453,Withdrawn,serotonin receptor partial agonist,HTR2A|HTR2B|HTR2C|HTR4,"","",3360|3356|106480180|3358,No-Effect
6097,BRD-K51528698,teijin-compound-1,FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1,44453327,Preclinical,CC chemokine receptor antagonist,CCR2,"","",729230,No-Effect
6098,BRD-K72912098,telaprevir,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,3010818,Launched,HCV inhibitor,CTSA|PGR,infectious disease,hepatitis C,5241|5476,Very Weak (35%)
6099,BRD-K84564571,telatinib,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,9808844,Phase 2,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,"","",3791,No-Effect
6101,BRD-K91159026,telcagepant,Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F,11319053,Phase 3,calcitonin antagonist,CALCRL|RAMP1,"","",10267|10203,No-Effect
6102,BRD-K06147391,telenzepine,CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1,5387,Phase 3,acetylcholine receptor antagonist,CHRM1,"","",1128,No-Effect
6103,BRD-K82240271,telithromycin,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC,,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7,infectious disease,pneumonia,100861540|1544|1577|1576|1565,No-Effect
6105,BRD-K73999723,telmisartan,CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C,65999,Launched,angiotensin receptor antagonist,AGTR1|PPARG,cardiology,hypertension,185|5468,No-Effect
6106,BRD-K63178091,telotristat,Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,25025298,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,7166,No-Effect
6107,BRD-K94559059,telotristat-ethyl,CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1,25181577,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,7166,Very Weak (35%)
6111,BRD-K10784860,temocapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,443874,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology|nephrology,hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD),1636,No-Effect
6113,BRD-K32107296,temozolomide,Cn1nnc2c(ncn2c1=O)C(N)=O,5394,Launched,DNA alkylating agent,MGMT,oncology,glioblastoma|astrocytoma,4255,No-Effect
6115,BRD-K08177763,temsirolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|",134812825,Launched,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),2475,No-Effect
6119,BRD-A42270467,tenatoprazole,COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,11552393,Phase 2,ATPase inhibitor,IDO1,"","",3620,No-Effect
6120,BRD-K48068743,teneligliptin,Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1,11949652,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
6121,BRD-K00004279,tenidap,"NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|",,Phase 3,cyclooxygenase inhibitor,KCNJ4|PTGS1,"","",3761|5742,No-Effect
6123,BRD-K10362825,teniposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12,452548,Launched,topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute lymphoblastic leukemia (ALL),7153|7155,Cyto
6126,BRD-K61868322,tenofovir-disoproxil,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C,5481350,Launched,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B,1544,No-Effect
6127,BRD-K05977823,tenovin-1,CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1,1013376,Preclinical,SIRT inhibitor|TP53 activator,SIRT1,"","",23411,No-Effect
6128,BRD-K13949769,tenovin-6,CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1,24772043,Preclinical,SIRT inhibitor,SIRT1|SIRT2|SIRT3,"","",23410|23411|22933,Very Weak (35%)
6129,BRD-A22844106,tenoxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|,54677971,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|orthopedics,rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis,5742|5743,Weak (50%)
6131,BRD-K89714990,tepoxalin,COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1,59757,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5,rheumatology|orthopedics,rheumatoid arthritis|hip dysplasia,240,No-Effect
6132,BRD-K01826017,TEPP-46,Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|,60156291,Preclinical,pyruvate kinase isozyme activator,PKM,"","",5315,No-Effect
6134,BRD-K76788410,terameprocol,COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,476861,Phase 1/Phase 2,lipoxygenase inhibitor,BIRC5|CDK1,"","",332|983,No-Effect
6135,BRD-K01826569,terazosin,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|",1398859,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,146|147,No-Effect
6136,BRD-K68132782,terbinafine,CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12,1549008,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis,6713,No-Effect
6137,BRD-A50157456,terbutaline,CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|,11354816,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|bronchitis|emphysema,154,No-Effect
6140,BRD-A06352418,terfenadine,"CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|",6604035,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,"","",3756|3269|3757,Very Weak (35%)
6141,BRD-A89207210,terguride,"CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|",443951,Launched,dopamine receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease,3352|1815|146|106480180|1813|150|151|152|1814|3350|3356|3351|3358,No-Effect
6142,BRD-A42699921,teriflunomide,"CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|",,Launched,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,1723,No-Effect
6143,BRD-K73451719,terlipressin,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,133566182,Launched,vasopressin receptor agonist,AVPR1A,cardiology,hypotension,552,No-Effect
6147,BRD-K00024725,terreic-acid-(-),C[C@@H]1C(=O)[C@H]2O[C@H]2C(=O)C1=O |&1:1|,,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,"","",695,No-Effect
6148,BRD-K43975632,terutroban,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,9938840,Phase 3,prostanoid receptor antagonist,TBXA2R,"","",6915,No-Effect
6149,BRD-K15507868,tesaglitazar,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O,208901,Phase 3,insulin sensitizer|PPAR receptor agonist,PPARA|PPARG,"","",5465|5468,Low (25%)
6150,BRD-K00004564,tetomilast,CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O,3025803,Phase 2,phosphodiesterase inhibitor,PDE4D,"","",5144,No-Effect
6151,BRD-K95739795,tetrabenazine,COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC,11634155,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,infectious disease|neurology/psychiatry,cholera|Huntington's disease,6570|6571,No-Effect
6152,BRD-K45071273,tetracaine,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,5411,Launched,membrane integrity inhibitor,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,anesthetic,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335,No-Effect
6155,BRD-K41298358,tetraethylenepentamine,NCCNCCNCCNCCN,8197,Phase 2/Phase 3,superoxide dismutase inhibitor,SOD1|SOD2,"","",100129518|6647,No-Effect
6156,BRD-A36978621,tetrahydrofolic-acid,"Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|",135398650,Launched,"",FOLR2,"","",2350,No-Effect
6158,BRD-A86248581,tetrahydrouridine,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|",9543506,Phase 2,cytidine deaminase inhibitor,CDA,"","",978,No-Effect
6161,BRD-A46393198,tetramisole,"C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|",26879,Launched,immunostimulant,ALPPL2|CHRNA3,infectious disease,gastrointestinal parasites,1136|251,No-Effect
6162,BRD-K08078237,tetrandrine,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,73078,Preclinical,calcium channel blocker,SLC6A3,"","",6531,Strong (80%)
6163,BRD-A14757586,tetrazol-5-yl-glycine-(RS),"N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|",15024268,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,"","",114787|2903|2904|2905|2906,No-Effect
6164,BRD-A52660433,tetrindole,C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1,54792409,Phase 3,monoamine oxidase inhibitor,MAOA,"","",4128,Weak (50%)
6167,BRD-K57708067,TFC-007,O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1,16040067,Preclinical,prostaglandin inhibitor,HPGDS,"","",27306,No-Effect
6168,BRD-K97072811,TG-003,CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O,1893668,Preclinical,CLK inhibitor,CLK1|CLK4|DYRK1A|DYRK1B,"","",1859|1195|57396|9149,No-Effect
6169,BRD-K14560436,TG-02,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|,16739650,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,"","",1025|3717|2322|983|1017|1022,Cyto
6170,BRD-K18424115,TG-100572,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,11712625,Preclinical,SRC inhibitor|VEGFR inhibitor,KDR|SRC,"","",6714|3791,Weak (50%)
6172,BRD-K12735121,TG-100801,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl,11973736,Phase 2,SRC inhibitor|VEGFR inhibitor,CSK|FGFR1|FLT1|FLT4|KDR|SRC,"","",1445|3791|2321|2324|2260|6714,No-Effect
6173,BRD-K39841531,TG-101209,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,16722832,Preclinical,JAK inhibitor,JAK2|JAK3,"","",3717|3718,Cyto
6174,BRD-K64785675,TG100-115,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,10427712,Phase 1/Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,"","",5290|5291|5294|22883,No-Effect
6176,BRD-A41692738,TGX-221,"C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|",51601993,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD,"","",5291|22883,No-Effect
6178,BRD-K01054709,TH-588,Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl,73389731,Preclinical,MTH1 inhibitor,NUDT1,"","",4521,No-Effect
6180,BRD-A93255169,thalidomide,"O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|",92142,Launched,tumor necrosis factor production inhibitor,TNF,oncology,myeloma,7124,No-Effect
6182,BRD-K34888156,theobromine,Cn1cnc2n(C)c(=O)[nH]c(=O)c12,5429,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|PDE4B,"","",5142|134|135,No-Effect
6183,BRD-K38380126,thiamet-g,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|,24808478,Preclinical,GLCNAC phosphotransferase inhibitor,MGEA5,"","",10724,Low (25%)
6184,BRD-K95785345,thiamine,Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N,1130,Launched,vitamin B,SLC19A2|SLC19A3|TPK1,metabolism,thiamine deficiency,10560|27010|80704,No-Effect
6187,BRD-A23970436,thiamylal,"CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|",3033021,Launched,glutamate receptor antagonist,GABRA1,neurology/psychiatry,sedative,2554,No-Effect
6189,BRD-K69600043,thiethylperazine,CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,5440,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD4,gastroenterology,nausea,1812|1813|1815,Weak (50%)
6190,BRD-K26619122,thiocolchicoside,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,9915886,Launched,GABA receptor antagonist,GABRA1|GABRB2|GABRG2|GLRA1|GLRB,neurology/psychiatry,muscle relaxant,2561|2566|2741|2743|2554,Low (25%)
6191,BRD-A16347691,thioctic-acid,"OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|",445125,Launched,reducing agent,ACHE|PTGS2,nephrology,diabetic nephropathy,43|5743,No-Effect
6193,BRD-K49350383,thioguanine,Nc1nc2nc[nH]c2c(=S)[nH]1,2723601,Launched,purine antagonist,IMPDH1|IMPDH2,hematologic malignancy,acute myeloid leukemia (AML),727833|3615,Strong (80%)
6194,BRD-K61443650,thiomersal,CC[Hg]Sc1ccccc1C(O)=O,67361,Launched,other antibiotic,OXCT1,infectious disease,preservative,5019,Strong (80%)
6195,BRD-A72603112,thiopental,"CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|",3033017,Launched,GABA receptor antagonist,FAAH,neurology/psychiatry,anesthetic,79152,No-Effect
6196,BRD-A85424553,thioperamide,"S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|",6604452,Preclinical,histamine receptor antagonist,HRH3|HRH4,"","",59340|11255,No-Effect
6198,BRD-K08619574,thioproperazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,9429,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,146|147|1812|1813|3350|3356,Strong (80%)
6199,BRD-A84481105,thioridazine,CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1,66062,Withdrawn,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7,"","",3362|3363|3269|1812|1813|1814|1815|1816|3350|3356|3358,Strong (80%)
6200,BRD-A56012032,thiorphan,"OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|",4369380,Phase 1,membrane metalloendopeptidase inhibitor,MME,"","",4321,No-Effect
6201,BRD-K58049875,thiostrepton,"CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|",16154490,Launched,FOXM1 inhibitor|protein synthesis inhibitor,FOXM1,obstetrics/gynecology,mastitis,2305,Very Weak (35%)
6202,BRD-K09631521,thiotepa,S=P(N1CC1)(N1CC1)N1CC1,5453,Launched,cytochrome P450 inhibitor,CYP2B6|CYP3A4,oncology,breast cancer|ovarian cancer|bladder cancer,1576|1555,No-Effect
6203,BRD-K04175245,thiothixene,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1,941651,Launched,dopamine receptor antagonist,DRD1|DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia,3269|3356|1812|1813,No-Effect
6204,BRD-K29254801,thiram,CN(C)C(=S)SSC(=S)N(C)C,5455,Launched,"",JAK2,ophthalmology,contact dermatitis,3717,No-Effect
6210,BRD-K17458574,thymol,CC(C)c1ccc(C)cc1O,6989,Launched,GABA receptor positive allosteric modulator,TRPA1,infectious disease,ringworm|antiseptic,8989,Low (25%)
6213,BRD-K66401437,THZ1,CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,73602827,Preclinical,CDK inhibitor,CDK7,"","",1022,No-Effect
6214,BRD-K02135007,THZ1-R,CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,119081415,Preclinical,CDK inhibitor,CDK7,"","",1022,No-Effect
6215,BRD-K95902121,THZ2,CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,78357763,Preclinical,CDK inhibitor,CDK7,"","",1022,No-Effect
6217,BRD-K60160658,tiagabine,Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C,60648,Launched,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,6529,No-Effect
6218,BRD-K01826304,tianeptine,"CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|",37888263,Launched,selective serotonin reuptake enhancer (SSRE),OPRD1|OPRK1|OPRM1,neurology/psychiatry|pulmonary|gastroenterology,depression|asthma|irritable bowel syndrome,4985|4986|4988,No-Effect
6219,BRD-K57432881,tiapride,CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O,5467,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,dyskinesia|abstinence from alcohol|psychosis,1813|1814,No-Effect
6220,BRD-A72988804,tiaprofenic-acid,"C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|",181380,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis,5743,No-Effect
6222,BRD-A82522119,tibolone,"C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|",124484332,Launched,androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist,ESR1,obstetrics/gynecology,endometriosis,2099,No-Effect
6223,BRD-K19939891,TIC10,"Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|",336423,Phase 2,AKT inhibitor|TRAIL modulator,AKT1|MAPK1,"","",5594|207,No-Effect
6224,BRD-K25838957,ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,9871419,Launched,purinergic receptor antagonist,P2RY12,cardiology,acute coronary syndrome (ACS)|myocardial infarction,64805,Low (25%)
6226,BRD-K00603606,ticlopidine,Clc1ccccc1CN1CCc2sccc2C1,5472,Launched,purinergic receptor antagonist,P2RY12,hematology|neurology/psychiatry,thrombosis|stroke,64805,No-Effect
6227,BRD-K81330143,tideglusib,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,11313622,Phase 2,glycogen synthase kinase inhibitor,GSK3B,"","",2932,No-Effect
6228,BRD-A92800748,tie2-kinase-inhibitor,COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|,92852530,Preclinical,TIE tyrosine kinase inhibitor,KDR|MAPK14,"","",1432|3791,No-Effect
6229,BRD-K34098590,tienilic-acid,OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,38409,Withdrawn,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,CYP2C9|SLC12A1,"","",6557|1559,No-Effect
6230,BRD-K20568871,tifenazoxide,CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|,135410911,Phase 1,ATP-sensitive potassium channel agonist,ABCC8|KCNJ11,"","",6833|3767,No-Effect
6234,BRD-K10845183,tiludronate,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,60937,Launched,bone resorption inhibitor|osteoclast inhibitor,ATP6V1A|MMP2|PTPN1,orthopedics,navicular syndrome,4313|5770|523,No-Effect
6235,BRD-A64406146,timofibrate,"CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|",51371472,Phase 2,cholesterol inhibitor|lipase clearing factor inhibitor,LPL,"","",3936,No-Effect
6236,BRD-K08806317,timolol,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,33624,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,ocular hypertension|glaucoma,153|154,No-Effect
6244,BRD-K11107424,tiotidine,CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N,50287,Phase 2,histamine receptor antagonist,HRH2,"","",1665,No-Effect
6245,BRD-K62782754,tiotropium,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131,No-Effect
6246,BRD-K41876534,tioxolone,Oc1ccc2sc(=O)oc2c1,72139,Preclinical,carbonic anhydrase inhibitor,CA2,"","",760,Very Weak (35%)
6248,BRD-K62965247,tipifarnib,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,159324,Phase 3,farnesyltransferase inhibitor,FNTA|FNTB,"","",2339|100529261,No-Effect
6250,BRD-K30882994,tiplaxtinin,OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1,6450819,Phase 1,plasminogen activator inhibitor,SERPINE1,"","",5054,No-Effect
6252,BRD-A73566563,tiprenolol,"CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|",76966339,Phase 2,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
6254,BRD-K75250001,tiracizine,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1,71264,Withdrawn,sodium channel blocker,SCN5A,"","",6331,No-Effect
6257,BRD-K61236135,tiratricol,OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,5803,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,Refetoff syndrome,7067|7068,No-Effect
6258,BRD-K37872686,tirofiban,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O,60947,Launched,platelet aggregation inhibitor|structural glycoprotein antagonist,ITGA2B|ITGB3,cardiology,myocardial infarction|refactory angina,3674|3690,No-Effect
6260,BRD-K33379087,tivantinib,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,11494412,Phase 3,tyrosine kinase inhibitor,MET,"","",8731,No-Effect
6261,BRD-K53414658,tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,9911830,Launched,VEGFR inhibitor,FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB,oncology,renal cell carcinoma (RCC),5156|3815|5159|3791|2321|2324,No-Effect
6262,BRD-K06335600,tizanidine,Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|,5487,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|NISCH,neurology/psychiatry,spasms,152|11188|150|151,No-Effect
6268,BRD-K53597484,TNP-470,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl,369976,Phase 2,methionine aminopeptidase inhibitor,METAP2,"","",10988,No-Effect
6270,BRD-K01826767,tocainide,"C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|",3080825,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,6331,No-Effect
6271,BRD-K62040061,toceranib,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1,5329106,Launched,protein tyrosine kinase inhibitor,FLT1|FLT3|KDR|PDGFRA|PDGFRB,oncology,cutaneous mast cell tumors,5156|5159|3791|2321|2322,No-Effect
6274,BRD-K31283835,tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,9926791,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis,3716|3717|3718,No-Effect
6275,BRD-K94830213,tofisopam,"CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|",129009868,Launched,cytochrome P450 inhibitor|phosphodiesterase inhibitor,CYP3A4,neurology/psychiatry,anxiety|abstinence from alcohol,1576,Low (25%)
6276,BRD-K96344439,tofogliflozin,CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1,46908929,Launched,sodium/glucose cotransporter inhibitor,GCK,endocrinology,diabetes mellitus,5871,No-Effect
6277,BRD-A60498477,tolamolol,"Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|",66743765,Phase 3,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,"","",153|154|155,No-Effect
6278,BRD-K32164935,tolazamide,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,5503,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus,6833|3766|3758|3767,No-Effect
6279,BRD-K46211610,tolazoline,C(C1=NCCN1)c1ccccc1 |t:1|,5504,Launched,adrenergic receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2,neurology/psychiatry,reverse sedative,1665|3269|146|150|151|152,Low (25%)
6280,BRD-K85119730,tolbutamide,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,5505,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ11|KCNJ8,endocrinology,diabetes mellitus,6833|3764|3758|3767,No-Effect
6281,BRD-K10852020,tolcapone,Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O,4659569,Withdrawn,catechol O methyltransferase inhibitor,COMT,"","",1312,No-Effect
6283,BRD-K41772907,tolimidone,Cc1cccc(Oc2cnc(=O)[nH]c2)c1,39065,Phase 2,SRC activator,LYN|SRC,"","",6714|4067,No-Effect
6284,BRD-K82562631,tolmetin,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,5509,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743,No-Effect
6286,BRD-K82687598,tolonidine,Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|,72138,Launched,adrenergic receptor antagonist,ADRA2A,"","",150,No-Effect
6288,BRD-A67182178,toloxatone,"Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|",13753599,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression,4128|4129,No-Effect
6289,BRD-A27732521,tolperisone,C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|,688589,Launched,voltage-gated sodium channel blocker,CYP2C19|CYP2D6,neurology/psychiatry|infectious disease|rheumatology|cardiology,muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease,1565|1557,No-Effect
6290,BRD-K85693895,tolrestat,COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O,53359,Withdrawn,aldose reductase inhibitor,AKR1A1|AKR1B1|AKR1B10,"","",57016|231|10327,Very Weak (35%)
6291,BRD-K54316499,tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C,443879,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency,1128|1129|1131|1132|1133,No-Effect
6293,BRD-A82035391,tolvaptan,"Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|",443894,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology|cardiology|gastroenterology,hyponatremia|congestive heart failure|hepatic cirrhosis,552|554,No-Effect
6295,BRD-K74765201,tomelukast,CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O,3969,Phase 3,leukotriene receptor antagonist,CYSLTR1,"","",10800,No-Effect
6299,BRD-K29653726,topiramate,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,5284627,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache,2560|2561|2562|771|2563|2564|2565|2566|2567|2568|766|11280|6323|6326|6328|6329|6331|6332|6334|6335|6336|55879|2890|2891|2892|2893|2897|2899|2900|2901|762|759|760|2554|2555|2556|2557|2558|2559,Low (25%)
6300,BRD-K77561571,topiroxostat,N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1,5288320,Launched,xanthine oxidase inhibitor,XDH,rheumatology|nephrology,gout|hyperuricemia,6652,No-Effect
6301,BRD-K55696337,topotecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O,60700,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,small cell lung cancer|cervical cancer,7150|116447,No-Effect
6302,BRD-K30480208,torasemide,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1,51371498,Launched,electrolyte reabsorption inhibitor|thromboxane receptor antagonist,SLC12A1,cardiology,edema|congestive heart failure|hypertension,6557,No-Effect
6303,BRD-K55675242,torcetrapib,CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F,159325,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,"","",1071,No-Effect
6304,BRD-K91822704,torcitabine,Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,13711,Phase 2,DNA polymerase inhibitor,DCK|TK2,"","",1633|7083,No-Effect
6305,BRD-K51350053,toremifene,CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1,3005573,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,oncology,breast cancer,2099,Weak (50%)
6306,BRD-K40175214,torin-1,CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,49836027,Preclinical,mTOR inhibitor,MTOR,"","",2475,No-Effect
6307,BRD-K68174511,torin-2,Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1,51358113,Preclinical,mTOR inhibitor,MTOR,"","",2475,Cyto
6308,BRD-K92241597,tosedostat,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1,15547703,Phase 2,peptidase inhibitor,ANPEP|LAP3|NPEPPS,"","",9520|290|7852,No-Effect
6310,BRD-K26420709,toyocamycin,Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,11824,Phase 1,serine/threonine kinase inhibitor,ERN1,"","",2081,Weak (50%)
6311,BRD-K93045741,tozadenant,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,11618368,Phase 3,adenosine receptor antagonist,ADORA2A,"","",135,No-Effect
6312,BRD-K59369769,tozasertib,CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1,5494449,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKA|AURKB|AURKC|LCK,"","",6795|9212|6790|3932,No-Effect
6313,BRD-K87941707,TP-003,CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N,10001434,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,No-Effect
6314,BRD-K84034737,TP-0903,CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl,56839178,Phase 1/Phase 2,AXL kinase inhibitor,AXL,"","",558,Cyto
6316,BRD-K51575138,TPCA-1,NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1,9903786,Preclinical,IKK inhibitor,IKBKB,"","",3551,No-Effect
6320,BRD-K34154330,tracazolate,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,5522,Phase 2,GABA receptor modulator,GABRA1,"","",2554,No-Effect
6322,BRD-K30071764,TRAM-34,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1,656734,Preclinical,potassium channel antagonist,KCNN4,"","",3783,No-Effect
6323,BRD-K81341251,TRAM-39,Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1,9861261,Preclinical,calcium-activated potassium channel activator,KCNN4,"","",3783,Very Weak (35%)
6324,BRD-K12343256,trametinib,CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O,11707110,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma,5604|5605,No-Effect
6325,BRD-K82234479,tramiprosate,NCCCS(O)(=O)=O,6991996,Phase 3,beta amyloid protein neurotoxicity inhibitor,APP,"","",351,No-Effect
6326,BRD-K28550399,trandolapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O,5484727,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction,1636,No-Effect
6327,BRD-K15014948,tranexamic-acid,NC[C@H]1CC[C@@H](CC1)C(O)=O |r|,,Launched,antifibrinolytic|plasminogen activator inhibitor,PLG,hematology,hemophilia,5340,No-Effect
6328,BRD-K17849083,tranilast,COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC,5282230,Launched,angiogenesis inhibitor,HPGDS|HRH1,pulmonary,asthma,27306|3269,No-Effect
6335,BRD-K00003699,tranylcypromine,"N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|",26070,Launched,monoamine oxidase inhibitor,KDM1A|MAOA|MAOB,neurology/psychiatry,depression,4128|4129|23028,No-Effect
6336,BRD-K69837166,trap-101,CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|,11494970,Preclinical,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,OPRL1,"","",4987,No-Effect
6337,BRD-K95763993,trapidil,CCN(CC)c1cc(C)nc2ncnn12,5531,Launched,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),5156,No-Effect
6338,BRD-K23976833,travoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F,5282226,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma,5737,No-Effect
6339,BRD-K38158531,traxoprodil,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1,219101,Phase 2,glutamate receptor antagonist,GRIN2B,"","",2904,No-Effect
6340,BRD-K70778732,trazodone,Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1,5533,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression,6532|3269|146|106480180|150|3350|3356|3358,No-Effect
6342,BRD-K36407194,trelagliptin,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,15983988,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
6345,BRD-K37543758,trepibutone,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,5536,Launched,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,irritable bowel syndrome,1128|1129|1131|1132,No-Effect
6346,BRD-K19706299,treprostinil,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O,6918140,Launched,prostanoid receptor agonist,P2RY12|PPARD|PTGIR,pulmonary,pulmonary arterial hypertension (PAH),5739|5467|64805,No-Effect
6347,BRD-K84663978,trequinsin,COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC,,Phase 1,phosphodiesterase inhibitor,PDE5A,"","",8654,No-Effect
6348,BRD-K08748705,tretazicar,NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O,89105,Phase 2,DNA replication inhibitor,NQO2,"","",4835,No-Effect
6349,BRD-K71879491,tretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|,444795,Launched,retinoid receptor agonist|retinoid receptor ligand,ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG,hematologic malignancy,acute promyelocytic leukemia (APL),5915|5916|7182|5918|6096|6097|6257|6258|8854|216|5914|5467|9052|190,Very Weak (35%)
6351,BRD-K77554836,triamcinolone,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|",31307,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908,No-Effect
6352,BRD-K53790871,triamcinolone-acetonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",6436,Launched,glucocorticoid receptor agonist|immunosuppressant,NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses,866|2908,No-Effect
6354,BRD-K92049597,triamterene,Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1,5546,Launched,sodium channel blocker,SCNN1A|SCNN1B|SCNN1D|SCNN1G,endocrinology|cardiology,hypokalemia|hypertension|edema,6337|6338|6339|6340,No-Effect
6355,BRD-K01669786,triapine,NC(=S)N\N=C\c1ncccc1N,9571836,Phase 2,ribonucleotide reductase inhibitor,RRM1|RRM2,"","",6240|6241,No-Effect
6361,BRD-A28940325,trichlormethiazide,"NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|",12444480,Launched,chloride channel blocker,PTGS1|PTGS2|SLC12A1,cardiology,hypertension|edema,6557|5742|5743,No-Effect
6364,BRD-K68202742,trichostatin-a,C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C,444732,Phase 1,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,"","",55869|9734|8841|10013|3065|3066|83933|10014|9759,Cyto
6365,BRD-K80431395,triciribine,Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,65399,Phase 1/Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,No-Effect
6367,BRD-K81916719,triclabendazole,CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,50248,Launched,microtubule inhibitor,DNMT1,infectious disease,tapeworm,1786,No-Effect
6369,BRD-K41731458,triclosan,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,5564,Launched,antibacterial agent,DNMT1,infectious disease,first-aid antiseptic,1786,No-Effect
6371,BRD-K37111771,trientine,NCCNCCNCCN,5565,Launched,chelating agent,CA14,metabolism,Wilson's disease,23632,No-Effect
6373,BRD-K89732114,trifluoperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,5566,Launched,dopamine receptor antagonist,ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1,neurology/psychiatry,schizophrenia,801|7137|6275|3269|50632|146|1813|1815|3356|3358,Weak (50%)
6374,BRD-K63675182,triflupromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F,5568,Launched,dopamine receptor antagonist,CHRM1|CHRM2|DRD1|DRD2|HTR2B,neurology/psychiatry|gastroenterology,psychosis|nausea|vomiting,1128|1129|1812|1813|106480180,No-Effect
6375,BRD-K03243820,trifluridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F,6256,Launched,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),7298,Low (25%)
6376,BRD-K71696703,triflusal,CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F,9458,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF),10846|339345|5742|4790,No-Effect
6378,BRD-K00003691,trihexyphenidyl,O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|,207845,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,parkinsonism,1128,No-Effect
6382,BRD-K00003635,trimebutine,CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|,13248159,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome,4985|4986|4988,No-Effect
6383,BRD-K88366685,trimetazidine,COc1ccc(CN2CCNCC2)c(OC)c1OC,21109,Launched,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris,10449,No-Effect
6384,BRD-K16606819,trimethadione,CN1C(=O)OC(C)(C)C1=O,5576,Launched,oxazolidine antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures,8912|8913|150350,Low (25%)
6385,BRD-K34415467,trimethobenzamide,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,5577,Launched,histamine receptor antagonist,DRD2,gastroenterology,vomiting|nausea|gastroenteritis,1813,No-Effect
6386,BRD-K07208025,trimethoprim,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,5578,Launched,dihydrofolate reductase inhibitor,DHFR|TYMS,infectious disease|gastroenterology,urinary tract infections|ear infections|diarrhea,7298|1719,No-Effect
6387,BRD-A56241705,trimethoquinol,COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|,12224034,Launched,adrenergic receptor antagonist,ADRB2|ADRB3,pulmonary,asthma,154|155,No-Effect
6390,BRD-K13642819,trimetrexate,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,5583,Phase 3,dihydrofolate reductase inhibitor,DHFR,"","",1719,Strong (80%)
6391,BRD-K01825162,trimipramine,C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|,6604024,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532,Low (25%)
6393,BRD-K57033106,tripelennamine,CN(C)CCN(Cc1ccccc1)c1ccccn1,5587,Launched,histamine receptor antagonist,HRH1,pulmonary|allergy,asthma|allergic rhinitis|urticaria,3269,Low (25%)
6394,BRD-K11742128,triprolidine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1,5282443,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269,No-Effect
6395,BRD-K19427720,triptan,CC(C)C(C)(C)C,10044,Phase 1,serotonin receptor agonist,HTR1B|HTR1D,"","",3352|3351,No-Effect
6396,BRD-K39484304,triptolide,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|,107985,Phase 3,RNA polymerase inhibitor,RELA,"","",5970,Weak (50%)
6397,BRD-K62685538,triptorelin,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,25074470,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology|endocrinology|obstetrics/gynecology,prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria,2798,No-Effect
6400,BRD-K83502127,trofinetide,NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O,3080768,Phase 2,cytokine production inhibitor,IFNG|IL6|TNF,"","",3569|3458|7124,No-Effect
6402,BRD-A13084692,troglitazone,"Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|",9824580,Withdrawn,insulin sensitizer|PPAR receptor agonist,CYP2C8|PPARG|TRPM3,"","",80036|5468|1558,No-Effect
6406,BRD-K47978074,trometamol,NC(CO)(CO)CO,6503,Launched,"",AMD1|CANT1|DCN|NEIL1|VEGFA,"","",1634|262|124583|79661|7422,No-Effect
6407,BRD-A84389633,"tropanyl-3,5-dimethylbenzoate","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|",,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,"","",9177|3359,No-Effect
6408,BRD-A34603619,tropesin,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|",12606305,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,"","",5742|5743,No-Effect
6409,BRD-A79672927,tropicamide,"CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|",688595,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,ophthalmology,mydriasis diagnostic|cycloplegia diagnostic,1131|1132,No-Effect
6411,BRD-K50866992,tropisetron,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12,,Launched,serotonin receptor antagonist,GLRA1|GLRA2|GLRB|HTR3A|HTR4,gastroenterology,nausea|vomiting,3360|2741|2742|2743|3359,No-Effect
6412,BRD-K00003641,trospium,"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|",,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence|urinary frequency,1128,No-Effect
6413,BRD-K00494077,trovafloxacin,N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,"","",7153,No-Effect
6418,BRD-K35626314,TRV130,COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1,66553195,Phase 3,opioid receptor agonist,OPRM1,"","",4988,No-Effect
6419,BRD-K76973696,tryptanthrin,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,73549,Preclinical,cyclooxygenase inhibitor,IDO1,"","",3620,No-Effect
6420,BRD-K83776863,tryptophan,N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O,6923516,Launched,serotonin receptor partial agonist,CASR|IDO1|SLC36A1|WARS|WARS2,neurology/psychiatry|gastroenterology,anxiety|bloating|constipation|fatigue|sleeplessness,3620|846|10352|206358|7453,Low (25%)
6422,BRD-K49685476,TTNPB,C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,5289501,Phase 1,retinoid receptor agonist,RARA|RARB|RARG,"","",5914|5915|5916,No-Effect
6423,BRD-K64852730,TTP-22,Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12,1536915,Preclinical,casein kinase inhibitor,CSNK2A1,"","",1459,No-Effect
6426,BRD-K00627859,tubastatin-A,CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO,49850262,Preclinical,HDAC inhibitor,HDAC6,"","",10013,No-Effect
6427,BRD-K99621550,tubocurarine,COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4,6000,Launched,acetylcholine receptor antagonist,ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN,neurology/psychiatry,anesthetic,3780|3781|3782|43|1135|353174|9177|3359,Very Weak (35%)
6428,BRD-K26026438,tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|,51039094,Phase 3,EGFR inhibitor,ERBB2,"","",2064,No-Effect
6431,BRD-K56086081,TUG-770,OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N,66553168,Preclinical,free fatty acid receptor agonist,FFAR1,"","",2864,No-Effect
6432,BRD-K24282351,TUG-891,Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1,57522038,Preclinical,free fatty acid receptor agonist,FFAR4,"","",338557,No-Effect
6433,BRD-K00003719,tulobuterol,CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|,688591,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154,No-Effect
6435,BRD-K28360340,TW-37,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O,11455910,Preclinical,BCL inhibitor,BCL2|BCL2L1|MCL1,"","",4170|596|598,Cyto
6436,BRD-K94176593,TWS-119,Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1,9549289,Preclinical,glycogen synthase kinase inhibitor,GSK3B|JUN|MYC,"","",4609|2932|3725,No-Effect
6438,BRD-K66584608,TY-52156,CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1,16046248,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR3,"","",1903,No-Effect
6442,BRD-K76064317,tyrphostin-AG-1296,COc1cc2ncc(nc2cc1OC)-c1ccccc1,2049,Preclinical,FLT3 inhibitor,FLT3,"","",2322,No-Effect
6443,BRD-K68336408,tyrphostin-AG-1478,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,2051,Preclinical,EGFR inhibitor,EGFR|MAPK14,"","",1432|1956,No-Effect
6444,BRD-K49657628,tyrphostin-AG-18,Oc1ccc(C=C(C#N)C#N)cc1O,2052,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,"","",1956,No-Effect
6445,BRD-K34533029,tyrphostin-AG-494,Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O,5328771,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
6446,BRD-K87919739,tyrphostin-AG-825,COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,6091659,Preclinical,protein tyrosine kinase inhibitor,ERBB2,"","",2064,No-Effect
6447,BRD-K17415526,tyrphostin-AG-835,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,5328769,Preclinical,protein tyrosine kinase inhibitor,EGFR,"","",1956,Very Weak (35%)
6448,BRD-K59469039,tyrphostin-AG-879,CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C,135419190,Preclinical,tyrosine kinase inhibitor,ERBB2|KDR|NTRK1,"","",2064|4914|3791,No-Effect
6449,BRD-K60184833,tyrphostin-AG-99,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,5328768,Preclinical,tyrosine kinase inhibitor,EGFR,"","",1956,No-Effect
6451,BRD-K18787491,U-0126,Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N,54539763,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,"","",5600|5604|5605|5609|5578|6093|6446|207|6300|2932|6037|6198|1111|1432|5594|3932|5599,Very Weak (35%)
6452,BRD-K08953028,U-0521,CC(C)C(=O)c1ccc(O)c(O)c1,21632,Preclinical,catechol O methyltransferase inhibitor,COMT,"","",1312,No-Effect
6453,BRD-K77867004,U-104,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,310360,Phase 1/Phase 2,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA9,"","",760|768|771|759,No-Effect
6455,BRD-K53532120,U-50488-(-),CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,6604724,Preclinical,opioid receptor agonist,OPRK1,"","",4986,No-Effect
6456,BRD-K20995441,U-54494A,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,183470,Preclinical,opioid receptor agonist,OPRK1,"","",4986,No-Effect
6457,BRD-K77070363,U-75799E,C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,9919153,Phase 1,growth hormone releasing factor agonist,GHSR,"","",2693,No-Effect
6458,BRD-K70281171,U-99194,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,5626,Preclinical,dopamine receptor antagonist,DRD3,"","",1814,No-Effect
6459,BRD-K38966689,UAMC-00039,N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1,11232124,Preclinical,dipeptidyl peptidase inhibitor,DPP4|DPP7,"","",29952|1803,No-Effect
6460,BRD-A14574269,UB-165,"Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|",6604855,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNB2,"","",1136|1137|1141,No-Effect
6461,BRD-K59574735,ubenimex,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O,72172,Launched,leukotriene synthesis inhibitor,LTA4H|RNPEP,hematologic malignancy,acute myeloid leukemia (AML),4048|6051,No-Effect
6462,BRD-A45499626,UBP-296,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|",6420161,Preclinical,glutamate receptor antagonist,GRIK1,"","",2897,No-Effect
6463,BRD-K79753741,UBP-302,N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O,6420161,Preclinical,glutamate receptor antagonist,GRIK1,"","",2897,No-Effect
6464,BRD-K09597601,UBP-310,Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O,6420160,Preclinical,glutamate receptor antagonist,GRIK1|GRIK5,"","",2897|2901,No-Effect
6465,BRD-K73610817,UC-112,Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12,3426979,Preclinical,XIAP inhibitor,XIAP,"","",331,Weak (50%)
6468,BRD-K20480395,UF-010,CCCCNNC(=O)c1ccc(Br)cc1,4596836,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,"","",3065|3066|8841|55869,No-Effect
6469,BRD-K84173274,ufenamate,CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,5632,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,dermatology,eczema|dermatitis,5742|5743,No-Effect
6470,BRD-K66715657,UH-232-(+),CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,6604756,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR1A,"","",3350|1813|1814|1815,No-Effect
6471,BRD-K57011718,UK-356618,C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1,10370504,Preclinical,metalloproteinase inhibitor,MMP13|MMP14|MMP2|MMP3|MMP9,"","",4322|4323|4313|4314|4318,No-Effect
6472,BRD-K06294530,UK-383367,NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO,9818682,Phase 1,procollagen C-endopeptidase inhibitor,BMP1,"","",649,No-Effect
6473,BRD-K19558579,UK-5099,OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N,6438504,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,"","",6566,No-Effect
6476,BRD-K64381438,ulipristal,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|",130904,Launched,progesterone receptor antagonist,PGR,endocrinology,contraceptive,5241,Weak (50%)
6477,BRD-K46692793,umeclidinium,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,11519070,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131,Very Weak (35%)
6479,BRD-K77428767,UNC0224,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1,44251522,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,No-Effect
6480,BRD-K74236984,UNC0321,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1,46901937,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,"","",10919,No-Effect
6481,BRD-K13060017,UNC0631,COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,53315868,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,"","",10919,Strong (80%)
6482,BRD-K86856088,UNC0638,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1,46224516,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,No-Effect
6483,BRD-K60130390,UNC0642,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1,53315878,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,Weak (50%)
6484,BRD-K87465484,UNC0646,COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,53315882,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,"","",10919,No-Effect
6485,BRD-K02988401,UNC0737,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,52953431,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,"","",79813|10919,Strong (80%)
6486,BRD-K83189926,UNC1215,O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1,57339144,Preclinical,L3MBTL antagonist,L3MBTL3,"","",84456,No-Effect
6487,BRD-K26989966,UNC1999,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C,72551585,Preclinical,histone lysine methyltransferase inhibitor,EZH2,"","",2146,Weak (50%)
6488,BRD-K91283740,UNC2025,CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|,,Preclinical,FLT3 inhibitor|MER tyrosine kinase inhibitor,FLT3|MERTK,"","",2322|10461,Strong (80%)
6489,BRD-K01773560,UNC2250,CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|,,Preclinical,MER tyrosine kinase inhibitor,MERTK,"","",10461,No-Effect
6490,BRD-K60635008,UNC2327,O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1,71583615,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,"","",10196,No-Effect
6491,BRD-K46344388,UNC3230,NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1,46355372,Preclinical,phosphatidyl-inositol activator,PIP5K1C,"","",23396,Weak (50%)
6492,BRD-K21906513,UNC669,Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1,46931242,Preclinical,L3MBTL antagonist,L3MBTL1,"","",26013,No-Effect
6493,BRD-K22229656,UNC926,Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1,61041645,Preclinical,MBT inhibitor,L3MBTL1,"","",26013,No-Effect
6497,BRD-K77950083,UPF-1069,O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1,25015515,Preclinical,PARP inhibitor,PARP2,"","",10038,No-Effect
6499,BRD-K38332599,uprosertib,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,51042438,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,"","",208|10000|207,No-Effect
6500,BRD-K80129304,uracil,O=c1cc[nH]c(=O)[nH]1,1174,Launched,"",DPYD|UCKL1,"","",54963|1806,No-Effect
6502,BRD-K73196317,urapidil,COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,5639,Launched,adrenergic receptor antagonist,HTR1A,cardiology,hypertension,3350,No-Effect
6503,BRD-K92169341,URB597,NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1,1383884,Phase 1,FAAH inhibitor,FAAH|FAAH2|TRPA1,"","",79152|158584|8989,No-Effect
6504,BRD-K88052444,urea,NC(N)=O,1176,Launched,hydroxy radical formation stimulant,ARG1|CA2|CTNNB1,dermatology,psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis,760|64129|1499,No-Effect
6506,BRD-K01295354,uric-acid,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,1175,Phase 3,"",PYGL,"","",5836,No-Effect
6507,BRD-K13050303,uridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O,6029,Phase 2,dopamine receptor agonist,LSM6|TYMP,"","",9997|11157,No-Effect
6508,BRD-K01825013,uridine-5'-triphosphate,"O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|",6133,Launched,purinergic receptor activator,P2RY11|P2RY2|P2RY4|P2RY6|UCK2,"","",5029|5030|5031|7371|692312,Weak (50%)
6510,BRD-K66908976,URMC-099,CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1,54764565,Preclinical,mixed lineage kinase inhibitor,CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2,"","",4293|4294|8999|4296|1613|6733|2322|10746|120892,Strong (80%)
6513,BRD-K15697815,ursodiol,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,31401,Launched,nuclear factor erythroid derived|like (NRF2) activator,AKR1C2|NR1H4,gastroenterology,gallstones,9971|1646,No-Effect
6514,BRD-K68185022,ursolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|,64945,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,"","",5770|3290|5837|5319,No-Effect
6523,BRD-K12994359,valdecoxib,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1,119607,Withdrawn,cyclooxygenase inhibitor,CA12|PTGS2,"","",771|5743,No-Effect
6524,BRD-A56613951,valethamate,"CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|",38989053,Launched,acetylcholine receptor antagonist,CHRM1|CHRM4|CHRM5,obstetrics/gynecology,labor induction,1128|1132|1133,No-Effect
6528,BRD-K41260949,valproic-acid,CCCC(CCC)C(O)=O,3121,Launched,benzodiazepine receptor agonist|HDAC inhibitor,ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures|seizures,9734|11280|18|36|6323|6324|6326|6327|6328|6329|6330|6331|6332|6334|6335|6336|4967|7915|55800|3065|3066,No-Effect
6531,BRD-K72951360,valrubicin,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,454216,Launched,DNA inhibitor|topoisomerase inhibitor,TOP2A,oncology,bladder cancer,7153,No-Effect
6532,BRD-K45158365,valsartan,CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,60846,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure|congestive heart failure,185,Weak (50%)
6533,BRD-K19412342,valspodar,C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C,5281884,Phase 3,P glycoprotein inhibitor,ABCB1,"","",5243,No-Effect
6535,BRD-K77625799,vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,3081361,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC),2048|2049|2050|2051|2064|2065|2066|2321|2324|5753|1956|285220|1969|6714|3791|5979|7422|7010|284656|2041|2042|2043|2044|2045|2046|2047,Strong (80%)
6536,BRD-K24258499,vanillin,COc1cc(C=O)ccc1O,1183,Preclinical,"",ABAT|ALDH5A1,"","",18|7915,No-Effect
6540,BRD-K32501161,vanoxerine,Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1,3455,Phase 3,dopamine reuptake inhibitor,SLC6A3,"","",6531,No-Effect
6542,BRD-K13926615,vardenafil,CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1,135400189,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H,urology,erectile dysfunction,5148|5149|8654,No-Effect
6543,BRD-K18855837,varenicline,"C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|",5310966,Launched,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNA6|CHRNA7,neurology/psychiatry,smoking cessation,1136|1137|89832|8973,No-Effect
6544,BRD-K09711437,varespladib,CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1,155815,Phase 3,secretory phospholipase inhibitor,PLA2G2A,"","",5320,No-Effect
6545,BRD-K73028949,vasopressin,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,133698096,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,gastroenterology,abdominal distension,552|553|554|5021,No-Effect
6546,BRD-K70163715,vatalanib,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,151194,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,"","",1956|5159|3791|2321|2324,Weak (50%)
6548,BRD-K36338614,VBY-825,CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1,70945511,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSS,"","",1520|1514|1508,Strong (80%)
6551,BRD-K04701033,VE-822,CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C,59472121,Phase 2,ATR kinase inhibitor,ATM|ATR|MTOR|PIK3CG,"","",472|545|2475|5294,Weak (50%)
6553,BRD-K20168442,vecuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,39765,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant,1135,No-Effect
6554,BRD-K00004714,vedaprofen,"C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|",25271747,Launched,anti-inflammatory agent,PTGS2,neurology/psychiatry|endocrinology,pain relief|fever,5743,No-Effect
6557,BRD-K12852738,veliflapon,OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1,123723,Phase 3,leukotriene synthesis inhibitor,ALOX5AP,"","",241,No-Effect
6558,BRD-K87142802,veliparib,C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1,11960529,Phase 3,PARP inhibitor,PARP1|PARP2,"","",10038|142,No-Effect
6559,BRD-K06357403,velneperit,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|,,Phase 2,neuropeptide receptor antagonist,NPY5R,"","",4889,No-Effect
6561,BRD-K56343971,vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F,42611257,Launched,RAF inhibitor,BRAF|RAF1,oncology,melanoma,673|6037,No-Effect
6562,BRD-K62391742,venetoclax,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|,49846579,Launched,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),596,No-Effect
6563,BRD-K01826548,venlafaxine,COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|,11846746,Launched,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder,6530|6532,Weak (50%)
6564,BRD-K32330832,VER-155008,Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12,25195348,Preclinical,HSP inhibitor,HSPA1A,"","",3303,No-Effect
6565,BRD-K38548312,VER-49009,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,4369536,Preclinical,HSP inhibitor,HSP90AA1,"","",3320,Very Weak (35%)
6567,BRD-A09533288,verapamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|,2520,Launched,calcium channel blocker,CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4,cardiology,hypertension,6532|773|774|775|776|778|779|782|783|784|785|3743|3744|259232|1576|3757|3767|6331|150350|8913|222962,No-Effect
6569,BRD-K47929404,vercirnon,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1,10343454,Phase 3,CC chemokine receptor antagonist,CCR9,"","",1238,No-Effect
6573,BRD-K36741660,verinurad,CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O,54767229,Phase 2,urate transporter inhibitor,SLC22A12,"","",116085,No-Effect
6574,BRD-K19741547,vernakalant,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,9930049,Launched,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF),3741,No-Effect
6577,BRD-K42673188,verubulin,COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12,11414799,Phase 2,tubulin polymerization inhibitor,TUBB,"","",7280,Very Weak (35%)
6579,BRD-K14765469,vesamicol,O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1,659840,Preclinical,acetylcholinesterase inhibitor,SLC18A3,"","",6572,No-Effect
6580,BRD-K13414800,vesnarinone,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1,5663,Launched,phosphodiesterase inhibitor,KCNH2|PDE3A,cardiology,congestive heart failure,5139|3757,No-Effect
6581,BRD-A32269193,VGX-1027,"OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|",92981775,Phase 1,tumor necrosis factor receptor antagonist,TLR4,"","",7099,No-Effect
6582,BRD-K84748119,vicriviroc,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,3009355,Phase 3,CC chemokine receptor antagonist,CCR5,"","",1234,No-Effect
6583,BRD-K72093121,vidarabine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,21704,Launched,antiviral,ADA,infectious disease,virus herpes simplex (HSV)|varicella-zoster virus (VZV),100,No-Effect
6584,BRD-K01825700,vigabatrin,N[C@@H](CCC(O)=O)C=C |&1:1|,40466946,Launched,GABA aminotransferase inhibitor,ABAT|SLC32A1,neurology/psychiatry,seizures|spasms,18|140679,No-Effect
6585,BRD-M36487418,vilanterol,OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl,44482554,Launched,adrenergic receptor agonist,ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD),154,No-Effect
6586,BRD-K58010567,vilazodone,NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1,6918314,Launched,serotonin reuptake inhibitor,DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4,neurology/psychiatry,depression,3360|6532|3269|1813|1814|3350,No-Effect
6587,BRD-K00003565,vildagliptin,O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N,,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803,No-Effect
6588,BRD-A59198242,viloxazine,CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|,12226596,Launched,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression,6530,No-Effect
6589,BRD-K06519765,vinblastine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|,13342,Launched,microtubule inhibitor|tubulin polymerization inhibitor,JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1,hematologic malignancy|infectious disease|oncology,Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma,51174|7846|51175|3725|7280|7283,Strong (80%)
6590,BRD-K40227168,vinburnine,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,71203,Launched,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,stroke,1128|1129|1131|1132,Cyto
6591,BRD-K40902647,vincamine,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC,15376,Withdrawn,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,"","",1128|1129|1131|1132,Low (25%)
6592,BRD-K12251893,vincristine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|,5388993,Launched,tubulin polymerization inhibitor,TUBA4A|TUBB,hematologic malignancy,acute lymphoblastic leukemia (ALL),7280|7277,Weak (50%)
6593,BRD-K59753975,vindesine,CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|,40839,Launched,tubulin polymerization inhibitor,TUBB|TUBB1,oncology,breast cancer|non-small cell lung cancer (NSCLC)|melanoma,7280|203068,Weak (50%)
6595,BRD-K04269837,vinorelbine,"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|",5311497,Launched,tubulin polymerization inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,non-small cell lung cancer (NSCLC),7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|347733|84790|203068,No-Effect
6596,BRD-K53318339,vinpocetine,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|,443955,Launched,phosphodiesterase inhibitor|sodium channel blocker,PDE1A|PDE1C,neurology/psychiatry,stroke|senile dementia,5136|5137,No-Effect
6598,BRD-K56565215,vipadenant,Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N,21874557,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
6599,BRD-K44827188,vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1,24776445,Launched,hedgehog pathway inhibitor|smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),54498,Very Weak (35%)
6602,BRD-K97091514,vitamin-E,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1,14985,Launched,LDL oxidation inhibitor|PKC inhibitor,ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4,"","",266629|1606|284904|5578|5515|5516|5579|240|23541|8856,No-Effect
6606,BRD-K26122255,VLX600,CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,6806409,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,"","",9097|7157,No-Effect
6607,BRD-K26122255,VLX600,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,6413301,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,"","",9097|7157,No-Effect
6610,BRD-K66850609,voglibose,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,444020,Launched,glucosidase inhibitor,MGAM,endocrinology,diabetes mellitus|hyperglycemia,8972,No-Effect
6611,BRD-K69776681,volasertib,CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O,,Phase 3,PLK inhibitor,PLK1,"","",5347,Cyto
6612,BRD-K23647661,volinanserin,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,5311271,Phase 3,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|KCNH2,"","",3356|3757|106480180|3358,No-Effect
6613,BRD-K32768103,vonoprazan,CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1,15981397,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD),495,No-Effect
6614,BRD-K93442924,vorapaxar,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1,10077130,Launched,thrombin inhibitor,F2R,cardiology,myocardial infarction|peripheral artery disease (PAD),2149,Very Weak (35%)
6616,BRD-K23677682,voreloxin,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,9952884,Phase 3,topoisomerase inhibitor,TOP2A,"","",7153,No-Effect
6617,BRD-K06557128,voriconazole,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,71616,Launched,cytochrome P450 inhibitor,CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1,infectious disease,esophageal candidiasis|aspergillosis|skin infections,1576|1577|5742|1557|1559,No-Effect
6618,BRD-K81418486,vorinostat,ONC(=O)CCCCCCC(=O)Nc1ccccc1,5311,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),55869|9734|8841|10013|79885|3065|3066|83933|10014,No-Effect
6619,BRD-K53963539,vortioxetine,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,9966051,Launched,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4,neurology/psychiatry,depression,3361|3362|3363|6532|3350|3351|3356|3358|3359,No-Effect
6622,BRD-K56291712,voxtalisib,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,16123056,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,"","",5290|2475,Very Weak (35%)
6623,BRD-K21071223,VP-20629,OC(=O)CCc1c[nH]c2ccccc12,3744,Phase 1,beta amyloid antagonist,PLA2G2E|SLC36A1,"","",30814|206358,Low (25%)
6625,BRD-K72005722,VT-464,CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1,78357816,Phase 2,cytochrome P450 inhibitor,CYP17A1,"","",1586,No-Effect
6626,BRD-K81694556,VTP-27999,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,16126898,Phase 1,renin inhibitor,REN,"","",147040,No-Effect
6627,BRD-K48535733,VU0155069,C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1,25105713,Preclinical,phospholipase inhibitor,PLD1,"","",5589,No-Effect
6628,BRD-K24187789,VU0238429,COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1,42633508,Preclinical,acetylcholine receptor allosteric modulator,CHRM5,"","",1133,No-Effect
6629,BRD-K27074404,VU0240551,Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1,7211972,Preclinical,potassium/chloride cotransporter inhibitor,SLC12A5,"","",57468,No-Effect
6630,BRD-K86109159,VU0357121,CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F,2296132,Preclinical,glutamate receptor positive allosteric modulator,GRM5,"","",2915,No-Effect
6631,BRD-K83649660,VU0360172,Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1,53318624,Preclinical,glutamate receptor positive allosteric modulator,GRM5,"","",2915,No-Effect
6632,BRD-K45462423,VU0361737,COc1cc(NC(=O)c2ccccn2)ccc1Cl,44191096,Preclinical,glutamate receptor positive allosteric modulator,GRM4,"","",2914,Very Weak (35%)
6633,BRD-K72687424,VU0364439,Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl,46934289,Preclinical,glutamate receptor positive allosteric modulator,GRM4,"","",2914,No-Effect
6634,BRD-K93317811,VU0364739,Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1,46937439,Preclinical,phospholipase inhibitor,PLD2,"","",5338,Strong (80%)
6635,BRD-K66527818,VU0364770,Clc1cccc(NC(=O)c2ccccn2)c1,836002,Preclinical,glutamate receptor positive allosteric modulator,GRM4,"","",2914,No-Effect
6636,BRD-K68674163,VU0422288,Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1,73058507,Preclinical,glutamate receptor positive allosteric modulator,GRM3,"","",2913,No-Effect
6637,BRD-K12483104,VU10010,Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1,714286,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,"","",1132,No-Effect
6638,BRD-K87727457,VU152100,COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,864492,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,"","",1132,No-Effect
6639,BRD-K48371964,VU1545,[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1,11625520,Preclinical,glutamate receptor positive allosteric modulator,GRM5,"","",2915,No-Effect
6640,BRD-K54783522,VU29,[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1,11610682,Preclinical,glutamate receptor potentiator,GRM5,"","",2915,No-Effect
6641,BRD-K72063794,VU591,[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1,44123657,Preclinical,potassium channel blocker,KCNJ1,"","",3758,No-Effect
6642,BRD-K11046126,VUF10166,CN1CCN(CC1)c1nc2ccccc2nc1Cl,24278976,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,"","",9177|3359,Cyto
6643,BRD-K90082312,VUF10460,CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1,25129523,Preclinical,histamine receptor agonist,HRH4,"","",59340,No-Effect
6644,BRD-A93717708,VUF11207,COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|,97018453,Preclinical,CC chemokine receptor agonist,ACKR3,"","",57007,No-Effect
6645,BRD-K93725829,VX-11e,Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1,11634725,Preclinical,MAP kinase inhibitor,MAPK1,"","",5594,No-Effect
6647,BRD-K07736136,VX-702,NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F,10341154,Phase 2,p38 MAPK inhibitor,IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF,"","",5600|3553|3569|7124|1432|6300,No-Effect
6648,BRD-K91900765,VX-745,Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1,3038525,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK14,"","",5600|6300|1432,No-Effect
6649,BRD-K78430341,VX-765,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,11398092,Phase 2,caspase inhibitor,CASP1,"","",834,No-Effect
6650,BRD-A00559310,W-54011,COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|,59597209,Preclinical,anaphylatoxin chemotactic receptor antagonist,C5AR1,"","",728,No-Effect
6652,BRD-K25991148,warfarin,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|,54688261,Launched,vitamin K antagonist,VKORC1,hematology|cardiology,deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction,79001,No-Effect
6653,BRD-K69812556,WAY-100635,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,5684,Phase 1,serotonin receptor antagonist,HTR1A,"","",3350,No-Effect
6654,BRD-A62021152,WAY-161503,Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|,6604916,Preclinical,serotonin receptor agonist,HTR2C,"","",3358,No-Effect
6655,BRD-K36198571,WAY-170523,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO,9830392,Preclinical,metalloproteinase inhibitor,MMP13,"","",4322,No-Effect
6656,BRD-K08223200,WAY-200070,Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1,135418373,Preclinical,estrogen receptor agonist,ERBB2|ERBB3|ERBB4|ESR2,"","",2064|2065|2066|2100,No-Effect
6657,BRD-K08657056,WAY-207024,CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1,11496610,Preclinical,gonadotropin releasing factor hormone receptor antagonist,GNRHR|HRH2|TACR2,"","",1665|6865|2798,No-Effect
6658,BRD-K63483542,WAY-208466,CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1,10337743,Preclinical,serotonin receptor agonist,DRD2|HTR2A|HTR2C|HTR6|HTR7,"","",3362|3363|1813|3356|3358,No-Effect
6659,BRD-K96758128,WAY-213613,N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O,11531745,Preclinical,glutamate inhibitor,SLC1A2,"","",6506,No-Effect
6661,BRD-K61871885,WAY-316606,FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1,16727102,Preclinical,secreted frizzled related protein inhibitor,SFRP1,"","",6422,Low (25%)
6662,BRD-K54640016,WAY-362450,CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|,10026128,Phase 1,FXR agonist,NR1H4,"","",9971,No-Effect
6663,BRD-K85920262,WAY-600,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,25229526,Preclinical,mTOR inhibitor,MTOR,"","",2475,Strong (80%)
6665,BRD-A01493904,WB-4101,COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|,13305910,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A,"","",146|147|150|151|152|3350,No-Effect
6666,BRD-K47726410,WDR5-0103,COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1,6457069,Preclinical,histone lysine methyltransferase inhibitor,WDR5,"","",11091,No-Effect
6668,BRD-K50199947,WH-4-023,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1,11844351,Preclinical,SRC inhibitor,LCK|SRC,"","",6714|3932,Weak (50%)
6669,BRD-K07487750,WHI-P154,COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC,3795,Preclinical,JAK inhibitor,EGFR|JAK1|JAK2|JAK3,"","",3716|1956|3717|3718,No-Effect
6670,BRD-K19316653,WIKI4,COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1,2984337,Preclinical,tankyrase inhibitor|WNT pathway inhibitor,TNKS2,"","",80351,No-Effect
6671,BRD-K30930903,WIN-18446,ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl,15134,Preclinical,aldehyde dehydrogenase inhibitor,ALDH1A2,"","",8854,No-Effect
6672,BRD-K22662557,WIN-64338,CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1,132928,Preclinical,bradykinin receptor antagonist,BDKRB2,"","",623,No-Effect
6673,BRD-A18579359,wiskostatin,"CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|",981326,Preclinical,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,WASL,"","",8976,Weak (50%)
6674,BRD-K78455053,wnt-c59,Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1,57519544,Preclinical,porcupine inhibitor,PORCN,"","",64840,No-Effect
6676,BRD-K05445342,WP1066,C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,11210478,Phase 1,STAT inhibitor,STAT3,"","",6774,Strong (80%)
6677,BRD-K43644456,WP1130,CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,11222830,Preclinical,deubiquitinase inhibitor,JAK2|UCHL5|USP14|USP9X,"","",51377|9097|3717|8239,No-Effect
6679,BRD-K45973863,WR99210,"CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|",121750,Preclinical,dihydrofolate reductase inhibitor,TYMS,infectious disease,malaria,7298,No-Effect
6680,BRD-K49389158,WWL-113,CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1,17759482,Preclinical,carboxylesterase inhibitor,CES3,"","",23491,No-Effect
6681,BRD-K83176916,WWL-123,CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O,90209976,Preclinical,monoacylglycerol lipase inhibitor,ABHD6,"","",57406,No-Effect
6683,BRD-K00003540,WYE-125132,"CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|",25227469,Preclinical,mTOR inhibitor,MTOR,"","",2475,Weak (50%)
6684,BRD-K77008974,WYE-354,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,44219749,Preclinical,mTOR inhibitor,MTOR,"","",2475,Weak (50%)
6685,BRD-K49900195,WYE-687,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1,25229450,Preclinical,mTOR inhibitor,MTOR,"","",2475,Very Weak (35%)
6686,BRD-K73293050,WZ-3146,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,44607360,Preclinical,EGFR inhibitor,EGFR,"","",1956,No-Effect
6687,BRD-K72420232,WZ-4002,COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1,44607530,Preclinical,EGFR inhibitor,EGFR|ERBB2,"","",2064|1956,Cyto
6688,BRD-K45909031,WZ4003,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1,72200024,Preclinical,AMPK inhibitor,NUAK1|NUAK2,"","",9891|81788,No-Effect
6689,BRD-K81728688,WZ8040,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,44607531,Preclinical,EGFR inhibitor,EGFR,"","",1956,Low (25%)
6690,BRD-K25359048,WZ811,C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1,11565518,Preclinical,CC chemokine receptor antagonist,CXCR4,"","",7852,No-Effect
6691,BRD-K88358234,xaliproden,FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|,128919,Phase 3,serotonin receptor agonist,HTR1A,"","",3350,No-Effect
6692,BRD-A59337442,xamoterol,OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1,6917710,Phase 3,adrenergic receptor agonist,ADRB1,"","",153,No-Effect
6693,BRD-K72815923,xanomeline,CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|,60809,Phase 3,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7,"","",3362|3363|1128|1129|1131|1132|1133|106480180|3350|3351|3352|3354|3355|3356|3358,No-Effect
6695,BRD-K12762134,XAV-939,FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1,135418940,Preclinical,tankyrase inhibitor,TNKS|TNKS2,"","",8658|80351,No-Effect
6696,BRD-K45875383,XBD173,CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1,6433109,Phase 2,benzodiazepine receptor ligand,TSPO,"","",706,No-Effect
6697,BRD-K69211575,XD-14,CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1,52670832,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4|BRDT,"","",676|8019|23476|6046,No-Effect
6698,BRD-K42748308,XE-991,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,656732,Preclinical,potassium channel blocker,KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5,"","",3784|3785|3786|9132|56479,No-Effect
6702,BRD-K27393415,xipamide,Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O,26618,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension,6559,No-Effect
6703,BRD-K04266228,XL019,O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1,57990869,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,"","",3716|3717|3718,Weak (50%)
6705,BRD-K95901403,XL147,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1,1893730,Phase 2,PI3K inhibitor,PIK3CA|PIK3CD|PIK3CG,"","",5290|22883|5294,No-Effect
6706,BRD-K14274271,XL228,CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1,59757974,Phase 1,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,IGF1R|SRC,"","",3480|6714,No-Effect
6707,BRD-K03549949,XL388,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,59604787,Preclinical,mTOR inhibitor,MTOR,"","",2475,No-Effect
6708,BRD-K03765900,XL647,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,,Phase 3,EGFR inhibitor|VEGFR inhibitor,EGFR|EPHB4|ERBB2|FLT4|KDR,"","",2050|1956|3791|2064|2324,Very Weak (35%)
6710,BRD-K48449981,XMD17-109,CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1,71604307,Preclinical,MAP kinase inhibitor,MAPK7,"","",5598,Very Weak (35%)
6711,BRD-K50387473,XMD8-92,CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1,46843772,Preclinical,MAP kinase inhibitor,DCLK2|MAPK7|PLK4|TNK1,"","",10733|5598|166614|8711,Weak (50%)
6712,BRD-K21565985,xylazine,Cc1cccc(C)c1NC1=NCCCS1 |t:10|,5707,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,anesthetic,152|150|151,No-Effect
6713,BRD-K08356259,xylometazoline,Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|,5709,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,otolaryngology|allergy,nasal congestion|allergic rhinitis,146|147|150|151|152,No-Effect
6715,BRD-K09317629,Y-11,OCC[N+]12CN3CN(CN(C3)C1)C2,427018,Preclinical,focal adhesion kinase inhibitor,PTK2,"","",5747,No-Effect
6716,BRD-K94832621,Y-134,CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1,11784736,Preclinical,estrogen receptor antagonist,ESR1|ESR2,"","",2099|2100,Strong (80%)
6717,BRD-K45117373,Y-26763,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,121878,Phase 1,potassium channel activator,KCNJ8,"","",3764,Low (25%)
6718,BRD-K42679050,Y-27152,CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,6918184,Phase 1,potassium channel activator,KCNJ8,"","",3764,No-Effect
6719,BRD-K44084986,Y-27632,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1,,Preclinical,rho associated kinase inhibitor,PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2,"","",5569|9475|5578|6093|5581|5586,No-Effect
6720,BRD-K48449073,Y-29794,CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1,195609,Preclinical,prolyl endopeptidase inhibitor,PREP,"","",5550,Strong (80%)
6721,BRD-K96259238,Y-320,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,22227931,Preclinical,interleukin inhibitor,IL17A,"","",3605,Strong (80%)
6722,BRD-K56751279,Y-39983,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,9810884,Phase 2,rho associated kinase inhibitor,ROCK1|ROCK2,"","",9475|6093,No-Effect
6723,BRD-K81865756,Y16,Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1,989521,Preclinical,rho associated kinase inhibitor,RHOA,"","",387,No-Effect
6724,BRD-K60476892,YC-1,OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12,5712,Preclinical,guanylyl cyclase activator,GUCY1A2|GUCY1A3|GUCY1B3|HIF1A,"","",2977|3091|2982|2983,No-Effect
6725,BRD-K91403886,YIL-781,CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1,23631116,Preclinical,ghrelin receptor antagonist,GHSR,"","",2693,No-Effect
6726,BRD-A62182663,YK-4-279,"COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|",93948843,Preclinical,apoptosis inhibitor,EWSR1|FLI1,"","",2313|2130,No-Effect
6728,BRD-K09436144,YM-022,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|,122130,Phase 2,CCK receptor antagonist,CCKBR,"","",887,No-Effect
6729,BRD-K76703230,YM-155,COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O,10126189,Phase 2,survivin inhibitor,BIRC5,"","",332,No-Effect
6732,BRD-K59650319,YM-298198,CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C,9819432,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
6733,BRD-K48059230,YM-298198-desmethyl,Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1,11716890,Preclinical,glutamate receptor antagonist,GRM1,"","",2911,No-Effect
6734,BRD-K38398115,YM-511,Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1,177865,Phase 2,aromatase inhibitor,CYP19A1,"","",1588,No-Effect
6735,BRD-K42563464,YM-58483,Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F,2455,Preclinical,calcium channel blocker,TRPC3|TRPC5|TRPM4,"","",7224|54795|7222,Low (25%)
6736,BRD-K91716465,YM-750,Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1,9911716,Phase 1,ACAT inhibitor,SOAT1,"","",6646,No-Effect
6737,BRD-K06712146,YM-90709,COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC,1103147,Preclinical,IL5 inhibitor,CSF2RB|IL5RA,"","",3568|1439,No-Effect
6738,BRD-K12932420,YM-976,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,6604918,Phase 1,phosphodiesterase inhibitor,PDE4A,"","",5141,Low (25%)
6740,BRD-K88570498,yoda-1,Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1,2746822,Preclinical,piezo channel activator,PIEZO1,"","",9780,No-Effect
6741,BRD-K35586044,yohimbine,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,8969,Launched,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8,cardiology,cardiac arrythmia|bradycardia,1813|1814|150|3352|152|3354|151|3350|3355|3351|3356|3358|3361|3363|3758|106480180|3764|3766|3767|3768|3770|3772,No-Effect
6744,BRD-K53438416,YZ9,CCOC(=O)c1cc2ccc(O)cc2oc1=O,5289613,Preclinical,phosphofructokinase inhibitor,MIF|PFKFB3,"","",5209|4282,No-Effect
6745,BRD-K16037980,Z160,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,4988454,Phase 2,N-type calcium channel blocker,CACNA2D1,"","",781,No-Effect
6746,BRD-K01826799,zacopride,"COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|",9819593,Phase 2,serotonin receptor antagonist,HTR3A|HTR3B|HTR4|HTR5A,"","",3360|9177|3361|3359,No-Effect
6747,BRD-K71289571,zafirlukast,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,5717,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2,pulmonary,asthma,10800|57105,No-Effect
6749,BRD-A26032986,zaldaride,C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|,92460626,Phase 3,calmodulin antagonist,CALM1,"","",801,No-Effect
6750,BRD-K12261274,zaltidine,Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1,56051,Phase 3,histamine receptor antagonist,HRH2,"","",1665,No-Effect
6753,BRD-K80451230,zamifenacin,C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1,3086618,Phase 3,acetylcholine receptor antagonist,CHRM3,"","",1131,No-Effect
6754,BRD-K23067689,zanamivir,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|,60855,Launched,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection,4759,No-Effect
6757,BRD-K16542329,zaprinast,CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1,135399235,Phase 2,phosphodiesterase inhibitor,GPR35|PDE1A|PDE4D|PDE5A|PDE9A,"","",5152|2859|8654|5136|5144,No-Effect
6758,BRD-K37561857,zardaverine,COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1,5723,Phase 2,phosphodiesterase inhibitor,PDE4D,"","",5144,No-Effect
6759,BRD-K92446736,zatebradine,COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,65637,Phase 3,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,"","",57657|610|348980|10021,No-Effect
6762,BRD-K64157027,ZD-2079,O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1,158794,Phase 2,adrenergic receptor agonist,ADRB3,"","",155,No-Effect
6763,BRD-K28971625,ZD-7114,COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,121877,Phase 1,adrenergic receptor agonist,ADRB3,"","",155,No-Effect
6764,BRD-K11373525,ZD-7155,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1,4673492,Preclinical,angiotensin receptor antagonist,AGTR1,"","",185,No-Effect
6765,BRD-K18678457,ZD-7288,CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1,123984,Phase 2,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,"","",57657|610|348980|10021,No-Effect
6767,BRD-K87714311,zebularine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O,100016,Preclinical,DNA methyltransferase inhibitor,CDA|DNMT1,"","",978|1786,No-Effect
6768,BRD-K31553034,zibotentan,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1,9910224,Phase 3,endothelin receptor antagonist,EDNRA,"","",1909,No-Effect
6769,BRD-K72903603,zidovudine,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,35370,Launched,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS),7015,No-Effect
6770,BRD-A56359832,zileuton,"C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|",10681296,Launched,leukotriene synthesis inhibitor|lipoxygenase inhibitor,ALOX5,pulmonary,asthma,240,No-Effect
6771,BRD-K42816473,zilpaterol,CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O,25218684,Launched,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid,154,No-Effect
6772,BRD-K46914825,zimelidine,CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1,5365247,Withdrawn,selective serotonin reuptake inhibitor (SSRI),MAOA|MAOB|SLC6A4,"","",4128|4129|6532,No-Effect
6775,BRD-K29582115,ziprasidone,Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12,60854,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4,neurology/psychiatry,schizophrenia|bipolar disorder,6532|146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133,No-Effect
6777,BRD-K05151076,ZK-164015,CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1,9806489,Preclinical,estrogen receptor antagonist,ESR1|ESR2,"","",2099|2100,No-Effect
6779,BRD-K91825936,ZK-811752,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,512282,Phase 2,CC chemokine receptor antagonist,CCR1,"","",1230,No-Effect
6780,BRD-K33882852,ZK-93423,CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,121926,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,"","",2561|2566|2554|2555|2556|2558,No-Effect
6781,BRD-K68392338,ZK-93426,CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,115210,Phase 1,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA5,"","",2554|2555|2556|2558,Low (25%)
6783,BRD-K64103579,ZLN024,Cc1ccc(OCCSc2ncccn2)c(Br)c1,1825716,Preclinical,AMPK activator,PRKAA1|PRKAB1|PRKAG1,"","",5562|5571|5564,No-Effect
6785,BRD-K19605405,ZM-241385,Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1,176407,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,"","",136|140|134|135,No-Effect
6786,BRD-K41337261,ZM-306416,COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,5329006,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR,"","",2321|1956|2324|3791,No-Effect
6787,BRD-K67831364,ZM-323881,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,16759369,Preclinical,VEGFR inhibitor,KDR,"","",3791,No-Effect
6788,BRD-K73789395,ZM-336372,CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1,5730,Preclinical,RAF inhibitor,BRAF|LCK|MAPK14|RAF1,"","",1432|673|3932|6037,No-Effect
6789,BRD-K40624912,ZM-39923,CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1,3797,Preclinical,JAK inhibitor,JAK1|JAK3,"","",3716|3718,No-Effect
6790,BRD-K72703948,ZM-447439,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,9914412,Preclinical,Aurora kinase inhibitor,AURKA|AURKB,"","",9212|6790,No-Effect
6791,BRD-K46654563,zofenopril-calcium,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1,92400,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636,No-Effect
6793,BRD-K84253429,zoledronic-acid,OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O,68740,Launched,bone resorption inhibitor,FDPS|GGPS1,endocrinology,Paget's disease,2224|9453,No-Effect
6796,BRD-K54314721,zolmitriptan,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,60857,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355,Weak (50%)
6797,BRD-K81326768,zomepirac,Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1,5733,Withdrawn,prostaglandin synthesis inhibitor,PTGDR2,"","",11251,Low (25%)
6799,BRD-K43992824,zoniporide,NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12,6433110,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,"","",6548,No-Effect
6800,BRD-K48300629,zonisamide,NS(=O)(=O)Cc1noc2ccccc12,5734,Launched,sodium channel blocker|T-type calcium channel blocker,CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures|epilepsy,768|771|11280|4128|4129|55800|6323|6324|6326|6327|6328|6329|6330|6331|6332|6334|6335|6336|377677|150350|23632|8913|8912|56287|56934|11238|759|760|761|762|763|765|766|767,No-Effect
6801,BRD-K47710001,zopolrestat,OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12,1613,Phase 2,"",AKR1B1|AKR1B10,"","",57016|231,No-Effect
6802,BRD-K70557564,zosuquidar,O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F,,Phase 3,P glycoprotein inhibitor,ABCB1|ABCB4,"","",5243|5244,No-Effect
6803,BRD-K46843573,zotarolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|",,Launched,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,2280,No-Effect
6804,BRD-K64557645,zotepine,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|,5736,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4,neurology/psychiatry,schizophrenia,3352|3362|3363|6530|3269|6532|1813|1814|1815|151|3350|3354|3356|3351|3358,Low (25%)
6807,BRD-K63068307,ZSTK-474,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,11647372,Phase 1/Phase 2,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,"","",5291|5294|22883,No-Effect
6808,BRD-K28761384,zuclopenthixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,5311507,Launched,dopamine receptor antagonist,ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder,3269|146|1812|1813|150|1816|3356,No-Effect
,BRD-K01129913,walrycin-B,,,,,,,,,No-Effect
,BRD-K04264130,favipiravir,,,,,,,,,No-Effect
,BRD-K59597909,phenothiazine,,,,,,,,,No-Effect
,BRD-K26665484,avridine,,,,,,,,,No-Effect
,BRD-K01826800,NSC-23766,,,,,,,,,No-Effect
,BRD-K82239282,ASP-6537,,,,,,,,,No-Effect
,BRD-K74227494,riboflavin-tetrabutyrate,,,,,,,,,No-Effect
,BRD-K00004700,CORT-108297,,,,,,,,,No-Effect
,BRD-K43449605,oncrasin-1,,,,,,,,,No-Effect
,BRD-K00003483,GSK656,,,,,,,,,No-Effect
,BRD-K00003451,LY334370,,,,,,,,,Weak (50%)
,BRD-K00003487,tomeglovir,,,,,,,,,No-Effect
,BRD-K00003492,apararenone,,,,,,,,,No-Effect
,BRD-K00003464,pocapavir,,,,,,,,,No-Effect
,BRD-K00003467,temanogrel,,,,,,,,,No-Effect
,BRD-K00005338,VL285,,,,,,,,,No-Effect
,BRD-K00003471,rislenemdaz,,,,,,,,,No-Effect
,BRD-K00003207,ethynylcytidine,,,,,,,,,No-Effect
,BRD-K00003486,DG051,,,,,,,,,No-Effect
,BRD-K00003278,TCV-309,,,,,,,,,No-Effect
,BRD-K00003321,dalfopristin,,,,,,,,,No-Effect
,BRD-K00003188,capromorelin,,,,,,,,,No-Effect
,BRD-K00004749,NCX-1015,,,,,,,,,No-Effect
,BRD-K00005244,CCT196969,,,,,,,,,No-Effect
,BRD-K00003455,S-38093,,,,,,,,,No-Effect
,BRD-K00003478,epristeride,,,,,,,,,No-Effect
,BRD-K00003152,AM211,,,,,,,,,No-Effect
,BRD-K00003408,iberdomide,,,,,,,,,No-Effect
,BRD-K00003378,FT011,,,,,,,,,No-Effect
,BRD-K00003369,eltanexor,,,,,,,,,No-Effect
,BRD-K00003366,linaprazan,,,,,,,,,No-Effect
,BRD-K00003433,veralipride,,,,,,,,,No-Effect
,BRD-K00003372,CGP-25454A,,,,,,,,,No-Effect
,BRD-K00003374,esaxerenone,,,,,,,,,No-Effect
,BRD-K00004667,ciluprevir,,,,,,,,,No-Effect
,BRD-K00004596,telratolimod,,,,,,,,,No-Effect
,BRD-K00003397,MK-8617,,,,,,,,,No-Effect
,BRD-K00003327,hydroxysafflor-yellow-A,,,,,,,,,No-Effect
,BRD-K00003439,XL041,,,,,,,,,No-Effect
,BRD-K00003367,uki-1,,,,,,,,,No-Effect
,BRD-K00003336,tuftsin,,,,,,,,,No-Effect
,BRD-K49460120,10058-F4,,,,,,,,,No-Effect
,BRD-K25317177,modaline,,,,,,,,,Low (25%)
,BRD-K00003245,belizatinib,,,,,,,,,Weak (50%)
,BRD-K00004642,PF-514273,,,,,,,,,No-Effect
,BRD-K00010389,RAF709,,,,,,,,,No-Effect
,BRD-K00021095,PDD-00017273,,,,,,,,,No-Effect
,BRD-K00003146,MIW-815,,,,,,,,,No-Effect
,BRD-K60842365,theaflavin,,,,,,,,,No-Effect
,BRD-K00004622,MM-206,,,,,,,,,No-Effect
,BRD-K00004585,soraprazan,,,,,,,,,No-Effect
,BRD-K00004686,NPS-2407,,,,,,,,,No-Effect
,BRD-K00005326,PF-06928215,,,,,,,,,No-Effect
,BRD-K00005340,SBI-115,,,,,,,,,No-Effect
,BRD-K00003489,gamithromycin,,,,,,,,,Strong (80%)
,BRD-K00003105,IACS-10759,,,,,,,,,No-Effect
,BRD-K00003126,G-749,,,,,,,,,Weak (50%)
,BRD-K00005342,trifloxystrobin,,,,,,,,,Strong (80%)
,BRD-K00003114,C188-9,,,,,,,,,No-Effect
,BRD-K00005327,scabertopin,,,,,,,,,Strong (80%)
,BRD-K39084158,liquiritin,,,,,,,,,No-Effect
,BRD-K00003434,miridesap,,,,,,,,,No-Effect
,BRD-K00003212,omtriptolide,,,,,,,,,Cyto
,BRD-K00003252,sacubitrilat,,,,,,,,,No-Effect
,BRD-K00003351,methacycline,,,,,,,,,No-Effect
,BRD-K00005339,A-381393,,,,,,,,,No-Effect
,BRD-K77817104,N-(p-amylcinnamoyl)-anthranilic-acid,,,,,,,,,No-Effect
,BRD-K30431096,domiphen,,,,,,,,,Cyto
,BRD-K67760597,barium-6-O-phosphonato-D-glucose,,,,,,,,,No-Effect
,BRD-K00003272,dextrorotation-nimorazole-phosphate-ester,,,,,,,,,No-Effect
,BRD-K00004633,PF-4191834,,,,,,,,,No-Effect
,BRD-K04552268,4-pyrimidinecarbonitrile,,,,,,,,,No-Effect
,BRD-K42859542,CFM-2,,,,,,,,,No-Effect
,BRD-K00003315,nelociguat,,,,,,,,,No-Effect
,BRD-K00004572,Ro-48-6791,,,,,,,,,No-Effect
,BRD-K09118247,tribomsalan,,,,,,,,,No-Effect
,BRD-K30233223,A-485,,,,,,,,,Strong (80%)
,BRD-K00004618,S-17092,,,,,,,,,No-Effect
,BRD-K96391852,aloperine,,,,,,,,,No-Effect
,BRD-A34751532,homosalate,,,,,,,,,No-Effect
,BRD-K04622161,YO-01027,,,,,,,,,No-Effect
,BRD-K00003217,transcrocetinate,,,,,,,,,No-Effect
,BRD-K46392623,TG-100713,,,,,,,,,No-Effect
,BRD-K00004582,sufugolix,,,,,,,,,No-Effect
,BRD-A62209527,ZM-226600,,,,,,,,,No-Effect
,BRD-K00004221,RS-16566,,,,,,,,,No-Effect
,BRD-K11631773,sesamin,,,,,,,,,No-Effect
,BRD-A51407134,2-octyldodecan-1-ol,,,,,,,,,No-Effect
,BRD-K00003529,cloperastine-fendizoate,,,,,,,,,No-Effect
,BRD-K00003318,decloxizine,,,,,,,,,No-Effect
,BRD-K00025564,cephalosporin-c-zn,,,,,,,,,No-Effect
,BRD-K89306950,ML130,,,,,,,,,No-Effect
,BRD-K65480835,siremadlin,,,,,,,,,No-Effect
,BRD-K46531780,methylbenzethonium-chloride,,,,,,,,,No-Effect
,BRD-K32485706,pinanediol,,,,,,,,,No-Effect
,BRD-K79145749,dibenzepine,,,,,,,,,No-Effect
,BRD-K08188887,astragaloside-a,,,,,,,,,No-Effect
,BRD-A23127772,sclareol,,,,,,,,,No-Effect
,BRD-K00004971,chloralose,,,,,,,,,No-Effect
,BRD-K83023055,GR-135531,,,,,,,,,No-Effect
,BRD-K08996725,zolantidine,,,,,,,,,No-Effect
,BRD-K00003712,neohesperidin,,,,,,,,,No-Effect
,BRD-K61032563,neohesperidin-dihydrochalcone,,,,,,,,,No-Effect
,BRD-K72522627,naringin-dihydrochalcone,,,,,,,,,No-Effect
,BRD-K00004217,3-CPMT,,,,,,,,,No-Effect
,BRD-A57798112,PD-318088,,,,,,,,,No-Effect
,BRD-K55487946,WEHI-345-analog,,,,,,,,,No-Effect
,BRD-K07549832,erythrosine,,,,,,,,,No-Effect
,BRD-A44500574,FLI-06,,,,,,,,,No-Effect
,BRD-K94659840,pyrintegrin,,,,,,,,,Low (25%)
,BRD-K00004723,HP-228,,,,,,,,,No-Effect
,BRD-K00004592,PI3Kd-IN-2,,,,,,,,,Low (25%)
,BRD-K00004559,convallatoxin,,,,,,,,,Strong (80%)
,BRD-K00003476,ningetinib-tosylate,,,,,,,,,No-Effect
,BRD-K00003527,sofosbuvir-impurity-m,,,,,,,,,No-Effect
,BRD-K00003186,SSR240612,,,,,,,,,No-Effect
,BRD-K00005331,BAY-8002,,,,,,,,,No-Effect
,BRD-K00005330,AUT-1,,,,,,,,,No-Effect
,BRD-K00003328,madecassoside,,,,,,,,,No-Effect
,BRD-K83834509,PTC-209,,,,,,,,,Strong (80%)
,BRD-K00010387,bafilomycin-a1,,,,,,,,,Strong (80%)
,BRD-K00004576,clamikalant,,,,,,,,,No-Effect
,BRD-K00004689,GSK239512,,,,,,,,,No-Effect
,BRD-K00004693,furvina,,,,,,,,,No-Effect
,BRD-K00004737,nitroflurbiprofen,,,,,,,,,No-Effect
,BRD-K78973789,MMV-390048,,,,,,,,,No-Effect
,BRD-K00004738,apyramide,,,,,,,,,No-Effect
,BRD-K23952234,AM095,,,,,,,,,No-Effect
,BRD-K31238592,devazepide,,,,,,,,,No-Effect
,BRD-K00003517,4-(aminomethyl)benzoic-acid,,,,,,,,,No-Effect
,BRD-K00003389,HTHQ,,,,,,,,,No-Effect
,BRD-K00003195,LY2795050,,,,,,,,,No-Effect
,BRD-K00003465,fantofarone,,,,,,,,,Low (25%)
,BRD-K00003523,tauroglycocholate,,,,,,,,,No-Effect
,BRD-K00004685,TS-011,,,,,,,,,No-Effect
,BRD-K00003510,FLT3-IN-1,,,,,,,,,Strong (80%)
,BRD-K00005337,DIM-C-pPhCO2Me,,,,,,,,,No-Effect
,BRD-K35984734,ZSET1446,,,,,,,,,No-Effect
,BRD-K00003507,farampator,,,,,,,,,No-Effect
,BRD-K14063023,ibiglustat,,,,,,,,,No-Effect
,BRD-K00003136,mitapivat,,,,,,,,,No-Effect
,BRD-K00003502,rovazolac,,,,,,,,,No-Effect
,BRD-K00003109,AB-423,,,,,,,,,No-Effect
,BRD-K00003199,MK-7246,,,,,,,,,No-Effect
,BRD-K00003228,seletalisib,,,,,,,,,No-Effect
,BRD-K00003522,bromisoval,,,,,,,,,No-Effect
,BRD-K00003484,mirogabalin-besylate,,,,,,,,,No-Effect
,BRD-K26526496,GS-967,,,,,,,,,No-Effect
,BRD-K00003137,lotamilast,,,,,,,,,No-Effect
,BRD-K52416806,sulfisomidin,,,,,,,,,No-Effect
,BRD-K00003113,O-304,,,,,,,,,No-Effect
,BRD-K00004590,RG7800,,,,,,,,,No-Effect
,BRD-K00003598,HOKU-81,,,,,,,,,No-Effect
,BRD-K91876515,S63845,,,,,,,,,No-Effect
,BRD-K00003140,hPGDS-IN-1,,,,,,,,,No-Effect
,BRD-K00003098,IDF-11774,,,,,,,,,No-Effect
,BRD-K00003504,licogliflozin,,,,,,,,,No-Effect
,BRD-K00003530,pirmenol,,,,,,,,,No-Effect
,BRD-K00003388,CXD101,,,,,,,,,No-Effect
,BRD-K00004735,BIA-10-2474,,,,,,,,,No-Effect
,BRD-K58938839,cyclopamine,,,,,,,,,No-Effect
,BRD-K00004593,BW-348U87,,,,,,,,,No-Effect
,BRD-K00004657,motapizone,,,,,,,,,No-Effect
,BRD-K00004747,KME-4,,,,,,,,,No-Effect
,BRD-K20168484,MK-886,,,,,,,,,No-Effect
,BRD-K00003382,nicainoprol,,,,,,,,,No-Effect
,BRD-K00003390,YL0919,,,,,,,,,No-Effect
,BRD-K33963447,GNE-7915,,,,,,,,,No-Effect
,BRD-K00004746,YS-201,,,,,,,,,No-Effect
,BRD-K00004607,monepantel,,,,,,,,,No-Effect
,BRD-K00004674,verdinexor,,,,,,,,,No-Effect
,BRD-K00004721,BMS-935177,,,,,,,,,No-Effect
,BRD-K00004610,entasobulin,,,,,,,,,Cyto
,BRD-K00004671,panipenem,,,,,,,,,No-Effect
,BRD-K00004742,lusaperidone,,,,,,,,,No-Effect
,BRD-K00004743,nuvenzepine,,,,,,,,,No-Effect
,BRD-K00003437,BTK-IN-1,,,,,,,,,Very Weak (35%)
,BRD-K00003452,desidustat,,,,,,,,,No-Effect
,BRD-K00003384,fosfluconazole,,,,,,,,,No-Effect
,BRD-K00004733,NSP-805,,,,,,,,,No-Effect
,BRD-K85030058,benactyzine,,,,,,,,,No-Effect
,BRD-K00003537,chlorphenoxamine,,,,,,,,,No-Effect
,BRD-K44845912,astilbin,,,,,,,,,No-Effect
,BRD-K00004726,ametantrone,,,,,,,,,No-Effect
,BRD-K00004717,R-121919,,,,,,,,,No-Effect
,BRD-K00004706,ST-1535,,,,,,,,,No-Effect
,BRD-M56212252,DMSO,,,,,,,,,No-Effect
,BRD-K73323637,levobunolol-(+),,,,,,,,,No-Effect
,BRD-K54170555,NMS-P715,,,,,,,,,No-Effect
,BRD-A32796301,4-galactosyllactose,,,,,,,,,No-Effect
,BRD-K91356052,palmitoleic-acid,,,,,,,,,No-Effect
,BRD-K62914667,hippuric-acid,,,,,,,,,No-Effect
,BRD-K13473780,benethamine,,,,,,,,,No-Effect
,BRD-K06050544,5-methylhydantoin-(D),,,,,,,,,No-Effect
,BRD-K82178523,L-asparagine-N-hydroxy,,,,,,,,,No-Effect
,BRD-K36998189,o-mercapto-benzoic-acid,,,,,,,,,No-Effect
,BRD-K28030264,N-hydroxynicotinamide,,,,,,,,,No-Effect
,BRD-K94948151,macelignan,,,,,,,,,No-Effect
,BRD-K48996094,pentacosanoic-acid,,,,,,,,,No-Effect
,BRD-K46416130,acetriazoic-acid,,,,,,,,,No-Effect
,BRD-K51799616,"4,4'-DDT",,,,,,,,,No-Effect
,BRD-K20501889,octadecan-1-ol,,,,,,,,,No-Effect
,BRD-K26362911,basic-fuchsin,,,,,,,,,No-Effect
,BRD-K36617478,thymol-iodide,,,,,,,,,No-Effect
,BRD-K98250023,iothalamic-acid-d3,,,,,,,,,No-Effect
,BRD-K18619710,digoxigenin,,,,,,,,,Strong (80%)
,BRD-K65377893,7-aminocephalosporanic-acid,,,,,,,,,No-Effect
,BRD-K94485812,LDN-57444,,,,,,,,,No-Effect
,BRD-K08287586,butyl-paraben,,,,,,,,,No-Effect
,BRD-K39467894,nithiamide,,,,,,,,,No-Effect
,BRD-K17008822,BD-1008,,,,,,,,,No-Effect
,BRD-A41385909,bornyl-acetate,,,,,,,,,No-Effect
,BRD-K93502141,amylene-hydrate,,,,,,,,,No-Effect
,BRD-K28121004,N-acetylglycyl-D-glutamic-acid,,,,,,,,,No-Effect
,BRD-K71823332,epothilone-A,,,,,,,,,No-Effect
,BRD-K85804405,LY231617,,,,,,,,,No-Effect
,BRD-K11576103,benzyldimethyloctylammonium,,,,,,,,,No-Effect
,BRD-A55902763,2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose,,,,,,,,,No-Effect
,BRD-K33422401,phenylmethylsulfonyl-fluoride,,,,,,,,,No-Effect
,BRD-A26105646,3-deazauridine,,,,,,,,,No-Effect
,BRD-K96631475,10-deacetylbaccatin,,,,,,,,,No-Effect
,BRD-K44777625,FH1,,,,,,,,,No-Effect
,BRD-K31468676,oxonic-acid,,,,,,,,,No-Effect
,BRD-K42332878,indium-tri(2-propanolate),,,,,,,,,No-Effect
,BRD-K75167327,2-(1-adamantylamino)benzoic-acid,,,,,,,,,No-Effect
,BRD-A05457250,BAY-K-8644-(+/-),,,,,,,,,No-Effect
,BRD-K97365803,PI-828,,,,,,,,,Weak (50%)
,BRD-K43363084,atglistatin,,,,,,,,,No-Effect
,BRD-K00003130,epetraborole,,,,,,,,,No-Effect
,BRD-K15241725,NBI-98782,,,,,,,,,No-Effect
,BRD-K38018935,OTS514,,,,,,,,,Cyto
,BRD-K90168339,thiophanate,,,,,,,,,No-Effect
,BRD-K96527333,prasterone-acetate,,,,,,,,,No-Effect
,BRD-A45929034,benzoclidine,,,,,,,,,No-Effect
,BRD-K33442414,meta-cresyl-acetate,,,,,,,,,No-Effect
,BRD-K69577666,SGC-0946,,,,,,,,,No-Effect
,BRD-K00003410,GAL-021,,,,,,,,,No-Effect
,BRD-K00003411,bamaquimast,,,,,,,,,No-Effect
,BRD-K42959922,trans-2-undecenoic-acid,,,,,,,,,No-Effect
,BRD-K51885093,quinolinic-acid,,,,,,,,,No-Effect
,BRD-K69216798,iodoantipyrine,,,,,,,,,No-Effect
,BRD-A31454688,monostearin,,,,,,,,,No-Effect
,BRD-K27536248,TCID,,,,,,,,,No-Effect
,BRD-K55305701,SC-144,,,,,,,,,No-Effect
,BRD-K00003682,imidurea,,,,,,,,,Low (25%)
,BRD-K78844995,N-[2-(piperidinylamino)ethyl]-4-iodobenzamide,,,,,,,,,No-Effect
,BRD-K20013301,LY411575,,,,,,,,,Low (25%)
,BRD-K00004214,N-benzylnaltrindole,,,,,,,,,No-Effect
,BRD-K72231366,TAME,,,,,,,,,No-Effect
,BRD-K76406695,CCT128930,,,,,,,,,No-Effect
,BRD-K39166528,ID-8,,,,,,,,,Cyto
,BRD-K27911943,"chromanol-293B-(-)-[3R,4S]",,,,,,,,,Very Weak (35%)
,BRD-K62056274,N-methylquipazine,,,,,,,,,No-Effect
,BRD-K47177710,DAPT,,,,,,,,,No-Effect
,BRD-K50325075,UCL-2077,,,,,,,,,No-Effect
,BRD-K36851334,TRIM,,,,,,,,,Low (25%)
,BRD-K42624714,BML-284,,,,,,,,,No-Effect
,BRD-K00003319,felypressin,,,,,,,,,No-Effect
,BRD-K68395654,EVP4593,,,,,,,,,No-Effect
,BRD-A43518428,flumexadol,,,,,,,,,No-Effect
,BRD-K50888640,MDL-27531,,,,,,,,,No-Effect
,BRD-K46989997,"2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",,,,,,,,,No-Effect
,BRD-K08927448,nitrosodimethylurea,,,,,,,,,No-Effect
,BRD-A17224697,dimethyl-isosorbide,,,,,,,,,No-Effect
,BRD-K58146797,"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one",,,,,,,,,No-Effect
,BRD-K41143549,N20C,,,,,,,,,No-Effect
,BRD-A38747044,KU14R,,,,,,,,,No-Effect
,BRD-K01825681,"1-(1,2-diphenylethyl)piperidine-(+/-)",,,,,,,,,No-Effect
,BRD-K56077740,MMPX,,,,,,,,,No-Effect
,BRD-K99170882,NSC-319726,,,,,,,,,Strong (80%)
,BRD-K26134695,calpeptin,,,,,,,,,Strong (80%)
,BRD-K01666923,5-hydroxydecanoic-acid,,,,,,,,,No-Effect
,BRD-K92726801,hydrastinine,,,,,,,,,No-Effect
,BRD-K83459933,sinomenine,,,,,,,,,No-Effect
,BRD-K06208435,YS-035,,,,,,,,,No-Effect
,BRD-K03301001,A-7,,,,,,,,,No-Effect
,BRD-K54521836,thiodiglycol,,,,,,,,,No-Effect
,BRD-K19094907,bicuculline-methochloride-(-),,,,,,,,,No-Effect
,BRD-K82421491,IPAG,,,,,,,,,Strong (80%)
,BRD-K38292725,azalomycin-B,,,,,,,,,No-Effect
,BRD-K90177246,tetroquinone,,,,,,,,,No-Effect
,BRD-K25186396,tangeritin,,,,,,,,,No-Effect
,BRD-K67536197,cyclocytidine,,,,,,,,,No-Effect
,BRD-K36222532,broxaldine,,,,,,,,,No-Effect
,BRD-K92377961,catharanthine,,,,,,,,,No-Effect
,BRD-K48905682,madrasin,,,,,,,,,No-Effect
,BRD-K04282412,capobenic-acid,,,,,,,,,No-Effect
,BRD-K57284066,Ro-9187,,,,,,,,,No-Effect
,BRD-A45419686,L-ascorbyl-6-palmitate,,,,,,,,,Low (25%)
,BRD-K81807412,N6-methyladenosine,,,,,,,,,No-Effect
,BRD-K60946979,CGP-78608,,,,,,,,,No-Effect
,BRD-K81048131,AG-556,,,,,,,,,No-Effect
,BRD-K00005344,DCP-LA,,,,,,,,,No-Effect
,BRD-K73394555,oxolinic-acid,,,,,,,,,No-Effect
,BRD-K26833429,costunolide,,,,,,,,,No-Effect
,BRD-K49545903,"4,4-pentamethylenepiperidine",,,,,,,,,No-Effect
,BRD-K56115039,BU226,,,,,,,,,Low (25%)
,BRD-K00005334,guancydine,,,,,,,,,Low (25%)
,BRD-K57027742,N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide,,,,,,,,,No-Effect
,BRD-K43687498,dimethadione,,,,,,,,,No-Effect
,BRD-K90976994,dehydrocholate-acid,,,,,,,,,Very Weak (35%)
,BRD-K73771095,geniposidic-acid,,,,,,,,,Low (25%)
,BRD-K78720403,SB-328437,,,,,,,,,No-Effect
,BRD-K77634909,AEG3482,,,,,,,,,Very Weak (35%)
,BRD-K74193284,phenylmercuric-acetate,,,,,,,,,No-Effect
,BRD-K89709433,HER2-Inhibitor-1,,,,,,,,,No-Effect
,BRD-K97360717,N-oxydiethylenebenzothiazole-2-sulfenamide,,,,,,,,,No-Effect
,BRD-K25521961,L-phenylisopropyladenosine,,,,,,,,,No-Effect
,BRD-K78633253,EXO-1,,,,,,,,,No-Effect
,BRD-K41262162,DHBP,,,,,,,,,No-Effect
,BRD-K00005345,20-HETE,,,,,,,,,No-Effect
,BRD-K26502378,vanitiolide,,,,,,,,,Low (25%)
,BRD-K02464583,ethyl-paraben,,,,,,,,,No-Effect
,BRD-K08493205,salicyl-alcohol,,,,,,,,,No-Effect
,BRD-K92015269,GBR-12783,,,,,,,,,No-Effect
,BRD-K10878147,OAC1,,,,,,,,,No-Effect
,BRD-K38055836,ethamivan,,,,,,,,,No-Effect
,BRD-K46435528,trichloroethylene,,,,,,,,,No-Effect
,BRD-A55455283,"2-ethyl-1,3-hexanediol",,,,,,,,,No-Effect
,BRD-K53156781,omega-(4-iodophenyl)pentadecanoic-acid,,,,,,,,,No-Effect
,BRD-K01826509,anabasine,,,,,,,,,No-Effect
,BRD-A52169337,"2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione",,,,,,,,,No-Effect
,BRD-K77756533,"7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one",,,,,,,,,No-Effect
,BRD-K04254814,sulfanilate-zinc,,,,,,,,,No-Effect
,BRD-K18280217,Nampt-IN-1,,,,,,,,,No-Effect
,BRD-K36889451,tetramethylthiuram-monosulfide,,,,,,,,,No-Effect
,BRD-K60600693,sodium-orthovanadate,,,,,,,,,No-Effect
,BRD-K46863940,dibenzothiophene,,,,,,,,,Low (25%)
,BRD-K00535541,9-aminoacridine,,,,,,,,,No-Effect
,BRD-K36982194,oxacyclohexadecan-2-one,,,,,,,,,No-Effect
,BRD-K31086665,NH125,,,,,,,,,No-Effect
,BRD-K18613660,mexeneone,,,,,,,,,No-Effect
,BRD-K85479953,STF-62247,,,,,,,,,Cyto
,BRD-K33510429,vanillylacetone,,,,,,,,,No-Effect
,BRD-A09554849,8-bromo-cAMP,,,,,,,,,No-Effect
,BRD-K07395323,17-PA,,,,,,,,,No-Effect
,BRD-K77012840,AY-9944,,,,,,,,,Weak (50%)
,BRD-K41918892,A-769662,,,,,,,,,No-Effect
,BRD-K22025381,U-18666A,,,,,,,,,Strong (80%)
,BRD-K46384212,o-3M3FBS,,,,,,,,,No-Effect
,BRD-K61269089,daphnetin,,,,,,,,,No-Effect
,BRD-K56792340,ethoxyquin,,,,,,,,,No-Effect
,BRD-K00025573,dehydroacetic-acid,,,,,,,,,No-Effect
,BRD-K00003714,L-(+)-rhamnose-monohydrate,,,,,,,,,No-Effect
,BRD-K94239562,paeonol,,,,,,,,,No-Effect
,BRD-K50785021,cyclamic-acid,,,,,,,,,No-Effect
,BRD-K00003674,terpene,,,,,,,,,No-Effect
,BRD-K78294846,osthol,,,,,,,,,No-Effect
,BRD-K05906022,limonin,,,,,,,,,No-Effect
,BRD-K72735080,BET-BAY-002,,,,,,,,,Very Weak (35%)
,BRD-K65890018,SSR128129E,,,,,,,,,No-Effect
,BRD-K18905250,ST-91,,,,,,,,,No-Effect
,BRD-K41809988,oxidopamine,,,,,,,,,No-Effect
,BRD-K06204668,"3,4-DCPG-(R)",,,,,,,,,No-Effect
,BRD-K63151507,MNITMT,,,,,,,,,No-Effect
,BRD-K03635852,U-0124,,,,,,,,,No-Effect
,BRD-K06159959,CCMQ,,,,,,,,,No-Effect
,BRD-K39706510,MIRA-1,,,,,,,,,No-Effect
,BRD-K22631935,neurodazine,,,,,,,,,No-Effect
,BRD-K26824830,azomycin-(2-nitroimidazole),,,,,,,,,No-Effect
,BRD-K97375133,ferrostatin-1,,,,,,,,,No-Effect
,BRD-K38860038,JK-184,,,,,,,,,Low (25%)
,BRD-K61951118,FG-7142,,,,,,,,,No-Effect
,BRD-K09619578,DS2-(806622),,,,,,,,,Low (25%)
,BRD-K41853443,"1,3-dipropyl-8-phenylxanthine",,,,,,,,,No-Effect
,BRD-K20417253,oxiniacic-acid,,,,,,,,,No-Effect
,BRD-K11094367,acetanilide,,,,,,,,,No-Effect
,BRD-K89634775,allylthiourea,,,,,,,,,No-Effect
,BRD-K49313711,ribitol,,,,,,,,,No-Effect
,BRD-K84075000,2-chloropyrazine,,,,,,,,,No-Effect
,BRD-A21276153,"2,6-dimethylpiperidine",,,,,,,,,No-Effect
,BRD-A37873789,octodrine,,,,,,,,,No-Effect
,BRD-K00003718,nornicotine,,,,,,,,,No-Effect
,BRD-K00003671,idramantone,,,,,,,,,No-Effect
,BRD-K75608666,hydroxytoluic-acid,,,,,,,,,No-Effect
,BRD-A78093359,MRS-1845,,,,,,,,,No-Effect
,BRD-K55790047,ON-01500,,,,,,,,,No-Effect
,BRD-K24297741,urethane,,,,,,,,,No-Effect
,BRD-K26273521,trans-4-methoxycinnamic-acid,,,,,,,,,No-Effect
,BRD-K03044000,80841-78-7,,,,,,,,,No-Effect
,BRD-K19958299,TCS-2210,,,,,,,,,No-Effect
,BRD-K93035859,butylated-hydroxyanisole,,,,,,,,,No-Effect
,BRD-A53504839,sennoside-protonated,,,,,,,,,No-Effect
,BRD-K68653965,picolamine,,,,,,,,,No-Effect
,BRD-K12362304,diphenylguanidine,,,,,,,,,No-Effect
,BRD-K62929068,6-benzylaminopurine,,,,,,,,,No-Effect
,BRD-A85472596,L-670596,,,,,,,,,No-Effect
,BRD-K00003706,norvancomycin,,,,,,,,,No-Effect
,BRD-K49721826,3-anilinopropan-1-ol,,,,,,,,,No-Effect
,BRD-K41422683,stigmasterol,,,,,,,,,No-Effect
,BRD-K00003337,ALX-40-4C,,,,,,,,,No-Effect
,BRD-K05919151,dixanthogen,,,,,,,,,No-Effect
,BRD-A90201073,GPi-688,,,,,,,,,No-Effect
,BRD-K87424134,alpha-D-glucopyranose,,,,,,,,,No-Effect
,BRD-K97019106,"4-acetyl-1,1-dimethylpiperazinium",,,,,,,,,No-Effect
,BRD-K30990140,FR-122047,,,,,,,,,No-Effect
,BRD-K00004684,squaric-acid-dibutyl-ester,,,,,,,,,No-Effect
,BRD-K00003535,polaprezinc,,,,,,,,,No-Effect
,BRD-K00003171,DWK-1339,,,,,,,,,No-Effect
,BRD-K23403298,benzyldimethylhexadecylammonium,,,,,,,,,No-Effect
,BRD-K61802864,chlorindione,,,,,,,,,No-Effect
,BRD-K12329651,androsterone,,,,,,,,,No-Effect
,BRD-K65230684,oxaceprol,,,,,,,,,No-Effect
,BRD-K54395039,PR-619,,,,,,,,,No-Effect
,BRD-K09774593,S-trityl-L-cysteine,,,,,,,,,No-Effect
,BRD-K08619838,tremorine,,,,,,,,,No-Effect
,BRD-K63979671,etifenin,,,,,,,,,No-Effect
,BRD-K20655524,mefexamide,,,,,,,,,No-Effect
,BRD-K59570838,homoveratrylamine,,,,,,,,,No-Effect
,BRD-K06341478,PNU-37883,,,,,,,,,No-Effect
,BRD-K00005341,ogerin,,,,,,,,,No-Effect
,BRD-K91298281,tenylidone,,,,,,,,,No-Effect
,BRD-K08699567,cinoctramide,,,,,,,,,No-Effect
,BRD-K75080769,"trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",,,,,,,,,No-Effect
,BRD-K00004728,allopurinol-riboside,,,,,,,,,No-Effect
,BRD-K00004615,PBT-1033,,,,,,,,,No-Effect
,BRD-K56634222,2-iodohippuric-acid,,,,,,,,,No-Effect
,BRD-K08837089,actinoquinol,,,,,,,,,No-Effect
,BRD-K00004617,imidazoacridinone,,,,,,,,,No-Effect
,BRD-K00004739,hepsulfam,,,,,,,,,No-Effect
,BRD-K00004740,parcetasal,,,,,,,,,No-Effect
,BRD-K00004729,manitimus,,,,,,,,,No-Effect
,BRD-K00004744,lintopride,,,,,,,,,No-Effect
,BRD-K00004568,eniporide,,,,,,,,,No-Effect
,BRD-K00004745,HSR6071,,,,,,,,,No-Effect
,BRD-K00004552,sameridine,,,,,,,,,No-Effect
,BRD-K00004545,crisdesalazine,,,,,,,,,No-Effect
,BRD-K00004734,AVE-3085,,,,,,,,,No-Effect
,BRD-K00004556,WAY-255348,,,,,,,,,No-Effect
,BRD-K00004708,OP-0595,,,,,,,,,No-Effect
,BRD-K16605796,T-025,,,,,,,,,No-Effect
,BRD-K44825564,ZAPA,,,,,,,,,No-Effect
,BRD-K73201113,octamethyltrisiloxane,,,,,,,,,No-Effect
,BRD-K34591242,methoprene-(s),,,,,,,,,No-Effect
,BRD-K00003435,AVex-73,,,,,,,,,No-Effect
,BRD-K00004641,PHA-543613,,,,,,,,,No-Effect
,BRD-K40767677,RP67580,,,,,,,,,No-Effect
,BRD-K56839624,CQS,,,,,,,,,No-Effect
,BRD-K18834913,LB42708,,,,,,,,,No-Effect
,BRD-K00004212,PG-9,,,,,,,,,No-Effect
,BRD-K03164761,thiazovivin,,,,,,,,,No-Effect
,BRD-K00003206,emiglitate,,,,,,,,,Low (25%)
,BRD-K00003230,asapiprant,,,,,,,,,No-Effect
,BRD-K00003396,CEP-40783,,,,,,,,,No-Effect
,BRD-K00003271,JD-5037,,,,,,,,,No-Effect
,BRD-K00004631,T-1095,,,,,,,,,No-Effect
,BRD-K68332390,statil,,,,,,,,,No-Effect
,BRD-K00004681,5-octanoylsalicylic-acid,,,,,,,,,No-Effect
,BRD-K91644281,kasugamycin,,,,,,,,,Low (25%)
,BRD-K00003301,ASP-9521,,,,,,,,,Weak (50%)
,BRD-K00003518,methylbenactyzium-bromide,,,,,,,,,No-Effect
,BRD-K00004548,NS-11394,,,,,,,,,No-Effect
,BRD-K00004573,RG7834,,,,,,,,,No-Effect
,BRD-A37752546,1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime,,,,,,,,,No-Effect
,BRD-K62378877,clanfenur,,,,,,,,,No-Effect
,BRD-K00004702,funapide,,,,,,,,,No-Effect
,BRD-K00004553,SAM-315,,,,,,,,,No-Effect
,BRD-K00004634,BMS-207940,,,,,,,,,No-Effect
,BRD-K00004705,AQW-051,,,,,,,,,No-Effect
,BRD-K00004696,leonurine,,,,,,,,,No-Effect
,BRD-K00004581,pirozadil,,,,,,,,,No-Effect
,BRD-K00004561,E-2001,,,,,,,,,No-Effect
,BRD-K00004578,KAF-156,,,,,,,,,No-Effect
,BRD-K29066607,D-157495,,,,,,,,,Weak (50%)
,BRD-K00004587,KR-33494,,,,,,,,,No-Effect
,BRD-K00004711,GSK356278,,,,,,,,,No-Effect
,BRD-K00004678,DOTMP,,,,,,,,,No-Effect
,BRD-K00004583,AC260584,,,,,,,,,No-Effect
,BRD-K00004654,"CP-105,696",,,,,,,,,No-Effect
,BRD-K00003302,adomeglivant,,,,,,,,,No-Effect
,BRD-K06520168,propyphenazone,,,,,,,,,No-Effect
,BRD-K00004570,DSPC,,,,,,,,,No-Effect
,BRD-K00005246,CK-101,,,,,,,,,No-Effect
,BRD-K00003335,iRGD-peptide,,,,,,,,,No-Effect
,BRD-K00003325,topilutamide,,,,,,,,,No-Effect
,BRD-K00003341,ketohexokinase-inhibitor-1,,,,,,,,,No-Effect
,BRD-K00004649,E3330,,,,,,,,,No-Effect
,BRD-K00004601,HC-070,,,,,,,,,No-Effect
,BRD-K00004565,LY311727,,,,,,,,,No-Effect
,BRD-K00003424,roblitinib,,,,,,,,,No-Effect
,BRD-K00003375,visomitin,,,,,,,,,No-Effect
,BRD-K00003733,ganoderic-acid-a,,,,,,,,,No-Effect
,BRD-K00003340,JPH203,,,,,,,,,No-Effect
,BRD-K00003291,BEBT-908,,,,,,,,,Cyto
,BRD-K00003491,morphothiadin,,,,,,,,,No-Effect
,BRD-K00004673,LP-533401,,,,,,,,,No-Effect
,BRD-K00010388,PTC-028,,,,,,,,,No-Effect
,BRD-K00004968,acetylspiramycin,,,,,,,,,No-Effect
,BRD-K00003303,acoziborole,,,,,,,,,No-Effect
,BRD-K00003276,CCT245737,,,,,,,,,No-Effect
,BRD-K00003277,vatinoxan,,,,,,,,,No-Effect
,BRD-K00003317,pipofezine,,,,,,,,,No-Effect
,BRD-K00003154,imisopasem-manganese,,,,,,,,,No-Effect
,BRD-K14661019,AZ-7371,,,,,,,,,No-Effect
,BRD-K00003299,F-16915,,,,,,,,,No-Effect
,BRD-K00003339,dixyrazine,,,,,,,,,No-Effect
,BRD-K00003312,sultopride,,,,,,,,,No-Effect
,BRD-K00003262,nicodicosapent,,,,,,,,,No-Effect
,BRD-K00003242,sancycline,,,,,,,,,No-Effect
,BRD-K00003155,TAK-779,,,,,,,,,No-Effect
,BRD-K00003147,S49076,,,,,,,,,No-Effect
,BRD-K03336321,AZD8797,,,,,,,,,No-Effect
,BRD-K00003185,EMD534085,,,,,,,,,No-Effect
,BRD-K00010386,RMC-4550,,,,,,,,,No-Effect
,BRD-K00003259,edonerpic-maleate,,,,,,,,,No-Effect
,BRD-K00003129,crenigacestat,,,,,,,,,No-Effect
,BRD-K70327191,benzoxiquine,,,,,,,,,No-Effect
,BRD-K40782193,QX-222,,,,,,,,,No-Effect
,BRD-A64125466,dehydrocholate,,,,,,,,,No-Effect
,BRD-K46428823,liothyronine-(isomer),,,,,,,,,No-Effect
,BRD-K64191834,N-cyclohexyl-2-benzothiazolesulfenamide,,,,,,,,,No-Effect
,BRD-K08288352,1-ethyl-2-pyrrolidone,,,,,,,,,No-Effect
,BRD-K21452876,chlorazanil,,,,,,,,,No-Effect
,BRD-K00256256,AMZ30,,,,,,,,,No-Effect
,BRD-A42746051,melengestrol-acetate,,,,,,,,,No-Effect
,BRD-K01827294,methyl-5-hydroxytryptamine,,,,,,,,,No-Effect
,BRD-A11662333,meparfylon,,,,,,,,,No-Effect
,BRD-K54824716,procodazole,,,,,,,,,No-Effect
,BRD-K63165456,norcyclobenzaprine,,,,,,,,,No-Effect
,BRD-A05674712,"D,L-mevalonic-acid-lactone",,,,,,,,,No-Effect
,BRD-K61295575,blebbistatin-(-),,,,,,,,,No-Effect
,BRD-K73381198,5-fluoro-3-pyridyl-methanol,,,,,,,,,No-Effect
,BRD-A68509429,ethylnorepinephrine,,,,,,,,,No-Effect
,BRD-K79402892,sitosterol,,,,,,,,,No-Effect
,BRD-K26160755,RS-45041-190,,,,,,,,,No-Effect
,BRD-K91614056,trans-4-hydroxycrotonic-acid,,,,,,,,,No-Effect
,BRD-A24252652,hygromycin-B,,,,,,,,,No-Effect
,BRD-K00003196,ansamitocin-p-3,,,,,,,,,Cyto
,BRD-K13495773,creatinine,,,,,,,,,No-Effect
,BRD-K77548206,bitoscanate,,,,,,,,,No-Effect
,BRD-K68474068,MM-102,,,,,,,,,No-Effect
,BRD-K95701999,metaphit,,,,,,,,,Strong (80%)
,BRD-K78496197,SCS,,,,,,,,,No-Effect
,BRD-K01825672,SN-6,,,,,,,,,No-Effect
,BRD-K21164796,beta-naphthol,,,,,,,,,No-Effect
,BRD-K54799382,parethoxycaine,,,,,,,,,No-Effect
,BRD-M02075109,chromanol-(+/-),,,,,,,,,No-Effect
,BRD-K16474819,metacetamol,,,,,,,,,No-Effect
,BRD-K24507548,cintriamide,,,,,,,,,No-Effect
,BRD-K60060639,N-methyllidocaine-iodide,,,,,,,,,No-Effect
,BRD-K88956297,"1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",,,,,,,,,No-Effect
,BRD-K78092779,2'-C-methylguanosine,,,,,,,,,No-Effect
,BRD-K67445247,flurofamide,,,,,,,,,No-Effect
,BRD-K42108215,4-propylbenzoic-acid,,,,,,,,,No-Effect
,BRD-A64242993,lanatoside-C,,,,,,,,,Weak (50%)
,BRD-K68075732,atenolol-(+),,,,,,,,,No-Effect
,BRD-K15898725,maytansinol-isobutyrate,,,,,,,,,Cyto
,BRD-K41104902,GSK2656157,,,,,,,,,Very Weak (35%)
,BRD-K17061841,stattic,,,,,,,,,No-Effect
,BRD-K59146805,AZ3146,,,,,,,,,Weak (50%)
,BRD-K28824103,genipin,,,,,,,,,No-Effect
,BRD-K59036917,ML161,,,,,,,,,No-Effect
,BRD-K81645907,captamine,,,,,,,,,No-Effect
,BRD-K64341947,CFM-1571,,,,,,,,,No-Effect
,BRD-A09062839,amyleine,,,,,,,,,No-Effect
,BRD-K00005352,epiestriol,,,,,,,,,No-Effect
,BRD-A46876182,levobunolol-(+/-),,,,,,,,,No-Effect
,BRD-K96055017,1-acetyl-4-methylpiperazine,,,,,,,,,No-Effect
,BRD-M01344114,threo-2-methylisocitrate-(DL),,,,,,,,,No-Effect
,BRD-K76139886,compound-58112,,,,,,,,,No-Effect
,BRD-K65417056,meprylcaine,,,,,,,,,No-Effect
,BRD-K52219182,ICI-63197,,,,,,,,,No-Effect
,BRD-K03564313,DMNB,,,,,,,,,No-Effect
,BRD-K73700643,N-acetyltryptamine,,,,,,,,,No-Effect
,BRD-K01825503,niguldipine-(R)-(-),,,,,,,,,No-Effect
,BRD-K13238618,carsalam,,,,,,,,,No-Effect
,BRD-K82104468,ethyl-vanillin,,,,,,,,,No-Effect
,BRD-K01826521,"Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,",,,,,,,,,No-Effect
,BRD-A49952467,salsolinol-1-carboxylic-acid,,,,,,,,,No-Effect
,BRD-K20484910,ampyrone,,,,,,,,,No-Effect
,BRD-K83036479,salicylanilide,,,,,,,,,No-Effect
,BRD-K47464228,azaserine,,,,,,,,,No-Effect
,BRD-A63267145,hexonic-acid,,,,,,,,,No-Effect
,BRD-K05674516,PSI-7976,,,,,,,,,No-Effect
,BRD-K00003557,ONX-0914,,,,,,,,,No-Effect
,BRD-K22327730,2-methyl-5-nitrophenol,,,,,,,,,No-Effect
,BRD-A14440173,lipoamide,,,,,,,,,No-Effect
,BRD-K22193694,dioxybenzone,,,,,,,,,No-Effect
,BRD-K99174507,cardiogenol-C,,,,,,,,,No-Effect
,BRD-K01826784,palmitoylcarnitine,,,,,,,,,Cyto
,BRD-K57091285,dicyclohexylamine,,,,,,,,,Very Weak (35%)
,BRD-K49119234,TMPH,,,,,,,,,No-Effect
,BRD-K56033645,5-methylhydantoin-(L),,,,,,,,,No-Effect
,BRD-K55166090,efloxate,,,,,,,,,No-Effect
,BRD-K15337272,C-751,,,,,,,,,No-Effect
,BRD-K17874929,bromebric-acid,,,,,,,,,No-Effect
,BRD-K66101666,PYR-41,,,,,,,,,No-Effect
,BRD-K24483849,trimethylolpropane-triacrylate,,,,,,,,,No-Effect
,BRD-A64011898,androstenone,,,,,,,,,No-Effect
,BRD-K02764365,methiazole,,,,,,,,,No-Effect
,BRD-K14763542,flurothyl,,,,,,,,,No-Effect
,BRD-M17926088,FPA-124,,,,,,,,,No-Effect
,BRD-K23728266,chlorophyllin,,,,,,,,,Weak (50%)
,BRD-K77115421,phthalylsulfacetamide,,,,,,,,,No-Effect
,BRD-K68904758,cephalomannine,,,,,,,,,No-Effect
,BRD-K56908511,fluroxene,,,,,,,,,No-Effect
,BRD-K48488978,YM-201636,,,,,,,,,Weak (50%)
,BRD-K41024817,4-phenolsulfonic-acid,,,,,,,,,No-Effect
,BRD-K59527975,S-sulfo-L-cysteine,,,,,,,,,No-Effect
,BRD-K24443618,etebenecid,,,,,,,,,No-Effect
,BRD-A07164067,meluadrine,,,,,,,,,No-Effect
,BRD-M56276249,bismuth(III)-trifluoromethanesulfonate,,,,,,,,,No-Effect
,BRD-K01294196,sucrose-octaacetate,,,,,,,,,Low (25%)
,BRD-K93806173,N-MPPP,,,,,,,,,No-Effect
,BRD-M08274809,indium(III)-isopropoxide,,,,,,,,,No-Effect
,BRD-K00004661,declopramide,,,,,,,,,No-Effect
,BRD-K16229414,SR-11302,,,,,,,,,No-Effect
,BRD-K00005343,reynoutrin,,,,,,,,,No-Effect
,BRD-K73073971,ZLN005,,,,,,,,,No-Effect
,BRD-K00003314,furagin,,,,,,,,,Low (25%)
,BRD-K64178227,BTS,,,,,,,,,No-Effect
,BRD-K42371134,phenylethyl-alcohol,,,,,,,,,No-Effect
,BRD-K39371216,cyacetacide,,,,,,,,,No-Effect
,BRD-K05724540,ftaxilide,,,,,,,,,No-Effect
,BRD-A98083480,"benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]",,,,,,,,,No-Effect
,BRD-K78342372,hematoxylin,,,,,,,,,Very Weak (35%)
,BRD-K00003282,esonarimod,,,,,,,,,No-Effect
,BRD-K72384124,sulbentine,,,,,,,,,No-Effect
,BRD-K00003333,ornipressin,,,,,,,,,No-Effect
,BRD-K01614093,dihydromyricetin,,,,,,,,,No-Effect
,BRD-A77118605,D609,,,,,,,,,No-Effect
,BRD-K68534611,2-methylimidazole,,,,,,,,,No-Effect
,BRD-K00003334,sincalide,,,,,,,,,No-Effect
,BRD-A95802703,1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol,,,,,,,,,No-Effect
,BRD-K26005076,gramine,,,,,,,,,No-Effect
,BRD-K00004549,irganox-1010,,,,,,,,,No-Effect
,BRD-A57957888,citiolone,,,,,,,,,No-Effect
,BRD-K00004562,deazaguanine,,,,,,,,,Weak (50%)
,BRD-K33642804,symclosene,,,,,,,,,No-Effect
,BRD-K00004623,Ro-5263397,,,,,,,,,No-Effect
,BRD-K28354016,homidium,,,,,,,,,No-Effect
,BRD-K00004626,CGP-39551,,,,,,,,,No-Effect
,BRD-K30360804,buramate,,,,,,,,,No-Effect
,BRD-K06338106,4-tert-butylphenol,,,,,,,,,No-Effect
,BRD-K00004563,napamezole,,,,,,,,,No-Effect
,BRD-K00004664,NDD-094,,,,,,,,,No-Effect
,BRD-K36137799,plumbagin,,,,,,,,,No-Effect
,BRD-K00004630,val-tyr,,,,,,,,,No-Effect
,BRD-K00004580,velaresol,,,,,,,,,No-Effect
,BRD-K48173020,ameltolide,,,,,,,,,No-Effect
,BRD-K00004620,ZD-0947,,,,,,,,,No-Effect
,BRD-K01653460,chlorindanol,,,,,,,,,No-Effect
,BRD-K00005248,WP921,,,,,,,,,No-Effect
,BRD-K42336459,p-dimethylinamyl-benzoate,,,,,,,,,No-Effect
,BRD-A37942872,eucatropine,,,,,,,,,No-Effect
,BRD-K28773847,RLX,,,,,,,,,No-Effect
,BRD-K15834839,lobendazole,,,,,,,,,No-Effect
,BRD-K08791496,fenaclon,,,,,,,,,No-Effect
,BRD-K60914966,etosalamide,,,,,,,,,No-Effect
,BRD-K00004571,fasoracetam,,,,,,,,,No-Effect
,BRD-K00004647,NB-001,,,,,,,,,No-Effect
,BRD-K30284967,6-aminopenicillanic-acid,,,,,,,,,No-Effect
,BRD-K96714749,isobutamben,,,,,,,,,No-Effect
,BRD-K58648841,cresopirine,,,,,,,,,No-Effect
,BRD-K93611241,diacetamate,,,,,,,,,No-Effect
,BRD-K80253852,benzyl-isothiocyanate,,,,,,,,,No-Effect
,BRD-A41657926,dicloralurea,,,,,,,,,No-Effect
,BRD-K03871161,5-hydroxyectoine,,,,,,,,,No-Effect
,BRD-A30590053,MR-16728,,,,,,,,,No-Effect
,BRD-K49759007,4-hydroxy-phenazone,,,,,,,,,No-Effect
,BRD-K73191876,alizarin,,,,,,,,,No-Effect
,BRD-K27135764,xanthone,,,,,,,,,No-Effect
,BRD-K02816415,CRT0044876,,,,,,,,,No-Effect
,BRD-K00003524,apronal,,,,,,,,,No-Effect
,BRD-K78299798,mepiroxol,,,,,,,,,No-Effect
,BRD-A40504327,"4-phenyl-1,2,3,4-tetrahydroisoquinoline",,,,,,,,,No-Effect
,BRD-A78588743,editol,,,,,,,,,No-Effect
,BRD-K65508953,monocrotaline,,,,,,,,,No-Effect
,BRD-K11548689,lauric-diethanolamide,,,,,,,,,No-Effect
,BRD-K35698076,laurocapram,,,,,,,,,No-Effect
,BRD-K87548127,thaliblastine,,,,,,,,,Strong (80%)
,BRD-K00004709,alinidine,,,,,,,,,No-Effect
,BRD-A05334458,lisofylline,,,,,,,,,No-Effect
,BRD-K22316123,BMS-983970,,,,,,,,,No-Effect
,BRD-K41213548,KW-2478,,,,,,,,,No-Effect
,BRD-K02780233,geranyl-farnesylacetate,,,,,,,,,No-Effect
,BRD-K36040345,TXA127,,,,,,,,,No-Effect
,BRD-K95941975,piperazinedione,,,,,,,,,No-Effect
,BRD-A07815743,kakonein,,,,,,,,,No-Effect
,BRD-K88153212,myristyl-nicotinate,,,,,,,,,No-Effect
,BRD-K66353228,zoxazolamine,,,,,,,,,Very Weak (35%)
,BRD-K00004648,PF-06747775,,,,,,,,,No-Effect
,BRD-K46908090,GDC-0623,,,,,,,,,No-Effect
,BRD-K00656370,6-aminochrysene,,,,,,,,,No-Effect
,BRD-K20958582,TH-302,,,,,,,,,No-Effect
,BRD-K39230570,clomesone,,,,,,,,,No-Effect
,BRD-K99498722,plinabulin,,,,,,,,,Weak (50%)
,BRD-K81136890,leucylleucine-methyl-ester,,,,,,,,,No-Effect
,BRD-K07202345,frentizole,,,,,,,,,No-Effect
,BRD-A53037217,BTZ043-racemate,,,,,,,,,No-Effect
,BRD-K44590731,TU-2100,,,,,,,,,No-Effect
,BRD-A46813902,iododexetimide,,,,,,,,,No-Effect
,BRD-K74057757,indibulin,,,,,,,,,No-Effect
,BRD-K44009692,hyodeoxycholic-acid,,,,,,,,,No-Effect
,BRD-K71698503,I-BZA2,,,,,,,,,Very Weak (35%)
,BRD-K91733562,secoisolariciresinol-(-),,,,,,,,,No-Effect
,BRD-K00004605,ALS-8176,,,,,,,,,No-Effect
,BRD-K73524797,ST-1859,,,,,,,,,No-Effect
,BRD-K46133855,NXY-059,,,,,,,,,No-Effect
,BRD-K22261391,pirodavir,,,,,,,,,No-Effect
,BRD-K15447284,gastrodin,,,,,,,,,No-Effect
,BRD-K00003298,setmelanotide,,,,,,,,,No-Effect
,BRD-K61195623,combretastatin-A-4,,,,,,,,,Strong (80%)
,BRD-K75956464,VCH-916,,,,,,,,,No-Effect
,BRD-K64614248,salicin,,,,,,,,,No-Effect
,BRD-K40621224,pentetic-acid,,,,,,,,,No-Effect
,BRD-K30968378,INT-747,,,,,,,,,No-Effect
,BRD-A53134341,Ro-106-9920,,,,,,,,,Very Weak (35%)
,BRD-M02179497,bismuth-oxalate,,,,,,,,,No-Effect
,BRD-K28405228,mecarbinate,,,,,,,,,No-Effect
,BRD-A96503329,safflower-yellow,,,,,,,,,No-Effect
,BRD-K93631643,hordenine,,,,,,,,,No-Effect
,BRD-K00003208,imirestat,,,,,,,,,No-Effect
,BRD-A62562325,deoxyarbutin,,,,,,,,,No-Effect
,BRD-K20431737,benzoylpas,,,,,,,,,No-Effect
,BRD-K00004653,S15535,,,,,,,,,No-Effect
,BRD-K00004732,camobucol,,,,,,,,,No-Effect
,BRD-K00005242,TEN-010,,,,,,,,,Cyto
,BRD-K00003436,AVN-492,,,,,,,,,No-Effect
,BRD-K69632891,tribromoethanol,,,,,,,,,No-Effect
,BRD-K75282704,BL-5583,,,,,,,,,No-Effect
,BRD-K11696279,BU-239,,,,,,,,,No-Effect
,BRD-K24556407,ETP-46464,,,,,,,,,Low (25%)
,BRD-K82236108,"N-methyl-(-)ephedrine-[1R,2S]",,,,,,,,,No-Effect
,BRD-K00003237,mavatrep,,,,,,,,,No-Effect
,BRD-K16343284,macozinone,,,,,,,,,No-Effect
,BRD-K00005335,CycLuc1,,,,,,,,,No-Effect
,BRD-K00005333,H-151,,,,,,,,,No-Effect
,BRD-K28492574,piconol,,,,,,,,,No-Effect
,BRD-K58819470,2-thiouracil,,,,,,,,,No-Effect
,BRD-K00003516,emamectin,,,,,,,,,Cyto
,BRD-K00004599,PRN1008,,,,,,,,,No-Effect
,BRD-K00003165,sardomozide,,,,,,,,,No-Effect
,BRD-K33743361,ML133,,,,,,,,,No-Effect
,BRD-K18316707,O-1918,,,,,,,,,No-Effect
,BRD-K03326591,amyl-nitrite,,,,,,,,,No-Effect
,BRD-K00003239,fluralaner,,,,,,,,,No-Effect
,BRD-K00004690,SKLB-1028,,,,,,,,,Weak (50%)
,BRD-K00004727,simurosertib,,,,,,,,,No-Effect
,BRD-K96233303,TMS,,,,,,,,,No-Effect
,BRD-K00003479,AX-024,,,,,,,,,No-Effect
,BRD-K00004567,florifenine,,,,,,,,,No-Effect
,BRD-K00003732,atractylenolide-i,,,,,,,,,No-Effect
,BRD-K00005336,PZ-2891,,,,,,,,,No-Effect
,BRD-K52087522,YM-244769,,,,,,,,,No-Effect
,BRD-K00003460,vorasidenib,,,,,,,,,No-Effect
,BRD-K00004704,DBPR-211,,,,,,,,,No-Effect
,BRD-K00005238,alpha-glucosyl-hesperidin,,,,,,,,,No-Effect
,BRD-K00003505,nemorexant,,,,,,,,,No-Effect
,BRD-K44665581,bromosporine,,,,,,,,,Very Weak (35%)
,BRD-K82484347,GSK-J2,,,,,,,,,No-Effect
,BRD-K00004731,Gln-1062,,,,,,,,,No-Effect
,BRD-K84924563,6-diazo-5-oxo-L-norleucine,,,,,,,,,No-Effect
,BRD-K00003167,macitentan-n-butyl-analogue,,,,,,,,,No-Effect
,BRD-K39061174,beta-glycerophosphoric-acid,,,,,,,,,No-Effect
,BRD-K00003364,GSK2239633A,,,,,,,,,No-Effect
,BRD-K00003526,uprifosbuvir,,,,,,,,,No-Effect
,BRD-K00004715,butaprost,,,,,,,,,No-Effect
,BRD-K40255344,tyrphostin-A9,,,,,,,,,No-Effect
,BRD-K28690501,diosgenin,,,,,,,,,No-Effect
,BRD-K00003145,PF-05089771,,,,,,,,,No-Effect
,BRD-A73871920,nanchangmycin,,,,,,,,,Strong (80%)
,BRD-K00003399,ocaperidone,,,,,,,,,No-Effect
,BRD-K00003279,PF-06282999,,,,,,,,,No-Effect
,BRD-K66241279,cinromide,,,,,,,,,Cyto
,BRD-K00003270,galidesivir,,,,,,,,,Very Weak (35%)
,BRD-K00003290,emixustat,,,,,,,,,No-Effect
,BRD-K23301018,broxyquinoline,,,,,,,,,No-Effect
,BRD-K03289534,lersivirine,,,,,,,,,No-Effect
,BRD-K43055376,ADD-233089,,,,,,,,,No-Effect
,BRD-K00003531,acelarin,,,,,,,,,No-Effect
,BRD-K32804101,valrocemide,,,,,,,,,No-Effect
,BRD-K25970317,resibufogenin,,,,,,,,,Low (25%)
,BRD-A22971209,DMPS,,,,,,,,,No-Effect
,BRD-A75263867,"2,3-cis/exo-pinanediol",,,,,,,,,No-Effect
,BRD-K79424231,NM107,,,,,,,,,No-Effect
,BRD-K96042922,etanidazole,,,,,,,,,No-Effect
,BRD-K00025603,LB-100,,,,,,,,,No-Effect
,BRD-K15203492,MLN9708,,,,,,,,,No-Effect
,BRD-K12047401,palifosfamide,,,,,,,,,No-Effect
,BRD-A39935389,teroxirone,,,,,,,,,No-Effect
,BRD-K20468903,BNC105,,,,,,,,,Very Weak (35%)
,BRD-K55822903,imeglimin,,,,,,,,,No-Effect
,BRD-K77432251,abafungin,,,,,,,,,No-Effect
,BRD-K97643133,amiprilose,,,,,,,,,No-Effect
,BRD-K27625831,pleconaril,,,,,,,,,No-Effect
,BRD-K87386013,diroximel-fumarate,,,,,,,,,No-Effect
,BRD-K23791635,AFN-1252,,,,,,,,,No-Effect
,BRD-K79633074,xilobam,,,,,,,,,No-Effect
,BRD-M97302542,dichloroacetate,,,,,,,,,No-Effect
,BRD-K36169695,sangivamycin,,,,,,,,,Weak (50%)
,BRD-A96051074,carnosine,,,,,,,,,No-Effect
,BRD-K96684644,spirobromin,,,,,,,,,No-Effect
,BRD-K70007857,hexasodium-phytate,,,,,,,,,No-Effect
,BRD-K44602126,"2,3-cis/exo-camphanediol",,,,,,,,,No-Effect
,BRD-A92872453,N-acetylmannosamine,,,,,,,,,No-Effect
,BRD-K36379990,riodipine,,,,,,,,,No-Effect
,BRD-K79565391,elemene,,,,,,,,,No-Effect
,BRD-A67521319,pimonidazole,,,,,,,,,No-Effect
,BRD-K60284353,titanocene-dichloride,,,,,,,,,No-Effect
,BRD-K65428967,cordycepin,,,,,,,,,No-Effect
,BRD-K43812936,Mps1-IN-5,,,,,,,,,No-Effect
,BRD-K03503561,ravuconazole,,,,,,,,,No-Effect
,BRD-K00228584,bisoctrizole,,,,,,,,,No-Effect
,BRD-K23163214,dizocilpine-(-),,,,,,,,,No-Effect
,BRD-K85014146,AZD2461,,,,,,,,,No-Effect
,BRD-K45245728,ursodeoxycholyltaurine,,,,,,,,,No-Effect
,BRD-K00003715,harringtonine,,,,,,,,,Strong (80%)
,BRD-K38287497,narlaprevir,,,,,,,,,No-Effect
,BRD-K59424860,L-valine,,,,,,,,,No-Effect
,BRD-K42019693,pyridoxal-isonicotinoyl-hydrazone,,,,,,,,,No-Effect
,BRD-K01231377,BMS-191095,,,,,,,,,No-Effect
,BRD-K61339991,kevetrin,,,,,,,,,No-Effect
,BRD-K31329721,centazolone,,,,,,,,,No-Effect
,BRD-K53422148,BI-224436,,,,,,,,,No-Effect
,BRD-K36201510,verbascoside,,,,,,,,,No-Effect
,BRD-K21920947,AN2718,,,,,,,,,No-Effect
,BRD-K56405978,TBA-354,,,,,,,,,No-Effect
,BRD-A29125379,INS316,,,,,,,,,No-Effect
,BRD-K73132780,pyronaridine,,,,,,,,,Weak (50%)
,BRD-A09911125,prolylleucylglycinamide,,,,,,,,,No-Effect
,BRD-M12328004,C106,,,,,,,,,No-Effect
,BRD-K06388517,lofemizole,,,,,,,,,No-Effect
,BRD-K00003393,BGP-15,,,,,,,,,No-Effect
,BRD-A79857384,captan,,,,,,,,,No-Effect
,BRD-K31339321,lirimilast,,,,,,,,,No-Effect
,BRD-A78195072,imexon,,,,,,,,,No-Effect
,BRD-K66845263,sophocarpine,,,,,,,,,No-Effect
,BRD-K15327298,fmoc-L-leucine,,,,,,,,,No-Effect
,BRD-A34255068,rolipram,,,,,,,,,No-Effect
,BRD-A40302156,A-33903,,,,,,,,,No-Effect
,BRD-K66437909,KT-433,,,,,,,,,No-Effect
,BRD-A56320380,decamethoxine,,,,,,,,,No-Effect
,BRD-K00005264,AZD5991,,,,,,,,,Low (25%)
,BRD-K21892374,ethyl-2-(carbamoyloxy)benzoate,,,,,,,,,Low (25%)
,BRD-K70840370,MDMS,,,,,,,,,No-Effect
,BRD-K34149328,bonaphthone,,,,,,,,,No-Effect
,BRD-K60612034,picolinic-acid,,,,,,,,,No-Effect
,BRD-M00184283,acrylate,,,,,,,,,No-Effect
,BRD-K90069354,isovaleramide,,,,,,,,,No-Effect
,BRD-K11984358,ZAMI-633,,,,,,,,,No-Effect
,BRD-A41835910,tenilsetam,,,,,,,,,No-Effect
,BRD-K22520627,DVD-111,,,,,,,,,No-Effect
,BRD-K04603573,"1,12-Besm",,,,,,,,,Very Weak (35%)
,BRD-K48988407,cytochlor,,,,,,,,,No-Effect
,BRD-K59853741,Q-203,,,,,,,,,No-Effect
,BRD-K32256160,solithromycin,,,,,,,,,No-Effect
,BRD-K00989047,trovirdine,,,,,,,,,No-Effect
,BRD-K52579889,TGR-1202,,,,,,,,,No-Effect
,BRD-K45906612,presatovir,,,,,,,,,No-Effect
,BRD-A45906415,K-MAP,,,,,,,,,No-Effect
,BRD-K21612934,leteprinim,,,,,,,,,No-Effect
,BRD-K01423020,ciaftalan-zinc,,,,,,,,,Low (25%)
,BRD-K18878288,schisandrol-B,,,,,,,,,No-Effect
,BRD-K00003264,zoliflodacin,,,,,,,,,No-Effect
,BRD-K28982731,emoxipin,,,,,,,,,No-Effect
,BRD-K00003503,vecabrutinib,,,,,,,,,No-Effect
,BRD-K00003514,diquafosol,,,,,,,,,No-Effect
,BRD-K00003119,pradefovir,,,,,,,,,No-Effect
,BRD-K00003355,fucoxanthin,,,,,,,,,No-Effect
,BRD-K00003128,beclabuvir,,,,,,,,,No-Effect
,BRD-K00003138,asivatrep,,,,,,,,,No-Effect
,BRD-K00003406,milademetan,,,,,,,,,No-Effect
,BRD-K22379844,BAY-2402234,,,,,,,,,Strong (80%)
,BRD-K00003100,AZD7594,,,,,,,,,No-Effect
,BRD-K00003107,LXH254,,,,,,,,,Weak (50%)
,BRD-K00003117,ceftobiprole,,,,,,,,,No-Effect
,BRD-K00003192,PSI-697,,,,,,,,,No-Effect
,BRD-K00003190,MK-0557,,,,,,,,,No-Effect
,BRD-K00003405,evobrutinib,,,,,,,,,No-Effect
,BRD-K00003418,BMS-986205,,,,,,,,,No-Effect
,BRD-K00003238,sitravatinib,,,,,,,,,Low (25%)
,BRD-K00003294,avitinib,,,,,,,,,Cyto
,BRD-K00003419,avapritinib,,,,,,,,,No-Effect
,BRD-K00003215,squalamine,,,,,,,,,No-Effect
,BRD-K00003445,vaniprevir,,,,,,,,,No-Effect
,BRD-K00003236,firsocostat,,,,,,,,,Strong (80%)
,BRD-K00003730,HPPH,,,,,,,,,No-Effect
,BRD-K00003385,IPI549,,,,,,,,,No-Effect
,BRD-K00003377,fisogatinib,,,,,,,,,No-Effect
,BRD-K00003257,cefiderocol,,,,,,,,,No-Effect
,BRD-K00003430,PRN1371,,,,,,,,,No-Effect
,BRD-K00003224,avoralstat,,,,,,,,,No-Effect
,BRD-K00003288,glesatinib,,,,,,,,,No-Effect
,BRD-K00003313,trabectedin,,,,,,,,,Strong (80%)
,BRD-K00003118,retagliptin,,,,,,,,,No-Effect
,BRD-K00003403,JNJ-39758979,,,,,,,,,No-Effect
,BRD-K00003391,PBI-4050,,,,,,,,,No-Effect
,BRD-K00003400,PF-06840003,,,,,,,,,No-Effect
,BRD-K00003469,larazotide-acetate,,,,,,,,,No-Effect
,BRD-K00003482,MK-4074,,,,,,,,,Weak (50%)
,BRD-K00003191,fostemsavir,,,,,,,,,No-Effect
,BRD-K00003515,AZ7550,,,,,,,,,Strong (80%)
,BRD-K00003214,sapacitabine,,,,,,,,,No-Effect
,BRD-K00004680,bevenopran,,,,,,,,,No-Effect
,BRD-K00005328,radiprodil,,,,,,,,,No-Effect
,BRD-K10034334,camphor-(+),,,,,,,,,No-Effect
,BRD-K68502831,dianhydrogalactitol,,,,,,,,,No-Effect
,BRD-K92303087,oglemilast,,,,,,,,,Weak (50%)
,BRD-A01412266,hydroxypropyl-beta-cyclodextrin,,,,,,,,,No-Effect
,BRD-K03384561,roquinimex,,,,,,,,,No-Effect
,BRD-K96029467,alagebrium,,,,,,,,,No-Effect
,BRD-K26341917,L-ergothioneine,,,,,,,,,No-Effect
,BRD-K54028654,cabaletta,,,,,,,,,No-Effect
,BRD-K91147684,m-THP,,,,,,,,,No-Effect
,BRD-K59998349,aminolevulinic-acid-benzyl-ester,,,,,,,,,No-Effect
,BRD-K69035426,omeprazole-sulfide,,,,,,,,,No-Effect
,BRD-K56691760,pikamilone,,,,,,,,,Low (25%)
,BRD-K51751936,alfadolone-acetate,,,,,,,,,Low (25%)
,BRD-K15045219,salazodine,,,,,,,,,No-Effect
,BRD-K00003121,GSK369796,,,,,,,,,Strong (80%)
,BRD-K00003203,BMS-214662,,,,,,,,,No-Effect
,BRD-K00003463,pyrotinib,,,,,,,,,No-Effect
,BRD-K00003213,PCI-27483,,,,,,,,,No-Effect
,BRD-K00003501,lazertinib,,,,,,,,,No-Effect
,BRD-A35868371,troventol,,,,,,,,,No-Effect
,BRD-K26556907,benzofenac,,,,,,,,,No-Effect
,BRD-K71281111,SNX-2112,,,,,,,,,Weak (50%)
,BRD-K00003331,NIM811,,,,,,,,,No-Effect
,BRD-K85066592,gly-gln,,,,,,,,,No-Effect
,BRD-K70592483,phenylacetylglutamine,,,,,,,,,No-Effect
,BRD-K01825687,edelfosine,,,,,,,,,No-Effect
,BRD-K80607346,FK-962,,,,,,,,,No-Effect
,BRD-K58277159,NPC-01,,,,,,,,,No-Effect
,BRD-K27938825,ASA-404,,,,,,,,,No-Effect
,BRD-K00003500,delgocitinib,,,,,,,,,No-Effect
,BRD-K00003498,tapinarof,,,,,,,,,No-Effect
,BRD-K00003468,delcasertib,,,,,,,,,No-Effect
,BRD-K35589454,danegaptide,,,,,,,,,No-Effect
,BRD-K00003407,vadadustat,,,,,,,,,No-Effect
,BRD-K00003363,delpazolid,,,,,,,,,No-Effect
,BRD-K00003401,THK5351,,,,,,,,,Low (25%)
,BRD-K00003472,voclosporin,,,,,,,,,No-Effect
,BRD-K20879694,D-limonene,,,,,,,,,No-Effect
,BRD-K37682401,piromidic-acid,,,,,,,,,No-Effect
,BRD-A86871940,nicaraven,,,,,,,,,No-Effect
,BRD-K47084954,PF-06651600,,,,,,,,,No-Effect
,BRD-K08398903,GSK2838232,,,,,,,,,No-Effect
,BRD-K48888725,CG-400549,,,,,,,,,No-Effect
,BRD-K86670086,sutezolid,,,,,,,,,No-Effect
,BRD-K32372024,D-7193,,,,,,,,,Low (25%)
,BRD-K80353807,khellin,,,,,,,,,No-Effect
,BRD-K25154476,cinflumide,,,,,,,,,No-Effect
,BRD-K52914072,LTA,,,,,,,,,No-Effect
,BRD-K96669468,pyridoxamine,,,,,,,,,No-Effect
,BRD-K28059174,INCB-003284,,,,,,,,,No-Effect
,BRD-K55160477,benzo[d]thiazole-2(3H)-thione,,,,,,,,,Low (25%)
,BRD-K44963273,HQK-1001,,,,,,,,,Low (25%)
,BRD-K00003371,paquinimod,,,,,,,,,No-Effect
,BRD-K00003373,GSK3179106,,,,,,,,,No-Effect
,BRD-K00003359,BAY-1436032,,,,,,,,,No-Effect
,BRD-K00004741,estradiol-3-O-sulfamate,,,,,,,,,No-Effect
,BRD-K00004750,PF-06873600,,,,,,,,,No-Effect
,BRD-K00004616,PRX-07034,,,,,,,,,No-Effect
,BRD-K00004636,DpC,,,,,,,,,No-Effect
,BRD-K00003423,BMS-986158,,,,,,,,,Weak (50%)
,BRD-K00003413,zanubrutinib,,,,,,,,,No-Effect
,BRD-K00003409,CFI-402257,,,,,,,,,Low (25%)
,BRD-K00004666,triciribine-phosphate,,,,,,,,,No-Effect
,BRD-K00004614,GSK3117391,,,,,,,,,Cyto
,BRD-K00005249,LY2828360,,,,,,,,,No-Effect
,BRD-K00004551,efletirizine,,,,,,,,,No-Effect
,BRD-K00004611,olumacostat-glasaretil,,,,,,,,,Weak (50%)
,BRD-K00004643,EF5,,,,,,,,,No-Effect
,BRD-K00004624,CJ-13610,,,,,,,,,No-Effect
,BRD-K73991644,isoquercitrin,,,,,,,,,No-Effect
,BRD-K00004604,PRLX-93936,,,,,,,,,No-Effect
,BRD-K83157152,BLZ945,,,,,,,,,No-Effect
,BRD-K00003231,doravirine,,,,,,,,,No-Effect
,BRD-K17500877,bropirimine,,,,,,,,,No-Effect
,BRD-K00926464,IMREG-1,,,,,,,,,No-Effect
,BRD-K50490982,bromindione,,,,,,,,,No-Effect
,BRD-K00004722,LY3295668,,,,,,,,,No-Effect
,BRD-K00003274,selonsertib,,,,,,,,,No-Effect
,BRD-K00010938,BTS-71321,,,,,,,,,No-Effect
,BRD-K43900408,AMG-176,,,,,,,,,No-Effect
,BRD-K00004651,talsaclidine,,,,,,,,,No-Effect
,BRD-K00003398,AZD7986,,,,,,,,,No-Effect
,BRD-K00003404,CYC065,,,,,,,,,Cyto
,BRD-K00003425,LXS196,,,,,,,,,Weak (50%)
,BRD-K35498911,DSM265,,,,,,,,,No-Effect
,BRD-K00003106,AZD4573,,,,,,,,,Weak (50%)
,BRD-K00003307,COH29,,,,,,,,,Strong (80%)
,BRD-K00003415,iclaprim,,,,,,,,,No-Effect
,BRD-K86677390,MK-8998,,,,,,,,,No-Effect
,BRD-K00003381,MSDC-0160,,,,,,,,,No-Effect
,BRD-K00003387,lanabecestat,,,,,,,,,No-Effect
,BRD-K00003438,CM-4620,,,,,,,,,No-Effect
,BRD-K27677357,ruboxistaurin,,,,,,,,,Low (25%)
,BRD-K00003426,peposertib,,,,,,,,,No-Effect
,BRD-K00003528,AZD5153,,,,,,,,,Weak (50%)
,BRD-K00003395,bisantrene,,,,,,,,,No-Effect
,BRD-K00003428,pagoclone,,,,,,,,,No-Effect
,BRD-K00003417,MRX-2843,,,,,,,,,Strong (80%)
,BRD-K00003416,LY3214996,,,,,,,,,No-Effect
,BRD-K00003370,cadazolid,,,,,,,,,No-Effect
,BRD-K00003441,selitrectinib,,,,,,,,,No-Effect
,BRD-K00003461,pamiparib,,,,,,,,,No-Effect
,BRD-K00003448,zuranolone,,,,,,,,,No-Effect
,BRD-K00003497,mavacamten,,,,,,,,,No-Effect
,BRD-K00003357,BAY1125976,,,,,,,,,Weak (50%)
,BRD-K69555850,AZD0156,,,,,,,,,Very Weak (35%)
,BRD-K00003358,rogaratinib,,,,,,,,,No-Effect
,BRD-K00003449,E7046,,,,,,,,,No-Effect
,BRD-K00003470,Neu2000,,,,,,,,,No-Effect
,BRD-K00003490,NGP555,,,,,,,,,No-Effect
,BRD-K00003453,CT7001,,,,,,,,,Cyto
,BRD-K00003457,IDH-305,,,,,,,,,No-Effect
,BRD-K00003533,BAY-1251152,,,,,,,,,Cyto
,BRD-K00003459,dilmapimod,,,,,,,,,Low (25%)
,BRD-K95216408,tucidinostat,,,,,,,,,No-Effect
,BRD-K00003442,CPI-444,,,,,,,,,No-Effect
,BRD-K00003446,LY3200882,,,,,,,,,No-Effect
,BRD-K00003447,repotrectinib,,,,,,,,,No-Effect
,BRD-K00003181,cenicriviroc,,,,,,,,,No-Effect
,BRD-K00003148,batefenterol,,,,,,,,,No-Effect
,BRD-K00003493,padsevonil,,,,,,,,,No-Effect
,BRD-K00004965,talaporfin,,,,,,,,,Low (25%)
,BRD-K00003443,AZD4635,,,,,,,,,No-Effect
,BRD-K83022601,CI-844,,,,,,,,,No-Effect
,BRD-K47169076,rhodamine-123,,,,,,,,,No-Effect
,BRD-K50122911,boronophenylalanine,,,,,,,,,No-Effect
,BRD-K24864897,JNJ-26990990,,,,,,,,,No-Effect
,BRD-A16263897,misonidazole,,,,,,,,,No-Effect
,BRD-A11731518,BAY-85-8050,,,,,,,,,No-Effect
,BRD-A08079565,CDBA,,,,,,,,,No-Effect
,BRD-A29844814,ABT-202,,,,,,,,,No-Effect
,BRD-A21446384,xibenolol,,,,,,,,,No-Effect
,BRD-A61188230,cedrol,,,,,,,,,No-Effect
,BRD-K00003201,tenapanor,,,,,,,,,No-Effect
,BRD-A96529864,isosteviol,,,,,,,,,No-Effect
,BRD-A27274504,butofilolol,,,,,,,,,No-Effect
,BRD-K13281575,semustine,,,,,,,,,No-Effect
,BRD-K91234829,napirimus,,,,,,,,,No-Effect
,BRD-A50016482,CI-923,,,,,,,,,Low (25%)
,BRD-K60150658,glucaric-acid,,,,,,,,,No-Effect
,BRD-A74347210,minerval,,,,,,,,,No-Effect
,BRD-K53448858,acadesine,,,,,,,,,No-Effect
,BRD-K00003508,ASTX660,,,,,,,,,No-Effect
,BRD-K98006098,oleandrin,,,,,,,,,Strong (80%)
,BRD-K97656802,GSK2881078,,,,,,,,,No-Effect
,BRD-K03083257,1-octacosanol,,,,,,,,,No-Effect
,BRD-K87573013,CL-225385,,,,,,,,,No-Effect
,BRD-K49555808,BMS-707035,,,,,,,,,No-Effect
,BRD-K46690591,KP-1212,,,,,,,,,No-Effect
,BRD-K44471774,BAY-W-9798,,,,,,,,,No-Effect
,BRD-K05434375,HA-1004,,,,,,,,,No-Effect
,BRD-K92968657,tirapazamine,,,,,,,,,No-Effect
,BRD-K22097830,OCO-1112,,,,,,,,,No-Effect
,BRD-A93407926,allopurinol-riboside,,,,,,,,,No-Effect
,BRD-K78096648,oxiperomide,,,,,,,,,No-Effect
,BRD-K92426617,esaprazole,,,,,,,,,No-Effect
,BRD-K23005288,SP-420,,,,,,,,,No-Effect
,BRD-K99506538,xenalipin,,,,,,,,,No-Effect
,BRD-K26530649,carboxypyridine-disulfide,,,,,,,,,No-Effect
,BRD-K49659468,TMC647055,,,,,,,,,Low (25%)
,BRD-K36802417,diiodothyropropionic-acid,,,,,,,,,No-Effect
,BRD-K39576764,mivobulin,,,,,,,,,Cyto
,BRD-K46648676,gallium-triquinolin-8-olate,,,,,,,,,No-Effect
,BRD-K00003386,HT-2157,,,,,,,,,No-Effect
,BRD-K70161083,caroverin,,,,,,,,,No-Effect
,BRD-K00004550,BMS-626531,,,,,,,,,No-Effect
,BRD-K00003112,GDC-0575,,,,,,,,,No-Effect
,BRD-K00003141,vixotrigine,,,,,,,,,No-Effect
,BRD-K71500795,TAK-659,,,,,,,,,No-Effect
,BRD-K00004751,inarigivir-soproxil,,,,,,,,,No-Effect
,BRD-K00003173,SJG-136,,,,,,,,,No-Effect
,BRD-K58775955,gynostemma-extract,,,,,,,,,No-Effect
,BRD-K69857269,sonepiprazole,,,,,,,,,No-Effect
,BRD-K00003509,AZD1390,,,,,,,,,Strong (80%)
,BRD-K00003221,basmisanil,,,,,,,,,No-Effect
,BRD-K00003432,EDO-S101,,,,,,,,,No-Effect
,BRD-K00003731,PF-06409577,,,,,,,,,Low (25%)
,BRD-K00003450,AAI101,,,,,,,,,No-Effect
,BRD-K00003275,lifirafenib,,,,,,,,,Low (25%)
,BRD-K00003368,BFH772,,,,,,,,,No-Effect
,BRD-K00003475,S-3304,,,,,,,,,No-Effect
,BRD-K00004730,ABT-072,,,,,,,,,No-Effect
,BRD-K00003444,BT-11,,,,,,,,,No-Effect
,BRD-K66465025,ACPC,,,,,,,,,No-Effect
,BRD-K00005240,tulrampator,,,,,,,,,No-Effect
,BRD-K00005247,salvianolic-acid-A,,,,,,,,,No-Effect
,BRD-K00003481,PAT-1251,,,,,,,,,No-Effect
,BRD-K25290930,fenebrutinib,,,,,,,,,No-Effect
,BRD-K76911699,ITX5061,,,,,,,,,No-Effect
,BRD-K40002998,ORG-26576,,,,,,,,,No-Effect
,BRD-K64114733,naquotinib,,,,,,,,,Strong (80%)
,BRD-K00003187,guadecitabine,,,,,,,,,No-Effect
,BRD-K00003365,AQ-13,,,,,,,,,Strong (80%)
,BRD-K00003421,GSK3326595,,,,,,,,,No-Effect
,BRD-K00003485,SB-649868,,,,,,,,,No-Effect
,BRD-K99077012,befuraline,,,,,,,,,No-Effect
,BRD-K83030136,AT-406,,,,,,,,,Very Weak (35%)
,BRD-K00004699,J147,,,,,,,,,No-Effect
,BRD-K00004712,PF-06305591,,,,,,,,,No-Effect
,BRD-K00003462,lanifibranor,,,,,,,,,No-Effect
,BRD-K42497885,satraplatin,,,,,,,,,No-Effect
,BRD-A84810646,ginsenoside-RD,,,,,,,,,No-Effect
,BRD-K61695967,MKT-077,,,,,,,,,No-Effect
,BRD-K00003458,cintirorgon,,,,,,,,,No-Effect
,BRD-K00003204,celgosivir,,,,,,,,,Weak (50%)
,BRD-K00003342,aticaprant,,,,,,,,,No-Effect
,BRD-K00003376,TAK-243,,,,,,,,,Weak (50%)
,BRD-K00004598,PF-06751979,,,,,,,,,No-Effect
,BRD-K61693562,pyrazinoylguanidine,,,,,,,,,No-Effect
,BRD-K00003210,osilodrostat,,,,,,,,,No-Effect
,BRD-K00003096,FN-1501,,,,,,,,,No-Effect
,BRD-K00004646,aramchol,,,,,,,,,No-Effect
,BRD-K00003174,soblidotin,,,,,,,,,Weak (50%)
,BRD-K00003295,elacestrant,,,,,,,,,Strong (80%)
,BRD-K00003254,tavilermide,,,,,,,,,No-Effect
,BRD-K93228461,lusutrombopag,,,,,,,,,No-Effect
,BRD-K00003253,sparsentan,,,,,,,,,No-Effect
,BRD-K00004591,BMS-986142,,,,,,,,,No-Effect
,BRD-K00003480,tropifexor,,,,,,,,,No-Effect
,BRD-K00003132,LGD-6972,,,,,,,,,No-Effect
,BRD-K00004719,CP-547632,,,,,,,,,No-Effect
,BRD-K00003326,ginsenoside-RE,,,,,,,,,No-Effect
,BRD-K27040396,CFI-400945,,,,,,,,,No-Effect
,BRD-K00003520,glycerol-phenylbutyrate,,,,,,,,,No-Effect
,BRD-K00003143,BAY1217389,,,,,,,,,No-Effect
,BRD-K00003108,ABBV-744,,,,,,,,,No-Effect
,BRD-K00003232,fevipiprant,,,,,,,,,No-Effect
,BRD-K00004672,brincidofovir,,,,,,,,,No-Effect
,BRD-K00010385,AMG-510,,,,,,,,,No-Effect
,BRD-K77897005,ridinilazole,,,,,,,,,No-Effect
,BRD-K00003227,ralinepag,,,,,,,,,No-Effect
,BRD-K00003131,LY2510924,,,,,,,,,No-Effect
,BRD-K65840970,GW274150,,,,,,,,,No-Effect
,BRD-K00003225,eleclazine,,,,,,,,,No-Effect
,BRD-K00003248,cenerimod,,,,,,,,,No-Effect
,BRD-K33499285,gepotidacin,,,,,,,,,No-Effect
,BRD-K00003134,deslorelin,,,,,,,,,No-Effect
,BRD-K00003235,veledimex,,,,,,,,,No-Effect
,BRD-K00003229,verubecestat,,,,,,,,,No-Effect
,BRD-K00003249,cenobamate,,,,,,,,,No-Effect
,BRD-K00003099,PLX51107,,,,,,,,,Very Weak (35%)
,BRD-K00003474,letrazuril,,,,,,,,,No-Effect
,BRD-K00003194,MK-7622,,,,,,,,,No-Effect
,BRD-K00003144,atuveciclib,,,,,,,,,Low (25%)
,BRD-K00003111,BOS-172722,,,,,,,,,No-Effect
,BRD-K20497775,L-kynurenine,,,,,,,,,No-Effect
,BRD-K00003220,acumapimod,,,,,,,,,No-Effect
,BRD-K00003246,bexagliflozin,,,,,,,,,No-Effect
,BRD-K00002423,PF-05175157,,,,,,,,,Weak (50%)
,BRD-K00003110,BMS-986195,,,,,,,,,No-Effect
,BRD-K00003094,JNJ-38877618,,,,,,,,,No-Effect
,BRD-K00003127,pimodivir,,,,,,,,,No-Effect
,BRD-K00003512,BMS-813160,,,,,,,,,No-Effect
,BRD-K00003343,VLX1570,,,,,,,,,No-Effect
,BRD-K00003095,GLPG1837,,,,,,,,,No-Effect
,BRD-K00003102,INCB-057643,,,,,,,,,Very Weak (35%)
,BRD-K00003125,sulfatinib,,,,,,,,,Strong (80%)
,BRD-K00003139,etrasimod,,,,,,,,,No-Effect
,BRD-K00003123,resmetirom,,,,,,,,,No-Effect
,BRD-K00003454,seclidemstat,,,,,,,,,No-Effect
,BRD-K00003142,dasotraline,,,,,,,,,Strong (80%)
,BRD-K00003205,D-3263,,,,,,,,,Strong (80%)
,BRD-K00003115,ETC-206,,,,,,,,,No-Effect
,BRD-K00003116,CC-90003,,,,,,,,,No-Effect
,BRD-K00003093,SD-0006,,,,,,,,,No-Effect
,BRD-K00003097,PF-05180999,,,,,,,,,No-Effect
,BRD-K00003511,CA-4948,,,,,,,,,No-Effect
,BRD-K00003120,BI-409306,,,,,,,,,No-Effect
,BRD-K00003166,GSK189254,,,,,,,,,No-Effect
,BRD-K00003380,GLPG0187,,,,,,,,,No-Effect
,BRD-K74319597,HM-30181,,,,,,,,,No-Effect
,BRD-K00003240,eravacycline,,,,,,,,,No-Effect
,BRD-K00003101,GDC-0927,,,,,,,,,No-Effect
,BRD-K00004575,JNJ-54175446,,,,,,,,,No-Effect
,BRD-K00004600,JNJ-678,,,,,,,,,No-Effect
,BRD-K00003251,pemafibrate,,,,,,,,,No-Effect
,BRD-K00003281,ferroquine,,,,,,,,,Strong (80%)
,BRD-K00003189,BMS-911543,,,,,,,,,No-Effect
,BRD-K00003124,trodusquemine,,,,,,,,,No-Effect
,BRD-K00003149,Ro-5028442,,,,,,,,,No-Effect
,BRD-K00003420,GDC-0077,,,,,,,,,No-Effect
,BRD-K00003379,GSK2256098,,,,,,,,,No-Effect
,BRD-K00003394,ABX464,,,,,,,,,No-Effect
,BRD-K00003422,BAY-1895344,,,,,,,,,Very Weak (35%)
,BRD-A88644406,avadomide,,,,,,,,,No-Effect
,BRD-K00004577,vapendavir,,,,,,,,,No-Effect
,BRD-K00004701,KPT-9274,,,,,,,,,Very Weak (35%)
,BRD-K89274813,DMP-543,,,,,,,,,No-Effect
,BRD-K25691735,chuanxiongzine,,,,,,,,,No-Effect
,BRD-K67525671,ZK-200775,,,,,,,,,No-Effect
,BRD-K25140590,CX-516,,,,,,,,,No-Effect
,BRD-K40715924,medorinone,,,,,,,,,No-Effect
,BRD-K00004713,sulopenem,,,,,,,,,No-Effect
,BRD-K00004665,SY-640,,,,,,,,,No-Effect
,BRD-K00004632,PF-02413873,,,,,,,,,No-Effect
,BRD-K00004645,rimeporide,,,,,,,,,No-Effect
,BRD-K00004619,centhaquin,,,,,,,,,No-Effect
,BRD-K00004554,lodenosine,,,,,,,,,No-Effect
,BRD-K02260986,butylidenephthalide,,,,,,,,,No-Effect
,BRD-K00004677,2-fluorofucose,,,,,,,,,No-Effect
,BRD-K00004662,nemazoline,,,,,,,,,No-Effect
,BRD-K47195926,acedoben,,,,,,,,,No-Effect
,BRD-K06762493,isbufylline,,,,,,,,,No-Effect
,BRD-K00004588,centanafadine,,,,,,,,,No-Effect
,BRD-K00004547,prisotinol,,,,,,,,,No-Effect
,BRD-K00004683,MS-424,,,,,,,,,No-Effect
,BRD-K60480335,ilepcimide,,,,,,,,,No-Effect
,BRD-K24084088,paraxanthine,,,,,,,,,No-Effect
,BRD-K88553858,benurestat,,,,,,,,,No-Effect
,BRD-K96298462,Imazodan,,,,,,,,,No-Effect
,BRD-K00004687,pelrinone,,,,,,,,,No-Effect
,BRD-K00004644,PF-06260414,,,,,,,,,No-Effect
,BRD-K96362839,cedrol-(+),,,,,,,,,No-Effect
,BRD-K47539947,tetradecylthioacetic-acid,,,,,,,,,No-Effect
,BRD-K00004660,MK-1903,,,,,,,,,No-Effect
,BRD-K00004718,alanosine,,,,,,,,,No-Effect
,BRD-K00005243,FK-409,,,,,,,,,No-Effect
,BRD-K00003383,urolithin-A,,,,,,,,,No-Effect
,BRD-K12968785,bergapten,,,,,,,,,No-Effect
,BRD-K00004659,dapansutrile,,,,,,,,,No-Effect
,BRD-K01827427,linalool,,,,,,,,,No-Effect
,BRD-K00004612,verdiperstat,,,,,,,,,No-Effect
,BRD-K00004635,PF-04995274,,,,,,,,,No-Effect
,BRD-K00004670,naxagolide,,,,,,,,,No-Effect
,BRD-K20548681,SCP-1,,,,,,,,,No-Effect
,BRD-K00004557,MK-0608,,,,,,,,,No-Effect
,BRD-K00004748,CI-953,,,,,,,,,No-Effect
,BRD-K00004569,ICI-169369,,,,,,,,,No-Effect
,BRD-K07798980,PSI-6130,,,,,,,,,No-Effect
,BRD-A89594340,carnitine-(D/L),,,,,,,,,No-Effect
,BRD-K11244467,ambazone,,,,,,,,,No-Effect
,BRD-K87036601,azodicarbonamide,,,,,,,,,No-Effect
,BRD-K90065682,5-iodo-A-85380,,,,,,,,,No-Effect
,BRD-K61279411,oxaloacetate,,,,,,,,,No-Effect
,BRD-K70053378,SM-108,,,,,,,,,Low (25%)
,BRD-K74227499,Se-methylselenocysteine,,,,,,,,,Low (25%)
,BRD-K58937086,glutathione-monoisopropyl-ester,,,,,,,,,No-Effect
,BRD-K57865272,A0001,,,,,,,,,No-Effect
,BRD-A74648924,K-247,,,,,,,,,No-Effect
,BRD-K14276241,daucosterol,,,,,,,,,No-Effect
,BRD-A28958257,centpropazine,,,,,,,,,No-Effect
,BRD-K18210059,olesoxime,,,,,,,,,No-Effect
,BRD-K37747025,sanazole,,,,,,,,,No-Effect
,BRD-K63651590,pirquinozol,,,,,,,,,No-Effect
,BRD-K75052463,V-51,,,,,,,,,No-Effect
,BRD-K76819217,cabotegravir,,,,,,,,,No-Effect
,BRD-K77320845,secoisolariciresinol-diglucoside,,,,,,,,,No-Effect
,BRD-K63018010,relebactam,,,,,,,,,No-Effect
,BRD-K01825499,clinafloxacin,,,,,,,,,No-Effect
,BRD-A87673115,moguisteine,,,,,,,,,No-Effect
,BRD-K86687746,R306465,,,,,,,,,Cyto
,BRD-K00004579,RV1729,,,,,,,,,Very Weak (35%)
,BRD-K00004676,rilapladib,,,,,,,,,No-Effect
,BRD-K00004595,cilofexor,,,,,,,,,No-Effect
,BRD-K00004597,RGX-104,,,,,,,,,No-Effect
,BRD-K00003198,revefenacin,,,,,,,,,No-Effect
,BRD-K00003293,mertansine,,,,,,,,,Weak (50%)
,BRD-K90991629,delafloxacin,,,,,,,,,No-Effect
,BRD-K00003175,rolapitant,,,,,,,,,No-Effect
,BRD-K00003392,futibatinib,,,,,,,,,Weak (50%)
,BRD-K00003356,mivebresib,,,,,,,,,Weak (50%)
,BRD-K00004725,voruciclib,,,,,,,,,No-Effect
,BRD-K30421675,JNJ-64619178,,,,,,,,,No-Effect
,BRD-K00004720,acolbifene,,,,,,,,,Weak (50%)
,BRD-K00003309,GDC-0084,,,,,,,,,Weak (50%)
,BRD-K00003361,tomivosertib,,,,,,,,,No-Effect
,BRD-K00003269,LEQ506,,,,,,,,,No-Effect
,BRD-K00003170,pavinetant,,,,,,,,,No-Effect
,BRD-K00003172,E7820,,,,,,,,,No-Effect
,BRD-K00003223,amiselimod,,,,,,,,,No-Effect
,BRD-K00003354,cinobufotalin,,,,,,,,,Strong (80%)
,BRD-K00003218,upamostat,,,,,,,,,No-Effect
,BRD-K00003360,CPI-1205,,,,,,,,,No-Effect
,BRD-K00003412,trilaciclib,,,,,,,,,No-Effect
,BRD-K00003532,inarigivir,,,,,,,,,No-Effect
,BRD-K00003226,emeramide,,,,,,,,,No-Effect
,BRD-K27529556,epigallocatechin-(-),,,,,,,,,No-Effect
,BRD-K00003429,GSK2982772,,,,,,,,,No-Effect
,BRD-K00004703,MSDC-0602K,,,,,,,,,No-Effect
,BRD-K00004710,R-1487,,,,,,,,,No-Effect
,BRD-K00004652,PF-06412562,,,,,,,,,No-Effect
,BRD-K00004682,taminadenant,,,,,,,,,No-Effect
,BRD-K00004555,HBED,,,,,,,,,No-Effect
,BRD-K29343434,BMS-906024,,,,,,,,,No-Effect
,BRD-K00004627,tipelukast,,,,,,,,,No-Effect
,BRD-K00004608,sograzepide,,,,,,,,,No-Effect
,BRD-K00004638,PF-06273340,,,,,,,,,No-Effect
,BRD-K00004698,trabodenoson,,,,,,,,,No-Effect
,BRD-K00004594,parsaclisib,,,,,,,,,No-Effect
,BRD-K00004589,gefapixant,,,,,,,,,No-Effect
,BRD-K51041191,PF-03882845,,,,,,,,,No-Effect
,BRD-K00004655,BMS-770767,,,,,,,,,No-Effect
,BRD-K00004675,LSZ-102,,,,,,,,,No-Effect
,BRD-K00005241,ripretinib,,,,,,,,,No-Effect
,BRD-K00004688,evenamide,,,,,,,,,No-Effect
,BRD-K00005239,TP-3654,,,,,,,,,No-Effect
,BRD-K00003496,baloxavir,,,,,,,,,No-Effect
,BRD-K00003202,citarinostat,,,,,,,,,No-Effect
,BRD-K00004716,radotinib,,,,,,,,,No-Effect
,BRD-K00005245,KM-0118,,,,,,,,,No-Effect
,BRD-K00003473,pridopidine,,,,,,,,,No-Effect
,BRD-K00003456,asciminib,,,,,,,,,No-Effect
,BRD-K00003466,nelotanserin,,,,,,,,,No-Effect
,BRD-K30159788,RSV604,,,,,,,,,No-Effect
,BRD-K28343777,20-hydroxyecdysone,,,,,,,,,No-Effect
,BRD-K84794093,dideoxyadenosine,,,,,,,,,No-Effect
,BRD-K84798689,sodium-tanshinone-II-A-sulfonate,,,,,,,,,No-Effect
,BRD-A96466199,nuclomedone,,,,,,,,,No-Effect
,BRD-K92116564,isoxepac,,,,,,,,,No-Effect
,BRD-K00004531,benaxibine,,,,,,,,,No-Effect
,BRD-K62374002,PI3K-IN-2,,,,,,,,,No-Effect
,BRD-K00003402,T-807,,,,,,,,,Weak (50%)
,BRD-K00003494,rosiptor,,,,,,,,,No-Effect
,BRD-K37087535,DPC-681,,,,,,,,,No-Effect
,BRD-K00003308,TD139,,,,,,,,,No-Effect
,BRD-K00004679,5-fluoropyrimidine,,,,,,,,,No-Effect
,BRD-K00003311,PF-06459988,,,,,,,,,No-Effect
,BRD-K53605365,proacipimox,,,,,,,,,No-Effect
,BRD-K04843302,2-ethoxybenzoic-acid,,,,,,,,,No-Effect
,BRD-K85140930,aphidicolin,,,,,,,,,No-Effect
,BRD-K00003216,relugolix,,,,,,,,,No-Effect
,BRD-K51730347,diphencyprone,,,,,,,,,No-Effect
,BRD-A66143912,3-hydroxy-3-phenylpentanamide,,,,,,,,,No-Effect
,BRD-K60798049,fanetizole,,,,,,,,,No-Effect
,BRD-A09368919,FPL-12495,,,,,,,,,No-Effect
,BRD-K37069697,fexinidazole,,,,,,,,,No-Effect
,BRD-K00003222,tradipitant,,,,,,,,,Strong (80%)
,BRD-K43647122,nerbacadol,,,,,,,,,No-Effect
,BRD-K39693230,N-salicoylaminophenol,,,,,,,,,No-Effect
,BRD-A26835809,PX-478,,,,,,,,,No-Effect
,BRD-K59875992,FPL-62064,,,,,,,,,No-Effect
,BRD-K00003280,PIM-447,,,,,,,,,No-Effect
,BRD-A65562236,solamargine,,,,,,,,,No-Effect
,BRD-K18157228,fdcyd,,,,,,,,,No-Effect
,BRD-A92960111,chlorophyllin-copper,,,,,,,,,No-Effect
,BRD-A07704283,isofloxythepin,,,,,,,,,No-Effect
,BRD-K59590127,chlorpropham,,,,,,,,,No-Effect
,BRD-K60241851,isodibut,,,,,,,,,No-Effect
,BRD-K09109825,indole-3-pyrubate,,,,,,,,,No-Effect
,BRD-K10415035,tasuldine,,,,,,,,,No-Effect
,BRD-K69231085,trigonelline,,,,,,,,,No-Effect
,BRD-K55773932,BMS-806,,,,,,,,,No-Effect
,BRD-K34801930,SRT3190,,,,,,,,,No-Effect
,BRD-K04993719,LY2334737,,,,,,,,,No-Effect
,BRD-K25204779,pritelivir,,,,,,,,,No-Effect
,BRD-K98548675,parthenolide,,,,,,,,,No-Effect
,BRD-K47976015,balapiravir,,,,,,,,,No-Effect
,BRD-K43002771,SR-33805,,,,,,,,,No-Effect
,BRD-A96456596,FPL-55712,,,,,,,,,No-Effect
,BRD-K00003414,emodepside,,,,,,,,,No-Effect
,BRD-K51087630,tirasemtiv,,,,,,,,,No-Effect
,BRD-K23672206,BCI-540,,,,,,,,,No-Effect
,BRD-K05048137,phytosphingosine,,,,,,,,,No-Effect
,BRD-K00004000,RS-0481,,,,,,,,,No-Effect
,BRD-A72297358,ozolinone,,,,,,,,,Very Weak (35%)
,BRD-K14762862,I-BZA,,,,,,,,,No-Effect
,BRD-K24820488,CH-170,,,,,,,,,No-Effect
,BRD-K87873585,pinitol,,,,,,,,,Very Weak (35%)
,BRD-K50850824,acesulfame-potassium,,,,,,,,,No-Effect
,BRD-K89409436,chlorfenson,,,,,,,,,No-Effect
,BRD-K14571191,zometapine,,,,,,,,,No-Effect
,BRD-A53472930,seclazone,,,,,,,,,No-Effect
,BRD-K43890836,gemcadiol,,,,,,,,,No-Effect
,BRD-K85764479,somantadine,,,,,,,,,No-Effect
,BRD-K47738867,ethyl-pyruvate,,,,,,,,,No-Effect
,BRD-K52732207,N-methylpyrrolidone,,,,,,,,,No-Effect
,BRD-K38564664,rolziracetam,,,,,,,,,No-Effect
,BRD-K33445938,N-methylformamide,,,,,,,,,No-Effect
,BRD-K14379200,cyclocreatine,,,,,,,,,No-Effect
,BRD-K95053546,tempol,,,,,,,,,No-Effect
,BRD-K38969488,tributyrin,,,,,,,,,No-Effect
,BRD-K41592905,7-methylxanthine,,,,,,,,,No-Effect
,BRD-K92413528,procysteine,,,,,,,,,No-Effect
,BRD-K51364817,etoxybamide,,,,,,,,,No-Effect
,BRD-K26598477,zindotrine,,,,,,,,,No-Effect
,BRD-K10132944,methyl-nicotinate,,,,,,,,,No-Effect
,BRD-K46254452,GABA-linoleamide,,,,,,,,,No-Effect
,BRD-A20686268,trebenzomine,,,,,,,,,No-Effect
,BRD-K55172746,apricitabine,,,,,,,,,No-Effect
,BRD-K29133151,"ICI-185,282",,,,,,,,,No-Effect
,BRD-K47371940,ecabapide,,,,,,,,,No-Effect
,BRD-K02950022,BMS-299897,,,,,,,,,No-Effect
,BRD-K43410529,MLN2480,,,,,,,,,No-Effect
,BRD-K69726595,mericitabine,,,,,,,,,No-Effect
,BRD-K48213016,CC-930,,,,,,,,,No-Effect
,BRD-K47554101,eperezolid,,,,,,,,,No-Effect
,BRD-K00004299,bicifadine,,,,,,,,,No-Effect
,BRD-K61691541,PF-03084014,,,,,,,,,No-Effect
,BRD-K19672466,ethimizol,,,,,,,,,Low (25%)
,BRD-K09877029,VS-4718,,,,,,,,,No-Effect
,BRD-K90239174,AMG-487,,,,,,,,,No-Effect
,BRD-K00003558,XL888,,,,,,,,,Very Weak (35%)
,BRD-K26701552,tegobuvir,,,,,,,,,No-Effect
,BRD-K00004542,TPPS4,,,,,,,,,No-Effect
,BRD-K00004537,FCE-22250,,,,,,,,,No-Effect
,BRD-K00003675,antimony-potassium,,,,,,,,,Low (25%)
,BRD-K94144010,cotinine,,,,,,,,,No-Effect
,BRD-K00004538,rosamicin,,,,,,,,,No-Effect
,BRD-K08111240,danoprevir,,,,,,,,,No-Effect
,BRD-K16898998,bevirimat-dimeglumine,,,,,,,,,No-Effect
,BRD-K87028197,asunaprevir,,,,,,,,,No-Effect
,BRD-K33082088,retapamulin,,,,,,,,,No-Effect
,BRD-K47031502,eupatilin,,,,,,,,,No-Effect
,BRD-K01825844,propylhexedrine,,,,,,,,,No-Effect
,BRD-K15541734,antioxine,,,,,,,,,No-Effect
,BRD-K00026984,sofosbuvir,,,,,,,,,No-Effect
,BRD-K77564118,fenoverine,,,,,,,,,No-Effect
,BRD-K01825663,valganciclovir,,,,,,,,,No-Effect
,BRD-A53539450,neo-gilurytmal,,,,,,,,,No-Effect
,BRD-K01825685,bopindolol,,,,,,,,,No-Effect
,BRD-K02733959,cefuroxime,,,,,,,,,No-Effect
,BRD-K74664543,selenomethionine,,,,,,,,,No-Effect
,BRD-K18323388,uridine-triacetate,,,,,,,,,No-Effect
,BRD-A12454076,L-hydroxyproline,,,,,,,,,No-Effect
,BRD-A07600638,meclocycline-sulfosalicylate,,,,,,,,,No-Effect
,BRD-A53151380,prednisolone-tebutate,,,,,,,,,No-Effect
,BRD-K10667240,ethacizin,,,,,,,,,No-Effect
,BRD-K25209357,chloramphenicol-sodium-succinate,,,,,,,,,No-Effect
,BRD-K84810336,sulfisoxazole-acetyl,,,,,,,,,No-Effect
,BRD-K15891719,tenofovir,,,,,,,,,No-Effect
,BRD-A56152450,dimercaprol,,,,,,,,,No-Effect
,BRD-K77484724,adefovir,,,,,,,,,No-Effect
,BRD-K82118441,pyrantel,,,,,,,,,No-Effect
,BRD-A51747092,moprolol,,,,,,,,,No-Effect
,BRD-K85603128,resorcinol-monoacetate,,,,,,,,,No-Effect
,BRD-K43860855,iobenguane,,,,,,,,,No-Effect
,BRD-A37492983,iocetamic-acid,,,,,,,,,No-Effect
,BRD-K12539416,sulbutiamine,,,,,,,,,No-Effect
,BRD-A61850409,alpha-tochopheryl-acetate,,,,,,,,,No-Effect
,BRD-K10974103,diloxanide,,,,,,,,,No-Effect
,BRD-K22009844,phenprobamate,,,,,,,,,No-Effect
,BRD-K32311154,nifekalant,,,,,,,,,No-Effect
,BRD-K00003273,cbl0137,,,,,,,,,Cyto
,BRD-K34798115,SJ-733,,,,,,,,,No-Effect
,BRD-K00003250,evocalcet,,,,,,,,,No-Effect
,BRD-K00003286,upadacitinib,,,,,,,,,No-Effect
,BRD-K00003284,seladelpar,,,,,,,,,Very Weak (35%)
,BRD-K00003263,tenalisib,,,,,,,,,No-Effect
,BRD-K00003304,MK-1064,,,,,,,,,No-Effect
,BRD-K00003499,adavivint,,,,,,,,,No-Effect
,BRD-K00003310,derazantinib,,,,,,,,,No-Effect
,BRD-K00003209,JI-101,,,,,,,,,No-Effect
,BRD-K00003258,edasalonexent,,,,,,,,,No-Effect
,BRD-K00003283,roluperidone,,,,,,,,,No-Effect
,BRD-K00003296,PF-06650833,,,,,,,,,No-Effect
,BRD-K00003348,COTI-2,,,,,,,,,No-Effect
,BRD-K00003261,leniolisib,,,,,,,,,No-Effect
,BRD-K00003292,GSK2981278,,,,,,,,,No-Effect
,BRD-K00003267,ombrabulin,,,,,,,,,Weak (50%)
,BRD-K13699028,AZD9056,,,,,,,,,Weak (50%)
,BRD-K00003255,acebilustat,,,,,,,,,No-Effect
,BRD-K00003122,prinomastat,,,,,,,,,No-Effect
,BRD-K00003164,oglufanide,,,,,,,,,No-Effect
,BRD-K00003234,vericiguat,,,,,,,,,No-Effect
,BRD-K00003506,risdiplam,,,,,,,,,No-Effect
,BRD-K00003168,BMS-582949,,,,,,,,,No-Effect
,BRD-K00003157,Debio-0932,,,,,,,,,Strong (80%)
,BRD-K00003135,alisporivir,,,,,,,,,No-Effect
,BRD-K00003169,RAD140,,,,,,,,,No-Effect
,BRD-K27811785,cipargamin,,,,,,,,,No-Effect
,BRD-K00003180,verucerfont,,,,,,,,,No-Effect
,BRD-K00003344,incyclinide,,,,,,,,,No-Effect
,BRD-K00003431,ziritaxestat,,,,,,,,,Cyto
,BRD-K00003244,amcasertib,,,,,,,,,No-Effect
,BRD-K00003305,BMS-779788,,,,,,,,,No-Effect
,BRD-K00004603,ABX-1431,,,,,,,,,No-Effect
,BRD-K00004752,INX-08189,,,,,,,,,Low (25%)
,BRD-K00003151,olodanrigan,,,,,,,,,No-Effect
,BRD-K00003162,crolibulin,,,,,,,,,Cyto
,BRD-K00003332,argireline,,,,,,,,,No-Effect
,BRD-K00003160,belotecan,,,,,,,,,No-Effect
,BRD-K49456274,pilaralisib,,,,,,,,,No-Effect
,BRD-K53083666,"1,5-dicaffeoylquinic-acid",,,,,,,,,No-Effect
,BRD-K12787259,CX-5461,,,,,,,,,No-Effect
,BRD-K72093555,procyanidin-B-2,,,,,,,,,No-Effect
,BRD-K97883416,BMS-626529,,,,,,,,,No-Effect
,BRD-K91438851,oprozomib,,,,,,,,,Cyto
,BRD-K28965160,BVD-523,,,,,,,,,No-Effect
,BRD-K79095980,broxuridine,,,,,,,,,No-Effect
,BRD-K01824719,sulmazole,,,,,,,,,No-Effect
,BRD-K00003300,LTX-315,,,,,,,,,Low (25%)
,BRD-K00003534,methylcobalamin,,,,,,,,,No-Effect
,BRD-K64120610,vinflunine,,,,,,,,,No-Effect
,BRD-A24857382,N-acetyl-tyrosine,,,,,,,,,No-Effect
,BRD-K41707108,ceramide,,,,,,,,,No-Effect
,BRD-K02275692,cefotiam,,,,,,,,,No-Effect
,BRD-A78723049,cefotetan,,,,,,,,,No-Effect
,BRD-K35798650,polidocanol,,,,,,,,,No-Effect
,BRD-K15262564,mupirocin,,,,,,,,,No-Effect
,BRD-A21858158,praziquantel,,,,,,,,,No-Effect
,BRD-A19795905,atovaquone,,,,,,,,,No-Effect
,BRD-K38938675,morniflumate,,,,,,,,,No-Effect
,BRD-K67117832,dextran,,,,,,,,,No-Effect
,BRD-K73027814,oxyfedrine,,,,,,,,,No-Effect
,BRD-K49841478,rosoxacin,,,,,,,,,No-Effect
,BRD-K68379918,silver-sulfadiazine,,,,,,,,,No-Effect
,BRD-K76609936,imidacloprid,,,,,,,,,No-Effect
,BRD-K48427910,dibekacin,,,,,,,,,No-Effect
,BRD-K01826536,ribostamycin-sulfate,,,,,,,,,No-Effect
,BRD-A41698174,bacampicillin,,,,,,,,,No-Effect
,BRD-K72922393,linsidomine,,,,,,,,,No-Effect
,BRD-M49658242,acrisorcin,,,,,,,,,No-Effect
,BRD-K01825010,hematoporphyrin,,,,,,,,,Low (25%)
,BRD-K21372554,cefetamet-pivoxil,,,,,,,,,No-Effect
,BRD-K74759733,isepamicin,,,,,,,,,No-Effect
,BRD-A49622760,faropenem,,,,,,,,,No-Effect
,BRD-K13240081,nimustine,,,,,,,,,No-Effect
,BRD-K27853494,"1S,2R-phenylpropanolamine",,,,,,,,,No-Effect
,BRD-K47887731,nitenpyram,,,,,,,,,No-Effect
,BRD-K37688416,fipexide,,,,,,,,,No-Effect
,BRD-A27370296,cyclandelate,,,,,,,,,No-Effect
,BRD-K01825697,penicillamine-(racemic),,,,,,,,,No-Effect
,BRD-K16742848,lutein,,,,,,,,,No-Effect
,BRD-K54472332,elvitegravir,,,,,,,,,No-Effect
,BRD-K71026158,carumonam,,,,,,,,,No-Effect
,BRD-A12077521,cefepime,,,,,,,,,No-Effect
,BRD-K00005354,proscillaridin-A,,,,,,,,,Strong (80%)
,BRD-A46136514,butibufen,,,,,,,,,No-Effect
,BRD-K79124250,ioxaglic-acid,,,,,,,,,No-Effect
,BRD-K15514357,cefalonium,,,,,,,,,No-Effect
,BRD-K36756879,ethaverine,,,,,,,,,No-Effect
,BRD-K94420399,PF-04136309,,,,,,,,,No-Effect
,BRD-K89048337,puerarin,,,,,,,,,Weak (50%)
,BRD-K81881550,licostinel,,,,,,,,,No-Effect
,BRD-K00003211,lurbinectedin,,,,,,,,,Very Weak (35%)
,BRD-K00003256,avacopan,,,,,,,,,No-Effect
,BRD-K42495768,tasisulam,,,,,,,,,No-Effect
,BRD-K00004625,cipamfylline,,,,,,,,,No-Effect
,BRD-K00004697,alovudine,,,,,,,,,No-Effect
,BRD-K00003287,fezolinetant,,,,,,,,,No-Effect
,BRD-K59929863,CB-10-277,,,,,,,,,No-Effect
,BRD-K00003184,ozenoxacin,,,,,,,,,No-Effect
,BRD-K00003178,lasmiditan,,,,,,,,,No-Effect
,BRD-K96194081,cepharanthine,,,,,,,,,No-Effect
,BRD-K30933884,unbs-5162,,,,,,,,,No-Effect
,BRD-K00004966,amenamevir,,,,,,,,,No-Effect
,BRD-K00003285,nemiralisib,,,,,,,,,Weak (50%)
,BRD-K68805147,pafuramidine,,,,,,,,,No-Effect
,BRD-K39079086,cinchonidine,,,,,,,,,No-Effect
,BRD-K28442028,R-1479,,,,,,,,,No-Effect
,BRD-K00004584,remetinostat,,,,,,,,,No-Effect
,BRD-K62277907,PYM50028,,,,,,,,,No-Effect
,BRD-K30126819,dimesna,,,,,,,,,No-Effect
,BRD-A36057565,bruceantin,,,,,,,,,Strong (80%)
,BRD-K74371986,NSI-189,,,,,,,,,No-Effect
,BRD-A85876464,nibentan,,,,,,,,,No-Effect
,BRD-K00004658,etrabamine,,,,,,,,,No-Effect
,BRD-K66097663,TMC-353121,,,,,,,,,No-Effect
,BRD-A74328360,antimonyl,,,,,,,,,No-Effect
,BRD-K00025602,lappaconite,,,,,,,,,No-Effect
,BRD-K00025601,hydrocortisone-hemisuccinate,,,,,,,,,No-Effect
,BRD-K51742987,esculin,,,,,,,,,No-Effect
,BRD-K27963513,fosfructose,,,,,,,,,No-Effect
,BRD-K66048476,rifamycin-sv,,,,,,,,,No-Effect
,BRD-K17026858,pibenzimol,,,,,,,,,No-Effect
,BRD-K74796838,NKP-1339,,,,,,,,,No-Effect
,BRD-K29673530,hypericin,,,,,,,,,No-Effect
,BRD-K87512222,taltobulin,,,,,,,,,Weak (50%)
,BRD-K70610771,VX-222,,,,,,,,,No-Effect
,BRD-K54187111,dichlorisone-acetate,,,,,,,,,No-Effect
,BRD-K79989959,nesbuvir,,,,,,,,,No-Effect
,BRD-K84683831,radezolid,,,,,,,,,No-Effect
,BRD-K07160047,fiacitabine,,,,,,,,,No-Effect
,BRD-K36970462,tonabersat,,,,,,,,,No-Effect
,BRD-K02206208,rapastinel,,,,,,,,,No-Effect
,BRD-K18850819,MK-0752,,,,,,,,,No-Effect
,BRD-K86799112,5-HMF,,,,,,,,,No-Effect
,BRD-K90033078,zeatin,,,,,,,,,No-Effect
,BRD-K90727284,pincainide,,,,,,,,,No-Effect
,BRD-K43419711,WY-16922,,,,,,,,,No-Effect
,BRD-A56754222,gepon,,,,,,,,,No-Effect
,BRD-K72078047,MUT056399,,,,,,,,,No-Effect
,BRD-K57416838,MRK-409,,,,,,,,,No-Effect
,BRD-K21415491,ALS-8112,,,,,,,,,No-Effect
,BRD-A92448440,sari-59-801,,,,,,,,,No-Effect
,BRD-K80403280,alafosfalin,,,,,,,,,No-Effect
,BRD-A02933148,isotiquimide,,,,,,,,,No-Effect
,BRD-K01826018,terciprazine,,,,,,,,,No-Effect
,BRD-K64834129,eterobarb,,,,,,,,,No-Effect
,BRD-K10226125,AC1NDSS5,,,,,,,,,No-Effect
,BRD-K54538117,LY450108,,,,,,,,,No-Effect
,BRD-K80595380,retinyl-palmitate,,,,,,,,,No-Effect
,BRD-K97028990,quinine-ethyl-carbonate,,,,,,,,,No-Effect
,BRD-K89920762,paritaprevir,,,,,,,,,No-Effect
,BRD-K62326629,dichlorophen,,,,,,,,,No-Effect
,BRD-K00531707,cinepazet,,,,,,,,,No-Effect
,BRD-K47178855,isosorbide,,,,,,,,,No-Effect
,BRD-K08206212,entecavir,,,,,,,,,No-Effect
,BRD-K90629600,emorfazone,,,,,,,,,No-Effect
,BRD-K26674746,dimethicone,,,,,,,,,No-Effect
,BRD-K27352494,amphotericin-b,,,,,,,,,Low (25%)
,BRD-K80043866,sodium-gualenate,,,,,,,,,No-Effect
,BRD-K51807679,dithranol,,,,,,,,,No-Effect
,BRD-K34388247,methicillin,,,,,,,,,No-Effect
,BRD-K00003495,baloxavir-marboxil,,,,,,,,,Low (25%)
,BRD-K22641081,cefodizime,,,,,,,,,Very Weak (35%)
,BRD-K07283971,oxyclozanide,,,,,,,,,No-Effect
,BRD-A02232681,isoleucine,,,,,,,,,Low (25%)
,BRD-K01824977,hydrocortisone-phosphate,,,,,,,,,Low (25%)
,BRD-K11298197,florfenicol,,,,,,,,,No-Effect
,BRD-K00003353,chlortetracycline,,,,,,,,,No-Effect
,BRD-K00004546,perfluorohexyloctane,,,,,,,,,No-Effect
,BRD-K77073709,cefminox,,,,,,,,,No-Effect
,BRD-K00004736,betamethasone-butyrate-propionate,,,,,,,,,Low (25%)
,BRD-K73469236,nedaplatin,,,,,,,,,Very Weak (35%)
,BRD-K73425385,bekanamycin,,,,,,,,,No-Effect
,BRD-K00003347,demeclocycline,,,,,,,,,No-Effect
,BRD-K37851352,isopentyl-4-methoxycinnamate,,,,,,,,,No-Effect
,BRD-K61452026,emtricitabine,,,,,,,,,No-Effect
,BRD-K51768138,lomustine,,,,,,,,,No-Effect
,BRD-K00003156,eribulin,,,,,,,,,No-Effect
,BRD-K00003260,glecaprevir,,,,,,,,,No-Effect
,BRD-K60443845,chlormidazole,,,,,,,,,No-Effect
,BRD-K37516142,idebenone,,,,,,,,,No-Effect
,BRD-K80684056,cantharidin,,,,,,,,,No-Effect
,BRD-K43977121,thymopentin,,,,,,,,,No-Effect
,BRD-K00003604,netilmicin,,,,,,,,,No-Effect
,BRD-K49384696,lincomycin,,,,,,,,,Low (25%)
,BRD-K04358951,chlorothymol,,,,,,,,,Weak (50%)
,BRD-K31139048,omega-3-acid-esters,,,,,,,,,No-Effect
,BRD-K00003427,ilaprazole,,,,,,,,,Very Weak (35%)
,BRD-K00003219,deferasirox-iron-chelate,,,,,,,,,No-Effect
,BRD-A08899266,moxalactam,,,,,,,,,No-Effect
,BRD-K93618743,ipriflavone,,,,,,,,,No-Effect
,BRD-K38602774,sulisobenzone,,,,,,,,,No-Effect
,BRD-K54838207,fudosteine,,,,,,,,,No-Effect
,BRD-A37348498,candicidin,,,,,,,,,Low (25%)
,BRD-K04568635,octenidine,,,,,,,,,No-Effect
,BRD-K94288301,letermovir,,,,,,,,,No-Effect
,BRD-A42628519,iopanic-acid,,,,,,,,,No-Effect
,BRD-K37753391,tylosin,,,,,,,,,No-Effect
,BRD-K00003581,doramectin,,,,,,,,,No-Effect
,BRD-K97101532,tezacaftor,,,,,,,,,No-Effect
,BRD-K00003542,spiramycin,,,,,,,,,No-Effect
,BRD-K00003673,methylprednisolone-sodium-succinate,,,,,,,,,No-Effect
,BRD-K02943813,dasabuvir,,,,,,,,,No-Effect
,BRD-K01826567,chlorphenamine,,,,,,,,,No-Effect
,BRD-K76845197,sulfanitran,,,,,,,,,No-Effect
,BRD-K28210218,cephalothin,,,,,,,,,No-Effect
,BRD-K00003611,daptomycin,,,,,,,,,No-Effect
,BRD-K16277217,piperacetazine,,,,,,,,,No-Effect
,BRD-K63001556,orbifloxacin,,,,,,,,,No-Effect
,BRD-K56940463,oxethazaine,,,,,,,,,No-Effect
,BRD-A47790386,balofloxacin,,,,,,,,,No-Effect
,BRD-K64514229,toltrazuril,,,,,,,,,Weak (50%)
,BRD-K59436580,tedizolid,,,,,,,,,No-Effect
,BRD-K71058253,luliconazole,,,,,,,,,No-Effect
,BRD-K42596464,oxolamine,,,,,,,,,No-Effect
,BRD-K42635745,suloctidil,,,,,,,,,No-Effect
,BRD-K24312986,tecovirimat,,,,,,,,,No-Effect
,BRD-K78815826,suxibuzone,,,,,,,,,No-Effect
,BRD-K47878171,bephenium-hydroxynaphthoate,,,,,,,,,No-Effect
,BRD-K51805276,temefos,,,,,,,,,No-Effect
,BRD-K34568562,tilorone,,,,,,,,,Weak (50%)
,BRD-A67862938,naftidrofuryl,,,,,,,,,No-Effect
,BRD-K14705039,sulfathiazole,,,,,,,,,No-Effect
,BRD-K46523383,pramoxine,,,,,,,,,No-Effect
,BRD-K90027121,amprolium,,,,,,,,,No-Effect
,BRD-K18250272,propoxycaine,,,,,,,,,No-Effect
,BRD-K65866076,hydroquinidine,,,,,,,,,No-Effect
,BRD-K93524252,sulfamerazine,,,,,,,,,No-Effect
,BRD-K55250441,sulfadoxine,,,,,,,,,No-Effect
,BRD-A00578795,zaltoprofen,,,,,,,,,No-Effect
,BRD-K21123171,pramiracetam,,,,,,,,,No-Effect
,BRD-K14401183,avobenzone,,,,,,,,,No-Effect
,BRD-K11099631,gadoterate-meglumine,,,,,,,,,No-Effect
,BRD-K51199656,fluoromethylcholine,,,,,,,,,No-Effect
,BRD-A96510685,piroctone-olamine,,,,,,,,,No-Effect
,BRD-K70976396,cefoxitin,,,,,,,,,No-Effect
,BRD-K51832961,astaxanthin,,,,,,,,,No-Effect
,BRD-K34411947,streptozotocin,,,,,,,,,No-Effect
,BRD-K90817094,bedaquiline,,,,,,,,,No-Effect
,BRD-M78068755,miriplatin,,,,,,,,,No-Effect
,BRD-A39230911,chlorphensin-carbamate,,,,,,,,,No-Effect
,BRD-A44181516,flumecinol,,,,,,,,,Very Weak (35%)
,BRD-A61633223,ulifloxacin,,,,,,,,,No-Effect
,BRD-A04497688,trilostane,,,,,,,,,No-Effect
,BRD-A22152765,tridihexethyl,,,,,,,,,No-Effect
,BRD-A33447119,oxfendazole,,,,,,,,,No-Effect
,BRD-K23200955,imipenem,,,,,,,,,Very Weak (35%)
,BRD-A34205213,cefpodoxime,,,,,,,,,No-Effect
,BRD-M63173034,clonixin-lysinate,,,,,,,,,No-Effect
,BRD-K35170555,caprylic-acid,,,,,,,,,Low (25%)
,BRD-K59983611,sulfabenzamide,,,,,,,,,Low (25%)
,BRD-K90563805,natamycin,,,,,,,,,No-Effect
,BRD-A42379279,viomycin,,,,,,,,,No-Effect
,BRD-K27293958,tiaramide,,,,,,,,,Low (25%)
,BRD-K43786866,opipramol,,,,,,,,,No-Effect
,BRD-K65331431,retinyl-acetate,,,,,,,,,No-Effect
,BRD-K11900042,methylthiouracil,,,,,,,,,No-Effect
,BRD-K65992024,pirenoxine,,,,,,,,,No-Effect
,BRD-A76533773,lisadimate,,,,,,,,,No-Effect
,BRD-A63675168,brivudine,,,,,,,,,Weak (50%)
,BRD-K21771665,merbromin,,,,,,,,,No-Effect
,BRD-K11124378,ceftibuten,,,,,,,,,Weak (50%)
,BRD-K01826479,ofloxacin,,,,,,,,,No-Effect
,BRD-A94709349,metaxalone,,,,,,,,,No-Effect
,BRD-K56940914,cresol,,,,,,,,,No-Effect
,BRD-K12014493,betaine,,,,,,,,,No-Effect
,BRD-K01825158,tosufloxacin,,,,,,,,,No-Effect
,BRD-K27130738,cefamandole,,,,,,,,,No-Effect
,BRD-K67217586,fenthion,,,,,,,,,No-Effect
,BRD-A85295731,tiopronin,,,,,,,,,No-Effect
,BRD-K00633793,drotaverine,,,,,,,,,Low (25%)
,BRD-A04506385,stepronin,,,,,,,,,No-Effect
,BRD-K37083340,lycopene,,,,,,,,,No-Effect
,BRD-K10990317,clotiapine,,,,,,,,,No-Effect
,BRD-K39495750,chlorobutanol,,,,,,,,,Very Weak (35%)
,BRD-K56542719,cefpirome,,,,,,,,,Low (25%)
,BRD-K13032584,procarbazine,,,,,,,,,Weak (50%)
,BRD-K05658747,raltegravir,,,,,,,,,Very Weak (35%)
,BRD-K32021043,sulfachlorpyridazine,,,,,,,,,No-Effect
,BRD-K56104152,oxiconazole,,,,,,,,,No-Effect
,BRD-K13330768,zinc-undecylenate,,,,,,,,,No-Effect
,BRD-K66937583,lodoxamide,,,,,,,,,No-Effect
,BRD-K39462424,dexchlorpheniramine,,,,,,,,,No-Effect
,BRD-A06426627,diclazuril,,,,,,,,,No-Effect
,BRD-K01826750,procyclidine,,,,,,,,,No-Effect
,BRD-K00003664,octisalate,,,,,,,,,No-Effect
,BRD-K14704277,cinoxacin,,,,,,,,,No-Effect
,BRD-K73753850,hexaminolevulinate,,,,,,,,,No-Effect
,BRD-K00004694,sultamicillin,,,,,,,,,No-Effect
,BRD-K00003352,tetracycline,,,,,,,,,No-Effect
,BRD-K00005329,levamlodipine,,,,,,,,,Strong (80%)
,BRD-K00004669,cangrelor,,,,,,,,,No-Effect
,BRD-K00004629,pralmorelin,,,,,,,,,No-Effect
,BRD-K00003266,udenafil,,,,,,,,,No-Effect
,BRD-K00003362,mitoquinone,,,,,,,,,No-Effect
,BRD-K00003349,tigecycline,,,,,,,,,No-Effect
,BRD-K00003133,velpatasvir,,,,,,,,,No-Effect
,BRD-K00004574,aripiprazole-lauroxil,,,,,,,,,Low (25%)
,BRD-K00004292,efonidipine,,,,,,,,,No-Effect
,BRD-K75989555,melanotan-ii,,,,,,,,,No-Effect
,BRD-K00003233,valbenazine,,,,,,,,,Low (25%)
,BRD-K00003338,triamcinolone-hexacetonide,,,,,,,,,No-Effect
,BRD-K57365211,mangafodipir,,,,,,,,,No-Effect
,BRD-K60265345,lifitegrast,,,,,,,,,No-Effect
,BRD-K00003247,bictegravir,,,,,,,,,No-Effect
,BRD-K00003103,desisobutyryl-ciclesonide,,,,,,,,,No-Effect
,BRD-K84313779,tinoridine,,,,,,,,,Low (25%)
,BRD-K55191674,benzylpenicillin,,,,,,,,,No-Effect
,BRD-K87595680,sobuzoxane,,,,,,,,,No-Effect
,BRD-K60379054,bendazol,,,,,,,,,No-Effect
,BRD-K00003346,minocycline,,,,,,,,,No-Effect
,BRD-K01029106,chromium-picolinate,,,,,,,,,No-Effect
,BRD-K00003306,vaborbactam,,,,,,,,,No-Effect
,BRD-K00004724,flurbiprofen-axetil,,,,,,,,,No-Effect
,BRD-K34566599,ectoine,,,,,,,,,No-Effect
,BRD-K71847383,cytidine,,,,,,,,,No-Effect
,BRD-K00004691,megestrol,,,,,,,,,Low (25%)
,BRD-K97009491,calcium-levofolinate,,,,,,,,,No-Effect
,BRD-K00004707,solriamfetol,,,,,,,,,No-Effect
,BRD-K90947825,carboplatin,,,,,,,,,No-Effect
,BRD-K62374253,rufloxacin,,,,,,,,,No-Effect
,BRD-K00003182,gemigliptin,,,,,,,,,No-Effect
,BRD-K78960041,oxaliplatin,,,,,,,,,Cyto
,BRD-K40992116,parachlorophenol,,,,,,,,,No-Effect
,BRD-K93880783,stavudine,,,,,,,,,No-Effect
,BRD-K15329706,propyl-benzoate,,,,,,,,,Low (25%)
,BRD-A66284731,fenipentol,,,,,,,,,No-Effect
,BRD-K54208592,carbaril,,,,,,,,,No-Effect
,BRD-K00004566,febuprol,,,,,,,,,No-Effect
,BRD-K00004663,tinazoline,,,,,,,,,No-Effect
,BRD-K91422571,tromaril,,,,,,,,,No-Effect
,BRD-K00004656,denopamine,,,,,,,,,Very Weak (35%)
,BRD-K04843140,L-theanine,,,,,,,,,Very Weak (35%)
,BRD-K00004535,3-bromocamphor,,,,,,,,,No-Effect
,BRD-K73157543,phenyl-aminosalicylate,,,,,,,,,No-Effect
,BRD-K23779958,dichlorvos,,,,,,,,,Very Weak (35%)
,BRD-K12609457,exalamide,,,,,,,,,No-Effect
,BRD-K76375510,troclosene,,,,,,,,,No-Effect
,BRD-K76606751,mebicar,,,,,,,,,No-Effect
,BRD-K00405906,phloroglucin,,,,,,,,,No-Effect
,BRD-K00004530,perchlozone,,,,,,,,,No-Effect
,BRD-K95957366,isaxonine,,,,,,,,,No-Effect
,BRD-K00004695,monomethyl-fumarate,,,,,,,,,No-Effect
,BRD-K23586533,clindamycin,,,,,,,,,No-Effect
,BRD-K01825837,ractopamine,,,,,,,,,No-Effect
,BRD-K56735750,carbadox,,,,,,,,,No-Effect
,BRD-A22267103,drofenine,,,,,,,,,Strong (80%)
,BRD-K14116214,sulfamonomethoxine,,,,,,,,,Weak (50%)
,BRD-K81101512,fosfomycin,,,,,,,,,Low (25%)
,BRD-K22685337,roxarsone,,,,,,,,,No-Effect
,BRD-K66035042,sorbitol,,,,,,,,,No-Effect
,BRD-K71055333,etamsylate,,,,,,,,,No-Effect
,BRD-K78097265,adelmidrol,,,,,,,,,Low (25%)
,BRD-K10759270,clindamycin-palmitate,,,,,,,,,No-Effect
,BRD-A55464252,3-(4-methylbenzylidene)camphor,,,,,,,,,No-Effect
,BRD-K18552138,micronomicin,,,,,,,,,Low (25%)
,BRD-K86872788,sparteine-(-),,,,,,,,,No-Effect
,BRD-K50406511,hycanthone,,,,,,,,,No-Effect
,BRD-K99622919,butacaine,,,,,,,,,No-Effect
,BRD-M41245765,lithium-citrate,,,,,,,,,No-Effect
,BRD-K43966364,penicillin-v-potassium,,,,,,,,,No-Effect
,BRD-A62336573,rolitetracycline,,,,,,,,,Very Weak (35%)
,BRD-K27771035,clindamycin-phosphate,,,,,,,,,No-Effect
,BRD-K86873305,piperacillin,,,,,,,,,No-Effect
,BRD-A67060370,albendazole-oxide,,,,,,,,,No-Effect
,BRD-A02990301,lofexidine,,,,,,,,,No-Effect
,BRD-K01826512,nefopam,,,,,,,,,No-Effect
,BRD-K79892937,phenolsulfonphthalein,,,,,,,,,No-Effect
,BRD-K73701464,croconazole,,,,,,,,,No-Effect
,BRD-K99048103,acetarsol,,,,,,,,,No-Effect
,BRD-K37203094,1-hexadecanol,,,,,,,,,No-Effect
,BRD-K82861010,daclatasvir,,,,,,,,,No-Effect
,BRD-K15567837,clopamide,,,,,,,,,No-Effect
,BRD-K15976406,telbivudine,,,,,,,,,No-Effect
,BRD-K28935038,loracarbef,,,,,,,,,No-Effect
,BRD-A24587114,isoetharine,,,,,,,,,No-Effect
,BRD-M15413738,dihydrostreptomycin,,,,,,,,,No-Effect
,BRD-K45114938,mezlocillin,,,,,,,,,No-Effect
,BRD-K00005353,hetacillin,,,,,,,,,No-Effect
,BRD-K71125570,anisotropine,,,,,,,,,No-Effect
,BRD-A65818372,ioversol,,,,,,,,,No-Effect
,BRD-K00003549,selamectin,,,,,,,,,No-Effect
,BRD-K57305459,tocofersolan,,,,,,,,,No-Effect
,BRD-K85307935,novobiocin,,,,,,,,,No-Effect
,BRD-K96737756,apramycin,,,,,,,,,No-Effect
,BRD-K00003555,eprinomectin,,,,,,,,,No-Effect
,BRD-K88043978,amikacin,,,,,,,,,No-Effect
,BRD-A60217728,iohexol,,,,,,,,,No-Effect
,BRD-K68764924,pantethine,,,,,,,,,Low (25%)
,BRD-K00003660,moxidectin,,,,,,,,,Very Weak (35%)
,BRD-K86204871,terconazole,,,,,,,,,Weak (50%)
,BRD-K63712959,temoporfin,,,,,,,,,Very Weak (35%)
,BRD-K54790157,trioxsalen,,,,,,,,,No-Effect
,BRD-K08231299,propoxur,,,,,,,,,No-Effect
,BRD-K57718010,pentylenetetrazol,,,,,,,,,No-Effect
,BRD-K00003322,sugammadex,,,,,,,,,No-Effect
,BRD-K28494619,sulfamethoxazole,,,,,,,,,Very Weak (35%)
,BRD-K97197005,gestodene,,,,,,,,,No-Effect
,BRD-K08327065,kanamycin,,,,,,,,,Low (25%)
,BRD-A10039652,tipranavir,,,,,,,,,No-Effect
,BRD-A43809092,clobutinol,,,,,,,,,No-Effect
,BRD-K00003606,sodium-nitroprusside,,,,,,,,,No-Effect
,BRD-A55272860,sulpiride,,,,,,,,,Very Weak (35%)
,BRD-K57179821,crotamiton,,,,,,,,,No-Effect
,BRD-K47079459,cetrimonium,,,,,,,,,Cyto
,BRD-K00938507,sulfamethoxypyridazine,,,,,,,,,No-Effect
,BRD-K22938173,valnemulin,,,,,,,,,No-Effect
,BRD-K02992638,lamivudine,,,,,,,,,No-Effect
,BRD-K00003556,primaquine,,,,,,,,,No-Effect
,BRD-K17903788,cefamandole-nafate,,,,,,,,,No-Effect
,BRD-K00003324,crystal-violet,,,,,,,,,No-Effect
,BRD-K44993696,atenolol-(-),,,,,,,,,No-Effect
,BRD-K01825586,rimantadine,,,,,,,,,No-Effect
,BRD-K48470486,cefmetazole,,,,,,,,,No-Effect
,BRD-K33710385,ethionamide,,,,,,,,,Very Weak (35%)
,BRD-K47608922,dipyrocetyl,,,,,,,,,No-Effect
,BRD-A33749298,oxyphenbutazone,,,,,,,,,Weak (50%)
,BRD-A78134170,cadralazine,,,,,,,,,No-Effect
,BRD-K96786677,oxacillin,,,,,,,,,No-Effect
,BRD-K85333151,ramifenazone,,,,,,,,,No-Effect
,BRD-A05523972,telmesteine,,,,,,,,,Low (25%)
,BRD-K71133585,sulfaquinoxaline,,,,,,,,,No-Effect
,BRD-A29349577,dropropizine,,,,,,,,,No-Effect
,BRD-K42090719,trichloroacetic-acid,,,,,,,,,No-Effect
,BRD-K72728560,dimetridazole,,,,,,,,,No-Effect
,BRD-A19232309,propylene-glycol,,,,,,,,,No-Effect
,BRD-K37848908,ceforanide,,,,,,,,,No-Effect
,BRD-K07785030,7-keto-DHEA,,,,,,,,,No-Effect
,BRD-K66918327,enbucrilate,,,,,,,,,No-Effect
,BRD-K54698528,valpromide,,,,,,,,,No-Effect
,BRD-K62751771,levomenol,,,,,,,,,No-Effect
,BRD-K30374899,mannitol-D,,,,,,,,,No-Effect
,BRD-K58262380,sobrepin,,,,,,,,,No-Effect
,BRD-K27871792,flucloxacillin,,,,,,,,,No-Effect
,BRD-K98765504,taurolidine,,,,,,,,,No-Effect
,BRD-K42991124,creatinol-phosphate,,,,,,,,,No-Effect
,BRD-K11595419,dipeptamin,,,,,,,,,No-Effect
,BRD-K30758549,isopropyl-palmitate,,,,,,,,,No-Effect
,BRD-K92988025,perflubron,,,,,,,,,Low (25%)
,BRD-A10662413,prenylamine,,,,,,,,,Strong (80%)
,BRD-K99241550,metrizoic-acid,,,,,,,,,Very Weak (35%)
,BRD-K78659596,ixazomib,,,,,,,,,Strong (80%)
,BRD-K71059170,cefixime,,,,,,,,,No-Effect
,BRD-K85882401,avibactam,,,,,,,,,No-Effect
,BRD-A92341659,prulifloxacin,,,,,,,,,No-Effect
,BRD-K55401595,perfluorodecalin,,,,,,,,,No-Effect
,BRD-K81092066,phenacaine,,,,,,,,,No-Effect
,BRD-A40787240,gemifloxacin,,,,,,,,,No-Effect
,BRD-K22662435,ganciclovir,,,,,,,,,Weak (50%)
,BRD-K71926323,marbofloxacin,,,,,,,,,Weak (50%)
,BRD-A32597168,letosteine,,,,,,,,,No-Effect
,BRD-K27515606,cefcapene-pivoxil,,,,,,,,,No-Effect
,BRD-K77552740,tiquizium,,,,,,,,,Very Weak (35%)
,BRD-K87700323,cetylpyridinium,,,,,,,,,Very Weak (35%)
,BRD-K01825841,butylscopolamine-bromide,,,,,,,,,No-Effect
,BRD-K20338176,cefaclor,,,,,,,,,No-Effect
,BRD-K82181219,pyritinol,,,,,,,,,No-Effect
,BRD-A37390343,amorolfine,,,,,,,,,No-Effect
,BRD-K51431759,dextrose,,,,,,,,,Low (25%)
,BRD-K98384930,finafloxacin,,,,,,,,,No-Effect
,BRD-K74057164,hemin,,,,,,,,,No-Effect
,BRD-A10131665,phosphatidylcholine,,,,,,,,,No-Effect
,BRD-K94882685,tolonium,,,,,,,,,Strong (80%)
,BRD-K24697665,bucillamine,,,,,,,,,No-Effect
,BRD-K45916615,danofloxacin,,,,,,,,,Low (25%)
,BRD-K92490248,anethole-trithione,,,,,,,,,No-Effect
,BRD-K00003607,alizapride,,,,,,,,,No-Effect
,BRD-K73529671,troxerutin,,,,,,,,,Weak (50%)
,BRD-A42759514,ornidazole,,,,,,,,,No-Effect
,BRD-K79926543,monosodium-alpha-luminol,,,,,,,,,No-Effect
,BRD-A67265925,sodium-ascorbate,,,,,,,,,Very Weak (35%)
,BRD-K93546328,chloramine-T,,,,,,,,,No-Effect
,BRD-K71210479,dexpanthenol,,,,,,,,,No-Effect
,BRD-K00003562,clevudine,,,,,,,,,No-Effect
,BRD-K11640013,sulfamethazine,,,,,,,,,No-Effect
,BRD-A86044036,flurbiprofen-(+/-),,,,,,,,,No-Effect
,BRD-K32273377,sulfadiazine,,,,,,,,,No-Effect
,BRD-K35775715,liranaftate,,,,,,,,,No-Effect
,BRD-K44273375,tolnaftate,,,,,,,,,No-Effect
,BRD-K01824979,furaltadone,,,,,,,,,No-Effect
,BRD-K26739552,fenspiride,,,,,,,,,No-Effect
,BRD-K58265391,meticrane,,,,,,,,,No-Effect
,BRD-K45033733,famciclovir,,,,,,,,,No-Effect
,BRD-K29713308,mebhydrolin,,,,,,,,,No-Effect
,BRD-K81144366,moxisylyte,,,,,,,,,No-Effect
,BRD-K86892782,edoxudine,,,,,,,,,No-Effect
,BRD-K53852914,menbutone,,,,,,,,,No-Effect
,BRD-K89125793,tinidazole,,,,,,,,,No-Effect
,BRD-K50133271,tolfenamic-acid,,,,,,,,,No-Effect
,BRD-K17205817,sulfametopyrazine,,,,,,,,,No-Effect
,BRD-K71125014,sulphadimethoxine,,,,,,,,,No-Effect
,BRD-K31682896,sulfamethizole,,,,,,,,,No-Effect
,BRD-K41866823,2-hydroxyethyl-salicylate,,,,,,,,,No-Effect
,BRD-K83335125,chloroxoquinoline,,,,,,,,,No-Effect
,BRD-A54635441,levopropoxyphene,,,,,,,,,No-Effect
,BRD-A66025870,phenethicillin,,,,,,,,,No-Effect
,BRD-K63835048,cefathiamidine,,,,,,,,,No-Effect
,BRD-K00005349,betamethasone-phosphate,,,,,,,,,Very Weak (35%)
,BRD-K73391359,dimethisoquin,,,,,,,,,Weak (50%)
,BRD-K16547679,actinomycin-d,,,,,,,,,Strong (80%)
,BRD-K00004318,itraconazole,,,,,,,,,No-Effect
,BRD-K33483813,actarit,,,,,,,,,No-Effect
,BRD-K91544578,nikethamide,,,,,,,,,No-Effect
,BRD-K44133266,sulbactam,,,,,,,,,No-Effect
,BRD-A72075775,iopromide,,,,,,,,,Very Weak (35%)
,BRD-K93240442,dinitolmide,,,,,,,,,Very Weak (35%)
,BRD-K82142815,betamipron,,,,,,,,,No-Effect
,BRD-K48247567,diatrizoic-acid,,,,,,,,,No-Effect
,BRD-K94080537,diethyltoluamide,,,,,,,,,No-Effect
,BRD-K00003569,omadacycline,,,,,,,,,No-Effect
,BRD-K97884852,malotilate,,,,,,,,,No-Effect
,BRD-K46970505,cefozopran,,,,,,,,,Very Weak (35%)
,BRD-K99451608,lopinavir,,,,,,,,,No-Effect
,BRD-K77695569,tiabendazole,,,,,,,,,No-Effect
,BRD-K96159438,adefovir-dipivoxil,,,,,,,,,No-Effect
,BRD-K32847234,sparteine-sulfate,,,,,,,,,Very Weak (35%)
,BRD-A90515964,guaifenesin,,,,,,,,,No-Effect
,BRD-K11973162,tipiracil,,,,,,,,,Very Weak (35%)
,BRD-K97863768,protionamide,,,,,,,,,No-Effect
,BRD-K02292852,cefoperazone,,,,,,,,,No-Effect
,BRD-K07441213,paroxypropione,,,,,,,,,No-Effect
,BRD-K41406082,sulfapyridine,,,,,,,,,No-Effect
,BRD-K62607865,aztreonam,,,,,,,,,No-Effect
,BRD-K10065684,dantron,,,,,,,,,Weak (50%)
,BRD-K79092138,nitrofurazone,,,,,,,,,No-Effect
,BRD-K13486660,sulfacarbamide,,,,,,,,,Very Weak (35%)
,BRD-K72915123,cinchophen,,,,,,,,,Weak (50%)
,BRD-K00003630,tioconazole,,,,,,,,,No-Effect
,BRD-K00003560,anidulafungin,,,,,,,,,No-Effect
,BRD-K44442813,pidotimod,,,,,,,,,Very Weak (35%)
,BRD-K00002625,caspofungin,,,,,,,,,No-Effect
,BRD-K10314788,meclofenoxate,,,,,,,,,Low (25%)
,BRD-K00003591,fidaxomicin,,,,,,,,,Cyto
,BRD-K01666935,colistin,,,,,,,,,No-Effect
,BRD-K40407248,micafungin,,,,,,,,,No-Effect
,BRD-K01826774,atracurium,,,,,,,,,Very Weak (35%)
,BRD-K19388745,colforsin-daproate,,,,,,,,,No-Effect
,BRD-K96153583,cidofovir,,,,,,,,,No-Effect
,BRD-K47407372,nifenazone,,,,,,,,,No-Effect
,BRD-K47780086,penciclovir,,,,,,,,,No-Effect
,BRD-K47886988,nalidixic-acid,,,,,,,,,No-Effect
,BRD-K44091963,phenyl-salicylate,,,,,,,,,No-Effect
,BRD-K07220430,cinnarazine,,,,,,,,,No-Effect
,BRD-K40645748,mefloquine,,,,,,,,,Very Weak (35%)
,BRD-A88684804,bucetin,,,,,,,,,No-Effect
,BRD-A90926615,adrafinil,,,,,,,,,No-Effect
,BRD-K75923785,scopine,,,,,,,,,No-Effect
,BRD-K83551379,levodropropizine,,,,,,,,,No-Effect
,BRD-A28887267,Proxyphylline,,,,,,,,,No-Effect
,BRD-K62213621,dihydroartemisinin,,,,,,,,,Weak (50%)
,BRD-K94720315,chromocarb,,,,,,,,,No-Effect
,BRD-K66019333,oxantel,,,,,,,,,No-Effect
,BRD-K45086103,sulfaguanidine,,,,,,,,,No-Effect
,BRD-K29392254,pantothenic-acid,,,,,,,,,No-Effect
,BRD-K93201765,sodium-gluconate,,,,,,,,,No-Effect
,BRD-K33457401,bronopol,,,,,,,,,No-Effect
,BRD-K76381435,nitromide,,,,,,,,,No-Effect
,BRD-K01825680,closantel,,,,,,,,,No-Effect
,BRD-K05673000,dicloxacillin,,,,,,,,,No-Effect
,BRD-A09370961,ioxilan,,,,,,,,,No-Effect
,BRD-K11905747,spectinomycin,,,,,,,,,No-Effect
,BRD-A17846016,trolox,,,,,,,,,No-Effect
,BRD-K53484294,rifaximin,,,,,,,,,No-Effect
,BRD-K09757388,atazanavir,,,,,,,,,No-Effect
,BRD-A65671304,candesartan-cilexetil,,,,,,,,,No-Effect
,BRD-K55375480,monensin,,,,,,,,,Strong (80%)
,BRD-K31484631,rifabutin,,,,,,,,,No-Effect
,BRD-K47827687,amprenavir,,,,,,,,,No-Effect
,BRD-K52756523,dirithromycin,,,,,,,,,No-Effect
,BRD-K79315489,erythritol,,,,,,,,,No-Effect
,BRD-K81130846,salicylamide,,,,,,,,,No-Effect
,BRD-A59303141,quinethazone,,,,,,,,,No-Effect
,BRD-K00003705,josamycin,,,,,,,,,No-Effect
,BRD-K92107055,pimecrolimus,,,,,,,,,No-Effect
,BRD-K72167406,cefditoren-pivoxil,,,,,,,,,No-Effect
,BRD-K23414042,salinomycin,,,,,,,,,Strong (80%)
,BRD-K51956333,iopodic-acid,,,,,,,,,No-Effect
,BRD-K07712545,teicoplanin,,,,,,,,,No-Effect
,BRD-K76600340,nicotinyl-alcohol-tartrate,,,,,,,,,No-Effect
,BRD-K17518951,penicillamine-(D),,,,,,,,,No-Effect
,BRD-K36524108,paromomycin,,,,,,,,,No-Effect
,BRD-K92844263,triacetin,,,,,,,,,No-Effect
,BRD-K88308881,ethenzamide,,,,,,,,,No-Effect
,BRD-A19958636,tuaminoheptane,,,,,,,,,No-Effect
,BRD-K36474365,tartaric-acid,,,,,,,,,No-Effect
,BRD-A91448670,mandelic-acid,,,,,,,,,No-Effect
,BRD-K17223896,chloroxylenol,,,,,,,,,No-Effect
,BRD-K00003683,timonacic,,,,,,,,,No-Effect
,BRD-A28856712,tetrahydrozoline,,,,,,,,,No-Effect
,BRD-A57133233,chlorcyclizine,,,,,,,,,Strong (80%)
,BRD-K88786763,moroxydine,,,,,,,,,Low (25%)
,BRD-K80036624,clopidol,,,,,,,,,No-Effect
,BRD-K12568846,amidopyrine,,,,,,,,,No-Effect
,BRD-K90374350,chlorquinaldol,,,,,,,,,Strong (80%)
,BRD-K94266545,ronidazole,,,,,,,,,Low (25%)
,BRD-A40777960,aminohydroxybutyric-acid,,,,,,,,,No-Effect
,BRD-K88734090,sorbic-acid,,,,,,,,,No-Effect
,BRD-K00010129,pyrethrins,,,,,,,,,No-Effect
,BRD-A55469827,mephenesin,,,,,,,,,No-Effect
,BRD-K76452401,piperonyl-butoxide,,,,,,,,,No-Effect
,BRD-K00003688,octinoxate,,,,,,,,,No-Effect
,BRD-K91495480,AGP-103,,,,,,,,,No-Effect
,BRD-K49880111,cephapirin,,,,,,,,,No-Effect
,BRD-A80908310,cloperastine,,,,,,,,,Low (25%)
,BRD-A60294240,tribenoside,,,,,,,,,No-Effect
,BRD-M64062803,ibuprofen-lysine,,,,,,,,,No-Effect
,BRD-A22303829,cefuroxime-axetil,,,,,,,,,No-Effect
,BRD-K34234316,benzalkonium,,,,,,,,,No-Effect
,BRD-K52284881,chiniofon,,,,,,,,,No-Effect
,BRD-A53576514,orphenadrine,,,,,,,,,No-Effect
,BRD-K85146014,foscarnet,,,,,,,,,No-Effect
,BRD-A62798249,cypermethrin,,,,,,,,,No-Effect
,BRD-K56707426,nitarsone,,,,,,,,,No-Effect
,BRD-A50675702,fipronil,,,,,,,,,No-Effect
,BRD-A66419424,ixazomib-citrate,,,,,,,,,Cyto
,BRD-A72212290,eprazinone,,,,,,,,,No-Effect
,BRD-A06629414,silymarin,,,,,,,,,Very Weak (35%)
,BRD-K46435977,valaciclovir,,,,,,,,,No-Effect
,BRD-K12413266,casanthranol-variant,,,,,,,,,No-Effect
,BRD-K73923631,difloxacin,,,,,,,,,No-Effect
,BRD-K72925150,sclareolide,,,,,,,,,No-Effect
,BRD-K17565903,pridinol,,,,,,,,,No-Effect
,BRD-K72339976,cefoselis,,,,,,,,,Low (25%)
,BRD-K09735259,elbasvir,,,,,,,,,Very Weak (35%)
,BRD-K88625236,nonoxynol-9,,,,,,,,,Low (25%)
,BRD-A21474126,methoxyphenamine,,,,,,,,,No-Effect
,BRD-K03907181,cefsulodin,,,,,,,,,No-Effect
,BRD-K90733503,cephalexin,,,,,,,,,No-Effect
,BRD-K01825622,bevantolol,,,,,,,,,No-Effect
,BRD-K64659768,phthalylsulfathiazole,,,,,,,,,Weak (50%)
,BRD-K36163066,rose-bengal-lactone,,,,,,,,,No-Effect
,BRD-A33317514,alanine,,,,,,,,,No-Effect
,BRD-A09994331,thiamine-pyrophosphate,,,,,,,,,No-Effect
,BRD-A78965079,tafenoquine,,,,,,,,,Strong (80%)
,BRD-K13664493,naphthoquine-phosphate,,,,,,,,,No-Effect
,BRD-K01612348,meropenem,,,,,,,,,No-Effect
,BRD-K05619559,tobramycin,,,,,,,,,No-Effect
,BRD-K80076813,diftalone,,,,,,,,,No-Effect
,BRD-A79643124,flosequinan,,,,,,,,,No-Effect
,BRD-A30370660,sennoside-A,,,,,,,,,No-Effect
,BRD-K94934625,spizofurone,,,,,,,,,No-Effect
,BRD-K36711084,cyromazine,,,,,,,,,No-Effect
,BRD-K26807903,aklomide,,,,,,,,,No-Effect
,BRD-K24871708,cefprozil,,,,,,,,,Very Weak (35%)
,BRD-K02900412,clofoctol,,,,,,,,,Low (25%)
,BRD-K21520694,sulfacetamide,,,,,,,,,Low (25%)
,BRD-K00004536,lymecycline,,,,,,,,,No-Effect
,BRD-K36368047,plicamycin,,,,,,,,,Strong (80%)
,BRD-A54275602,lanoconazole,,,,,,,,,No-Effect
,BRD-K00003579,gadobutrol,,,,,,,,,Low (25%)
,BRD-A45543382,metrizamide,,,,,,,,,No-Effect
,BRD-K38140108,gadodiamide,,,,,,,,,Low (25%)
,BRD-K46839850,cinepazide,,,,,,,,,No-Effect
,BRD-K24943235,grazoprevir,,,,,,,,,No-Effect
,BRD-K50859149,sulfafurazole,,,,,,,,,No-Effect
,BRD-K78355918,fusidic-acid,,,,,,,,,Very Weak (35%)
,BRD-K82800842,inositol-hexanicotinate,,,,,,,,,No-Effect
,BRD-K35952844,calcium-gluceptate,,,,,,,,,No-Effect
,BRD-K56156805,benznidazole,,,,,,,,,No-Effect
,BRD-K53123955,niridazole,,,,,,,,,No-Effect
,BRD-K93900986,stetaderm,,,,,,,,,No-Effect
,BRD-K20902145,treosulfan,,,,,,,,,No-Effect
,BRD-K17068645,bendamustine,,,,,,,,,No-Effect
,BRD-A58193911,oxyphencyclimine,,,,,,,,,No-Effect
,BRD-K04301924,ceftizoxim,,,,,,,,,No-Effect
,BRD-K75043328,coenzyme-Q10,,,,,,,,,No-Effect
,BRD-K01825113,colfosceril-palmitate,,,,,,,,,No-Effect
,BRD-K96206066,difenpiramide,,,,,,,,,Very Weak (35%)
,BRD-K85925969,zalcitabine,,,,,,,,,Weak (50%)
,BRD-K10103010,methyl-salicylate,,,,,,,,,No-Effect
,BRD-K80262108,amifampridine,,,,,,,,,No-Effect
,BRD-K04704168,clemizole,,,,,,,,,No-Effect
,BRD-K78321730,methylparaben,,,,,,,,,Weak (50%)
,BRD-K27217864,butamben,,,,,,,,,Very Weak (35%)
,BRD-K82960980,ceftiofur,,,,,,,,,No-Effect
,BRD-K10207760,lasalocid,,,,,,,,,Strong (80%)
,BRD-K00003661,cefmenoxime,,,,,,,,,No-Effect
,BRD-K39252998,atipamezole,,,,,,,,,No-Effect
,BRD-K36796419,tilmicosin,,,,,,,,,No-Effect
,BRD-K59670716,mitomycin-C,,,,,,,,,No-Effect
,BRD-K56614220,clofazimine,,,,,,,,,Weak (50%)
,BRD-K52523550,N-acetylcarnosine,,,,,,,,,No-Effect
,BRD-A25988899,tenofovir-alafenamide,,,,,,,,,No-Effect
,BRD-K33623053,rose-bengal,,,,,,,,,Very Weak (35%)
,BRD-M31057929,LCZ696,,,,,,,,,No-Effect
,BRD-K00005140,capreomycin,,,,,,,,,Low (25%)
,BRD-K77251551,sodium-picosulfate,,,,,,,,,No-Effect
,BRD-A03216249,mepivacaine,,,,,,,,,No-Effect
,BRD-A61154809,gliclazide,,,,,,,,,No-Effect
,BRD-A80321291,biapenem,,,,,,,,,No-Effect
,BRD-K68693535,lidamidine,,,,,,,,,No-Effect
,BRD-K15656090,pipobroman,,,,,,,,,No-Effect
,BRD-K51474575,taurine,,,,,,,,,No-Effect
,BRD-K01109406,nitisinone,,,,,,,,,No-Effect
,BRD-K96734425,ceftriaxone,,,,,,,,,No-Effect
,BRD-K89121095,tedizolid-phosphate,,,,,,,,,No-Effect
,BRD-K11072003,ombitasvir,,,,,,,,,No-Effect
,BRD-K87827419,melphalan,,,,,,,,,No-Effect
,BRD-K96571715,teicoplanin-A2-3,,,,,,,,,No-Effect
,BRD-K60102752,alibendol,,,,,,,,,No-Effect
,BRD-A13078313,carbenicillin,,,,,,,,,Low (25%)
,BRD-K84971356,etafenone,,,,,,,,,Very Weak (35%)
,BRD-K36116267,pyrithyldione,,,,,,,,,No-Effect
,BRD-K00739965,guacetisal,,,,,,,,,No-Effect
,BRD-K07625016,norethisterone-enanthate,,,,,,,,,Weak (50%)
,BRD-A71407503,inimur,,,,,,,,,No-Effect
,BRD-K00003330,afamelanotide,,,,,,,,,Low (25%)
,BRD-K16758059,perfluamine,,,,,,,,,Low (25%)
,BRD-K01826559,oxytetracycline,,,,,,,,,Low (25%)
,BRD-K71454870,morantel,,,,,,,,,Very Weak (35%)
,BRD-K29229654,ticarcillin,,,,,,,,,Very Weak (35%)
,BRD-K61937613,doconexent-ethyl-ester,,,,,,,,,Very Weak (35%)
,BRD-K68822425,midecamycin,,,,,,,,,No-Effect
,BRD-K67100011,pivmecillinam,,,,,,,,,No-Effect
,BRD-K01773083,denotivir,,,,,,,,,No-Effect
,BRD-A40472231,ertapenem,,,,,,,,,No-Effect
,BRD-K62186992,hydroxystilbamidine,,,,,,,,,No-Effect
,BRD-K94072573,medronic-acid,,,,,,,,,Weak (50%)
,BRD-K68553471,todralazine,,,,,,,,,Very Weak (35%)
,BRD-K04657451,D-delta-tocopherol,,,,,,,,,Low (25%)
,BRD-A08660406,iodixanol,,,,,,,,,No-Effect
,BRD-K39707084,lynestrenol,,,,,,,,,No-Effect
,BRD-K43639297,voxelotor,,,,,,,,,Weak (50%)
,BRD-K88405679,thonzylamine,,,,,,,,,No-Effect
,BRD-A76661185,cefotiam-cilexetil,,,,,,,,,No-Effect
,BRD-K05446112,ledipasvir,,,,,,,,,No-Effect
,BRD-K79884267,retinaldehyde,,,,,,,,,No-Effect
,BRD-K13238168,haloprogin,,,,,,,,,No-Effect
,BRD-K02729857,phenylbenzimidazole-sulfonic-acid,,,,,,,,,No-Effect
,BRD-A17655518,ibuprofen,,,,,,,,,Weak (50%)
,BRD-K19742012,sulfamoxole,,,,,,,,,No-Effect
,BRD-K46741531,cafestol,,,,,,,,,No-Effect
,BRD-K29458283,chlorambucil,,,,,,,,,No-Effect
,BRD-A99388803,metipranolol,,,,,,,,,No-Effect
,BRD-K17977438,oxelaidin,,,,,,,,,Weak (50%)
,BRD-K75868704,iopamidol,,,,,,,,,No-Effect
,BRD-K81849500,verteporfin,,,,,,,,,Weak (50%)
,BRD-K55847762,lobenzarit,,,,,,,,,No-Effect
,BRD-A04447196,gepefrine,,,,,,,,,Low (25%)
,BRD-K71075093,pempidine,,,,,,,,,Low (25%)
,BRD-A32988684,heptaminol,,,,,,,,,No-Effect
,BRD-A33479817,terodiline,,,,,,,,,No-Effect
,BRD-K10029415,enisamium-iodide,,,,,,,,,No-Effect
,BRD-K92872987,cefpiramide,,,,,,,,,No-Effect
,BRD-K50677762,oxiracetam,,,,,,,,,No-Effect
,BRD-A91733352,camylofine-chlorhydrate,,,,,,,,,Weak (50%)
,BRD-K12742203,moxaverine,,,,,,,,,No-Effect
,BRD-K28542495,benzydamine,,,,,,,,,No-Effect
,BRD-K58497451,potassium-p-aminobenzoate,,,,,,,,,Very Weak (35%)
,BRD-K30114692,methenamine,,,,,,,,,No-Effect
,BRD-K02475039,ethopabate,,,,,,,,,No-Effect
,BRD-K74236708,acitazanolast,,,,,,,,,No-Effect
,BRD-K68188368,nifuroxazide,,,,,,,,,No-Effect
,BRD-A68997559,sisomicin-sulfate,,,,,,,,,No-Effect
,BRD-K56276053,propatylnitrate,,,,,,,,,No-Effect
,BRD-A48938994,monoctanoin,,,,,,,,,No-Effect
,BRD-K65667145,kinetin,,,,,,,,,No-Effect
,BRD-K13409143,isopropyl-myristate,,,,,,,,,No-Effect
,BRD-K41504985,cabagin,,,,,,,,,No-Effect
,BRD-K82103381,hydralazine,,,,,,,,,No-Effect
,BRD-K19189338,undecylenic-acid,,,,,,,,,No-Effect
,BRD-K17443395,abacavir,,,,,,,,,No-Effect
,BRD-K30764557,miocamycin,,,,,,,,,No-Effect
,BRD-K17480742,delamanid,,,,,,,,,No-Effect
,BRD-K11256763,niceritrol,,,,,,,,,Low (25%)
,BRD-K45125084,zolimidine,,,,,,,,,No-Effect
,BRD-A92262698,chlorphenesin,,,,,,,,,No-Effect
,BRD-K00005346,anecortave-acetate,,,,,,,,,No-Effect
,BRD-K00010936,escin,,,,,,,,,No-Effect
,BRD-A43435802,mercaptosuccinic-acid,,,,,,,,,No-Effect
,BRD-K37252028,ceftaroline-fosamil,,,,,,,,,No-Effect
,BRD-K54634444,artesunate,,,,,,,,,No-Effect
,BRD-A20742938,cibenzoline,,,,,,,,,No-Effect
,BRD-K00005348,algestone-acetophenide,,,,,,,,,No-Effect
,BRD-K75649340,tioguanine,,,,,,,,,Strong (80%)
,BRD-K48963429,riodoxol,,,,,,,,,No-Effect
,BRD-A72401848,gadoteridol,,,,,,,,,No-Effect
,BRD-K00005347,ajmaline,,,,,,,,,No-Effect
,BRD-K75864342,menatetrenone,,,,,,,,,No-Effect
,BRD-K88090157,pimethixene,,,,,,,,,Strong (80%)
,BRD-A60635434,ecamsule-triethanolamine,,,,,,,,,Cyto
,BRD-A09761158,teicoplanin-A2-1,,,,,,,,,No-Effect
,BRD-M71167108,sucralfate,,,,,,,,,No-Effect
,BRD-A08641215,polymyxin-B-sulfate,,,,,,,,,No-Effect
,BRD-A64610707,pranoprofen,,,,,,,,,No-Effect
,BRD-K76634210,idoxuridine,,,,,,,,,No-Effect
,BRD-A33697453,fenticonazole,,,,,,,,,No-Effect
,BRD-K08525451,sarafloxacin,,,,,,,,,No-Effect
,BRD-A94543220,bifonazole,,,,,,,,,No-Effect
,BRD-K01825581,leucovorin,,,,,,,,,No-Effect
,BRD-A05515753,erdosteine,,,,,,,,,No-Effect
,BRD-K47635719,dexamethasone-acetate,,,,,,,,,No-Effect
,BRD-K47631482,bromhexine,,,,,,,,,No-Effect
,BRD-K91938660,memantine,,,,,,,,,No-Effect
,BRD-K01825804,pronethalol,,,,,,,,,No-Effect
,BRD-A14262390,guanadrel,,,,,,,,,Very Weak (35%)
,BRD-K01825659,sertaconazole,,,,,,,,,No-Effect
,BRD-K17641316,decoquinate,,,,,,,,,No-Effect
,BRD-K10196357,besifloxacin,,,,,,,,,No-Effect
,BRD-A70649075,sulconazole,,,,,,,,,No-Effect
,BRD-K00519864,peramivir,,,,,,,,,No-Effect
,BRD-K44942188,fomocaine,,,,,,,,,No-Effect
,BRD-K00004639,ormeloxifene,,,,,,,,,Very Weak (35%)
,BRD-A22106989,phenothrin,,,,,,,,,Very Weak (35%)
,BRD-A79981887,midodrine,,,,,,,,,No-Effect
,BRD-K94848716,carbarsone,,,,,,,,,No-Effect
,BRD-A56675431,althiazide,,,,,,,,,No-Effect
,BRD-K80025777,"cis-9,trans-11-conjugated-linoleic-acid",,,,,,,,,No-Effect
,BRD-K40787673,lacitol,,,,,,,,,No-Effect
,BRD-K26222048,"trans-10,cis-12-conjugated-linoleic-acid",,,,,,,,,No-Effect
,BRD-K41051431,amdinocillin,,,,,,,,,No-Effect
,BRD-A91386192,trofosfamide,,,,,,,,,No-Effect
,BRD-K97417064,acedapsone,,,,,,,,,No-Effect
,BRD-A84020532,nifurtimox,,,,,,,,,No-Effect
,BRD-K68091065,halazone,,,,,,,,,No-Effect
,BRD-K79145628,nimorazole,,,,,,,,,No-Effect
,BRD-A07947329,buparvaquone,,,,,,,,,Strong (80%)
,BRD-K08999871,pipemidic-acid,,,,,,,,,No-Effect
,BRD-K44824027,beclamide,,,,,,,,,No-Effect
,BRD-K27406233,acetyl-l-leucine,,,,,,,,,No-Effect
,BRD-K13619941,aceglutamide,,,,,,,,,No-Effect
,BRD-K14312455,tazobactam,,,,,,,,,No-Effect
,BRD-A29944538,proxodolol,,,,,,,,,No-Effect
,BRD-A41250306,cyclopenthiazide,,,,,,,,,No-Effect
,BRD-K60783397,propylparaben,,,,,,,,,No-Effect
,BRD-A47494775,dipivefrine,,,,,,,,,No-Effect
,BRD-K74225533,beta-carotene,,,,,,,,,No-Effect
,BRD-K78364995,cefotaxime,,,,,,,,,No-Effect
,BRD-K00003713,oxymatrine,,,,,,,,,No-Effect
,BRD-K53220666,trimetozine,,,,,,,,,No-Effect
,BRD-K67043667,altretamine,,,,,,,,,Low (25%)
,BRD-K11756522,furazolidone,,,,,,,,,No-Effect
,BRD-A90807417,cephradine,,,,,,,,,No-Effect
,BRD-A98427211,suplatast,,,,,,,,,No-Effect
,BRD-K78185697,ademetionine,,,,,,,,,No-Effect
,BRD-K86358349,bromantan,,,,,,,,,No-Effect
,BRD-K94250879,clavulanate,,,,,,,,,No-Effect
,BRD-K79711234,thiamphenicol,,,,,,,,,No-Effect
,BRD-K32791151,pivampicillin,,,,,,,,,No-Effect
,BRD-K97464279,diaveridine,,,,,,,,,No-Effect
,BRD-A10773072,glycerol-monolaurate,,,,,,,,,No-Effect
,BRD-A70514680,articaine,,,,,,,,,No-Effect
,BRD-K76927775,nitrofurantoin,,,,,,,,,No-Effect
,BRD-K34058848,cefonicid,,,,,,,,,Low (25%)
,BRD-A24397426,nadifloxacin,,,,,,,,,No-Effect
,BRD-A61676498,climbazole,,,,,,,,,No-Effect
,BRD-K82259334,methyldopate,,,,,,,,,No-Effect
,BRD-K91308639,apalutamide,,,,,,,,,No-Effect
,BRD-A25366096,permethrin,,,,,,,,,No-Effect
,BRD-K11510141,teprenone,,,,,,,,,No-Effect
,BRD-A96407378,allantoin,,,,,,,,,No-Effect
,BRD-A65683612,phenylpiracetam,,,,,,,,,No-Effect
,BRD-K76867903,propiolactone,,,,,,,,,No-Effect
,BRD-K84011460,nizofenone,,,,,,,,,No-Effect
,BRD-K09821361,deferoxamine-mesylate,,,,,,,,,No-Effect
,BRD-A64743628,isometheptene-mucate,,,,,,,,,Very Weak (35%)
,BRD-K96691275,mebrofenin,,,,,,,,,No-Effect
,BRD-K64636206,D-alpha-tocopheryl-succinate,,,,,,,,,No-Effect
,BRD-K78781788,barnidipine,,,,,,,,,No-Effect
,BRD-K04725460,anthralin,,,,,,,,,Cyto
,BRD-K26581543,bifendate,,,,,,,,,No-Effect
,BRD-K59110290,fosamprenavir,,,,,,,,,No-Effect
,BRD-K07166362,streptomycin,,,,,,,,,No-Effect
,BRD-K01825594,doxapram,,,,,,,,,No-Effect
,BRD-K21656326,nystatin,,,,,,,,,Very Weak (35%)
,BRD-A69777949,flumequine,,,,,,,,,No-Effect
,BRD-K74141488,naftifine,,,,,,,,,No-Effect
,BRD-A68589262,troxipide,,,,,,,,,No-Effect
,BRD-K01825701,lomefloxacin,,,,,,,,,No-Effect
,BRD-A62893078,fotemustine,,,,,,,,,No-Effect
,BRD-K01244426,cloxacillin,,,,,,,,,No-Effect
,BRD-K39987650,bisacodyl,,,,,,,,,No-Effect
,BRD-K13387373,thonzonium,,,,,,,,,No-Effect
,BRD-K76534306,enrofloxacin,,,,,,,,,No-Effect
,BRD-K66412701,pazufloxacin,,,,,,,,,No-Effect
,BRD-K99984802,flunixin-meglumin,,,,,,,,,No-Effect
,BRD-K38310698,troleandomycin,,,,,,,,,No-Effect
,BRD-K01666924,colistimethate,,,,,,,,,Weak (50%)
,BRD-K96471533,nitazoxanide,,,,,,,,,Weak (50%)
,BRD-K96006160,artemotil,,,,,,,,,Low (25%)
,BRD-M67659203,pamabrom,,,,,,,,,No-Effect
,BRD-K38203080,sparteine-(+),,,,,,,,,Low (25%)
,BRD-K68432770,ampicillin,,,,,,,,,Very Weak (35%)
,BRD-K81993098,mecysteine,,,,,,,,,No-Effect
,BRD-K01825698,gatifloxacin,,,,,,,,,Very Weak (35%)
,BRD-K33742430,chloramphenicol-palmitate,,,,,,,,,Weak (50%)
,BRD-K49060658,anethole,,,,,,,,,No-Effect
,BRD-A93683007,mabuprofen,,,,,,,,,No-Effect
,BRD-K00003625,bacitracin-zinc,,,,,,,,,No-Effect
,BRD-K27382019,piperaquine-phosphate,,,,,,,,,No-Effect
,BRD-K00004602,thymalfasin,,,,,,,,,No-Effect
,BRD-K45170529,gramicidin,,,,,,,,,No-Effect
,BRD-A18043272,phensuximide,,,,,,,,,No-Effect
,BRD-A25608658,narasin,,,,,,,,,Strong (80%)
,BRD-K01624185,maltobionic-acid,,,,,,,,,No-Effect
,BRD-K60348325,brilliant-green,,,,,,,,,Cyto
,BRD-K69247067,afloqualone,,,,,,,,,No-Effect
,BRD-K52256627,chlorhexidine,,,,,,,,,No-Effect
,BRD-A12994259,pomalidomide,,,,,,,,,Low (25%)
,BRD-K00004533,bleomycetin,,,,,,,,,No-Effect
,BRD-K00003629,vitamin-B12,,,,,,,,,No-Effect
,BRD-K00003525,hydroxocobalamin,,,,,,,,,No-Effect
,BRD-K00005332,calcitonin,,,,,,,,,No-Effect
,BRD-K64414150,tymazoline,,,,,,,,,No-Effect
,BRD-K00003161,buserelin,,,,,,,,,Weak (50%)
,BRD-K00003588,bleomycin,,,,,,,,,No-Effect
,BRD-K91065602,vancomycin,,,,,,,,,No-Effect
,BRD-K00003704,oritavancin,,,,,,,,,Very Weak (35%)
,BRD-A71774530,lufenuron,,,,,,,,,No-Effect
,BRD-A92974210,bemotrizinol,,,,,,,,,No-Effect
,BRD-K27798832,cefetamet,,,,,,,,,No-Effect
,BRD-A82892199,alpha-tochopherol,,,,,,,,,No-Effect
,BRD-A62421304,mepenzolate,,,,,,,,,No-Effect
,BRD-K58968598,sucralose,,,,,,,,,No-Effect
,BRD-A77291778,cyclopentolate,,,,,,,,,No-Effect
,BRD-K01824994,butoconazole,,,,,,,,,No-Effect
,BRD-K97521363,clorsulon,,,,,,,,,No-Effect
,BRD-K93231391,ethambutol,,,,,,,,,No-Effect
,BRD-A71157293,fursultiamine,,,,,,,,,No-Effect
,BRD-K60663764,azlocillin,,,,,,,,,No-Effect
,BRD-K93767137,oseltamivir-carboxylate,,,,,,,,,No-Effect
,BRD-K77258318,lactulose,,,,,,,,,No-Effect
,BRD-K82603084,ethylenediaminetetraacetic-acid,,,,,,,,,No-Effect
,BRD-K23204545,busulfan,,,,,,,,,No-Effect
,BRD-K00003587,choline-alfoscerate,,,,,,,,,No-Effect
,BRD-A00092689,docusate,,,,,,,,,No-Effect
,BRD-K37793595,afobazole,,,,,,,,,No-Effect
,BRD-A11070335,carbazochrome,,,,,,,,,No-Effect
,BRD-K24790130,tricaprylin,,,,,,,,,Low (25%)
,BRD-K75855670,iodoquinol,,,,,,,,,No-Effect
,BRD-K17828029,cinoxate,,,,,,,,,No-Effect
,BRD-K85757157,nifursol,,,,,,,,,Low (25%)
,BRD-K25029121,triclocarban,,,,,,,,,Very Weak (35%)
,BRD-K00003605,octocrylene,,,,,,,,,Weak (50%)
,BRD-K10836013,sitafloxacin,,,,,,,,,Low (25%)
,BRD-A85548292,piketoprofen,,,,,,,,,No-Effect
,BRD-K61230716,sodium-nitrite,,,,,,,,,No-Effect
,BRD-A96644976,valnoctamide,,,,,,,,,No-Effect
,BRD-K18637542,dihydroxyacetone,,,,,,,,,No-Effect
,BRD-K98494274,benzyl-alcohol,,,,,,,,,No-Effect
,BRD-K52117081,ceftazidime,,,,,,,,,No-Effect
,BRD-K01666936,bismuth-subcitrate-potassium,,,,,,,,,No-Effect
,BRD-K59986511,benzoyl-peroxide,,,,,,,,,No-Effect
,BRD-K14003026,ritodrine,,,,,,,,,No-Effect
,BRD-K49954789,mesna,,,,,,,,,No-Effect
,BRD-K71772032,sisomicin,,,,,,,,,No-Effect
,BRD-K10759144,xylose,,,,,,,,,No-Effect
,BRD-A70083328,secnidazole,,,,,,,,,No-Effect
,BRD-K89056082,chlorocresol,,,,,,,,,No-Effect
,BRD-M55321172,potassium-iodide,,,,,,,,,Low (25%)
,BRD-A59747053,indeloxazine,,,,,,,,,No-Effect
,BRD-A63431791,sulbactam-pivoxil,,,,,,,,,No-Effect
,BRD-K28595280,meglumine,,,,,,,,,No-Effect
,BRD-K28580965,metafolin,,,,,,,,,No-Effect
,BRD-A18605525,hexetidine,,,,,,,,,No-Effect
,BRD-K76713213,tavaborole,,,,,,,,,No-Effect
,BRD-K20672254,pyrantel-pamoate,,,,,,,,,No-Effect
,BRD-K59045783,faropenem-medoxomil,,,,,,,,,Low (25%)
,BRD-A00218260,flutrimazole,,,,,,,,,Low (25%)
,BRD-K10180294,uracil-mustard,,,,,,,,,Very Weak (35%)
,BRD-K80528473,bismuth-subsalicylate,,,,,,,,,Very Weak (35%)
,,Control,,,,,,,,,No-Effect
